{"DataElement":{"publicId":"2183600","version":"2","preferredName":"Concomitant Agent Name","preferredDefinition":"Name of a nonstudy agent taken during a course (cycle) of a protocol.","longName":"CONCT_AGT_NM","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"2195361","version":"1","preferredName":"Concomitant Medication Administered","preferredDefinition":"information related to the concomitant medication administered.","longName":"CONCOM_MEDS_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2206481","version":"1","preferredName":"Concomitant Medication","preferredDefinition":"Concomitant; following as a consequence.:biologically active substance, including those intended for use in diagnosis, treatment, or prevention of disease or other abnormalities, for the relief of suffering, or control or improvement of a physical or mental state; includes biological products.","longName":"C25730:C459","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Concomitant","conceptCode":"C25730","definition":"Accessory, accompanying especially in a subordinate or incidental way, occurring or existing during the same period of time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Medication","conceptCode":"C459","definition":"A drug product that contains one or more active and/or inactive ingredients; it is intended to treat, prevent or alleviate the symptoms of disease. This term does not refer to the individual ingredients that make up the product.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0428-F6E6-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177665","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"Administered","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-516D-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ED56CEE5-E520-67E4-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-10","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-01-10","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2183599","version":"2","preferredName":"Concomitant Agent Name","preferredDefinition":"Text terms to identify nonstudy agents/medications.","longName":"CONCT_AGT_NM","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"80","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Empagliflozin/Linagliptin","valueDescription":"Empagliflozin/Linagliptin","ValueMeaning":{"publicId":"7693083","version":"1","preferredName":"Empagliflozin/Linagliptin","longName":"7693083","preferredDefinition":"A fixed dose combination of empagliflozin, an inhibitor of sodium-glucose co-transporter 2 (SGLT2; SLC5A2), and linagliptin, a dihydropurinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with antihyperglycemic activity. Upon oral administration of empagliflozin/linagliptin, empagliflozin selectively and potently inhibits SGLT2 in the kidneys, thereby suppressing the reabsorption of glucose in the proximal tubule. Inhibition of SGLT2 increases urinary glucose excretion by the kidneys, resulting in a reduction of plasma glucose levels in an insulin-independent manner. Linagliptin binds to and inhibits DPP-4, thereby inhibiting the breakdown of the incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This prolongs the activity of these incretin hormones, increases postprandial insulin secretion from pancreatic beta cells, decreases glucagon secretion and lowers blood glucose levels. SGLT2, a transport protein exclusively expressed in the proximal renal tubules, mediates approximately 90% of renal glucose reabsorption from tubular fluid. DPP-4 is a serine protease that degrades the incretin hormones GLP-1 and GIP, which play important roles in the regulation of glucose homeostasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Empagliflozin/Linagliptin","conceptCode":"C180533","definition":"A fixed dose combination of empagliflozin, an inhibitor of sodium-glucose co-transporter 2 (SGLT2; SLC5A2), and linagliptin, a dihydropurinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with antihyperglycemic activity. Upon oral administration of empagliflozin/linagliptin, empagliflozin selectively and potently inhibits SGLT2 in the kidneys, thereby suppressing the reabsorption of glucose in the proximal tubule. Inhibition of SGLT2 increases urinary glucose excretion by the kidneys, resulting in a reduction of plasma glucose levels in an insulin-independent manner. Linagliptin binds to and inhibits DPP-4, thereby inhibiting the breakdown of the incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This prolongs the activity of these incretin hormones, increases postprandial insulin secretion from pancreatic beta cells, decreases glucagon secretion and lowers blood glucose levels. SGLT2, a transport protein exclusively expressed in the proximal renal tubules, mediates approximately 90% of renal glucose reabsorption from tubular fluid. DPP-4 is a serine protease that degrades the incretin hormones GLP-1 and GIP, which play important roles in the regulation of glucose homeostasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4FF8F9F-E374-6EA0-E053-4EBD850AE17B","latestVersionIndicator":"Yes","beginDate":"2021-06-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-06-17","modifiedBy":"ONEDATA","dateModified":"2021-06-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4FF8F9F-E38F-6EA0-E053-4EBD850AE17B","beginDate":"2021-06-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-06-17","modifiedBy":"ONEDATA","dateModified":"2021-06-17","deletedIndicator":"No"},{"value":"Chondrus crispus","valueDescription":"Chondrus crispus","ValueMeaning":{"publicId":"7693084","version":"1","preferredName":"Chondrus crispus","longName":"7693084","preferredDefinition":"An edible red seaweed, with potential antioxidant, anti-inflammatory and anti-microbial activities. Chondrus crispus contains a variety of bioactive compounds, such as caroteinoids, including beta-carotene, zeaxanthin and lutein, polyphenols, including flavonoids and tannins, and sulfated polysaccharides, including carrageenans. Upon administration, the active compounds in Chondrus crispus scavenge reactive oxygen species (ROS) and may protect cells from the damage of oxidative stress, and may prevent inflammation and microbial infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chondrus crispus","conceptCode":"C180534","definition":"An edible red seaweed, with potential antioxidant, anti-inflammatory and anti-microbial activities. Chondrus crispus contains a variety of bioactive compounds, such as caroteinoids, including beta-carotene, zeaxanthin and lutein, polyphenols, including flavonoids and tannins, and sulfated polysaccharides, including carrageenans. Upon administration, the active compounds in Chondrus crispus scavenge reactive oxygen species (ROS) and may protect cells from the damage of oxidative stress, and may prevent inflammation and microbial infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4FF8F9F-E39B-6EA0-E053-4EBD850AE17B","latestVersionIndicator":"Yes","beginDate":"2021-06-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-06-17","modifiedBy":"ONEDATA","dateModified":"2021-06-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4FF8F9F-E3B6-6EA0-E053-4EBD850AE17B","beginDate":"2021-06-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-06-17","modifiedBy":"ONEDATA","dateModified":"2021-06-17","deletedIndicator":"No"},{"value":"Ticagrelor","valueDescription":"Ticagrelor","ValueMeaning":{"publicId":"7693086","version":"1","preferredName":"Ticagrelor","longName":"7693086","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ticagrelor","conceptCode":"C76404","definition":"An orally bioavailable cyclopentyltriazolopyrimidine, with antiplatelet activity. Upon oral administration, ticagrelor and its major metabolite targets and reversibly binds to the platelet adenosine diphosphate (ADP) P2Y12 receptor (P2Y12R) at a site distinct from that of the endogenous agonist ADP. This blocks the platelet signaling pathway, thereby inhibiting the activation of the glycoprotein complex GPIIb/IIIa, fibrinogen binding to platelets and platelet adhesion and aggregation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4FF8F9F-E3C3-6EA0-E053-4EBD850AE17B","latestVersionIndicator":"Yes","beginDate":"2021-06-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-06-17","modifiedBy":"ONEDATA","dateModified":"2021-06-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4FF8F9F-E3DE-6EA0-E053-4EBD850AE17B","beginDate":"2021-06-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-06-17","modifiedBy":"ONEDATA","dateModified":"2021-06-17","deletedIndicator":"No"},{"value":"Glucagon","valueDescription":"Glucagon","ValueMeaning":{"publicId":"3218917","version":"1","preferredName":"Glucagon","longName":"3218917","preferredDefinition":"A pancreatic hormone consisting of 29 amino acids that causes increases in blood sugar levels by stimulating hepatic glycogenolysis and gluconeogenesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glucagon","conceptCode":"C2268","definition":"Glucagon (29 aa, ~3 kDa) is encoded by the human GCG gene. This protein plays a role in the regulation of blood sugar levels through the stimulation of hepatic glycogenolysis and gluconeogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9FCB1285-708D-D8CA-E040-BB89AD433739","latestVersionIndicator":"Yes","beginDate":"2011-03-31","endDate":null,"createdBy":"MAESKEB","dateCreated":"2011-03-31","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4FF8F9F-E3E8-6EA0-E053-4EBD850AE17B","beginDate":"2021-06-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-06-17","modifiedBy":"ONEDATA","dateModified":"2021-06-17","deletedIndicator":"No"},{"value":"Patiromer","valueDescription":"Patiromer","ValueMeaning":{"publicId":"7693088","version":"1","preferredName":"Patiromer","longName":"7693088","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patiromer","conceptCode":"C166500","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4FF8F9F-E3F6-6EA0-E053-4EBD850AE17B","latestVersionIndicator":"Yes","beginDate":"2021-06-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-06-17","modifiedBy":"ONEDATA","dateModified":"2021-06-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C4FF8F9F-E40F-6EA0-E053-4EBD850AE17B","beginDate":"2021-06-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-06-17","modifiedBy":"ONEDATA","dateModified":"2021-06-17","deletedIndicator":"No"},{"value":"Metoprolol","valueDescription":"Metoprolol","ValueMeaning":{"publicId":"7060442","version":"1","preferredName":"Metoprolol","longName":"7060442","preferredDefinition":"A cardioselective competitive beta-1 adrenergic receptor antagonist with antihypertensive properties and devoid of intrinsic sympathomimetic activity. Metoprolol antagonizes beta 1-adrenergic receptors in the myocardium, thereby reducing the rate and force of myocardial contraction leading to a reduction in cardiac output. This agent may also reduce the secretion of renin with subsequent reduction in levels of angiotensin II thereby preventing vasoconstriction and aldosterone secretion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metoprolol","conceptCode":"C61845","definition":"A cardioselective competitive beta-1 adrenergic receptor antagonist with antihypertensive properties and devoid of intrinsic sympathomimetic activity. Metoprolol antagonizes beta 1-adrenergic receptors in the myocardium, thereby reducing the rate and force of myocardial contraction leading to a reduction in cardiac output. This agent may also reduce the secretion of renin with subsequent reduction in levels of angiotensin II thereby preventing vasoconstriction and aldosterone secretion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A00723-66A0-558A-E053-F662850A380C","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BB6CCA7-9E18-4476-E053-F662850A148C","beginDate":"2020-01-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-01-09","modifiedBy":"ONEDATA","dateModified":"2020-01-09","deletedIndicator":"No"},{"value":"B Vitamin","valueDescription":"B Vitamin","ValueMeaning":{"publicId":"7130488","version":"1","preferredName":"B Vitamin","longName":"7130488","preferredDefinition":"A class of nutrients that are in the water-soluble B-vitamin family.  B vitamins include thiamine, riboflavin, niacin (nicotinic acid), niacinamide (nicotinamide), the vitamin B6 group (including pyridoxine, pyridoxal, pyridoxamine), biotin, pantothenic acid, folic acid, and possibly para-aminobenzoic.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B Vitamin","conceptCode":"C45812","definition":"A class of nutrients that are in the water-soluble B-vitamin family.  B vitamins include thiamine, riboflavin, niacin (nicotinic acid), niacinamide (nicotinamide), the vitamin B6 group (including pyridoxine, pyridoxal, pyridoxamine), biotin, pantothenic acid, folic acid, and possibly para-aminobenzoic.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BA67215-1909-470C-E053-F662850A9908","latestVersionIndicator":"Yes","beginDate":"2020-01-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-01-09","modifiedBy":"TAYLORT","dateModified":"2020-01-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BA67215-1922-470C-E053-F662850A9908","beginDate":"2020-01-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-01-09","modifiedBy":"ONEDATA","dateModified":"2020-01-09","deletedIndicator":"No"},{"value":"Lidocaine","valueDescription":"Lidocaine","ValueMeaning":{"publicId":"5212038","version":"1","preferredName":"Lidocaine","longName":"5212038","preferredDefinition":"A synthetic aminoethylamide with local anesthetic and antiarrhythmic properties. Lidocaine stabilizes the neuronal membrane by binding to and inhibiting voltage-gated sodium channels, thereby inhibiting the ionic fluxes required for the initiation and conduction of impulses and effecting local anesthesia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lidocaine","conceptCode":"C614","definition":"A synthetic aminoethylamide with local anesthetic and antiarrhythmic properties. Lidocaine stabilizes the neuronal membrane by binding to and inhibiting voltage-gated sodium channels, thereby inhibiting the ionic fluxes required for the initiation and conduction of impulses and effecting local anesthesia.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2FD71FC3-4535-99FC-E050-BB89AD433CEF","latestVersionIndicator":"Yes","beginDate":"2016-04-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-04-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BA67215-192C-470C-E053-F662850A9908","beginDate":"2020-01-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-01-09","modifiedBy":"ONEDATA","dateModified":"2020-01-09","deletedIndicator":"No"},{"value":"Docusate Sodium-Senna","valueDescription":"Docusate Sodium-Senna ","ValueMeaning":{"publicId":"7130497","version":"1","preferredName":"Docusate Sodium-Senna ","longName":"7130497v1.00","preferredDefinition":"A combination preparation composed of a standardized senna concentrate and the sodium salt form of the emollient laxative docusate, with laxative and stool softening activity. Senna concentrate consists of the anthraquinone glycosides sennosides extracted from senna leaves. Sennosides act on and irritate the lining of the intestine wall, thereby causing increased intestinal muscle contractions leading to vigorous bowel movement and relief of constipation. Docusate, an anionic surfactant, decreases surface tension and emulsification of fecal matter and allows water to penetrate and mix with stool. This softens the stool for smoother and easier evacuation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Docusate Sodium-Senna","conceptCode":"C29450","definition":"A combination preparation composed of a standardized senna concentrate and the sodium salt form of the emollient laxative docusate, with laxative and stool softening activity. Senna concentrate consists of the anthraquinone glycosides sennosides extracted from senna leaves. Sennosides act on and irritate the lining of the intestine wall, thereby causing increased intestinal muscle contractions leading to vigorous bowel movement and relief of constipation. Docusate, an anionic surfactant, decreases surface tension and emulsification of fecal matter and allows water to penetrate and mix with stool. This softens the stool for smoother and easier evacuation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BA5935F-F5F8-2EF6-E053-F662850A9D24","latestVersionIndicator":"Yes","beginDate":"2020-01-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-01-09","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BA5935F-F611-2EF6-E053-F662850A9D24","beginDate":"2020-01-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-01-09","modifiedBy":"ONEDATA","dateModified":"2020-01-09","deletedIndicator":"No"},{"value":"Pentamidine","valueDescription":"Pentamidine","ValueMeaning":{"publicId":"2743481","version":"1","preferredName":"Pentamidine","longName":"2743481","preferredDefinition":"A synthetic derivative of amidine with antiprotozoal and antifungal activities.  Although the precise mode of action of pentamidine is unclear, it appears to interact directly with the pathogen genome by binding to AT-rich regions of duplex DNA and the minor groove of DNA, thereby interfering with DNA replication. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pentamidine","conceptCode":"C731","definition":"A synthetic derivative of amidine with antiprotozoal and antifungal activities.  Although the precise mode of action of pentamidine is unclear, it appears to interact directly with the pathogen genome by binding to AT-rich regions of duplex DNA and the minor groove of DNA, thereby interfering with DNA replication. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B3433CB-B5A6-3213-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-04-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BA5935F-F625-2EF6-E053-F662850A9D24","beginDate":"2020-01-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-01-09","modifiedBy":"ONEDATA","dateModified":"2020-01-09","deletedIndicator":"No"},{"value":"Varenicline","valueDescription":"Varenicline","ValueMeaning":{"publicId":"7130499","version":"1","preferredName":"Varenicline","longName":"7130499","preferredDefinition":"A partial agonist of the nicotinic acetylcholine receptor (nAChR) subtype alpha4beta2. Nicotine stimulation of central alpha4beta2 nAChRs located at presynaptic terminals in the nucleus accumbens causes the release of the neurotransmitter dopamine, which may be associated with the experience of pleasure; nicotine addiction constitutes a physiologic dependence related to this dopaminergic reward system. As an AChR partial agonist, varenicline attenuates the craving and withdrawal symptoms that occur with abstinence from nicotine but is not habit-forming itself.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Varenicline","conceptCode":"C73609","definition":"A partial agonist of the nicotinic acetylcholine receptor (nAChR) subtype alpha4beta2. Nicotine stimulation of central alpha4beta2 nAChRs located at presynaptic terminals in the nucleus accumbens causes the release of the neurotransmitter dopamine, which may be associated with the experience of pleasure; nicotine addiction constitutes a physiologic dependence related to this dopaminergic reward system. As an AChR partial agonist, varenicline attenuates the craving and withdrawal symptoms that occur with abstinence from nicotine but is not habit-forming itself.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BA5935F-F632-2EF6-E053-F662850A9D24","latestVersionIndicator":"Yes","beginDate":"2020-01-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-01-09","modifiedBy":"ONEDATA","dateModified":"2020-01-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BA5935F-F64B-2EF6-E053-F662850A9D24","beginDate":"2020-01-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-01-09","modifiedBy":"ONEDATA","dateModified":"2020-01-09","deletedIndicator":"No"},{"value":"Proparacaine","valueDescription":"Proparacaine","ValueMeaning":{"publicId":"7115562","version":"1","preferredName":"Proparacaine","longName":"7115562","preferredDefinition":"A benzoic acid derivative anesthetic agent, with local anesthetic activity. Upon administration, proparacaine stabilizes the neuronal membrane by binding to and inhibiting voltage-gated sodium channels. This inhibits the sodium ion influx required for the initiation and conduction of impulses within the neuronal cell, increases the threshold for electrical stimulation and results in a loss of sensation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Proparacaine","conceptCode":"C61910","definition":"A benzoic acid derivative anesthetic agent, with local anesthetic activity. Upon administration, proparacaine stabilizes the neuronal membrane by binding to and inhibiting voltage-gated sodium channels. This inhibits the sodium ion influx required for the initiation and conduction of impulses within the neuronal cell, increases the threshold for electrical stimulation and results in a loss of sensation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9AB128FE-001C-5B22-E053-F662850A5022","latestVersionIndicator":"Yes","beginDate":"2019-12-27","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-12-27","modifiedBy":"SOKKERL","dateModified":"2020-01-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BB76AF8-5BCF-446E-E053-F662850AFE9F","beginDate":"2020-01-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-01-09","modifiedBy":"ONEDATA","dateModified":"2020-01-09","deletedIndicator":"No"},{"value":"Povidone-Iodine","valueDescription":"Povidone-Iodine","ValueMeaning":{"publicId":"7115557","version":"1","preferredName":"Povidone-Iodine","longName":"7115557","preferredDefinition":"An iodophor solution containing a water-soluble complex of iodine and polyvinylpyrrolidone (PVP) with broad microbicidal activity. Free iodine, slowly liberated from the polyvinylpyrrolidone iodine (PVPI) complex in solution, kills eukaryotic or prokaryotic cells through iodination of lipids and oxidation of cytoplasmic and membrane compounds. This agent exhibits a broad range of microbicidal activity against bacteria, fungi, protozoa, and viruses. Slow release of iodine from the PVPI complex in solution minimizes iodine toxicity towards mammalian cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Povidone-Iodine","conceptCode":"C766","definition":"An iodophor solution containing a water-soluble complex of iodine and polyvinylpyrrolidone (PVP) with broad microbicidal activity. Free iodine, slowly liberated from the polyvinylpyrrolidone iodine (PVPI) complex in solution, kills eukaryotic or prokaryotic cells through iodination of lipids and oxidation of cytoplasmic and membrane compounds. This agent exhibits a broad range of microbicidal activity against bacteria, fungi, protozoa, and viruses. Slow release of iodine from the PVPI complex in solution minimizes iodine toxicity towards mammalian cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9AB128FD-FFAA-5B22-E053-F662850A5022","latestVersionIndicator":"Yes","beginDate":"2019-12-27","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-12-27","modifiedBy":"TAYLORT","dateModified":"2020-01-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BB94100-BBEF-5091-E053-F662850A2184","beginDate":"2020-01-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-01-09","modifiedBy":"ONEDATA","dateModified":"2020-01-09","deletedIndicator":"No"},{"value":"Ephedrine","valueDescription":"Ephedrine","ValueMeaning":{"publicId":"7115559","version":"1","preferredName":"Ephedrine","longName":"7115559","preferredDefinition":"An alkaloid that is an hydroxylated form of phenethylamineand sympathomimetic amine, with potential bronchodilatory and anti-hypotensive activities. Following administration, ephedrine activates post-synaptic noradrenergic receptors. Activation of alpha-adrenergic receptors in the vasculature induces vasoconstriction, and activation of beta-adrenergic receptors in the lungs leads to bronchodilation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ephedrine","conceptCode":"C472","definition":"An alkaloid that is an hydroxylated form of phenethylamineand sympathomimetic amine, with potential bronchodilatory and anti-hypotensive activities. Following administration, ephedrine activates post-synaptic noradrenergic receptors. Activation of alpha-adrenergic receptors in the vasculature induces vasoconstriction, and activation of beta-adrenergic receptors in the lungs leads to bronchodilation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9AB128FD-FFD0-5B22-E053-F662850A5022","latestVersionIndicator":"Yes","beginDate":"2019-12-27","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-12-27","modifiedBy":"ONEDATA","dateModified":"2019-12-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BB7FC21-6427-4A7A-E053-F662850A916F","beginDate":"2020-01-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-01-09","modifiedBy":"ONEDATA","dateModified":"2020-01-09","deletedIndicator":"No"},{"value":"Ophthalmic Solution","valueDescription":"Ophthalmic Solution","ValueMeaning":{"publicId":"2574200","version":"1","preferredName":"Ophthalmic Solution","longName":"2574200","preferredDefinition":"A sterile solution containing a particular pharmaceutical agent administered to the external eye, usually in the form of droplets. An ophthalmic solution may contain different drugs with different mechanisms of actions, to target symptoms and their underlying cause. Classes of pharmacological agents used include antibiotics, beta-adrenergic agents, antihistamines, corticosteroids and prostanoids. The ophthalmic solution can be used to treat increased intraocular pressure, symptoms of allergic conjunctivitis, and ocular bacterial infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ophthalmic Solution","conceptCode":"C29302","definition":"A sterile solution containing a substance or multiple substances administered to the external eye, usually in the form of droplets. An ophthalmic solution may contain different drugs with different mechanisms of actions, to target symptoms and their underlying cause. Classes of pharmacological agents used may include antibiotics, beta-adrenergic agents, antihistamines, corticosteroids and prostanoids. The ophthalmic solution may be used to treat increased intraocular pressure, symptoms of allergic conjunctivitis, and ocular bacterial infections, among others.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EEE5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-30","endDate":null,"createdBy":"PFOWLER","dateCreated":"2005-03-30","modifiedBy":"COOPERM","dateModified":"2019-11-18","changeDescription":"Added concept with definition. mc 11/18/19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"979F6FF7-CA3C-565F-E053-F662850A6624","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Oprelvekin","valueDescription":"Oprelvekin","ValueMeaning":{"publicId":"2664856","version":"1","preferredName":"Oprelvekin","longName":"2664856","preferredDefinition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin 11 (IL-11). Secreted by bone marrow stromal cells and a number of mesenchymal cells, IL-11 binds to and activates its cell-surface receptor, promoting primary and secondary immune responses, modulating antigen-specific antibody reactions, and preventing apoptotic cell death.  This agent also stimulates the T-cell-dependent development of IgG-secreting B-cells in spleen cell cultures and may be an important regulator of megakaryocytopoiesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oprelvekin","conceptCode":"C1303","definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin 11 (IL-11). Secreted by bone marrow stromal cells and a number of mesenchymal cells, IL-11 binds to and activates its cell-surface receptor, promoting primary and secondary immune responses, modulating antigen-specific antibody reactions, and preventing apoptotic cell death.  This agent also stimulates the T-cell-dependent development of IgG-secreting B-cells in spleen cell cultures and may be an important regulator of megakaryocytopoiesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"35A00595-9C5C-3A15-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-07-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-07-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"979F6FF7-CA47-565F-E053-F662850A6624","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Opium Tincture","valueDescription":"Opium Tincture","ValueMeaning":{"publicId":"7060424","version":"1","preferredName":"Opium Tincture","longName":"7060424","preferredDefinition":"Also known as Laudanum and formulated for oral administration, Opium tincture is made of air-dried poppy (Papaver somniferum) latex and contains alkaloids such as morphine and codeine. As an antidiarrheal agent, it slows transit of intestinal contents by increasing intestinal smooth muscle tone and inhibiting motility; water is absorbed from fecal contents, decreasing diarrhea. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Opium Tincture","conceptCode":"C29300","definition":"Also known as Laudanum and formulated for oral administration, Opium tincture is made of air-dried poppy (Papaver somniferum) latex and contains alkaloids such as morphine and codeine. As an antidiarrheal agent, it slows transit of intestinal contents by increasing intestinal smooth muscle tone and inhibiting motility; water is absorbed from fecal contents, decreasing diarrhea. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"979F6FF7-CA54-565F-E053-F662850A6624","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"979F6FF7-CA6D-565F-E053-F662850A6624","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Olopatadine HCL","valueDescription":"Olopatadine Hydrochloride","ValueMeaning":{"publicId":"7060426","version":"1","preferredName":"Olopatadine Hydrochloride","longName":"7060426","preferredDefinition":"The hydrochloride salt form of olopatadine, a dual action selective histamine H1 receptor antagonist and mast cell stabilizer with anti-allergic activity. Olopatadine stabilizes mast cells and prevents histamine release from mast cells. In addition, this agent also blocks histamine H1 receptors, thereby preventing histamine from binding to these receptors. Both actions prevent the effects of histamine on capillaries, bronchial smooth muscle, and gastrointestinal (GI) smooth muscle, including histamine-induced vasodilation, increased capillary permeability, bronchoconstriction, and spasmodic contraction of GI smooth muscle. This drug also prevents histamine-induced pain and itching of mucous membranes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Olopatadine Hydrochloride","conceptCode":"C61867","definition":"The hydrochloride salt form of olopatadine, a dual action selective histamine H1 receptor antagonist and mast cell stabilizer with anti-allergic activity. Olopatadine stabilizes mast cells and prevents histamine release from mast cells. In addition, this agent also blocks histamine H1 receptors, thereby preventing histamine from binding to these receptors. Both actions prevent the effects of histamine on capillaries, bronchial smooth muscle, and gastrointestinal (GI) smooth muscle, including histamine-induced vasodilation, increased capillary permeability, bronchoconstriction, and spasmodic contraction of GI smooth muscle. This drug also prevents histamine-induced pain and itching of mucous membranes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"979F6FF7-CA7A-565F-E053-F662850A6624","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"979F6FF7-CA93-565F-E053-F662850A6624","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Potassium gluconate","valueDescription":"Potassium Gluconate","ValueMeaning":{"publicId":"7060584","version":"1","preferredName":"Potassium Gluconate","longName":"7060584","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Potassium Gluconate","conceptCode":"C81070","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A4DC41-373A-447D-E053-F662850AC4BA","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A4DC41-3753-447D-E053-F662850AC4BA","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Potassium Citrate","valueDescription":"Potassium Citrate","ValueMeaning":{"publicId":"7060586","version":"1","preferredName":"Potassium Citrate","longName":"7060586","preferredDefinition":"The potassium salt form of citrate with alkalinizing property. Following absorption, potassium citrate causes increased plasma bicarbonate concentration, thereby raising blood and urinary pH. A simultaneous decrease in calcium ion activity occurs as a result of increasing calcium complex formation with dissociated anions. Levels of urinary citrate are increased due to modification of the renal handling of citrate. By promoting excretion of free bicarbonate ion and by increasing urinary pH in addition to an increased ionization of uric acid to more soluble urate ions, this agent exerts the alkalizing and anti-urolithic effect.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Potassium Citrate","conceptCode":"C29372","definition":"The potassium salt form of citrate, with alkalinizing activity and that can be used for potassium supplementation. Upon oral administration, potassium citrate provides potassium. Potassium maintains normal fluid and electrolyte balance, regulates the proper functioning of heart and muscle contractions, supports healthy bone density and blood pressure. It also plays an important role in the transmission of nerve impulses and energy production. Amino acid chelated minerals are highly bioavailable and better absorbed than non-amino acid-chelated minerals. Potassium citrate also causes increased plasma bicarbonate concentration, thereby raising blood and urinary pH. A simultaneous decrease in calcium ion activity occurs as a result of increasing calcium complex formation with dissociated anions. Levels of urinary citrate are increased due to modification of the renal handling of citrate. By promoting excretion of free bicarbonate ion and by increasing urinary pH in addition to an increased ionization of uric acid to more soluble urate ions, this agent exerts alkalizing and anti-urolithic effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A4DC41-3760-447D-E053-F662850AC4BA","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A4DC41-3779-447D-E053-F662850AC4BA","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Posaconazole","valueDescription":"Posaconazole","ValueMeaning":{"publicId":"2794973","version":"1","preferredName":"Posaconazole","longName":"2794973","preferredDefinition":"A broad-spectrum, second generation, triazole compound with antifungal activity. Posaconazole strongly inhibits 14-alpha demethylase, a cytochrome P450-dependent enzyme. Inhibition of 14-alpha-demethylase prevents the conversion of lanosterol to ergosterol, an important component of the fungal cell wall. Inhibition of ergosterol synthesis changes the fungal cell membrane composition and integrity, alters membrane permeability and eventually leads to fungal cell lysis. Compared to other azole antifungals, posaconazole is a significantly more potent inhibitor of sterol 14-alpha demethylase.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Posaconazole","conceptCode":"C61500","definition":"A broad-spectrum, second generation, triazole compound with antifungal activity. Posaconazole strongly inhibits 14-alpha demethylase, a cytochrome P450-dependent enzyme. Inhibition of 14-alpha-demethylase prevents the conversion of lanosterol to ergosterol, an important component of the fungal cell wall. Inhibition of ergosterol synthesis changes the fungal cell membrane composition and integrity, alters membrane permeability and eventually leads to fungal cell lysis. Compared to other azole antifungals, posaconazole is a significantly more potent inhibitor of sterol 14-alpha demethylase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A01A143-F070-52D0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A4DC41-3783-447D-E053-F662850AC4BA","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Primidone (Mysoline)","valueDescription":"Primidone","ValueMeaning":{"publicId":"5625811","version":"1","preferredName":"Primidone","longName":"5625811","preferredDefinition":"An analog of phenobarbital with antiepileptic property. Although the mechanism of action has not been fully elucidated, primidone probably exerts its actions, in a manner similar to phenobarbital, via activation of gamma-aminobutyric acid (GABA)-A receptor/chloride ionophore complex, which leads to prolonged and increased frequency of opening of the chloride channel within the receptor complex. This results in an alteration in the electrical activity of the nerve cell membrane, causing hyperpolarization and prevention of partial and tonic-clonic seizures. In addition, this agent is partially metabolized to phenobarbital and phenylethylmalonamide (PEMA), which may also contribute to its anti-seizure properties.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primidone","conceptCode":"C47686","definition":"An analog of phenobarbital with antiepileptic property. Although the mechanism of action has not been fully elucidated, primidone probably exerts its actions, in a manner similar to phenobarbital, via activation of gamma-aminobutyric acid (GABA)-A receptor/chloride ionophore complex, which leads to prolonged and increased frequency of opening of the chloride channel within the receptor complex. This results in an alteration in the electrical activity of the nerve cell membrane, causing hyperpolarization and prevention of partial and tonic-clonic seizures. In addition, this agent is partially metabolized to phenobarbital and phenylethylmalonamide (PEMA), which may also contribute to its anti-seizure properties.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45D958C0-7D8D-5173-E053-F662850AAAF2","latestVersionIndicator":"Yes","beginDate":"2017-01-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A39E9F-9A2A-4341-E053-F662850A0D2A","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Primaquine","valueDescription":"Primaquine","ValueMeaning":{"publicId":"7060588","version":"1","preferredName":"Primaquine","longName":"7060588","preferredDefinition":"A synthetic, 8-aminoquinoline derivative with antimalarial properties.  Although its mechanism of action is unclear, primaquine bind to and alter the properties of protozoal DNA.  This agent eliminates tissue (exo-erythrocytic) malarial infection, preventing the development of the erythrocytic forms of the parasite which are responsible for relapses in Plasmodium vivax and ovale malaria.  Primaquine is active against late hepatic stages (hypnozoites, schizonts). (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primaquine","conceptCode":"C62071","definition":"A synthetic, 8-aminoquinoline derivative with antimalarial properties.  Although its mechanism of action is unclear, primaquine bind to and alter the properties of protozoal DNA.  This agent eliminates tissue (exo-erythrocytic) malarial infection, preventing the development of the erythrocytic forms of the parasite which are responsible for relapses in Plasmodium vivax and ovale malaria.  Primaquine is active against late hepatic stages (hypnozoites, schizonts). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A39E9F-9A38-4341-E053-F662850A0D2A","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A39E9F-9A51-4341-E053-F662850A0D2A","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Preparation H","valueDescription":"Anti-hemorrhoidal Formulation","ValueMeaning":{"publicId":"7060590","version":"1","preferredName":"Anti-hemorrhoidal Formulation","longName":"7060590","preferredDefinition":"A brand of combination medications, by Wyeth Pharmaceuticals, used in the treatment of hemorrhoids. Preparation H is used to relieve pain, swelling and pruritis, as well as, to soothe and protect the hemorrhoidal tissue. Preparation H products are formulated as a cream, ointment, cooling gel, suppositories and witch hazel wipes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-hemorrhoidal Formulation","conceptCode":"C29378","definition":"A brand of combination medications, by Wyeth Pharmaceuticals, used in the treatment of hemorrhoids. Preparation H is used to relieve pain, swelling and pruritis, as well as, to soothe and protect the hemorrhoidal tissue. Preparation H products are formulated as a cream, ointment, cooling gel, suppositories and witch hazel wipes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A39E9F-9A5E-4341-E053-F662850A0D2A","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A39E9F-9A77-4341-E053-F662850A0D2A","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Prempro","valueDescription":"Conjugated Estrogen/Medroxyprogesterone-containing Formulation","ValueMeaning":{"publicId":"7060592","version":"1","preferredName":"Conjugated Estrogen/Medroxyprogesterone-containing Formulation","longName":"7060592","preferredDefinition":"A combination preparation of conjugated estrogens, including sodium estrone sulfate, sodium equilin sulfate, and the progestin medroxyprogesterone acetate. The conjugated estrogens increase the diminishing levels of estrogen in menopausal and postmenopausal women. Maintaining adequate estrogen levels decreases symptoms such as hot flashes, night sweats, irregular menstruation, fat redistribution, mood swings, sleep disorders, vaginal dryness and osteoporosis. Medroxyprogesterone acetate is added to prevent endometrial proliferation and a subsequent elevated risk of estrogen-induced endometrial cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Conjugated Estrogen/Medroxyprogesterone-containing Formulation","conceptCode":"C29377","definition":"A combination preparation of conjugated estrogens, including sodium estrone sulfate, sodium equilin sulfate, and the progestin medroxyprogesterone acetate. The conjugated estrogens increase the diminishing levels of estrogen in menopausal and postmenopausal women. Maintaining adequate estrogen levels decreases symptoms such as hot flashes, night sweats, irregular menstruation, fat redistribution, mood swings, sleep disorders, vaginal dryness and osteoporosis. Medroxyprogesterone acetate is added to prevent endometrial proliferation and a subsequent elevated risk of estrogen-induced endometrial cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A39E9F-9A84-4341-E053-F662850A0D2A","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A39E9F-9A9D-4341-E053-F662850A0D2A","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Premarin","valueDescription":"Estrogens, Conjugated","ValueMeaning":{"publicId":"6148658","version":"1","preferredName":"Estrogens, Conjugated","longName":"6148658","preferredDefinition":"Purified orally bioavailable female sex hormones isolated from pregnant mare urine or synthetically derived from plant materials and primarily conjugated as sulfate esters. Estrogen binds to and activates specific nuclear receptors, which, in turn, bind to estrogen response elements (EREs) in target genes, resulting in histone acetylation, alteration of chromatin conformation, and initiation of transcription. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Estrogens, Conjugated","conceptCode":"C482","definition":"Purified orally bioavailable female sex hormones isolated from pregnant mare urine or synthetically derived from plant materials and primarily conjugated as sulfate esters. Estrogen binds to and activates specific nuclear receptors, which, in turn, bind to estrogen response elements (EREs) in target genes, resulting in histone acetylation, alteration of chromatin conformation, and initiation of transcription. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"683B72D8-17EC-2741-E053-F662850AA7F3","latestVersionIndicator":"Yes","beginDate":"2018-03-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-25","modifiedBy":"ONEDATA","dateModified":"2018-03-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A39E9F-9AB1-4341-E053-F662850A0D2A","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Pregabalin","valueDescription":"Pregabalin","ValueMeaning":{"publicId":"3835527","version":"1","preferredName":"Pregabalin","longName":"3835527","preferredDefinition":"A 3-isobutyl derivative of gamma-amino butyric acid (GABA) with anti-convulsant, anti-epileptic, anxiolytic, and analgesic activities. Although the exact mechanism of action is unknown, pregabalin selectively binds to alpha2delta (A2D) subunits of presynaptic voltage-dependent calcium channels (VDCCs) located in the central nervous system (CNS). Binding of pregabalin to VDCC A2D subunits prevents calcium influx and the subsequent calcium-dependent release of various neurotransmitters, including glutamate, norepinephrine, serotonin, dopamine, and substance P, from the presynaptic nerve terminals of hyperexcited neurons; synaptic transmission is inhibited and neuronal excitability is diminished. Pregabalin does not bind directly to GABA-A or GABA-B receptors and does not alter GABA uptake or degradation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pregabalin","conceptCode":"C64625","definition":"A 3-isobutyl derivative of gamma-amino butyric acid (GABA) with anti-convulsant, anti-epileptic, anxiolytic, and analgesic activities. Although the exact mechanism of action is unknown, pregabalin selectively binds to alpha2delta (A2D) subunits of presynaptic voltage-dependent calcium channels (VDCCs) located in the central nervous system (CNS). Binding of pregabalin to VDCC A2D subunits prevents calcium influx and the subsequent calcium-dependent release of various neurotransmitters, including glutamate, norepinephrine, serotonin, dopamine, and substance P, from the presynaptic nerve terminals of hyperexcited neurons; synaptic transmission is inhibited and neuronal excitability is diminished. Pregabalin does not bind directly to GABA-A or GABA-B receptors and does not alter GABA uptake or degradation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E2D696CA-9334-9226-E040-BB89AD4309FC","latestVersionIndicator":"Yes","beginDate":"2013-07-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-07-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A39E9F-9ABB-4341-E053-F662850A0D2A","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Pravastatin","valueDescription":"Pravastatin","ValueMeaning":{"publicId":"3379491","version":"1","preferredName":"Pravastatin","longName":"3379491","preferredDefinition":"A synthetic lipid-lowering agent. Pravastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. Pravastatin lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pravastatin","conceptCode":"C62070","definition":"A synthetic lipid-lowering agent. Pravastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. Pravastatin lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-264A-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A39E9F-9AC5-4341-E053-F662850A0D2A","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Pramipexole Dihydrochloride","valueDescription":"Pramipexole Dihydrochloride","ValueMeaning":{"publicId":"7060594","version":"1","preferredName":"Pramipexole Dihydrochloride","longName":"7060594","preferredDefinition":"The hydrochloride salt of pramipexole, a benzothiazole derivative. As a nonergot dopamine agonist, pramipexole binds to D2 and D3 dopamine receptors in the striatum and substantia nigra of the brain. Compared to other dopamine agonists, the use of this agent may be associated with fewer dyskinetic side effects in treated subjects. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pramipexole Dihydrochloride","conceptCode":"C29374","definition":"The hydrochloride salt of pramipexole, a benzothiazole derivative. As a nonergot dopamine agonist, pramipexole binds to D2 and D3 dopamine receptors in the striatum and substantia nigra of the brain. Compared to other dopamine agonists, the use of this agent may be associated with fewer dyskinetic side effects in treated subjects. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A39E9F-9AD2-4341-E053-F662850A0D2A","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A39E9F-9AEB-4341-E053-F662850A0D2A","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"PPD","valueDescription":"Purified Protein Derivative","ValueMeaning":{"publicId":"2585787","version":"1","preferredName":"Purified Protein Derivative","longName":"2585787","preferredDefinition":"A purified protein extract derived from the bacterium Mycobacterium tuberculosis. Intradermally-administered, PPD stimulates preprimed CD4 T cells in immunologically competent subjects previously exposed to the bacterium Mycobacterium tuberculosis; these activated CD4 T cells secrete various cytokines that attract granulocytes, monocytes, and macrophages in an inflammatory response known as delayed hypersensitivity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Purified Protein Derivative","conceptCode":"C29329","definition":"A purified protein extract derived from the bacterium Mycobacterium tuberculosis. Intradermally-administered, PPD stimulates preprimed CD4 T cells in immunologically competent subjects previously exposed to the bacterium Mycobacterium tuberculosis; these activated CD4 T cells secrete various cytokines that attract granulocytes, monocytes, and macrophages in an inflammatory response known as delayed hypersensitivity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"26B7D4AD-FE8D-162C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2007-01-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A39E9F-9AF5-4341-E053-F662850A0D2A","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Potassium phosphate","valueDescription":"Potassium Phosphate","ValueMeaning":{"publicId":"7060595","version":"1","preferredName":"Potassium Phosphate","longName":"7060595","preferredDefinition":"An inorganic compound used as a laxative, dietary supplement and for electrolyte-replacement purposes. Phosphate, a predominant intracellular anion, plays an important role in energy storage, osteoblastic and osteoclastic activities, regulating serum calcium concentrations and numerous cellular phosphate-transfer reactions. Potassium phosphate increases fluidity of the intestinal contents by retention of water by osmotic forces, thereby indirectly inducing intestinal smooth muscle constriction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Potassium Phosphate","conceptCode":"C29373","definition":"An inorganic compound used as a laxative, dietary supplement and for electrolyte-replacement purposes. Phosphate, a predominant intracellular anion, plays an important role in energy storage, osteoblastic and osteoclastic activities, regulating serum calcium concentrations and numerous cellular phosphate-transfer reactions. Potassium phosphate increases fluidity of the intestinal contents by retention of water by osmotic forces, thereby indirectly inducing intestinal smooth muscle constriction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A39E9F-9B00-4341-E053-F662850A0D2A","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A39E9F-9B19-4341-E053-F662850A0D2A","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Ryna-12 S","valueDescription":"Phenylephrine Tannate and Pyrilamine Tannate","ValueMeaning":{"publicId":"7063342","version":"1","preferredName":"Phenylephrine Tannate and Pyrilamine Tannate","longName":"7063342","preferredDefinition":"An antihistamine/nasal decongestant combination used for symptomatic relief of the coryza and nasal congestion associated with the common cold, sinusitis, allergic rhinitis and other upper respiratory tract conditions.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97D08F32-9B81-20A7-E053-F662850A5238","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97D08F32-9B9A-20A7-E053-F662850A5238","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Roxithromycin","valueDescription":"Roxithromycin","ValueMeaning":{"publicId":"7063344","version":"1","preferredName":"Roxithromycin","longName":"7063344","preferredDefinition":"A semi-synthetic derivative of the macrolide antibiotic erythromycin that includes an N-oxime side chain on the lactone ring, with antibacterial and anti-malarial activities. Roxithromycin binds to the subunit 50S of the bacterial ribosome, which inhibits bacterial protein synthesis and leads to inhibition of bacterial cell growth and replication.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Roxithromycin","conceptCode":"C818","definition":"A semi-synthetic derivative of the macrolide antibiotic erythromycin that includes an N-oxime side chain on the lactone ring, with antibacterial and anti-malarial activities. Roxithromycin binds to the subunit 50S of the bacterial ribosome, which inhibits bacterial protein synthesis and leads to inhibition of bacterial cell growth and replication.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97D08F32-9BA7-20A7-E053-F662850A5238","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97D08F32-9BC0-20A7-E053-F662850A5238","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Rosuvastatin","valueDescription":"Rosuvastatin","ValueMeaning":{"publicId":"2573145","version":"1","preferredName":"Rosuvastatin","longName":"2573145","preferredDefinition":"A statin with antilipidemic and potential antineoplastic activities. Rosuvastatin selectively and competitively binds to and inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a precursor of cholesterol. This leads to a decrease in hepatic cholesterol levels and increase in uptake of LDL cholesterol. In addition, rosuvastatin, like other statins, exhibits pro-apoptotic, growth inhibitory, and pro-differentiation activities in a variety of tumor cell types; these antineoplastic activities may be due, in part, to inhibition of the isoprenylation of Ras and Rho GTPases and related signaling cascades.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rosuvastatin","conceptCode":"C66523","definition":"A statin with antilipidemic and potential antineoplastic activities. Rosuvastatin selectively and competitively binds to and inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a precursor of cholesterol. This leads to a decrease in hepatic cholesterol levels and increase in uptake of LDL cholesterol. In addition, rosuvastatin, like other statins, exhibits pro-apoptotic, growth inhibitory, and pro-differentiation activities in a variety of tumor cell types; these antineoplastic activities may be due, in part, to inhibition of the isoprenylation of Ras and Rho GTPases and related signaling cascades.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EAC6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-02-09","modifiedBy":"COOPERM","dateModified":"2019-11-20","changeDescription":"Added concept and definition. mc 11/20/19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97D08F32-9BD4-20A7-E053-F662850A5238","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Rosiglitazone","valueDescription":"Rosiglitazone","ValueMeaning":{"publicId":"7063346","version":"1","preferredName":"Rosiglitazone","longName":"7063346","preferredDefinition":"An agent belonging to the glitazone class of antidiabetic agents with antihyperglycemic and anti-inflammatory activities. In addition to its selective affinity for peroxisome proliferator-activated receptor (PPAR) gamma and its ability to lower blood glucose levels, rosiglitazone also exerts anti-inflammatory activity through its ability to inhibit nuclear factor-kappaB (NF-KB) activity and increase I-kappaB levels. In addition, rosiglitazone may cause fluid retention and may worsen congestive heart failure. This agent is also associated with an increased risk of heart attacks.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rosiglitazone","conceptCode":"C62076","definition":"An agent belonging to the glitazone class of antidiabetic agents with antihyperglycemic and anti-inflammatory activities. In addition to its selective affinity for peroxisome proliferator-activated receptor (PPAR) gamma and its ability to lower blood glucose levels, rosiglitazone also exerts anti-inflammatory activity through its ability to inhibit nuclear factor-kappaB (NF-KB) activity and increase I-kappaB levels. In addition, rosiglitazone may cause fluid retention and may worsen congestive heart failure. This agent is also associated with an increased risk of heart attacks.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97D08F32-9BE1-20A7-E053-F662850A5238","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97D08F32-9BFA-20A7-E053-F662850A5238","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Rosemary","valueDescription":"Rosemary Oil","ValueMeaning":{"publicId":"7063348","version":"1","preferredName":"Rosemary Oil","longName":"7063348","preferredDefinition":"The essential oil of Rosmarinus officinalis. Rosemary oil is used primarily for its aromatic properties.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rosemary Oil","conceptCode":"C107360","definition":"The essential oil of Rosmarinus officinalis. Rosemary oil is used primarily for its aromatic properties.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97D08F32-9C07-20A7-E053-F662850A5238","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97D08F32-9C20-20A7-E053-F662850A5238","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Ropivacaine HCL","valueDescription":"Ropivacaine Hydrochloride","ValueMeaning":{"publicId":"7063350","version":"1","preferredName":"Ropivacaine Hydrochloride","longName":"7063350","preferredDefinition":"The hydrochloride salt of ropivacaine, a local anesthetic of the amide type with analgesic activity. Ropivacaine binds to voltage-gated sodium ion channels in the neuronal membrane, thereby preventing the permeability of sodium ions and resulting in a stabilization of the neuronal membrane and inhibition of depolarization; nerve impulse generation and propagation are blocked, resulting in a reversible loss of sensation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ropivacaine Hydrochloride","conceptCode":"C52198","definition":"The hydrochloride salt of ropivacaine, a local anesthetic of the amide type with analgesic activity. Ropivacaine binds to voltage-gated sodium ion channels in the neuronal membrane, thereby preventing the permeability of sodium ions and resulting in a stabilization of the neuronal membrane and inhibition of depolarization; nerve impulse generation and propagation are blocked, resulting in a reversible loss of sensation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97D08F32-9C2D-20A7-E053-F662850A5238","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97D08F32-9C46-20A7-E053-F662850A5238","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Ropinirole HCL","valueDescription":"Ropinirole Hydrochloride","ValueMeaning":{"publicId":"7063352","version":"1","preferredName":"Ropinirole Hydrochloride","longName":"7063352","preferredDefinition":"The hydrochloride salt form of ropinirole, a non-ergot dopamine agonist with antiparkinsonian property. Acting as a substitute for dopamine, ropinirole hydrochloride binds to and activates dopamine D2 and D3 receptors within the caudate putamen in the brain, thereby improving motor function.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ropinirole Hydrochloride","conceptCode":"C47710","definition":"The hydrochloride salt form of ropinirole, a non-ergot dopamine agonist with antiparkinsonian property. Acting as a substitute for dopamine, ropinirole hydrochloride binds to and activates dopamine D2 and D3 receptors within the caudate putamen in the brain, thereby improving motor function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97D08F32-9C53-20A7-E053-F662850A5238","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97D08F32-9C6C-20A7-E053-F662850A5238","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Rofecoxib","valueDescription":"Rofecoxib","ValueMeaning":{"publicId":"7063354","version":"1","preferredName":"Rofecoxib","longName":"7063354","preferredDefinition":"A synthetic, nonsteroidal derivative of phenyl-furanone with antiinflammatory, antipyretic and analgesic properties and potential antineoplastic properties.  Rofecoxib binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in an inhibition of the conversion of arachidonic acid to prostaglandins.  COX-related metabolic pathways may represent key regulators of cell proliferation and neo-angiogenesis. Some epithelial tumor cell types overexpress pro-angiogenic COX-2. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rofecoxib","conceptCode":"C1832","definition":"A synthetic, nonsteroidal derivative of phenyl-furanone with antiinflammatory, antipyretic and analgesic properties and potential antineoplastic properties.  Rofecoxib binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in an inhibition of the conversion of arachidonic acid to prostaglandins.  COX-related metabolic pathways may represent key regulators of cell proliferation and neo-angiogenesis. Some epithelial tumor cell types overexpress pro-angiogenic COX-2. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97D08F32-9C79-20A7-E053-F662850A5238","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97D08F32-9C92-20A7-E053-F662850A5238","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Rocuronium","valueDescription":"Rocuronium bromide","ValueMeaning":{"publicId":"7063355","version":"1","preferredName":"Rocuronium bromide","longName":"7063355","preferredDefinition":"An aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia to facilitate tracheal intubation by providing skeletal muscle relaxation, most commonly required for surgery or mechanical ventilation.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97D08F32-9C9C-20A7-E053-F662850A5238","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97D08F32-9CB5-20A7-E053-F662850A5238","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Rizatriptan Benzoate","valueDescription":"Rizatriptan Benzoate","ValueMeaning":{"publicId":"7063357","version":"1","preferredName":"Rizatriptan Benzoate","longName":"7063357","preferredDefinition":"The benzoate salt form of rizatriptan, a member of the triptan class agents with anti-migraine property. Rizatriptan benzoate selectively binds to and activates serotonin (5-HT) 1B receptors expressed in intracranial arteries, and to 5-HT 1D receptors located on peripheral trigeminal sensory nerve terminals in the meninges and central terminals in brain stem sensory nuclei. Receptor binding results in constriction of cranial vessels and inhibition of nociceptive transmission, thereby providing relief of migraine headaches. Rizatriptan benzoate may also relief migraine headaches by inhibition of pro-inflammatory neuropeptide release.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rizatriptan Benzoate","conceptCode":"C47708","definition":"The benzoate salt form of rizatriptan, a member of the triptan class agents with anti-migraine property. Rizatriptan benzoate selectively binds to and activates serotonin (5-HT) 1B receptors expressed in intracranial arteries, and to 5-HT 1D receptors located on peripheral trigeminal sensory nerve terminals in the meninges and central terminals in brain stem sensory nuclei. Receptor binding results in constriction of cranial vessels and inhibition of nociceptive transmission, thereby providing relief of migraine headaches. Rizatriptan benzoate may also relief migraine headaches by inhibition of pro-inflammatory neuropeptide release.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97D08F32-9CC2-20A7-E053-F662850A5238","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97D08F32-9CDB-20A7-E053-F662850A5238","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Rituximab","valueDescription":"Rituximab","ValueMeaning":{"publicId":"5127434","version":"1","preferredName":"Rituximab","longName":"5127434","preferredDefinition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rituximab","conceptCode":"C1702","definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FBA0-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97D08F32-9CE5-20A7-E053-F662850A5238","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Ritonavir","valueDescription":"Ritonavir","ValueMeaning":{"publicId":"2575709","version":"1","preferredName":"Ritonavir","longName":"2575709","preferredDefinition":"A peptidomimetic agent that inhibits both HIV-1 and HIV-2 proteases. Ritonavir is highly inhibited by serum proteins but boosts the effect of other HIV proteases by blocking their degradation by cytochrome P450.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ritonavir","conceptCode":"C1609","definition":"A peptidomimetic agent that inhibits both HIV-1 and HIV-2 proteases. Ritonavir is highly inhibited by serum proteins but boosts the effect of other HIV proteases by blocking their degradation by cytochrome P450.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4CA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"COOPERM","dateModified":"2019-11-20","changeDescription":"Updated definition with current NCIt. mc 11/20/19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97D08F32-9CEF-20A7-E053-F662850A5238","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Risperidone","valueDescription":"Risperidone","ValueMeaning":{"publicId":"7063359","version":"1","preferredName":"Risperidone","longName":"7063359","preferredDefinition":"A benzisoxazole derivative with antipsychotic property. Risperidone selectively antagonizes serotonin (5-HT) effects via cortical 5-HT2 receptor, and, to a lesser extent, competes with dopamine at the limbic dopamine D2 receptor. The antagonism leads to decreased psychotic effects, such as hallucinations and delusions. In addition, risperidone has low to moderate affinity for histamine H1, 5-HT1A, 5-HT1C, and 5-HT1D receptors, while it has weak affinity for dopamine D1 and haloperidol-sensitive sigma site receptors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Risperidone","conceptCode":"C29416","definition":"A benzisoxazole derivative with antipsychotic property. Risperidone selectively antagonizes serotonin (5-HT) effects via cortical 5-HT2 receptor, and, to a lesser extent, competes with dopamine at the limbic dopamine D2 receptor. The antagonism leads to decreased psychotic effects, such as hallucinations and delusions. In addition, risperidone has low to moderate affinity for histamine H1, 5-HT1A, 5-HT1C, and 5-HT1D receptors, while it has weak affinity for dopamine D1 and haloperidol-sensitive sigma site receptors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97D08F32-9CFC-20A7-E053-F662850A5238","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97D08F32-9D15-20A7-E053-F662850A5238","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Risedronate Sodium","valueDescription":"Risedronate Sodium","ValueMeaning":{"publicId":"5709611","version":"1","preferredName":"Risedronate Sodium","longName":"5709611","preferredDefinition":"The sodium salt of risedronic acid, a synthetic pyridinyl bisphosphonate. Risedronic acid binds to hydroxyapatite crystals in bone and inhibits osteoclast-dependent bone resorption.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Risedronate Sodium","conceptCode":"C1528","definition":"The sodium salt of risedronic acid, a synthetic pyridinyl bisphosphonate. Risedronic acid binds to hydroxyapatite crystals in bone and inhibits osteoclast-dependent bone resorption.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AA0A7DB-1CE4-7C8E-E053-F662850A3136","latestVersionIndicator":"Yes","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"ZHANGWE","dateModified":"2021-09-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97D08F32-9D29-20A7-E053-F662850A5238","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Rifampin","valueDescription":"Rifampin","ValueMeaning":{"publicId":"2575708","version":"1","preferredName":"Rifampin","longName":"2575708","preferredDefinition":"A semisynthetic derivative of rifamycin with broad antibacterial activity. Rifampin inhibits DNA-dependent RNA polymerase in susceptible bacteria and is often used in combination with other antibiotics for various infections including tuberculosis. ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rifampin","conceptCode":"C811","definition":"A semisynthetic derivative of rifamycin with broad antibacterial activity. Rifampin inhibits DNA-dependent RNA polymerase in susceptible bacteria and is often used in combination with other antibiotics for various infections including tuberculosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4C9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"COOPERM","dateModified":"2019-11-20","changeDescription":"Updated definition with current NCIt. mc 11/20/19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97D08F32-9D59-20A7-E053-F662850A5238","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Rifaximin","valueDescription":"Rifaximin","ValueMeaning":{"publicId":"7063361","version":"1","preferredName":"Rifaximin","longName":"7063361","preferredDefinition":"An orally administered, semi-synthetic, nonsystemic antibiotic derived from rifamycin SV with antibacterial activity. Rifaximin binds to the beta-subunit of bacterial DNA-dependent RNA polymerase, inhibiting bacterial RNA synthesis and bacterial cell growth. As rifaximin is not well absorbed, its antibacterial activity is largely localized to the gastrointestinal tract.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rifaximin","conceptCode":"C61926","definition":"An orally administered, semi-synthetic, nonsystemic antibiotic derived from rifamycin SV with antibacterial activity. Rifaximin binds to the beta-subunit of bacterial DNA-dependent RNA polymerase, inhibiting bacterial RNA synthesis and bacterial cell growth. As rifaximin is not well absorbed, its antibacterial activity is largely localized to the gastrointestinal tract.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97D08F32-9D36-20A7-E053-F662850A5238","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97D08F32-9D4F-20A7-E053-F662850A5238","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Rifabutin","valueDescription":"Rifabutin","ValueMeaning":{"publicId":"2575707","version":"1","preferredName":"Rifabutin","longName":"2575707","preferredDefinition":"A semisynthetic ansamycin antibiotic with potent antimycobacterial properties.  Rifabutin inhibits bacterial DNA-dependent RNA polymerase, thereby suppressing the initiation of RNA formation and leading to inhibition of RNA synthesis and transcription. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rifabutin","conceptCode":"C1408","definition":"A semisynthetic ansamycin antibiotic with potent antimycobacterial properties.  Rifabutin inhibits bacterial DNA-dependent RNA polymerase, thereby suppressing the initiation of RNA formation and leading to inhibition of RNA synthesis and transcription. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4C8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97D08F32-9D63-20A7-E053-F662850A5238","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Ribavirin","valueDescription":"Ribavirin","ValueMeaning":{"publicId":"5633390","version":"1","preferredName":"Ribavirin","longName":"5633390","preferredDefinition":"A synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses. Ribavirin is incorporated into viral RNA, thereby inhibiting viral RNA synthesis, inducing viral genome mutations, and inhibiting normal viral replication.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ribavirin","conceptCode":"C807","definition":"A synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses. Ribavirin is incorporated into viral RNA, thereby inhibiting viral RNA synthesis, inducing viral genome mutations, and inhibiting normal viral replication.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46EDA67D-D730-41DC-E053-F662850A0513","latestVersionIndicator":"Yes","beginDate":"2017-01-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-01-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97D08F32-9D6D-20A7-E053-F662850A5238","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"RHO (D) immune globulin","valueDescription":"Human Rho(D) Immune Globulin","ValueMeaning":{"publicId":"7063363","version":"1","preferredName":"Human Rho(D) Immune Globulin","longName":"7063363","preferredDefinition":"An immunoglobulin blood product given to the pregnant mother that helps to prevent the Rh negative mother from developing an antibody response to the Rh positive blood cells of the fetus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Human Rho(D) Immune Globulin","conceptCode":"C80832","definition":"A preparation of immunoglobulin G (IgG) antibodies against Rho(D) antigen (anti-RhD; anti-Rho(D); anti-Rhesus factor; anti-Rh; anti-D), manufactured from pools of human donor plasma containing anti-D, that can be used in the prevention of an immune response and suppression of Rhesus (Rh) immunization to Rho(D)-positive blood in people with an Rho(D)-negative blood type during pregnancy or transfusion with Rho(D)-positive red blood cells (RBCs). Upon intravenous or intramuscular administration, human Rho(D) immune globulin provides Rho(D) antibodies against Rho(D) antigens which suppresses Rh isoimmunization. By providing sufficient anti-Rho(D) antibodies, human anti-Rho(D) immune globulin accelerates the phagocytosis of Rho(D)-positive RBCs, which clears these RBCs from the circulation. This prevents the recognition of Rho(D)-positive RBCs by the immune system and the subsequent formation of anti-Rho(D) antibodies in individuals with Rh-negative blood after exposure to Rh-positive RBCs. This prevents the production of alloantibodies to paternally inherited RhD antigen expressed on fetal erythrocytes in Rho-negative mothers and prevents hemolytic diseases in newborns. Rho(D) immune globulin increases platelet counts and reduces bleeding in Rho-positive patients with immune thrombocytopenic purpura (ITP) by inhibiting autoantibody-mediated platelet clearance. A Rh-negative person can be exposed to Rh-positive blood through a mismatched blood transfusion or during pregnancy when the baby has the opposite blood type.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97D08F32-9D7B-20A7-E053-F662850A5238","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97D08F32-9D94-20A7-E053-F662850A5238","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"rhGH","valueDescription":"Somatropin","ValueMeaning":{"publicId":"3378837","version":"1","preferredName":"Somatropin","longName":"3378837","preferredDefinition":"A recombinant form of endogenous human growth hormone (GH), a polypeptide produced by the anterior lobe of the human pituitary gland. GH exhibits growth-promoting effects and metabolic effects on carbohydrate, fat, protein and bone metabolism. GH stimulates protein synthesis and the uptake of amino acids into cells, and induces lipolysis in adipose tissues. The secretion of GH increases with sexual maturation and then declines steadily.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Somatropin","conceptCode":"C837","definition":"A recombinant form of endogenous human growth hormone (GH), a polypeptide produced by the anterior lobe of the human pituitary gland. GH exhibits growth-promoting effects and metabolic effects on carbohydrate, fat, protein and bone metabolism. GH stimulates protein synthesis and the uptake of amino acids into cells, and induces lipolysis in adipose tissues. The secretion of GH increases with sexual maturation and then declines steadily.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-1746-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97D08F32-9D9E-20A7-E053-F662850A5238","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Replens","valueDescription":"Polycarbophil/Carbomer/Glycerin/Palm Oil Glyceride/Mineral Oil-containing Vaginal Moisturizer","ValueMeaning":{"publicId":"7063365","version":"1","preferredName":"Polycarbophil/Carbomer/Glycerin/Palm Oil Glyceride/Mineral Oil-containing Vaginal Moisturizer","longName":"7063365","preferredDefinition":"A commercial combination preparation that contains an adhesive polycarbophil polymer, which is used for vaginal lubrication. Polycarbophil is an insoluble compound that absorbs water and, after topical administration, adheres to vaginal epithelial cells. As a result, it helps both moisturize vaginal tissue and relieve the discomfort that is associated with vaginal dryness.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polycarbophil/Carbomer/Glycerin/Palm Oil Glyceride/Mineral Oil-containing Vaginal Moisturizer","conceptCode":"C29414","definition":"A commercial combination preparation that contains an adhesive polycarbophil polymer, which is used for vaginal lubrication. Polycarbophil is an insoluble compound that absorbs water and, after topical administration, adheres to vaginal epithelial cells. As a result, it helps both moisturize vaginal tissue and relieve the discomfort that is associated with vaginal dryness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97D08F32-9DAB-20A7-E053-F662850A5238","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97D08F32-9DC4-20A7-E053-F662850A5238","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Repaglinide","valueDescription":"Repaglinide","ValueMeaning":{"publicId":"7063367","version":"1","preferredName":"Repaglinide","longName":"7063367","preferredDefinition":"A nonsulfonylurea insulin secretagogue belonging to the melgitinide class with hypoglycemic activity. Repaglinide is rapidly absorbed and has a rapid onset and short duration of action. This agent is metabolized in the liver by CYP2C8 and CYP3A4 and its metabolites are excreted in the bile. Repaglinide has a half-life of one hour.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Repaglinide","conceptCode":"C47703","definition":"A nonsulfonylurea insulin secretagogue belonging to the melgitinide class with hypoglycemic activity. Repaglinide is rapidly absorbed and has a rapid onset and short duration of action. This agent is metabolized in the liver by CYP2C8 and CYP3A4 and its metabolites are excreted in the bile. Repaglinide has a half-life of one hour.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97D08F32-9DD1-20A7-E053-F662850A5238","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97D08F32-9DEA-20A7-E053-F662850A5238","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Remifentanil HCL","valueDescription":"Remifentanil Hydrochloride","ValueMeaning":{"publicId":"7063369","version":"1","preferredName":"Remifentanil Hydrochloride","longName":"7063369","preferredDefinition":"The hydrochloride salt form of remifentanil, a synthetic anilidopiperidine derivative and short-acting opiate agonist with analgesic and anesthetic properties. Remifentanil selectively binds to and activates the mu-opioid receptor, thereby producing analgesia, respiratory depression, miosis, reduced gastrointestinal motility, and euphoria.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Remifentanil Hydrochloride","conceptCode":"C47702","definition":"The hydrochloride salt form of remifentanil, a synthetic anilidopiperidine derivative and short-acting opiate agonist with analgesic and anesthetic properties. Remifentanil selectively binds to and activates the mu-opioid receptor, thereby producing analgesia, respiratory depression, miosis, reduced gastrointestinal motility, and euphoria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97D08F32-9DF7-20A7-E053-F662850A5238","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97D08F32-9E10-20A7-E053-F662850A5238","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Refresh PM Lubricant","valueDescription":"Mineral Oil/Petrolatum-containing Eye Ointment","ValueMeaning":{"publicId":"7063371","version":"1","preferredName":"Mineral Oil/Petrolatum-containing Eye Ointment","longName":"7063371","preferredDefinition":"A commercial combination preparation, by Allergan, containing mineral oil and white petrolatum. Refresh PM Lubricant, an ointment, is used to moisturize and relieve discomfort due to ocular dryness and irritation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mineral Oil/Petrolatum-containing Eye Ointment","conceptCode":"C29413","definition":"A commercial combination preparation, by Allergan, containing mineral oil and white petrolatum. Refresh PM Lubricant, an ointment, is used to moisturize and relieve discomfort due to ocular dryness and irritation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97D08F32-9E1D-20A7-E053-F662850A5238","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97D08F32-9E36-20A7-E053-F662850A5238","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Ranitidine HCL","valueDescription":"Ranitidine Hydrochloride","ValueMeaning":{"publicId":"6159905","version":"1","preferredName":"Ranitidine Hydrochloride","longName":"6159905","preferredDefinition":"A member of the class of histamine H2-receptor antagonists with antacid activity. Ranitidine is a competitive and reversible inhibitor of the action of histamine, released by enterochromaffin-like (ECL) cells, at the histamine H2-receptors on parietal cells in the stomach, thereby inhibiting the normal and meal-stimulated secretion of stomach acid. In addition, other substances that promote acid secretion have a reduced effect on parietal cells when the H2 receptors are blocked.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ranitidine Hydrochloride","conceptCode":"C66506","definition":"A member of the class of histamine H2-receptor antagonists with antacid activity. Ranitidine is a competitive and reversible inhibitor of the action of histamine, released by enterochromaffin-like (ECL) cells, at the histamine H2-receptors on parietal cells in the stomach, thereby inhibiting the normal and meal-stimulated secretion of stomach acid. In addition, other substances that promote acid secretion have a reduced effect on parietal cells when the H2 receptors are blocked.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68A6D7EC-5AF7-2303-E053-F662850A11B7","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97D08F32-9E4A-20A7-E053-F662850A5238","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Ramipril","valueDescription":"Ramipril","ValueMeaning":{"publicId":"7063372","version":"1","preferredName":"Ramipril","longName":"7063372","preferredDefinition":"A prodrug and nonsulfhydryl angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Ramipril is converted in the liver by de-esterification into its active form ramiprilat, which inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This abolishes the potent vasoconstrictive actions of angiotensin II and leads to vasodilatation. This agent also causes an increase in bradykinin levels and a decrease in angiotensin II-induced aldosterone secretion by the adrenal cortex, thereby promoting diuresis and natriuresis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ramipril","conceptCode":"C29411","definition":"A prodrug and nonsulfhydryl angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Ramipril is converted in the liver by de-esterification into its active form ramiprilat, which inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This abolishes the potent vasoconstrictive actions of angiotensin II and leads to vasodilatation. This agent also causes an increase in bradykinin levels and a decrease in angiotensin II-induced aldosterone secretion by the adrenal cortex, thereby promoting diuresis and natriuresis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97D08F32-9E56-20A7-E053-F662850A5238","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97D08F32-9E6F-20A7-E053-F662850A5238","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Ramelteon","valueDescription":"Ramelteon","ValueMeaning":{"publicId":"7063374","version":"1","preferredName":"Ramelteon","longName":"7063374","preferredDefinition":"A synthetic melatonin analogue with hypnotic and circadian rhythm-modulating activities. Ramelteon binds to and activates melatonin receptors 1 and 2 in the suprachiasmatic nucleus (SCN) of the brain, thereby promoting the onset of sleep. Unlike the nonbenzodiazepine sedative hypnotics zolpidem and zaleplon, this agent does not activate GABA receptors and, so, produces no GABA receptor-mediated anxiolytic, myorelaxant, and amnesic effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ramelteon","conceptCode":"C66504","definition":"A synthetic melatonin analogue with hypnotic and circadian rhythm-modulating activities. Ramelteon binds to and activates melatonin receptors 1 and 2 in the suprachiasmatic nucleus (SCN) of the brain, thereby promoting the onset of sleep. Unlike the nonbenzodiazepine sedative hypnotics zolpidem and zaleplon, this agent does not activate GABA receptors and, so, produces no GABA receptor-mediated anxiolytic, myorelaxant, and amnesic effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97D08F32-9E7C-20A7-E053-F662850A5238","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97D08F32-9E95-20A7-E053-F662850A5238","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Phenylephrine","valueDescription":"Phenylephrine","ValueMeaning":{"publicId":"7060518","version":"1","preferredName":"Phenylephrine","longName":"7060518","preferredDefinition":"A direct-acting sympathomimetic amine chemically related to adrenaline and ephedrine with potent vasoconstrictor property. Phenylephrine is a post-synaptic alpha-adrenergic receptor agonist that causes vasoconstriction, increases systolic/diastolic pressures, reflex bradycardia, and stroke output.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phenylephrine","conceptCode":"C62067","definition":"A direct-acting sympathomimetic amine chemically related to adrenaline and ephedrine with potent vasoconstrictor property. Phenylephrine is a post-synaptic alpha-adrenergic receptor agonist that causes vasoconstriction, increases systolic/diastolic pressures, reflex bradycardia, and stroke output.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A03366-6921-411C-E053-F662850A5653","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A03366-693A-411C-E053-F662850A5653","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Phenylephed/Phenylprop/Guaifen","valueDescription":"Phenylephrine/Phenylpropanolamine/Guaifenesin","ValueMeaning":{"publicId":"7060520","version":"1","preferredName":"Phenylephrine/Phenylpropanolamine/Guaifenesin","longName":"7060520","preferredDefinition":"A combination preparation containing phenylephrine, phenylpropanolamine and guaifenesin with decongestant and expectorant activities. Phenylephrine and phenylpropanolamine, direct-acting sympathicomimetic amines, activate alpha-adrenergic receptors in the nasal mucosa thereby causing vasoconstriction, reduces swelling of nasal mucous membranes and decreasing nasal and sinus congestion. Phenylpropanolamine also releases norepinephrine from its storage sites resulting in the effects already described. Guaifenesin increases respiratory tract mucus secretions and reduces the viscosity of mucus secretion by reducing adhesiveness and surface tension as well as increasing hydration of mucus, thereby increasing the efficiency of removing accumulated secretions from the upper and lower airways and making cough more productive.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phenylephrine/Phenylpropanolamine/Guaifenesin","conceptCode":"C29362","definition":"A combination preparation containing phenylephrine, phenylpropanolamine and guaifenesin with decongestant and expectorant activities. Phenylephrine and phenylpropanolamine, direct-acting sympathicomimetic amines, activate alpha-adrenergic receptors in the nasal mucosa thereby causing vasoconstriction, reduces swelling of nasal mucous membranes and decreasing nasal and sinus congestion. Phenylpropanolamine also releases norepinephrine from its storage sites resulting in the effects already described. Guaifenesin increases respiratory tract mucus secretions and reduces the viscosity of mucus secretion by reducing adhesiveness and surface tension as well as increasing hydration of mucus, thereby increasing the efficiency of removing accumulated secretions from the upper and lower airways and making cough more productive.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A03366-6947-411C-E053-F662850A5653","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A03366-6960-411C-E053-F662850A5653","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Phenylbutyrate","valueDescription":"Sodium Phenylbutyrate","ValueMeaning":{"publicId":"3379478","version":"1","preferredName":"Sodium Phenylbutyrate","longName":"3379478","preferredDefinition":"The sodium salt of phenylbutyrate, a derivative of the short-chain fatty acid butyrate, with potential antineoplastic activity. Phenylbutyrate reversibly inhibits class I and II histone deacetylases (HDACs), which may result in a global increase in gene expression, decreased cellular proliferation, increased cell differentiation, and the induction of apoptosis in susceptible tumor cell populations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sodium Phenylbutyrate","conceptCode":"C1440","definition":"The sodium salt of phenylbutyrate, a derivative of the short-chain fatty acid butyrate, with potential antineoplastic activity. Phenylbutyrate reversibly inhibits class I and II histone deacetylases (HDACs), which may result in a global increase in gene expression, decreased cellular proliferation, increased cell differentiation, and the induction of apoptosis in susceptible tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-2542-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A03366-696A-411C-E053-F662850A5653","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Phenylacetate","valueDescription":"Phenylacetate","ValueMeaning":{"publicId":"3379476","version":"1","preferredName":"Phenylacetate","longName":"3379476","preferredDefinition":"An aromatic fatty acid metabolite of phenylalanine with potential antineoplastic activity.  Naturally occurring in mammals, phenylacetate induces differentiation, growth inhibition, and apoptosis in tumor cells.  Implicated mechanisms of action include decreased protein prenylation, activation of the peroxisome proliferation-activated receptors, inhibition of DNA methylation, and depletion of glutamine. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phenyl Acetate","conceptCode":"C1501","definition":"An aromatic fatty acid metabolite of phenylalanine with potential antineoplastic activity.  Naturally occurring in mammals, phenylacetate induces differentiation, growth inhibition, and apoptosis in tumor cells.  Implicated mechanisms of action include decreased protein prenylation, activation of the peroxisome proliferation-activated receptors, inhibition of DNA methylation, and depletion of glutamine. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-251C-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A03366-6974-411C-E053-F662850A5653","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Phentermine HCL","valueDescription":"Phentermine Hydrochloride","ValueMeaning":{"publicId":"7060522","version":"1","preferredName":"Phentermine Hydrochloride","longName":"7060522","preferredDefinition":"The hydrochloride salt form of phentermine, a sympathomimetic amine with central nervous system (CNS) stimulant and appetite depressant properties. Phentermine hydrochloride stimulates the release of norepinephrine and dopamine from nerve endings and blocks the reuptake of these monoamines at the neuronal junctions, resulting in CNS stimulation and metabolic effects, including appetite-suppression, decreased gastric acid secretion and increased blood pressure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phentermine Hydrochloride","conceptCode":"C29361","definition":"The hydrochloride salt form of phentermine, a sympathomimetic amine with central nervous system (CNS) stimulant and appetite depressant properties. Phentermine hydrochloride stimulates the release of norepinephrine and dopamine from nerve endings and blocks the reuptake of these monoamines at the neuronal junctions, resulting in CNS stimulation and metabolic effects, including appetite-suppression, decreased gastric acid secretion and increased blood pressure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A03366-6981-411C-E053-F662850A5653","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A03366-699A-411C-E053-F662850A5653","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Phenoxybenzamine HCL","valueDescription":"Phenoxybenzamine Hydrochloride","ValueMeaning":{"publicId":"7060524","version":"1","preferredName":"Phenoxybenzamine Hydrochloride","longName":"7060524","preferredDefinition":"The hydrochloride salt form of phenoxybenzamine, a synthetic, dibenzamine alpha-adrenergic antagonist with antihypertensive and vasodilatory properties. Phenoxybenzamine non-selectively and irreversibly blocks the postsynaptic alpha-adrenergic receptor in smooth muscle, thereby preventing vasoconstriction, relieving vasospasms, and decreasing peripheral resistance. Reflex tachycardia may occur and may be enhanced by blockade of alpha-2 receptors which enhances norepinephrine release. Phenoxybenzamine is reasonably anticipated to be a human carcinogen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phenoxybenzamine Hydrochloride","conceptCode":"C44435","definition":"The hydrochloride salt form of phenoxybenzamine, a synthetic, dibenzamine alpha-adrenergic antagonist with antihypertensive and vasodilatory properties. Phenoxybenzamine non-selectively and irreversibly blocks the postsynaptic alpha-adrenergic receptor in smooth muscle, thereby preventing vasoconstriction, relieving vasospasms, and decreasing peripheral resistance. Reflex tachycardia may occur and may be enhanced by blockade of alpha-2 receptors which enhances norepinephrine release. Phenoxybenzamine is reasonably anticipated to be a human carcinogen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A03366-69A7-411C-E053-F662850A5653","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A03366-69C0-411C-E053-F662850A5653","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Phenolphthalein","valueDescription":"Phenolphthalein","ValueMeaning":{"publicId":"7060526","version":"1","preferredName":"Phenolphthalein","longName":"7060526","preferredDefinition":"An organic compound used as a laboratory reagent and pH indicator. Phenolphthalein exerts laxative effects by stimulating the intestinal mucosa and constricting smooth muscles. However, phenolphthalein is no longer used as a laxative due to the suspected carcinogenicity of this compound.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phenolphthalein","conceptCode":"C29359","definition":"An organic compound used as a laboratory reagent and pH indicator. Phenolphthalein exerts laxative effects by stimulating the intestinal mucosa and constricting smooth muscles. However, phenolphthalein is no longer used as a laxative due to the suspected carcinogenicity of this compound.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A03366-69CD-411C-E053-F662850A5653","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A03366-69E6-411C-E053-F662850A5653","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Phenobarbital","valueDescription":"Phenobarbital","ValueMeaning":{"publicId":"5625813","version":"1","preferredName":"Phenobarbital","longName":"5625813","preferredDefinition":"A long-acting barbituric acid derivative with antipsychotic property. Phenobarbital binds to and activates the gamma-aminobutyric acid (GABA)-A receptor, thereby mimicking the inhibitory actions of GABA in the brain.  The activation effects of the phenobarbital-receptor-ionophore complex include increased frequency of chloride channel openings, membrane hyperpolarization and ultimately synaptic inhibition and decreased neuronal excitability. In addition, this agent inhibits glutamate induced depolarization.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phenobarbital","conceptCode":"C739","definition":"A long-acting barbituric acid derivative with antipsychotic property. Phenobarbital binds to and activates the gamma-aminobutyric acid (GABA)-A receptor, thereby mimicking the inhibitory actions of GABA in the brain.  The activation effects of the phenobarbital-receptor-ionophore complex include increased frequency of chloride channel openings, membrane hyperpolarization and ultimately synaptic inhibition and decreased neuronal excitability. In addition, this agent inhibits glutamate induced depolarization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45D958C0-7DD7-5173-E053-F662850AAAF2","latestVersionIndicator":"Yes","beginDate":"2017-01-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A03366-69FA-411C-E053-F662850A5653","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Pheniramine Maleate","valueDescription":"Pheniramine Maleate","ValueMeaning":{"publicId":"3379472","version":"1","preferredName":"Pheniramine Maleate","longName":"3379472","preferredDefinition":"The maleate salt form of pheniramine, an alkylamine derivative with antihistaminic and vasodilatory properties. Pheniramine maleate binds to histamine H1 receptors, thereby inhibiting phospholipase A2 and production of endothelium-derived relaxing factor, nitric oxide. Subsequent lack of activation of guanylyl cyclase through nitric oxide results in decreased cyclic GMP (cGMP) levels, thereby inhibiting constriction of smooth muscle tissue, and decreased capillary permeability and histamine-activated allergic reactions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pheniramine Maleate","conceptCode":"C29358","definition":"The maleate salt form of pheniramine, an alkylamine derivative with antihistaminic and vasodilatory properties. Pheniramine maleate binds to histamine H1 receptors, thereby inhibiting phospholipase A2 and production of endothelium-derived relaxing factor, nitric oxide. Subsequent lack of activation of guanylyl cyclase through nitric oxide results in decreased cyclic GMP (cGMP) levels, thereby inhibiting constriction of smooth muscle tissue, and decreased capillary permeability and histamine-activated allergic reactions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-24D0-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A03366-6A05-411C-E053-F662850A5653","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Phenazopyridine","valueDescription":"Phenazopyridine","ValueMeaning":{"publicId":"7060528","version":"1","preferredName":"Phenazopyridine","longName":"7060528","preferredDefinition":"A synthetic pyridine derivative anesthetic, Phenazopyridine is used as a local anesthetic in urinary tract disorders to relieve pain of lower urinary-tract irritation, as in cystitis, urethritis or prostatitis. Compatible with relief of pain and discomfort in antibacterial therapy, its use is limited however due to toxicity (primarily blood disorders) and potential carcinogenicity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phenazopyridine","conceptCode":"C29357","definition":"A synthetic pyridine derivative anesthetic, Phenazopyridine is used as a local anesthetic in urinary tract disorders to relieve pain of lower urinary-tract irritation, as in cystitis, urethritis or prostatitis. Compatible with relief of pain and discomfort in antibacterial therapy, its use is limited however due to toxicity (primarily blood disorders) and potential carcinogenicity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A03366-6A12-411C-E053-F662850A5653","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A03366-6A2B-411C-E053-F662850A5653","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Petrolatum Hydrophilic","valueDescription":"Petrolatum Hydrophilic","ValueMeaning":{"publicId":"3379470","version":"1","preferredName":"Petrolatum Hydrophilic","longName":"3379470","preferredDefinition":"A non-polar semi-solid mixture of hydrocarbons that is derived from petroleum. This agent has application as a lubricant, emollient, and a carrier for other agents.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Petrolatum Hydrophilic","conceptCode":"C29356","definition":"A non-polar semi-solid mixture of hydrocarbons that is derived from petroleum. This agent has application as a lubricant, emollient, and a carrier for other agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-24AA-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"COOPERM","dateModified":"2019-11-18","changeDescription":"Adding current NCIt definition. mc 11/18/19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A03366-6A35-411C-E053-F662850A5653","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Perphenazine","valueDescription":"Perphenazine","ValueMeaning":{"publicId":"7060530","version":"1","preferredName":"Perphenazine","longName":"7060530","preferredDefinition":"A phenothiazine derivative and a dopamine antagonist with antiemetic and antipsychotic properties. Perphenazine blocks postsynaptic dopamine 2(D2) receptors in the mesolimbic and medullary chemoreceptor trigger zone (CTZ), thereby preventing the excess of dopamine in the brain. This leads to reduction in psychotic symptoms, such as hallucinations and delusions. Perphenazine appears to exert its antiemetic activity by blocking the dopamine and histamine-1 receptor in the CTZ thereby relieving nausea and vomiting in the brain. In addition, perphenazine binds to alpha-adrenergic receptors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Perphenazine","conceptCode":"C29355","definition":"A phenothiazine derivative and a dopamine antagonist with antiemetic and antipsychotic properties. Perphenazine blocks postsynaptic dopamine 2(D2) receptors in the mesolimbic and medullary chemoreceptor trigger zone (CTZ), thereby preventing the excess of dopamine in the brain. This leads to reduction in psychotic symptoms, such as hallucinations and delusions. Perphenazine appears to exert its antiemetic activity by blocking the dopamine and histamine-1 receptor in the CTZ thereby relieving nausea and vomiting in the brain. In addition, perphenazine binds to alpha-adrenergic receptors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A03366-6A42-411C-E053-F662850A5653","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A03366-6A5B-411C-E053-F662850A5653","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Permethrin","valueDescription":"Permethrin","ValueMeaning":{"publicId":"2575701","version":"1","preferredName":"Permethrin","longName":"2575701","preferredDefinition":"A synthetic pyrethroid and neurotoxin. Permethrin affects the neuronal membrane by blocking the movement of sodium ions from outside to inside the neuronal cell membrane thereby disrupting the sodium channel current that regulates the polarization of the membrane. This leads to delayed repolarization and subsequent paralysis of the nervous system. Permethrin is used to eradicate parasites such as head lice, ticks and scabies from humans and animals.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Permethrin","conceptCode":"C29354","definition":"A synthetic pyrethroid and neurotoxin. Permethrin affects the neuronal membrane by blocking the movement of sodium ions from outside to inside the neuronal cell membrane thereby disrupting the sodium channel current that regulates the polarization of the membrane. This leads to delayed repolarization and subsequent paralysis of the nervous system. Permethrin is used to eradicate parasites such as head lice, ticks and scabies from humans and animals.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4C2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A03366-6A65-411C-E053-F662850A5653","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Perifosine","valueDescription":"Perifosine","ValueMeaning":{"publicId":"3379467","version":"1","preferredName":"Perifosine","longName":"3379467","preferredDefinition":"An orally active alkyl-phosphocholine compound with potential antineoplastic activity.  Targeting cellular membranes, perifosine modulates membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth.  This agent also inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis.  Perifosine has a lower gastrointestinal toxicity profile than the related agent miltefosine. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Perifosine","conceptCode":"C1727","definition":"An orally active alkyl-phosphocholine compound with potential antineoplastic activity.  Targeting cellular membranes, perifosine modulates membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth.  This agent also inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis.  Perifosine has a lower gastrointestinal toxicity profile than the related agent miltefosine. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-244B-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A03366-6A6F-411C-E053-F662850A5653","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Pentoxifylline","valueDescription":"Pentoxifylline","ValueMeaning":{"publicId":"3379459","version":"1","preferredName":"Pentoxifylline","longName":"3379459","preferredDefinition":"A methylxanthine derivative with hemorrheologic and immunomodulating properties. Pentoxifylline inhibits phosphodiesterase, resulting in increased levels of cyclic adenosine monophosphate (cAMP) in erythrocytes, endothelium, and the surrounding tissues. This leads to vasodilation, improves erythrocyte flexibility, and enhances blood flow. In addition, the increased level of cAMP in platelets inhibits platelet aggregation, which may contribute to a reduction in blood viscosity. This agent also inhibits production of tumor necrosis factor-alpha and interferon-gamma, while it induces Th2-like (T-helper 2) cytokine production, thereby inhibiting Th1-mediated (T-helper 1) inflammatory and autoimmune responses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pentoxifylline","conceptCode":"C733","definition":"A methylxanthine derivative with hemorrheologic and immunomodulating properties. Pentoxifylline inhibits phosphodiesterase, resulting in increased levels of cyclic adenosine monophosphate (cAMP) in erythrocytes, endothelium, and the surrounding tissues. This leads to vasodilation, improves erythrocyte flexibility, and enhances blood flow. In addition, the increased level of cAMP in platelets inhibits platelet aggregation, which may contribute to a reduction in blood viscosity. This agent also inhibits production of tumor necrosis factor-alpha and interferon-gamma, while it induces Th2-like (T-helper 2) cytokine production, thereby inhibiting Th1-mediated (T-helper 1) inflammatory and autoimmune responses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-23B2-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A03366-6A79-411C-E053-F662850A5653","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Pentostatin","valueDescription":"Pentostatin","ValueMeaning":{"publicId":"5127413","version":"1","preferredName":"Pentostatin","longName":"5127413","preferredDefinition":"The active ingredient in a drug that is used to treat hairy cell leukemia and is being studied in the treatment of other types of cancer. Pentostatin blocks a protein needed for cell growth and may kill cancer cells. It is made by a bacterium. It is a type of adenosine deaminase inhibitor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pentostatin","conceptCode":"C732","definition":"A purine nucleotide analogue antibiotic isolated from the bacterium Streptomyces antibioticus. Also known as 2'-deoxycoformycin, pentostatin binds to and inhibits adenine deaminase (ADA), an enzyme essential to purine metabolism; ADA activity is greatest in cells of the lymphoid system with T-cells having higher activity than B-cells and T-cell malignancies higher ADA activity than B-cell malignancies. Pentostatin inhibition of ADA appears to result in elevated intracellular levels of dATP which may block DNA synthesis through the inhibition of ribonucleotide reductase. This agent may also inhibit RNA synthesis and may selectively deplete CD26+ lymphocytes. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FAA7-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A03366-6A83-411C-E053-F662850A5653","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Pentosan Polysulfate Sodium","valueDescription":"Pentosan Polysulfate Sodium","ValueMeaning":{"publicId":"3379402","version":"1","preferredName":"Pentosan Polysulfate Sodium","longName":"3379402","preferredDefinition":"The sodium salt of a semisynthetic heparin-like glucosaminoglycan.  Although its mechanism of action is unknown, pentosan polysulfate may act as a buffer to control cell permeability by preventing irritating solutes from reaching cells coated with it. Administered orally, excreted pentosan polysulfate adheres to the urinary bladder wall, preventing irritants from entering bladder cells and the development or progression of interstitial cystitis (IC), a complication of some chemotherapies. This agent also exhibits anticoagulant and fibrinolytic properties.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pentosan Polysulfate Sodium","conceptCode":"C946","definition":"The sodium salt of a semisynthetic heparin-like glucosaminoglycan.  Although its mechanism of action is unknown, pentosan polysulfate may act as a buffer to control cell permeability by preventing irritating solutes from reaching cells coated with it. Administered orally, excreted pentosan polysulfate adheres to the urinary bladder wall, preventing irritants from entering bladder cells and the development or progression of interstitial cystitis (IC), a complication of some chemotherapies. This agent also exhibits anticoagulant and fibrinolytic properties. In addition, pentosan polysulfate may block endothelial P-selectin and increase microvascular blood flow in sickle cell disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-1E2B-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A03366-6A97-411C-E053-F662850A5653","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Pentamidine Isethionate","valueDescription":"Pentamidine Isethionate","ValueMeaning":{"publicId":"2575700","version":"1","preferredName":"Pentamidine Isethionate","longName":"2575700","preferredDefinition":"A synthetic amidine derivative, Pentamidine Isethionate is an antiprotozoal and antifungal agent that appears to interact with the minor groove of AT-rich DNA regions of the pathogen genome, interfering with DNA replication and function. It is effective in the treatment of trypanosomiasis, leishmaniasis, some fungal infections, and Pneumocystis carinii pneumonia in HIV-infected patients. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pentamidine Isethionate","conceptCode":"C29349","definition":"A synthetic amidine derivative, Pentamidine Isethionate is an antiprotozoal and antifungal agent that appears to interact with the minor groove of AT-rich DNA regions of the pathogen genome, interfering with DNA replication and function. It is effective in the treatment of trypanosomiasis, leishmaniasis, some fungal infections, and Pneumocystis carinii pneumonia in HIV-infected patients. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4C1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"COOPERM","dateModified":"2019-11-18","changeDescription":"Adding concept to VM. mc 11/18/19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A03366-6AA1-411C-E053-F662850A5653","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Penicillin V","valueDescription":"Penicillin V","ValueMeaning":{"publicId":"2575699","version":"1","preferredName":"Penicillin V","longName":"2575699","preferredDefinition":"A member of the penicillin family exhibiting broad-spectrum antibiotic property. Penicillin V binds to penicillin binding proteins (PBP), the enzymes that catalyze the synthesis of peptidoglycan, which is a critical component of the bacterial cell wall. This leads to the interruption of cell wall synthesis, consequently leading to bacterial cell growth inhibition and cell lysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Penicillin V","conceptCode":"C62064","definition":"A member of the penicillin family exhibiting broad-spectrum antibiotic property. Penicillin V binds to penicillin binding proteins (PBP), the enzymes that catalyze the synthesis of peptidoglycan, which is a critical component of the bacterial cell wall. This leads to the interruption of cell wall synthesis, consequently leading to bacterial cell growth inhibition and cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4C0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"COOPERM","dateModified":"2019-11-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A03366-6AAB-411C-E053-F662850A5653","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Pegfilgrastim","valueDescription":"Pegfilgrastim","ValueMeaning":{"publicId":"2775105","version":"1","preferredName":"Pegfilgrastim","longName":"2775105","preferredDefinition":"A long-acting pegylated form of a recombinant therapeutic agent which is chemically identical to or similar to an endogenous human granulocyte colony-stimulating factor (G-CSF). Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions. Conjugation of the cytokine with a branched polyethylene glycol molecule (pegylation) significantly increases its therapeutic half-life. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pegfilgrastim","conceptCode":"C1854","definition":"A long-acting pegylated form of a recombinant therapeutic agent which is chemically identical to or similar to an endogenous human granulocyte colony-stimulating factor (G-CSF). Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions. Conjugation of the cytokine with a branched polyethylene glycol molecule (pegylation) significantly increases its therapeutic half-life. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54D3AA38-DF52-52EA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-08-19","modifiedBy":"KUMMEROA","dateModified":"2023-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A03366-6AB5-411C-E053-F662850A5653","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Paroxetine HCL","valueDescription":"Paroxetine Hydrochloride","ValueMeaning":{"publicId":"7060532","version":"1","preferredName":"Paroxetine Hydrochloride","longName":"7060532","preferredDefinition":"The hydrochloride salt form of paroxetine, a phenylpiperidine derivative and a selective serotonin reuptake inhibitor (SSRI) with antidepressant and anxiolytic properties. Paroxetine binds to the pre-synaptic serotonin transporter complex resulting in negative allosteric modulation of the complex thereby blocking reuptake of serotonin by the pre-synaptic transporter. Inhibition of serotonin recycling enhances serotonergic function through serotonin accumulation in the synaptic cleft, resulting in long-term desensitization and downregulation of 5HT1 (serotonin) receptors and leading to symptomatic relief of depressive illness.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paroxetine Hydrochloride","conceptCode":"C1837","definition":"The hydrochloride salt form of paroxetine, a phenylpiperidine derivative and a selective serotonin reuptake inhibitor (SSRI) with antidepressant and anxiolytic properties. Paroxetine binds to the pre-synaptic serotonin transporter complex resulting in negative allosteric modulation of the complex thereby blocking reuptake of serotonin by the pre-synaptic transporter. Inhibition of serotonin recycling enhances serotonergic function through serotonin accumulation in the synaptic cleft, resulting in long-term desensitization and downregulation of 5HT1 (serotonin) receptors and leading to symptomatic relief of depressive illness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A03366-6AC2-411C-E053-F662850A5653","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A03366-6ADB-411C-E053-F662850A5653","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Pantoprazole","valueDescription":"Pantoprazole","ValueMeaning":{"publicId":"7060534","version":"1","preferredName":"Pantoprazole","longName":"7060534","preferredDefinition":"A substituted benzimidazole and proton pump inhibitor with antacid activity. Pantoprazole is a lipophilic weak base that crosses the parietal cell membrane and enters the acidic parietal cell canaliculus where it becomes protonated, producing the active metabolite sulphenamide, which forms an irreversible covalent bond with two sites of the H+/K+-ATPase enzyme located on the gastric parietal cell, thereby inhibiting both basal and stimulated gastric acid production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pantoprazole","conceptCode":"C29346","definition":"A substituted benzimidazole and proton pump inhibitor with antacid activity. Pantoprazole is a lipophilic weak base that crosses the parietal cell membrane and enters the acidic parietal cell canaliculus where it becomes protonated, producing the active metabolite sulphenamide, which forms an irreversible covalent bond with two sites of the H+/K+-ATPase enzyme located on the gastric parietal cell, thereby inhibiting both basal and stimulated gastric acid production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A03366-6AE8-411C-E053-F662850A5653","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A03366-6B01-411C-E053-F662850A5653","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Pancrelipase","valueDescription":"Pancrelipase","ValueMeaning":{"publicId":"7060536","version":"1","preferredName":"Pancrelipase","longName":"7060536","preferredDefinition":"A standardized enzyme concentrate containing the pancreatic enzymes, lipase, protease and amylase used in enzyme substitution therapy. Lipase, protease and amylase break down fat, protein, and starches, respectively in the small intestine, thereby promoting digestion. Pancrelipase is used to reduce malabsorption when the pancreas is unable to secrete sufficient amounts of these enzymes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancrelipase","conceptCode":"C29345","definition":"A standardized enzyme concentrate containing the pancreatic enzymes, lipase, protease and amylase used in enzyme substitution therapy. Lipase, protease and amylase break down fat, protein, and starches, respectively in the small intestine, thereby promoting digestion. Pancrelipase is used to reduce malabsorption when the pancreas is unable to secrete sufficient amounts of these enzymes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A03366-6B0E-411C-E053-F662850A5653","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A03366-6B27-411C-E053-F662850A5653","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Pamidronate Disodium","valueDescription":"Pamidronate Disodium","ValueMeaning":{"publicId":"2576642","version":"1","preferredName":"Pamidronate Disodium","longName":"2576642","preferredDefinition":"The disodium salt of the synthetic bisphosphonate pamidronate. Although its mechanism of action is not completely understood, pamidronate appears to adsorb to calcium phosphate crystals in bone, blocking their dissolution by inhibiting osteoclast-mediated bone resorption. This agent does not inhibit bone mineralization and formation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pamidronate Disodium","conceptCode":"C1345","definition":"The disodium salt of the synthetic bisphosphonate pamidronate. Although its mechanism of action is not completely understood, pamidronate appears to adsorb to calcium phosphate crystals in bone, blocking their dissolution by inhibiting osteoclast-mediated bone resorption. This agent does not inhibit bone mineralization and formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F86F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ZHANGWE","dateModified":"2021-09-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A03366-6B31-411C-E053-F662850A5653","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Palonosetron HCL","valueDescription":"Palonosetron Hydrochloride","ValueMeaning":{"publicId":"7060538","version":"1","preferredName":"Palonosetron Hydrochloride","longName":"7060538","preferredDefinition":"The hydrochloride salt of palonosetron, a carbazole derivative and a selective serotonin receptor antagonist with antiemetic activity. Palonosetron competitively blocks the action of serotonin at 5-hydroxytryptamine type 3 (5-HT3) receptors located on vagal afferents in the chemoreceptor trigger zone (CTZ), resulting in suppression of chemotherapy-induced nausea and vomiting. The CTZ is located in the area postrema on the dorsal surface of the medulla oblongata at the caudal end of the fourth ventricle and outside the blood-brain barrier (BBB).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Palonosetron Hydrochloride","conceptCode":"C47650","definition":"The hydrochloride salt of palonosetron, a carbazole derivative and a selective serotonin receptor antagonist with antiemetic activity. Palonosetron competitively blocks the action of serotonin at 5-hydroxytryptamine type 3 (5-HT3) receptors located on vagal afferents in the chemoreceptor trigger zone (CTZ), resulting in suppression of chemotherapy-induced nausea and vomiting. The CTZ is located in the area postrema on the dorsal surface of the medulla oblongata at the caudal end of the fourth ventricle and outside the blood-brain barrier (BBB).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A03366-6B3E-411C-E053-F662850A5653","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A03366-6B57-411C-E053-F662850A5653","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Phytonadione","valueDescription":"Phytonadione","ValueMeaning":{"publicId":"7060540","version":"1","preferredName":"Phytonadione","longName":"7060540","preferredDefinition":"An analogue of the naphthoquinone vitamin K found in plants.  The vitamins K are essential for blood coagulation as it is necessary for the hepatic synthesis of the coagulation factors II, VII, IX, and X; deficiency results in a bleeding diathesis. These vitamins are lipo-soluble; absorption via intestinal lymphatics requires the presence of bile salts. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phytonadione","conceptCode":"C29365","definition":"An analogue of the naphthoquinone vitamin K found in plants.  The vitamins K are essential for blood coagulation as it is necessary for the hepatic synthesis of the coagulation factors II, VII, IX, and X; deficiency results in a bleeding diathesis. These vitamins are lipo-soluble; absorption via intestinal lymphatics requires the presence of bile salts. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"979FF0CB-9797-4679-E053-F662850A2D69","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"979FF0CB-97B0-4679-E053-F662850A2D69","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Phosphatidyl Choline","valueDescription":"Phosphatidylcholine","ValueMeaning":{"publicId":"7060541","version":"1","preferredName":"Phosphatidylcholine","longName":"7060541","preferredDefinition":"a class of phospholipids that incorporate choline as a headgroup. They are a major component of biological membranes and can be easily obtained from a variety of readily available sources, such as egg yolk or soybeans, from which they are mechanically or chemically extracted using hexane. They are also a member of the lecithin group of yellow-brownish fatty substances occurring in animal and plant tissues.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"979FF0CB-97BA-4679-E053-F662850A2D69","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"979FF0CB-97D3-4679-E053-F662850A2D69","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Phenytoin","valueDescription":"Phenytoin","ValueMeaning":{"publicId":"7060542","version":"1","preferredName":"Phenytoin","longName":"7060542","preferredDefinition":"A hydantoin derivative and a non-sedative antiepileptic agent with anticonvulsant activity. Phenytoin potentially acts by promoting sodium efflux from neurons located in the motor cortex reducing post-tetanic potentiation at synapses. The reduction of potentiation prevents cortical seizure foci spreading to adjacent areas, stabilizing the threshold against hyperexcitability. In addition, this agent appears to reduce sensitivity of muscle spindles to stretch causing muscle relaxation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phenytoin","conceptCode":"C741","definition":"A hydantoin derivative and a non-sedative antiepileptic agent with anticonvulsant activity. Phenytoin potentially acts by promoting sodium efflux from neurons located in the motor cortex reducing post-tetanic potentiation at synapses. The reduction of potentiation prevents cortical seizure foci spreading to adjacent areas, stabilizing the threshold against hyperexcitability. In addition, this agent appears to reduce sensitivity of muscle spindles to stretch causing muscle relaxation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"979FF0CB-97DF-4679-E053-F662850A2D69","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"979FF0CB-97F8-4679-E053-F662850A2D69","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Phenylpropanolamine","valueDescription":"Phenylpropanolamine","ValueMeaning":{"publicId":"7060544","version":"1","preferredName":"Phenylpropanolamine","longName":"7060544","preferredDefinition":"An alpha- and beta-adrenergic receptor agonist with sympathomimetic activity. Phenylpropanolamine (PPA) binds to and activates alpha- and beta-adrenergic receptors in the mucosa of the respiratory tract resulting in vasoconstriction and reduction in swelling of nasal mucous membranes and reduction in tissue hyperemia, edema, and nasal congestion. This agent also stimulates the release of norepinephrine from its storage sites resulting in the effects already described. Finally, PPA indirectly stimulates beta-receptors producing tachycardia and a positive inotropic effect.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phenylpropanolamine","conceptCode":"C29364","definition":"An alpha- and beta-adrenergic receptor agonist with sympathomimetic activity. Phenylpropanolamine (PPA) binds to and activates alpha- and beta-adrenergic receptors in the mucosa of the respiratory tract resulting in vasoconstriction and reduction in swelling of nasal mucous membranes and reduction in tissue hyperemia, edema, and nasal congestion. This agent also stimulates the release of norepinephrine from its storage sites resulting in the effects already described. Finally, PPA indirectly stimulates beta-receptors producing tachycardia and a positive inotropic effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"979FF0CB-9805-4679-E053-F662850A2D69","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"979FF0CB-981E-4679-E053-F662850A2D69","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Phenylprop/Guaifenesin","valueDescription":"Phenylpropanolamine/Guaifenesin","ValueMeaning":{"publicId":"7060545","version":"1","preferredName":"Phenylpropanolamine/Guaifenesin","longName":"7060545","preferredDefinition":"A combination medication used to treat the symptoms of the common cold and of infections of the sinuses, lungs, and throat.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"979FF0CB-9828-4679-E053-F662850A2D69","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"979FF0CB-9841-4679-E053-F662850A2D69","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Raloxifene","valueDescription":"Raloxifene","ValueMeaning":{"publicId":"2561707","version":"1","preferredName":"Raloxifene","longName":"2561707","preferredDefinition":"A selective benzothiophene estrogen receptor modulator (SERM).  Raloxifene binds to estrogen receptors (ER) as a mixed estrogen agonist/antagonist; it displays both an ER-alpha-selective partial agonist/antagonist effect and a pure ER-beta-selective antagonist effect.  This agent functions as an estrogen agonist in some tissues (bones, lipid metabolism) and as an estrogen antagonist in others (endometrium and breasts), with the potential for producing some of estrogen's beneficial effects without producing its adverse effects. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Raloxifene","conceptCode":"C1518","definition":"A selective benzothiophene estrogen receptor modulator (SERM).  Raloxifene binds to estrogen receptors (ER) as a mixed estrogen agonist/antagonist; it displays both an ER-alpha-selective partial agonist/antagonist effect and a pure ER-beta-selective antagonist effect.  This agent functions as an estrogen agonist in some tissues (bones, lipid metabolism) and as an estrogen antagonist in others (endometrium and breasts), with the potential for producing some of estrogen's beneficial effects without producing its adverse effects. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BE18-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-08","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-08","modifiedBy":"COOPERM","dateModified":"2016-08-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CFA8BF-562F-66BC-E053-F662850AF2FF","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Rabeprazole","valueDescription":"Rabeprazole","ValueMeaning":{"publicId":"7063274","version":"1","preferredName":"Rabeprazole","longName":"7063274","preferredDefinition":"An alpha-pyridylmethylsulfinyl benzimidazole and a selective and irreversible proton pump inhibitor with antisecretory property. Rabeprazole enters the parietal cell and accumulates in the acidic secretory canaliculi where the agent is activated by a proton-catalyzed process that results in the formation of a thiophilic sulfonamide or sulfenic acid. The activated rabeprazole forms covalent bonds with the sulfhydryl amino acids cysteine on the extracellular domain of the proton pump (H+/K+ ATPase) at the secretory surface, thereby inhibiting the transport of hydrogen ions, via exchange with potassium ions, into the gastric lumen. Binding to cysteine 813, in particular, is essential for inhibition of gastric acid production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rabeprazole","conceptCode":"C29410","definition":"An alpha-pyridylmethylsulfinyl benzimidazole and a selective and irreversible proton pump inhibitor with antisecretory property. Rabeprazole enters the parietal cell and accumulates in the acidic secretory canaliculi where the agent is activated by a proton-catalyzed process that results in the formation of a thiophilic sulfonamide or sulfenic acid. The activated rabeprazole forms covalent bonds with the sulfhydryl amino acids cysteine on the extracellular domain of the proton pump (H+/K+ ATPase) at the secretory surface, thereby inhibiting the transport of hydrogen ions, via exchange with potassium ions, into the gastric lumen. Binding to cysteine 813, in particular, is essential for inhibition of gastric acid production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97CFA8BF-563C-66BC-E053-F662850AF2FF","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CFA8BF-5655-66BC-E053-F662850AF2FF","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Quinine Sulfate","valueDescription":"Quinine Sulfate","ValueMeaning":{"publicId":"7063276","version":"1","preferredName":"Quinine Sulfate","longName":"7063276","preferredDefinition":"The sulfate salt form of the quinidine alkaloid isolate quinine. Quinine has many mechanisms of action, including reduction of oxygen intake and carbohydrate metabolism; disruption of DNA replication and transcription via DNA intercalation; and reduction of the excitability of muscle fibers via alteration of calcium distribution.  This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Quinine Sulfate","conceptCode":"C29399","definition":"The sulfate salt form of the quinidine alkaloid isolate quinine. Quinine has many mechanisms of action, including reduction of oxygen intake and carbohydrate metabolism; disruption of DNA replication and transcription via DNA intercalation; and reduction of the excitability of muscle fibers via alteration of calcium distribution.  This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97CFA8BF-5662-66BC-E053-F662850AF2FF","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CFA8BF-567B-66BC-E053-F662850AF2FF","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Quinapril","valueDescription":"Quinapril","ValueMeaning":{"publicId":"7063278","version":"1","preferredName":"Quinapril","longName":"7063278","preferredDefinition":"A prodrug and non-sulfhydryl angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Quinapril is hydrolized into its active form quinaprilat, which binds to and inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This abolishes the potent vasoconstrictive actions of angiotensin II and leads to vasodilatation. Quinapril also causes a decrease in angiotensin II-induced aldosterone secretion by the adrenal cortex, thereby promoting diuresis and natriuresis, and increases bradykinin levels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Quinapril","conceptCode":"C62074","definition":"A prodrug and non-sulfhydryl angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Quinapril is hydrolized into its active form quinaprilat, which binds to and inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This abolishes the potent vasoconstrictive actions of angiotensin II and leads to vasodilatation. Quinapril also causes a decrease in angiotensin II-induced aldosterone secretion by the adrenal cortex, thereby promoting diuresis and natriuresis, and increases bradykinin levels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97CFA8BF-5688-66BC-E053-F662850AF2FF","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CFA8BF-56A1-66BC-E053-F662850AF2FF","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Quetiapine Fumarate","valueDescription":"Quetiapine Fumarate","ValueMeaning":{"publicId":"7063280","version":"1","preferredName":"Quetiapine Fumarate","longName":"7063280","preferredDefinition":"The fumarate salt form of quetiapine, a dibenzothiazepine derivative with antipsychotic property. Quetiapine fumarate antagonizes serotonin activity mediated by 5-HT 1A and 5-HT2 receptors. With a lower affinity, this agent also reversibly binds to dopamine D1 and D2 receptors in the mesolimbic and mesocortical areas of the brain leading to decreased psychotic effects, such as hallucinations and delusions. In addition, quetiapine fumarate also binds to other alpha-1, alpha-2 adrenergic and histamine H1 receptors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Quetiapine Fumarate","conceptCode":"C47700","definition":"The fumarate salt form of quetiapine, a dibenzothiazepine derivative with antipsychotic property. Quetiapine fumarate antagonizes serotonin activity mediated by 5-HT 1A and 5-HT2 receptors. With a lower affinity, this agent also reversibly binds to dopamine D1 and D2 receptors in the mesolimbic and mesocortical areas of the brain leading to decreased psychotic effects, such as hallucinations and delusions. In addition, quetiapine fumarate also binds to other alpha-1, alpha-2 adrenergic and histamine H1 receptors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97CFA8BF-56AE-66BC-E053-F662850AF2FF","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CFA8BF-56C7-66BC-E053-F662850AF2FF","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Pyrimethamine","valueDescription":"Pyrimethamine","ValueMeaning":{"publicId":"2575705","version":"1","preferredName":"Pyrimethamine","longName":"2575705","preferredDefinition":"A synthetic derivative of ethyl-pyrimidine with potent antimalarial properties.  Pyrimethamine is a competitive inhibitor of dihydrofolate reductase (DHFR).  DHFR is a key enzyme in the redox cycle for production of tetrahydrofolate, a cofactor that is required for the synthesis of DNA and proteins.  This agent is often used in combination with other antimalarials for the treatment of uncomplicated falciparum malaria. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pyrimethamine","conceptCode":"C788","definition":"A synthetic derivative of ethyl-pyrimidine with potent antimalarial properties.  Pyrimethamine is a competitive inhibitor of dihydrofolate reductase (DHFR).  DHFR is a key enzyme in the redox cycle for production of tetrahydrofolate, a cofactor that is required for the synthesis of DNA and proteins.  This agent is often used in combination with other antimalarials for the treatment of uncomplicated falciparum malaria. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4C6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CFA8BF-56D1-66BC-E053-F662850AF2FF","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Pyridoxine","valueDescription":"Pyridoxine","ValueMeaning":{"publicId":"7063282","version":"1","preferredName":"Pyridoxine","longName":"7063282","preferredDefinition":"A nutrient in the vitamin B complex that the body needs in small amounts to function and stay healthy. Pyridoxine helps keep nerves and skin healthy, fight infections, keep blood sugar levels normal, produce red blood cells, and some enzymes work properly. Pyridoxine is a group of related compounds (pyridoxine, pyridoxal, and pyridoxamine) found in cereals, beans, peas, nuts, meat, poultry, fish, eggs, and bananas. It is water-soluble (can dissolve in water). Not enough pyridoxine can cause mouth and tongue sores and nervous disorders. Pyridoxine is being studied in the prevention of hand-foot syndrome (a disorder caused by certain anticancer drugs and marked by pain, swelling, numbness, tingling, or redness of the hands or feet).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pyridoxine","conceptCode":"C62619","definition":"A nutrient in the vitamin B complex that the body needs in small amounts to function and stay healthy. Pyridoxine helps keep nerves and skin healthy, fight infections, keep blood sugar levels normal, produce red blood cells, and some enzymes work properly. Pyridoxine is a group of related compounds (pyridoxine, pyridoxal, and pyridoxamine) found in cereals, beans, peas, nuts, meat, poultry, fish, eggs, and bananas. It is water-soluble (can dissolve in water). Not enough pyridoxine can cause mouth and tongue sores and nervous disorders. Pyridoxine is being studied in the prevention of hand-foot syndrome (a disorder caused by certain anticancer drugs and marked by pain, swelling, numbness, tingling, or redness of the hands or feet).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97CFA8BF-56DE-66BC-E053-F662850AF2FF","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CFA8BF-56F7-66BC-E053-F662850AF2FF","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Pyridostigmine Bromide","valueDescription":"Pyridostigmine Bromide","ValueMeaning":{"publicId":"7063284","version":"1","preferredName":"Pyridostigmine Bromide","longName":"7063284","preferredDefinition":"The bromide salt form of pyridostigmine, a quaternary ammonium carbamate derivative and a acetylcholinesterase inhibitor. Pyridostigmine bromide binds reversibly to acetylcholinesterase active sites in the peripheral nervous system, thereby preventing the breakdown of acetylcholine. This leads to an accumulation of acetylcholine at cholinergic synapses and facilitates transmission of impulses across the neuromuscular junction. Mediated through muscarinic receptors, this agent increases contraction of bronchial and intestinal smooth muscle and the exocrine glands secretions, while it causes paralysis of the skeletal muscles mediated through nicotinic receptors. In addition, pyridostigmine is used as a reversible blocking agent to prevent organophosphates from binding to the acetylcholinesterase receptors and thereby protect the nervous system from the effects of nerve agents such as Soman.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pyridostigmine Bromide","conceptCode":"C47697","definition":"The bromide salt form of pyridostigmine, a quaternary ammonium carbamate derivative and a acetylcholinesterase inhibitor. Pyridostigmine bromide binds reversibly to acetylcholinesterase active sites in the peripheral nervous system, thereby preventing the breakdown of acetylcholine. This leads to an accumulation of acetylcholine at cholinergic synapses and facilitates transmission of impulses across the neuromuscular junction. Mediated through muscarinic receptors, this agent increases contraction of bronchial and intestinal smooth muscle and the exocrine glands secretions, while it causes paralysis of the skeletal muscles mediated through nicotinic receptors. In addition, pyridostigmine is used as a reversible blocking agent to prevent organophosphates from binding to the acetylcholinesterase receptors and thereby protect the nervous system from the effects of nerve agents such as Soman.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97CFA8BF-5704-66BC-E053-F662850AF2FF","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CFA8BF-571D-66BC-E053-F662850AF2FF","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Pyrazinamide","valueDescription":"Pyrazinamide","ValueMeaning":{"publicId":"3379510","version":"1","preferredName":"Pyrazinamide","longName":"3379510","preferredDefinition":"A synthetic pyrazinoic acid amide derivative with bactericidal property. Pyrazinamide is particularly active against slowly multiplying intracellular bacilli (unaffected by other drugs) by an unknown mechanism of action. Its bactericidal action is dependent upon the presence of bacterial pyrazinamidase, which removes the amide group to produce active pyrazinoic acid. Pyrazinamide is an important component of multidrug therapy for tuberculosis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pyrazinamide","conceptCode":"C29395","definition":"A synthetic pyrazinoic acid amide derivative with bactericidal property. Pyrazinamide is particularly active against slowly multiplying intracellular bacilli (unaffected by other drugs) by an unknown mechanism of action. Its bactericidal action is dependent upon the presence of bacterial pyrazinamidase, which removes the amide group to produce active pyrazinoic acid. Pyrazinamide is an important component of multidrug therapy for tuberculosis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92A1160-3554-5002-E040-BB89AD4338DD","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CFA8BF-5727-66BC-E053-F662850AF2FF","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Psyllium","valueDescription":"Psyllium","ValueMeaning":{"publicId":"2578287","version":"1","preferredName":"Psyllium","longName":"2578287","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Psyllium Husk","conceptCode":"C29250","definition":"The husk of the dried ripe seeds of the Plantago psyllium, P. Indica, P. Ovata, and P. Arenaria plants with laxative and cholesterol lowering activities. The husks contain mucilage that swells on exposure to water and provides an indigestible mucilaginous mass in the intestines, thereby causing lubrication, contraction of the smooth muscles of the intestinal walls, and thus stimulating bowel movement. Psyllium husk is rich in soluble fiber and has a cholesterol-lowering effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEDC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CFA8BF-573B-66BC-E053-F662850AF2FF","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Pseudoephedrine Sulfate","valueDescription":"Pseudoephedrine Sulfate","ValueMeaning":{"publicId":"7063286","version":"1","preferredName":"Pseudoephedrine Sulfate","longName":"7063286","preferredDefinition":"The sulfate salt form of pseudoephedrine, a phenethylamine and a diastereomer of ephedrine with sympathomimetic property. Pseudoephedrine sulfate displaces norepinephrine from storage vesicles in presynaptic neurones, thereby releasing norepinephrine into the neuronal synapses where it stimulates primarily alpha-adrenergic receptors. It also has weak direct agonist activity at alpha- and beta- adrenergic receptors. Receptor stimulation results in vasoconstriction and decreases nasal and sinus congestion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pseudoephedrine Sulfate","conceptCode":"C47696","definition":"The sulfate salt form of pseudoephedrine, a phenethylamine and a diastereomer of ephedrine with sympathomimetic property. Pseudoephedrine sulfate displaces norepinephrine from storage vesicles in presynaptic neurones, thereby releasing norepinephrine into the neuronal synapses where it stimulates primarily alpha-adrenergic receptors. It also has weak direct agonist activity at alpha- and beta- adrenergic receptors. Receptor stimulation results in vasoconstriction and decreases nasal and sinus congestion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97CFA8BF-5748-66BC-E053-F662850AF2FF","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CFA8BF-5761-66BC-E053-F662850AF2FF","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Pseudoephedrine HCL","valueDescription":"Pseudoephedrine Hydrochloride","ValueMeaning":{"publicId":"7063288","version":"1","preferredName":"Pseudoephedrine Hydrochloride","longName":"7063288","preferredDefinition":"The hydrochloride salt form of pseudoephedrine, a phenethylamine and an diastereomer of ephedrine with sympathomimetic property. Pseudoephedrine hydrochloride displaces norepinephrine from storage vesicles in presynaptic neurones, thereby releasing norepinephrine into the neuronal synapses where it stimulates primarily alpha-adrenergic receptors. It also has weak direct agonist activity at alpha- and beta- adrenergic receptors. Receptor stimulation results in vasoconstriction and decreases nasal and sinus congestion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pseudoephedrine Hydrochloride","conceptCode":"C29390","definition":"The hydrochloride salt form of pseudoephedrine, a phenethylamine and an diastereomer of ephedrine with sympathomimetic property. Pseudoephedrine hydrochloride displaces norepinephrine from storage vesicles in presynaptic neurones, thereby releasing norepinephrine into the neuronal synapses where it stimulates primarily alpha-adrenergic receptors. It also has weak direct agonist activity at alpha- and beta- adrenergic receptors. Receptor stimulation results in vasoconstriction and decreases nasal and sinus congestion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97CFA8BF-576E-66BC-E053-F662850AF2FF","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CFA8BF-5787-66BC-E053-F662850AF2FF","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Protamine Sulfate","valueDescription":"Protamine Sulfate","ValueMeaning":{"publicId":"7063289","version":"1","preferredName":"Protamine Sulfate","longName":"7063289","preferredDefinition":"A medication that is used to reverse the effects of heparin. It is specifically used in heparin overdose, in low molecular weight heparin overdose, and to reverse the effects of heparin during delivery and heart surgery.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97CFA8BF-5791-66BC-E053-F662850AF2FF","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CFA8BF-57AA-66BC-E053-F662850AF2FF","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Propylthiouracil","valueDescription":"Propylthiouracil","ValueMeaning":{"publicId":"7063290","version":"1","preferredName":"Propylthiouracil","longName":"7063290","preferredDefinition":"A thiourea derivative with antithyroid property. Propylthiouracil (PTU) interferes with the oxidation of iodine possibly by interaction with peroxidase or a peroxidase-mediated complex reaction, thereby inhibiting synthesis of thyroid hormones tri-iodothyronine (T3) and thyroxine (T4). In addition, this agent inhibits the Type I 5'-deiodinase (D1), an enzyme involved in the peripheral conversion of thyroxine to tri-iodothyronine. This results in decreased plasma triodothyronine concentrations and decreased entrance of thyroxine into cells thereby reducing thyroid hormone activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Propylthiouracil","conceptCode":"C781","definition":"A thiourea derivative with antithyroid property. Propylthiouracil (PTU) interferes with the oxidation of iodine possibly by interaction with peroxidase or a peroxidase-mediated complex reaction, thereby inhibiting synthesis of thyroid hormones tri-iodothyronine (T3) and thyroxine (T4). In addition, this agent inhibits the Type I 5'-deiodinase (D1), an enzyme involved in the peripheral conversion of thyroxine to tri-iodothyronine. This results in decreased plasma triodothyronine concentrations and decreased entrance of thyroxine into cells thereby reducing thyroid hormone activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97CFA8BF-57B4-66BC-E053-F662850AF2FF","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CFA8BF-57CD-66BC-E053-F662850AF2FF","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Propranolol HCL","valueDescription":"Propranolol Hydrochloride","ValueMeaning":{"publicId":"7063292","version":"1","preferredName":"Propranolol Hydrochloride","longName":"7063292","preferredDefinition":"The hydrochloride form of propranolol, a synthetic beta-adrenergic receptor blocker with antianginal, antiarrhythmic, and antihypertensive properties. Propranolol competitively antagonizes beta-adrenergic receptors, thereby inhibiting beta-adrenergic reactions, such as vasodilation, and negative chronotropic and inotropic effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Propranolol Hydrochloride","conceptCode":"C29382","definition":"The hydrochloride form of propranolol, a synthetic beta-adrenergic receptor blocker with antianginal, antiarrhythmic, and antihypertensive properties. Propranolol competitively antagonizes beta-adrenergic receptors, thereby inhibiting beta-adrenergic reactions, such as vasodilation, and negative chronotropic and inotropic effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97CFA8BF-57DA-66BC-E053-F662850AF2FF","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CFA8BF-57F3-66BC-E053-F662850AF2FF","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Goserelin","valueDescription":"GOSERELIN","ValueMeaning":{"publicId":"2563645","version":"1","preferredName":"GOSERELIN","longName":"2563645","preferredDefinition":"GOSERELIN","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Goserelin","conceptCode":"C1374","definition":"A synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity. Goserelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors. Prolonged administration of goserelin inhibits the secretion of pituitary gonadotropin, thereby decreasing levels of testosterone (in males) and estradiol (in females).  Administration of this agent in a depot formulation may result in the regression of sex hormone-sensitive tumors and a reduction in sex organ size and function. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C5AA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-12-05","endDate":null,"createdBy":"CVALMONT","dateCreated":"2002-12-05","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7F71-18F7-E053-F662850A60B1","beginDate":"2006-02-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Granisetron","valueDescription":"Granisetron Hydrochloride","ValueMeaning":{"publicId":"2577910","version":"1","preferredName":"Granisetron Hydrochloride","longName":"2577910","preferredDefinition":"The hydrochloride salt of an indazole derivative with antiemetic properties. As a selective serotonin receptor antagonist, granisetron competitively blocks the action of serotonin at 5-hydroxytryptamine3 (5-HT3) receptors, resulting in the suppression of chemotherapy- and radiotherapy-induced nausea and vomiting.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Granisetron Hydrochloride","conceptCode":"C1353","definition":"The hydrochloride salt of an indazole derivative with antiemetic properties. As a selective serotonin receptor antagonist, granisetron competitively blocks the action of serotonin at 5-hydroxytryptamine3 (5-HT3) receptors, resulting in the suppression of chemotherapy- and radiotherapy-induced nausea and vomiting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD63-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-23","modifiedBy":"ONEDATA","dateModified":"2006-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7F7B-18F7-E053-F662850A60B1","beginDate":"2006-02-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Grape Seed Extract","valueDescription":"GRAPE SEED EXTRACT","ValueMeaning":{"publicId":"2577911","version":"1","preferredName":"GRAPE SEED EXTRACT","longName":"2577911","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"GRAPE SEED EXTRACT","conceptCode":"C0772454","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD64-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-23","modifiedBy":"ONEDATA","dateModified":"2006-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7F85-18F7-E053-F662850A60B1","beginDate":"2006-02-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Guaifenesin","valueDescription":"Guaifenesin","ValueMeaning":{"publicId":"2577912","version":"1","preferredName":"Guaifenesin","longName":"2577912","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Guaifenesin","conceptCode":"C29081","definition":"A glyceryl guaiacolate with expectorant effects. Guaifenesin increases respiratory tract mucus secretions, acts as an irritant to gastric vagal receptors and recruits efferent parasympathetic reflexes that cause glandular exocytosis. This agent reduces the viscosity of mucus secretion by reducing adhesiveness and surface tension as well as increasing hydration of mucus. Guaifenesin promotes the efficiency of the mucociliary mechanism important in removing accumulated secretions from the upper and lower airway.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD65-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-23","modifiedBy":"ONEDATA","dateModified":"2006-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7F8F-18F7-E053-F662850A60B1","beginDate":"2006-02-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lotion","valueDescription":"Lotion","ValueMeaning":{"publicId":"2581083","version":"1","preferredName":"Lotion","longName":"2581083","preferredDefinition":"A liquid preparation for bathing the skin, or an injured or diseased part, either for a medicinal purpose, or for improving its appearance.|On-line Medical Dictionary\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lotion Dosage Form","conceptCode":"C29167","definition":"A semi-solid composed of an oil in water emulsion, with lower viscosity than cream or gel.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-09C8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"REEVESD","dateModified":"2006-09-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7F99-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lovastatin","valueDescription":"lovastatin","ValueMeaning":{"publicId":"2578246","version":"1","preferredName":"lovastatin","longName":"2578246","preferredDefinition":"A lactone metabolite isolated from the fungus Aspergillus terreus with cholesterol-lowering activity and potential antineoplastic activity. Lovastatin is hydrolyszed to the active beta-hydroxyacid form, which competitively inhibits 3-hydroxyl-3-methylgutarylcoenzyme A (HMG-CoA) reductase, an enzyme involved in the cholesterol biosynthesis.  In addition, this agent may inhibit tumor cell proliferation and reduce tumor cell invasiveness, thereby decreasing tumor metastatic potential; induce tumor cell apoptosis, possibly by inhibiting protein geranylgeranylation and; arrest cells in the G1 phase of the cell cycle, an effect that sensitizes tumor cells to the cytotoxic effects of ionizing radiation.  (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lovastatin","conceptCode":"C620","definition":"A lactone metabolite isolated from the fungus Aspergillus terreus with cholesterol-lowering and potential antineoplastic activities. Lovastatin is hydrolyzed to the active beta-hydroxyacid form, which competitively inhibits 3-hydroxyl-3-methylgutarylcoenzyme A (HMG-CoA) reductase, an enzyme involved in cholesterol biosynthesis. In addition, this agent may induce tumor cell apoptosis and inhibit tumor cell invasiveness, possibly by inhibiting protein farnesylation and protein geranylgeranylation, and may arrest cells in the G1 phase of the cell cycle. The latter effect sensitizes tumor cells to the cytotoxic effects of ionizing radiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEB3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-02-09","modifiedBy":"REEVESD","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7FA3-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lubriderm","valueDescription":"Lubriderm","ValueMeaning":{"publicId":"2578247","version":"1","preferredName":"Lubriderm","longName":"2578247","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Skin Care Product","conceptCode":"C29169","definition":"Any skin care product containing humectants, emollients and emulsifiers with moisturizing activity. These products increase the skin's hydration and are used to soften and protect dry skin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEB4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7FAD-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lubrin","valueDescription":"Lubrin","ValueMeaning":{"publicId":"2578248","version":"1","preferredName":"Lubrin","longName":"2578248","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vaginal Lubricant","conceptCode":"C29170","definition":"A vaginal lubricant containing a mixture of polyethylene glycols, glycerol and caprylic/capric triglyceride used to relieve discomfort due to vaginal dryness when applied intravaginally.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEB5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7FB7-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lutein","valueDescription":"Lutein","ValueMeaning":{"publicId":"2578249","version":"1","preferredName":"Lutein","longName":"2578249","preferredDefinition":"Lutein (LOO-teen) is a oxygenated carotenoid found in vegetables and fruits.  lutein is found in the macula of the eye, where it is believed to act as a yellow filter. Lutein acts as an antioxidant, protecting cells against the damaging effects of free radicals.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lutein","conceptCode":"C1965","definition":"Lutein (LOO-teen) is a oxygenated carotenoid found in vegetables and fruits.  lutein is found in the macula of the eye, where it is believed to act as a yellow filter. Lutein acts as an antioxidant, protecting cells against the damaging effects of free radicals.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEB6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7FC1-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lycopene","valueDescription":"Lycopene","ValueMeaning":{"publicId":"2578250","version":"1","preferredName":"Lycopene","longName":"2578250","preferredDefinition":"A linear, unsaturated hydrocarbon carotenoid, the major red pigment in fruits such as tomatoes, pink grapefruit, apricots, red oranges, watermelon, rosehips, and guava.  As a class, carotenoids are pigment compounds found in photosynthetic organisms (plants, algae, and some types of fungus), and are chemically characterized by a large polyene chain containing 35-40 carbon atoms; some carotenoid polyene chains are terminated by two 6-carbon rings.  In animals, carotenoids such as lycopene may possess antioxidant properties which may retard ageing and many degenerative diseases.  As an essential nutrient, lycopene is required in the animal diet. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lycopene","conceptCode":"C2226","definition":"A linear, unsaturated hydrocarbon carotenoid, the major red pigment in fruits such as tomatoes, pink grapefruit, apricots, red oranges, watermelon, rosehips, and guava.  As a class, carotenoids are pigment compounds found in photosynthetic organisms (plants, algae, and some types of fungus), and are chemically characterized by a large polyene chain containing 35-40 carbon atoms; some carotenoid polyene chains are terminated by two 6-carbon rings.  In animals, carotenoids such as lycopene may possess antioxidant properties which may retard aging and many degenerative diseases.  As an essential nutrient, lycopene is required in the animal diet. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEB7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7FCB-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lysine","valueDescription":"Lysine","ValueMeaning":{"publicId":"2578251","version":"1","preferredName":"Lysine","longName":"2578251","preferredDefinition":"One of nine essential amino acids in humans required for growth and tissue repair, Lysine is supplied by many foods, especially red meats, fish, and dairy products. Lysine seems to be active against herpes simplex viruses and present in many forms of diet supplements. The mechanism underlying this effect is based on the viral need for amino acid arginine; lysine competes with arginine for absorption and entry into cells. Lysine inhibits HSV growth by knocking out arginine. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lysine","conceptCode":"C29171","definition":"One of nine essential amino acids in humans required for growth and tissue repair, Lysine is supplied by many foods, especially red meats, fish, and dairy products. Lysine seems to be active against herpes simplex viruses and present in many forms of diet supplements. The mechanism underlying this effect is based on the viral need for amino acid arginine; lysine competes with arginine for absorption and entry into cells. Lysine inhibits HSV growth by knocking out arginine. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEB8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7FD5-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Maalox","valueDescription":"Maalox","ValueMeaning":{"publicId":"2578252","version":"1","preferredName":"Maalox","longName":"2578252","preferredDefinition":"An antacid consisting of either a single agent (Calcium Carbonate) or combination of agents (Aluminum Hydroxide and Magnesium Hydroxide). Some formulations contain an anti-gas agent (Simethicone). (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aluminum Hydroxide/Magnesium Hydroxide","conceptCode":"C1149","definition":"An oral suspension containing aluminum hydroxide and magnesium hydroxide, with antacid effects. Aluminum hydroxide and magnesium hydroxide neutralizes or reduces gastric acid, thereby relieving symptoms associated with indigestion, gastritis, and gastroesophageal disease (GERD). Combined with other liquid ingredients (such as lidocaine and diphenhydramine), this antacid provides relief for painful stomatitis, mucositis, and esophagitis associated with both chemotherapy and radiation therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEB9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7FDF-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Magic Mouthwash","valueDescription":"Magic Mouthwash","ValueMeaning":{"publicId":"2578253","version":"1","preferredName":"Magic Mouthwash","longName":"2578253","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Magic Mouthwash","conceptCode":"C29238","definition":"A combination preparation of mouth rinsing suspension containing an antacid, an antihistamine and an anesthetic agent. Usually, magic mouthwash consists of lidocaine for its anesthetic activity, the antihistamine diphenhydramine and the antacids aluminum hydroxide and/or magnesium hydroxide. Sucralfate, an anti-ulcer agent, can be added to the mouthwash to form a protective coating over the lesion areas by binding to the proteins at the inflamed mucous lining. In addition, the antimycotic agent nystatin is often added to stop fungal growth. Magic mouthwash is used to treat chemotherapy- and/or radiation-induced oral mucositis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEBA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7FE9-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Magnesium","valueDescription":"Magnesium","ValueMeaning":{"publicId":"2570438","version":"1","preferredName":"Magnesium","longName":"2570438","preferredDefinition":"An alkaline earth metal, Magnesium is important for many biochemical functions and reactions; for bone and muscle function, protein and fatty acid formation, activation of B vitamins, blood clotting, insulin secretion, and ATP formation. More than 300 enzymes require magnesium for catalytic action. The adult daily requirement is about 300 mg/day. Magnesium is found in many green plants, vegetables, and seeds; chlorophyll is a magnesium-centered porphyrin compound. Magnesium salts are used for magnesium deficiency supplementation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Magnesium","conceptCode":"C29239","definition":"An alkaline earth metal, Magnesium is important for many biochemical functions and reactions; for bone and muscle function, protein and fatty acid formation, activation of B vitamins, blood clotting, insulin secretion, and ATP formation. More than 300 enzymes require magnesium for catalytic action. The adult daily requirement is about 300 mg/day. Magnesium is found in many green plants, vegetables, and seeds; chlorophyll is a magnesium-centered porphyrin compound. Magnesium salts are used for magnesium deficiency supplementation. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E033-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7FF3-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Magnesium Chloride","valueDescription":"Magnesium Chloride","ValueMeaning":{"publicId":"2578254","version":"1","preferredName":"Magnesium Chloride","longName":"2578254","preferredDefinition":"Magnesium Chloride was used as a laxative. An alkaline earth metal, magnesium is important for many biochemical functions and reactions; for bone and muscle function, protein and fatty acid formation, activation of B vitamins, blood clotting, insulin secretion, and ATP formation. More than 300 enzymes require magnesium for catalytic action. The adult daily requirement is about 300 mg/day. Magnesium is found in many green plants, vegetables, and seeds; chlorophyll is a magnesium-centered porphyrin compound. Magnesium salts are used for magnesium deficiency supplementation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Magnesium Chloride","conceptCode":"C29240","definition":"Magnesium Chloride was used as a laxative. An alkaline earth metal, magnesium is important for many biochemical functions and reactions; for bone and muscle function, protein and fatty acid formation, activation of B vitamins, blood clotting, insulin secretion, and ATP formation. More than 300 enzymes require magnesium for catalytic action. The adult daily requirement is about 300 mg/day. Magnesium is found in many green plants, vegetables, and seeds; chlorophyll is a magnesium-centered porphyrin compound. Magnesium salts are used for magnesium deficiency supplementation. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEBB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7FFD-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Magnesium Citrate","valueDescription":"Magnesium Citrate","ValueMeaning":{"publicId":"2578255","version":"1","preferredName":"Magnesium Citrate","longName":"2578255","preferredDefinition":"Well absorbed into the bloodstream, Magnesium Citrate is used as a laxative or for supplementation in magnesium deficiency. Important for many biochemical functions and reactions, magnesium is needed for bone and muscle function, protein and fatty acid formation, activation of B vitamins, blood clotting, insulin secretion, and ATP formation. More than 300 enzymes require magnesium for catalytic action. The adult daily requirement is about 300 mg/day. Magnesium is found in many green plants, vegetables, and seeds; chlorophyll is a magnesium-centered porphyrin compound. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Magnesium Citrate","conceptCode":"C29241","definition":"The citrate salt of the element magnesium with cathartic activity. The cathartic action of magnesium cations appears to result, in part, from osmotically mediated water retention, which subsequently stimulates peristalsis. In addition, magnesium ions may also stimulate the activity of nitric oxide (NO) synthase and increase the biosynthesis of the phospholipid proinflammatory mediator platelet activating factor (PAF) in the gut. NO may stimulate intestinal secretion via prostaglandin- and cyclic GMP-dependent mechanisms while PAF produces significant stimulation of colonic secretion and gastrointestinal motility.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEBC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8007-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Magnesium Hydroxide","valueDescription":"Magnesium Hydroxide","ValueMeaning":{"publicId":"2578256","version":"1","preferredName":"Magnesium Hydroxide","longName":"2578256","preferredDefinition":"A solution of magnesium hydroxide with antacid and laxative properties. Milk of magnesium exerts its antacid activity in low doses such that all hydroxide ions that enter the stomach are used to neutralize stomach acid. This agent exerts its laxative effect in higher doses so that hydroxide ions are able to move from the stomach to the intestines where they attract and retain water, thereby increasing intestinal movement (peristalsis) and inducing the urge to defecate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Magnesium Hydroxide","conceptCode":"C29262","definition":"A solution of magnesium hydroxide with antacid and laxative properties. Milk of magnesium exerts its antacid activity in low doses such that all hydroxide ions that enter the stomach are used to neutralize stomach acid. This agent exerts its laxative effect in higher doses so that hydroxide ions are able to move from the stomach to the intestines where they attract and retain water, thereby increasing intestinal movement (peristalsis) and inducing the urge to defecate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEBD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8011-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Magnesium Oxide","valueDescription":"Magnesium Oxide","ValueMeaning":{"publicId":"2578257","version":"1","preferredName":"Magnesium Oxide","longName":"2578257","preferredDefinition":"An oxide of magnesium with antacid and laxative effects. Magnesium combines with water to form magnesium hydroxide that reacts chemically to neutralize or buffer existing quantities of stomach acid therefore increasing the pH of the stomach content as well as increasing the intra-esophageal pH resulting in a decrease in pepsin activity. Its laxative effect is executed in higher doses by attracting water from the intestines.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Magnesium Oxide","conceptCode":"C29242","definition":"The oxide salt of magnesium with antacid, laxative and vascular smooth muscle relaxant activities. Magnesium combines with water to form magnesium hydroxide which reacts chemically to neutralize or buffer existing quantities of stomach acid; stomach-content and intra-esophageal pH rise, resulting in a decrease in pepsin activity. This agent's laxative effect is the result, in part, of osmotically mediated water retention, which subsequently stimulates peristalsis. In addition, magnesium ions may behave as calcium antagonists in vascular smooth muscle.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEBE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-801B-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Magnesium Sulfate","valueDescription":"Magnesium Sulfate","ValueMeaning":{"publicId":"2578258","version":"1","preferredName":"Magnesium Sulfate","longName":"2578258","preferredDefinition":"A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Magnesium Sulfate","conceptCode":"C623","definition":"A magnesium salt of sulfuric acid, that can be used to normalize magnesium levels in the body, and to prevent seizures in eclampsia and preeclampsia. Magnesium is a divalent cation essential for a number of biochemical processes involved in nerve signaling, bone mineralization and muscle contractions. About 350 enzymes involved in glycolysis and the Krebs cycle, formation of cyclic-AMP and ATP, cellular signal transduction and protein and nucleic acid synthesis are dependent on magnesium. Magnesium blocks neuromuscular transmission and decreases the amount of acetylcholine liberated at the end plate by the motor nerve impulse, thereby preventing convulsions and seizures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEBF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8025-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Mannitol","valueDescription":"Mannitol","ValueMeaning":{"publicId":"2578259","version":"1","preferredName":"Mannitol","longName":"2578259","preferredDefinition":"A naturally occurring alcohol found in fruits and vegetables and used as an osmotic diuretic. Mannitol is freely filtered by the glomerulus and poorly reabsorbed from the renal tubule, thereby causing an increase in osmolarity of the glomerular filtrate. An increase in osmolarity limits tubular reabsorption of water and inhibits the renal tubular reabsorption of sodium, chloride, and other solutes, thereby promoting diuresis. In addition, mannitol elevates blood plasma osmolarity, resulting in enhanced flow of water from tissues into interstitial fluid and plasma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mannitol","conceptCode":"C625","definition":"A naturally occurring alcohol found in fruits and vegetables and used as an osmotic diuretic. Mannitol is freely filtered by the glomerulus and poorly reabsorbed from the renal tubule, thereby causing an increase in osmolarity of the glomerular filtrate. An increase in osmolarity limits tubular reabsorption of water and inhibits the renal tubular reabsorption of sodium, chloride, and other solutes, thereby promoting diuresis. In addition, mannitol elevates blood plasma osmolarity, resulting in enhanced flow of water from tissues into interstitial fluid and plasma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEC0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-802F-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Maxzide","valueDescription":"Maxzide","ValueMeaning":{"publicId":"2578260","version":"1","preferredName":"Maxzide","longName":"2578260","preferredDefinition":"A combination drug containing hydrochlorothiazide and triamterene used as a diuretic.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydrochlorothiazide-Triamterene","conceptCode":"C1388","definition":"A combination drug containing hydrochlorothiazide and triamterene used as a diuretic.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEC1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8039-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Medroxyprogesterone","valueDescription":"Medroxyprogesterone","ValueMeaning":{"publicId":"2578261","version":"1","preferredName":"Medroxyprogesterone","longName":"2578261","preferredDefinition":"A synthetic derivative of progesterone administered as an acetate salt (medroxyprogesterone acetate) with antiestrogenic activity. As a do all progestins, medroxyprogesterone binds to and activates nuclear receptors which subsequently bind to and activate target genes for transcription. As an antiestrogen, this agent may inhibit the growth-stimulating effects of estrogen on estrogen-sensitive tumor cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Medroxyprogesterone","conceptCode":"C629","definition":"A synthetic derivative of progesterone administered as an acetate salt (medroxyprogesterone acetate) with antiestrogenic activity. As a do all progestins, medroxyprogesterone binds to and activates nuclear receptors which subsequently bind to and activate target genes for transcription. As an antiestrogen, this agent may inhibit the growth-stimulating effects of estrogen on estrogen-sensitive tumor cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEC2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8043-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Megestrol","valueDescription":"Megestrol","ValueMeaning":{"publicId":"2576649","version":"1","preferredName":"Megestrol","longName":"2576649","preferredDefinition":"A synthetic derivative of progesterone with antiestrogenic activity.  Megestrol binds to and activates nuclear receptors which subsequently bind to and activate target genes for transcription. As an antiestrogen, this agent may inhibit the growth-stimulating effects of estrogen on estrogen-sensitive tumor cells. In addition, megestrol stimulates the appetite in cachectic subjects. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Megestrol","conceptCode":"C630","definition":"A synthetic derivative of progesterone with antiestrogenic activity. Megestrol binds to and activates nuclear receptors which subsequently bind to and activate target genes for transcription. As an antiestrogen, this agent may inhibit the growth-stimulating effects of estrogen on estrogen-sensitive tumor cells. In addition, megestrol stimulates appetite in cachectic subjects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F876-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-804D-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Meglumine Amidotrizoate","valueDescription":"Meglumine Amidotrizoate","ValueMeaning":{"publicId":"2578262","version":"1","preferredName":"Meglumine Amidotrizoate","longName":"2578262","preferredDefinition":"A contrast medium based on diatrizoic acid or amidotrizoic acid solutions.  Meglumine amidotrizoate is used in a wide variety of imaging procedures including: cerebral, thoracic, abdominal and extremity angiography, phlebography, computerized tomography, for visualisation of cavities of the body, amniography, arthrography, fistulography, hysterosalpingography, vesiculography. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diatrizoate Meglumine","conceptCode":"C29247","definition":"The meglumine salt form of diatrizoate, an organic, iodinated, radiopaque X-ray contrast medium used in diagnostic radiography. The iodine moiety of diatrizoate meglumine is not penetrable by X-rays, therefore blocks the X-ray film exposure by radiation. This makes it possible to distinguish on X-ray film, body parts that contain diatrizoate meglumine from body parts that do not contain this agent and allows for visualization of different body structures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEC3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8057-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Melatonin","valueDescription":"Melatonin","ValueMeaning":{"publicId":"2578263","version":"1","preferredName":"Melatonin","longName":"2578263","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melatonin","conceptCode":"C2267","definition":"A hormone involved in sleep regulatory activity, and a tryptophan-derived neurotransmitter, which inhibits the synthesis and secretion of other neurotransmitters such as dopamine and GABA. Melatonin is synthesized from serotonin intermediate in the pineal gland and the retina where the enzyme 5-hydroxyindole-O-methyltransferase, that catalyzes the last step of synthesis, is found. This hormone binds to and activates melatonin receptors and is involved in regulating the sleep and wake cycles. In addition, melatonin possesses antioxidative and immunoregulatory properties via regulating other neurotransmitters.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEC4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8061-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Meropenem","valueDescription":"Meropenem","ValueMeaning":{"publicId":"2578264","version":"1","preferredName":"Meropenem","longName":"2578264","preferredDefinition":"A broad-spectrum carbapenem with antibacterial properties, synthetic Meropenem inhibits cell wall synthesis in gram-positive and gram-negative bacteria. It penetrates cell walls and binds to penicillin-binding protein targets. Meropenem acts against aerobes and anaerobes including Klebsiella, E. coli, Enterococcus, Clostridium sp.. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Meropenem","conceptCode":"C1160","definition":"A broad-spectrum carbapenem with antibacterial properties, synthetic Meropenem inhibits cell wall synthesis in gram-positive and gram-negative bacteria. It penetrates cell walls and binds to penicillin-binding protein targets. Meropenem acts against aerobes and anaerobes including Klebsiella, E. coli, Enterococcus, Clostridium sp.. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEC5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-806B-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Mesalamine","valueDescription":"Mesalamine","ValueMeaning":{"publicId":"2578265","version":"1","preferredName":"Mesalamine","longName":"2578265","preferredDefinition":"An agent derived from sulfasalazine, an antiinflammatory agent.  Mesalamine may reduce inflammation through inhibition of cyclooxygenase and prostaglandin production. Following rectal or oral administration, only a small amount of mesalamine is absorbed; the remainder, acting topically, reduces bowel inflammation, diarrhea, rectal bleeding and stomach pain. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mesalamine","conceptCode":"C29249","definition":"An agent derived from sulfasalazine, an antiinflammatory agent.  Mesalamine may reduce inflammation through inhibition of cyclooxygenase and prostaglandin production. Following rectal or oral administration, only a small amount of mesalamine is absorbed; the remainder, acting topically, reduces bowel inflammation, diarrhea, rectal bleeding and stomach pain. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEC6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8075-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Mesna","valueDescription":"Mesna","ValueMeaning":{"publicId":"2578266","version":"1","preferredName":"Mesna","longName":"2578266","preferredDefinition":"A sulfhydryl compound that is used to reduce the incidence of hemorrhagic cystitis associated with certain chemotherapeutic agents.  Mesna is converted to a free thiol compound in the kidney, where it binds to and inactivates acrolein and other urotoxic metabolites of ifosfamide and cyclophosphamide, thereby reducing their toxic effects on the urinary tract during urinary excretion. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mesna","conceptCode":"C192","definition":"A sulfhydryl compound that is used to reduce the incidence of hemorrhagic cystitis associated with certain chemotherapeutic agents.  Mesna is converted to a free thiol compound in the kidney, where it binds to and inactivates acrolein and other urotoxic metabolites of ifosfamide and cyclophosphamide, thereby reducing their toxic effects on the urinary tract during urinary excretion. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEC7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-807F-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Methimazole","valueDescription":"Methimazole","ValueMeaning":{"publicId":"2578267","version":"1","preferredName":"Methimazole","longName":"2578267","preferredDefinition":"A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methimazole","conceptCode":"C641","definition":"A thioamide inhibitor of the enzyme thyroid peroxidase (TPO), with antithyroid activity. Upon administration, methimazole inhibits the metabolism of iodide and the iodination of tyrosine residues in the thyroid hormone precursor thyroglobulin by TPO; this prevents the synthesis of the thyroid hormones triiodothyronine (T3) and thyroxine (T4).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEC8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8089-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Methocarbamol","valueDescription":"Methocarbamol","ValueMeaning":{"publicId":"2578268","version":"1","preferredName":"Methocarbamol","longName":"2578268","preferredDefinition":"A carbamate with centrally acting muscle relaxant properties. Though the exact mechanism of action of methocarbamol was not established, it's postulated to be via a mechanism similar of carbamate, inhibition of acetylcholinesterase at synapses in the autonomic nervous system, neuromuscular junction, and central nervous system. Methocarbamol has no direct effect on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methocarbamol","conceptCode":"C29252","definition":"A carbamate with centrally acting muscle relaxant properties. Though the exact mechanism of action of methocarbamol was not established, it's postulated to be via a mechanism similar of carbamate, inhibition of acetylcholinesterase at synapses in the autonomic nervous system, neuromuscular junction, and central nervous system. Methocarbamol has no direct effect on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEC9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8093-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Methotrexate","valueDescription":"METHOTREXATE","ValueMeaning":{"publicId":"2561702","version":"1","preferredName":"METHOTREXATE","longName":"2561702","preferredDefinition":"METHOTREXATE","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methotrexate","conceptCode":"C642","definition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BE13-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-08","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-08","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-809D-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Methylcellulose","valueDescription":"Methylcellulose","ValueMeaning":{"publicId":"2577811","version":"1","preferredName":"Methylcellulose","longName":"2577811v1.00","preferredDefinition":"The methyl ether of cellulose with laxative activity. Methylcellulose is not absorbed by the intestines and attracts large amounts of water into the colon, thereby increasing viscosity, producing a softer and bulkier stool and stimulating the constriction of intestinal smooth muscles.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methylcellulose","conceptCode":"C29253","definition":"The methyl ether of cellulose with laxative activity. Methylcellulose is not absorbed by the intestines and attracts large amounts of water into the colon, thereby increasing viscosity, producing a softer and bulkier stool and stimulating the constriction of intestinal smooth muscles.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD00-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"CLOHNES","dateModified":"2023-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-80A7-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Methylprednisolone","valueDescription":"Methylprednisolone","ValueMeaning":{"publicId":"2578269","version":"1","preferredName":"Methylprednisolone","longName":"2578269","preferredDefinition":"A synthetic corticosteroid with anti-inflammatory and immunomodulating properties.  Methylprednisolone binds to and activates specific nuclear receptors, resulting in altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methylprednisolone","conceptCode":"C647","definition":"A synthetic corticosteroid with anti-inflammatory and immunomodulating properties.  Methylprednisolone binds to and activates specific nuclear receptors, resulting in altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FECA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-80B1-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Methyltestosterone","valueDescription":"Methyltestosterone","ValueMeaning":{"publicId":"2578270","version":"1","preferredName":"Methyltestosterone","longName":"2578270","preferredDefinition":"A methylated synthetic androgen receptor agonist with anabolic effects. Methyltestosterone, mimicking testosterone, binds to cytosolic androgen receptors, and the subsequent nuclear transfer of the ligand-receptor complex induces transcription initiation of androgen responsive genes. The gene products are responsible for normal growth and development of male sex organs and secondary sex characteristics. The agent also causes retention of nitrogen, sodium, potassium, phosphorus, as well as calcium.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methyltestosterone","conceptCode":"C648","definition":"A methylated synthetic androgen receptor agonist with anabolic effects. Methyltestosterone, mimicking testosterone, binds to cytosolic androgen receptors, and the subsequent nuclear transfer of the ligand-receptor complex induces transcription initiation of androgen responsive genes. The gene products are responsible for normal growth and development of male sex organs and secondary sex characteristics. The agent also causes retention of nitrogen, sodium, potassium, phosphorus, as well as calcium.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FECB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-80BB-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Metolazone","valueDescription":"Metolazone","ValueMeaning":{"publicId":"2578271","version":"1","preferredName":"Metolazone","longName":"2578271","preferredDefinition":"A sulfonamide derivative and a member of the quinazoline family, chemically related to thiazides, with diuretic, antihypertensive and antiurolithic properties. By blocking Na/Cl transporter, metolazone inhibits electrolyte reabsorption in the distal convoluted tubule and proximal tubule in the kidney. This prevents salt and fluid retention, leading to decreased plasma volume and reduce peripheral resistance of blood vessels, thereby reversal of hypertension.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metolazone","conceptCode":"C650","definition":"A long acting, quinazoline-based sulfonamide thiazide-like, diuretic. Similar to the thiazides, metolazone acts on the distal convoluted tubule (DCT) and inhibits the sodium-chloride symporter, thereby preventing sodium and chloride reabsorption and excretion of water.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FECC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-80C5-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Metoprolol Succinate","valueDescription":"Metoprolol Succinate","ValueMeaning":{"publicId":"2578272","version":"1","preferredName":"Metoprolol Succinate","longName":"2578272","preferredDefinition":"The succinate salt form of metoprolol, a cardioselective competitive beta-1 adrenergic receptor antagonist with antihypertensive properties and devoid of intrinsic sympathomimetic activity. Metoprolol succinate antagonizes beta 1-adrenergic receptors in the myocardium, thereby reducing the rate and force of myocardial contraction, and consequently a diminished cardiac output. This agent may also reduce the secretion of renin with subsequent reduction in levels of angiotensin II thus decreasing sympathetic activation, including vasoconstriction, aldosterone secretion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metoprolol Succinate","conceptCode":"C29254","definition":"The succinate salt form of metoprolol, a cardioselective competitive beta-1 adrenergic receptor antagonist with antihypertensive properties and devoid of intrinsic sympathomimetic activity. Metoprolol succinate antagonizes beta 1-adrenergic receptors in the myocardium, thereby reducing the rate and force of myocardial contraction, and consequently a diminished cardiac output. This agent may also reduce the secretion of renin with subsequent reduction in levels of angiotensin II thus decreasing sympathetic activation, including vasoconstriction, aldosterone secretion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FECD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-80CF-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Metoprolol Tartrate","valueDescription":"Metoprolol Tartrate","ValueMeaning":{"publicId":"2578273","version":"1","preferredName":"Metoprolol Tartrate","longName":"2578273","preferredDefinition":"The tartrate salt form of metoprolol, a cardioselective competitive beta-1 adrenergic receptor antagonist with antihypertensive properties and devoid of intrinsic sympathomimetic activity. Metoprolol tartrate antagonizes beta 1-adrenergic receptors in the myocardium, thereby reducing the rate and force of myocardial contraction, and consequently a diminished cardiac output. This agent may also reduce the secretion of renin with subsequent reduction in levels of angiotensin II thus decreasing sympathetic activation, including vasoconstriction, aldosterone secretion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metoprolol Tartrate","conceptCode":"C29255","definition":"The tartrate salt form of metoprolol, a cardioselective competitive beta-1 adrenergic receptor antagonist with antihypertensive properties and devoid of intrinsic sympathomimetic activity. Metoprolol tartrate antagonizes beta 1-adrenergic receptors in the myocardium, thereby reducing the rate and force of myocardial contraction, and consequently a diminished cardiac output. This agent may also reduce the secretion of renin with subsequent reduction in levels of angiotensin II thus decreasing sympathetic activation, including vasoconstriction, aldosterone secretion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FECE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-80D9-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Metronidazole","valueDescription":"Metronidazole","ValueMeaning":{"publicId":"2578274","version":"1","preferredName":"Metronidazole","longName":"2578274","preferredDefinition":"A synthetic nitroimidazole derivative with antiprotozoal and antibacterial. The mechanism of action is not fully elucidated but un-ionized metronidazole is readily taken up by obligate anaerobic organisms and is reduced by low-redox potential electron-transport proteins to an active, intermediate product. Reduced metronidazole causes DNA strand breaks, thereby inhibiting DNA synthesis and blocking growth of bacterial cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metronidazole","conceptCode":"C651","definition":"A synthetic nitroimidazole derivative with antiprotozoal and antibacterial activities. Although its mechanism of action is not fully elucidated, un-ionized metronidazole is readily taken up by obligate anaerobic organisms and is subsequently reduced by low-redox potential electron-transport proteins to an active, intermediate product. Reduced metronidazole causes DNA strand breaks, thereby inhibiting DNA synthesis and bacterial cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FECF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-80E3-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Hydroxyurea","valueDescription":"Hydroxyurea","ValueMeaning":{"publicId":"2578118","version":"1","preferredName":"Hydroxyurea","longName":"2578118","preferredDefinition":"A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle.  This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydroxyurea","conceptCode":"C560","definition":"A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle.  This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE33-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-80ED-18F7-E053-F662850A60B1","beginDate":"2006-03-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Hydroxyzine","valueDescription":"Hydroxyzine","ValueMeaning":{"publicId":"2578119","version":"1","preferredName":"Hydroxyzine","longName":"2578119","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydroxyzine","conceptCode":"C29103","definition":"A piperazine derivative with antihistamine, antiemetic, and anxiolytic properties. Hydroxyzine's antihistaminic effect is due to its metabolite, cetirizine, a potent H1 receptor antagonist and selective inhibitor of peripheral H1 receptors. This agent competes with histamine for binding at H1-receptor sites on the effector cell surface. The sedative properties of hydroxyzine occur as a result of suppression of certain subcortical regions of the brain. Secondary to its central anticholinergic actions, hydroxyzine may be effective as an antiemetic.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE34-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-80F7-18F7-E053-F662850A60B1","beginDate":"2006-03-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Hepatox","valueDescription":"Hepatitis B Vaccine","ValueMeaning":{"publicId":"2578114","version":"1","preferredName":"Hepatitis B Vaccine","longName":"2578114","preferredDefinition":"A non-infectious mixture containing recombinant hepatitis B surface antigen (HBsAg) in a liquid vehicle.  Immunization with the hepatitis B vaccine induces the formation of specific anti-hepatitis B antibodies and an active immunity against hepatitis B infection. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatitis B Vaccine","conceptCode":"C29091","definition":"A non-infectious mixture containing recombinant hepatitis B surface antigen (HBsAg) in a liquid vehicle. Immunization with the hepatitis B vaccine induces the formation of specific anti-hepatitis B antibodies and an active immunity against hepatitis B infection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE2F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"ONEDATA","dateModified":"2006-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8101-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Losartan/Hydrochlorothiazide","valueDescription":"Losartan/Hydrochlorothiazide","ValueMeaning":{"publicId":"2578278","version":"1","preferredName":"Losartan/Hydrochlorothiazide","longName":"2578278v1.00","preferredDefinition":"A combination preparation of a synthetic angiotensin II antagonist and a diuretic thiazide, with antihypertensive activity. Losartan, and its metabolite, selectively and competitively block the binding of angiotensin II to the angiotensin II (AT1) receptor. As a result, angiotensin II-AT1 mediated physiological effects such as vasoconstriction and stimulation of aldosterone synthesis and secretion, which regulates extracellular sodium concentration, are blocked. Hydrochlorothiazide inhibits electrolytes reabsorption via binding to Na-Cl cotransporter on the renal distal tubular, thereby increasing excretion of sodium, potassium, chloride, bicarbonate and water. Both agents lead to a reduction in blood pressure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Losartan/Hydrochlorothiazide","conceptCode":"C29166","definition":"A combination preparation of a synthetic angiotensin II antagonist and a diuretic thiazide, with antihypertensive activity. Losartan, and its metabolite, selectively and competitively block the binding of angiotensin II to the angiotensin II (AT1) receptor. As a result, angiotensin II-AT1 mediated physiological effects such as vasoconstriction and stimulation of aldosterone synthesis and secretion, which regulates extracellular sodium concentration, are blocked. Hydrochlorothiazide inhibits electrolytes reabsorption via binding to Na-Cl cotransporter on the renal distal tubular, thereby increasing excretion of sodium, potassium, chloride, bicarbonate and water. Both agents lead to a reduction in blood pressure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FED3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"CLOHNES","dateModified":"2023-09-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-810B-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lotrel","valueDescription":"Amlodipine Besylate/Benazepril Hydrochloride","ValueMeaning":{"publicId":"2578279","version":"1","preferredName":"Amlodipine Besylate/Benazepril Hydrochloride","longName":"2578279","preferredDefinition":"Having a substantial blood pressure lowering capability, Amlodipine Besylate Benazepril Hydrochloride contains a dihydropyridine calcium blocker (amlodipine) and an angiotensin-converting enzyme (ACE) inhibitor (benazepril). A long-acting calcium channel antagonist, Amlodipine inhibits transmembrane calcium influx into vascular smooth muscle. Blocking ACE, Benazepril decreases vasopressive plasma angiotensin II. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amlodipine Besylate/Benazepril Hydrochloride","conceptCode":"C29168","definition":"Having a substantial blood pressure lowering capability, Amlodipine Besylate Benazepril Hydrochloride contains a dihydropyridine calcium blocker (amlodipine) and an angiotensin-converting enzyme (ACE) inhibitor (benazepril). A long-acting calcium channel antagonist, Amlodipine inhibits transmembrane calcium influx into vascular smooth muscle. Blocking ACE, Benazepril decreases vasopressive plasma angiotensin II. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FED4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8115-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Magnesium Gluconate","valueDescription":"Magnesium Gluconate","ValueMeaning":{"publicId":"2578280","version":"1","preferredName":"Magnesium Gluconate","longName":"2578280v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Magnesium Gluconate","conceptCode":"C76081","definition":"No value exists.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FED5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"CLOHNES","dateModified":"2023-08-04","changeDescription":null,"administrativeNotes":"8/4/23 Added missing concept per cleanup activities cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-811F-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Magnesium Trisalicylate","valueDescription":"Choline Magnesium Trisalicylate","ValueMeaning":{"publicId":"2578281","version":"1","preferredName":"Choline Magnesium Trisalicylate","longName":"2578281v1.00","preferredDefinition":"A nonsteroidal anti-inflammatory drug (NSAID) belonging to the salicylate family.  Choline magnesium trisalicylate inhibits inflammation-related prostaglandin synthesis. This agent's analgesic effect is mediated through peripheral and central pathways, resulting in a decrease in pain perception; its antipyretic effect is mediated via the hypothalamic heat regulation center. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Choline Magnesium Trisalicylate","conceptCode":"C29244","definition":"A nonsteroidal anti-inflammatory drug (NSAID) belonging to the salicylate family.  Choline magnesium trisalicylate inhibits inflammation-related prostaglandin synthesis. This agent's analgesic effect is mediated through peripheral and central pathways, resulting in a decrease in pain perception; its antipyretic effect is mediated via the hypothalamic heat regulation center. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FED6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"CLOHNES","dateModified":"2023-09-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8129-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Meclizine HCL","valueDescription":"Meclizine Hydrochloride","ValueMeaning":{"publicId":"2578282","version":"1","preferredName":"Meclizine Hydrochloride","longName":"2578282","preferredDefinition":"The hydrochloride salt form of meclizine, a synthetic piperazine with anti-emetic, sedative and histamine H1 antagonistic properties. Meclizine hydrochloride blocks the H1 histamine receptor and prevents the symptoms that are caused by histamine activity on capillaries, bronchial and gastrointestinal smooth muscles, including vasodilation, increased capillary permeability, bronchoconstriction, and spasmodic contraction of gastrointestinal smooth muscles. Meclizine hydrochloride may exert its antiemetic effects by its anticholinergic actions or due to a direct effect on the medullary chemoreceptive trigger zone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Meclizine Hydrochloride","conceptCode":"C29245","definition":"The hydrochloride salt form of meclizine, a synthetic piperazine with anti-emetic, sedative and histamine H1 antagonistic properties. Meclizine hydrochloride blocks the H1 histamine receptor and prevents the symptoms that are caused by histamine activity on capillaries, bronchial and gastrointestinal smooth muscles, including vasodilation, increased capillary permeability, bronchoconstriction, and spasmodic contraction of gastrointestinal smooth muscles. Meclizine hydrochloride may exert its antiemetic effects by its anticholinergic actions or due to a direct effect on the medullary chemoreceptive trigger zone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FED7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8133-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Medroxyprogesterone Acetate","valueDescription":"Medroxyprogesterone 17-Acetate","ValueMeaning":{"publicId":"2578283","version":"1","preferredName":"Medroxyprogesterone 17-Acetate","longName":"2578283","preferredDefinition":"A synthetic, acetate derivative of the sex hormone progesterone.  Medroxyprogesterone 17-acetate (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Medroxyprogesterone Acetate","conceptCode":"C1155","definition":"A synthetic, acetate derivative of the sex hormone progesterone.  Medroxyprogesterone 17-acetate (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FED8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-813D-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Meloxicam","valueDescription":"Meloxicam","ValueMeaning":{"publicId":"2578284","version":"1","preferredName":"Meloxicam","longName":"2578284","preferredDefinition":"An oxicam derivative and a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Unlike traditional nonselective NSAIDs, meloxicam preferentially inhibits the activity of cyclo-oxygenase II (COX-II), resulting in a decreased conversion of arachidonic acid into prostaglandin precursors. The resulting decrease in prostaglandin synthesis is responsible for the therapeutic effects of meloxicam.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Meloxicam","conceptCode":"C61439","definition":"An oxicam derivative and a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Unlike traditional nonselective NSAIDs, meloxicam preferentially inhibits the activity of cyclo-oxygenase II (COX-II), resulting in a decreased conversion of arachidonic acid into prostaglandin precursors. The resulting decrease in prostaglandin synthesis is responsible for the therapeutic effects of meloxicam.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FED9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"COOPERM","dateModified":"2020-10-29","changeDescription":"Updated definition with current NCIt concept. 10.29.20 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8147-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Meperidine","valueDescription":"Meperidine Hydrochloride","ValueMeaning":{"publicId":"2578285","version":"1","preferredName":"Meperidine Hydrochloride","longName":"2578285","preferredDefinition":"A synthetic piperidine ester with opioid analgesic activity. Mepiridine mimics the actions of endogenous neuropeptides via opioid receptors, thereby producing the characteristic morphine-like effects on the mu-opioid receptor, including analgesia, euphoria, sedation, respiratory depression, miosis, bradycardia and physical dependence.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Meperidine Hydrochloride","conceptCode":"C635","definition":"The hydrochloride salt of a synthetic piperidine ester with opioid analgesic activity. Meperidine mimics the actions of endogenous neuropeptides via opioid receptors such as the mu-opioid receptor, thereby producing characteristic morphine-like effects including analgesia, euphoria, sedation, respiratory depression, miosis, bradycardia and physical dependence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEDA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8151-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Mephenytoin","valueDescription":"Mephenytoin","ValueMeaning":{"publicId":"2578286","version":"1","preferredName":"Mephenytoin","longName":"2578286v1.00","preferredDefinition":"A heterocyclic organic compound with anticonvulsant property. Although the mechanism of action is not well established, mephenytoin potentially promotes sodium efflux from neurons in motor cortex, and stabilizes the threshold against hyperexcitability caused by excessive stimulation. Thus this agent reduces the membrane sodium gradient and prevents cortical seizure signal spreading. It may cause blood dyscrasias, therefore, this agent was only used after other less toxic anticonvulsants had failed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mephenytoin","conceptCode":"C66091","definition":"A heterocyclic organic compound with anticonvulsant property. Although the mechanism of action is not well established, mephenytoin potentially promotes sodium efflux from neurons in motor cortex, and stabilizes the threshold against hyperexcitability caused by excessive stimulation. Thus this agent reduces the membrane sodium gradient and prevents cortical seizure signal spreading. It may cause blood dyscrasias, therefore, this agent was only used after other less toxic anticonvulsants had failed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEDB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"CLOHNES","dateModified":"2023-09-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-815B-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Nystatin/Triamcinolone Acetonide","valueDescription":"Nystatin/Triamcinolone Acetonide","ValueMeaning":{"publicId":"7060411","version":"1","preferredName":"Nystatin/Triamcinolone Acetonide","longName":"7060411","preferredDefinition":"A combination medicine used to treat skin infections caused by fungus or yeast.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"979E2D86-BA6B-5C1A-E053-F662850A4840","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"COOPERM","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"979E2D86-BA84-5C1A-E053-F662850A4840","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Nisoldipine","valueDescription":"Nisoldipine","ValueMeaning":{"publicId":"7060412","version":"1","preferredName":"Nisoldipine","longName":"7060412","preferredDefinition":"A dihydropyridine calcium channel blocking agent. Nisoldipine inhibits the transmembrane influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility. This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in some multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nisoldipine","conceptCode":"C29291","definition":"A dihydropyridine calcium channel blocking agent. Nisoldipine inhibits the transmembrane influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility. This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in some multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"979E2D86-BA90-5C1A-E053-F662850A4840","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"979E2D86-BAA9-5C1A-E053-F662850A4840","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Neomycin Sulfate/Polymyxin B Sulfate/Dexamethasone","valueDescription":"Neomycin Sulfate/Polymyxin B Sulfate/Dexamethasone","ValueMeaning":{"publicId":"7060413","version":"1","preferredName":"Neomycin Sulfate/Polymyxin B Sulfate/Dexamethasone","longName":"7060413","preferredDefinition":"A topical combination preparation containing the sulfate salt form of the aminoglycoside antibiotic neomycin, the sulfate salt form of the polypeptide antibiotic polymyxin B, and the glucocorticoid dexamethasone, with antimicrobial, anti-infective and anti-inflammatory activities. Upon topical application, neomycin irreversibly binds to the bacterial 30S ribosomal subunit, thereby preventing mRNA from binding, causing both misreading and the inhibition of protein synthesis. Polymyxin B binds, with its positively charged amino groups, to negatively charged phospholipids in the outer cell membrane of Gram-negative bacteria, thereby disrupting cell wall integrity and altering the permeability of the bacterial cytoplasmic membrane. Dexamethasone binds to the cytoplasmic glucocorticoid receptor, and this receptor-ligand complex is translocated to the nucleus where it initiates the transcription of genes encoding for anti-inflammatory mediators, such as cytokines and lipocortins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neomycin Sulfate/Polymyxin B Sulfate/Dexamethasone","conceptCode":"C121617","definition":"A topical combination preparation containing the sulfate salt form of the aminoglycoside antibiotic neomycin, the sulfate salt form of the polypeptide antibiotic polymyxin B, and the glucocorticoid dexamethasone, with antimicrobial, anti-infective and anti-inflammatory activities. Upon topical application, neomycin irreversibly binds to the bacterial 30S ribosomal subunit, thereby preventing mRNA from binding, causing both misreading and the inhibition of protein synthesis. Polymyxin B binds, with its positively charged amino groups, to negatively charged phospholipids in the outer cell membrane of Gram-negative bacteria, thereby disrupting cell wall integrity and altering the permeability of the bacterial cytoplasmic membrane. Dexamethasone binds to the cytoplasmic glucocorticoid receptor, and this receptor-ligand complex is translocated to the nucleus where it initiates the transcription of genes encoding for anti-inflammatory mediators, such as cytokines and lipocortins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"979E2D86-BAB5-5C1A-E053-F662850A4840","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"979E2D86-BAD0-5C1A-E053-F662850A4840","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Methyldopa","valueDescription":"Methyldopa","ValueMeaning":{"publicId":"7060415","version":"1","preferredName":"Methyldopa","longName":"7060415","preferredDefinition":"A phenylalanine derivative and an aromatic amino acid decarboxylase inhibitor with antihypertensive activity. Methyldopa is a prodrug and is metabolized in the central nervous system. The antihypertensive action of methyldopa seems to be attributable to its conversion into alpha-methylnorepinephrine, which is a potent alpha-2 adrenergic agonist that binds to and stimulates potent central inhibitory alpha-2 adrenergic receptors. This results in a decrease in sympathetic outflow and decreased blood pressure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methyldopa","conceptCode":"C47616","definition":"A phenylalanine derivative and an aromatic amino acid decarboxylase inhibitor with antihypertensive activity. Methyldopa is a prodrug and is metabolized in the central nervous system. The antihypertensive action of methyldopa seems to be attributable to its conversion into alpha-methylnorepinephrine, which is a potent alpha-2 adrenergic agonist that binds to and stimulates potent central inhibitory alpha-2 adrenergic receptors. This results in a decrease in sympathetic outflow and decreased blood pressure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"979E2D86-BADD-5C1A-E053-F662850A4840","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"979E2D86-BAFA-5C1A-E053-F662850A4840","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Everolimus","valueDescription":"Everolimus","ValueMeaning":{"publicId":"3379525","version":"1","preferredName":"Everolimus","longName":"3379525","preferredDefinition":"A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Everolimus","conceptCode":"C48387","definition":"A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-3294-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"COOPERM","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"979E2D86-BB04-5C1A-E053-F662850A4840","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Enzalutamide","valueDescription":"Enzalutamide","ValueMeaning":{"publicId":"5424693","version":"1","preferredName":"Enzalutamide","longName":"5424693","preferredDefinition":"An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Enzalutamide","conceptCode":"C71744","definition":"An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A6CD4EC-B2B3-871B-E050-BB89AD435B24","latestVersionIndicator":"Yes","beginDate":"2016-08-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"979E2D86-BB18-5C1A-E053-F662850A4840","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Metamucil","valueDescription":"Psyllium","ValueMeaning":{"publicId":"2578287","version":"1","preferredName":"Psyllium","longName":"2578287","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Psyllium Husk","conceptCode":"C29250","definition":"The husk of the dried ripe seeds of the Plantago psyllium, P. Indica, P. Ovata, and P. Arenaria plants with laxative and cholesterol lowering activities. The husks contain mucilage that swells on exposure to water and provides an indigestible mucilaginous mass in the intestines, thereby causing lubrication, contraction of the smooth muscles of the intestinal walls, and thus stimulating bowel movement. Psyllium husk is rich in soluble fiber and has a cholesterol-lowering effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEDC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8165-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Metformin HCL","valueDescription":"Metformin Hydrochloride","ValueMeaning":{"publicId":"2578288","version":"1","preferredName":"Metformin Hydrochloride","longName":"2578288","preferredDefinition":"The hydrochloride salt form of metformin, a biguanide with antihyperglycemic activity. Metformin hydrochloride exerts its action by improving hepatic sensitivity to insulin, thereby suppressing hepatic glucose production and increasing hepatic glycogen stores. In addition, metformin hydrochloride increases the number and/or affinity of insulin receptors on cell surface membranes in muscle and adipose tissue, thereby increasing the sensitivity to insulin at receptor and post-receptor binding sites and increasing glucose uptake peripherally.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metformin Hydrochloride","conceptCode":"C29251","definition":"The hydrochloride salt of the biguanide metformin with antihyperglycemic and potential antineoplastic activities. Metformin inhibits complex I (NADPH:ubiquinone oxidoreductase) of the mitochondrial respiratory chain, thereby increasing the cellular AMP to ATP ratio and leading to activation of AMP-activated protein kinase (AMPK) and regulating AMPK-mediated transcription of target genes. This eventually prevents hepatic gluconeogenesis, enhances insulin sensitivity and fatty acid oxidation and ultimately leads to a decrease in glucose levels. Metformin may exert antineoplastic effects through AMPK-mediated or AMPK-independent inhibition of mammalian target of rapamycin (mTOR), which is up-regulated in many cancer tissues. Furthermore, this agent also inhibits tumor cell migration and invasion by inhibiting matrix metalloproteinase-9 (MMP-9) expression which is mediated through the suppression of transcription activator protein-1 (AP-1) activation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEDD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-816F-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Methadone HCL","valueDescription":"Methadone Hydrochloride","ValueMeaning":{"publicId":"2578289","version":"1","preferredName":"Methadone Hydrochloride","longName":"2578289","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methadone Hydrochloride","conceptCode":"C0721688","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEDE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8179-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Methenamine","valueDescription":"Methenamine Hippurate","ValueMeaning":{"publicId":"2578290","version":"1","preferredName":"Methenamine Hippurate","longName":"2578290v1.00","preferredDefinition":"The hippurate salt form of methenamine, a prodrug and inactive weak base that slowly hydrolyzes in acidic urine to ammonia and the effective, urinary tract antiseptic formaldehyde. Formaldehyde probably exerts its antibacterial effect by denaturation of protein. Depending on the urinary concentrations, formaldehyde is either bactericidal or bacteriostatic. Formaldehyde urinary concentrations are dependent on urine pH, volume, and flow rate. Formaldehyde acts as an antibacterial agent against gram-positive and gram-negative organisms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methenamine Hippurate","conceptCode":"C47610","definition":"The hippurate salt form of methenamine, a prodrug and inactive weak base that slowly hydrolyzes in acidic urine to ammonia and the effective, urinary tract antiseptic formaldehyde. Formaldehyde probably exerts its antibacterial effect by denaturation of protein. Depending on the urinary concentrations, formaldehyde is either bactericidal or bacteriostatic. Formaldehyde urinary concentrations are dependent on urine pH, volume, and flow rate. Formaldehyde acts as an antibacterial agent against gram-positive and gram-negative organisms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEDF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"CLOHNES","dateModified":"2023-09-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8183-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Methylphenidate HCL","valueDescription":"Methylphenidate Hydrochloride","ValueMeaning":{"publicId":"2578291","version":"1","preferredName":"Methylphenidate Hydrochloride","longName":"2578291","preferredDefinition":"The hydrochloride salt of a synthetic central nervous system stimulant. Methylphenidate appears to activate the brain stem arousal system and cortex to produce its stimulant effect and, in some clinical settings, may improve cognitive function.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methylphenidate Hydrochloride","conceptCode":"C646","definition":"The hydrochloride salt of the synthetic central nervous system stimulant methylphenidate. Methylphenidate appears to activate the brain stem arousal system and cortex to produce its stimulant effect and, in some clinical settings, may improve cognitive function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEE0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-818D-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Methylsulfonyl Methane","valueDescription":"dimethyl sulfone","ValueMeaning":{"publicId":"2578292","version":"1","preferredName":"dimethyl sulfone","longName":"2578292","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"dimethyl sulfone","conceptCode":"C0058231","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEE1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8197-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Metoclopramide","valueDescription":"Metoclopramide Hydrochloride","ValueMeaning":{"publicId":"2578293","version":"1","preferredName":"Metoclopramide Hydrochloride","longName":"2578293","preferredDefinition":"A substituted benzamide and a derivative of para-aminobenzoic acid (PABA) that is structurally related to procainamide, with gastroprokinetic and antiemetic effects. Metoclopramide exerts its prokinetic effect by antagonizing dopamine mediated relaxation effect on gastrointestinal smooth muscle. This enhances the response of the gastrointestinal smooth muscle to cholinergic stimulation, thereby leading to an increase of gastric emptying into the intestines. Metoclopramide may also strengthen the lower esophagus sphincter, thereby preventing acid reflux. This agent antagonizes D2 dopamine receptors in chemoreceptive trigger zone (CTZ) of the medulla, thereby preventing nausea and vomiting.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metoclopramide Hydrochloride","conceptCode":"C649","definition":"The hydrochloride salt of the substituted benzamide metoclopramide, a para-aminobenzoic acid (PABA) derivative that is structurally related to procainamide, with gastroprokinetic and antiemetic activities. Metoclopramide binds to dopamine 2 (D2) receptors in the peripheral nervous system (PNS), antagonizing dopamine-mediated relaxation of gastrointestinal smooth muscle and promoting gastroprokinesis; the pyloric sphincter and the duodenal bulb are relaxed, peristalsis of the duodenum and jejunum increase, and gastric emptying and intestinal transit accelerate. This agent may also increase the resting tone of the lower esophagus sphincter (LES), preventing acid reflux. In the central nervous system (CNS), metoclopramide antagonizes D2 dopamine receptors in the chemoreceptive trigger zone (CTZ) of the medulla, thereby preventing nausea and vomiting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEE2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-81A1-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Mexiletine","valueDescription":"Mexiletine Hydrochloride","ValueMeaning":{"publicId":"2578294","version":"1","preferredName":"Mexiletine Hydrochloride","longName":"2578294","preferredDefinition":"A local anesthetic and antiarrhythmic (Class IB) agent structurally related to lidocaine. Mexiletine exerts its antiarrhythmic effect by inhibiting the inward sodium current in cardiac cells, thereby reducing the rate of rise of the cardiac action potential (phase 0) and decreases automaticity in the Purkinje fibers. This slows nerve impulses in the heart and stabilizes the heartbeat. Mexiletine's anesthetic activity is due to its ability to block sodium influx in peripheral nerves, thereby reducing the rate and intensity of pain impulses reaching the central nervous system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mexiletine Hydrochloride","conceptCode":"C652","definition":"The hydrochloride salt form of mexiletine, a local anesthetic and antiarrhythmic (Class IB) agent structurally related to lidocaine. Mexiletine exerts its antiarrhythmic effect by inhibiting the inward sodium current in cardiac cells, thereby reducing the rate of rise of the cardiac action potential (phase 0) and decreases automaticity in the Purkinje fibers. This slows nerve impulses in the heart and stabilizes the heartbeat. Mexiletine's anesthetic activity is due to its ability to block sodium influx in peripheral nerves, thereby reducing the rate and intensity of pain impulses reaching the central nervous system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEE3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-81AB-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Milk Thistle","valueDescription":"Milk Thistle","ValueMeaning":{"publicId":"2578295","version":"1","preferredName":"Milk Thistle","longName":"2578295","preferredDefinition":"A substance derived from any of several Old World coarse prickly-leaved shrubs and subshrubs including the plant Silybum marianum.  Milk thistle's active chemical component is silymarin, which is a combination of flavonoids such as silibinin, dehydrosilibinin, silychristin and silydianin.  These compounds are antioxidants and may alter the membrane structure of the liver cell, thereby blocking the absorption of toxins; they may also stimulate the production of new liver cells. In addition, milk thistle may increase cellular adenosine triphosphate (ATP) levels, exhibiting dose-dependent cardiac myocyte cytoprotection against doxorubicin.  The silibinin component of milk thistle has been shown to inhibit growth factor receptor-mediated mitogenic and cell survival signaling, thereby inhibiting tumor growth. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Milk Thistle","conceptCode":"C29261","definition":"A substance derived from any of several Old World coarse prickly-leaved shrubs and subshrubs including the plant Silybum marianum.  Milk thistle's active chemical component is silymarin, which is a combination of flavonoids such as silibinin, dehydrosilibinin, silychristin and silydianin.  These compounds are antioxidants and may alter the membrane structure of the liver cell, thereby blocking the absorption of toxins; they may also stimulate the production of new liver cells. In addition, milk thistle may increase cellular adenosine triphosphate (ATP) levels, exhibiting dose-dependent cardiac myocyte cytoprotection against doxorubicin.  The silibinin component of milk thistle has been shown to inhibit growth factor receptor-mediated mitogenic and cell survival signaling, thereby inhibiting tumor growth. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEE4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-81B5-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Milrinone Lactate","valueDescription":"Milrinone Lactate","ValueMeaning":{"publicId":"2578296","version":"1","preferredName":"Milrinone Lactate","longName":"2578296","preferredDefinition":"A bipyridine agent with positive inotropic and vasodilator properties.  Milrinone lactate selectively inhibits fraction III cyclic adenosine monophosphate (cAMP) phosphodiesterase isozymes in the heart and vascular muscles, thereby increasing cAMP and, consequently, an increase in cAMP-dependent intracellular ionized calcium and myocardium contractile force, and vasodilation in arteriolar and venous vascular smooth muscle.  This agent improves hemodynamics in patients with ventricular dysfunction by increasing the stroke volume index and left ventricular contractility and by producing pulmonary vasodilation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Milrinone Lactate","conceptCode":"C29263","definition":"The lactate salt form of milrinone, a cardiovascular bipyridine agent and phosphodiesterase (PDE) III inhibitor, with positive inotropic and vasodilator activities.  Upon administration, milrinone selectively inhibits PDE-mediated degradation of cyclic adenosine monophosphate (cAMP) in the heart and vascular muscles, thereby increasing cAMP and activates protein kinase A (PKA). This leads to phosphorylation of calcium ion channels and improve myocardium contractile force. Milrinone also causes vasodilation in arteriolar and venous vascular smooth muscle.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEE5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-81BF-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Mineral Oil","valueDescription":"Mineral Oil","ValueMeaning":{"publicId":"2578297","version":"1","preferredName":"Mineral Oil","longName":"2578297","preferredDefinition":"A mixture of liquid paraffinic, naphthenic and polycyclic aromatic hydrocarbons obtained from petroleum in which the amount and types of aromatic hydrocarbons is dependent on the treatment process. Untreated and mildly treated mineral oils contain the highest amount of aromatic and unsaturated compounds and are primarily used as a lubricant base oil to produce further refined oil products. Exposure to these types of mineral oils can cause rapid respiration, cyanosis, tachycardia and low-grade fever. Untreated and mildly treated mineral oils are strongly associated with an increased risk of scrotal and skin cancer but can also cause gastrointestinal, rectal, bladder and certain respiratory-tract cancers. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mineral Oil","conceptCode":"C29264","definition":"A mixture of liquid paraffinic, naphthenic and polycyclic aromatic hydrocarbons obtained from petroleum in which the amount and types of aromatic hydrocarbons is dependent on the treatment process. Untreated and mildly treated mineral oils contain the highest amount of aromatic and unsaturated compounds and are primarily used as a lubricant base oil to produce further refined oil products. Exposure to these types of mineral oils can cause rapid respiration, cyanosis, tachycardia and low-grade fever. Untreated and mildly treated mineral oils are strongly associated with an increased risk of scrotal and skin cancer but can also cause gastrointestinal, rectal, bladder and certain respiratory-tract cancers. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEE6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-81C9-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Mirtazapine","valueDescription":"Mirtazapine","ValueMeaning":{"publicId":"2578298","version":"1","preferredName":"Mirtazapine","longName":"2578298","preferredDefinition":"A synthetic derivative of piperazino-azepines, tetracyclic antidepressant Mirtazapine acts by an unknown mechanism that enhances central adrenergic and serotonergic transmission. Structurally unrelated to selective serotonin reuptake inhibitors, tricyclics, or monoamine oxidase inhibitors (MAOI), it also affects muscarinic transmission and has parasympatholytic properties. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mirtazapine","conceptCode":"C29265","definition":"A synthetic tetracyclic derivative of the piperazino-azepines with antidepressant activity. Although its mechanism of action is unknown, mirtazapine enhances central adrenergic and serotonergic transmission, possibly by acting as an antagonist at central presynaptic alpha 2 adrenergic inhibitory autoreceptors and heteroreceptors. This agent is a potent antagonist of 5-hydroxytryptamine type 2 (5-HT2), 5-HT3, and histamine 1 (H1) receptors, and a moderate antagonist of peripheral alpha 1 adrenergic and muscarinic receptors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEE7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-81D3-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Misoprostol","valueDescription":"Misoprostol","ValueMeaning":{"publicId":"2578299","version":"1","preferredName":"Misoprostol","longName":"2578299","preferredDefinition":"A synthetic analog of natural prostaglandin E1. It produces a dose-related inhibition of gastric acid and pepsin secretion, and enhances mucosal resistance to injury. It is an effective anti-ulcer agent and also has oxytocic properties.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Misoprostol","conceptCode":"C1313","definition":"A synthetic analog of natural prostaglandin E1. It produces a dose-related inhibition of gastric acid and pepsin secretion, and enhances mucosal resistance to injury. It is an effective anti-ulcer agent and also has oxytocic properties.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEE8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-81DD-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Mitotane","valueDescription":"Mitotane","ValueMeaning":{"publicId":"2578300","version":"1","preferredName":"Mitotane","longName":"2578300","preferredDefinition":"A synthetic derivative of the insecticide dichlorodiphenyl trichloroethane (DDT) with anti-adrenocorticoid properties.  Following its metabolism in the adrenal cortex to a reactive acyl chloride intermediate, mitotane covalently binds to adrenal proteins, specifically inhibiting adrenal cortical hormone production. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mitotane","conceptCode":"C664","definition":"A synthetic derivative of the insecticide dichlorodiphenyl trichloroethane (DDT) with anti-adrenocorticoid properties.  Following its metabolism in the adrenal cortex to a reactive acyl chloride intermediate, mitotane covalently binds to adrenal proteins, specifically inhibiting adrenal cortical hormone production. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEE9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-81E7-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Mivopenim","valueDescription":"Mivopenim","ValueMeaning":{"publicId":"2578301","version":"1","preferredName":"Mivopenim","longName":"2578301","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mivopenim","conceptCode":"C29266","definition":"No value exists.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEEA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-81F1-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Modafinil","valueDescription":"Modafinil","ValueMeaning":{"publicId":"2578302","version":"1","preferredName":"Modafinil","longName":"2578302","preferredDefinition":"A drug that is being studied as a treatment for fatigue in patients with cancer.  It belongs to the family of drugs called stimulants.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Modafinil","conceptCode":"C26661","definition":"A synthetic central nervous system stimulant with wakefulness-promoting activity. Modafinil appears to inhibit dopamine reuptake, resulting in an increase in extracellular dopamine.  This agent exhibits pronounced wakefulness-promoting activity (without sympathomimetic activity) and may improve cognitive function in certain clinical settings. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEEB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-81FB-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Mometasone Furoate","valueDescription":"Mometasone Furoate 0.1% (Elocon)","ValueMeaning":{"publicId":"2578303","version":"1","preferredName":"Mometasone Furoate 0.1% (Elocon)","longName":"2578303","preferredDefinition":"The furoate salt form of mometasone, a synthetic topical glucocorticosteroid receptor agonist with anti-inflammatory, anti-pruritic and vasoconstrictive properties. Mometasone furoate exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression.  This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators.. Specifically, mometasone furoate appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from phospholipid membrane by phospholipase A2.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mometasone Furoate","conceptCode":"C29268","definition":"The furoate ester form of mometasone, a synthetic topical glucocorticoid receptor (GR) agonist with anti-inflammatory, anti-pruritic and vasoconstrictive properties. Upon administration, mometasone binds to cytoplasmic GRs and subsequently activates GR-mediated gene expression. This results in the synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators. Specifically, mometasone appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from phospholipid membrane by phospholipase A2.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEEC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"REEVESD","dateModified":"2011-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8205-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Montelukast Sodium","valueDescription":"Montelukast Sodium (Singulair)","ValueMeaning":{"publicId":"2578304","version":"1","preferredName":"Montelukast Sodium (Singulair)","longName":"2578304","preferredDefinition":"The monosodium salt of montelukast, a selective and orally active leukotriene receptor antagonist with anti-inflammatory and bronchodilator activity. Montelukast sodium selectively and competitively blocks the cysteinyl leukotriene 1 (CysLT1) receptor, thereby preventing leukotriene D4 from binding to its receptor. This prevents leukotriene-mediated activities, including enhanced migration of eosinophils and neutrophils, increased adhesion of leukocytes, increased monocyte and neutrophil aggregation, increased airway edema, increased capillary permeability and bronchoconstriction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Montelukast Sodium","conceptCode":"C47625","definition":"The orally bioavailable monosodium salt of montelukast, a selective cysteinyl leukotriene receptor antagonist with anti-inflammatory and bronchodilating activities. Montelukast selectively and competitively blocks the cysteinyl leukotriene 1 (CysLT1) receptor, preventing binding of the inflammatory mediator leukotriene D4 (LTD4). Inhibition of LTD4 activity results in inhibition of leukotriene-mediated inflammatory events including: migration of eosinophils and neutrophils; adhesion of leukocytes to vascular endothelium, monocyte and neutrophil aggregation; increased airway edema; increased capillary permeability; and bronchoconstriction. The CysLT1 receptor is found in a number of tissues including spleen, lung, placenta, small intestine, and nasal mucosa, and in a variety of cell types including monocyte/macrophages, mast cells, eosinophils, CD34-positive hemopoietic progenitor cells, neutrophils and endothelial cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEED-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"REEVESD","dateModified":"2010-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-820F-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Morphine Sulfate","valueDescription":"Morphine Sulfate","ValueMeaning":{"publicId":"2578305","version":"1","preferredName":"Morphine Sulfate","longName":"2578305","preferredDefinition":"An opiate alkaloid isolated from the plant Papaver somniferum and produced synthetically. Morphine binds to and activates specific opiate receptors (delta, mu and kappa), each of which are involved in controlling different brain functions. In the central nervous and gastrointestinal systems, this agent exhibits widespread effects including analgesia, anxiolysis, euphoria, sedation, respiratory depression, and gastrointestinal system smooth muscle contraction. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Morphine Sulfate","conceptCode":"C669","definition":"The sulfate salt of morphine, an opiate alkaloid isolated from the plant Papaver somniferum and produced synthetically. Morphine binds to and activates specific opiate receptors (delta, mu and kappa), each of which are involved in controlling different brain functions. In the central nervous and gastrointestinal systems, this agent has widespread effects including analgesia, anxiolysis, euphoria, sedation, respiratory depression, and gastrointestinal system smooth muscle contraction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEEE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8219-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Multivitamins/Minerals","valueDescription":"Multivitamins/Minerals","ValueMeaning":{"publicId":"2578306","version":"1","preferredName":"Multivitamins/Minerals","longName":"2578306v1.00","preferredDefinition":"A dietary supplement containing all or most of the vitamins that may not be readily available in the diet. Vitamins may be classified according to their solubility either in lipids (vitamins A, D, E, K, F) or in water (vitamins C, B-complex). Present in minute amounts in various foods, vitamins are essential to maintaining normal metabolism and biochemical functions. (NCI04)_An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._A solid, homogeneous, inorganic substance occurring in nature and having a definite chemical composition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multivitamin","conceptCode":"C1654","definition":"A dietary supplement containing all or most of the vitamins that may not be readily available in the diet. Vitamins may be classified according to their solubility either in lipids (vitamins A, D, E, K, F) or in water (vitamins C, B-complex). Present in minute amounts in various foods, vitamins are essential to maintaining normal metabolism and biochemical functions. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Mineral","conceptCode":"C656","definition":"A solid, homogeneous, inorganic substance occurring in nature and having a definite chemical composition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEEF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"CLOHNES","dateModified":"2023-09-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8223-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Multivitamin","valueDescription":"Multivitamin","ValueMeaning":{"publicId":"2578307","version":"1","preferredName":"Multivitamin","longName":"2578307v1.00","preferredDefinition":"A dietary supplement containing all or most of the vitamins that may not be readily available in the diet. Vitamins may be classified according to their solubility either in lipids (vitamins A, D, E, K, F) or in water (vitamins C, B-complex). Present in minute amounts in various foods, vitamins are essential to maintaining normal metabolism and biochemical functions. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multivitamin","conceptCode":"C1654","definition":"A dietary supplement containing all or most of the vitamins that may not be readily available in the diet. Vitamins may be classified according to their solubility either in lipids (vitamins A, D, E, K, F) or in water (vitamins C, B-complex). Present in minute amounts in various foods, vitamins are essential to maintaining normal metabolism and biochemical functions. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEF0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"CLOHNES","dateModified":"2023-09-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-822D-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Mumps vaccination","valueDescription":"Mumps vaccination","ValueMeaning":{"publicId":"2578308","version":"1","preferredName":"Mumps vaccination","longName":"2578308","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mumps vaccination","conceptCode":"C0042202","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEF1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8237-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Mupirocin","valueDescription":"Mupirocin","ValueMeaning":{"publicId":"2578309","version":"1","preferredName":"Mupirocin","longName":"2578309","preferredDefinition":"A natural crotonic acid derivative extracted from Pseudomonas fluorescens, Mupirocin inhibits bacterial protein synthesis by specific reversible binding to bacterial isoleucyl transfer-RNA synthetase. With excellent activity against gram-positive staphylococci and streptococci, it is primarily used for treatment of primary and secondary skin disorders, nasal infections, and wound healing. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mupirocin","conceptCode":"C29271","definition":"A natural crotonic acid derivative extracted from Pseudomonas fluorescens. Mupirocin inhibits bacterial protein synthesis by specific reversible binding to bacterial isoleucyl tRNA synthase. With excellent activity against gram-positive staphylococci and streptococci, it is primarily used for treatment of primary and secondary skin disorders, nasal infections, and wound healing. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEF2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8241-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Mycophenolate","valueDescription":"Mycophenolate","ValueMeaning":{"publicId":"2578310","version":"1","preferredName":"Mycophenolate","longName":"2578310","preferredDefinition":"The morpholinoethyl ester of mycophenolic acid (MPA).  As an immunosuppressive agent in vivo, the active metabolite mycophenolate reversibly inhibits inosine 5'-monophosphate dehydrogenase (IMPDH), an enzyme involved in the de novo synthesis of guanine nucleotides, thereby retarding T-cell and B-cell proliferation.  MPA displays high lymphocyte specificity and cytotoxicity because lymphocyte metabolism is highly dependent on both salvage and de novo synthesis of guanine nucleotides. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycophenolate","conceptCode":"C29272","definition":"The morpholinoethyl ester of mycophenolic acid (MPA).  As an immunosuppressive agent in vivo, the active metabolite mycophenolate reversibly inhibits inosine 5'-monophosphate dehydrogenase (IMPDH), an enzyme involved in the de novo synthesis of guanine nucleotides, thereby retarding T-cell and B-cell proliferation.  MPA displays high lymphocyte specificity and cytotoxicity because lymphocyte metabolism is highly dependent on both salvage and de novo synthesis of guanine nucleotides. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEF3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-824B-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Mylanta","valueDescription":"Mylanta","ValueMeaning":{"publicId":"2578311","version":"1","preferredName":"Mylanta","longName":"2578311v1.00","preferredDefinition":"An oral suspension containing aluminum hydroxide and magnesium hydroxide, with antacid effects. Aluminum hydroxide and magnesium hydroxide neutralizes or reduces gastric acid, thereby relieving symptoms associated with indigestion, gastritis, and gastroesophageal disease (GERD). Combined with other liquid ingredients (such as lidocaine and diphenhydramine), this antacid provides relief for painful stomatitis, mucositis, and esophagitis associated with both chemotherapy and radiation therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aluminum Hydroxide/Magnesium Hydroxide","conceptCode":"C1149","definition":"An oral suspension containing aluminum hydroxide and magnesium hydroxide, with antacid effects. Aluminum hydroxide and magnesium hydroxide neutralizes or reduces gastric acid, thereby relieving symptoms associated with indigestion, gastritis, and gastroesophageal disease (GERD). Combined with other liquid ingredients (such as lidocaine and diphenhydramine), this antacid provides relief for painful stomatitis, mucositis, and esophagitis associated with both chemotherapy and radiation therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEF4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"CLOHNES","dateModified":"2023-09-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8255-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Nabumetone","valueDescription":"Nabumetone","ValueMeaning":{"publicId":"2578312","version":"1","preferredName":"Nabumetone","longName":"2578312","preferredDefinition":"A naphthylalkanone and non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activity. Nabumetone is a prodrug that upon hepatic catalysis converts into the active moiety 6-methoxy-2-naphthylacetic acid (6MNA). 6MNA inhibits the activity of the enzymes cyclo-oxygenase I and II, resulting in decreased formation of precursors of prostaglandins and thromboxanes. The resulting decrease in prostaglandin synthesis is responsible for the therapeutic effects of nabumetone. The formation of thromboxane A2, by thromboxane synthase, is also decreased and results in an inhibition of platelet aggregation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nabumetone","conceptCode":"C47627","definition":"A naphthylalkanone and non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Nabumetone is a prodrug that upon hepatic catalysis converts into the active moiety 6-methoxy-2-naphthylacetic acid (6MNA). 6MNA inhibits the activity of the enzymes cyclo-oxygenase I and II, resulting in decreased formation of precursors of prostaglandins and thromboxanes. The resulting decrease in prostaglandin synthesis is responsible for the therapeutic effects of nabumetone. The formation of thromboxane A2, by thromboxane synthase, is also decreased and results in an inhibition of platelet aggregation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEF5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-825F-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Hyoscyamine Sulfate","valueDescription":"Hyoscyamine Sulfate","ValueMeaning":{"publicId":"2578120","version":"1","preferredName":"Hyoscyamine Sulfate","longName":"2578120","preferredDefinition":"A belladonna alkaloid derivative isolated from the plants Hyoscyamus niger and Atropa belladonna exhibiting anticholinergic activity.  Hyoscyamine functions as a non-selective, competitive antagonist of muscarinic receptors, thereby inhibiting parasympathetic effects.  This agent may induce tachycardia, inhibit secretions, and relax smooth muscles. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hyoscyamine","conceptCode":"C29104","definition":"A belladonna alkaloid derivative and the levorotatory form of racemic atropine isolated from the plants Hyoscyamus niger or Atropa belladonna, which exhibits anticholinergic activity. Hyoscyamine functions as a non-selective, competitive antagonist of muscarinic receptors, thereby inhibiting the parasympathetic activities of acetylcholine on the salivary, bronchial, and sweat glands, as well as the eye, heart, bladder, and gastrointestinal tract. These inhibitory effects cause a decrease in saliva, bronchial mucus, gastric juices, and sweat. Furthermore, its inhibitory action on smooth muscle prevents bladder contraction and decreases gastrointestinal motility.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE35-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8269-18F7-E053-F662850A60B1","beginDate":"2006-03-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ibuprofen","valueDescription":"Ibuprofen","ValueMeaning":{"publicId":"2578121","version":"1","preferredName":"Ibuprofen","longName":"2578121v1.00","preferredDefinition":"A propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic effects. Ibuprofen inhibits the activity of cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. This leads to decreased prostaglandin synthesis, by prostaglandin synthase, the main physiologic effect of ibuprofen. Ibuprofen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ibuprofen","conceptCode":"C561","definition":"A propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic effects. Ibuprofen inhibits the activity of cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. This leads to decreased prostaglandin synthesis, by prostaglandin synthase, the main physiologic effect of ibuprofen. Ibuprofen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE36-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"MMADDINENI","dateModified":"2023-08-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8273-18F7-E053-F662850A60B1","beginDate":"2006-03-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Imipenem","valueDescription":"Imipenem","ValueMeaning":{"publicId":"2578122","version":"1","preferredName":"Imipenem","longName":"2578122","preferredDefinition":"A broad-spectrum, semi-synthetic beta-lactam carbapenem derived from thienamycin, produced by Streptomyces cattleya. Imipenem binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes that are involved in the last stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. This inactivation results in the weakening of the bacterial cell wall and eventually causes cell lysis. Imipenem has the greatest affinity for PBP 1A, 1B, and 2, and its lethal effect is related to binding to PBP 2 and 1B. This antibiotic is active against a wide range of gram-positive and gram-negative organisms and is stable in the presence of beta-lactamases. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Imipenem","conceptCode":"C570","definition":"A broad-spectrum, semi-synthetic beta-lactam carbapenem derived from thienamycin, produced by Streptomyces cattleya. Imipenem binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes that are involved in the last stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. This inactivation results in the weakening of the bacterial cell wall and eventually causes cell lysis. Imipenem has the greatest affinity for PBP 1A, 1B, and 2, and its lethal effect is related to binding to PBP 2 and 1B. This antibiotic is active against a wide range of gram-positive and gram-negative organisms and is stable in the presence of beta-lactamases. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE37-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-827D-18F7-E053-F662850A60B1","beginDate":"2006-03-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Hydralazine","valueDescription":"Hydralazine Hydrochloride","ValueMeaning":{"publicId":"2578105","version":"1","preferredName":"Hydralazine Hydrochloride","longName":"2578105","preferredDefinition":"A direct-acting vasodilator that is used as an antihypertensive agent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydralazine Hydrochloride","conceptCode":"C551","definition":"The hydrochloride salt of hydralazine, a phthalazine derivative with antihypertensive and potential antineoplastic activities. Hydralazine alters intracellular calcium release and interferes with smooth muscle cell calcium influx, resulting in arterial vasodilatation. This agent also inhibits the phosphorylation of myosin protein and chelation of trace metals required for smooth muscle contraction, resulting in an increase in heart rate, stroke volume and cardiac output. In addition to its cardiovascular effects, hydralazine inhibits DNA methyltransferase, which may result in inhibition of DNA methylation in tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE26-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"ONEDATA","dateModified":"2006-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8287-18F7-E053-F662850A60B1","beginDate":"2006-03-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Hydrochlorthiazide/Triamterene","valueDescription":"hydrochlorothiazide-triamterene","ValueMeaning":{"publicId":"2578106","version":"1","preferredName":"hydrochlorothiazide-triamterene","longName":"2578106","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"hydrochlorothiazide-triamterene","conceptCode":"C0813211","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE27-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"ONEDATA","dateModified":"2006-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8291-18F7-E053-F662850A60B1","beginDate":"2006-03-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Hydrocodone","valueDescription":"Hydrocodone Bitartrate","ValueMeaning":{"publicId":"2578107","version":"1","preferredName":"Hydrocodone Bitartrate","longName":"2578107","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydrocodone Bitartrate","conceptCode":"C29099","definition":"The bitartrate salt form of hydrocodone, a semisynthetic hydrogenated codeine derivative and opioid agonist with analgesic and antitussive effects. Hydrocodone primarily binds to and activates the mu-opioid receptor in the central nervous system (CNS). This leads to analgesia, euphoria, respiratory depression, miosis, decreased gastrointestinal motility, cough suppression and physical dependence. Hydrocodone is converted to hydromorphone by the cytochrome P450 enzyme CYP2D6.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE28-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"ONEDATA","dateModified":"2006-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-829B-18F7-E053-F662850A60B1","beginDate":"2006-03-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Immutol","valueDescription":"Immutol","ValueMeaning":{"publicId":"2578123","version":"1","preferredName":"Immutol","longName":"2578123","preferredDefinition":"A purified Norwegian Beta-Glucan (NBG), extracted from the cell walls of baker's yeast. Used as an immunostimulant in complementary medicine, NBG binds specifically to receptors found on the surface of specialized macrophages, granulocytes and natural killer cells and may stimulate these cells to become more active in engulfing and digesting foreign antigens; NBG also induces the production of cytokines that further augment the host immune response to foreign antigens. Use of this agent may enhance overall resistance to infectious agents and promote wound healing and tissue repair. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immutol","conceptCode":"C29117","definition":"A purified Norwegian Beta-Glucan (NBG), extracted from the cell walls of baker's yeast. Used as an immunostimulant in complementary medicine, NBG binds specifically to receptors found on the surface of specialized macrophages, granulocytes and natural killer cells and may stimulate these cells to become more active in engulfing and digesting foreign antigens; NBG also induces the production of cytokines that further augment the host immune response to foreign antigens. Use of this agent may enhance overall resistance to infectious agents and promote wound healing and tissue repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE38-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"ONEDATA","dateModified":"2006-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-82A5-18F7-E053-F662850A60B1","beginDate":"2006-03-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Nadolol","valueDescription":"Nadolol","ValueMeaning":{"publicId":"2578313","version":"1","preferredName":"Nadolol","longName":"2578313","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nadolol","conceptCode":"C29280","definition":"A non-selective beta-adrenergic antagonist with antihypertensive and antiarrhythmic activities. Nadolol competitively blocks beta-1 adrenergic receptors located in the heart and vascular smooth muscle, inhibiting the activities of the catecholamines epinephrine and norepinephrine and producing negative inotropic and chronotropic effects. This agent exhibits antiarrhythmic activity via the impairment of atrioventricular (AV) node conduction and a corresponding reduction in sinus rate. In the kidney, inhibition of the beta-2 receptor within the juxtaglomerular apparatus results in the inhibition of renin production and a subsequent reduction in angiotensin II and aldosterone levels, thus inhibiting angiotensin II-dependent vasoconstriction and aldosterone-dependent water retention.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEF6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-82AF-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Naproxen","valueDescription":"Naproxen","ValueMeaning":{"publicId":"2578314","version":"1","preferredName":"Naproxen","longName":"2578314","preferredDefinition":"A propionic acid derivative and a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Naproxen inhibits the activity of the enzymes cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. The resulting decrease in prostaglandin synthesis is responsible for the therapeutic effects of naproxen. Naproxen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Naproxen","conceptCode":"C680","definition":"A propionic acid derivative and a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Naproxen inhibits the activity of the enzymes cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. The resulting decrease in prostaglandin synthesis is responsible for the therapeutic effects of naproxen. Naproxen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEF7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-82B9-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Natures Remedy Oral Tablet","valueDescription":"Natures Remedy Oral Tablet","ValueMeaning":{"publicId":"2578315","version":"1","preferredName":"Natures Remedy Oral Tablet","longName":"2578315","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Natures Remedy Oral Tablet","conceptCode":"C1242414","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEF8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-82C3-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Nelfinavir","valueDescription":"Nelfinavir","ValueMeaning":{"publicId":"2575692","version":"1","preferredName":"Nelfinavir","longName":"2575692","preferredDefinition":"A synthetic antiviral agent.  Nelfinavir selectively inhibits human immunodeficiency virus (HIV) protease, thereby preventing cleavage of the gag-pol viral polyprotein and resulting in the release of immature, noninfectious virions.  In vivo, this agent exhibits broad tissue distribution compared to related agents. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nelfinavir","conceptCode":"C29285","definition":"A synthetic antiviral agent that selectively binds to and inhibits human immunodeficiency virus (HIV) protease. Nelfinavir has activity against HIV 1 and 2.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4B9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-82CD-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Neosporin Cream","valueDescription":"Neosporin Cream","ValueMeaning":{"publicId":"2578316","version":"1","preferredName":"Neosporin Cream","longName":"2578316v1.00","preferredDefinition":"A combination preparation containing the aminoglycoside antibiotic neomycin sulfate, the polypeptide antibiotic polymyxin B sulfate and bacitracin zinc, with topical antibacterial activity. Polymyxin B sulfate, a polypeptide produced by Bacillus polymyxa, binds to negatively charged phospholipids in the cell membrane, thereby altering the permeability of the bacterial cytoplasmic membrane. Neomycin sulfate, an aminoglycoside antibiotic, irreversibly binds to the bacterial 30S ribosomal subunit, thereby preventing mRNA from binding to the 30S subunit, causes misreading and inhibits protein synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neomycin/Polymyxin B/Bacitracin Zinc","conceptCode":"C29286","definition":"A combination preparation containing the aminoglycoside antibiotic neomycin sulfate, the polypeptide antibiotic polymyxin B sulfate and bacitracin zinc, with topical antibacterial activity. Polymyxin B sulfate, a polypeptide produced by Bacillus polymyxa, binds to negatively charged phospholipids in the cell membrane, thereby altering the permeability of the bacterial cytoplasmic membrane. Neomycin sulfate, an aminoglycoside antibiotic, irreversibly binds to the bacterial 30S ribosomal subunit, thereby preventing mRNA from binding to the 30S subunit, causes misreading and inhibits protein synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEF9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"KUMMEROA","dateModified":"2023-08-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-82D7-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Neosporin Ophthalmic","valueDescription":"Neosporin Ophthalmic","ValueMeaning":{"publicId":"2578317","version":"1","preferredName":"Neosporin Ophthalmic","longName":"2578317","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neomycin/Polymyxin B/Bacitracin Zinc Ophthalmic Ointment","conceptCode":"C29287","definition":"A sterile combination preparationscontaining neomycin sulfate, polymyxin B sulfate and bacitracin zinc, as the main active ingredients, for ophthalmic treatments. Polymyxin B sulfate, a polypeptide produced by Bacillus polymyxa, binds to the negatively charged phospholipids in the cell membrane, thereby altering the permeability of the bacterial cytoplasmic membrane. Neomycin sulfate, an aminoglycoside antibiotic, irreversibly binds to the bacterial 30S subunit proteins and 16S rRNA of ribosome, thereby causing misreading and inhibiting protein synthesis which results in bactericidal effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEFA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-82E1-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Nevirapine","valueDescription":"Nevirapine","ValueMeaning":{"publicId":"2578318","version":"1","preferredName":"Nevirapine","longName":"2578318","preferredDefinition":"A synthetic, non-nucleoside reverse transcriptase (RT) inhibitor with antiviral properties.  Nevirapine binds directly to the human immunodeficiency virus type 1 (HIV-1) RT, an RNA-dependent DNA polymerase, blocking its function in viral DNA replication.  In combination with other antiretroviral drugs, this agent reduces HIV viral loads and increases CD4 counts, thereby retarding or preventing the damage to the immune system and reducing the risk of developing AIDS. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nevirapine","conceptCode":"C29277","definition":"A benzodiazepine non-nucleoside reverse transcriptase inhibitor. In combination with other antiretroviral drugs, nevirapine reduces HIV viral loads and increases CD4 counts, thereby retarding or preventing the damage to the immune system and reducing the risk of developing AIDS.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEFB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-82EB-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Niacin","valueDescription":"Niacin","ValueMeaning":{"publicId":"2578319","version":"1","preferredName":"Niacin","longName":"2578319","preferredDefinition":"A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Niacin","conceptCode":"C689","definition":"A water-soluble vitamin belonging to the vitamin B family, which occurs in many animal and plant tissues, with antihyperlipidemic activity. Niacin is converted to its active form niacinamide, which is a component of the coenzymes nicotinamide adenine dinucleotide (NAD) and its phosphate form, NADP. These coenzymes play an important role in tissue respiration and in glycogen, lipid, amino acid, protein, and purine metabolism. Although the exact mechanism of action by which niacin lowers cholesterol is not fully understood, it may act by inhibiting the synthesis of very low density lipoproteins (VLDL), inhibiting the release of free fatty acids from adipose tissue, increasing lipoprotein lipase activity, and reducing the hepatic synthesis of VLDL-C and LDL-C.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEFC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-82F5-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Nicotine Patch","valueDescription":"Nicotine Patch","ValueMeaning":{"publicId":"2578320","version":"1","preferredName":"Nicotine Patch","longName":"2578320","preferredDefinition":"A transepidermal patch designed to deliver nicotine, the addictive substance contained in cigarettes, directly through the skin and into the blood stream. Used for cessation of smoking.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nicotine Patch","conceptCode":"C17955","definition":"A transdermal patch containing the alkaloid nicotine with nicotine replacement activity. Upon administration of the patch, nicotine is slowly released into the bloodstream and, although nicotine binds to nicotinic cholinergic receptors at the autonomic ganglia, adrenal medulla and at neuromuscular junctions as well, the binding of nicotine to the receptors in the central nervous system (CNS) appears to be responsible for the addictive nature of nicotine. Binding to CNS nicotinic acetylcholine receptors causes the release of the neurotransmitter dopamine which appears to be responsible for the addiction of nicotine. Administration of nicotine may prevent nicotine craving and may help with the withdrawal symptoms associated with smoking cessation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEFD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-82FF-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Nifedipine","valueDescription":"Nifedipine","ValueMeaning":{"publicId":"2578321","version":"1","preferredName":"Nifedipine","longName":"2578321","preferredDefinition":"A dihydropyridine calcium channel blocking agent. Nifedipine inhibits the transmembrane influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility. This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in some multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nifedipine","conceptCode":"C29290","definition":"A dihydropyridine calcium channel blocking agent. Nifedipine inhibits the transmembrane influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility. This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in some multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEFE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8309-18F7-E053-F662850A60B1","beginDate":"2006-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Apharesis","valueDescription":"Pheresis","ValueMeaning":{"publicId":"2576539","version":"1","preferredName":"Pheresis","longName":"2576539v1.00","preferredDefinition":"A procedure that collects a component of the peripheral blood while returning the rest to the donor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pheresis","conceptCode":"C15191","definition":"A procedure that collects a component of the peripheral blood while returning the rest to the donor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F808-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-12","modifiedBy":"GDEEN","dateModified":"2023-08-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8313-18F7-E053-F662850A60B1","beginDate":"2006-02-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Apolizumab","valueDescription":"Apolizumab","ValueMeaning":{"publicId":"2576004","version":"1","preferredName":"Apolizumab","longName":"2576004","preferredDefinition":"A humanized monoclonal antibody directed against 1D10, a polymorphic determinant on the HLA-DR beta chain that is expressed on normal and neoplastic B cells. Apolizumab induces complement-mediated cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and apoptosis of 1D10 antigen-positive B cells in vitro.  (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Apolizumab","conceptCode":"C2228","definition":"A humanized monoclonal antibody directed against 1D10, a polymorphic determinant on the HLA-DR beta chain that is expressed on normal and neoplastic B cells. Apolizumab induces complement-mediated cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and apoptosis of 1D10 antigen-positive B cells in vitro.  (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F5F1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-831D-18F7-E053-F662850A60B1","beginDate":"2006-02-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Aprepitant","valueDescription":"Aprepitant","ValueMeaning":{"publicId":"2577680","version":"1","preferredName":"Aprepitant","longName":"2577680","preferredDefinition":"A small molecule, high-affinity substance P antagonist (SPA) with antiemetic activity. Crossing the blood brain barrier, aprepitant binds selectively to the human substance P/neurokinin receptor in the central nervous system (CNS), thereby inhibiting receptor binding of endogenous substance P and substance P-induced emesis. This agent has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aprepitant","conceptCode":"C49173","definition":"A small molecule, high-affinity substance P antagonist (SPA) with antiemetic activity. Crossing the blood brain barrier, aprepitant binds selectively to the human substance P/neurokinin 1 receptor in the central nervous system (CNS), thereby inhibiting receptor binding of endogenous substance P and substance P-induced emesis. This agent has little or no affinity for serotonin type 3 (5-HT3), dopamine, and corticosteroid receptors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FC7D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8327-18F7-E053-F662850A60B1","beginDate":"2006-02-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Aquaphor","valueDescription":"Aquaphor","ValueMeaning":{"publicId":"2577681","version":"1","preferredName":"Aquaphor","longName":"2577681","preferredDefinition":"A petrolatum-based ointment absorbed by dry and moist skin, Aquaphor is non-comedogenic, non-irritating, and non-sensitizing. It can reduce healing time of cracked, dry skin on hands, elbows, and knees, and helps prevent diaper rash. The original ointment also contained mineral oil, ceresin, lanolin alcohol. Its use is indicated in atopic dermatitis, eczema, and psoriasis when extra protection from a heavier base is needed. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment","conceptCode":"C28832","definition":"A petrolatum-based ointment absorbed by dry and moist skin, petrolatum-mineral oil-lanolin-ceresin ointment is non-comedogenic, non-irritating, and non-sensitizing. It can reduce healing time of cracked, dry skin on hands, elbows, and knees, and helps prevent diaper rash. The original ointment also contained mineral oil, ceresin, lanolin alcohol. Its use is indicated in atopic dermatitis, eczema, and psoriasis when extra protection from a heavier base is needed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FC7E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8331-18F7-E053-F662850A60B1","beginDate":"2006-02-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ascorbic Acid","valueDescription":"Ascorbic Acid","ValueMeaning":{"publicId":"2577682","version":"1","preferredName":"Ascorbic Acid","longName":"2577682","preferredDefinition":"A natural water-soluble vitamin (Vitamin C). Ascorbic acid is a potent reducing and antioxidant agent that functions in fighting bacterial infections, in detoxifying reactions, and in the formation of collagen in fibrous tissue, teeth, bones, connective tissue, skin, and capillaries. Found in citrus and other fruits, and in vegetables, vitamin C cannot be produced or stored by humans and must be obtained in the diet. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ascorbic Acid","conceptCode":"C285","definition":"A natural water-soluble vitamin (Vitamin C). Ascorbic acid is a potent reducing and antioxidant agent that functions in fighting bacterial infections, in detoxifying reactions, and in the formation of collagen in fibrous tissue, teeth, bones, connective tissue, skin, and capillaries. Found in citrus and other fruits, and in vegetables, vitamin C cannot be produced or stored by humans and must be obtained in the diet. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FC7F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-833B-18F7-E053-F662850A60B1","beginDate":"2006-02-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Aspartic Acid","valueDescription":"Aspartic Acid","ValueMeaning":{"publicId":"2577683","version":"1","preferredName":"Aspartic Acid","longName":"2577683","preferredDefinition":"A non-essential amino acid in humans, Aspartic Acid has an overall negative charge and plays an important role in the synthesis of other amino acids and in the citric acid and urea cycles. Asparagine, arginine, lysine, methionine, isoleucine, and some nucleotides are synthesized from aspartic acid. Aspartic acid also serves as a neurotransmitter. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aspartic Acid","conceptCode":"C29608","definition":"A non-essential amino acid in humans, Aspartic Acid has an overall negative charge and plays an important role in the synthesis of other amino acids and in the citric acid and urea cycles. Asparagine, arginine, lysine, methionine, isoleucine, and some nucleotides are synthesized from aspartic acid. Aspartic acid also serves as a neurotransmitter. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FC80-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8345-18F7-E053-F662850A60B1","beginDate":"2006-02-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Astemizole","valueDescription":"Astemizole","ValueMeaning":{"publicId":"2577684","version":"1","preferredName":"Astemizole","longName":"2577684","preferredDefinition":"A synthetic piperidinyl-benzimidazol derivative with antiallergic properties, Astemizole acts as a reversible competitive inhibitor of histamine H1 receptors, with less anticholinergic effects compared to related agents. It is a long-acting, non-sedative antihistaminic used in the treatment of seasonal allergic rhinitis, asthma, allergic conjunctivitis, and chronic idiopathic urticaria. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Astemizole","conceptCode":"C28834","definition":"A synthetic piperidinyl-benzimidazol derivative with antiallergic properties, Astemizole acts as a reversible competitive inhibitor of histamine H1 receptors, with less anticholinergic effects compared to related agents. It is a long-acting, non-sedative antihistaminic used in the treatment of seasonal allergic rhinitis, asthma, allergic conjunctivitis, and chronic idiopathic urticaria. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FC81-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-834F-18F7-E053-F662850A60B1","beginDate":"2006-02-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Olmesartan Medoxomil","valueDescription":"Olmesartan Medoxomil","ValueMeaning":{"publicId":"3835825","version":"1","preferredName":"Olmesartan Medoxomil","longName":"3835825","preferredDefinition":"A synthetic imidazole derivative prodrug with an antihypertensive property. Upon hydrolysis, olmesartan medoxomil is converted to olmesartan. Olmesartan selectively binds to the angiotensin type 1 (AT1) receptor of angiotensin II in vascular smooth muscle and adrenal gland, thereby competing angiotensin II binding to the receptor. This prevents angiotensin II-induced vasoconstriction and decreases aldosterone production, thereby preventing aldosterone-stimulated sodium retention and potassium excretion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Olmesartan Medoxomil","conceptCode":"C47640","definition":"A synthetic imidazole derivative prodrug with an antihypertensive property. Upon hydrolysis, olmesartan medoxomil is converted to olmesartan. Olmesartan selectively binds to the angiotensin type 1 (AT1) receptor of angiotensin II in vascular smooth muscle and adrenal gland, thereby competing angiotensin II binding to the receptor. This prevents angiotensin II-induced vasoconstriction and decreases aldosterone production, thereby preventing aldosterone-stimulated sodium retention and potassium excretion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E2E72669-F8F8-E72F-E040-BB89AD436C77","latestVersionIndicator":"Yes","beginDate":"2013-08-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-08-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"979F0749-03D0-2135-E053-F662850AB674","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Olmesartan/hydrochlorothiazide","valueDescription":"Olmesartan/hydrochlorothiazide","ValueMeaning":{"publicId":"7060416","version":"1","preferredName":"Olmesartan/hydrochlorothiazide","longName":"7060416","preferredDefinition":"A combination of an angiotensin II receptor antagonist (AT1 subtype), olmesartan medoxomil, and a thiazide diuretic, hydrochlorothiazide (HCTZ).","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"979F0749-03DA-2135-E053-F662850AB674","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"COOPERM","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"979F0749-03F3-2135-E053-F662850AB674","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Olizumab","valueDescription":"Omalizumab","ValueMeaning":{"publicId":"7060418","version":"1","preferredName":"Omalizumab","longName":"7060418","preferredDefinition":"A humanized monoclonal antibody directed against the C-epsilon 3 domain of immunoglobulin E.  Olizumab binds to this IgE domain, thereby preventing IgE from binding to its high-affinity mast-cell receptor. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Omalizumab","conceptCode":"C29299","definition":"A humanized monoclonal antibody directed against the C-epsilon 3 domain of immunoglobulin E.  Olizumab binds to this IgE domain, thereby preventing IgE from binding to its high-affinity mast-cell receptor. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"979F0749-0400-2135-E053-F662850AB674","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"979F0749-0419-2135-E053-F662850AB674","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Ofloxacin","valueDescription":"Ofloxacin","ValueMeaning":{"publicId":"2575696","version":"1","preferredName":"Ofloxacin","longName":"2575696","preferredDefinition":"An antibiotic drug used to treat infection. It belongs to the family of drugs called quinolone antibiotics.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ofloxacin","conceptCode":"C712","definition":"A fluoroquinolone antibacterial antibiotic. Ofloxacin binds to and inhibits bacterial topoisomerase II (DNA gyrase) and topoisomerase IV, enzymes involved in DNA replication and repair, resulting in cell death in sensitive bacterial species. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4BD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"979F0749-0423-2135-E053-F662850AB674","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Ocuvite","valueDescription":"Ocuvite","ValueMeaning":{"publicId":"7060419","version":"1","preferredName":"Ocuvite","longName":"7060419","preferredDefinition":"A multivitamin product used to treat or prevent vitamin deficiency due to poor diet, certain illnesses, or during pregnancy.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"979F0749-042D-2135-E053-F662850AB674","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"979F0749-0446-2135-E053-F662850AB674","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Octreotide acetate","valueDescription":"Octreotide Acetate","ValueMeaning":{"publicId":"3919466","version":"1","preferredName":"Octreotide Acetate","longName":"3919466","preferredDefinition":"The acetate salt of a synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Octreotide is a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Similar to somatostatin, this agent also suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Octreotide Acetate","conceptCode":"C53447","definition":"The acetate salt of a synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Octreotide is a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Similar to somatostatin, this agent also suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E8CA7C7F-FF37-3690-E040-BB89AD43404F","latestVersionIndicator":"Yes","beginDate":"2013-10-15","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2013-10-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"979F0749-045A-2135-E053-F662850AB674","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Atazanavir","valueDescription":"Atazanavir Sulfate","ValueMeaning":{"publicId":"2577678","version":"1","preferredName":"Atazanavir Sulfate","longName":"2577678","preferredDefinition":"A synthetic antiviral agent.  As a symmetric azapeptide agent structurally different from other HIV protease inhibitors, atazanavir selectively binds to and inhibits human immunodeficiency virus (HIV) protease, thereby preventing cleavage of the gag-pol viral polyprotein and resulting in the release of immature, noninfectious virions.  This agent does not elevate serum lipids, a common problem with other protease inhibitors. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atazanavir Sulfate","conceptCode":"C28835","definition":"A sulfate salt form of atazanavir, an aza-dipeptide analogue with a bis-aryl substituent on the (hydroxethyl)hydrazine moiety with activity against both wild type and mutant forms of HIV protease. Atazanavir does not elevate serum lipids, a common problem with other protease inhibitors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FC7B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-14","modifiedBy":"ONEDATA","dateModified":"2006-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8359-18F7-E053-F662850A60B1","beginDate":"2006-02-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Atenolol","valueDescription":"Atenolol","ValueMeaning":{"publicId":"2577685","version":"1","preferredName":"Atenolol","longName":"2577685","preferredDefinition":"A synthetic isopropylamino-propanol derivative used as an antihypertensive, hypotensive and antiarrhythmic Atenolol acts as a peripheral, cardioselective beta blocker specific for beta1-receptors, without intrinsic sympathomimetic effects. It reduces exercise heart rates and delays atrioventricular conduction, with overall oxygen requirements decreasing. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atenolol","conceptCode":"C28836","definition":"A synthetic isopropylamino-propanol derivative used as an antihypertensive, hypotensive and antiarrhythmic Atenolol acts as a peripheral, cardioselective beta blocker specific for beta-1 adrenergic receptors, without intrinsic sympathomimetic effects. It reduces exercise heart rates and delays atrioventricular conduction, with overall oxygen requirements decreasing. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FC82-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8363-18F7-E053-F662850A60B1","beginDate":"2006-02-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Atomoxetine HCL","valueDescription":"Atomoxetine Hydrochloride","ValueMeaning":{"publicId":"2577679","version":"1","preferredName":"Atomoxetine Hydrochloride","longName":"2577679","preferredDefinition":"The hydrochloride salt form of atomoxetine, a selective non-stimulant, norepinephrine reuptake inhibitor. Atomoxetine hydrochloride selectively inhibits the presynaptic reabsorption of norepinephrine, with minimal effect on other noradrenergic receptors or neurotransmitter transporters. Norepinephrine improves cognitive functioning, is secreted in the locus ceruleus, and released into the prefrontal cortex.  The action of atomoxetine hydrochloride prolongs the activity of norepinephrine in the synaptic cleft. Therefore, it is used in conjunction with norepinephrine in the symptomatic treatment of attention-deficit hyperactivity disorder.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atomoxetine Hydrochloride","conceptCode":"C47405","definition":"The hydrochloride salt of atomoxetine, a phenoxy-3-propylamine derivative and selective non-stimulant, norepinephrine reuptake inhibitor with cognitive-enhancing activity. Although its precise mechanism of action is unknown, atomoxetine appears to selectively inhibit the pre-synaptic norepinephrine transporter, resulting in inhibition of the presynaptic reabsorption of norepinephrine and prolongation of norepinephrine activity in the synaptic cleft. The effect on cognitive brain function may result in improved attention and decreased impulsivity and activity levels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FC7C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-14","modifiedBy":"ONEDATA","dateModified":"2006-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-836D-18F7-E053-F662850A60B1","beginDate":"2006-02-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Atorvastatin Calcium","valueDescription":"atorvastatin","ValueMeaning":{"publicId":"2573142","version":"1","preferredName":"atorvastatin","longName":"2573142","preferredDefinition":"A synthetic lipid-lowering agent.  Atorvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis.  Atorvastatin also increases the number of LDL receptors on hepatic cell surfaces to enhance uptake and catabolism of LDL and reduces LDL production and the number of LDL particles.  This agent lowers plasma cholesterol and lipoprotein levels and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atorvastatin Calcium","conceptCode":"C28837","definition":"The calcium salt of atorvastatin, a synthetic lipid-lowering agent. Atorvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent increases the number of LDL receptors on hepatic cell surfaces, enhancing the uptake and catabolism of LDL and reducing LDL production and the number of LDL particles, and lowers plasma cholesterol and lipoprotein levels. Like other statins, atorvastatin may also display direct antineoplastic activity, possibly by inhibiting farnesylation and geranylgeranylation of proteins such as small GTP-binding proteins, which may result in the arrest of cells in the G1 phase of the cell cycle. This agent may also sensitize tumor cells to cyctostatic drugs, possibly through the mTOR-dependent inhibition of Akt phosphorylation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EAC3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-02-09","modifiedBy":"REEVESD","dateModified":"2006-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8377-18F7-E053-F662850A60B1","beginDate":"2006-02-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ginseng","valueDescription":"Ginseng","ValueMeaning":{"publicId":"2569632","version":"1","preferredName":"Ginseng","longName":"2569632","preferredDefinition":"A Chinese herb derived from either the Panax ginseng, the Asian species, Panax quinquefolius, the American species, or P. pseudoginseng, known as Siberian or Russian ginseng, plant containing a complex mixture of saponins, ginsenosides and panaxosides, available as a nutritional supplement and is reported to enhance the immune system and reduce fatigue. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"American Ginseng","conceptCode":"C26651","definition":"The aromatic root of the perennial herb Panax quinquefolius, native to eastern North America. American ginseng, used in Chinese traditional medicine and available as a nutritional supplement, is classified as an adaptogenic herb with multiple effects, many of which are regulatory in nature. It contains a complex mixture of saponin glycosides, also known as ginsenosides or panaxosides. Although the mechanism of action is unclear, this agent is reported to enhance the immune system and reduce fatigue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DD0D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-05-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-05-20","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8381-18F7-E053-F662850A60B1","beginDate":"2006-02-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Guaifenesin/Codeine","valueDescription":"Guaifenesin/Codeine","ValueMeaning":{"publicId":"2578108","version":"1","preferredName":"Guaifenesin/Codeine","longName":"2578108","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Guaifenesin/Codeine","conceptCode":"C0717642","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE29-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"ONEDATA","dateModified":"2006-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-838B-18F7-E053-F662850A60B1","beginDate":"2006-03-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Guaifenisin/Pseudoephedrine","valueDescription":"Guaifenisin/Pseudoephedrine","ValueMeaning":{"publicId":"2578109","version":"1","preferredName":"Guaifenisin/Pseudoephedrine","longName":"2578109","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Guaifenesin/Pseudoephedrine","conceptCode":"C29084","definition":"A combination preparation containing guaifenesin and the indirect-acting sympathicomimetic agent pseudoephedrine with expectorant and decongestant activities, respectively. Guaifenesin works by drawing water into respiratory tracts, by which reducing adhesiveness and surface tension of mucus as well as increasing hydration of mucus, thereby reducing the viscosity of mucus and making cough more productive. Pseudoephedrine displaces norepinephrine from storage vesicles in presynaptic neurons, thereby releasing norepinephrine into the neuronal synapses where it stimulates primarily alpha-adrenergic receptors in the nasal mucosa, thereby producing vasoconstriction, reduces swelling of nasal mucous membranes and decreasing nasal and sinus congestion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE2A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"ONEDATA","dateModified":"2006-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8395-18F7-E053-F662850A60B1","beginDate":"2006-03-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Guaifenisin-DM","valueDescription":"Guaifenisin-DM","ValueMeaning":{"publicId":"2578110","version":"1","preferredName":"Guaifenisin-DM","longName":"2578110","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Guaifenesin-DM","conceptCode":"C29083","definition":"A combination preparation containing guaifenesin and the opioid agonist dextrometorphan with expectorant and antitussive activities, respectively. Guaifenesin works by drawing water into respiratory tracts, by which reducing adhesiveness and surface tension of mucus as well as increasing hydration of mucus, thereby reducing the viscosity of mucus and making cough more productive. Dextrometorphan, a synthetic, methylated dextrorotary analogue of levorphanol, exhibits antitussive activity by activating opioid receptors in the cough center in the central nervous system, thereby raising the threshold for coughing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE2B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"ONEDATA","dateModified":"2006-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-839F-18F7-E053-F662850A60B1","beginDate":"2006-03-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"H2O2","valueDescription":"Hydrogen Peroxide","ValueMeaning":{"publicId":"2578104","version":"1","preferredName":"Hydrogen Peroxide","longName":"2578104","preferredDefinition":"A strong oxidizing agent used in aqueous solution as a ripening agent, bleach, and topical anti-infective. It is relatively unstable and solutions deteriorate over time unless stabilized by the addition of acetanilide or similar organic materials.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydrogen Peroxide","conceptCode":"C28156","definition":"A peroxide and oxidizing agent with disinfectant, antiviral and anti-bacterial activities. Upon rinsing and gargling or topical application, hydrogen peroxide exerts its oxidizing activity and produces free radicals which leads to oxidative damage to proteins and membrane lipids. This may inactivate and destroy pathogens and may prevent spreading of infection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE25-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-83A9-18F7-E053-F662850A60B1","beginDate":"2006-03-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Haloperidol","valueDescription":"Haloperidol","ValueMeaning":{"publicId":"2578111","version":"1","preferredName":"Haloperidol","longName":"2578111","preferredDefinition":"A drug that is used primarily to treat schizophrenia and other psychoses. It is also used in schizoaffective disorder, delusional disorder, ballism, and Tourette's syndrome (a drug of choice) and occasionally as adjunctive therapy in mental retardation and the chorea of Huntington's disease. It is a potent antiemetic and is effective in the treatment of intractable hiccups. (From AMA Drug Evaluations Annual, 1994, p279)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Haloperidol","conceptCode":"C537","definition":"A phenylbutylpiperadine derivative with antipsychotic, neuroleptic, and antiemetic activities. Haloperidol competitively blocks postsynaptic dopamine (D2) receptors in the mesolimbic system of the brain, thereby eliminating dopamine neurotransmission and leading to antidelusionary and antihallucinagenic effects. Antagonistic activity mediated through D2 dopamine receptors in the chemoreceptive trigger zone (CTZ) accounts for its antiemetic activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE2C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"ONEDATA","dateModified":"2006-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-83B3-18F7-E053-F662850A60B1","beginDate":"2006-03-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Heparin Sodium","valueDescription":"Heparin Sodium","ValueMeaning":{"publicId":"2578112","version":"1","preferredName":"Heparin Sodium","longName":"2578112","preferredDefinition":"The sodium salt form of heparin.  As a glycosaminoglycan anticoagulant, heparin sodium binds to antithrombin III to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Heparin Sodium","conceptCode":"C833","definition":"The sodium salt form of heparin.  As a glycosaminoglycan anticoagulant, heparin sodium binds to antithrombin III to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE2D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"ONEDATA","dateModified":"2006-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-83BD-18F7-E053-F662850A60B1","beginDate":"2006-03-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Hepatitis A Vaccine","valueDescription":"Hepatitis A Vaccine","ValueMeaning":{"publicId":"2578113","version":"1","preferredName":"Hepatitis A Vaccine","longName":"2578113","preferredDefinition":"An inactivated virus vaccine that provides active immunization against hepatitis A virus (HAV).  Immunization with hepatitis A vaccine induces the formation of anti-HAV antibodies which provide protection against hepatitis A infection. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatitis A Vaccine","conceptCode":"C29090","definition":"An inactivated virus vaccine that provides active immunization against hepatitis A virus (HAV). Immunization with hepatitis A vaccine induces the formation of anti-HAV antibodies which provide protection against hepatitis A infection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE2E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"ONEDATA","dateModified":"2006-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-83C7-18F7-E053-F662850A60B1","beginDate":"2006-03-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Hepatitis B Vaccine","valueDescription":"Hepatitis B Vaccine","ValueMeaning":{"publicId":"2578114","version":"1","preferredName":"Hepatitis B Vaccine","longName":"2578114","preferredDefinition":"A non-infectious mixture containing recombinant hepatitis B surface antigen (HBsAg) in a liquid vehicle.  Immunization with the hepatitis B vaccine induces the formation of specific anti-hepatitis B antibodies and an active immunity against hepatitis B infection. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatitis B Vaccine","conceptCode":"C29091","definition":"A non-infectious mixture containing recombinant hepatitis B surface antigen (HBsAg) in a liquid vehicle. Immunization with the hepatitis B vaccine induces the formation of specific anti-hepatitis B antibodies and an active immunity against hepatitis B infection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE2F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"ONEDATA","dateModified":"2006-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-83D1-18F7-E053-F662850A60B1","beginDate":"2006-03-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Hexylresorcinol","valueDescription":"Hexylresorcinol","ValueMeaning":{"publicId":"2578115","version":"1","preferredName":"Hexylresorcinol","longName":"2578115v1.00","preferredDefinition":"A substituted phenol with bactericidal, antihelminthic and potential antineoplastic activities. Hexylresorcinol is used as an antiseptic in mouthwashes and skin wound cleansers. Hexylresorcinol may also inhibit oxidative DNA damage by enhancing the activity of antioxidant enzymes, including glutathione peroxidase and glutathione reductase, which facilitate scavenging reactive oxygen molecules by glutathione (GSH).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hexylresorcinol","conceptCode":"C29092","definition":"A substituted phenol with bactericidal, antihelminthic and potential antineoplastic activities. Hexylresorcinol is used as an antiseptic in mouthwashes and skin wound cleansers. Hexylresorcinol may also inhibit oxidative DNA damage by enhancing the activity of antioxidant enzymes, including glutathione peroxidase and glutathione reductase, which facilitate scavenging reactive oxygen molecules by glutathione (GSH).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE30-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"KUMMEROA","dateModified":"2023-08-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-83DB-18F7-E053-F662850A60B1","beginDate":"2006-03-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Histussin-HC","valueDescription":"Histussin-HC","ValueMeaning":{"publicId":"2578116","version":"1","preferredName":"Histussin-HC","longName":"2578116","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Histussin-HC","conceptCode":"C0720887","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE31-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-83E5-18F7-E053-F662850A60B1","beginDate":"2006-03-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Hydrochlorothiazide","valueDescription":"Hydrochlorothiazide","ValueMeaning":{"publicId":"2578117","version":"1","preferredName":"Hydrochlorothiazide","longName":"2578117","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydrochlorothiazide","conceptCode":"C29098","definition":"A short acting thiazide diuretic. Hydrochlorothiazide (HCTZ) is widely used to treat hypertension and edema. This agent's metabolite appears to preferentially bind to and accumulate in red blood cells. This agent is primarily excreted by the kidneys.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE32-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-83EF-18F7-E053-F662850A60B1","beginDate":"2006-03-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Atovoquone","valueDescription":"Atovoquone","ValueMeaning":{"publicId":"2575655","version":"1","preferredName":"Atovoquone","longName":"2575655","preferredDefinition":"A synthetic hydroxynaphthoquinone with antiprotozoal activity. Atovoquone blocks the mitochondrial electron transport at complex III of the respiratory chain of protozoa, thereby inhibiting pyrimidine synthesis, preventing DNA synthesis and leading to protozoal death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atovaquone","conceptCode":"C28838","definition":"A synthetic hydroxynaphthoquinone with antiprotozoal activity. Atovoquone blocks the mitochondrial electron transport at complex III of the respiratory chain of protozoa, thereby inhibiting pyrimidine synthesis, preventing DNA synthesis and leading to protozoal death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F494-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"CURTIST","dateModified":"2010-01-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-83F9-18F7-E053-F662850A60B1","beginDate":"2006-02-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Atropine","valueDescription":"Atropine","ValueMeaning":{"publicId":"2577722","version":"1","preferredName":"Atropine","longName":"2577722","preferredDefinition":"A synthetically-derived form of the endogenous alkaloid isolated from the plant Atropa belladonna.  Atropine functions as a sympathetic, competitive antagonist of muscarinic cholinergic receptors, thereby abolishing the effects of parasympathetic stimulation.  This agent may induce tachycardia, inhibit secretions, and relax smooth muscles. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atropine","conceptCode":"C28840","definition":"A synthetically-derived form of the endogenous alkaloid isolated from the plant Atropa belladonna.  Atropine functions as a sympathetic, competitive antagonist of muscarinic cholinergic receptors, thereby abolishing the effects of parasympathetic stimulation.  This agent may induce tachycardia, inhibit secretions, and relax smooth muscles. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCA7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8403-18F7-E053-F662850A60B1","beginDate":"2006-02-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Attapulgite","valueDescription":"Attapulgite","ValueMeaning":{"publicId":"2576011","version":"1","preferredName":"Attapulgite","longName":"2576011","preferredDefinition":"A natural clay-like mineral mixture of hydrated aluminum silicate containing magnesium, adsorbent Attapulgite (kaopectate) acts locally in the intestines to adsorb bacteria and toxins; reduce water loss; and treat diarrhea. Sometimes it is activated by heat to increase absorbency. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Attapulgite","conceptCode":"C28841","definition":"A natural clay-like mineral mixture of hydrated aluminum silicate containing magnesium, adsorbent Attapulgite (kaopectate) acts locally in the intestines to adsorb bacteria and toxins; reduce water loss; and treat diarrhea. Sometimes it is activated by heat to increase absorbency. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F5F8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-840D-18F7-E053-F662850A60B1","beginDate":"2006-02-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Aveeno","valueDescription":"Oatmeal Powder","ValueMeaning":{"publicId":"2577718","version":"1","preferredName":"Oatmeal Powder","longName":"2577718","preferredDefinition":"Colloidal oatmeal, whole oats milled to a fine powder, with anti-pruritic activity. Oatmeal powder, especially when added to a warm bath, is used to provide temporary relief of itching and irritation caused by insect bites, eczema, sun burns, reactions to poisonous plants and various other skin rashes and allergies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oatmeal Powder","conceptCode":"C29298","definition":"Colloidal oatmeal, whole oats milled to a fine powder, with anti-pruritic activity. Oatmeal powder, especially when added to a warm bath, is used to provide temporary relief of itching and irritation caused by insect bites, eczema, sun burns, reactions to poisonous plants and various other skin rashes and allergies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCA3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-17","modifiedBy":"COOPERM","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8417-18F7-E053-F662850A60B1","beginDate":"2006-02-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Azithromycin","valueDescription":"Azithromycin","ValueMeaning":{"publicId":"2575656","version":"1","preferredName":"Azithromycin","longName":"2575656","preferredDefinition":"An azalide, derived from erythromycin, and a member of a subclass of macrolide antibiotics with bacteriocidal and bacteriostatic activities. Azithromycin reversibly binds to the 50S ribosomal subunit of the 70S ribosome of sensitive microorganisms, thereby inhibiting the translocation step of protein synthesis, wherein a newly synthesized peptidyl tRNA molecule moves from the acceptor site on the ribosome to the peptidyl (donor) site, and consequently inhibiting RNA-dependent protein synthesis leading to cell growth inhibition and cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Azithromycin","conceptCode":"C28844","definition":"An azalide, derived from erythromycin, and a member of a subclass of macrolide antibiotics with bacteriocidal and bacteriostatic activities. Azithromycin reversibly binds to the 50S ribosomal subunit of the 70S ribosome of sensitive microorganisms, thereby inhibiting the translocation step of protein synthesis, wherein a newly synthesized peptidyl tRNA molecule moves from the acceptor site on the ribosome to the peptidyl (donor) site, and consequently inhibiting RNA-dependent protein synthesis leading to cell growth inhibition and cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F495-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"TAYLORT","dateModified":"2018-05-15","changeDescription":"5/15/18 tt added concept definition.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8421-18F7-E053-F662850A60B1","beginDate":"2006-02-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Aztreonam","valueDescription":"Aztreonam","ValueMeaning":{"publicId":"2575657","version":"1","preferredName":"Aztreonam","longName":"2575657","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aztreonam","conceptCode":"C28845","definition":"A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum with bactericidal activity. Aztreonam preferentially binds to and inactivates penicillin-binding protein-3 (PBP-3), which is involved in bacterial cell wall synthesis, thereby inhibiting bacterial cell wall integrity and leading to cell lysis and death. This agent differs from other beta-lactam antibiotics because it is resistant to beta-lactamase hydrolysis, and it is usually used to treat infections caused by gram-negative aerobic microorganisms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F496-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-842B-18F7-E053-F662850A60B1","beginDate":"2006-02-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Bacitracin","valueDescription":"Bacitracin","ValueMeaning":{"publicId":"2577723","version":"1","preferredName":"Bacitracin","longName":"2577723","preferredDefinition":"A complex of cyclic peptide antibiotics produced by the Tracy-I strain of Bacillus subtilis. The commercial preparation is a mixture of at least nine bacitracins with bacitracin A as the major constituent. It is used topically to treat open infections such as infected eczema and infected dermal ulcers. (From Goodman and Gilman, The Pharmacological Basis of Therapeutics, 8th ed, p1140)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bacitracin","conceptCode":"C295","definition":"A complex of cyclic polypeptide antibiotics, mainly bacitracin A, produced by spore-forming organisms belonging to the licheniformin group of the Bacillus subtilis with antibacterial activity. Bacitracin binds to C55-isoprenyl pyrophosphate, a biphosphate lipid transport molecule that carries the building blocks of the peptidoglycan bacterial cell wall. The binding interferes with the enzymatic dephosphorylation of the C55-isoprenyl pyrophosphate and prevents peptidoglycan synthesis, thereby inhibiting bacterial cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCA8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8435-18F7-E053-F662850A60B1","beginDate":"2006-02-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Bacitracin Zinc","valueDescription":"Bacitracin Zinc","ValueMeaning":{"publicId":"2575658","version":"1","preferredName":"Bacitracin Zinc","longName":"2575658","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bacitracin Zinc","conceptCode":"C28857","definition":"The zinc salt form of bacitracin, a complex of cyclic polypeptide antibiotics, mainly bacitracin A, produced by spore-forming organisms belonging to the licheniformin group of the Bacillus subtilis with antibacterial activity. Bacitracin zinc binds to C55-isoprenyl pyrophosphate, a biphosphate lipid transport molecule that carries the building blocks of the peptidoglycan bacterial cell wall, thereby interfering with the enzymatic dephosphorylation of the C55-isoprenyl pyrophosphate and preventing peptidoglycan synthesis which leads to cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F497-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-843F-18F7-E053-F662850A60B1","beginDate":"2006-02-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Baclofen","valueDescription":"Baclofen","ValueMeaning":{"publicId":"2577724","version":"1","preferredName":"Baclofen","longName":"2577724","preferredDefinition":"A synthetic chlorophenyl-butanoic acid derivative used to treat spasms due to spinal cord damage and multiple sclerosis, muscle-relaxing Baclofen acts as a gamma-aminobutyric acid (GABA) agonist specific for GABA-B receptors. It acts at spinal and supraspinal sites, reducing excitatory transmission. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Baclofen","conceptCode":"C28858","definition":"A synthetic chlorophenyl-butanoic acid derivative used to treat spasms due to spinal cord damage and multiple sclerosis, muscle-relaxing Baclofen acts as a gamma-aminobutyric acid (GABA) agonist specific for GABA-B receptors. It acts at spinal and supraspinal sites, reducing excitatory transmission. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCA9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8449-18F7-E053-F662850A60B1","beginDate":"2006-02-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Bactrim","valueDescription":"Trimethoprim-Sulfamethoxazole","ValueMeaning":{"publicId":"2577719","version":"1","preferredName":"Trimethoprim-Sulfamethoxazole","longName":"2577719","preferredDefinition":"A combination of two anti-infection drugs, sulfamethoxazole and trimethoprim. It is used to fight bacterial and protozoal infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trimethoprim-Sulfamethoxazole","conceptCode":"C909","definition":"A synthetic combination of two antibacterial agents, trimethoprim and sulfamethoxazole. This synergistic combination, also known as Co-Trimoxazole, inhibits two sequential steps in the bacterial metabolism of folic acid. Trimethoprim is a pyrimidine inhibitor of dihydrofolate reductase; sulfamethoxazole is a sulfamide inhibitor of bacterial dihydrofolate synthase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCA4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-17","modifiedBy":"ONEDATA","dateModified":"2006-02-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8453-18F7-E053-F662850A60B1","beginDate":"2006-02-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Bactrim DS","valueDescription":"Bactrim DS","ValueMeaning":{"publicId":"2576014","version":"1","preferredName":"Bactrim DS","longName":"2576014","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bactrim DS","conceptCode":"C1154231","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F5FB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-845D-18F7-E053-F662850A60B1","beginDate":"2006-02-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Barium Sulfate","valueDescription":"Barium Sulfate","ValueMeaning":{"publicId":"2577725","version":"1","preferredName":"Barium Sulfate","longName":"2577725","preferredDefinition":"The sulfate salt of barium, an alkaline, divalent metal.  Barium sulfate is quite insoluble in water, and is used as a radiopaque agent to diagnose gastrointestinal medical conditions.  Barium sulfate is taken by mouth or given rectally. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Barium Sulfate","conceptCode":"C28859","definition":"The sulfate salt of barium, an alkaline, divalent metal.  Barium sulfate is quite insoluble in water, and is used as a radiopaque agent to diagnose gastrointestinal medical conditions.  Barium sulfate is taken by mouth or given rectally. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCAA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8467-18F7-E053-F662850A60B1","beginDate":"2006-02-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Beclomethasone Dipropionate","valueDescription":"Beclomethasone Dipropionate","ValueMeaning":{"publicId":"2577726","version":"1","preferredName":"Beclomethasone Dipropionate","longName":"2577726","preferredDefinition":"The dipropionate salt of a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, beclomethasone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Beclomethasone Dipropionate","conceptCode":"C299","definition":"The dipropionate ester of a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, beclomethasone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCAB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8471-18F7-E053-F662850A60B1","beginDate":"2006-02-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Belladona/Phenobarb/Ergotamine","valueDescription":"Belladonna/Phenobarbital/Ergotamine","ValueMeaning":{"publicId":"2577720","version":"1","preferredName":"Belladonna/Phenobarbital/Ergotamine","longName":"2577720","preferredDefinition":"Used to relieve stomach/intestinal symptoms, menopause (hot flashes, sweats, restlessness, and insomnia), headaches, and tachycardia, Belladona Phenobarbital Ergotamine is a combination of an Atropa belladonna alkaloid, a Claviceps purpurea (Ergotamine) alkaloid, and a synthetic barbiturate. Parasympathomimetic Belladona decreases secretion, smooth muscle stimulant Ergotamine blocks alpha-adrenergic activity, and sedative Phenobarbital induces sleep. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Belladonna/Phenobarbital/Ergotamine","conceptCode":"C0717480","definition":"Used to relieve stomach/intestinal symptoms, menopause (hot flashes, sweats, restlessness, and insomnia), headaches, and tachycardia, Belladona Phenobarbital Ergotamine is a combination of an Atropa belladonna alkaloid, a Claviceps purpurea (Ergotamine) alkaloid, and a synthetic barbiturate. Parasympathomimetic Belladona decreases secretion, smooth muscle stimulant Ergotamine blocks alpha-adrenergic activity, and sedative Phenobarbital induces sleep. (NCI04)","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCA5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-17","modifiedBy":"ONEDATA","dateModified":"2006-02-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-847B-18F7-E053-F662850A60B1","beginDate":"2006-02-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Belladona Alkaloids/Phenobarb","valueDescription":"Belladonna-Phenobarbital","ValueMeaning":{"publicId":"2577721","version":"1","preferredName":"Belladonna-Phenobarbital","longName":"2577721","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Belladonna-Phenobarbital","conceptCode":"C0718861","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCA6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-17","modifiedBy":"ONEDATA","dateModified":"2006-02-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8485-18F7-E053-F662850A60B1","beginDate":"2006-02-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Albuterolsulfide/Ipratropium","valueDescription":"Albuterol+ipratropium bromide","ValueMeaning":{"publicId":"2576897","version":"1","preferredName":"Albuterol+ipratropium bromide","longName":"2576897","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Albuterol+ipratropium bromide","conceptCode":"CL310758","definition":"No value exists.","evsSource":"NCI_META_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F96E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-09","modifiedBy":"ONEDATA","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-848F-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Benazepril HCL","valueDescription":"Benazepril Hydrochloride","ValueMeaning":{"publicId":"2577727","version":"1","preferredName":"Benazepril Hydrochloride","longName":"2577727","preferredDefinition":"A synthetic benzazepine derivative used with other agents for hypertension.  Benazepril is metabolized to active benazeprilat, a non-sulfhydryl angiotensin-converting enzyme inhibitor that decreases vasoconstrictor angiotensin ll. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benazepril Hydrochloride","conceptCode":"C28862","definition":"The hydrochloride salt of benazepril, a carboxyl-containing angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. As a prodrug, benazepril is metabolized to its active form benazeprilat. Benazeprilat competitively binds to and inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the potent vasoconstrictive actions of angiotensin II, resulting in vasodilation. Benazeprilat also decreases angiotensin II-induced aldosterone secretion by the adrenal cortex, which leads to an increase in sodium excretion and subsequently increases water outflow.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCAC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-17","modifiedBy":"ONEDATA","dateModified":"2006-02-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8499-18F7-E053-F662850A60B1","beginDate":"2006-02-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"BeneFiber","valueDescription":"Fiber","ValueMeaning":{"publicId":"2577756","version":"1","preferredName":"Fiber","longName":"2577756","preferredDefinition":"Substances in plant foods (fruits and vegetables) that are not digested or absorbed by the gastrointestinal tract.  Fiber is classified into two categories, soluble and insoluble fiber.  Due to increasing the rate of gastrointestinal digestion and possible absorption of cancer causing agents, fiber may possess chemopreventive properties. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fiber","conceptCode":"C1502","definition":"Substances in plant foods (fruits and vegetables) that are not digested or absorbed by the gastrointestinal tract.  Fiber is classified into two categories, soluble and insoluble fiber.  Due to increasing the rate of gastrointestinal digestion and possible absorption of cancer causing agents, fiber may possess chemopreventive properties. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCC9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-19","modifiedBy":"ONEDATA","dateModified":"2006-02-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-84A3-18F7-E053-F662850A60B1","beginDate":"2006-02-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Benzocaine","valueDescription":"Benzocaines","ValueMeaning":{"publicId":"2577757","version":"1","preferredName":"Benzocaines","longName":"2577757","preferredDefinition":"A surface anesthetic that acts by preventing transmission of impulses along nerve fibers and at nerve endings.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benzocaines","conceptCode":"C0005059","definition":"A surface anesthetic that acts by preventing transmission of impulses along nerve fibers and at nerve endings.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCCA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-19","modifiedBy":"ONEDATA","dateModified":"2006-02-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-84AD-18F7-E053-F662850A60B1","beginDate":"2006-02-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Benzonatate","valueDescription":"Benzonatate","ValueMeaning":{"publicId":"2576020","version":"1","preferredName":"Benzonatate","longName":"2576020","preferredDefinition":"A synthetic butylamino-benzoate derivative related to tetracaine and a peripherally acting antitussive, nonnarcotic Benzonatate reduces the cough reflex by anesthetizing and depressing mechanoreceptors in the respiratory passages, lungs, and pleura. It is recommended for cough relief in the common cold, bronchitis, pneumonia, and for chronic cough such as in asthma. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benzonatate","conceptCode":"C28863","definition":"A synthetic butylamino-benzoate derivative related to tetracaine and a peripherally acting antitussive, nonnarcotic Benzonatate reduces the cough reflex by anesthetizing and depressing mechanoreceptors in the respiratory passages, lungs, and pleura. It is recommended for cough relief in the common cold, bronchitis, pneumonia, and for chronic cough such as in asthma. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F601-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-84B7-18F7-E053-F662850A60B1","beginDate":"2006-02-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Benztropine Mesylate","valueDescription":"Benztropine Mesylate","ValueMeaning":{"publicId":"2576021","version":"1","preferredName":"Benztropine Mesylate","longName":"2576021","preferredDefinition":"A synthetic antiparkinson tertiary amine structurally related to atropine, Benztropine Mesylate acts as a central muscarinic antagonist and inhibits dopamine uptake. With antihistaminic and local anesthetic properties as well, it is indicated for symptomatic relief of parkinsonism and drug-induced extrapyramidal reactions. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benztropine Mesylate","conceptCode":"C28864","definition":"A synthetic antiparkinson tertiary amine structurally related to atropine, Benztropine Mesylate acts as a central muscarinic antagonist and inhibits dopamine uptake. With antihistaminic and local anesthetic properties as well, it is indicated for symptomatic relief of parkinsonism and drug-induced extrapyramidal reactions. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F602-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-84C1-18F7-E053-F662850A60B1","beginDate":"2006-02-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Benzylpenicillin Sodium","valueDescription":"Benzylpenicillin Sodium","ValueMeaning":{"publicId":"2575659","version":"1","preferredName":"Benzylpenicillin Sodium","longName":"2575659","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Penicillin G Sodium","conceptCode":"C28865","definition":"The sodium salt form of benzylpenicillin, a semi-synthetic, broad-spectrum penicillin antibiotic with bactericidal activity. Benzylpenicillin sodium binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F498-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-84CB-18F7-E053-F662850A60B1","beginDate":"2006-02-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Beta Carotene","valueDescription":"Beta Carotene","ValueMeaning":{"publicId":"2569626","version":"1","preferredName":"Beta Carotene","longName":"2569626","preferredDefinition":"A vitamin A precursor. Beta carotene belongs to the family of fat-soluble vitamins called carotenoids.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Beta-Carotene","conceptCode":"C1016","definition":"A naturally-occurring retinol (vitamin A) precursor obtained from certain fruits and vegetables with potential antineoplastic and chemopreventive activities.  As an anti-oxidant, beta carotene inhibits free-radical damage to DNA.  This agent also induces cell differentiation and apoptosis of some tumor cell types, particularly in early stages of tumorigenesis, and enhances immune system activity by stimulating the release of natural killer cells, lymphocytes, and monocytes. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DD07-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-05-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-05-20","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-84D5-18F7-E053-F662850A60B1","beginDate":"2006-02-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Betaine HCL","valueDescription":"Betaine","ValueMeaning":{"publicId":"2577758","version":"1","preferredName":"Betaine","longName":"2577758","preferredDefinition":"A naturally occurring compound that has been of interest for its role in osmoregulation. As a drug, betaine hydrochloride has been used as a source of hydrochloric acid in the treatment of hypochlorhydria. Betaine has also been used in the treatment of liver disorders, for hyperkalemia, for homocystinuria, and for gastrointestinal disturbances. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1341)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Betaine","conceptCode":"C0005304","definition":"A naturally occurring compound that has been of interest for its role in osmoregulation. As a drug, betaine hydrochloride has been used as a source of hydrochloric acid in the treatment of hypochlorhydria. Betaine has also been used in the treatment of liver disorders, for hyperkalemia, for homocystinuria, and for gastrointestinal disturbances. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1341)","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCCB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-19","modifiedBy":"ONEDATA","dateModified":"2006-02-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-84DF-18F7-E053-F662850A60B1","beginDate":"2006-02-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Betamethasone","valueDescription":"Betamethasone","ValueMeaning":{"publicId":"2577761","version":"1","preferredName":"Betamethasone","longName":"2577761","preferredDefinition":"A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Betamethasone","conceptCode":"C303","definition":"A synthetic glucocorticoid with metabolic, immunosuppressive and anti-inflammatory activities. Betamethasone binds to specific intracellular glucocorticoid receptors and subsequently binds to DNA to modify gene expression. The synthesis of certain anti-inflammatory proteins is induced while the synthesis of certain inflammatory mediators is inhibited.  As a result, there is an overall reduction in chronic inflammation and autoimmune reactions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCCE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-84E9-18F7-E053-F662850A60B1","beginDate":"2006-02-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Bethanechol Chloride","valueDescription":"Bethanechol Chloride","ValueMeaning":{"publicId":"2577762","version":"1","preferredName":"Bethanechol Chloride","longName":"2577762","preferredDefinition":"A synthetic quaternary ammonium base derivative, parasympathomimetic Bethanechol is a slowly hydrolyzed muscarinic agonist with no nicotinic effects. Generally used to increase smooth muscle tone, Bethanechol is used to treat reflux esophagitis and to initiate urination after surgery, in urinary infections, or for enlarged prostate. It may cause hypotension, cardiac rate changes, and bronchial spasms. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bethanechol Chloride","conceptCode":"C28866","definition":"A synthetic quaternary ammonium base derivative, parasympathomimetic Bethanechol is a slowly hydrolyzed muscarinic agonist with no nicotinic effects. Generally used to increase smooth muscle tone, Bethanechol is used to treat reflux esophagitis and to initiate urination after surgery, in urinary infections, or for enlarged prostate. It may cause hypotension, cardiac rate changes, and bronchial spasms. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCCF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-84F3-18F7-E053-F662850A60B1","beginDate":"2006-02-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Bexarotene","valueDescription":"Bexarotene","ValueMeaning":{"publicId":"2567420","version":"1","preferredName":"Bexarotene","longName":"2567420","preferredDefinition":"A synthetic retinoic acid agent with potential antineoplastic, chemopreventive, teratogenic and embryotoxic properties.  Bexarotene selectively binds to and activates retinoid X receptors (RXRs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, apoptosis of some cancer cell types, and tumor regression. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bexarotene","conceptCode":"C1635","definition":"A synthetic retinoic acid agent with potential antineoplastic, chemopreventive, teratogenic and embryotoxic properties.  Bexarotene selectively binds to and activates retinoid X receptors (RXRs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, apoptosis of some cancer cell types, and tumor regression. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D469-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"COOPERM","dateModified":"2017-12-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-84FD-18F7-E053-F662850A60B1","beginDate":"2006-02-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Bicalutamide","valueDescription":"Bicalutamide","ValueMeaning":{"publicId":"2573403","version":"1","preferredName":"Bicalutamide","longName":"2573403","preferredDefinition":"A synthetic, nonsteroidal antiandrogen.  Bicalutamide competitively binds to cytosolic androgen receptors in target tissues, thereby inhibiting the receptor binding of androgens. This agent does not bind to most mutated forms of androgen receptors. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bicalutamide","conceptCode":"C1599","definition":"A synthetic, nonsteroidal antiandrogen.  Bicalutamide competitively binds to cytosolic androgen receptors in target tissues, thereby inhibiting the receptor binding of androgens. This agent does not bind to most mutated forms of androgen receptors. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EBC8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-11","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8507-18F7-E053-F662850A60B1","beginDate":"2006-02-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Bicarb/ASA/Citric Acid","valueDescription":"Sodium Bicarbonate/Aspirin/Citric Acid","ValueMeaning":{"publicId":"2576905","version":"1","preferredName":"Sodium Bicarbonate/Aspirin/Citric Acid","longName":"2576905","preferredDefinition":"A combination preparation containing sodium bicarbonate, aspirin and citric acid, with analgesic and acid neutralizing properties. Sodium bicarbonate and citric acid provide rapid dissolution of aspirin in water. Sodium bicarbonate also neutralizes stomach acid. Aspirin, a salicylate, binds to and blocks the activities of cyclooxygenases thereby exerting analgesic, antipyretic and anti-inflammatory effects. This preparation is used to relief pain associated with stomach acid.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sodium Bicarbonate/Aspirin/Citric Acid","conceptCode":"C28867","definition":"A combination preparation containing sodium bicarbonate, aspirin and citric acid, with analgesic and acid neutralizing properties. Sodium bicarbonate and citric acid provide rapid dissolution of aspirin in water. Sodium bicarbonate also neutralizes stomach acid. Aspirin, a salicylate, binds to and blocks the activities of cyclooxygenases thereby exerting analgesic, antipyretic and anti-inflammatory effects. This preparation is used to relief pain associated with stomach acid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F976-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-09","modifiedBy":"TAYLORT","dateModified":"2018-05-15","changeDescription":"5/15/18 tt added concept definition.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8511-18F7-E053-F662850A60B1","beginDate":"2006-02-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Biotene Mouthwash","valueDescription":"Biotene Mouthwash","ValueMeaning":{"publicId":"2577763","version":"1","preferredName":"Biotene Mouthwash","longName":"2577763","preferredDefinition":"Formulated for oral hygiene, Biotene Mouthwash contains antibacterial enzymes that boost natural salivary antibacterial defenses, protects teeth and gums, and provides relief or prevents dry mouth (xerostomia) induced by some drug therapies, as well as by acute renal failure, bone marrow transplant, hypertension, kidney dialysis, stroke, and radiation therapy. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Biotene Mouthwash","conceptCode":"C0673636","definition":"Formulated for oral hygiene, Biotene Mouthwash contains antibacterial enzymes that boost natural salivary antibacterial defenses, protects teeth and gums, and provides relief or prevents dry mouth (xerostomia) induced by some drug therapies, as well as by acute renal failure, bone marrow transplant, hypertension, kidney dialysis, stroke, and radiation therapy. (NCI04)","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCD0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-851B-18F7-E053-F662850A60B1","beginDate":"2006-02-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Biotene Gum","valueDescription":"BIOTENE DENTAL CHEWING GUM","ValueMeaning":{"publicId":"2577759","version":"1","preferredName":"BIOTENE DENTAL CHEWING GUM","longName":"2577759v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BIOTENE DENTAL CHEWING GUM","conceptCode":"C0981300","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCCC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-19","modifiedBy":"CLOHNES","dateModified":"2023-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8525-18F7-E053-F662850A60B1","beginDate":"2006-02-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Birth Control","valueDescription":"BIRTH CONTROL","ValueMeaning":{"publicId":"2563611","version":"1","preferredName":"BIRTH CONTROL","longName":"2563611","preferredDefinition":"BIRTH CONTROL","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Birth control","conceptCode":"C0005601","definition":"Definition not available.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-12-04","endDate":null,"createdBy":"CVALMONT","dateCreated":"2002-12-04","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-852F-18F7-E053-F662850A60B1","beginDate":"2006-02-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Bisacodyl","valueDescription":"Bisacodyl","ValueMeaning":{"publicId":"2577764","version":"1","preferredName":"Bisacodyl","longName":"2577764","preferredDefinition":"A synthetic pyridinylmethylene-diacetate ester derivative stimulant laxative, Bisacodyl acts with a parasympathetic effect directly on mucosal sensory nerves, increasing peristaltic contractions. It is used for occasional constipation, in pre- and postoperative treatment, and in conditions that require facilitation of defecation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bisacodyl","conceptCode":"C28870","definition":"A synthetic pyridinylmethylene-diacetate ester derivative stimulant laxative, Bisacodyl acts with a parasympathetic effect directly on mucosal sensory nerves, increasing peristaltic contractions. It is used for occasional constipation, in pre- and postoperative treatment, and in conditions that require facilitation of defecation. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCD1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8539-18F7-E053-F662850A60B1","beginDate":"2006-02-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Bismuth Subsalicylate","valueDescription":"Bismuth Subsalicylate","ValueMeaning":{"publicId":"2576025","version":"1","preferredName":"Bismuth Subsalicylate","longName":"2576025","preferredDefinition":"A bismuth salt of salicylic acid.  Little absorbed from the gastrointestinal tract, bismuth subsalicylate exerts a local effect on the gastric mucosa, coating it and protecting it from the corrosive effects of acid and pepsin.  This agent also has local antimicrobial properties. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bismuth Subsalicylate","conceptCode":"C1020","definition":"A bismuth salt of salicylic acid.  Little absorbed from the gastrointestinal tract, bismuth subsalicylate exerts a local effect on the gastric mucosa, coating it and protecting it from the corrosive effects of acid and pepsin.  This agent also has local antimicrobial properties. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F606-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8543-18F7-E053-F662850A60B1","beginDate":"2006-02-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Bisoprolol Fumarate","valueDescription":"Bisoprolol Fumarate","ValueMeaning":{"publicId":"2577765","version":"1","preferredName":"Bisoprolol Fumarate","longName":"2577765","preferredDefinition":"A synthetic phenoxy-2-propanol derivative, antihypertensive Bisoprolol Fumarate acts as a selective beta-1 (cardio) adrenergic antagonist, without membrane stabilizing activity or intrinsic sympathomimetic activity. Used in the management of hypertension and angina pectoris, Bisoprolol may target bronchial and vascular beta-2 adrenoreceptors at higher doses. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bisoprolol Fumarate","conceptCode":"C28871","definition":"The fumarate salt of a synthetic phenoxy-2-propanol-derived cardioselective beta-1 adrenergic receptor antagonist with antihypertensive and potential cardioprotective activities. Devoid of intrinsic sympathomimetic activity, bisoprolol selectively and competitively binds to and blocks beta-1 adrenergic receptors in the heart, decreasing cardiac contractility and rate, reducing cardiac output, and lowering blood pressure. In addition, this agent may exhibit antihypertensive activity through the inhibition of renin secretion by juxtaglomerular epithelioid (JGE) cells in the kidney, thus inhibiting activation of the renin-angiotensin system (RAS). Bisoprolol has been shown to be cardioprotective in animal models.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCD2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-854D-18F7-E053-F662850A60B1","beginDate":"2006-02-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Bisoprolol/Hydrochlorthiazide","valueDescription":"Bisoprolol Fumarate/Hydrochlorothiazide","ValueMeaning":{"publicId":"2577760","version":"1","preferredName":"Bisoprolol Fumarate/Hydrochlorothiazide","longName":"2577760","preferredDefinition":"A combination of a synthetic antihypertensive phenoxy-2-propanol derivative and a diuretic thiazide used for hypertension, Bisoprolol Fumarate Hydrochlorothiazide acts as a selective beta-1 (cardio) adrenergic antagonist, without membrane stabilizing activity or intrinsic sympathomimetic activity. Hydrochlorothiazide affects renal tubular electrolyte reabsorption, increasing excretion of sodium and chloride. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bisoprolol Fumarate/Hydrochlorothiazide","conceptCode":"CL310716","definition":"A combination of a synthetic antihypertensive phenoxy-2-propanol derivative and a diuretic thiazide used for hypertension, Bisoprolol Fumarate Hydrochlorothiazide acts as a selective beta-1 (cardio) adrenergic antagonist, without membrane stabilizing activity or intrinsic sympathomimetic activity. Hydrochlorothiazide affects renal tubular electrolyte reabsorption, increasing excretion of sodium and chloride. (NCI04)","evsSource":"NCI_META_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCCD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-19","modifiedBy":"ONEDATA","dateModified":"2006-02-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8557-18F7-E053-F662850A60B1","beginDate":"2006-02-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Blephamide","valueDescription":"Blephamide","ValueMeaning":{"publicId":"2576027","version":"1","preferredName":"Blephamide","longName":"2576027","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blephamide","conceptCode":"C0718966","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F608-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8561-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Bovine Cartilage","valueDescription":"Bovine Cartilage","ValueMeaning":{"publicId":"2577775","version":"1","preferredName":"Bovine Cartilage","longName":"2577775","preferredDefinition":"Cartilage extracted from various parts of a cow and is proposed to stimulate the immune system and inhibit tumor cell growth.  It was used in the 1950s and 60s to enhance wound healing. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bovine Cartilage","conceptCode":"C2418","definition":"Cartilage extracted from various parts of a cow and is proposed to stimulate the immune system and inhibit tumor cell growth.  It was used in the 1950s and 60s to enhance wound healing. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCDC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-856B-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Brimodine","valueDescription":"Brimodine","ValueMeaning":{"publicId":"2577776","version":"1","preferredName":"Brimodine","longName":"2577776","preferredDefinition":"A synthetic quinoxaline derivative, Brimodine (brimonidine) acts as a relatively selective alpha-2 adrenergic receptor agonist. Used for open angle glaucoma and eye hypertension, topical administration decreases intraocular pressure with minimal effect on cardiovascular parameters, reducing aqueous humor production and increasing uveoscleral outflow. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brimodine","conceptCode":"C28873","definition":"A synthetic quinoxaline derivative, Brimodine (brimonidine) acts as a relatively selective alpha-2 adrenergic receptor agonist. Used for open angle glaucoma and eye hypertension, topical administration decreases intraocular pressure with minimal effect on cardiovascular parameters, reducing aqueous humor production and increasing uveoscleral outflow. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCDD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8575-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Bromocriptine","valueDescription":"Bromocriptine","ValueMeaning":{"publicId":"2577766","version":"1","preferredName":"Bromocriptine","longName":"2577766","preferredDefinition":"Bromocriptine belongs to the group of medicines known as ergot alkaloids. It acts as a dopamine agonist primarily activating the dopamine D2 receptors. It blocks release of prolactin from the pituitary gland, and is used in the therapy of amenorrhea, infertility in women, abnormal breast milk discharge, hypogonadism, Parkinsons disease, and acromegaly. It is also used in the treatment of pituitary prolactinoma, neuroleptic malignant syndrome, cocaine addiction, and painful breast condition. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bromocriptine Mesylate","conceptCode":"C317","definition":"The mesylate salt of bromocriptine, a semisynthetic ergot alkaloid with dopaminergic, antidyskinetic, and antiprolactinemic activities. Bromocriptine selectively binds to and activates postsynaptic dopamine D2 receptors in the corpus striatum of the central nervous system (CNS). Activation of these D2 receptors activate inhibitory G-proteins, which inhibit adenylyl cyclase, preventing signal transduction mediated via cAMP and resulting in the inhibition of neurotransmission and an antidyskinetic effect. This agent also stimulates dopamine D2 receptors in the anterior pituitary gland, which results in the inhibition of prolactin secretion and lactation and may inhibit the proliferation of prolactin-dependent breast cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCD3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-20","modifiedBy":"ONEDATA","dateModified":"2006-02-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-857F-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Bromphenex","valueDescription":"Dextromethorphan Elixir","ValueMeaning":{"publicId":"2577773","version":"1","preferredName":"Dextromethorphan Elixir","longName":"2577773v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dextromethorphan Elixir","conceptCode":"C1250553","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCDA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"CLOHNES","dateModified":"2023-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8589-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Brompheniramine Maleate/Pseudo","valueDescription":"Brompheniramine maleate + pseudoephedrine hydrochloride","ValueMeaning":{"publicId":"2577767","version":"1","preferredName":"Brompheniramine maleate + pseudoephedrine hydrochloride","longName":"2577767","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brompheniramine maleate + pseudoephedrine hydrochloride","conceptCode":"CL311551","definition":"No value exists.","evsSource":"NCI_META_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCD4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-20","modifiedBy":"ONEDATA","dateModified":"2006-02-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8593-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Brotizolam","valueDescription":"Brotizolam","ValueMeaning":{"publicId":"2576031","version":"1","preferredName":"Brotizolam","longName":"2576031","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"brotizolam","conceptCode":"C0054151","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F60C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-859D-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Budesonide","valueDescription":"Budesonide","ValueMeaning":{"publicId":"2576032","version":"1","preferredName":"Budesonide","longName":"2576032","preferredDefinition":"A glucocorticoid used in the management of asthma, the treatment of various skin disorders, and allergic rhinitis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Budesonide","conceptCode":"C1027","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. Upon administration, budesonide binds to intracellular glucocorticoid receptors (GRs) and induces the expression of glucocorticoid-responsive genes that encode for anti-inflammatory mediators, such as certain anti-inflammatory cytokines, including interleukin 10 (IL-10), and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both mediators of inflammation. In addition, budesonide prevents the release of pro-inflammatory cytokines from epithelial cells and macrophages, including interleukin 6 (IL-6), IL-8, interferon-beta (IFNb), and inhibits nuclear factor kappa-B (NF-kB) activation thereby decreasing NF-kB-mediated inflammation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F60D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2012-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-85A7-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Bumetanide","valueDescription":"Bumetanide","ValueMeaning":{"publicId":"2577777","version":"1","preferredName":"Bumetanide","longName":"2577777","preferredDefinition":"A synthetic butylamino-sulfamoylbenzoic acid derivative, Bumetanide is a loop diuretic that inhibits sodium reabsorption in the ascending limb of the loop of Henle; potassium excretion is increased in a dose-related fashion. Bumetanide is used for edema associated with congestive heart failure, cirrhosis, and nephrotic syndrome. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bumetanide","conceptCode":"C28875","definition":"A potent sulfamoylanthranilic acid derivative belonging to the class of loop diuretics. In the brain, bumetanide may prevent seizures in neonates by blocking the bumetanide-sensitive sodium-potassium-chloride cotransporter (NKCC1), thereby inhibiting chloride uptake thus, decreasing the internal chloride concentration in neurons and may block the excitatory effect of GABA in neonates.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCDE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-85B1-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Bupivacaine","valueDescription":"Bupivacaine Hydrochloride","ValueMeaning":{"publicId":"2577768","version":"1","preferredName":"Bupivacaine Hydrochloride","longName":"2577768v1.00","preferredDefinition":"A long-acting, amide-type local anesthetic. Bupivicaine reversibly binds to specific sodium ion channels in the neuronal membrane, resulting in a decrease in the voltage-dependent membrane permeability to sodium ions and membrane stabilization; inhibition of depolarization and nerve impulse conduction; and a reversible loss of sensation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bupivacaine Hydrochloride","conceptCode":"C28876","definition":"A long-acting, amide-type local anesthetic. Bupivicaine reversibly binds to specific sodium ion channels in the neuronal membrane, resulting in a decrease in the voltage-dependent membrane permeability to sodium ions and membrane stabilization; inhibition of depolarization and nerve impulse conduction; and a reversible loss of sensation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCD5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-20","modifiedBy":"CLOHNES","dateModified":"2023-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-85BB-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Bupropion HCL","valueDescription":"Bupropion Hydrochloride","ValueMeaning":{"publicId":"2577769","version":"1","preferredName":"Bupropion Hydrochloride","longName":"2577769","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bupropion Hydrochloride","conceptCode":"C0700563","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCD6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-20","modifiedBy":"ONEDATA","dateModified":"2006-02-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-85C5-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Buspirone HCL","valueDescription":"Buspirone HCL","ValueMeaning":{"publicId":"2576035","version":"1","preferredName":"Buspirone HCL","longName":"2576035","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Buspirone HCL","conceptCode":"C0700444","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F610-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-85CF-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Caffeine","valueDescription":"Caffeine","ValueMeaning":{"publicId":"2577778","version":"1","preferredName":"Caffeine","longName":"2577778","preferredDefinition":"1,3,7-trimethylxanthine, a central stimulant found in coffee and tea; action may be mediated by adenosine receptors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Caffeine","conceptCode":"C328","definition":"A methylxanthine alkaloid found in the seeds, nuts, or leaves of a number of plants native to South America and East Asia that is structurally related to adenosine and acts primarily as an adenosine receptor antagonist with psychotropic and anti-inflammatory activities. Upon ingestion, caffeine binds to adenosine receptors in the central nervous system (CNS), which inhibits adenosine binding. This inhibits the adenosine-mediated downregulation of CNS activity; thus, stimulating the activity of the medullary, vagal, vasomotor, and respiratory centers in the brain. This agent also promotes neurotransmitter release that further stimulates the CNS. The anti-inflammatory effects of caffeine are due the nonselective competitive inhibition of phosphodiesterases (PDEs). Inhibition of PDEs raises the intracellular concentration of cyclic AMP (cAMP), activates protein kinase A, and inhibits leukotriene synthesis, which leads to reduced inflammation and innate immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCDF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-85D9-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Calcitriol","valueDescription":"Calcitriol","ValueMeaning":{"publicId":"2577779","version":"1","preferredName":"Calcitriol","longName":"2577779","preferredDefinition":"A synthetic physiologically-active analog of vitamin D, specifically the vitamin D3 form.  Calcitriol regulates calcium in vivo by promoting absorption in the intestine, reabsorption in the kidneys, and, along with parathyroid hormone, regulation of bone growth.  A calcitriol receptor-binding protein appears to exist in the mucosa of human intestine. Calcitriol also induces cell cycle arrest at G0/G1 phase of the cell cycle, cell differentiation, and apoptosis, resulting in inhibition of proliferation of some tumor cell types.  This agent may be chemopreventive for colon and prostate cancers. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Calcitriol","conceptCode":"C330","definition":"A synthetic physiologically-active analog of vitamin D, specifically the vitamin D3 form.  Calcitriol regulates calcium in vivo by promoting absorption in the intestine, reabsorption in the kidneys, and, along with parathyroid hormone, regulation of bone growth.  A calcitriol receptor-binding protein appears to exist in the mucosa of human intestine. Calcitriol also induces cell cycle arrest at G0/G1 phase of the cell cycle, cell differentiation, and apoptosis, resulting in inhibition of proliferation of some tumor cell types.  This agent may be chemopreventive for colon and prostate cancers. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCE0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-85E3-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Calcium Carbonate","valueDescription":"Calcium Carbonate","ValueMeaning":{"publicId":"2577780","version":"1","preferredName":"Calcium Carbonate","longName":"2577780","preferredDefinition":"The carbonic salt of calcium (CaCO3). Calcium carbonate is used therapeutically as a phosphate buffer in hemodialysis, as an antacid in gastric hyperacidity for temporary relief of indigestion and heartburn, and as a calcium supplement for preventing and treating osteoporosis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Calcium Carbonate","conceptCode":"C332","definition":"The carbonic salt of calcium (CaCO3). Calcium carbonate is used therapeutically as a phosphate buffer in hemodialysis, as an antacid in gastric hyperacidity for temporary relief of indigestion and heartburn, and as a calcium supplement for preventing and treating osteoporosis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCE1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-85ED-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Calcium Chloride","valueDescription":"Calcium Chloride","ValueMeaning":{"publicId":"2577781","version":"1","preferredName":"Calcium Chloride","longName":"2577781","preferredDefinition":"A crystalline, white substance, soluble in water, Calcium Chloride is the chloride salt of calcium, a bivalent metallic element with many crucial biological roles. Calcium is a major constituent of the skeleton but plays many roles as an intracellular and plasma ion as well. In medicine, calcium chloride is also used as a 10% solution in injection, for calcium replenishment. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Calcium Chloride","conceptCode":"C28901","definition":"A crystalline, white substance, soluble in water, Calcium Chloride is the chloride salt of calcium, a bivalent metallic element with many crucial biological roles. Calcium is a major constituent of the skeleton but plays many roles as an intracellular and plasma ion as well. In medicine, calcium chloride is also used as a 10% solution in injection, for calcium replenishment. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCE2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-85F7-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Calcium Citrate","valueDescription":"Calcium Citrate","ValueMeaning":{"publicId":"2576036","version":"1","preferredName":"Calcium Citrate","longName":"2576036","preferredDefinition":"The citrate salt of calcium. An element necessary for normal nerve, muscle, and cardiac function, calcium as the citrate salt helps to maintain calcium balance and prevent bone loss when taken orally. This agent may also be chemopreventive for colon and other cancers. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Calcium Citrate","conceptCode":"C1355","definition":"The citrate salt of calcium. An element necessary for normal nerve, muscle, and cardiac function, calcium as the citrate salt helps to maintain calcium balance and prevent bone loss when taken orally. This agent may also be chemopreventive for colon and other cancers. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F611-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8601-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Calcium Gluconate","valueDescription":"Calcium Gluconate","ValueMeaning":{"publicId":"2577782","version":"1","preferredName":"Calcium Gluconate","longName":"2577782","preferredDefinition":"The gluconate salt of calcium. An element or mineral necessary for normal nerve, muscle, and cardiac function, calcium as the gluconate salt helps to maintain calcium balance and prevent bone loss when taken orally. This agent may also be chemopreventive for colon and other cancers. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Calcium Gluconate","conceptCode":"C336","definition":"The gluconate salt of calcium. An element or mineral necessary for normal nerve, muscle, and cardiac function, calcium as the gluconate salt helps to maintain calcium balance and prevent bone loss when taken orally. This agent may also be chemopreventive for colon and other cancers. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCE3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-860B-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Calcium Polycarbophil","valueDescription":"Calcium Polycarbophil","ValueMeaning":{"publicId":"2577783","version":"1","preferredName":"Calcium Polycarbophil","longName":"2577783","preferredDefinition":"A loosely cross-linked synthetic polycarboxylic-type hydrophilic polymer resin, laxative and anti-diarrheal Calcium Polycarbophil increases stool frequency, fecal water content, and fecal weight in a dose-dependent manner. It is used for idiopathic constipation, secretory diarrhea, and irritable bowel syndrome. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Calcium Polycarbophil","conceptCode":"C28902","definition":"A loosely cross-linked synthetic polycarboxylic-type hydrophilic polymer resin, laxative and anti-diarrheal Calcium Polycarbophil increases stool frequency, fecal water content, and fecal weight in a dose-dependent manner. It is used for idiopathic constipation, secretory diarrhea, and irritable bowel syndrome. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCE4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8615-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Calcium/Vitamin D","valueDescription":"calcium-vitamin D","ValueMeaning":{"publicId":"2577770","version":"1","preferredName":"calcium-vitamin D","longName":"2577770","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"calcium-vitamin D","conceptCode":"C0719107","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCD7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-20","modifiedBy":"ONEDATA","dateModified":"2006-02-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-861F-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Calmoseptine Ointment","valueDescription":"CALMOSEPTINE OINT","ValueMeaning":{"publicId":"2577771","version":"1","preferredName":"CALMOSEPTINE OINT","longName":"2577771","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CALMOSEPTINE OINT","conceptCode":"C0994892","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCD8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-20","modifiedBy":"ONEDATA","dateModified":"2006-02-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8629-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Campath","valueDescription":"Alemtuzumab","ValueMeaning":{"publicId":"2577772","version":"1","preferredName":"Alemtuzumab","longName":"2577772","preferredDefinition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alemtuzumab","conceptCode":"C1681","definition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCD9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-20","modifiedBy":"ALEYR","dateModified":"2008-04-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8633-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Candesartan Cilexetil","valueDescription":"Candesartan Cilexetil","ValueMeaning":{"publicId":"2577784","version":"1","preferredName":"Candesartan Cilexetil","longName":"2577784","preferredDefinition":"A synthetic antihypertensive benzimidazole-carboxylate derivative, Candesartan Cilexetil (Candesartan prodrug) selectively blocks angiotensin ll binding to specific receptors, inducing vasodilation and reduced aldosterone production. With other hypotensive agents, it is indicated in hypertension. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Candesartan Cilexetil","conceptCode":"C28903","definition":"A synthetic, benzimidazole-derived angiotensin II receptor antagonist prodrug with antihypertensive activity. After hydrolysis of candesartan cilexetil to candesartan during gastrointestinal absorption, candesartan selectively competes with angiotensin II for the binding of the angiotensin II receptor subtype 1 (AT1) in vascular smooth muscle, blocking angiotensin II-mediated vasoconstriction and inducing vasodilatation. In addition, antagonism of AT1 in the adrenal gland inhibits angiotensin II-stimulated aldosterone synthesis and secretion by the adrenal cortex; sodium and water excretion increase, followed by a reduction in plasma volume and blood pressure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCE5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-863D-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Capsaicin","valueDescription":"Capsaicin","ValueMeaning":{"publicId":"2577785","version":"1","preferredName":"Capsaicin","longName":"2577785","preferredDefinition":"A chili pepper extract with analgesic properties.  Capsaicin is a neuropeptide releasing agent selective for primary sensory peripheral neurons.  Used topically, capsaicin aids in controlling peripheral nerve pain.  This agent has been used experimentally to manipulate substance P and other tachykinins.  In addition, capsaicin may be useful in controlling chemotherapy- and radiotherapy-induced mucositis. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Capsaicin","conceptCode":"C339","definition":"A chili pepper extract with analgesic properties.  Capsaicin is a neuropeptide releasing agent selective for primary sensory peripheral neurons.  Used topically, capsaicin aids in controlling peripheral nerve pain.  This agent has been used experimentally to manipulate substance P and other tachykinins.  In addition, capsaicin may be useful in controlling chemotherapy- and radiotherapy-induced mucositis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCE6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8647-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Captopril","valueDescription":"Captopril","ValueMeaning":{"publicId":"2577786","version":"1","preferredName":"Captopril","longName":"2577786","preferredDefinition":"A sulfhydryl-containing analog of proline with antihypertensive activity and potential antineoplastic activity. Captopril competitively inhibits angiotensin converting enzyme (ACE), thereby decreasing levels of angiotensin II, increasing plasma renin activity, and decreasing aldosterone secretion.  This agent may also inhibit tumor angiogenesis by inhibiting endothelial cell matrix metalloproteinases (MMPs) and endothelial cell migration. Captopril may also exhibit antineoplastic activity independent of effects on tumor angiogenesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Captopril","conceptCode":"C340","definition":"A sulfhydryl-containing analog of proline with antihypertensive activity and potential antineoplastic activity. Captopril competitively inhibits angiotensin converting enzyme (ACE), thereby decreasing levels of angiotensin II, increasing plasma renin activity, and decreasing aldosterone secretion.  This agent may also inhibit tumor angiogenesis by inhibiting endothelial cell matrix metalloproteinases (MMPs) and endothelial cell migration. Captopril may also exhibit antineoplastic activity independent of effects on tumor angiogenesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCE7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8651-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Carbamazepine","valueDescription":"Carbamazepine","ValueMeaning":{"publicId":"2576040","version":"1","preferredName":"Carbamazepine","longName":"2576040","preferredDefinition":"An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of PHENYTOIN; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carbamazepine","conceptCode":"C341","definition":"A tricyclic compound chemically related to tricyclic antidepressants (TCA) with anticonvulsant and analgesic properties. Carbamazepine exerts its anticonvulsant activity by reducing polysynaptic responses and blocking post-tetanic potentiation. Its analgesic activity is not understood; however, carbamazepine is commonly used to treat pain associated with trigeminal neuralgia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F615-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-865B-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Carboxymethylcellulose","valueDescription":"Carboxymethylcellulose","ValueMeaning":{"publicId":"2577787","version":"1","preferredName":"Carboxymethylcellulose","longName":"2577787","preferredDefinition":"It is used as an emulsifier, thickener, suspending agent, etc., in cosmetics and pharmaceuticals; in research as a culture medium; in chromatography as a stabilizer for reagents; and therapeutically as a bulk laxative with antacid properties.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboxymethylcellulose","conceptCode":"C0007068","definition":"It is used as an emulsifier, thickener, suspending agent, etc., in cosmetics and pharmaceuticals; in research as a culture medium; in chromatography as a stabilizer for reagents; and therapeutically as a bulk laxative with antacid properties.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCE8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8665-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Carisoprodol","valueDescription":"Carisoprodol","ValueMeaning":{"publicId":"2577788","version":"1","preferredName":"Carisoprodol","longName":"2577788","preferredDefinition":"A synthetic propanediol dicarbamate derivative and an adjunct in the treatment of painful muscle spasms, Carisoprodol is a centrally acting skeletal muscle relaxant that relieves stiffness, pain, and discomfort caused by muscle injuries. Its mechanism of action is not clear yet; perhaps due to its sedative actions. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carisoprodol","conceptCode":"C28904","definition":"A synthetic propanediol dicarbamate derivative and an adjunct in the treatment of painful muscle spasms, Carisoprodol is a centrally acting skeletal muscle relaxant that relieves stiffness, pain, and discomfort caused by muscle injuries. Its mechanism of action is not clear yet; perhaps due to its sedative actions. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCE9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-866F-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Carteolol HCL","valueDescription":"Carteolol Hydrochloride","ValueMeaning":{"publicId":"2577774","version":"1","preferredName":"Carteolol Hydrochloride","longName":"2577774","preferredDefinition":"A synthetic quinolinone derivative, antihypertensive Carteolol Hydrochloride is a nonselective beta-adrenoceptor blocking agent for beta-1 and beta-2 receptors with no membrane-stabilizing activity but moderate intrinsic sympathomimetic effects. It is used for treatment of hypertension and certain arrhythmias, and as an anti-angina and antiglaucoma agent. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carteolol Hydrochloride","conceptCode":"C0543450","definition":"A synthetic quinolinone derivative, antihypertensive Carteolol Hydrochloride is a nonselective beta-adrenoceptor blocking agent for beta-1 and beta-2 receptors with no membrane-stabilizing activity but moderate intrinsic sympathomimetic effects. It is used for treatment of hypertension and certain arrhythmias, and as an anti-angina and antiglaucoma agent. (NCI04)","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCDB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8679-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Carvedilol","valueDescription":"Carvedilol","ValueMeaning":{"publicId":"2577792","version":"1","preferredName":"Carvedilol","longName":"2577792","preferredDefinition":"A synthetic antihypertensive methoxyphenoxy- 2-propanol derivative with no intrinsic sympathomimetic activity, Carvedilol acts as a nonselective beta-adrenoceptor blocking agent (S(-) enantiomer) and as an alpha 1-adrenoceptor blocker (R(+) and S(-) enantiomers). Its acts more strongly on beta-receptors than on alpha 1-receptors, reduces peripheral vascular resistance by vasodilation, and prevents reflex tachycardia (beta-blockade) so that heart rate is either unchanged or decreased. Carvedilol also reduces renin release through beta-blockade. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carvedilol","conceptCode":"C28906","definition":"A synthetic antihypertensive methoxyphenoxy- 2-propanol derivative with no intrinsic sympathomimetic activity, Carvedilol acts as a nonselective beta-adrenoceptor blocking agent (S(-) enantiomer) and as an alpha 1-adrenoceptor blocker (R(+) and S(-) enantiomers). Its acts more strongly on beta-receptors than on alpha 1-receptors, reduces peripheral vascular resistance by vasodilation, and prevents reflex tachycardia (beta-blockade) so that heart rate is either unchanged or decreased. Carvedilol also reduces renin release through beta-blockade. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCED-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8683-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Casanthranol","valueDescription":"Casanthranol","ValueMeaning":{"publicId":"2577793","version":"1","preferredName":"Casanthranol","longName":"2577793","preferredDefinition":"A concentrated mixture of anthranol glycosides from cascara sagrada (dried bark of Rhamnus p.) and used as a laxative in constipation and various medical conditions, stimulant laxative Casanthranol encourages bowel movements by acting on the intestinal wall to increase muscle contractions. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Casanthranol","conceptCode":"C28907","definition":"A concentrated mixture of anthranol glycosides from cascara sagrada (dried bark of Rhamnus p.) and used as a laxative in constipation and various medical conditions, stimulant laxative Casanthranol encourages bowel movements by acting on the intestinal wall to increase muscle contractions. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCEE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-868D-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Casanthranol/Docusate","valueDescription":"Casanthranol/Docusate","ValueMeaning":{"publicId":"2577794","version":"1","preferredName":"Casanthranol/Docusate","longName":"2577794","preferredDefinition":"A combination of laxatives, Casanthranol Docusate is used in constipation and various medical conditions. Casanthranol is a concentrated mixture of anthranol glycosides from cascara sagrada (dried bark of Rhamnus p.) and a stimulant laxative that encourages bowel movements by acting on the intestinal wall to increase muscle contractions. A surface-active emollient, stool softener Docusate helps liquids to mix into dry stool, allowing patients to have a bowel movement without straining. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Casanthranol/Docusate","conceptCode":"C28908","definition":"A combination of laxatives, Casanthranol Docusate is used in constipation and various medical conditions. Casanthranol is a concentrated mixture of anthranol glycosides from cascara sagrada (dried bark of Rhamnus p.) and a stimulant laxative that encourages bowel movements by acting on the intestinal wall to increase muscle contractions. A surface-active emollient, stool softener Docusate helps liquids to mix into dry stool, allowing patients to have a bowel movement without straining. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCEF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"COOPERM","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8697-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cascara","valueDescription":"Cascara","ValueMeaning":{"publicId":"2576042","version":"1","preferredName":"Cascara","longName":"2576042","preferredDefinition":"Used as a laxative in constipation and various medical conditions, Cascara (cascara sagrada) is dried bark of Picramnia sp. (Simarubaceae) or Rhamnus purshiana (Rhamnaceae) containing stimulant laxative anthranol glycosides that act on the intestinal wall to increase muscle contractions and encourage bowel movements. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Frangula purshiana Bark","conceptCode":"C28909","definition":"Used as a laxative in constipation and various medical conditions, Cascara (cascara sagrada) is dried bark of Picramnia sp. (Simarubaceae) or Rhamnus purshiana (Rhamnaceae) containing stimulant laxative anthranol glycosides that act on the intestinal wall to increase muscle contractions and encourage bowel movements. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F617-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-86A1-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Caspofungin","valueDescription":"Caspofungin","ValueMeaning":{"publicId":"2577795","version":"1","preferredName":"Caspofungin","longName":"2577795","preferredDefinition":"The acetate salt of an antimycotic echinocandin lipopeptide, semisynthetically derived from a fermentation product of the fungus Glarea lozoyensis. Caspofungin inhibits 1,3-beta-glucan synthase, resulting in decreased synthesis of beta(1,3)-D-glucan (an essential component of the fungal cell wall), weakening of the fungal cell wall, and fungal cell wall rupture. This agent is active against Aspergillus and Candida species.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Caspofungin","conceptCode":"C28910","definition":"An antimycotic echinocandin lipopeptide, semisynthetically derived from a fermentation product of the fungus Glarea lozoyensis. Caspofungin inhibits 1,3-beta-glucan synthase, resulting in decreased synthesis of beta(1,3)-D-glucan (an essential component of the fungal cell wall), weakening of the fungal cell wall, and fungal cell wall rupture. This agent is active against Aspergillus and Candida species.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCF0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-86AB-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cefaclor","valueDescription":"Cefaclor","ValueMeaning":{"publicId":"2575660","version":"1","preferredName":"Cefaclor","longName":"2575660","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cefaclor","conceptCode":"C28911","definition":"A beta-lactam, second-generation cephalosporin antibiotic with bactericidal activity. Cefaclor binds to and inactivates penicillin-binding proteins (PBP) located in bacterial cytoplasmic membranes. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F499-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-86B5-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cefadroxil","valueDescription":"Cefadroxil","ValueMeaning":{"publicId":"2575661","version":"1","preferredName":"Cefadroxil","longName":"2575661","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cefadroxil","conceptCode":"C28912","definition":"A semi-synthetic, beta-lactam, first-generation cephalosporin antibiotic with bactericidal activity. Cefadroxil binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F49A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-86BF-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cefazolin","valueDescription":"Cefazolin","ValueMeaning":{"publicId":"2575662","version":"1","preferredName":"Cefazolin","longName":"2575662","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cefazolin","conceptCode":"C28913","definition":"A beta-lactam antibiotic and first-generation cephalosporin with bactericidal activity. Cefazolin binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F49B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-86C9-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cefdinir","valueDescription":"Cefdinir","ValueMeaning":{"publicId":"2575663","version":"1","preferredName":"Cefdinir","longName":"2575663","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cefdinir","conceptCode":"C28914","definition":"A semi-synthetic cephalosporin and a beta-lactam antibiotic with bactericidal activity. Cefdinir's effect is dependent on its binding to penicillin-binding proteins (PBPs) located in the bacterial cytoplasmic membrane. Binding results in the inhibition of the transpeptidase enzymes, thereby preventing cross-linking of the pentaglycine bridge with the fourth residue of the pentapeptide and interrupting consequent synthesis of peptidoglycan chains. As a result, cefdinir inhibits bacterial septum and cell wall synthesis formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F49C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-86D3-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cefepime","valueDescription":"Cefepime","ValueMeaning":{"publicId":"2577796","version":"1","preferredName":"Cefepime","longName":"2577796","preferredDefinition":"A semi-synthetic, broad spectrum, fourth generation cephalosporin antibiotic which inhibits bacterial cell wall biosynthesis by interfering with the final transpeptidation step of peptidoglycan synthesis which ultimately causes the bacterial to lyse. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cefepime Hydrochloride","conceptCode":"C1041","definition":"The hydrochloride salt of a semi-synthetic, beta-lactamase-resistant, fourth-generation cephalosporin antibiotic derived from an Acremonium fungal species with broad-spectrum bactericidal activity. Administered parenterally, cefepime inhibits bacterial cell wall synthesis by binding to and inactivating penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity, resulting in a reduction of bacterial cell wall stability and cell lysis. This agent is more active against a variety of Gram-positive pathogens compared to third-generation cephalosporins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCF1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-86DD-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cefotaxime Sodium","valueDescription":"Cefotaxime Sodium","ValueMeaning":{"publicId":"2577797","version":"1","preferredName":"Cefotaxime Sodium","longName":"2577797","preferredDefinition":"The sodium salt form of cefotaxime.  Cefotaxime inhibits mucopeptide synthesis by binding to penicillin binding proteins, causing inhibition of bacterial cell wall synthesis. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cefotaxime Sodium","conceptCode":"C2328","definition":"The sodium salt form of cefotaxime, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Cefotaxime sodium binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linking of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, cefotaxime sodium is more active against gram-negative bacteria and less active against gram-positive bacteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCF2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-86E7-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cefoxitin Sodium","valueDescription":"Cefoxitin Sodium","ValueMeaning":{"publicId":"2575665","version":"1","preferredName":"Cefoxitin Sodium","longName":"2575665","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cefoxitin Sodium","conceptCode":"C28915","definition":"The sodium salt form of cefoxitin, a beta-lactam, second-generation cephalosporin antibiotic with bactericidal activity. Cefoxitin sodium binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F49E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-86F1-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cefpodoxime","valueDescription":"Cefpodoxime Proxetil","ValueMeaning":{"publicId":"2577789","version":"1","preferredName":"Cefpodoxime Proxetil","longName":"2577789","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cefpodoxime Proxetil","conceptCode":"C28916","definition":"A third generation semi-synthetic cephalosporin and a beta-lactam antibiotic with bactericidal activity. Cefpodoxime's effect is dependent on its binding to penicillin-binding proteins (PBPs) located in the bacterial cytoplasmic membrane. Binding results in the inhibition of the transpeptidase enzymes, thereby preventing cross-linking of the pentaglycine bridge with the fourth residue of the pentapeptide and interrupting consequent synthesis of peptidoglycan chains. As a result, cefpodoxime inhibits bacterial septum and cell wall synthesis formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCEA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-86FB-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cefprozil","valueDescription":"Cefprozil","ValueMeaning":{"publicId":"2575667","version":"1","preferredName":"Cefprozil","longName":"2575667","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cefprozil","conceptCode":"C28917","definition":"A semi-synthetic cephalosporin and a beta-lactam antibiotic with bactericidal activity. Cefprozil's effect is dependent on its binding to penicillin-binding proteins (PBPs) located in the bacterial cytoplasmic membrane. Binding results in the inhibition of the transpeptidase enzymes, thereby preventing cross-linking of the pentaglycine bridge with the fourth residue of the pentapeptide and interrupting consequent synthesis of peptidoglycan chains. As a result, cefprozil inhibits bacterial septum and cell wall synthesis formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4A0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8705-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ceftazidime","valueDescription":"Ceftazidime Sodium","ValueMeaning":{"publicId":"2577790","version":"1","preferredName":"Ceftazidime Sodium","longName":"2577790","preferredDefinition":"Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ceftazidime Sodium","conceptCode":"C355","definition":"The sodium salt of ceftazidime, a third-generation cephalosporin antibiotic with bactericidal activity. Ceftazidime binds to and inactivates penicillin-binding proteins (PBPs), enzymes located on the inner membrane of the bacterial cell wall, resulting in the weakening of the bacterial cell wall and cell lysis. Compared to the second and first generation cephalosporins, ceftazidime is more active against gram-negative bacteria and less active against gram-positive bacteria. Ceftazidine also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS). PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCEB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-870F-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ceftriaxone","valueDescription":"Ceftriaxone Sodium","ValueMeaning":{"publicId":"2577791","version":"1","preferredName":"Ceftriaxone Sodium","longName":"2577791","preferredDefinition":"An antibiotic drug used to treat infection. It belongs to the family of drugs called cephalosporin antibiotics.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ceftriaxone Sodium","conceptCode":"C817","definition":"The sodium salt form of ceftriaxone, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Ceftriaxone binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, ceftriaxone is more active against gram-negative bacteria and less active against gram-positive bacteria. Ceftriaxone also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCEC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8719-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cefurexine Axetil","valueDescription":"Cefuroxime Axetil","ValueMeaning":{"publicId":"2577798","version":"1","preferredName":"Cefuroxime Axetil","longName":"2577798","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cefuroxime Axetil","conceptCode":"C0055015","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCF3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8723-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Celecoxib","valueDescription":"Celecoxib","ValueMeaning":{"publicId":"2577801","version":"1","preferredName":"Celecoxib","longName":"2577801","preferredDefinition":"A nonsteroidal anti-inflammatory drug (NSAID) with a diaryl-substituted pyrazole structure. Celecoxib selectively inhibits cyclo-oxygenase-2 activity (COX-2); COX-2 inhibition may result in apoptosis and a reduction in tumor angiogenesis and metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Celecoxib","conceptCode":"C1728","definition":"A nonsteroidal anti-inflammatory drug (NSAID) with a diaryl-substituted pyrazole structure. Celecoxib selectively inhibits cyclo-oxygenase-2 activity (COX-2); COX-2 inhibition may result in apoptosis and a reduction in tumor angiogenesis and metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCF6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-872D-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cephalexin","valueDescription":"Cephalexin","ValueMeaning":{"publicId":"2577802","version":"1","preferredName":"Cephalexin","longName":"2577802","preferredDefinition":"A first generation semisynthetic cephalosporin antibiotic that inhibits mucopeptide synthesis by binding to penicillin binding proteins, causing inhibition of bacterial cell wall synthesis.(NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cephalexin","conceptCode":"C356","definition":"A beta-lactam, first-generation cephalosporin antibiotic with bactericidal activity. Cephalexin binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linking of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to second and third generation cephalosporins, cephalexin is more active against gram-positive and less active against gram-negative organisms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCF7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8737-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Propoxyphene Napsylate/Acetaminophen","valueDescription":"Propoxyphene Napsylate/Acetaminophen","ValueMeaning":{"publicId":"7063240","version":"1","preferredName":"Propoxyphene Napsylate/Acetaminophen","longName":"7063240","preferredDefinition":"A combination preparation of propoxyphene napsylate and acetaminophen, with analgesic and antipyretic activities. Propoxyphene napsylate is a mild narcotic analgesic that binds to mu-opioid receptors in the central nervous system (CNS), thereby mimicking the effect of endogenous opioids. Acetaminophen possesses analgesic and antipyretic effects by interfering with prostaglandin synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Propoxyphene Napsylate/Acetaminophen","conceptCode":"C29387","definition":"A combination preparation of propoxyphene napsylate and acetaminophen, with analgesic and antipyretic activities. Propoxyphene napsylate is a mild narcotic analgesic that binds to mu-opioid receptors in the central nervous system (CNS), thereby mimicking the effect of endogenous opioids. Acetaminophen possesses analgesic and antipyretic effects by interfering with prostaglandin synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97CFAB45-E9C7-1861-E053-F662850AF1A8","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"COOPERM","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CFAB45-E9E0-1861-E053-F662850AF1A8","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Propoxyphene Napsylate","valueDescription":"Propoxyphene Napsylate","ValueMeaning":{"publicId":"7063242","version":"1","preferredName":"Propoxyphene Napsylate","longName":"7063242","preferredDefinition":"A synthetic diphenyl propionate derivative structurally related to methadone, Propoxyphene Napsylate acts as a central narcotic and analgesic agent by interaction with mu opioid receptors, but with less selectivity then morphine. The dextro-isomer has analgesic effect, while the levo-isomer exerts an antitussive effect. The napsylate salt allows better dosage formulation than the hydrochloride salt. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Propoxyphene Napsylate","conceptCode":"C29386","definition":"A synthetic diphenyl propionate derivative structurally related to methadone, Propoxyphene Napsylate acts as a central narcotic and analgesic agent by interaction with mu opioid receptors, but with less selectivity then morphine. The dextro-isomer has analgesic effect, while the levo-isomer exerts an antitussive effect. The napsylate salt allows better dosage formulation than the hydrochloride salt. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97CFAB45-E9ED-1861-E053-F662850AF1A8","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CFAB45-EA06-1861-E053-F662850AF1A8","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Propoxyphene HCL","valueDescription":"Propoxyphene Hydrochloride","ValueMeaning":{"publicId":"7063244","version":"1","preferredName":"Propoxyphene Hydrochloride","longName":"7063244","preferredDefinition":"The hydrochloride salt form of the d-isomer of synthetic diphenyl propionate derivative propoxyphene, with narcotic analgesic effect. This agent mimics the effects of the endogenous opiate dextropropoxyphene, by binding to mu receptors located throughout the central nervous system. The binding results in GTP to GDP exchanges on the mu-G-protein complex, by which effector adenylate cyclase is inactivated thereby decreasing intracellular cAMP. This, in turn, inhibits the release of various nociceptive neurotransmitters, such as substance P, gamma-aminobutyric acid (GABA), dopamine, acetylcholine, noradrenaline, vasopressin, and somatostatin. In addition, dextropropoxyphene closes N-type voltage-gated calcium channels and opens calcium-dependent inwardly rectifying potassium channels. This results in hyperpolarization, thereby reducing neuronal excitability, which further decreases the perception of pain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Propoxyphene Hydrochloride","conceptCode":"C29385","definition":"The hydrochloride salt form of the d-isomer of synthetic diphenyl propionate derivative propoxyphene, with narcotic analgesic effect. This agent mimics the effects of the endogenous opiate dextropropoxyphene, by binding to mu receptors located throughout the central nervous system. The binding results in GTP to GDP exchanges on the mu-G-protein complex, by which effector adenylate cyclase is inactivated thereby decreasing intracellular cAMP. This, in turn, inhibits the release of various nociceptive neurotransmitters, such as substance P, gamma-aminobutyric acid (GABA), dopamine, acetylcholine, noradrenaline, vasopressin, and somatostatin. In addition, dextropropoxyphene closes N-type voltage-gated calcium channels and opens calcium-dependent inwardly rectifying potassium channels. This results in hyperpolarization, thereby reducing neuronal excitability, which further decreases the perception of pain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97CFAB45-EA13-1861-E053-F662850AF1A8","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CFAB45-EA2C-1861-E053-F662850AF1A8","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Propofol","valueDescription":"Propofol","ValueMeaning":{"publicId":"5212049","version":"1","preferredName":"Propofol","longName":"5212049","preferredDefinition":"A hypnotic alkylphenol derivative. Formulated for intravenous induction of sedation and hypnosis during anesthesia, propofol facilitates inhibitory neurotransmission mediated by gamma-aminobutyric acid (GABA). This agent is associated with minimal respiratory depression and has a short half-life with a duration of action of 2 to 10 minutes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Propofol","conceptCode":"C29384","definition":"A hypnotic alkylphenol derivative. Formulated for intravenous induction of sedation and hypnosis during anesthesia, propofol facilitates inhibitory neurotransmission mediated by gamma-aminobutyric acid (GABA). This agent is associated with minimal respiratory depression and has a short half-life with a duration of action of 2 to 10 minutes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2FD7CF95-9466-38AC-E050-BB89AD436C35","latestVersionIndicator":"Yes","beginDate":"2016-04-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-04-06","modifiedBy":"COOPERM","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CFAB45-EA36-1861-E053-F662850AF1A8","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Propantheline Bromide","valueDescription":"Propantheline Bromide","ValueMeaning":{"publicId":"7063246","version":"1","preferredName":"Propantheline Bromide","longName":"7063246","preferredDefinition":"The bromide salt form of propantheline, a quaternary ammonium compound structurally related to belladonna alkaloids. Propantheline bromide competitively antagonizes acetylcholine activity mediated by muscarinic receptors at neuroeffector sites on smooth muscle and exocrine gland cells. An aspartic acid residue present in the N-terminal portion of the third trans-membrane helix of the muscarinic receptor is believed to form an ionic bond with the tertiary or quaternary nitrogen of the antagonist. Antagonism leads to a reduction of exocrine glands secretions and to relax bronchial muscle and reduce tone and motility of intestinal smooth muscle.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Propantheline Bromide","conceptCode":"C29383","definition":"The bromide salt form of propantheline, a quaternary ammonium compound structurally related to belladonna alkaloids. Propantheline bromide competitively antagonizes acetylcholine activity mediated by muscarinic receptors at neuroeffector sites on smooth muscle and exocrine gland cells. An aspartic acid residue present in the N-terminal portion of the third trans-membrane helix of the muscarinic receptor is believed to form an ionic bond with the tertiary or quaternary nitrogen of the antagonist. Antagonism leads to a reduction of exocrine glands secretions and to relax bronchial muscle and reduce tone and motility of intestinal smooth muscle.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97CFAB45-EA44-1861-E053-F662850AF1A8","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CFAB45-EA5D-1861-E053-F662850AF1A8","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Propafenone","valueDescription":"Propafenone","ValueMeaning":{"publicId":"7063247","version":"1","preferredName":"Propafenone","longName":"7063247","preferredDefinition":"A class 1C anti-arrhythmic medication, which treats illnesses associated with rapid heart beats such as atrial and ventricular arrhythmias.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97CFAB45-EA67-1861-E053-F662850AF1A8","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CFAB45-EA80-1861-E053-F662850AF1A8","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Promethazine HCL","valueDescription":"Promethazine Hydrochloride","ValueMeaning":{"publicId":"7063249","version":"1","preferredName":"Promethazine Hydrochloride","longName":"7063249","preferredDefinition":"The hydrochloride salt form of promethazine, a phenothiazine derivative with antihistaminic, sedative and antiemetic properties. Promethazine hydrochloride selectively blocks peripheral H1 receptors thereby diminishing the effects of histamine on effector cells. Promethazine hydrochloride also blocks the central histaminergic receptors, thereby depressing the reticular system causing sedative and hypnotic effects. In addition, promethazine hydrochloride also has centrally acting anticholinergic properties and probably mediates nausea and vomiting by acting on the medullary chemoreceptive trigger zone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Promethazine Hydrochloride","conceptCode":"C45907","definition":"The hydrochloride salt form of promethazine, a phenothiazine derivative with antihistaminic, sedative and antiemetic properties. Promethazine hydrochloride selectively blocks peripheral H1 receptors thereby diminishing the effects of histamine on effector cells. Promethazine hydrochloride also blocks the central histaminergic receptors, thereby depressing the reticular system causing sedative and hypnotic effects. In addition, promethazine hydrochloride also has centrally acting anticholinergic properties and probably mediates nausea and vomiting by acting on the medullary chemoreceptive trigger zone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97CFAB45-EA8D-1861-E053-F662850AF1A8","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CFAB45-EAA6-1861-E053-F662850AF1A8","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Progesterone","valueDescription":"PROGESTERONE","ValueMeaning":{"publicId":"2563599","version":"1","preferredName":"PROGESTERONE","longName":"2563599","preferredDefinition":"Produced in the corpus luteum and by the placenta, as an antagonist of estrogens. Promotes proliferation of uterine mucosa and the implantation of the blastocyst, prevents further follicular development. (On-line Medical Dictionary)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progesterone","conceptCode":"C2297","definition":"Produced in the corpus luteum and by the placenta, as an antagonist of estrogens. Promotes proliferation of uterine mucosa and the implantation of the blastocyst, prevents further follicular development.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C57C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-12-04","endDate":null,"createdBy":"CVALMONT","dateCreated":"2002-12-04","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CFAB45-EAB0-1861-E053-F662850AF1A8","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Proctofoam","valueDescription":"Hydrocortisone/Pramoxine-containing Preparation","ValueMeaning":{"publicId":"7063251","version":"1","preferredName":"Hydrocortisone/Pramoxine-containing Preparation","longName":"7063251","preferredDefinition":"A combination preparation containing the glucocorticoid hydrocortisone acetate and the local anesthetic pramoxine hydrochloride, in aerosol foam form. Hydrocortisone has topical anti-inflammatory, vasoconstrictive and anti-pruritic activities and is used to relieve anorectal inflammation, pain, swelling, and pruritus caused by hemorrhoids.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydrocortisone/Pramoxine-containing Preparation","conceptCode":"C29380","definition":"A combination preparation containing the glucocorticoid hydrocortisone acetate and the local anesthetic pramoxine hydrochloride, in aerosol foam form. Hydrocortisone has topical anti-inflammatory, vasoconstrictive and anti-pruritic activities and is used to relieve anorectal inflammation, pain, swelling, and pruritus caused by hemorrhoids.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97CFAB45-EABE-1861-E053-F662850AF1A8","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CFAB45-EAD7-1861-E053-F662850AF1A8","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Procarbazine","valueDescription":"Procarbazine","ValueMeaning":{"publicId":"3379498","version":"1","preferredName":"Procarbazine","longName":"3379498","preferredDefinition":"A methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Procarbazine","conceptCode":"C62072","definition":"A methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-26E9-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CFAB45-EAE1-1861-E053-F662850AF1A8","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Probiotics","valueDescription":"Probiotic","ValueMeaning":{"publicId":"7063252","version":"1","preferredName":"Probiotic","longName":"7063252","preferredDefinition":"A live microorganism used as a dietary supplement to help with digestion and normal bowel function. It may also help keep the gastrointestinal (GI) tract healthy. A bacterium found in yogurt called Lactobacillus acidophilus, is the most common probiotic.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Probiotic","conceptCode":"C93144","definition":"A live microorganism used as a dietary supplement to help with digestion and normal bowel function. It may also help keep the gastrointestinal (GI) tract healthy. A bacterium found in yogurt called Lactobacillus acidophilus, is the most common probiotic.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97CFAB45-EAED-1861-E053-F662850AF1A8","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CFAB45-EB06-1861-E053-F662850AF1A8","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Probenecid/Colchicine","valueDescription":"Probenecid/Colchicine","ValueMeaning":{"publicId":"7063254","version":"1","preferredName":"Probenecid/Colchicine","longName":"7063254","preferredDefinition":"A combination of probenecid and colchicine with antihyperuricemic activity. Probenecid, a benzoic acid derivative, competitively inhibits the reabsorption of urate at the proximal tubule in the kidney, thereby increasing urinary excretion of uric acid and lowering serum urate concentrations. This prevents urate deposition and promotes resolution of existing urate deposits. Colchicine is a natural alkaloid with anti-gout and anti-inflammatory properties. Colchicine binds to tubulin, thereby interfering with the polymerization of tubulin, interrupting microtubule dynamics, and disrupting mitosis leading to an inhibition of leukocyte migration and reduction of the inflammatory response to deposited urate crystals. This agent also interrupts monosodium urate crystal deposition in joint tissues, thereby preventing the resultant inflammatory response.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Probenecid/Colchicine","conceptCode":"C29379","definition":"A combination of probenecid and colchicine with antihyperuricemic activity. Probenecid, a benzoic acid derivative, competitively inhibits the reabsorption of urate at the proximal tubule in the kidney, thereby increasing urinary excretion of uric acid and lowering serum urate concentrations. This prevents urate deposition and promotes resolution of existing urate deposits. Colchicine is a natural alkaloid with anti-gout and anti-inflammatory properties. Colchicine binds to tubulin, thereby interfering with the polymerization of tubulin, interrupting microtubule dynamics, and disrupting mitosis leading to an inhibition of leukocyte migration and reduction of the inflammatory response to deposited urate crystals. This agent also interrupts monosodium urate crystal deposition in joint tissues, thereby preventing the resultant inflammatory response.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97CFAB45-EB13-1861-E053-F662850AF1A8","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CFAB45-EB2C-1861-E053-F662850AF1A8","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Probenecid","valueDescription":"Probenecid","ValueMeaning":{"publicId":"7063256","version":"1","preferredName":"Probenecid","longName":"7063256","preferredDefinition":"A benzoic acid derivative with antihyperuricemic property. Probenecid competitively inhibits the active reabsorption of urate at the proximal tubule in the kidney thereby increasing urinary excretion of uric acid and lowering serum urate concentrations. This prevents urate deposition and promotes resolution of existing urate deposits. In addition, probenecid modulates the transport of organic acids and acidic drugs at the proximal and distal renal tubule, thereby increasing the drug serum concentration.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Probenecid","conceptCode":"C772","definition":"A benzoic acid derivative with antihyperuricemic property. Probenecid competitively inhibits the active reabsorption of urate at the proximal tubule in the kidney thereby increasing urinary excretion of uric acid and lowering serum urate concentrations. This prevents urate deposition and promotes resolution of existing urate deposits. In addition, probenecid modulates the transport of organic acids and acidic drugs at the proximal and distal renal tubule, thereby increasing the drug serum concentration.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97CFAB45-EB39-1861-E053-F662850AF1A8","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CFAB45-EB52-1861-E053-F662850AF1A8","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","deletedIndicator":"No"},{"value":"Thyroid Extract","valueDescription":"Thyroid Extract","ValueMeaning":{"publicId":"7115554","version":"1","preferredName":"Thyroid Extract","longName":"7115554","preferredDefinition":"An animal source of thyroid used in hormonal replacement therapy. Thyroid extract or desiccated thyroid contains both levothyroxine (thyroxine or T4) and liothyronine (triiodothyronine or T3). Levothyroxine is deiodinated in the peripheral tissues to produce increased levels of its active form, liothyronine (T3). Thyroid hormones play an important role in the regulation of cellular respiration, thermogenesis, cellular growth and differentiation as well as regulating the metabolism of proteins, carbohydrates, and lipids.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thyroid Extract","conceptCode":"C2565","definition":"An animal source of thyroid used in hormonal replacement therapy. Thyroid extract or desiccated thyroid contains both levothyroxine (thyroxine or T4) and liothyronine (triiodothyronine or T3). Levothyroxine is deiodinated in the peripheral tissues to produce increased levels of its active form, liothyronine (T3). Thyroid hormones play an important role in the regulation of cellular respiration, thermogenesis, cellular growth and differentiation as well as regulating the metabolism of proteins, carbohydrates, and lipids.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9AB128FD-FF5E-5B22-E053-F662850A5022","latestVersionIndicator":"Yes","beginDate":"2019-12-27","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-12-27","modifiedBy":"TAYLORT","dateModified":"2020-01-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BB75D1C-59CD-5010-E053-F662850A883F","beginDate":"2020-01-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-01-09","modifiedBy":"ONEDATA","dateModified":"2020-01-09","deletedIndicator":"No"},{"value":"Biotin","valueDescription":"Biotin","ValueMeaning":{"publicId":"7117241","version":"1","preferredName":"Biotin","longName":"7117241","preferredDefinition":"Hexahydro-2-oxo-1H-thieno(3,4-d)imidazole-4-pentanoic acid. Growth factor present in minute amounts in every living cell. It occurs mainly bound to proteins or polypeptides and is abundant in liver, kidney, pancreas, yeast, and milk. The biotin content of cancerous tissue is higher than that of normal tissue.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Biotin","conceptCode":"C309","definition":"Hexahydro-2-oxo-1H-thieno(3,4-d)imidazole-4-pentanoic acid. Growth factor present in minute amounts in every living cell. It occurs mainly bound to proteins or polypeptides and is abundant in liver, kidney, pancreas, yeast, and milk. The biotin content of cancerous tissue is higher than that of normal tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9AEF1C6C-8235-5692-E053-F662850ABC92","latestVersionIndicator":"Yes","beginDate":"2019-12-30","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-12-30","modifiedBy":"ONEDATA","dateModified":"2019-12-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9BB9F1A9-1886-74A1-E053-F662850AB9BC","beginDate":"2020-01-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-01-09","modifiedBy":"ONEDATA","dateModified":"2020-01-09","deletedIndicator":"No"},{"value":"Cerivastatin Sodium","valueDescription":"Cerivastatin Sodium","ValueMeaning":{"publicId":"2577803","version":"1","preferredName":"Cerivastatin Sodium","longName":"2577803","preferredDefinition":"The sodium salt of a synthetic lipid-lowering agent.  Cerivastatin sodium competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis.  This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. Muscle toxicity (myopathy and rhabdomyolysis) precludes the clinical use of this agent. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cerivastatin Sodium","conceptCode":"C28919","definition":"The sodium salt of cerivastatin, a synthetic lipid-lowering agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCF8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8741-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cetirizine HCL","valueDescription":"Cetirizine","ValueMeaning":{"publicId":"2577799","version":"1","preferredName":"Cetirizine","longName":"2577799","preferredDefinition":"Cetirizine is a metabolite of hydroxyzine and a selective peripheral histamine H1-receptor antagonist. It is used for symptomatic treatment of seasonal and perennial allergic rhinitis and for chronic urticaria. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cetirizine","conceptCode":"C1042","definition":"Cetirizine is a metabolite of hydroxyzine and a selective peripheral histamine H1-receptor antagonist. It is used for symptomatic treatment of seasonal and perennial allergic rhinitis and for chronic urticaria. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCF4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-874B-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Chloral Hydrate","valueDescription":"Chloral Hydrate","ValueMeaning":{"publicId":"2576045","version":"1","preferredName":"Chloral Hydrate","longName":"2576045","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chloral Hydrate","conceptCode":"C28922","definition":"A synthetic monohydrate of chloral with sedative, hypnotic, and anticonvulsive properties. Chloral hydrate is converted to the active compound trichloroethanol by hepatic alcohol dehydrogenase. The agent interacts with various neurotransmitter-operated ion channels, thereby enhancing gamma-aminobutyric acid (GABA)-A receptor mediated chloride currents and inhibiting amino acid receptor-activated ion currents. In addition, chloral hydrate enhances the agonistic effects of glycine receptors, inhibits AMPA-induced calcium influx in cortical neurons, and facilitates 5-HT 3 receptor-mediated currents in ganglionic neurons. Overall, this results in a depressive effect on the central nervous system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F61A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8755-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Chlorambucil","valueDescription":"Chlorambucil","ValueMeaning":{"publicId":"2577804","version":"1","preferredName":"Chlorambucil","longName":"2577804","preferredDefinition":"An orally-active antineoplastic aromatic nitrogen mustard. Chlorambucil alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chlorambucil","conceptCode":"C362","definition":"An orally-active antineoplastic aromatic nitrogen mustard. Chlorambucil alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCF9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-875F-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Chloraseptic","valueDescription":"Chloraseptic Spray","ValueMeaning":{"publicId":"2577800","version":"1","preferredName":"Chloraseptic Spray","longName":"2577800","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chloraseptic Spray","conceptCode":"C0876728","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCF5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8769-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Chlordiazepoxide","valueDescription":"Chlordiazepoxide","ValueMeaning":{"publicId":"2576047","version":"1","preferredName":"Chlordiazepoxide","longName":"2576047","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chlordiazepoxide","conceptCode":"C47443","definition":"A long-acting benzodiazepine with anxiolytic, sedative and hypnotic activity. Chlordiazepoxide exerts its effect by binding to the benzodiazepine site at the gamma-aminobutyric acid (GABA) receptor-chloride ionophore complex in the central nervous system (CNS). This leads to an increase in the opening of chloride channels, membrane hyperpolarization and increases the inhibitory effect of GABA on the CNS.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F61C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8773-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Chlorhexidine Gluconate","valueDescription":"Chlorhexidine Gluconate","ValueMeaning":{"publicId":"2576048","version":"1","preferredName":"Chlorhexidine Gluconate","longName":"2576048","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chlorhexidine Gluconate","conceptCode":"C47974","definition":"The gluconate salt form of chlorhexidine, a biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine gluconate is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine gluconate penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram positive bacteria are more negatively charged, they are more sensitive to this agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F61D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-877D-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Chlorothiazide","valueDescription":"Chlorothiazide","ValueMeaning":{"publicId":"2577805","version":"1","preferredName":"Chlorothiazide","longName":"2577805","preferredDefinition":"A synthetic thiazide derivative similar to hydrochlorothiazide and used in the treatment of edema, hypertension, diabetes insipidus, and hypoparathyroidism, diuretic Chlorothiazide reduces renal tubule electrolyte reabsorption and increases water and electrolyte excretion (sodium, potassium, chloride, and magnesium). (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chlorothiazide","conceptCode":"C28924","definition":"A short-acting, benzothiadiazinesulfonamide derivative and prototypical thiazide diuretic. Chlorothiazide is excreted unchanged by the kidneys.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCFA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8787-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Chlorpheniramine Maleate","valueDescription":"Chlorpheniramine Maleate","ValueMeaning":{"publicId":"2577806","version":"1","preferredName":"Chlorpheniramine Maleate","longName":"2577806","preferredDefinition":"A synthetic alkylamine derivative used in allergic reactions, hay fever, rhinitis, urticaria, and asthma, antihistamine Chlorpheniramine Maleate acts as a competitive histamine H1 receptor antagonist, and displays anticholinergic and mild sedative effects as well. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chlorpheniramine Maleate","conceptCode":"C28925","definition":"A synthetic alkylamine derivative used in allergic reactions, hay fever, rhinitis, urticaria, and asthma, antihistamine Chlorpheniramine Maleate acts as a competitive histamine H1 receptor antagonist, and displays anticholinergic and mild sedative effects as well. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCFB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8791-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Chlorpromazine","valueDescription":"Chlorpromazine","ValueMeaning":{"publicId":"2577807","version":"1","preferredName":"Chlorpromazine","longName":"2577807","preferredDefinition":"The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chlorpromazine","conceptCode":"C367","definition":"A phenothiazine and traditional antipsychotic agent with anti-emetic activity. Chlorpromazine exerts its antipsychotic effect by blocking postsynaptic dopamine receptors in cortical and limbic areas of the brain, thereby preventing the excess of dopamine in the brain. This leads to a reduction in psychotic symptoms, such as hallucinations and delusions. Chlorpromazine appears to exert its anti-emetic activity by blocking the dopamine receptors in the chemical trigger zone (CTZ) in the brain, thereby relieving nausea and vomiting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCFC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-879B-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Chlorthalidone","valueDescription":"Chlorthalidone","ValueMeaning":{"publicId":"2577808","version":"1","preferredName":"Chlorthalidone","longName":"2577808","preferredDefinition":"A thiazide diuretic of the sulfamoylbenzamide class. Chlorthalidone directly inhibits sodium and chloride reabsorption on the luminal membrane of the early segment in the distal convoluted tubule in the kidney. This leads to an increase in water, sodium, chloride, bicarbonate, and potassium secretion and a decrease in calcium and uric acid secretion. Chlorthalidone is used in the treatment of high blood pressure, edema and congestive heart failure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chlorthalidone","conceptCode":"C47449","definition":"A long acting thiazide-like diuretic of the sulfamoylbenzamide class that is devoid of the benzothiadiazine structure. Chlorthalidone directly inhibits sodium and chloride reabsorption on the luminal membrane of the early segment in the distal convoluted tubule (DCT) in the kidney. This leads to an increase in sodium, chloride, bicarbonate, and potassium secretion resulting in the excretion of water. In addition, this agent, like other thiazide diuretics, decreases calcium and uric acid secretion. In addition, this agent inhibits many carbonic anhydrase (CA) isoenzymes. Chlorthalidone is used in the treatment of high blood pressure, edema and congestive heart failure. The elimination half-life is about 40 to 50 hours.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCFD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-87A5-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Chlorzoxazone","valueDescription":"Chlorzoxazone","ValueMeaning":{"publicId":"2576049","version":"1","preferredName":"Chlorzoxazone","longName":"2576049","preferredDefinition":"A synthetic chlorobenzoxazolinone derivative, mild sedative, and centrally acting muscle relaxant in acute painful musculoskeletal diseases, Chlorzoxazone acts at the spinal cord and subcortical levels of the brain to inhibit multisynaptic reflex arcs that maintain muscle spasms. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chlorzoxazone","conceptCode":"C28926","definition":"A benzoxazolone derivative with mild sedative and centrally-acting muscle relaxant activities. Although its exact mechanism of action is unknown, chlorzoxazone (CZ) appears to act at the spinal cord and subcortical levels of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasms. This agent is extensively hydroxylated by cytochrome P450 2E1 (CYP2E1) to 6-hydroxychlorzoxazone (HCZ),11,12 which is subsequently glucuronidated and eliminated renally. Highly selective for CYP2E1, CZ may be used as a selective probe for phenotyping CYP2E1 in humans; the ratio of HCZ-to-CZ plasma concentrations obtained 2 to 4 hours after oral administration of CZ may be used as a phenotypic measure of CYP2E1 enzymatic activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F61E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-87AF-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Chlorzoxazone/Acetaminophen","valueDescription":"Chlorzoxazone/Acetaminophen","ValueMeaning":{"publicId":"2577812","version":"1","preferredName":"Chlorzoxazone/Acetaminophen","longName":"2577812","preferredDefinition":"Chlorzoxazone Acetaminophen is a combination of muscle relaxant (Chlorzoxazone) and anti-inflammatory analgesic (Acetaminophen) indicated in acute painful musculoskeletal diseases. The active principal metabolite of phenacetin, Acetaminophen appears to inhibit prostaglandin biosynthesis in the central nervous system and less in peripheral tissues. With mild sedative properties, centrally acting Chlorzoxazone inhibits muscle spasm at the spinal cord and subcortical levels of the brain. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chlorzoxazone/Acetaminophen","conceptCode":"C28927","definition":"Chlorzoxazone Acetaminophen is a combination of muscle relaxant (Chlorzoxazone) and anti-inflammatory analgesic (Acetaminophen) indicated in acute painful musculoskeletal diseases. The active principal metabolite of phenacetin, Acetaminophen appears to inhibit prostaglandin biosynthesis in the central nervous system and less in peripheral tissues. With mild sedative properties, centrally acting Chlorzoxazone inhibits muscle spasm at the spinal cord and subcortical levels of the brain. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD01-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-87B9-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Chlotrimazole","valueDescription":"Clotrimazole","ValueMeaning":{"publicId":"2577813","version":"1","preferredName":"Clotrimazole","longName":"2577813","preferredDefinition":"An imidazole derivative with a broad spectrum of antimycotic activity. It inhibits biosynthesis of the sterol ergostol, an important component of fungal cell membranes. Its action leads to increased membrane permeability and apparent disruption of enzyme systems bound to the membrane.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clotrimazole","conceptCode":"C381","definition":"A synthetic, imidazole derivate with broad-spectrum, antifungal activity. Clotrimazole inhibits biosynthesis of sterols, particularly ergosterol, an essential component of the fungal cell membrane, thereby damaging and affecting the permeability of the cell membrane. This results in leakage and loss of essential intracellular compounds, and eventually causes cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD02-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-87C3-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cholestyramine","valueDescription":"cholestyramine","ValueMeaning":{"publicId":"2577814","version":"1","preferredName":"cholestyramine","longName":"2577814","preferredDefinition":"An anion exchange resin.  Cholestyramine resin adsorbs and combines with bile acids in the intestine to form an insoluble complex, which is then excreted in the feces.  As a result, the absorption of bile acids from the enterohepatic circulation is partially prevented, resulting in an increased oxidation of cholesterol to bile acids, a decrease in low density lipoprotein in the plasma, and a decrease in serum cholesterol levels.  Cholestyramine also increases the elimination of methotrexate and leflunomide, thereby potentially decreasing related toxicities. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cholestyramine","conceptCode":"C28929","definition":"An anion exchange resin with hypolipidemic activity. Cholestyramine resin adsorbs and combines with bile acids in the intestine to form an insoluble complex, which is then excreted in the feces, resulting in an increased oxidation of cholesterol to bile acids, a decrease in low density lipoprotein in the plasma, and a decrease in serum cholesterol levels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD03-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-02-09","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-87CD-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Chondroitin","valueDescription":"Chondroitin Sulfate","ValueMeaning":{"publicId":"2577809","version":"1","preferredName":"Chondroitin Sulfate","longName":"2577809","preferredDefinition":"Derivatives of chondroitin which have a sulfate moiety esterified to the galactosamine moiety of chondroitin. Chondroitin sulfate A, or chondroitin 4-sulfate, and chondroitin sulfate C, or chondroitin 6-sulfate, have the sulfate esterified in the 4- and 6-positions, respectively. Chondroitin sulfate B (beta heparin; DERMATAN SULFATE) is a misnomer and this compound is not a true chondroitin sulfate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chondroitin Sulfate","conceptCode":"C28141","definition":"Derivatives of chondroitin which have a sulfate moiety esterified to the galactosamine moiety of chondroitin. Chondroitin sulfate A, or chondroitin 4-sulfate, and chondroitin sulfate C, or chondroitin 6-sulfate, have the sulfate esterified in the 4- and 6-positions, respectively. Chondroitin sulfate B (beta heparin; DERMATAN SULFATE) is a misnomer and this compound is not a true chondroitin sulfate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCFE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-87D7-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Chorionic Gonadotropin","valueDescription":"Human Chorionic Gonadotropin","ValueMeaning":{"publicId":"2577810","version":"1","preferredName":"Human Chorionic Gonadotropin","longName":"2577810","preferredDefinition":"A sialoglycoprotein hormone secreted by the placenta and maintains the corpus luteum at the beginning of the gestation period.(NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Human Chorionic Gonadotropin","conceptCode":"C2275","definition":"A sialoglycoprotein hormone secreted by the placenta and maintains the corpus luteum at the beginning of the gestation period.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCFF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-87E1-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Chromium Piccolinate","valueDescription":"Chromium Piccolinate","ValueMeaning":{"publicId":"2576053","version":"1","preferredName":"Chromium Piccolinate","longName":"2576053","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"chromium piccolinate","conceptCode":"C0724553","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F622-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-87EB-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ciclopirox","valueDescription":"Ciclopirox","ValueMeaning":{"publicId":"2576054","version":"1","preferredName":"Ciclopirox","longName":"2576054","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ciclopirox","conceptCode":"C0055711","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F623-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-87F5-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cidofovir","valueDescription":"Cidofovir","ValueMeaning":{"publicId":"2577815","version":"1","preferredName":"Cidofovir","longName":"2577815","preferredDefinition":"A synthetic nucleotide analog with antiviral activity against cytomegalovirus (CMV).  After conversion to the active metabolite cidofovir diphosphate, cidofovir selectively inhibits CMV DNA polymerase and incorporates into the growing viral DNA chain ultimately inhibiting viral DNA synthesis. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cidofovir","conceptCode":"C1600","definition":"A synthetic, acyclic, monophosphate nucleotide analog of deoxycytidine with antiviral activity, and mostly used against cytomegalovirus (CMV). After incorporation into the host cell, cidofovir is phosphorylated by pyruvate kinases to its active metabolite cidofovir diphosphate. Cidofovir diphosphate, bearing structural similarity to nucleotides, competes with deoxycytosine-5-triphosphate (dCTP) for viral DNA polymerase and gets incorporated into the growing viral DNA strands. As a result, it prevents further DNA polymerization and disrupts DNA replication of viruses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD04-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-87FF-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cimetidine","valueDescription":"Cimetidine","ValueMeaning":{"publicId":"2577816","version":"1","preferredName":"Cimetidine","longName":"2577816","preferredDefinition":"A histamine H(2)-receptor antagonist.  Enhancing anti-tumor cell-mediated responses, cimetidine blocks histamine's ability to stimulate suppressor T lymphocyte activity and to inhibit natural killer (NK) cell activity and interleukin-2 production.  Cimetidine also may inhibit tumor growth by suppressing histamine's growth-factor activity and blocking histamine-induced stimulation of vascular endothelial growth factor (VEGF), a pro-angiogenic growth factor. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cimetidine","conceptCode":"C374","definition":"A histamine H(2)-receptor antagonist.  Enhancing anti-tumor cell-mediated responses, cimetidine blocks histamine's ability to stimulate suppressor T lymphocyte activity and to inhibit natural killer (NK) cell activity and interleukin-2 production.  Cimetidine also may inhibit tumor growth by suppressing histamine's growth-factor activity and blocking histamine-induced stimulation of vascular endothelial growth factor (VEGF), a pro-angiogenic growth factor. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD05-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8809-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ciprofloxacin","valueDescription":"Ciprofloxacin","ValueMeaning":{"publicId":"2577817","version":"1","preferredName":"Ciprofloxacin","longName":"2577817","preferredDefinition":"A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication.  This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ciprofloxacin","conceptCode":"C375","definition":"A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication.  This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD06-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8813-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cisapride","valueDescription":"Cisapride","ValueMeaning":{"publicId":"2577818","version":"1","preferredName":"Cisapride","longName":"2577818","preferredDefinition":"A substituted piperidinyl benzamide prokinetic agent.  Cisapride facilitates release of acetylcholine from the myenteric plexus, resulting in increased gastrointestinal motility.  In addition, cisapride has been found to act as a serotonin agonist, stimulating type 4 receptors, and a serotonin 5-HT3 receptor antagonist. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisapride","conceptCode":"C1210","definition":"A substituted piperidinyl benzamide prokinetic agent.  Cisapride facilitates release of acetylcholine from the myenteric plexus, resulting in increased gastrointestinal motility.  In addition, cisapride has been found to act as a serotonin agonist, stimulating type 4 receptors, and a serotonin 5-HT3 receptor antagonist. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD07-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-881D-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Citalopram Hydrobromide","valueDescription":"Citalopram Hydrobromide","ValueMeaning":{"publicId":"2576055","version":"1","preferredName":"Citalopram Hydrobromide","longName":"2576055","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Citalopram Hydrobromide","conceptCode":"C28932","definition":"The orally bioavailable hydrobromide salt of the racemic bicyclic phthalene derivative citalopram with antidepressant activity. As a selective serotonin reuptake inhibitor (SSRI), citalopram selectively inhibits the CNS neuronal reuptake of serotonin, thereby potentiating serotonergic activity in the central nervous system (CNS). This agent has minimal effects on the CNS neuronal reuptake of norepinephrine (NE) and dopamine (DA).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F624-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8827-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Citrucel","valueDescription":"Methylcellulose","ValueMeaning":{"publicId":"2577811","version":"1","preferredName":"Methylcellulose","longName":"2577811v1.00","preferredDefinition":"The methyl ether of cellulose with laxative activity. Methylcellulose is not absorbed by the intestines and attracts large amounts of water into the colon, thereby increasing viscosity, producing a softer and bulkier stool and stimulating the constriction of intestinal smooth muscles.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methylcellulose","conceptCode":"C29253","definition":"The methyl ether of cellulose with laxative activity. Methylcellulose is not absorbed by the intestines and attracts large amounts of water into the colon, thereby increasing viscosity, producing a softer and bulkier stool and stimulating the constriction of intestinal smooth muscles.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD00-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"CLOHNES","dateModified":"2023-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8831-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Clarithromycin","valueDescription":"Clarithromycin","ValueMeaning":{"publicId":"2577826","version":"1","preferredName":"Clarithromycin","longName":"2577826","preferredDefinition":"A semisynthetic 14-membered ring macrolide antibiotic.  Clarithromycin binds to the 50S ribosomal subunit and inhibits RNA-dependent protein synthesis in susceptible organisms.  Clarithromycin has been shown to eradicate gastric MALT (mucosa-associated lymphoid tissue) lymphomas, presumably due to the eradication of tumorigenic Helicobacter pylori infection. This agent also acts as a biological response modulator, possibly inhibiting angiogenesis and tumor growth through alterations in growth factor expression. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clarithromycin","conceptCode":"C1054","definition":"A semisynthetic 14-membered ring macrolide antibiotic.  Clarithromycin binds to the 50S ribosomal subunit and inhibits RNA-dependent protein synthesis in susceptible organisms.  Clarithromycin has been shown to eradicate gastric MALT (mucosa-associated lymphoid tissue) lymphomas, presumably due to the eradication of tumorigenic Helicobacter pylori infection. This agent also acts as a biological response modulator, possibly inhibiting angiogenesis and tumor growth through alterations in growth factor expression. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD0F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-883B-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Clindamycin","valueDescription":"Clindamycin","ValueMeaning":{"publicId":"2575671","version":"1","preferredName":"Clindamycin","longName":"2575671","preferredDefinition":"A semisynthetic broad spectrum antibiotic produced by chemical modification of the parent compound lincomycin. Clindamycin dissociates peptidyl-tRNA from the bacterial ribosome, thereby disrupting bacterial protein synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clindamycin","conceptCode":"C377","definition":"A semisynthetic broad spectrum antibiotic produced by chemical modification of the parent compound lincomycin. Clindamycin dissociates peptidyl-tRNA from the bacterial ribosome, thereby disrupting bacterial protein synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4A4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8845-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Clobetasol Propionate","valueDescription":"Clobetasol Propionate 0.05% (Temovate)","ValueMeaning":{"publicId":"2576057","version":"1","preferredName":"Clobetasol Propionate 0.05% (Temovate)","longName":"2576057","preferredDefinition":"The propionate salt form of clobetasol, a topical synthetic corticosteroid with anti-inflammatory, anti-pruritic, and vasoconstrictive properties. Clobetasol propionate exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators. Specifically, clobetasol propionate appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from membrane phospholipids by phospholipase A2.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clobetasol Propionate","conceptCode":"C28934","definition":"The propionate salt form of clobetasol, a topical synthetic corticosteroid with anti-inflammatory, anti-pruritic, and vasoconstrictive properties. Clobetasol propionate exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators. Specifically, clobetasol propionate appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from membrane phospholipids by phospholipase A2.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F626-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2011-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-884F-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Clomiphene Citrate","valueDescription":"Clomid","ValueMeaning":{"publicId":"2577819","version":"1","preferredName":"Clomid","longName":"2577819","preferredDefinition":"A triphenylethylene nonsteroidal ovulatory stimulant evaluated for antineoplastic activity against breast cancer.  Clomiphene has both estrogenic and anti-estrogenic activities that compete with estrogen for binding at estrogen receptor sites in target tissues.  This agent causes the release of the pituitary gonadotropins follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to ovulation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clomiphene Citrate","conceptCode":"C379","definition":"The citrate salt form of clomiphene, a triphenylethylene nonsteroidal ovulatory stimulant evaluated for antineoplastic activity against breast cancer. Clomiphene has both estrogenic and anti-estrogenic activities that compete with estrogen for binding at estrogen receptor sites in target tissues.  This agent causes the release of the pituitary gonadotropins follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to ovulation. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD08-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"REEVESD","dateModified":"2010-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8859-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Clonazepam","valueDescription":"Clonazepam","ValueMeaning":{"publicId":"2577827","version":"1","preferredName":"Clonazepam","longName":"2577827","preferredDefinition":"A synthetic benzodiazepine derivative used for myotonic or atonic seizures, absence seizures, and photosensitive epilepsy, anticonvulsant Clonazepam appears to enhance gamma-aminobutyric acid receptor responses, although its mechanism of action is not clearly understood. It is seldom effective in generalized tonic-clonic or partial seizures. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clonazepam","conceptCode":"C28935","definition":"A synthetic benzodiazepine derivative used for myotonic or atonic seizures, absence seizures, and photosensitive epilepsy, anticonvulsant Clonazepam appears to enhance gamma-aminobutyric acid receptor responses, although its mechanism of action is not clearly understood. It is seldom effective in generalized tonic-clonic or partial seizures. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD10-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8863-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Clonidine","valueDescription":"Clonidine","ValueMeaning":{"publicId":"2577828","version":"1","preferredName":"Clonidine","longName":"2577828","preferredDefinition":"An alpha-2 adrenergic agonist that crosses the blood-brain barrier. Clonidine acts centrally by reducing sympathetic tone, resulting in a fall in diastolic and systolic blood pressure and a reduction in heart rate. It also acts peripherally, and this peripheral activity may be responsible for the transient increase in blood pressure seen during rapid intravenous administration. (From Martindale, the Extra Pharmacopoeia, 30th ed, p350)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clonidine","conceptCode":"C380","definition":"An imidazoline derivate and centrally-acting alpha-adrenergic agonist, with antihypertensive activity. Clonidine binds to and stimulates central alpha-2 adrenergic receptors, thereby reducing the amount of norepinephrine (NE) release and thus decreasing sympathetic outflow to the heart, kidneys, and peripheral vasculature. The reduction in sympathetic outflow leads to decreased peripheral vascular resistance, decreased blood pressure, and decreased heart rate. In addition, clonidine binds to imidazoline receptor subtype 1 (I1), which may also contribute to a reduction in blood pressure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD11-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-886D-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Clopidogrel Bisulfate","valueDescription":"Clopidogrel Bisulfate","ValueMeaning":{"publicId":"2577829","version":"1","preferredName":"Clopidogrel Bisulfate","longName":"2577829","preferredDefinition":"A thienopyridine with antiplatelet activity. Clopidogrel bisulfate irreversibly alters the platelet receptor for adenosine diphosphate (ADP), thereby blocking the binding of ADP to its receptor, inhibiting ADP-mediated activation of the glycoprotein complex GPIIb/IIIa, and inhibiting fibrinogen binding to platelets and platelet adhesion and aggregation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clopidogrel Bisulfate","conceptCode":"C2673","definition":"A thienopyridine with antiplatelet activity. Clopidogrel bisulfate irreversibly alters the platelet receptor for adenosine diphosphate (ADP), thereby blocking the binding of ADP to its receptor, inhibiting ADP-mediated activation of the glycoprotein complex GPIIb/IIIa, and inhibiting fibrinogen binding to platelets and platelet adhesion and aggregation. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD12-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8877-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Clotrimazole","valueDescription":"Clotrimazole","ValueMeaning":{"publicId":"2577813","version":"1","preferredName":"Clotrimazole","longName":"2577813","preferredDefinition":"An imidazole derivative with a broad spectrum of antimycotic activity. It inhibits biosynthesis of the sterol ergostol, an important component of fungal cell membranes. Its action leads to increased membrane permeability and apparent disruption of enzyme systems bound to the membrane.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clotrimazole","conceptCode":"C381","definition":"A synthetic, imidazole derivate with broad-spectrum, antifungal activity. Clotrimazole inhibits biosynthesis of sterols, particularly ergosterol, an essential component of the fungal cell membrane, thereby damaging and affecting the permeability of the cell membrane. This results in leakage and loss of essential intracellular compounds, and eventually causes cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD02-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8881-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Clozapine","valueDescription":"Clozapine","ValueMeaning":{"publicId":"2577830","version":"1","preferredName":"Clozapine","longName":"2577830","preferredDefinition":"A synthetic dibenzo-diazepine derivative, atypical antipsychotic Clozapine blocks several neurotransmitter receptors in the brain (dopamine type 4, serotonin type 2, norepinephrine, acetylcholine, and histamine receptors). Unlike traditional antipsychotic agents, it weakly blocks dopamine type 2 receptors. It relieves schizophrenic symptoms (hallucinations, delusions, dementia). (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clozapine","conceptCode":"C28936","definition":"A synthetic dibenzo-diazepine derivative, atypical antipsychotic Clozapine blocks several neurotransmitter receptors in the brain (dopamine type 4, serotonin type 2, norepinephrine, acetylcholine, and histamine receptors). Unlike traditional antipsychotic agents, it weakly blocks dopamine type 2 receptors. It relieves schizophrenic symptoms (hallucinations, delusions, dementia). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD13-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-888B-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Codeine Phosphate","valueDescription":"Codeine Phosphate","ValueMeaning":{"publicId":"2576059","version":"1","preferredName":"Codeine Phosphate","longName":"2576059","preferredDefinition":"An opioid analgesic related to MORPHINE but with less potent analgesic properties and mild sedative effects. It also acts centrally to suppress cough.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Codeine","conceptCode":"C383","definition":"A naturally occurring phenanthrene alkaloid and opioid agonist with analgesic, antidiarrheal and antitussive activities. Codeine mimics the actions of endogenous opioids by binding to the opioid receptors at many sites within the central nervous system (CNS). Stimulation of mu-subtype opioid receptors results in a decrease in the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline; in addition, the codeine metabolite morphine induces opening of G-protein-coupled inwardly rectifying potassium (GIRK) channels and blocks the opening of N-type voltage-gated calcium channels, resulting in hyperpolarization and reduced neuronal excitability. Stimulation of gut mu-subtype opioid receptors results in a reduction in intestinal motility and delayed intestinal transit times. Antitussive activity is mediated through codeine's action on the cough center in the medulla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F628-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8895-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Codeine Sulfate","valueDescription":"Codeine Sulfate","ValueMeaning":{"publicId":"2576060","version":"1","preferredName":"Codeine Sulfate","longName":"2576060","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Codeine sulfate","conceptCode":"C0304352","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F629-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-889F-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Coenzyme Q10","valueDescription":"Coenzyme-Q","ValueMeaning":{"publicId":"2577820","version":"1","preferredName":"Coenzyme-Q","longName":"2577820","preferredDefinition":"A naturally occurring benzoquinone important in electron transport in mitochondrial membranes. Coenzyme-Q functions as an endogenous antioxidant; deficiencies of this enzyme have been observed in patients with many different types of cancer and limited studies have suggested that coenzyme-Q may induce tumor regression in patients with breast cancer. This agent may have immunostimulatory effects. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Coenzyme Q10","conceptCode":"C916","definition":"A naturally occurring benzoquinone important in electron transport in mitochondrial membranes. Coenzyme Q10 functions as an endogenous antioxidant; deficiencies of this enzyme have been observed in patients with many different types of cancer and limited studies have suggested that coenzyme Q10 may induce tumor regression in patients with breast cancer. This agent may have immunostimulatory effects. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD09-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-88A9-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Colchicine","valueDescription":"Colchicine","ValueMeaning":{"publicId":"2577831","version":"1","preferredName":"Colchicine","longName":"2577831","preferredDefinition":"An alkaloid isolated from Colchicum autumnale L. and in other Colchicum species. Colchicine binds to tubulin, thereby inhibiting microtubule assembly, inducing microtubule disassembly, and disrupting mitosis. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Colchicine","conceptCode":"C385","definition":"An alkaloid isolated from Colchicum autumnale with anti-gout and anti-inflammatory activities. The exact mechanism of action by which colchicines exerts its effect has not been completely established. Colchicine binds to tubulin, thereby interfering with the polymerization of tubulin, interrupting microtubule dynamics, and disrupting mitosis. This leads to an inhibition of migration of leukocytes and other inflammatory cells, thereby reducing the inflammatory response to deposited urate crystals.  Colchicine may also interrupt the cycle of monosodium urate crystal deposition in joint tissues, thereby also preventing the resultant inflammatory response. Overall, colchicine decreases leukocyte chemotaxis/migration and phagocytosis to inflamed areas, and inhibits the formation and release of a chemotactic glycoprotein that is produced during phagocytosis of urate crystals.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD14-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-88B3-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Colesevelam HCL","valueDescription":"Colesevelam Hydrochloride","ValueMeaning":{"publicId":"2577821","version":"1","preferredName":"Colesevelam Hydrochloride","longName":"2577821","preferredDefinition":"A polymeric synthetic polyallylamine derivative cross-linked with epichlorohydrin, Colesevelam Hydrochloride is a non-absorbed, water-insoluble, lipid-lowering, hydrophilic agent that binds intestinal bile acids and impedes their reabsorption. Used alone or with other medications, Colesevelam increases cholesterol metabolism and decreases its plasma concentration. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Colesevelam Hydrochloride","conceptCode":"C0541154","definition":"A polymeric synthetic polyallylamine derivative cross-linked with epichlorohydrin, Colesevelam Hydrochloride is a non-absorbed, water-insoluble, lipid-lowering, hydrophilic agent that binds intestinal bile acids and impedes their reabsorption. Used alone or with other medications, Colesevelam increases cholesterol metabolism and decreases its plasma concentration. (NCI04)","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD0A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-88BD-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Colestipol HCL","valueDescription":"Colestipol Hydrochloride","ValueMeaning":{"publicId":"2577822","version":"1","preferredName":"Colestipol Hydrochloride","longName":"2577822","preferredDefinition":"A synthetic triamine and epoxypropane copolymer used alone or with other medications, oral Colestipol Hydrochloride is a cholesterol-lowering bile acid-binding agent that acts as a non-absorbed intestinal anion-exchange resin. By reducing absorption of bile acids, it increases their production from cholesterol and reduces the amount of plasma cholesterol. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Colestipol Hydrochloride","conceptCode":"C0354648","definition":"A synthetic triamine and epoxypropane copolymer used alone or with other medications, oral Colestipol Hydrochloride is a cholesterol-lowering bile acid-binding agent that acts as a non-absorbed intestinal anion-exchange resin. By reducing absorption of bile acids, it increases their production from cholesterol and reduces the amount of plasma cholesterol. (NCI04)","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD0B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-88C7-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Colostrum","valueDescription":"Colostrum","ValueMeaning":{"publicId":"2577832","version":"1","preferredName":"Colostrum","longName":"2577832","preferredDefinition":"thin, yellow, serous fluid secreted by the mammary glands during pregnancy and immediately postpartum before lactation begins; consists of immunologically active substances, white blood cells, water, protein, fat, and carbohydrates.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Colostrum","conceptCode":"C0009413","definition":"thin, yellow, serous fluid secreted by the mammary glands during pregnancy and immediately postpartum before lactation begins; consists of immunologically active substances, white blood cells, water, protein, fat, and carbohydrates.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD15-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-88D1-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Combivir","valueDescription":"Lamivudine/Zidovudine","ValueMeaning":{"publicId":"2577823","version":"1","preferredName":"Lamivudine/Zidovudine","longName":"2577823","preferredDefinition":"A combination of two synthetic nucleoside analogues with synergistic antiviral properties.  Lamivudine is phosphorylated intracellularly to its active 5'-triphosphate metabolite, lamivudine triphosphate (L-TP); zidovudine is phosphorylated to its active 5'-triphosphate metabolite, zidovudine triphosphate (ZDV-TP). These active metabolites inhibit human immunodeficiency virus (HIV) viral reverse transcriptase (RT) by incorporating into viral DNA and terminating viral DNA chain elongation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lamivudine/Zidovudine","conceptCode":"C28939","definition":"A combination of two synthetic nucleoside analogues with synergistic antiviral properties.  Lamivudine is phosphorylated intracellularly to its active 5'-triphosphate metabolite, lamivudine triphosphate (L-TP); zidovudine is phosphorylated to its active 5'-triphosphate metabolite, zidovudine triphosphate (ZDV-TP). These active metabolites inhibit human immunodeficiency virus (HIV) viral reverse transcriptase (RT) by incorporating into viral DNA and terminating viral DNA chain elongation. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD0C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-88DB-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Comtrex","valueDescription":"Comtrex","ValueMeaning":{"publicId":"2576076","version":"1","preferredName":"Comtrex","longName":"2576076","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acetaminophen-based Oral Cough and Cold Preparation","conceptCode":"C28940","definition":"A combination preparation containing the analgesic acetaminophen and a combination of one or more of the following agents: an antihistamine (chlorpheniramine maleate or brompheniramine maleate), the expectorant guaifenesin, the antitussive dextromethorphan maleate and/or the decongestant pseudoephedrine hydrochloride or phenylephrine hydrochloride. These preparations are used to relieve symptoms of cold, cough and flu.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F639-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-88E5-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cortisone Acetate","valueDescription":"Cortisone Acetate","ValueMeaning":{"publicId":"2576077","version":"1","preferredName":"Cortisone Acetate","longName":"2576077","preferredDefinition":"The acetate salt of Cortisone. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cortisone Acetate","conceptCode":"C1058","definition":"The acetate salt form of cortisone, a synthetic or semisynthetic analog of the naturally occurring cortisone hormone produced by the adrenal glands with anti-inflammatory and immunomodulating properties. Cortisone acetate diffuses through the cell membrane and binds to nuclear glucocorticoid receptors. The receptor-ligand complex binds to promotor regions of certain genes and initiates RNA transcription. This results in an induction of synthesis of certain anti-inflammatory proteins while inhibiting the synthesis of certain inflammatory mediators.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F63A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-88EF-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cosanthranol","valueDescription":"Casanthranol: C0205705","ValueMeaning":{"publicId":"2577825","version":"1","preferredName":"Casanthranol: C0205705","longName":"2577825","preferredDefinition":"A concentrated mixture of anthranol glycosides derived from cascara sagrada.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Casanthranol","conceptCode":"C0205705","definition":"A concentrated mixture of anthranol glycosides derived from cascara sagrada.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD0E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-88F9-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cotrimoxazole","valueDescription":"Trimethoprim-Sulfamethoxazole","ValueMeaning":{"publicId":"2577719","version":"1","preferredName":"Trimethoprim-Sulfamethoxazole","longName":"2577719","preferredDefinition":"A combination of two anti-infection drugs, sulfamethoxazole and trimethoprim. It is used to fight bacterial and protozoal infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trimethoprim-Sulfamethoxazole","conceptCode":"C909","definition":"A synthetic combination of two antibacterial agents, trimethoprim and sulfamethoxazole. This synergistic combination, also known as Co-Trimoxazole, inhibits two sequential steps in the bacterial metabolism of folic acid. Trimethoprim is a pyrimidine inhibitor of dihydrofolate reductase; sulfamethoxazole is a sulfamide inhibitor of bacterial dihydrofolate synthase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCA4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-17","modifiedBy":"ONEDATA","dateModified":"2006-02-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8903-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cranberry","valueDescription":"Cranberry","ValueMeaning":{"publicId":"2577833","version":"1","preferredName":"Cranberry","longName":"2577833","preferredDefinition":"Fruit of the Cranberry plant, a Native American wetland plant, can be consumed whole or made into food products such as jellies and juices. Prevention of urinary tract infections by cranberries has been documented. Natural, unprocessed cranberries contain anthocyanidins, which prevent Escherichia coli, the typical cause urinary tract infections, from attaching to the urinary tract wall. Anthocyanidins are potent antioxidant substances. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cranberry","conceptCode":"C28943","definition":"Fruit of the Cranberry plant, a Native American wetland plant, can be consumed whole or made into food products such as jellies and juices. Prevention of urinary tract infections by cranberries has been documented. Natural, unprocessed cranberries contain anthocyanidins, which prevent Escherichia coli, the typical cause urinary tract infections, from attaching to the urinary tract wall. Anthocyanidins are potent antioxidant substances. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD16-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-890D-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Creatine Supplement","valueDescription":"Creatine Supplement","ValueMeaning":{"publicId":"2577834","version":"1","preferredName":"Creatine Supplement","longName":"2577834","preferredDefinition":"Dietary Creatine Supplement, complements endogenous creatine produced in the liver, kidneys, and pancreas. An amino acid found in muscle cells, creatine phosphate stores energy for contraction. After intense effort, when ATP deposits are depleted, creatine phosphate donates phosphate groups toward the fast synthesis of ATP. Malnourished individuals benefit most from the increase of creatine in muscles after exogenous creatine supplement. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Creatine Monohydrate","conceptCode":"C28945","definition":"The monohydrate form of creatine similar or identical to endogenous creatine produced in the liver, kidneys, and pancreas. Creatine, in phosphate form, helps supply energy to muscle cells for contraction. After intense effort, when ATP deposits are depleted, creatine phosphate donates phosphate groups toward the fast synthesis of ATP. Dietary supplementation with creatine may improve muscle wasting associated with cancer and other chronic diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD17-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8917-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cromolyn Sodium","valueDescription":"Cromolyn Sodium","ValueMeaning":{"publicId":"2576080","version":"1","preferredName":"Cromolyn Sodium","longName":"2576080","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cromolyn Sodium","conceptCode":"C28946","definition":"The sodium salt form of cromolyn, a mast cell stabilizer with anti-inflammatory activity. Cromolyn sodium probably interferes with the antigen-stimulated calcium transport across the mast cell membrane, thereby inhibiting mast cell release of histamine, leukotrienes, and other substances that cause hypersensitivity reactions. Cromolyn sodium also inhibits eosinophil chemotaxis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F63D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8921-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cyanocobalamin","valueDescription":"Vitamin B12","ValueMeaning":{"publicId":"2577835","version":"1","preferredName":"Vitamin B12","longName":"2577835","preferredDefinition":"A cobalt-containing coordination compound produced by intestinal micro-organisms and found also in soil and water. Higher plants do not concentrate vitamin B 12 from the soil and so are a poor source of the substance as compared with animal tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cobalamin","conceptCode":"C939","definition":"An essential nutrient and natural water-soluble vitamin of the B-complex family that must combine with an intrinsic factor for absorption by the intestine, Vitamin B12 (cyanocobalamin) is necessary for hematopoiesis, neural metabolism, DNA and RNA production, and carbohydrate, fat, and protein metabolism. B12 improves iron functions in the metabolic cycle and assists folic acid in choline synthesis. B12 metabolism is interconnected with that of folic acid. Vitamin B12 deficiency causes pernicious anemia, megaloblastic anemia, and neurologic lesions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD18-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"GDEEN","dateModified":"2022-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-892B-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cyclobenzaprine","valueDescription":"Cyclobenzaprine","ValueMeaning":{"publicId":"2576082","version":"1","preferredName":"Cyclobenzaprine","longName":"2576082v1.00","preferredDefinition":"A centrally acting skeletal muscle relaxant with antidepressant activity. The exact mechanism of action of cyclobenzaprine has not been fully determined, but this drug seems to primarily act at the brain stem to reduce tonic somatic motor activity, influencing both gamma and alpha motor neurons leading to a reduction in muscle spasms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclobenzaprine","conceptCode":"C28947","definition":"A centrally acting skeletal muscle relaxant with antidepressant activity. The exact mechanism of action of cyclobenzaprine has not been fully determined, but this drug seems to primarily act at the brain stem to reduce tonic somatic motor activity, influencing both gamma and alpha motor neurons leading to a reduction in muscle spasms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F63F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"KUMMEROA","dateModified":"2023-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8935-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cyclopentolate HCL","valueDescription":"Cyclopentolate Hydrochloride","ValueMeaning":{"publicId":"2577836","version":"1","preferredName":"Cyclopentolate Hydrochloride","longName":"2577836","preferredDefinition":"The hydrochloride salt form of cyclopentolate, an anticholinergic drug. Administered in the eye, cyclopentolate hydrochloride blocks the acetylcholine receptor in the sphincter muscle of the iris and the ciliary muscle, thereby preventing contraction. This dilates the pupil, producing mydriasis, and prevents the eye from accommodating.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclopentolate Hydrochloride","conceptCode":"C28948","definition":"The hydrochloride salt form of cyclopentolate, an anticholinergic drug. Administered in the eye, cyclopentolate hydrochloride blocks the acetylcholine receptor in the sphincter muscle of the iris and the ciliary muscle, thereby preventing contraction. This dilates the pupil, producing mydriasis, and prevents the eye from accommodating.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD19-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"COOPERM","dateModified":"2020-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-893F-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cyproheptadine HCL","valueDescription":"Cyproheptadine Hydrochloride","ValueMeaning":{"publicId":"2577837","version":"1","preferredName":"Cyproheptadine Hydrochloride","longName":"2577837","preferredDefinition":"The hydrochloride salt of a synthetic methyl-piperidine derivative with antihistaminic and anti-serotoninergic properties. Cyproheptadine competes with free histamine (HA) for binding at HA-receptor sites, thereby competitively antagonizing histamine stimulation of HA-receptors in the gastrointestinal tract, large blood vessels, and bronchial smooth muscle. This agent also competes with free serotonin for binding at serotonin receptor sites. Cyproheptadine exhibits anticholinergic and sedative properties and has been shown to stimulate appetite and weight gain. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyproheptadine Hydrochloride","conceptCode":"C0031017","definition":"The hydrochloride salt of a synthetic methyl-piperidine derivative with antihistaminic and anti-serotoninergic properties. Cyproheptadine competes with free histamine (HA) for binding at HA-receptor sites, thereby competitively antagonizing histamine stimulation of HA-receptors in the gastrointestinal tract, large blood vessels, and bronchial smooth muscle. This agent also competes with free serotonin for binding at serotonin receptor sites. Cyproheptadine exhibits anticholinergic and sedative properties and has been shown to stimulate appetite and weight gain. (NCI04)","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD1A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8949-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"D5 1/2 Normal Saline","valueDescription":"DEXTROSE 5% IN 1/2 STRENGTH SALINE","ValueMeaning":{"publicId":"2577838","version":"1","preferredName":"DEXTROSE 5% IN 1/2 STRENGTH SALINE","longName":"2577838","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"DEXTROSE 5% IN 1/2 STRENGTH SALINE","conceptCode":"CL143592","definition":"No value exists.","evsSource":"NCI_META_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD1B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8953-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"D5 1/4 Normal Saline","valueDescription":"DEXTROSE 0.2 GM / SODIUM CHLORIDE 0.9 GM SOLUTION","ValueMeaning":{"publicId":"2577839","version":"1","preferredName":"DEXTROSE 0.2 GM / SODIUM CHLORIDE 0.9 GM SOLUTION","longName":"2577839","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"DEXTROSE 0.2 GM / SODIUM CHLORIDE 0.9 GM SOLUTION","conceptCode":"C1162392","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD1C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-895D-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"D5 Normal Saline","valueDescription":"Dextrose saline","ValueMeaning":{"publicId":"2577840","version":"1","preferredName":"Dextrose saline","longName":"2577840","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dextrose saline","conceptCode":"C0360665","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD1D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8967-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"D50W","valueDescription":"DEXTROSE 50 %","ValueMeaning":{"publicId":"2577841","version":"1","preferredName":"DEXTROSE 50 %","longName":"2577841","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"DEXTROSE 50 %","conceptCode":"C0308814","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD1E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8971-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"D5W","valueDescription":"DEXTROSE 5 %","ValueMeaning":{"publicId":"2577842","version":"1","preferredName":"DEXTROSE 5 %","longName":"2577842","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"DEXTROSE 5 %","conceptCode":"C0719833","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD1F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-897B-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"DES","valueDescription":"Diethylstilbestrol","ValueMeaning":{"publicId":"2577843","version":"1","preferredName":"Diethylstilbestrol","longName":"2577843","preferredDefinition":"DES; the acronym for diethylstilbestrol, a synthetic, nonsteroidal form of estrogen.  A well-known teratogen and carcinogen, DES inhibits the hypothalamic-pituitary-gonadal axis, thereby blocking the testicular synthesis of testosterone, lowering plasma testosterone, and inducing a chemical castration. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diethylstilbestrol","conceptCode":"C433","definition":"A synthetic, nonsteroidal form of estrogen. A well-known teratogen and carcinogen, diethylstilbestrol inhibits the hypothalamic-pituitary-gonadal axis, thereby blocking the testicular synthesis of testosterone, lowering plasma testosterone, and inducing a chemical castration.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD20-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8985-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"DHEA","valueDescription":"Therapeutic Dehydroepiandrosterone","ValueMeaning":{"publicId":"2577844","version":"1","preferredName":"Therapeutic Dehydroepiandrosterone","longName":"2577844","preferredDefinition":"A synthetic form of dehydroepiandrosterone with potential chemopreventive activity.  Produced endogenously, dehydroepiandrosterone (DHEA) is an intermediate in the conversion of cholesterol to androgens and estrogens.  Although the mechanisms of action of exogenously administered DHEA have not been fully illuminated, they may result in both direct and indirect physiologic effects. Direct effects include GABA-a receptor complex and NMDA receptor modulation, and enhanced pancreatic beta cell insulin secretion and antiglucocorticoid activities. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prasterone","conceptCode":"C2265","definition":"A synthetic form of dehydroepiandrosterone with potential chemopreventive activity.  Produced endogenously, dehydroepiandrosterone (DHEA) is an intermediate in the conversion of cholesterol to androgens and estrogens.  Although the mechanisms of action of exogenously administered DHEA have not been fully illuminated, they may result in both direct and indirect physiologic effects. Direct effects include GABA-a receptor complex and NMDA receptor modulation, and enhanced pancreatic beta cell insulin secretion and antiglucocorticoid activities. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD21-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-898F-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"DTO","valueDescription":"Deodorized Tincture of Opium","ValueMeaning":{"publicId":"2577845","version":"1","preferredName":"Deodorized Tincture of Opium","longName":"2577845","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Deodorized Tincture of Opium","conceptCode":"C28968","definition":"An opium tincture with antidiarrheal activity. The opiate morphine, in deodorized tincture of opium, increases the tone of the smooth muscle in the intestines. It stops the normal movement and slows down the passage of intestinal contents. This allows water to be absorbed from the liquid stool thereby decreasing diarrhea.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD22-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8999-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Daclizumab","valueDescription":"Daclizumab","ValueMeaning":{"publicId":"2576091","version":"1","preferredName":"Daclizumab","longName":"2576091","preferredDefinition":"A monoclonal antibody that is being studied for treatment of adult T-cell leukemia.  Also called dacliximab.  Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Daclizumab","conceptCode":"C1569","definition":"A recombinant monoclonal antibody interleukin-2 receptor antagonist.  Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F648-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-89A3-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Dakins","valueDescription":"Dakins Solution","ValueMeaning":{"publicId":"2576092","version":"1","preferredName":"Dakins Solution","longName":"2576092","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dakins Solution","conceptCode":"C1186762","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F649-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-89AD-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Dalteparin Sodium","valueDescription":"Dalteparin","ValueMeaning":{"publicId":"2577846","version":"1","preferredName":"Dalteparin","longName":"2577846","preferredDefinition":"A low molecular weight, synthetic heparin. As an anticoagulant/antithrombotic agent, dalteparin binds to antithrombin and enhances the inhibition of Factor Xa. Compared to unfractionated heparins, the use of dalteparin is associated with lower incidences of osteoporosis and heparin-induced thrombocytopenia. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dalteparin","conceptCode":"C1453","definition":"A low molecular weight, synthetic heparin. As an anticoagulant/antithrombotic agent, dalteparin binds to antithrombin and enhances the inhibition of Factor Xa. Compared to unfractionated heparins, the use of dalteparin is associated with lower incidences of osteoporosis and heparin-induced thrombocytopenia. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD23-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-89B7-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Danaparoid Sodium","valueDescription":"Danaparoid Sodium","ValueMeaning":{"publicId":"2576094","version":"1","preferredName":"Danaparoid Sodium","longName":"2576094","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Danaparoid Sodium","conceptCode":"C28971","definition":"The sodium salt form of danaparoid, a synthetic low molecular weight heparin (LMWH) derived from porcine gut mucosa with anticoagulant activity. Danaparoid sodium binds to antithrombin III and inhibits the activity of activated factor X (factor Xa) and, to a lesser extent, activated factor II (thrombin) thereby preventing fibrin formation. Compared to heparin, danaparoid sodium exhibits a much higher ratio of anti-factor Xa activity to anti-factor IIa activity (22:1).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F64B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-89C1-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Danazol","valueDescription":"Danazol","ValueMeaning":{"publicId":"2577849","version":"1","preferredName":"Danazol","longName":"2577849","preferredDefinition":"A synthetic androgen derived from ethinyl testosterone.  Danazol indirectly reduces estrogen production by decreasing pituitary secretion of follicle-stimulating hormone and luteinizing hormone, and binds to sex hormone receptors in target tissues, thereby exhibiting antiestrogenic, anabolic and weakly androgenic effects. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Danazol","conceptCode":"C414","definition":"A synthetic androgen derived from ethinyl testosterone.  Danazol indirectly reduces estrogen production by decreasing pituitary secretion of follicle-stimulating hormone and luteinizing hormone, and binds to sex hormone receptors in target tissues, thereby exhibiting antiestrogenic, anabolic and weakly androgenic effects. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD26-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-89CB-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Dapsone","valueDescription":"Dapsone","ValueMeaning":{"publicId":"2577850","version":"1","preferredName":"Dapsone","longName":"2577850","preferredDefinition":"A synthetic derivative of diamino-sulfone with anti-mycobacterial and anti-malarial properties.  A structural analog of p-aminobenzoic acid (PABA), dapsone inhibits dihydropteroate synthase (DHPS), an enzyme important in folate synthesis, resulting in a depletion of the folate pool and a reduction in the amount of thymidylate available for DNA synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dapsone","conceptCode":"C415","definition":"A synthetic derivative of diamino-sulfone with anti-inflammatory and anti-bacterial properties. As a structural analog of p-aminobenzoic acid (PABA), dapsone inhibits dihydropteroate synthase (DHPS), an enzyme important in folate synthesis, resulting in a depletion of the folate pool and a reduction in the amount of thymidylate available for DNA synthesis. Although the exact mechanism through which dapsone exerts its anti-inflammatory activity has yet to be fully elucidated, this agent interferes with the activation and oxidative damage of myeloperoxidase in neutrophils and inhibits the integrin-mediated adherence and chemotaxis of neutrophils. Dapsone's anti-inflammatory activities may contribute to the effects seen upon topical administration.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD27-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-89D5-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Darbepoetin Alfa","valueDescription":"Darbepoetin Alfa","ValueMeaning":{"publicId":"2577851","version":"1","preferredName":"Darbepoetin Alfa","longName":"2577851","preferredDefinition":"A recombinant analog of the endogenous cytokine erythropoietin, an erythropoiesis-stimulating protein.  Due to the addition of two carbohydrate chains, darbepoetin alfa exhibits a three-fold greater half-life than does erythropoietin.  Similar to erythropoietin, darbopoietin alfa binds to and activates epoetin receptors, thereby inducing the differentiation and maturation of erythrocyte progenitors, stimulating endothelial cell proliferation, and stimulating B-cell proliferation and immunoglobulin production. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Darbepoetin Alfa","conceptCode":"C1878","definition":"A recombinant analog of the endogenous cytokine erythropoietin, an erythropoiesis-stimulating protein.  Due to the addition of two carbohydrate chains, darbepoetin alfa exhibits a three-fold greater half-life than does erythropoietin.  Similar to erythropoietin, darbopoietin alfa binds to and activates epoetin receptors, thereby inducing the differentiation and maturation of erythrocyte progenitors, stimulating endothelial cell proliferation, and stimulating B-cell proliferation and immunoglobulin production. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD28-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-89DF-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Dayquil","valueDescription":"Dayquil","ValueMeaning":{"publicId":"2576095","version":"1","preferredName":"Dayquil","longName":"2576095","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dayquil","conceptCode":"C28973","definition":"A daytime non-drowsy preparation used to relieve common cold and flu symptoms. Dextromethorphan, one of the active ingredients, exerts its activity by raising the threshold for coughing in the cough center. Another ingredient of Dayquil, phenylephrine, a post-synaptic alpha-adrenergic receptor agonist, induces vasoconstriction, and thereby reduces blood flow, decreases swelling and prevents nasal and sinus congestion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F64C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-89E9-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Decitabine","valueDescription":"Decitabine","ValueMeaning":{"publicId":"2577852","version":"1","preferredName":"Decitabine","longName":"2577852","preferredDefinition":"A cytidine antimetabolite analogue with potential antineoplastic activity. Decitabine incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Decitabine","conceptCode":"C981","definition":"A cytidine antimetabolite analogue with potential antineoplastic activity. Decitabine incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD29-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-89F3-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Delavirdine Mesylate","valueDescription":"Delavirdine Mesylate","ValueMeaning":{"publicId":"2577853","version":"1","preferredName":"Delavirdine Mesylate","longName":"2577853","preferredDefinition":"A synthetic, non-nucleoside reverse transcriptase (RT) inhibitor with antiviral properties.  Delavirdine binds directly to the human immunodeficiency virus type 1 (HIV-1) RT, an RNA-dependent DNA polymerase, blocking its function in viral DNA replication.  In combination with at least two other anti-retroviral drugs, this agent has been shown to reduce HIV viral load and increase CD4 leukocyte counts in the majority of patients.  As an inhibitor of the cytochrome P450 system, delavirdine may result in increased serum levels of those co-administered protease inhibitors metabolized by the cytochrome P450 system. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Delavirdine Mesylate","conceptCode":"C28974","definition":"A mesylate salt form of delavirdine, a synthetic, non-nucleoside reverse transcriptase inhibitor. In combination with other anti-retroviral drugs, this agent has been shown to reduce HIV viral load and increase CD4 leukocyte counts in patients. As an inhibitor of the cytochrome P450 system, delavirdine may result in increased serum levels of co-administered protease inhibitors metabolized by the cytochrome P450 system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD2A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-89FD-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Demeclocycline HCL","valueDescription":"Demeclocycline Hydrochloride","ValueMeaning":{"publicId":"2577854","version":"1","preferredName":"Demeclocycline Hydrochloride","longName":"2577854","preferredDefinition":"A tetracycline derivative exhibiting antimicrobial activity. Demeclocycline hydrochloride blocks binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis. In addition, this agent inhibits ADH-induced water reabsorption in the kidneys, thereby causing water diuresis. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Demeclocycline Hydrochloride","conceptCode":"C0282125","definition":"A tetracycline derivative exhibiting antimicrobial activity. Demeclocycline hydrochloride blocks binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis. In addition, this agent inhibits ADH-induced water reabsorption in the kidneys, thereby causing water diuresis. (NCI)","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD2B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8A07-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Deniluekin","valueDescription":"Denileukin Diftitox","ValueMeaning":{"publicId":"2577847","version":"1","preferredName":"Denileukin Diftitox","longName":"2577847","preferredDefinition":"A cytotoxic recombinant protein consisting of interleukin-2 (IL-2) protein sequences fused to diphtheria toxin. The IL-2 protein sequence moiety of denileukin difitox directs the cytocidal action of diphtheria toxin to cells that express IL-2 receptors. After the toxin moiety is internalized into target IL-2 receptor-expressing cells, its catalytic domain catalyzes the transfer of the ADP-ribose moiety of NAD to a posttranslationally modified histidine residue of elongation factor 2 (EF-2), called diphthamine. This covalent modification inactivates EF-2 and disrupts polypeptide chain elongation, resulting in cell death. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Denileukin Diftitox","conceptCode":"C1476","definition":"A cytotoxic recombinant fusion protein consisting of the human cytokine interleukin-2 (IL-2) fused to diphtheria toxin fragments A and B, containing both the catalytic and translocation domains, with potential antineoplastic activity. Upon administration, the IL-2 moiety of denileukin difitox targets and binds to IL-2 receptors. After internalization by IL-2 receptor-expressing cells via endocytosis, denileukin difitox is proteolytically cleaved. This releases the catalytic domain of the toxin moiety, which catalyzes the transfer of the ADP-ribose moiety of NAD to a diphthamide residue of elongation factor 2 (EF-2). This covalent modification inactivates EF-2 and disrupts polypeptide chain elongation, resulting in an inhibition of translation and cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD24-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8A11-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Desipramine HCL","valueDescription":"Desipramine Hydrochloride","ValueMeaning":{"publicId":"2577848","version":"1","preferredName":"Desipramine Hydrochloride","longName":"2577848","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Desipramine Hydrochloride","conceptCode":"C0700529","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD25-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8A1B-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Didanosine EC","valueDescription":"Difenoxin","ValueMeaning":{"publicId":"2576106","version":"1","preferredName":"Difenoxin","longName":"2576106","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"difenoxin","conceptCode":"C0057981","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F657-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8A25-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Differin","valueDescription":"Adapalene","ValueMeaning":{"publicId":"2576903","version":"1","preferredName":"Adapalene","longName":"2576903","preferredDefinition":"A topical retinoid-like compound, chemically similar to vitamin A.  Although the exact mechanism of action is unknown, adapalene binds to specific retinoic acid receptors in the nucleus, leading to specific gene expression.  This agent stimulates skin growth through modulation of cellular differentiation, inflammatory processes and keratinization of follicular epithelial cells.  Adapalene may increase dermal sensitivity to ultraviolet radiation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adapalene","conceptCode":"C28989","definition":"A topical retinoid-like compound, chemically similar to vitamin A.  Although the exact mechanism of action is unknown, adapalene binds to specific retinoic acid receptors in the nucleus, leading to specific gene expression.  This agent stimulates skin growth through modulation of cellular differentiation, inflammatory processes and keratinization of follicular epithelial cells.  Adapalene may increase dermal sensitivity to ultraviolet radiation. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F974-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8A2F-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Digoxin","valueDescription":"Digoxin","ValueMeaning":{"publicId":"2577860","version":"1","preferredName":"Digoxin","longName":"2577860","preferredDefinition":"A cardiac glycoside. Digoxin inhibits the sodium potassium adenosine triphosphatase (ATPase) pump, thereby increasing intracellular calcium and enhancing cardiac contractility.  This agent also acts directly on the atrioventricular node to suppress conduction, thereby slowing conduction velocity.  Apparently due to its effects on intracellular calcium concentrations, digoxin induces apoptosis of tumor cells via a pathway involving mitochondrial cytochrome c and caspases 8 and 3. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Digoxin","conceptCode":"C28990","definition":"A cardiac glycoside. Digoxin inhibits the sodium potassium adenosine triphosphatase (ATPase) pump, thereby increasing intracellular calcium and enhancing cardiac contractility.  This agent also acts directly on the atrioventricular node to suppress conduction, thereby slowing conduction velocity.  Apparently due to its effects on intracellular calcium concentrations, digoxin induces apoptosis of tumor cells via a pathway involving mitochondrial cytochrome c and caspases 8 and 3. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD31-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8A39-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Diindolylmethane (DIM) Complex","valueDescription":"2-(indol-3-ylmethyl)-3,3'-diindolylmethane","ValueMeaning":{"publicId":"2577857","version":"1","preferredName":"2-(indol-3-ylmethyl)-3,3'-diindolylmethane","longName":"2577857","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"2-(indol-3-ylmethyl)-3,3'-diindolylmethane","conceptCode":"C0908038","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD2E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8A43-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Diltiazem HCL","valueDescription":"Diltiazem Hydrochloride","ValueMeaning":{"publicId":"2577861","version":"1","preferredName":"Diltiazem Hydrochloride","longName":"2577861","preferredDefinition":"A benzothiazepine calcium channel blocking agent. Diltiazem hydrochloride inhibits the transmembrane influx of extracellular calcium ions into select myocardial and vascular smooth muscle cells, causing dilatation of coronary and systemic arteries and decreasing myocardial contractility.  Because of its vasodilatory activity, this agent has been shown to improve the microcirculation in some tumors, thereby potentially improving the delivery of antineoplastic agents to tumor cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diltiazem Hydrochloride","conceptCode":"C398","definition":"A benzothiazepine calcium channel blocking agent. Diltiazem hydrochloride inhibits the transmembrane influx of extracellular calcium ions into select myocardial and vascular smooth muscle cells, causing dilatation of coronary and systemic arteries and decreasing myocardial contractility.  Because of its vasodilatory activity, this agent has been shown to improve the microcirculation in some tumors, thereby potentially improving the delivery of antineoplastic agents to tumor cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD32-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8A4D-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Dimenhydrinate","valueDescription":"Dimenhydrinate","ValueMeaning":{"publicId":"2576109","version":"1","preferredName":"Dimenhydrinate","longName":"2576109","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dimenhydrinate","conceptCode":"C28992","definition":"An ethanolamine and first-generation histamine antagonist with anti-allergic activity. Dimenhydrinate competitively blocks H1 receptors, thereby preventing the actions of histamine on bronchial smooth muscle, capillaries and gastrointestinal (GI) smooth muscle. This prevents histamine-induced bronchoconstriction, vasodilation, increased capillary permeability, GI smooth muscle spasm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F65A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8A57-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"DImetapp","valueDescription":"Dimetapp","ValueMeaning":{"publicId":"2576110","version":"1","preferredName":"Dimetapp","longName":"2576110","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dimetapp","conceptCode":"C28993","definition":"A commercial combination preparation, by Wyeth, containing brompheniramine maleate and phenylpropanolamine hydrochloride, with antihistaminergic and vasoconstrictive properties. Brompheniramine maleate, a propylamine antihistamine binds to and blocks H1 receptors thereby preventing the actions of histamine. Phenylpropanolamine hydrochloride is a decongestant that causes constriction of blood vessels mediated through its alpha-adrenergic signaling, thereby reducing blood flow and improving nasal air flow. Dimetapp is used to relieve nasal congestion and to treat rhinitis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F65B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8A61-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Diphencyprone","valueDescription":"Diphencyprone","ValueMeaning":{"publicId":"2576111","version":"1","preferredName":"Diphencyprone","longName":"2576111v1.00","preferredDefinition":"A synthetic, potent allergic contact sensitizer with potential immunostimulatory activity. After sensitization process by repeated topical application of diphencyprone to a specific area, further application of this agent to the affected area may stimulate an immune response and may potentially be useful to clear the affected area from infection or cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diphencyprone","conceptCode":"C28994","definition":"A synthetic, potent allergic contact sensitizer with potential immunostimulatory activity. After sensitization process by repeated topical application of diphencyprone to a specific area, further application of this agent to the affected area may stimulate an immune response and may potentially be useful to clear the affected area from infection or cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F65C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"KUMMEROA","dateModified":"2023-08-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8A6B-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cortrosyn","valueDescription":"Cortrosyn","ValueMeaning":{"publicId":"2577824","version":"1","preferredName":"Cortrosyn","longName":"2577824","preferredDefinition":"A synthetically-derived subunit of the endogenous peptide pituitary hormone adrenocorticotropic hormone (ACTH). Consisting of the first 24 amino acids from the amino terminal of ACTH, Cortrosyn is usually prepared for injection and intended for diagnostic and not therapeutic use. Similar to endogenous ACTH, this agent stimulates the adrenal secretion of specific adrenal steroids that can be measured in the plasma. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cortrosyn","conceptCode":"C0701510","definition":"A synthetically-derived subunit of the endogenous peptide pituitary hormone adrenocorticotropic hormone (ACTH). Consisting of the first 24 amino acids from the amino terminal of ACTH, Cortrosyn is usually prepared for injection and intended for diagnostic and not therapeutic use. Similar to endogenous ACTH, this agent stimulates the adrenal secretion of specific adrenal steroids that can be measured in the plasma. (NCI04)","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD0D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8A75-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Argatroban","valueDescription":"Argatroban: C28833","ValueMeaning":{"publicId":"2577862","version":"1","preferredName":"Argatroban: C28833","longName":"2577862","preferredDefinition":"A synthetic derivative of L-arginine with antithrombotic activity. Argatroban is a univalent and direct inhibitor of fibrin-bound thrombin. This agent reversibly binds to the thrombin active site thereby preventing the thrombin-dependent reactions, which include conversion of fibrinogen to fibrin; the activation of factors V, VIII and XI; the activation of protein C; and platelet aggregation. Argatroban is highly selective for thrombin and is able to inhibit the action of both free and clot-associated thrombin. As a result, stabilization of blood clots and coagulation is inhibited.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Argatroban","conceptCode":"C28833","definition":"A synthetic derivative of L-arginine with antithrombotic activity. Argatroban is a univalent and direct inhibitor of fibrin-bound thrombin. This agent reversibly binds to the thrombin active site thereby preventing the thrombin-dependent reactions, which include conversion of fibrinogen to fibrin; the activation of factors V, VIII and XI; the activation of protein C; and platelet aggregation. Argatroban is highly selective for thrombin and is able to inhibit the action of both free and clot-associated thrombin. As a result, stabilization of blood clots and coagulation is inhibited.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD33-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"TAYLORT","dateModified":"2018-05-15","changeDescription":"5/15/18 tt added concept definition.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8A7F-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Desloratadine","valueDescription":"Desloratadine","ValueMeaning":{"publicId":"2577867","version":"1","preferredName":"Desloratadine","longName":"2577867","preferredDefinition":"A long-acting piperidine derivate with selective H1 antihistaminergic and non-sedating properties. Desloratadine diminishes the typical histaminergic effects on H1-receptors in bronchial smooth muscle, capillaries and gastrointestinal smooth muscle, including vasodilation, bronchoconstriction, increased vascular permeability, pain, itching and spasmodic contractions of gastrointestinal smooth muscle. Desloratadine is used to provide symptomatic relieve of allergic symptoms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Desloratadine","conceptCode":"C47474","definition":"A long-acting piperidine derivate with selective H1 antihistaminergic and non-sedating properties. Desloratadine diminishes the typical histaminergic effects on H1-receptors in bronchial smooth muscle, capillaries and gastrointestinal smooth muscle, including vasodilation, bronchoconstriction, increased vascular permeability, pain, itching and spasmodic contractions of gastrointestinal smooth muscle. Desloratadine is used to provide symptomatic relieve of allergic symptoms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD38-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8A89-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Desmopressin Acetate","valueDescription":"Desmopressin Acetate","ValueMeaning":{"publicId":"2577868","version":"1","preferredName":"Desmopressin Acetate","longName":"2577868","preferredDefinition":"An analogue of the hormone vasopressin with antidiuretic and antihemorrhagic properties. Desmopressin acetate has selective affinity for the V2 receptor and acts on the distal kidney tubule by increasing the cellular permeability thereby stimulating water reabsorption. This antidiuretic agent is used in the treatment of central diabetes insipidus. An unrelated action of desmopressin acetate is to increases circulating factor VIII and is used in patients with haemophilia and von Willebrand's disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Desmopressin Acetate","conceptCode":"C47475","definition":"An analogue of the hormone vasopressin with antidiuretic and antihemorrhagic properties. Desmopressin acetate has selective affinity for the V2 receptor and acts on the distal kidney tubule by increasing the cellular permeability thereby stimulating water reabsorption. This antidiuretic agent is used in the treatment of central diabetes insipidus. An unrelated action of desmopressin acetate is to increases circulating factor VIII and is used in patients with haemophilia and von Willebrand's disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD39-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8A93-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Desogestrel/Ethinyl Estradiol","valueDescription":"desogestrel-ethinyl estradiol","ValueMeaning":{"publicId":"2577855","version":"1","preferredName":"desogestrel-ethinyl estradiol","longName":"2577855","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"desogestrel-ethinyl estradiol","conceptCode":"C1112096","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD2C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8A9D-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Devil's Foot/Jambul","valueDescription":"Devil's Foot/Jambul","ValueMeaning":{"publicId":"2577869","version":"1","preferredName":"Devil's Foot/Jambul","longName":"2577869","preferredDefinition":"An herbal combination of two plants, devil's claw (Harpagophytum procumbens) and jambul (Eugenia jambolana) that may be administered both orally and topically in various formulations. Devil's claw has been used as a tonic, as a hypoglycemic, to cleanse the lymph system, and in the treatment of arthritis and rheumatism. This agent may have anti-inflammatory and analgesic properties, possibly due to the presence of antioxidants, phenols, tannins, triterpenoids and volatile oils. Jambul seeds and fruits have important carminative and astringent properties and may reduce blood sugar levels. This agent contains glucosides, jamboline and ellagic acid which may check the conversion of starch into sugar. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Devil's Foot/Jambul","conceptCode":"CL319709","definition":"An herbal combination of two plants, devil's claw (Harpagophytum procumbens) and jambul (Eugenia jambolana) that may be administered both orally and topically in various formulations. Devil's claw has been used as a tonic, as a hypoglycemic, to cleanse the lymph system, and in the treatment of arthritis and rheumatism. This agent may have anti-inflammatory and analgesic properties, possibly due to the presence of antioxidants, phenols, tannins, triterpenoids and volatile oils. Jambul seeds and fruits have important carminative and astringent properties and may reduce blood sugar levels. This agent contains glucosides, jamboline and ellagic acid which may check the conversion of starch into sugar. (NCI04)","evsSource":"NCI_META_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD3A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8AA7-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Dexamethasone","valueDescription":"Dexamethasone","ValueMeaning":{"publicId":"2568530","version":"1","preferredName":"Dexamethasone","longName":"2568530v1.00","preferredDefinition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dexamethasone","conceptCode":"C422","definition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8BF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"KUMMEROA","dateModified":"2023-08-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8AB1-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Dextroamphetamine","valueDescription":"Dextroamphetamine","ValueMeaning":{"publicId":"2577870","version":"1","preferredName":"Dextroamphetamine","longName":"2577870","preferredDefinition":"A synthetic substance related to natural sympathomimetic amines and the synthetic agent amphetamine. In the central nervous system (CNS), dextroamphetamine induces the release of dopamine within the mesocorticolimbic system, a major component of the brain reward system, resulting in measurable behavioral changes such as euphoria. As a CNS stimulant, this agent may increase blood pressure and reduce appetite. Similar to other amphetamines, dextroamphetamine has a high potential for abuse, dependence, and addiction if used in large doses over extended periods of time. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dextroamphetamine","conceptCode":"C28981","definition":"A synthetic substance related to natural sympathomimetic amines and the synthetic agent amphetamine. In the central nervous system (CNS), dextroamphetamine induces the release of dopamine within the mesocorticolimbic system, a major component of the brain reward system, resulting in measurable behavioral changes such as euphoria. As a CNS stimulant, this agent may increase blood pressure and reduce appetite. Similar to other amphetamines, dextroamphetamine has a high potential for abuse, dependence, and addiction if used in large doses over extended periods of time. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD3B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8ABB-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Dextromethorphan Hydrobromide","valueDescription":"Dextromethorphan Hydrobromide","ValueMeaning":{"publicId":"2576101","version":"1","preferredName":"Dextromethorphan Hydrobromide","longName":"2576101","preferredDefinition":"The d-isomer of the codeine analog of LEVORPHANOL. Dextromethorphan shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is a NMDA receptor antagonist (RECEPTORS, N-METHYL-D-ASPARTATE) and acts as a non-competitive channel blocker. It is used widely as an antitussive agent, and is also used to study the involvement of glutamate receptors in neurotoxicity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dextromethorphan Hydrobromide","conceptCode":"C423","definition":"The hydrobromide salt form of dextromethorphan, a synthetic, methylated dextrorotary analogue of levorphanol, a substance related to codeine and a non-opioid derivate of morphine. Dextromethorphan exhibits antitussive activity and is devoid of analgesic or addictive property. This agent crosses the blood-brain-barrier and activates sigma opioid receptors on the cough center in the central nervous system, thereby suppressing the cough reflex.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F652-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8AC5-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Diazepam","valueDescription":"Diazepam","ValueMeaning":{"publicId":"2576102","version":"1","preferredName":"Diazepam","longName":"2576102","preferredDefinition":"A benzodiazepine derivative with anti-anxiety, sedative, hypnotic and anticonvulsant properties. Diazepam potentiates the inhibitory activities of gamma-aminobutyric acid (GABA) by binding to the GABA receptor, located in the limbic system and the hypothalamus. This increases the frequency of chloride channel opening, allowing the flow of chloride ions into the neuron and ultimately leading to membrane hyperpolarization and a decrease in neuronal excitability.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diazepam","conceptCode":"C28982","definition":"A benzodiazepine derivative with anti-anxiety, sedative, hypnotic and anticonvulsant properties. Diazepam potentiates the inhibitory activities of gamma-aminobutyric acid (GABA) by binding to the GABA receptor, located in the limbic system and the hypothalamus. This increases the frequency of chloride channel opening, allowing the flow of chloride ions into the neuron and ultimately leading to membrane hyperpolarization and a decrease in neuronal excitability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F653-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"COOPERM","dateModified":"2019-08-05","changeDescription":"Added definition to concept. mc 8/5/19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8ACF-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Dibucaine","valueDescription":"Dibucaine","ValueMeaning":{"publicId":"2577871","version":"1","preferredName":"Dibucaine","longName":"2577871","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dibucaine","conceptCode":"C28984","definition":"A quinoline derivative and amino amide with anesthetic activity. Dibucaine reversibly binds to and inactivates sodium channels in the neuronal cell membrane. Inhibition of sodium channels prevents the depolarization of nerve cell membranes and inhibits subsequent propagation of impulses along the course of the nerve, thereby limiting the excitation of nerve endings. This results in loss of sensation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD3C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8AD9-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Diclofenac","valueDescription":"Diclofenac","ValueMeaning":{"publicId":"2577872","version":"1","preferredName":"Diclofenac","longName":"2577872","preferredDefinition":"A nonsteroidal benzeneacetic acid derivative with anti-inflammatory activity.  As a nonsteroidal anti-inflammatory drug (NSAID), diclofenac binds and chelates both isoforms of cyclooxygenase (COX-1 and-2), thereby blocking the conversion of arachidonic acid to pro-inflammatory-proprostaglandins.  This agent also may inhibit COX-2-mediated tumor angiogenesis.  When inhibiting COX-2, diclofenac may be effective in relieving pain and inflammation; when inhibiting COX-1, it may produce unacceptable gastrointestinal side effects.  This agent may be more active against COX-2 than several other carboxylic acid-containing NSAIDs. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diclofenac","conceptCode":"C28985","definition":"A nonsteroidal benzeneacetic acid derivative with anti-inflammatory activity.  As a nonsteroidal anti-inflammatory drug (NSAID), diclofenac binds and chelates both isoforms of cyclooxygenase (COX-1 and-2), thereby blocking the conversion of arachidonic acid to pro-inflammatory-proprostaglandins.  This agent also may inhibit COX-2-mediated tumor angiogenesis.  When inhibiting COX-2, diclofenac may be effective in relieving pain and inflammation; when inhibiting COX-1, it may produce unacceptable gastrointestinal side effects.  This agent may be more active against COX-2 than several other carboxylic acid-containing NSAIDs. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD3D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8AE3-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Dicloxacillin","valueDescription":"Dicloxacillin","ValueMeaning":{"publicId":"2575677","version":"1","preferredName":"Dicloxacillin","longName":"2575677","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dicloxacillin","conceptCode":"C28986","definition":"A broad-spectrum, semi-synthetic, beta-lactam, penicillin antibiotic with bactericidal and beta-lactamase resistant activity. Dicloxacillin binds to penicillin binding proteins (PBP) located on the inner membrane of the bacterial cell wall.  It also inhibits the cross-linkage of peptidoglycan, a critical component of bacterial cell walls. This leads to the inhibition of bacterial cell wall synthesis and eventually causes cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4AA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8AED-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Dicyclomine HCL","valueDescription":"Dicyclomine","ValueMeaning":{"publicId":"2577856","version":"1","preferredName":"Dicyclomine","longName":"2577856","preferredDefinition":"A muscarinic antagonist used as an antispasmodic and in urinary incontinence. It has little effect on glandular secretion or the cardiovascular system. It does have some local anesthetic properties and is used in gastrointestinal, biliary, and urinary tract spasms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dicyclomine","conceptCode":"C0012125","definition":"A muscarinic antagonist used as an antispasmodic and in urinary incontinence. It has little effect on glandular secretion or the cardiovascular system. It does have some local anesthetic properties and is used in gastrointestinal, biliary, and urinary tract spasms.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD2D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8AF7-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Difenoxin","valueDescription":"Difenoxin","ValueMeaning":{"publicId":"2576106","version":"1","preferredName":"Difenoxin","longName":"2576106","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"difenoxin","conceptCode":"C0057981","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F657-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8B01-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Diphenoxylate","valueDescription":"Diphenoxylate Hydrochloride","ValueMeaning":{"publicId":"2577863","version":"1","preferredName":"Diphenoxylate Hydrochloride","longName":"2577863","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diphenoxylate Hydrochloride","conceptCode":"C28995","definition":"The hydrochloride salt form of diphenoxylate, a piperidine derivate, chemically related to narcotic meperidine, with antidiarrheal activity and devoid of central nervous system (CNS) activity. Diphenoxylate acts on opioid receptors in the gastrointestinal tract, thereby decreasing gastrointestinal motility and causing constipation or preventing diarrhea.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD34-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8B0B-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Diphenoxylate HCL/Atropine","valueDescription":"DIFENOXIN HCL/ATROPINE SULFATE TABLET","ValueMeaning":{"publicId":"2577864","version":"1","preferredName":"DIFENOXIN HCL/ATROPINE SULFATE TABLET","longName":"2577864","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"DIFENOXIN HCL/ATROPINE SULFATE TABLET","conceptCode":"C0773802","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD35-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8B15-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Doxycycline Chloride","valueDescription":"Doxycycline Monohydrate","ValueMeaning":{"publicId":"2577865","version":"1","preferredName":"Doxycycline Monohydrate","longName":"2577865","preferredDefinition":"A synthetic tetracycline derivative exhibiting antimicrobial activity.  Doxycycline blocks binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis.  In addition, this agent has exhibited inhibition of collagenase activity. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxycycline","conceptCode":"C457","definition":"A synthetic, broad-spectrum tetracycline antibiotic exhibiting antimicrobial activity. Doxycycline binds to the 30S ribosomal subunit, possibly to the 50S ribosomal subunit as well, thereby blocking the binding of aminoacyl-tRNA to the mRNA-ribosome complex. This leads to an inhibition of protein synthesis. In addition, this agent has exhibited inhibition of collagenase activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD36-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"REEVESD","dateModified":"2010-08-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8B1F-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cosyntropin","valueDescription":"Cosyntropin","ValueMeaning":{"publicId":"7092692","version":"1","preferredName":"Cosyntropin","longName":"7092692","preferredDefinition":"A synthetically-derived subunit of the endogenous peptide pituitary hormone adrenocorticotropic hormone (ACTH).  Consisting of the first 24 amino acids from the amino terminal of ACTH, Cortrosyn is usually prepared for injection and intended for diagnostic and not therapeutic use.  Similar to endogenous ACTH, this agent stimulates the adrenal secretion of specific adrenal steroids that can be measured in the plasma. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cosyntropin","conceptCode":"C28941","definition":"A synthetically-derived subunit of the endogenous peptide pituitary hormone adrenocorticotropic hormone (ACTH).  Consisting of the first 24 amino acids from the amino terminal of ACTH, Cortrosyn is usually prepared for injection and intended for diagnostic and not therapeutic use.  Similar to endogenous ACTH, this agent stimulates the adrenal secretion of specific adrenal steroids that can be measured in the plasma. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D63FC7-EAD6-7B51-E053-F662850A2C3A","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"99D63FC7-EAEF-7B51-E053-F662850A2C3A","beginDate":"2019-12-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","deletedIndicator":"No"},{"value":"Lactated Ringers","valueDescription":"Lactated Ringer Solution","ValueMeaning":{"publicId":"7092694","version":"1","preferredName":"Lactated Ringer Solution","longName":"7092694","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lactated Ringer Solution","conceptCode":"C65149","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D63FC7-EAFC-7B51-E053-F662850A2C3A","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"99D63FC7-EB15-7B51-E053-F662850A2C3A","beginDate":"2019-12-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","deletedIndicator":"No"},{"value":"Cisatracurium","valueDescription":"Cisatracurium Besylate","ValueMeaning":{"publicId":"7092696","version":"1","preferredName":"Cisatracurium Besylate","longName":"7092696","preferredDefinition":"A non-depolarizing skeletal muscle relaxant of the benzylisoquinolinium class. Cisatracurium besylate acts as a competitive acetylcholine antagonist that binds to nicotinic receptors at the neuromuscular junction. Compared to other neuromuscular blocking agents, it is intermediate in its onset and duration of action. Cisatracurium besylate is used to maintain neuromuscular relaxation during major surgical procedures, primarily to facilitate endotracheal intubation. Cisatracurium besylate can cause bronchospasms, hypotension, and bradycardia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisatracurium Besylate","conceptCode":"C47451","definition":"The besylate salt form of cisatracurium, a non-depolarizing skeletal muscle relaxant of the benzylisoquinolinium class, with skeletal muscle relaxing activity. Cisatracurium besylate acts as a competitive acetylcholine antagonist that binds to nicotinic receptors at the neuromuscular junction. This blocks neuromuscular transmission and causes neuromuscular relaxation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D63FC7-EB22-7B51-E053-F662850A2C3A","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"99D63FC7-EB3B-7B51-E053-F662850A2C3A","beginDate":"2019-12-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","deletedIndicator":"No"},{"value":"Eculizumab","valueDescription":"Eculizumab","ValueMeaning":{"publicId":"7092697","version":"1","preferredName":"Eculizumab","longName":"7092697","preferredDefinition":"A humanized monoclonal antibody directed against terminal complement protein C5. Eculizumab binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and blocking the complement-mediated destruction of paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eculizumab","conceptCode":"C48386","definition":"A humanized monoclonal antibody directed against terminal complement protein C5. Eculizumab binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and blocking the complement-mediated destruction of paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D63FC7-EB45-7B51-E053-F662850A2C3A","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"99D63FC7-EB5E-7B51-E053-F662850A2C3A","beginDate":"2019-12-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","deletedIndicator":"No"},{"value":"Iohexol","valueDescription":"IOHEXOL","ValueMeaning":{"publicId":"7092698","version":"1","preferredName":"IOHEXOL","longName":"7092698","preferredDefinition":"An X-ray contrast medium containing iohexol in various concentrations, from 140 to 350 milligrams of iodine per milliliter.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Iohexol","conceptCode":"C65939","definition":"An X-ray contrast medium containing iohexol in various concentrations, from 140 to 350 milligrams of iodine per milliliter.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D63FC7-EB6A-7B51-E053-F662850A2C3A","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"99D63FC7-EB83-7B51-E053-F662850A2C3A","beginDate":"2019-12-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","deletedIndicator":"No"},{"value":"Anakinra","valueDescription":"Anakinra","ValueMeaning":{"publicId":"7092700","version":"1","preferredName":"Anakinra","longName":"7092700","preferredDefinition":"A recombinant human nonglycosylated interleukin-1 (IL-1) receptor antagonist with potential antineoplastic activity. Anakinra binds to the IL-1 receptor, thereby blocking the binding of the IL-1 to and activation of its receptor. Blockade of IL-1 activity may inhibit the cascade of downstream pro-angiogenic factors such as vascular endothelial cell growth factor, tumor necrosis factor-alpha, and IL-6, resulting in inhibition of tumor angiogenesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anakinra","conceptCode":"C38717","definition":"A recombinant human nonglycosylated interleukin-1 (IL-1) receptor antagonist with potential antineoplastic activity. Anakinra binds to the IL-1 receptor, thereby blocking the binding of the IL-1 to and activation of its receptor. Blockade of IL-1 activity may inhibit the cascade of downstream pro-angiogenic factors such as vascular endothelial cell growth factor, tumor necrosis factor-alpha, and IL-6, resulting in inhibition of tumor angiogenesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D63FC7-EB90-7B51-E053-F662850A2C3A","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"99D63FC7-EBA9-7B51-E053-F662850A2C3A","beginDate":"2019-12-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","deletedIndicator":"No"},{"value":"Abacavir","valueDescription":"Abacavir Sulfate","ValueMeaning":{"publicId":"2576888","version":"1","preferredName":"Abacavir Sulfate","longName":"2576888","preferredDefinition":"A synthetic carbocyclic nucleoside analog.  In vivo, the activated triphosphate metabolite of abacavir is incorporated into the viral DNA instead of the natural substrate deoxyguanosine, thereby inhibiting human immunodeficiency virus (HIV) reverse transcriptase (RT) and, so, the replication of the viral DNA and infectious viral particles.  This agent decreases HIV viral loads, retards or prevents the damage to the immune system, and reduces the risk of developing AIDS. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abacavir Sulfate","conceptCode":"C28804","definition":"A sulfate salt form of abacavir, a nucleoside reverse transcriptase inhibitor analog of guanosine. This agent decreases HIV viral loads, retards or prevents the damage to the immune system, and reduces the risk of developing AIDS.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F965-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-09","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-74E4-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Abelcet","valueDescription":"Amphotericin B-Lipid Complex","ValueMeaning":{"publicId":"2576889","version":"1","preferredName":"Amphotericin B-Lipid Complex","longName":"2576889","preferredDefinition":"Consists of the macrolide antibiotic Amphotericin B complexed with dimyristoyl phosphatidylcholine and dimyristoyl phosphatidylglycerol, formulated to provide lower toxicity with efficacy similar to the parent compound, Amphotericin B.  Amphotericin B binds to ergosterol altering cell membrane integrity with subsequent cell death. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liposomal Amphotericin B","conceptCode":"C1566","definition":"A liposome-encapsulated formulation of the polyene antifungal antibiotic amphotericin B produced by the bacterium Streptomyces nodosus with antifungal activity. Amphotericin B binds to ergosterol, an essential component of the fungal cell membrane, and alters cell membrane integrity, resulting in leakage of intracellular components and cell rupture. This agent may also induce oxidative damage in fungal cells and has been reported to stimulate host immune cells. Compared to amphotericin B alone, liposomal delivery of amphotericin B allows for a greater drug concentration in target tissues while decreasing systemic side effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F966-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-09","modifiedBy":"ONEDATA","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-74EE-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Acarbose","valueDescription":"Acarbose","ValueMeaning":{"publicId":"2575980","version":"1","preferredName":"Acarbose","longName":"2575980","preferredDefinition":"An orally administered inhibitor of alpha glucosidase that decreases the digestion and absorption of carbohydrates in the small intestine and leads to decreased blood glucose levels after a carbohydrate load. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acarbose","conceptCode":"C983","definition":"A pseudotetrasaccharide and inhibitor of alpha-glucosidase and pancreatic alpha-amylase with antihyperglycemic activity. Acarbose binds to and inhibits alpha-glucosidase, an enteric enzyme found in the brush border of the small intestines that hydrolyzes oligosaccharides and disaccharides into glucose and other monosaccharides. This prevents the breakdown of larger carbohydrates into glucose and decreases the rise in postprandial blood glucose levels. In addition, acarbose inhibits pancreatic alpha-amylase which hydrolyzes complex starches to oligosaccharides in the small intestines.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F5D9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-74F8-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"ACDA Solution","valueDescription":"Acid citrate dextrose","ValueMeaning":{"publicId":"2576890","version":"1","preferredName":"Acid citrate dextrose","longName":"2576890","preferredDefinition":"A solution of citric acid, sodium citrate, and dextrose used as an anticoagulant in the collection and preservation of whole blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acid-Citrate-Dextrose","conceptCode":"C63375","definition":"A solution of citric acid, sodium citrate, and dextrose used as an anticoagulant in the collection and preservation of whole blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F967-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-09","modifiedBy":"COOPERM","dateModified":"2019-03-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7502-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Acebutolol","valueDescription":"Acebutolol Hydrochloride","ValueMeaning":{"publicId":"2576891","version":"1","preferredName":"Acebutolol Hydrochloride","longName":"2576891","preferredDefinition":"A synthetic butyranilide derivative, hypotensive and antiarrhythmic Acebutolol acts as a cardioselective beta-adrenergic antagonist with little effect on bronchial receptors and has intrinsic sympathomimetic properties. Having stabilizing and quinidine-like effects on cardiac rhythm, Acebutolol is used in ventricular arrhythmias. Other indications include hypertension, alone or in combinations with other agents. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acebutolol Hydrochloride","conceptCode":"C28806","definition":"The hydrochloride salt form of acebutolol, a synthetic butyranilide derivative with hypotensive and antiarrhythmic activity. Acebutolol acts as a cardioselective beta-adrenergic antagonist with little effect on bronchial receptors and has intrinsic sympathomimetic properties. Having stabilizing and quinidine-like effects on cardiac rhythm, Acebutolol is used in ventricular arrhythmias. Other indications include hypertension, alone or in combinations with other agents. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F968-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-09","modifiedBy":"ONEDATA","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-750C-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Acetaminophen","valueDescription":"Acetaminophen","ValueMeaning":{"publicId":"2575982","version":"1","preferredName":"Acetaminophen","longName":"2575982v1.00","preferredDefinition":"A p-aminophenol derivative with analgesic and antipyretic activities. Although the exact mechanism through which acetaminophen exert its effects has yet to be fully determined, acetaminophen may inhibit the nitric oxide (NO) pathway mediated by a variety of neurotransmitter receptors including N-methyl-D-aspartate (NMDA) and substance P, resulting in elevation of the pain threshold. The antipyretic activity may result from inhibition of prostaglandin synthesis and release in the central nervous system (CNS) and prostaglandin-mediated effects on the heat-regulating center in the anterior hypothalamus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acetaminophen","conceptCode":"C198","definition":"A p-aminophenol derivative with analgesic and antipyretic activities. Although the exact mechanism through which acetaminophen exert its effects has yet to be fully determined, acetaminophen may inhibit the nitric oxide (NO) pathway mediated by a variety of neurotransmitter receptors including N-methyl-D-aspartate (NMDA) and substance P, resulting in elevation of the pain threshold. The antipyretic activity may result from inhibition of prostaglandin synthesis and release in the central nervous system (CNS) and prostaglandin-mediated effects on the heat-regulating center in the anterior hypothalamus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F5DB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"MMADDINENI","dateModified":"2023-08-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7516-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Acetaminophen #3","valueDescription":"Acetaminophen #3","ValueMeaning":{"publicId":"2576898","version":"1","preferredName":"Acetaminophen #3","longName":"2576898","preferredDefinition":"A synthetic p-aminophenol derivative combined with codeine, anti-inflammatory and analgesic Acetaminophen 3 is used against inflammatory conditions, fever, and pain. Codeine is an opium alkaloid with analgesic properties. The active principal metabolite of phenacetin, Acetaminophen appears to inhibit prostaglandin biosynthesis in the central nervous system and less in peripheral tissues. Equipotent to acetylsalicylic acid, but more toxic, Acetaminophen may cause liver and kidney damage, especially in children. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acetaminophen/Codeine","conceptCode":"C28807","definition":"A synthetic p-aminophenol derivative combined with codeine, with anti-inflammatory and analgesic activites. Acetaminophen with codeine is used against inflammatory conditions, fever, and pain. Codeine is an opium alkaloid with analgesic properties. Acetaminophen appears to inhibit prostaglandin biosynthesis in the central nervous system and less in peripheral tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F96F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7520-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Acetaminophen/Caffeine/Butalbital","valueDescription":"Acetaminophen/Butalbital/Caffeine","ValueMeaning":{"publicId":"2576892","version":"1","preferredName":"Acetaminophen/Butalbital/Caffeine","longName":"2576892","preferredDefinition":"A combination preparation of acetaminophen, butalbital, and caffeine. Acetaminophen exerts antipyretic and analgesic activities by inhibiting prostaglandin synthesis. Butalbital, a barbiturate with an intermediate duration of action, depresses the central nervous system and exerts sedative activity. Caffeine is a central nervous system stimulant and causes constriction of dilated cerebral blood vessels. This combination is used for the relief and treatment of migraine and tension headaches.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acetaminophen/Butalbital/Caffeine","conceptCode":"C29051","definition":"A combination preparation of acetaminophen, butalbital, and caffeine. Acetaminophen exerts antipyretic and analgesic activities by inhibiting prostaglandin synthesis. Butalbital, a barbiturate with an intermediate duration of action, depresses the central nervous system and exerts sedative activity. Caffeine is a central nervous system stimulant and causes constriction of dilated cerebral blood vessels. This combination is used for the relief and treatment of migraine and tension headaches.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F969-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-09","modifiedBy":"COOPERM","dateModified":"2019-03-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-752A-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Acetaminophen/Diphenhydramine","valueDescription":"Acetaminophen/Diphenhydramine","ValueMeaning":{"publicId":"2575984","version":"1","preferredName":"Acetaminophen/Diphenhydramine","longName":"2575984","preferredDefinition":"A synthetic p-aminophenol derivative and diphenhydramine combination, anti-inflammatory, analgesic, and anti-allergic Acetaminophen Diphenhydramine is used to treat symptoms of allergies and hay fever. The active principal metabolite of phenacetin, Acetaminophen appears to inhibit prostaglandin biosynthesis in the central nervous system and less in peripheral tissues. Diphenhydramine blocks histamine effects, preventing sneezing and itchy, watery eyes, as well as nasal and other allergy and hay fever symptoms. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acetaminophen/Diphenhydramine","conceptCode":"C28808","definition":"A synthetic p-aminophenol derivative and diphenhydramine combination with anti-inflammatory, analgesic, and anti-allergic properties. Acetaminophen Diphenhydramine is used to treat symptoms of allergies and hay fever. The active principal metabolite of phenacetin, acetaminophen appears to inhibit prostaglandin biosynthesis in the central nervous system and less in peripheral tissues. Diphenhydramine blocks histamine effects, preventing sneezing and itchy, watery eyes, as well as nasal and other allergy and hay fever symptoms. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F5DD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7534-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Acetaminophen/Oxycodone HCL (Percocet)","valueDescription":"Acetaminophen + oxycodone hydrochloride","ValueMeaning":{"publicId":"2576893","version":"1","preferredName":"Acetaminophen + oxycodone hydrochloride","longName":"2576893","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acetaminophen + oxycodone hydrochloride","conceptCode":"C0718201","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F96A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-09","modifiedBy":"ONEDATA","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-753E-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Acetazolamide","valueDescription":"Acetazolamide","ValueMeaning":{"publicId":"2576900","version":"1","preferredName":"Acetazolamide","longName":"2576900","preferredDefinition":"An agent that inhibits the function of carbonic anhydrase, a zinc-containing enzyme that catalyzes the rapid conversion of carbon dioxide and water into carbonic acid, protons and bicarbonate ions.  Distributed throughout many cells and tissues, carbonic anhydrases play important roles in mineral and metabolic homeostasis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acetazolamide","conceptCode":"C28809","definition":"A sulfonamide derivative with diuretic, antiglaucoma, and anticonvulsant properties. Acetazolamide is a non-competitive inhibitor of carbonic anhydrase, an enzyme found in cells in the proximal tube of the kidney, the eye, and glial cells. Inhibition of this enzyme in the kidney prevents excretion of hydrogen, leading to increased bicarbonate and cation excretion and increased urinary volume, which results in an alkaline diuresis. Acetazolamide reduces the concentration of bicarbonate, resulting in a decreased synthesis of aqueous humor in the eye, thereby lowering intraocular pressure. Although its mechanism of action is unknown, acetazolamide has anti-convulsant properties resulting from indirect effects secondary to metabolic acidosis or direct effects on neuronal transmission. Acetazolamide also produces respiratory stimulant effects in response to changes to both carbon dioxide and oxygen tension levels within the lungs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F971-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7548-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Acetylsalicylic Acid","valueDescription":"Acetylsalicylic Acid","ValueMeaning":{"publicId":"2576901","version":"1","preferredName":"Acetylsalicylic Acid","longName":"2576901","preferredDefinition":"An orally administered non-steroidal antiinflammatory agent that inhibits cyclooxygenase synthesis of prostaglandin, preventing the formation of platelet aggregation and inflammation. It has analgesic and antipyretic properties. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aspirin","conceptCode":"C287","definition":"An orally administered non-steroidal antiinflammatory agent. Acetylsalicylic acid binds to and acetylates serine residues in cyclooxygenases, resulting in decreased synthesis of prostaglandin, platelet aggregation, and inflammation. This agent exhibits analgesic, antipyretic, and anticoagulant properties.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F972-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7552-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Acetylsalicylic Acid/Caffeine (Anacin)","valueDescription":"Anacin","ValueMeaning":{"publicId":"2576899","version":"1","preferredName":"Anacin","longName":"2576899","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anacin","conceptCode":"C0718504","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F970-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-09","modifiedBy":"ONEDATA","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-755C-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Econazole Nitrate","valueDescription":"Econazole Nitrate","ValueMeaning":{"publicId":"2577866","version":"1","preferredName":"Econazole Nitrate","longName":"2577866","preferredDefinition":"An imidazole derivative and broad-spectrum antimycotic agent with fungistatic properties. Econazole nitrate inhibits biosynthesis of ergosterol, thereby damaging the fungal cell wall membrane and altering its permeability which leads to a loss of essential intracellular components. In addition, econazole nitrate inhibits biosynthesis of triglycerides and phospholipids and inhibits oxidative and peroxidative enzyme activity which may contribute to cellular necrosis and cell death. Econazole nitrate is also active against some gram positive bacteria. This antifungal agent is used in the treatment various dermatomycoses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Econazole Nitrate","conceptCode":"C47506","definition":"An imidazole derivative and broad-spectrum antimycotic agent with fungistatic properties. Econazole nitrate inhibits biosynthesis of ergosterol, thereby damaging the fungal cell wall membrane and altering its permeability which leads to a loss of essential intracellular components. In addition, econazole nitrate inhibits biosynthesis of triglycerides and phospholipids and inhibits oxidative and peroxidative enzyme activity which may contribute to cellular necrosis and cell death. Econazole nitrate is also active against some gram positive bacteria. This antifungal agent is used in the treatment various dermatomycoses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD37-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8B29-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Famotina","valueDescription":"Famotidine","ValueMeaning":{"publicId":"2576843","version":"1","preferredName":"Famotidine","longName":"2576843v1.00","preferredDefinition":"A propanimidamide and histamine H2-receptor antagonist with antacid activity. As a competitive inhibitor of histamine H2-receptors located on the basolateral membrane of the parietal cell, famotidine reduces basal and nocturnal gastric acid secretion, resulting in a reduction in gastric volume, acidity, and amount of gastric acid released in response to various stimuli.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Famotidine","conceptCode":"C29045","definition":"A propanimidamide and histamine H2-receptor antagonist with antacid activity. As a competitive inhibitor of histamine H2-receptors located on the basolateral membrane of the parietal cell, famotidine reduces basal and nocturnal gastric acid secretion, resulting in a reduction in gastric volume, acidity, and amount of gastric acid released in response to various stimuli.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F938-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"KUMMEROA","dateModified":"2023-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8B33-18F7-E053-F662850A60B1","beginDate":"2006-02-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Hydrocodone/Acetaminophen","valueDescription":"Hydrocodone/Acetaminophen","ValueMeaning":{"publicId":"2578164","version":"1","preferredName":"Hydrocodone/Acetaminophen","longName":"2578164v1.00","preferredDefinition":"A combination preparation of the analgesic acetaminophen and the semisynthetic opioid agonist hydrocodone with analgesic and antitussive activities. Acetaminophen exerts its analgesic activity by inhibiting prostaglandin synthesis while hydrocodone exerts its analgesic activity by binding to the mu-receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opioids.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydrocodone/Acetaminophen","conceptCode":"C29100","definition":"A combination preparation of the analgesic acetaminophen and the semisynthetic opioid agonist hydrocodone with analgesic and antitussive activities. Acetaminophen exerts its analgesic activity by inhibiting prostaglandin synthesis while hydrocodone exerts its analgesic activity by binding to the mu-receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opioids.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE61-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"CLOHNES","dateModified":"2023-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8B3D-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Hydromorphone Hydrochloride","valueDescription":"Hydromorphone Hydrochloride","ValueMeaning":{"publicId":"2578165","version":"1","preferredName":"Hydromorphone Hydrochloride","longName":"2578165","preferredDefinition":"An opioid analgesic made from MORPHINE and used mainly as an analgesic. It has a shorter duration of action than morphine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydromorphone Hydrochloride","conceptCode":"C436","definition":"The hydrochloride salt form of hydromorphone, the hydrogenated ketone of morphine, a semi-synthetic opioid with analgesic effects. Hydromorphone selectively binds the mu-opioid receptor which is linked through G-proteins. Binding stimulates the exchange of guanosine triphosphate (GTP) for guanosine diphosphate (GDP) on the G-protein complex and interacts with and inhibits adenylate cyclase located at the inner surface of the plasma membrane. This leads to a reduction in intracellular cyclic 3',5'-adenosine monophosphate (cAMP). Further, voltage-gated potassium channels are activated, thereby causing hyperpolarization and reducing neuronal excitability. In addition, the opening of voltage-gated calcium channels is inhibited, thereby leading to an inhibition of calcium entry and a reduction in the release of various neurotransmitters, including GABA, vasopressin, somatostatin, insulin and glucagons.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE62-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8B47-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Hydroxychloroquine Sulfate","valueDescription":"Hydroxychloroquine Sulfate","ValueMeaning":{"publicId":"2578166","version":"1","preferredName":"Hydroxychloroquine Sulfate","longName":"2578166","preferredDefinition":"A synthetic derivative of quinolyl with chemotherapeutic and antibiotic properties, Hydroxychloroquine Sulfate acts against erythrocytic malarial parasites (Plasmodium vivax, ovale, and malariae) by concentrating in food vacuoles. It inhibits plasmodial heme polymerase and acts through other unknown mechanisms. Hydroxychloroquine also has anti-inflammatory properties and is used in the treatment of rheumatoid arthritis and lupus erythematosus. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydroxychloroquine Sulfate","conceptCode":"C29101","definition":"A synthetic derivative of quinolyl with chemotherapeutic and antibiotic properties, Hydroxychloroquine Sulfate acts against erythrocytic malarial parasites (Plasmodium vivax, ovale, and malariae) by concentrating in food vacuoles. It inhibits plasmodial heme polymerase and acts through other unknown mechanisms. Hydroxychloroquine also has anti-inflammatory properties and is used in the treatment of rheumatoid arthritis and lupus erythematosus. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE63-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8B51-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Indapamide","valueDescription":"Indapamide","ValueMeaning":{"publicId":"2578167","version":"1","preferredName":"Indapamide","longName":"2578167","preferredDefinition":"An indole derivative of chlorosulphonamide with antihypertensive activity.  Indapamide reduces vacular hypersensitivity and peripheral and arterial resistance possibly by inhibition of transmembrane ionic influx and stimulation of prostaglandin E2 synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indapamide","conceptCode":"C29119","definition":"An indole derivative of chlorosulphonamide and a sulfamyl diuretic with antihypertensive activity. Indapamide may interact directly with the subunits of delayed rectifier potassium channels, thereby blocking both slow and rapid K+ (IKs and IKr) currents through the channels. Through the homeostasis mechanism in balancing total ion concentration (Ca++, Na+), it reduces vascular hyperreactivity and peripheral and arterial vascular resistance, possibly by inhibiting transmembrane ionic influx, probably calcium ions, and stimulating prostaglandin E2 synthesis, thereby causing vasodilatation. Indapamide exerts its diuretic effect by inhibiting reabsorption of sodium and chloride, primarily as a result of action on the cortical diluting segment of the renal distal tubule, thereby promoting urinary excretion of water and electrolytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE64-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8B5B-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Infliximab","valueDescription":"Infliximab","ValueMeaning":{"publicId":"2567430","version":"1","preferredName":"Infliximab","longName":"2567430","preferredDefinition":"A monoclonal antibody that inhibits the function of TNF-alpha.  It is used in the treatment of rheumatoid arthritis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Infliximab","conceptCode":"C1789","definition":"A recombinant chimeric, mouse-human monoclonal antibody directed against tumor necrosis factor alpha (TNF-alpha), a protein involved in inflammation, cell survival, and apoptosis. Infliximab may be pro- apoptotic or anti-apoptotic, depending on cell type. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D473-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8B65-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Inositol","valueDescription":"Inositol","ValueMeaning":{"publicId":"2578168","version":"1","preferredName":"Inositol","longName":"2578168","preferredDefinition":"A natural sugar found in cell membrane phospholipids, plasma lipoproteins, and (as the phosphate form) in the nucleus with potential chemopreventive properties. As one of a number of intracellular phosphate compounds, inositol is involved in cell signaling and may stimulate tumor cell differentiation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inositol","conceptCode":"C28163","definition":"A natural sugar found in cell membrane phospholipids, plasma lipoproteins, and (as the phosphate form) in the nucleus with potential chemopreventive properties. As one of a number of intracellular phosphate compounds, inositol is involved in cell signaling and may stimulate tumor cell differentiation. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE65-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA_WA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8B6F-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Insulin, Lente","valueDescription":"Insulin, Lente","ValueMeaning":{"publicId":"2578169","version":"1","preferredName":"Insulin, Lente","longName":"2578169","preferredDefinition":"Sterile suspension, in a buffered water medium, of insulin modified by the addition of zinc chloride in a manner such that the solid phase of the suspension consists of a mixture of crystals and amorphous material in a ratio of approximately 7:3. (From The Merck Index, 11th ed, p4888)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Insulin, Lente","conceptCode":"C0021659","definition":"Sterile suspension, in a buffered water medium, of insulin modified by the addition of zinc chloride in a manner such that the solid phase of the suspension consists of a mixture of crystals and amorphous material in a ratio of approximately 7:3. (From The Merck Index, 11th ed, p4888)","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE66-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8B79-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Insulin, Lispro","valueDescription":"Insulin, Lispro","ValueMeaning":{"publicId":"2578170","version":"1","preferredName":"Insulin, Lispro","longName":"2578170","preferredDefinition":"A recombinant therapeutic agent which is chemically identical to or similar to endogenous human insulin. In lispro insulin, the amino acid proline at B-28 and the amino acid lysine at B-29 are reversed, resulting in the rapid dissolution of this insulin to a monomer that is absorbed rapidly after subcutaneous administration. Lispro insulin is equipotent to human insulin on a molar basis but its effects are faster and of shorter duration. Endogenous insulin, a pancreatic hormone composed of two polypeptide chains, is important in the normal metabolism of carbohydrates, proteins and fats, promoting glucose utilization and protein synthesis; it has anabolic effects on many types of tissues. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Insulin, Lispro","conceptCode":"C0293359","definition":"A recombinant therapeutic agent which is chemically identical to or similar to endogenous human insulin. In lispro insulin, the amino acid proline at B-28 and the amino acid lysine at B-29 are reversed, resulting in the rapid dissolution of this insulin to a monomer that is absorbed rapidly after subcutaneous administration. Lispro insulin is equipotent to human insulin on a molar basis but its effects are faster and of shorter duration. Endogenous insulin, a pancreatic hormone composed of two polypeptide chains, is important in the normal metabolism of carbohydrates, proteins and fats, promoting glucose utilization and protein synthesis; it has anabolic effects on many types of tissues. (NCI04)","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE67-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8B83-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Insulin, NPH","valueDescription":"Insulin, NPH","ValueMeaning":{"publicId":"2578171","version":"1","preferredName":"Insulin, NPH","longName":"2578171","preferredDefinition":"A modified form of insulin that contains protamine and zinc. Isophane insulin is an intermediate-acting INSULIN with time of onset of 2 hours and duration of 24 hours.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Insulin, NPH","conceptCode":"C0021658","definition":"A modified form of insulin that contains protamine and zinc. Isophane insulin is an intermediate-acting INSULIN with time of onset of 2 hours and duration of 24 hours.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE68-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8B8D-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Insulin, Regular","valueDescription":"Insulin, Regular","ValueMeaning":{"publicId":"2578172","version":"1","preferredName":"Insulin, Regular","longName":"2578172","preferredDefinition":"A short-acting form of insulin.  Regular insulin is obtained from animal or recombinant sources.  The onset of action of regular insulin occurs at 30-90 minutes after injection; its effect lasts for 6 to 8 hours.  Endogenous human insulin, a pancreatic hormone composed of two polypeptide chains, is important for the normal metabolism of carbohydrates, proteins and fats; it has anabolic effects on many types of tissues. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Insulin, Regular","conceptCode":"C29125","definition":"A recombinant form of the naturally occurring human pancreatic hormone insulin. Upon administration, regular insulin mimics the action of endogenous human insulin and binds to insulin receptors located on muscle and fat cells. This both facilitates the cellular uptake of glucose and lowers blood glucose levels. In addition, insulin inhibits the liver's conversion of stored glycogen into glucose, which also decreases blood glucose levels. Insulin also inhibits lipolysis in adipose tissue, inhibits proteolysis, and enhances protein synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE69-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8B97-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Insulin, Ultralente","valueDescription":"Insulin, Ultralente","ValueMeaning":{"publicId":"2578173","version":"1","preferredName":"Insulin, Ultralente","longName":"2578173","preferredDefinition":"A long-acting form of crystalline insulin often used in combination with a short-acting insulin in the treatment of diabetes mellitus.  Administered once daily, this type of insulin may be derived from porcine, bovine, or recombinant sources.  Endogenous human insulin, a pancreatic hormone composed of two polypeptide chains, is important for the normal metabolism of carbohydrates, proteins and fats; it has anabolic effects on many types of tissues. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Insulin, Ultralente","conceptCode":"C29126","definition":"A long-acting form of crystalline insulin often used in combination with a short-acting insulin in the treatment of diabetes mellitus.  Administered once daily, this type of insulin may be derived from porcine, bovine, or recombinant sources.  Endogenous human insulin, a pancreatic hormone composed of two polypeptide chains, is important for the normal metabolism of carbohydrates, proteins and fats; it has anabolic effects on many types of tissues. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE6A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8BA1-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Insulin, 70/30","valueDescription":"Insulin, 70/30","ValueMeaning":{"publicId":"2578174","version":"1","preferredName":"Insulin, 70/30","longName":"2578174","preferredDefinition":"A mixture of two types of insulin consisting of 70 percent long-acting insulin suspension and 30 percent rapid-acting insulin.  Typically administered twice a day, insulin 70/30 controls postprandial glycemia and allows convenient mealtime dosing. The long-acting insulin component controls blood glucose levels between meals. Endogenous human insulin, a pancreatic hormone composed of two polypeptide chains, is important for the normal metabolism of carbohydrates, proteins and fats; it has anabolic effects on many types of tissues. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Insulin, 70/30","conceptCode":"C29121","definition":"A mixture of two types of insulin consisting of 70 percent long-acting insulin suspension and 30 percent rapid-acting insulin.  Typically administered twice a day, insulin 70/30 controls postprandial glycemia and allows convenient mealtime dosing. The long-acting insulin component controls blood glucose levels between meals. Endogenous human insulin, a pancreatic hormone composed of two polypeptide chains, is important for the normal metabolism of carbohydrates, proteins and fats; it has anabolic effects on many types of tissues. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE6B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8BAB-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Interferon Beta","valueDescription":"Interferon Beta","ValueMeaning":{"publicId":"2578175","version":"1","preferredName":"Interferon Beta","longName":"2578175","preferredDefinition":"A class of interferon elaborated by fibroblasts.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interferon Beta","conceptCode":"C20495","definition":"Interferon beta (187 aa, ~22 kDa) is encoded by the human IFNB1 gene. This protein plays a role in interferon signaling and host defense.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE6C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8BB5-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Interferon Alpha","valueDescription":"Interferon Alpha","ValueMeaning":{"publicId":"2578176","version":"1","preferredName":"Interferon Alpha","longName":"2578176","preferredDefinition":"A class of interferon (leukocyte interferon) produced predominantly by B lymphocytes.  Located in a cluster on 9p22 there are at least 13 functional genes and 1 pseudogene.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interferon Alpha","conceptCode":"C20494","definition":"A class of interferon (leukocyte interferon) produced predominantly by B lymphocytes.  Located in a cluster on 9p22 there are at least 13 functional genes and 1 pseudogene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE6D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8BBF-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Interferon Gamma","valueDescription":"Interferon Gamma","ValueMeaning":{"publicId":"2578177","version":"1","preferredName":"Interferon Gamma","longName":"2578177","preferredDefinition":"Interferon gamma (IFNg) is produced by activated T cells and is an important immunoregulatory molecule, particularly in allergic diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interferon Gamma","conceptCode":"C20496","definition":"Interferon gamma (166 aa, ~19 kDa) is encoded by the human IFNG gene. This protein is involved in antiviral activity, macrophage activation, antiproliferative activity and immunopotentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE6E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8BC9-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Iopamidol","valueDescription":"Iopamidol","ValueMeaning":{"publicId":"2578178","version":"1","preferredName":"Iopamidol","longName":"2578178","preferredDefinition":"An organic iodine compound and used as a non-ionic water soluble radiographic contrast medium. Iopamidol blocks x-rays as they pass through the body, thereby allowing body structures not containing iodine to be visualized. The degree of opacity produced by iopamidol is directly proportional to the total amount of the iodinated contrast agent in the path of the x-rays. The visualization of body structures is dependent upon the distribution and elimination of iopamidol. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Iopamidol","conceptCode":"C47567","definition":"An organic iodine compound and used as a non-ionic water soluble radiographic contrast medium. Iopamidol blocks x-rays as they pass through the body, thereby allowing body structures not containing iodine to be visualized. The degree of opacity produced by iopamidol is directly proportional to the total amount of the iodinated contrast agent in the path of the x-rays. The visualization of body structures is dependent upon the distribution and elimination of iopamidol. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE6F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8BD3-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ipratropium Bromide","valueDescription":"Ipratropium Bromide","ValueMeaning":{"publicId":"2578179","version":"1","preferredName":"Ipratropium Bromide","longName":"2578179","preferredDefinition":"A synthetic quaternary ammonium compound related to atropine, an anticholinergic agent.  Ipratropium bromide competitively inhibits cholinergic receptors located in bronchial smooth muscle, thereby decreasing cholinergic activity and ultimately bronchodilation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ipratropium Bromide","conceptCode":"C29128","definition":"The bromide salt form of ipratropium, a synthetic derivative of the alkaloid atropine with anticholinergic properties. Ipratropium antagonizes the actions of acetylcholine at parasympathetic, postganglionic, effector-cell junctions. When inhaled, ipratropium binds competitively to cholinergic receptors in the bronchial smooth muscle thereby blocking the bronchoconstrictor actions of the acetylcholine mediated vagal impulses. Inhibition of the vagal tone leads to dilation of the large central airways resulting in bronchodilation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE70-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8BDD-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ipratropium/Albuterol","valueDescription":"Ipratropium/Albuterol","ValueMeaning":{"publicId":"2578180","version":"1","preferredName":"Ipratropium/Albuterol","longName":"2578180","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ipratropium/Albuterol","conceptCode":"C29129","definition":"A combination of albuterol and ipratropium with a bronchodilatory effect. Albuterol stimulates beta-2 adrenergic receptors in the lungs, thereby activating the enzyme adenylate cyclase that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'- adenosine monophosphate (cAMP). This results in the relaxation of bronchial smooth muscle, relieve of bronchospasms, and reduction of inflammatory cell mediator release. Ipratropium is a synthetic quaternary ammonium compound and a competitive muscarinic acetylcholine (Ach) receptor antagonist. This agent inhibits vagally mediated reflexes by antagonizing the action of Ach and consequently, prevents the increase in intracellular cyclic guanosine monophosphate, which is a result of ACh interacting with the muscarinic receptor on bronchial smooth muscle.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE71-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8BE7-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Irbesartan","valueDescription":"Irbesartan","ValueMeaning":{"publicId":"2578181","version":"1","preferredName":"Irbesartan","longName":"2578181","preferredDefinition":"A nonpeptide angiotensin II antagonist with antihypertensive activity. Irbesartan selectively and competitively blocks the binding of angiotensin II to the angiotensin I receptor. Angiotensin II stimulates aldosterone synthesis and secretion by adrenal cortex, which decreases the excretion of sodium and increases the excretion of potassium. Angiotensin II also acts as a vasoconstrictor in vascular smooth muscle. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Irbesartan","conceptCode":"C29130","definition":"A nonpeptide angiotensin II antagonist with antihypertensive activity. Irbesartan selectively and competitively blocks the binding of angiotensin II to the angiotensin I receptor. Angiotensin II stimulates aldosterone synthesis and secretion by adrenal cortex, which decreases the excretion of sodium and increases the excretion of potassium. Angiotensin II also acts as a vasoconstrictor in vascular smooth muscle. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE72-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8BF1-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Dextrose","valueDescription":"Glucose","ValueMeaning":{"publicId":"2570318","version":"1","preferredName":"Glucose","longName":"2570318v1.00","preferredDefinition":"A simple sugar monosaccharide having two isoforms, alpha and beta, with a chemical structure of C6H12O6 that acts as an energy source for both plants and animals by reacting with oxygen, generating carbon dioxide and water, and releasing energy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glucose","conceptCode":"C2831","definition":"A simple sugar monosaccharide having two isoforms, alpha and beta, with a chemical structure of C6H12O6 that acts as an energy source for both plants and animals by reacting with oxygen, generating carbon dioxide and water, and releasing energy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DFBB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"CLOHNES","dateModified":"2023-08-04","changeDescription":null,"administrativeNotes":"8/4/23 Added missing concept per cleanup activities cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8BFB-18F7-E053-F662850A60B1","beginDate":"2008-09-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Sirolimus","valueDescription":"Sirolimus","ValueMeaning":{"publicId":"2760061","version":"1","preferredName":"Sirolimus","longName":"2760061","preferredDefinition":"A drug used to help prevent rejection of organ and bone marrow transplants by the body.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sirolimus","conceptCode":"C1212","definition":"A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FE455C3-3ABF-5319-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-06-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8C05-18F7-E053-F662850A60B1","beginDate":"2008-06-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Dry mouth oral agent, NOS","valueDescription":"Dry mouth oral agent, Not Otherwise Specified","ValueMeaning":{"publicId":"2761352","version":"1","preferredName":"Dry mouth oral agent, Not Otherwise Specified","longName":"2761352","preferredDefinition":"Dry mouth oral agent, Not Otherwise Specified (NOS)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"50A99109-6FE3-2A8A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-06-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8C0F-18F7-E053-F662850A60B1","beginDate":"2008-06-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Anidulafungin","valueDescription":"Anidulafungin","ValueMeaning":{"publicId":"2762697","version":"1","preferredName":"Anidulafungin","longName":"2762697","preferredDefinition":"A cyclic lipopeptide echinocandin derivative with antifungal activity.  Anidulafungin inhibits 1,3 beta-D-glucan synthase, an enzyme involved in fungal cell wall synthesis, resulting in cell lysis and death. This agent is active against Candida species and Aspergillus. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anidulafungin","conceptCode":"C38716","definition":"A cyclic lipopeptide echinocandin derivative with antifungal activity.  Anidulafungin inhibits 1,3 beta-D-glucan synthase, an enzyme involved in fungal cell wall synthesis, resulting in cell lysis and death. This agent is active against Candida species and Aspergillus. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5111047F-8F59-4420-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-07-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8C19-18F7-E053-F662850A60B1","beginDate":"2008-07-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Trichloracetic Acid","valueDescription":"Trichloracetic Acid (TCA)","ValueMeaning":{"publicId":"2830036","version":"1","preferredName":"Trichloracetic Acid (TCA)","longName":"2830036","preferredDefinition":"Trichloracetic Acid (TCA)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6191B569-5313-B3A2-E040-BB89AD4312A4","latestVersionIndicator":"Yes","beginDate":"2009-01-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-01-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8C23-18F7-E053-F662850A60B1","beginDate":"2009-01-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Doxazosin","valueDescription":"Doxazosin","ValueMeaning":{"publicId":"2830038","version":"1","preferredName":"Doxazosin","longName":"2830038","preferredDefinition":"A quinazoline with antihypertensive and antineoplastic properties. Doxazosin is an alpha-adrenergic antagonist that selectively inhibits alpha-1 adrenergic receptors. Blockages of the alpha-1 adrenergic action on the vascular smooth muscles lead to a decrease in vascular resistance and antihypertensive activity. This agent also shows high affinity to alpha-1c adrenoceptor, the predominant functional type in the prostate, which may partially attribute to its effect in treatment of benign prostatic hyperplasia. Furthermore, doxazosin induces apoptosis in prostate cancer cells mediated through inhibition of protein kinase B (PKB)/Akt-signaling death receptor regulatory pathway.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxazosin","conceptCode":"C61737","definition":"A quinazoline with antihypertensive and antineoplastic properties. Doxazosin is an alpha-adrenergic antagonist that selectively inhibits alpha-1 adrenergic receptors. Blockages of the alpha-1 adrenergic action on the vascular smooth muscles lead to a decrease in vascular resistance and antihypertensive activity. This agent also shows high affinity to alpha-1c adrenoceptor, the predominant functional type in the prostate, which may partially attribute to its effect in treatment of benign prostatic hyperplasia. Furthermore, doxazosin induces apoptosis in prostate cancer cells mediated through inhibition of protein kinase B (PKB)/Akt-signaling death receptor regulatory pathway.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6191B569-533B-B3A2-E040-BB89AD4312A4","latestVersionIndicator":"Yes","beginDate":"2009-01-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-01-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8C2D-18F7-E053-F662850A60B1","beginDate":"2009-01-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Aripiprazole","valueDescription":"Aripiprazole","ValueMeaning":{"publicId":"2830040","version":"1","preferredName":"Aripiprazole","longName":"2830040","preferredDefinition":"A quinoline derivate and atypical anti-psychotic agent. Aripiprazole has partial agonistic activity at dopamine D2 receptors and serotonin 5-HT1A receptors, as well as potent antagonistic activity on serotonin 5-HT2A receptors. This drug stabilizes dopamine and serotonin activity in the limbic and cortical system. Aripiprazole is used in managing symptoms of schizophrenia and of acute manic and mixed episodes associated with bipolar I disorders.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aripiprazole","conceptCode":"C47403","definition":"A quinoline derivate and atypical anti-psychotic agent. Aripiprazole has partial agonistic activity at dopamine D2 receptors and serotonin 5-HT1A receptors, as well as potent antagonistic activity on serotonin 5-HT2A receptors. This drug stabilizes dopamine and serotonin activity in the limbic and cortical system. Aripiprazole is used in managing symptoms of schizophrenia and of acute manic and mixed episodes associated with bipolar I disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6191B569-5363-B3A2-E040-BB89AD4312A4","latestVersionIndicator":"Yes","beginDate":"2009-01-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-01-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8C37-18F7-E053-F662850A60B1","beginDate":"2009-01-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Levocetirize Dihydrochloride","valueDescription":"Levocetirize Dihydrochloride (Xyzal)","ValueMeaning":{"publicId":"2826999","version":"1","preferredName":"Levocetirize Dihydrochloride (Xyzal)","longName":"2826999v1.00","preferredDefinition":"The dihydrochloride salt form of the active levorotatory enantiomer of cetirizine, levocetirizine; a third generation, non-sedating, selective histamine H1 receptor antagonist, with antihistamine, anti-inflammatory and potential anti-angiogenic activities. Levocetirizine competes with endogenous histamine for binding at peripheral H1-receptor sites on the effector cell surface. This prevents the negative symptoms associated with histamine release and an allergic reaction. In addition, as histamine plays an important role in angiogenesis during an allergic inflammatory reaction, blocking the action of histamine may modulate the expression of proangiogenic factors and thus may prevent angiogenesis. As a third-generation histamine H1 receptor antagonist, levocetirizine has fewer side effects than most second-generation antihistamines.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Levocetirizine Dihydrochloride","conceptCode":"C72814","definition":"The dihydrochloride salt form of the active levorotatory enantiomer of cetirizine, levocetirizine; a third generation, non-sedating, selective histamine H1 receptor antagonist, with antihistamine, anti-inflammatory and potential anti-angiogenic activities. Levocetirizine competes with endogenous histamine for binding at peripheral H1-receptor sites on the effector cell surface. This prevents the negative symptoms associated with histamine release and an allergic reaction. In addition, as histamine plays an important role in angiogenesis during an allergic inflammatory reaction, blocking the action of histamine may modulate the expression of proangiogenic factors and thus may prevent angiogenesis. As a third-generation histamine H1 receptor antagonist, levocetirizine has fewer side effects than most second-generation antihistamines.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"60DD8944-DAD3-0124-E040-BB89AD436093","latestVersionIndicator":"Yes","beginDate":"2009-01-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-01-19","modifiedBy":"CLOHNES","dateModified":"2023-08-04","changeDescription":null,"administrativeNotes":"8/4/23 Added missing concept per cleanup activities cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8C41-18F7-E053-F662850A60B1","beginDate":"2009-01-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Xenaderm","valueDescription":"Xenaderm","ValueMeaning":{"publicId":"2827003","version":"1","preferredName":"Xenaderm","longName":"2827003","preferredDefinition":"Xenaderm","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"60EC4A65-CD23-DAA5-E040-BB89AD432F61","latestVersionIndicator":"Yes","beginDate":"2009-01-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-01-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8C4B-18F7-E053-F662850A60B1","beginDate":"2009-01-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Vardenafil","valueDescription":"Vardenafil","ValueMeaning":{"publicId":"2939035","version":"1","preferredName":"Vardenafil","longName":"2939035","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vardenafil","conceptCode":"C66650","definition":"A benzenesulfonamide derivative and phosphodiesterase type 5 (PDE5) inhibitor with vasodilatory activity. Vardenafil selectively inhibits PDE5, thus inhibiting the degradation of cyclic guanosine monophosphate (cGMP) found in the smooth muscle of the corpus cavernosa and corpus spongiosum of the penis. The inhibition of cGMP degradation results in prolonged muscle relaxation, vasodilation, and blood engorgement of the corpus cavernosa, prolonging penile erection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72F461DE-F0C7-6FF4-E040-BB89AD435049","latestVersionIndicator":"Yes","beginDate":"2009-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-09-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8C55-18F7-E053-F662850A60B1","beginDate":"2009-09-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Nebivolol","valueDescription":"Nebivolol","ValueMeaning":{"publicId":"2939002","version":"1","preferredName":"Nebivolol","longName":"2939002","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nebivolol","conceptCode":"C66221","definition":"A beta-1 adrenergic receptor antagonist with antihypertensive and vasodilatory activity. Nebivolol binds to and blocks the beta-1 adrenergic receptors in the heart, thereby decreasing cardiac contractility and rate. This leads to a reduction in cardiac output and lowers blood pressure. In addition, nebivolol potentiates nitric oxide (NO), thereby relaxing vascular smooth muscle and exerting a vasodilatory effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72DEE5B9-A662-5AE6-E040-BB89AD4309F7","latestVersionIndicator":"Yes","beginDate":"2009-09-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-09-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8C5F-18F7-E053-F662850A60B1","beginDate":"2009-09-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Atipamizole","valueDescription":"Atipamizole","ValueMeaning":{"publicId":"2936670","version":"1","preferredName":"Atipamizole","longName":"2936670","preferredDefinition":"Atipamizole","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72709709-33B3-BD71-E040-BB89AD437834","latestVersionIndicator":"Yes","beginDate":"2009-08-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-08-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8C69-18F7-E053-F662850A60B1","beginDate":"2009-08-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Aliskiren","valueDescription":"Aliskiren Aliskiren Aliskiren","ValueMeaning":{"publicId":"2947084","version":"1","preferredName":"Aliskiren Aliskiren Aliskiren","longName":"2947084","preferredDefinition":"An orally active nonpeptide renin inhibitor with antihypertensive activity. Aliskiren selectively binds to the S3 sub-pocket of renin, an enzyme in the renin-angiotensin-aldosterone system (RAAS) that is responsible for converting angiotensinogen to angiotensin I (AT I). By inhibiting the activity of renin, the conversion to AT I is prevented, which in turn prevents the conversion of AT I to AT II. This prevents arterial vasoconstriction by AT II and inhibits the production of aldosterone by AT II. As aldosterone causes re-uptake of sodium and water and eventually an increase in extracellular volume, aliskiren is able to prevent the effects that contribute to an increase in blood pressure.: An orally active nonpeptide renin inhibitor with antihypertensive activity. Aliskiren selectively binds to the S3 sub-pocket of renin, an enzyme in the renin-angiotensin-aldosterone system (RAAS) that is responsible for converting angiotensinogen to angiotensin I (AT I). By inhibiting the activity of renin, the conversion to AT I is prevented, which in turn prevents the conversion of AT I to AT II. This prevents arterial vasoconstriction by AT II and inhibits the production of aldosterone by AT II. As aldosterone causes re-uptake of sodium and water and eventually an increase in extracellular volume, aliskiren is able to prevent the effects that contribute to an increase in blood pressure.: An orally active nonpeptide renin inhibitor with antihypertensive activity. Aliskiren selectively binds to the S3 sub-pocket of renin, an enzyme in the renin-angiotensin-aldosterone system (RAAS) that is responsible for converting angiotensinogen to angiotensin I (AT I). By inhibiting the activity of renin, the conversion to AT I is prevented, which in turn prevents the conversion of AT I to AT II. This prevents arterial vasoconstriction by AT II and inhibits the production of aldosterone by AT II. As aldosterone causes re-uptake of sodium and water and eventually an increase in extracellular ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aliskiren","conceptCode":"C65222","definition":"An orally active nonpeptide renin inhibitor with antihypertensive activity. Aliskiren selectively binds to the S3 sub-pocket of renin, an enzyme in the renin-angiotensin-aldosterone system (RAAS) that is responsible for converting angiotensinogen to angiotensin I (AT I). By inhibiting the activity of renin, the conversion to AT I is prevented, which in turn prevents the conversion of AT I to AT II. This prevents arterial vasoconstriction by AT II and inhibits the production of aldosterone by AT II. As aldosterone causes re-uptake of sodium and water and eventually an increase in extracellular volume, aliskiren is able to prevent the effects that contribute to an increase in blood pressure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Aliskiren","conceptCode":"C65222","definition":"An orally active nonpeptide renin inhibitor with antihypertensive activity. Aliskiren selectively binds to the S3 sub-pocket of renin, an enzyme in the renin-angiotensin-aldosterone system (RAAS) that is responsible for converting angiotensinogen to angiotensin I (AT I). By inhibiting the activity of renin, the conversion to AT I is prevented, which in turn prevents the conversion of AT I to AT II. This prevents arterial vasoconstriction by AT II and inhibits the production of aldosterone by AT II. As aldosterone causes re-uptake of sodium and water and eventually an increase in extracellular volume, aliskiren is able to prevent the effects that contribute to an increase in blood pressure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Aliskiren","conceptCode":"C65222","definition":"An orally active nonpeptide renin inhibitor with antihypertensive activity. Aliskiren selectively binds to the S3 sub-pocket of renin, an enzyme in the renin-angiotensin-aldosterone system (RAAS) that is responsible for converting angiotensinogen to angiotensin I (AT I). By inhibiting the activity of renin, the conversion to AT I is prevented, which in turn prevents the conversion of AT I to AT II. This prevents arterial vasoconstriction by AT II and inhibits the production of aldosterone by AT II. As aldosterone causes re-uptake of sodium and water and eventually an increase in extracellular volume, aliskiren is able to prevent the effects that contribute to an increase in blood pressure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74B1B0F9-AB3D-2E07-E040-BB89AD43067D","latestVersionIndicator":"Yes","beginDate":"2009-09-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-09-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8C73-18F7-E053-F662850A60B1","beginDate":"2009-09-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Deferasirox","valueDescription":"Deferasirox","ValueMeaning":{"publicId":"2939024","version":"1","preferredName":"Deferasirox","longName":"2939024","preferredDefinition":"A synthetic, orally bioavailable, achiral, tridentate triazole derived from salicylic acid with iron-chelating activity. Deferasirox chelates iron at a 2:1 (ligand:iron) ratio. Because of its oral availability and long plasma half-life, this agent may be superior to desferrioxamine (desferal, DFO), which is orally inactive and has a short plasma half-life.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Deferasirox","conceptCode":"C48384","definition":"A synthetic, orally bioavailable, achiral, tridentate triazole derived from salicylic acid with iron-chelating activity. Deferasirox chelates iron at a 2:1 (ligand:iron) ratio. Because of its oral availability and long plasma half-life, this agent may be superior to desferrioxamine (desferal, DFO), which is orally inactive and has a short plasma half-life.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72F42843-4A44-DE11-E040-BB89AD43432F","latestVersionIndicator":"Yes","beginDate":"2009-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-09-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8C7D-18F7-E053-F662850A60B1","beginDate":"2009-09-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Daptomycin","valueDescription":"Daptomycin","ValueMeaning":{"publicId":"2939026","version":"1","preferredName":"Daptomycin","longName":"2939026","preferredDefinition":"A semi-synthetic cyclic lipopeptide antibiotic isolated form the bacterium Streptomyces roseosporus with broad-spectrum antibiotic activity against Gram-positive bacteria. Daptomycin has a distinct mechanism of action, in which it binds to bacterial membrane and causes rapid depolarization of the cell membrane due to calcium-dependant potassium efflux; the loss of membrane potential leads to inhibition of DNA, RNA and protein synthesis, resulting in bacterial cell death. This agent does not penetrate the outer membrane of gram-negative bacteria.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Daptomycin","conceptCode":"C47470","definition":"A semi-synthetic cyclic lipopeptide antibiotic isolated form the bacterium Streptomyces roseosporus with broad-spectrum antibiotic activity against Gram-positive bacteria. Daptomycin has a distinct mechanism of action, in which it binds to bacterial membrane and causes rapid depolarization of the cell membrane due to calcium-dependant potassium efflux; the loss of membrane potential leads to inhibition of DNA, RNA and protein synthesis, resulting in bacterial cell death. This agent does not penetrate the outer membrane of gram-negative bacteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72F42843-4A6A-DE11-E040-BB89AD43432F","latestVersionIndicator":"Yes","beginDate":"2009-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-09-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8C87-18F7-E053-F662850A60B1","beginDate":"2009-09-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Tigecycline","valueDescription":"Tigecycline","ValueMeaning":{"publicId":"2939028","version":"1","preferredName":"Tigecycline","longName":"2939028v1.00","preferredDefinition":"A broad-spectrum glycylcycline antibiotic derived from tetracycline. Tigecycline binds to the 30S ribosomal subunit, thereby interfering with the binding of aminoacyl-tRNA to the mRNA-ribosome complex. This prevents the incorporation of amino acid residues into the elongating peptide chain, inhibiting protein synthesis and eventually bacterial cell growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tigecycline","conceptCode":"C72865","definition":"A broad-spectrum glycylcycline antibiotic derived from tetracycline. Tigecycline binds to the 30S ribosomal subunit, thereby interfering with the binding of aminoacyl-tRNA to the mRNA-ribosome complex. This prevents the incorporation of amino acid residues into the elongating peptide chain, inhibiting protein synthesis and eventually bacterial cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72F42843-4A90-DE11-E040-BB89AD43432F","latestVersionIndicator":"Yes","beginDate":"2009-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-08-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8C91-18F7-E053-F662850A60B1","beginDate":"2009-09-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ezetimibe/Simvastatin","valueDescription":"Ezetimibe/Simvastatin (Vytorin)","ValueMeaning":{"publicId":"2940079","version":"1","preferredName":"Ezetimibe/Simvastatin (Vytorin)","longName":"2940079","preferredDefinition":"Ezetimibe/Simvastatin","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"739017C2-0E51-0A0F-E040-BB89AD43782F","latestVersionIndicator":"Yes","beginDate":"2009-09-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-09-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8C9B-18F7-E053-F662850A60B1","beginDate":"2009-09-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Oxaliplatin","valueDescription":"Oxaliplatin","ValueMeaning":{"publicId":"2579327","version":"1","preferredName":"Oxaliplatin","longName":"2579327","preferredDefinition":"An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oxaliplatin","conceptCode":"C1181","definition":"An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-02EC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-02","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-02","modifiedBy":"REEVESD","dateModified":"2006-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8CA5-18F7-E053-F662850A60B1","beginDate":"2010-02-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Pramoxine","valueDescription":"Pramocaine","ValueMeaning":{"publicId":"3013053","version":"1","preferredName":"Pramocaine","longName":"3013053","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pramocaine","conceptCode":"C61903","definition":"A morpholine derivative with local anesthetic property. Pramocaine decreases the permeability of the neuronal membrane to sodium ions by reversibly binding to and inhibiting voltage-gated sodium channels. This results in stabilization of the membrane and, thereby inhibiting the ionic fluxes required for membrane depolarization, hence resulting in the failure to initiate a propagated action potential and subsequent conduction blockade.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7FF4D250-992D-4F75-E040-BB89AD434B4C","latestVersionIndicator":"Yes","beginDate":"2010-02-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-02-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8CAF-18F7-E053-F662850A60B1","beginDate":"2010-02-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Azacitidine","valueDescription":"Azacitidine","ValueMeaning":{"publicId":"3013054","version":"1","preferredName":"Azacitidine","longName":"3013054","preferredDefinition":"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity. Azacitidine is incorporated into DNA, where it reversibly inhibits DNA methyltransferase, thereby blocking DNA methylation.  Hypomethylation of DNA by azacitidine may activate tumor suppressor genes silenced by hypermethylation, resulting in an antitumor effect. This agent is also incorporated into RNA, thereby disrupting normal RNA function and impairing tRNA cytosine-5-methyltransferase activity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Azacitidine","conceptCode":"C288","definition":"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity. Azacitidine is incorporated into DNA, where it reversibly inhibits DNA methyltransferase, thereby blocking DNA methylation.  Hypomethylation of DNA by azacitidine may activate tumor suppressor genes silenced by hypermethylation, resulting in an antitumor effect. This agent is also incorporated into RNA, thereby disrupting normal RNA function and impairing tRNA cytosine-5-methyltransferase activity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7FF4D250-9950-4F75-E040-BB89AD434B4C","latestVersionIndicator":"Yes","beginDate":"2010-02-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-02-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8CB9-18F7-E053-F662850A60B1","beginDate":"2010-02-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Desvenlafaxine","valueDescription":"Desvenlafaxine","ValueMeaning":{"publicId":"3021173","version":"1","preferredName":"Desvenlafaxine","longName":"3021173","preferredDefinition":"A synthetic phenethylamine bicyclic derivative with antidepressant activity. Desvenlafaxine is a selective reuptake inhibitor of serotonin and norepinephrine due to its high binding affinities to the pre-synaptic serotonin and norepinephrine transporters. By blocking both transporters, this agent prolongs neurotransmitter activities of both serotonin and norepinephrine, thereby alleviating depressive state.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Desvenlafaxine","conceptCode":"C61703","definition":"A synthetic phenethylamine bicyclic derivative with antidepressant activity. Desvenlafaxine is a selective reuptake inhibitor of serotonin and norepinephrine due to its high binding affinities to the pre-synaptic serotonin and norepinephrine transporters. By blocking both transporters, this agent prolongs neurotransmitter activities of both serotonin and norepinephrine, thereby alleviating depressive state.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"817312F9-5969-37DB-E040-BB89AD437AE8","latestVersionIndicator":"Yes","beginDate":"2010-03-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8CC3-18F7-E053-F662850A60B1","beginDate":"2010-03-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ketotifen Fumarate","valueDescription":"Ketotifen Fumarate","ValueMeaning":{"publicId":"3021175","version":"1","preferredName":"Ketotifen Fumarate","longName":"3021175","preferredDefinition":"The fumarate salt of ketotifen, a cycloheptathiophene derivative with anti-allergic activity. Ketotifen selectively blocks histamine (H1) receptors and prevents the typical symptoms caused by histamine release. This agent also interferes with the release of inflammatory mediators from mast cells involved in hypersensitivity reactions, thereby decreasing chemotaxis and activation of eosinophils.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ketotifen Fumarate","conceptCode":"C47579","definition":"The fumarate salt of ketotifen, a cycloheptathiophene derivative with anti-allergic activity. Ketotifen selectively blocks histamine (H1) receptors and prevents the typical symptoms caused by histamine release. This agent also interferes with the release of inflammatory mediators from mast cells involved in hypersensitivity reactions, thereby decreasing chemotaxis and activation of eosinophils.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"817312F9-598F-37DB-E040-BB89AD437AE8","latestVersionIndicator":"Yes","beginDate":"2010-03-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8CCD-18F7-E053-F662850A60B1","beginDate":"2010-03-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Candida albicans test antigen","valueDescription":"Candida Albicans Skin Test Reagent","ValueMeaning":{"publicId":"3129056","version":"1","preferredName":"Candida Albicans Skin Test Reagent","longName":"3129056","preferredDefinition":"A culture filtrate of cells of Candida Albicans propagated in a chemically defined medium and used as a recall antigen to evaluate cellular immunity in infection, cancer, and other disease states. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Candida Albicans Skin Test Reagent","conceptCode":"C2595","definition":"A culture filtrate of cells of Candida Albicans propagated in a chemically defined medium and used as a recall antigen to evaluate cellular immunity in infection, cancer, and other disease states. (NCI)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF74D29-8E49-8D8B-E040-BB89AD433733","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8CD7-18F7-E053-F662850A60B1","beginDate":"2010-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Becaplermin","valueDescription":"Becaplermin","ValueMeaning":{"publicId":"3129058","version":"1","preferredName":"Becaplermin","longName":"3129058","preferredDefinition":"The recombinant analog of endogenous beta (B) chain of the cytokine platelet-derived growth factor (PDGF).  Synthesized primarily by megakaryocytes, endogenous PDGF consists of two related peptide chains, PDGF-A and PDGF-B.  PDGF functions as a local autocrine and paracrine growth factor in many cellular processes.  Recombinant PDGF, alone and in combination with other agents, may be useful in promoting bone formation and soft tissue repair. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Becaplermin","conceptCode":"C1668","definition":"The recombinant analog of endogenous beta (B) chain of the cytokine platelet-derived growth factor (PDGF).  Synthesized primarily by megakaryocytes, endogenous PDGF consists of two related peptide chains, PDGF-A and PDGF-B.  PDGF functions as a local autocrine and paracrine growth factor in many cellular processes.  Recombinant PDGF, alone and in combination with other agents, may be useful in promoting bone formation and soft tissue repair. (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF74D29-8E6F-8D8B-E040-BB89AD433733","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8CE1-18F7-E053-F662850A60B1","beginDate":"2010-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Bevacizumab","valueDescription":"Bevacizumab","ValueMeaning":{"publicId":"2574306","version":"1","preferredName":"Bevacizumab","longName":"2574306","preferredDefinition":"A monoclonal antibody that may prevent the growth of blood vessels from surrounding tissue to a solid tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bevacizumab","conceptCode":"C2039","definition":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EF4F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-02","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-02","modifiedBy":"ALAIS","dateModified":"2006-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8CEB-18F7-E053-F662850A60B1","beginDate":"2010-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Bimatoprost","valueDescription":"Bimatoprost","ValueMeaning":{"publicId":"3129060","version":"1","preferredName":"Bimatoprost","longName":"3129060","preferredDefinition":"A synthetic prostamide and structural prostaglandin analogue with ocular hypotensive activity. Bimatoprost mimics the effects of the endogenous prostamides and reduces intraocular pressure by increasing outflow of aqueous humor through both the pressure-sensitive outflow pathway (the trabecular meshwork), and the pressure-insensitive outflow pathway (the uveoscleral routes).  It is not clear whether bimatoprost lowers intraocular pressure by stimulating F-Prostanoid receptors or by acting on specific prostamide receptors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bimatoprost","conceptCode":"C47414","definition":"A synthetic prostamide and structural prostaglandin analogue with ocular hypotensive activity. Bimatoprost mimics the effects of the endogenous prostamides and reduces intraocular pressure by increasing outflow of aqueous humor through both the pressure-sensitive outflow pathway (the trabecular meshwork), and the pressure-insensitive outflow pathway (the uveoscleral routes).  It is not clear whether bimatoprost lowers intraocular pressure by stimulating F-Prostanoid receptors or by acting on specific prostamide receptors.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF74D29-8E9F-8D8B-E040-BB89AD433733","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8CF5-18F7-E053-F662850A60B1","beginDate":"2010-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Methylnaltrexone Bromide","valueDescription":"Methylnaltrexone Bromide","ValueMeaning":{"publicId":"2967223","version":"1","preferredName":"Methylnaltrexone Bromide","longName":"2967223","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methylnaltrexone Bromide","conceptCode":"C80569","definition":"The bromide salt form of methylnaltrexone, a methyl derivative of noroxymorphone with selective, peripherally-acting mu-opioid receptor antagonistic activity. Methylnaltrexone displaces opioids from peripheral opioid receptors in the gastrointestinal tract, the bladder, and the skin, thereby reversing the opioid-related peripheral side-effects, such as constipation, urinary retention, and pruritis, respectively. Unlike naltrexone and due to the presence of a positively charged nitrogen atom in methylnaltrexone, this agent does not cross the blood-brain barrier and does not affect the centrally-mediated analgesic effect of opioids.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7AB133FF-983F-BF80-E040-BB89AD43245B","latestVersionIndicator":"Yes","beginDate":"2009-12-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8CFF-18F7-E053-F662850A60B1","beginDate":"2009-12-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Acyclovir","valueDescription":"Acyclovir","ValueMeaning":{"publicId":"2575648","version":"1","preferredName":"Acyclovir","longName":"2575648","preferredDefinition":"A synthetic analog of the purine nucleoside, guanosine, with potent antiviral activity against herpes simplex viruses type 1 and 2, varicella-zoster virus and other viruses.  After conversion in vitro to the active metabolite acyclovir triphosphate, acyclovir competitively inhibits viral DNA polymerase, incorporates into and terminates the growing viral DNA chain, and inactivates viral DNA polymerase. The greater antiviral activity of acyclovir against HSV compared to VZV is due to its more efficient phosphorylation by the thymidine kinase of HSV. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acyclovir","conceptCode":"C205","definition":"A synthetic analog of the purine nucleoside, guanosine, with potent antiviral activity against herpes simplex viruses type 1 and 2, varicella-zoster virus and other viruses of the herpesvirus family. After conversion in vivo to the active metabolite acyclovir triphosphate by viral thymidine kinase, acyclovir competitively inhibits viral DNA polymerase by incorporating into the growing viral DNA chain and terminating further polymerization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F48D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7570-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Acitretin","valueDescription":"Acitretin","ValueMeaning":{"publicId":"2576902","version":"1","preferredName":"Acitretin","longName":"2576902","preferredDefinition":"An orally-active metabolite of the synthetic aromatic retinoic acid agent etretinate with potential antineoplastic, chemopreventive, anti-psoratic, and embryotoxic properties.  Acitretin activates nuclear retinoic acid receptors (RAR), resulting in induction of cell differentiation, inhibition of cell proliferation, and inhibition of tissue infiltration by inflammatory cells.  This agent may also inhibit tumor angiogenesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acitretin","conceptCode":"C985","definition":"An orally-active metabolite of the synthetic aromatic retinoic acid agent etretinate with potential antineoplastic, chemopreventive, anti-psoratic, and embryotoxic properties.  Acitretin activates nuclear retinoic acid receptors (RAR), resulting in induction of cell differentiation, inhibition of cell proliferation, and inhibition of tissue infiltration by inflammatory cells.  This agent may also inhibit tumor angiogenesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F973-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7566-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Adapalene","valueDescription":"Adapalene","ValueMeaning":{"publicId":"2576903","version":"1","preferredName":"Adapalene","longName":"2576903","preferredDefinition":"A topical retinoid-like compound, chemically similar to vitamin A.  Although the exact mechanism of action is unknown, adapalene binds to specific retinoic acid receptors in the nucleus, leading to specific gene expression.  This agent stimulates skin growth through modulation of cellular differentiation, inflammatory processes and keratinization of follicular epithelial cells.  Adapalene may increase dermal sensitivity to ultraviolet radiation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adapalene","conceptCode":"C28989","definition":"A topical retinoid-like compound, chemically similar to vitamin A.  Although the exact mechanism of action is unknown, adapalene binds to specific retinoic acid receptors in the nucleus, leading to specific gene expression.  This agent stimulates skin growth through modulation of cellular differentiation, inflammatory processes and keratinization of follicular epithelial cells.  Adapalene may increase dermal sensitivity to ultraviolet radiation. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F974-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-757A-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Adderall","valueDescription":"Dextroamphetamine-Amphetamine","ValueMeaning":{"publicId":"2576895","version":"1","preferredName":"Dextroamphetamine-Amphetamine","longName":"2576895","preferredDefinition":"A combination of two synthetic agents with central nervous system stimulant activity.  Both agents are non-catecholamine, sympathomimetic agents that elevate blood pressure and cause bronchodilation.  These agents are commonly abused psychostimulant drugs that induce psychologic dependence manifested by elevated mood, increased wakefulness, concentration, physical performance and a feeling of well-being.  Tolerance to various effects develops unequally, so that tachycardia and enhanced alertness diminish while psychotoxic effects (hallucinations and delusions) may occur. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dextroamphetamine-Amphetamine","conceptCode":"C26643","definition":"A combination of two synthetic agents with central nervous system stimulant activity.  Both agents are non-catecholamine, sympathomimetic agents that elevate blood pressure and cause bronchodilation.  These agents are commonly abused psychostimulant drugs that induce psychologic dependence manifested by elevated mood, increased wakefulness, concentration, physical performance and a feeling of well-being.  Tolerance to various effects develops unequally, so that tachycardia and enhanced alertness diminish while psychotoxic effects (hallucinations and delusions) may occur. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F96C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-09","modifiedBy":"ONEDATA","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7584-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Adefovir","valueDescription":"Adefovir Dipivoxil","ValueMeaning":{"publicId":"2576896","version":"1","preferredName":"Adefovir Dipivoxil","longName":"2576896","preferredDefinition":"An acyclic nucleotide adenine analogue with potent antiviral activity. Adefovir is activated in vivo to a diphosphate metabolite which is incorporated into viral DNA, leading to viral RNA-dependent DNA polymerase inhibition, DNA chain termination and impairment of viral replication.  This agent inhibits the reverse transcriptases of hepatitis B, herpes and HIV viruses, induces natural killer cell activity, and stimulates endogenous interferon production.  Viral resistance to adefovir develops at a slower rate compared to other antivirals. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adefovir Dipivoxil","conceptCode":"C28811","definition":"A dipivoxil formulation of adefovir, a nucleoside reverse transcriptase inhibitor analog of adenosine with activity against hepatitis B virus (HBV), herpes virus, and human immunodeficiency virus (HIV).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F96D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-09","modifiedBy":"ONEDATA","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-758E-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Adenosine","valueDescription":"Adenosine","ValueMeaning":{"publicId":"2575575","version":"1","preferredName":"Adenosine","longName":"2575575","preferredDefinition":"A nucleoside that is composed of adenine and d-ribose. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter. (MeSH)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenosine","conceptCode":"C207","definition":"A ribonucleoside comprised of adenine bound to ribose, with vasodilatory, antiarrhythmic and analgesic activities. Phosphorylated forms of adenosine play roles in cellular energy transfer, signal transduction and the synthesis of RNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F444-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-13","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-07-13","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7598-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Albuterol","valueDescription":"Albuterol (Proventil, Ventolin, Volmax)","ValueMeaning":{"publicId":"2575988","version":"1","preferredName":"Albuterol (Proventil, Ventolin, Volmax)","longName":"2575988","preferredDefinition":"A racemic mixture with a 1:1 ratio of the r-isomer, levalbuterol, and s-albuterol. It is a short-acting beta2-adrenergic agonist with its main clinical use in asthma. (MeSH)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Albuterol","conceptCode":"C215","definition":"A racemic mixture of the r-isomer levalbuterol and s-albuterol, a short-acting sympathomimetic agent with bronchodilator activity. Albuterol stimulates beta-2 adrenergic receptors in the lungs, thereby activating the enzyme adenylate cyclase that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increased cAMP concentrations relax bronchial smooth muscle, relieve bronchospasms, and reduce inflammatory cell mediator release, especially from mast cells. Albuterol although to a lesser extent, also stimulates beta-1 adrenergic receptors, thereby increasing the force and rate of myocardial contraction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F5E1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"REEVESD","dateModified":"2010-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-75A2-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Alendronate Sodium","valueDescription":"Alendronate Sodium","ValueMeaning":{"publicId":"2576907","version":"1","preferredName":"Alendronate Sodium","longName":"2576907","preferredDefinition":"A bisphosphonate with increased antiresorption activity (100x-1000x that of etidronate).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alendronate Sodium","conceptCode":"C973","definition":"The sodium salt of alendronate, a second generation bisphosphonate and synthetic analog of pyrophosphate with bone anti-resorption activity. Alendronate sodium binds to and inhibits the activity of geranyltranstransferase (farnesyl pyrophosphate synthetase), an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which is important in the process of osteoclast turnover. As a result, osteoclast activity is inhibited and bone resorption and turnover are reduced.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-75AC-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Alitretinoin","valueDescription":"9-cis-Retinoic Acid","ValueMeaning":{"publicId":"2576904","version":"1","preferredName":"9-cis-Retinoic Acid","longName":"2576904","preferredDefinition":"An orally- and topically-active naturally- occurring retinoic acid agent with antineoplastic and potential chemopreventive, teratogenic, and embryotoxic properties.  9-Cis-retinoic acid binds to nuclear retinoic acid receptors (RAR) and retinoid X receptors (RXR), resulting in inhibition of cell proliferation, induction of cell differentiation, and apoptosis of some tumor cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alitretinoin","conceptCode":"C1574","definition":"An orally- and topically-active naturally-occurring retinoic acid with antineoplastic, chemopreventive, teratogenic, and embryotoxic activities. Alitretinoin binds to and activates nuclear retinoic acid receptors (RAR) and retinoid X receptors (RXR); these activated receptors act as transcription factors, regulating gene expression that results in the inhibition of cell proliferation, induction of cell differentiation, and apoptosis of both normal cells and tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F975-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-09","modifiedBy":"ONEDATA","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-75B6-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Alka Seltzer","valueDescription":"Sodium Bicarbonate/Aspirin/Citric Acid","ValueMeaning":{"publicId":"2576905","version":"1","preferredName":"Sodium Bicarbonate/Aspirin/Citric Acid","longName":"2576905","preferredDefinition":"A combination preparation containing sodium bicarbonate, aspirin and citric acid, with analgesic and acid neutralizing properties. Sodium bicarbonate and citric acid provide rapid dissolution of aspirin in water. Sodium bicarbonate also neutralizes stomach acid. Aspirin, a salicylate, binds to and blocks the activities of cyclooxygenases thereby exerting analgesic, antipyretic and anti-inflammatory effects. This preparation is used to relief pain associated with stomach acid.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sodium Bicarbonate/Aspirin/Citric Acid","conceptCode":"C28867","definition":"A combination preparation containing sodium bicarbonate, aspirin and citric acid, with analgesic and acid neutralizing properties. Sodium bicarbonate and citric acid provide rapid dissolution of aspirin in water. Sodium bicarbonate also neutralizes stomach acid. Aspirin, a salicylate, binds to and blocks the activities of cyclooxygenases thereby exerting analgesic, antipyretic and anti-inflammatory effects. This preparation is used to relief pain associated with stomach acid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F976-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-09","modifiedBy":"TAYLORT","dateModified":"2018-05-15","changeDescription":"5/15/18 tt added concept definition.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-75C0-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Allergy Shot","valueDescription":"Allergy Shot","ValueMeaning":{"publicId":"2575992","version":"1","preferredName":"Allergy Shot","longName":"2575992","preferredDefinition":"The injection of an allergen extract intended to increase resistance, tolerance, or immunity to the given allergens. When the allergen extract is administered in a series of increasing amounts the process is referred to as allergy therapy, immunotherapy or desensitization.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Allergy Shot","conceptCode":"C28814","definition":"The injection of an allergen extract intended to increase resistance, tolerance, or immunity to the given allergens. When the allergen extract is administered in a series of increasing amounts the process is referred to as allergy therapy, immunotherapy or desensitization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F5E5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"TAYLORT","dateModified":"2018-05-15","changeDescription":"5/15/18 tt added concept definition.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-75CA-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Allopurinol","valueDescription":"Allopurinol","ValueMeaning":{"publicId":"2576908","version":"1","preferredName":"Allopurinol","longName":"2576908","preferredDefinition":"A a structural isomer of hypoxanthine. Allopurinol inhibits xanthine oxidase, an enzyme that converts oxypurines to uric acid. By blocking the production of uric acid, this agent decreases serum and urine concentrations of uric acid, thereby providing protection against uric acid-mediated end organ damage in conditions associated with excessive production of uric acid, i.e. the massive cell lysis associated with the treatment of some malignancies. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Allopurinol","conceptCode":"C224","definition":"A structural isomer of hypoxanthine. Allopurinol inhibits xanthine oxidase, an enzyme that converts oxypurines to uric acid. By blocking the production of uric acid, this agent decreases serum and urine concentrations of uric acid, thereby providing protection against uric acid-mediated end organ damage in conditions associated with excessive production of uric acid, i.e. the massive cell lysis associated with the treatment of some malignancies. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F979-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-75D4-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Aloe Vera","valueDescription":"Aloe vera preparation","ValueMeaning":{"publicId":"2576906","version":"1","preferredName":"Aloe vera preparation","longName":"2576906","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aloe vera preparation","conceptCode":"C0995182","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F977-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-09","modifiedBy":"ONEDATA","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-75DE-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Alprazolam","valueDescription":"Alprazolam","ValueMeaning":{"publicId":"2576909","version":"1","preferredName":"Alprazolam","longName":"2576909","preferredDefinition":"A triazolo benzodiazepine agent with antianxiety and sedative-hypnotic activities. The exact mechanism of action is unknown but it affects the limbic, thalamic and hypothalamic regions of the CNS. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alprazolam","conceptCode":"C227","definition":"A triazolobenzodiazepine agent with anxiolytic, sedative-hypnotic and anticonvulsant activities. Alprazolam binds to a specific site distinct from the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) binding site on the benzodiazepine-GABA-A-chloride ionophore receptor complex located in the limbic, thalamic and hypothalamic regions of the central nervous system (CNS). This binding causes an allosteric modification of the receptor and enhances the affinity of GABA to the receptor leading to an increase in the frequency of chloride-channel opening events. This leads to an increase in chloride ion conductance, neuronal hyperpolarization, inhibition of the action potential and leads to a decrease in neuronal excitability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F97A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-75E8-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Alprostadil","valueDescription":"Alprostadil","ValueMeaning":{"publicId":"2576910","version":"1","preferredName":"Alprostadil","longName":"2576910","preferredDefinition":"The naturally occuring prostaglandin E1 (PGE1) which displays a variety of pharmacologic actions.  Alprostadil is a potent vasodilator agent that increases peripheral blood flow, inhibits platelet aggregation, and induces bronchodilation. Used in the treatment of erectile dysfunction, this agent produces corporal smooth muscle relaxation by binding to PGE receptors, resulting in the activation of adenylate cyclase and the subsequent accumulation of 3'5'-cAMP.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alprostadil","conceptCode":"C28816","definition":"The naturally occurring prostaglandin E1 (PGE1) which displays a variety of pharmacologic actions.  Alprostadil is a potent vasodilator agent that increases peripheral blood flow, inhibits platelet aggregation, and induces bronchodilation. Used in the treatment of erectile dysfunction, this agent produces corporal smooth muscle relaxation by binding to PGE receptors, resulting in the activation of adenylate cyclase and the subsequent accumulation of 3'5'-cAMP.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F97B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-75F2-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Alteplase","valueDescription":"Tissue Plasminogen Activator","ValueMeaning":{"publicId":"2576911","version":"1","preferredName":"Tissue Plasminogen Activator","longName":"2576911","preferredDefinition":"Tissue plasminogen activator (PLAT) is a serine protease that activates the proenzyme plasminogen to plasmin, which in turn is responsible for fibrinolytic activity. PLAT is synthesized in vascular endothelial cells as a single polypeptide chain. Proteolytic cleavage of the single chain protein at a centrally located arginine-isoleucine bond by plasmin gives rise to a 2-chain disulfide-linked form, composed of the N-terminally derived heavy chain and the C-terminal light chain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tissue-Type Plasminogen Activator","conceptCode":"C16995","definition":"Tissue-type plasminogen activator (562 aa, ~63 kDa) is encoded by the human PLAT gene. This protein plays a role in the cleavage of plasminogen between Arg-580 and Val-581 to form the fibrinolytic enzyme plasmin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F97C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-09","modifiedBy":"ONEDATA","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-75FC-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Alternative Therapy","valueDescription":"Complementary and Alternative Medicine","ValueMeaning":{"publicId":"2576538","version":"1","preferredName":"Complementary and Alternative Medicine","longName":"2576538","preferredDefinition":"Practices not generally recognized by the medical community as standard or conventional medical approaches and used to replace, enhance or complement standard treatments. Complementary medicine includes dietary supplements, megadose vitamins, herbal preparations, special teas, acupuncture, massage therapy, magnet therapy, spiritual healing, and meditation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complementary and Alternative Medicine","conceptCode":"C15178","definition":"A group of diverse medical and health care systems, practices, and products that are not presently considered to be part of conventional medicine. Complementary medicine as being used together with conventional medicine, whereas alternative medicine is used in place of conventional medicine. The National Center for Complementary and Alternative Medicine (NCCAM) groups CAM practices into four domains, recognizing there can be some overlap: mind-body medicine; biologically based practices, manipulative and body-based practices, and energy medicine. In addition, NCCAM studies CAM whole medical systems, which cut across all domains.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F807-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-12","modifiedBy":"ONEDATA","dateModified":"2005-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7606-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Altretamine","valueDescription":"Hexamethylmelamine (Altretamine)","ValueMeaning":{"publicId":"2576918","version":"1","preferredName":"Hexamethylmelamine (Altretamine)","longName":"2576918","preferredDefinition":"A synthetic cytotoxic s-triazine derivative similar in structure to alkylating agent triethylenemelamin with antineoplastic activity.  Although the precise mechanism by which altretamine exerts its cytotoxic effect is unknown, N-demethylation of altretamine may produce reactive intermediates which covalently bind to DNA, resulting in DNA damage. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Altretamine","conceptCode":"C544","definition":"A synthetic cytotoxic s-triazine derivative similar in structure to alkylating agent triethylenemelamin with antineoplastic activity.  Although the precise mechanism by which altretamine exerts its cytotoxic effect is unknown, N-demethylation of altretamine may produce reactive intermediates which covalently bind to DNA, resulting in DNA damage. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F983-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"REEVESD","dateModified":"2012-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7610-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Aluminum Hydroxide","valueDescription":"Aluminum Hydroxide","ValueMeaning":{"publicId":"2575995","version":"1","preferredName":"Aluminum Hydroxide","longName":"2575995","preferredDefinition":"An inorganic compound containing aluminium.  Used in various immunologic preparations to improve immunogenicity, aluminum hydroxide adjuvant consists of aluminium hydroxide gel in a saline solution.  In vaccines, this agent binds to the protein conjugate, resulting in improved antigen processing by the immune system. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aluminum Hydroxide","conceptCode":"C39707","definition":"An inorganic compound containing aluminum.  Used in various immunologic preparations to improve immunogenicity, aluminum hydroxide adjuvant consists of aluminum hydroxide gel in a saline solution.  In vaccines, this agent binds to the protein conjugate, resulting in improved antigen processing by the immune system. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F5E8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-761A-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Aluminum Magnesium","valueDescription":"Aluminum Magnesium","ValueMeaning":{"publicId":"2576919","version":"1","preferredName":"Aluminum Magnesium","longName":"2576919","preferredDefinition":"A salt or hydroxide mixture of aluminium and magnesium metals used as an antacid, Aluminum Magnesium absorbs and neutralizes stomach acid, helping to relieve intermittent, infrequent heartburn and indigestion. Aluminium and magnesium antiacids may be used to treat symptoms of peptic ulcer, gastritis, esophagitis, hiatal hernia and gastric hyperacidity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aluminum Magnesium","conceptCode":"C28817","definition":"A salt or hydroxide mixture of aluminum and magnesium metals used as an antacid, aluminum magnesium absorbs and neutralizes stomach acid, helping to relieve intermittent, infrequent heartburn and indigestion. Aluminum and magnesium antiacids may be used to treat symptoms of peptic ulcer, gastritis, esophagitis, hiatal hernia and gastric hyperacidity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F984-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7624-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Amantadine HCL","valueDescription":"Amantadine Hydrochloride","ValueMeaning":{"publicId":"2575650","version":"1","preferredName":"Amantadine Hydrochloride","longName":"2575650","preferredDefinition":"The hydrochloride salt of amantadine, a synthetic tricyclic amine with antiviral, antiparkinsonian, and antihyperalgesic activities. Amantadine appears to exert its antiviral effect against the influenza A virus by interfering with the function of the transmembrane domain of the viral M2 protein, thereby preventing the release of infectious viral nucleic acids into host cells; furthermore, this agent prevents virus assembly during virus replication. Amantadine exerts its antiparkinsonian effects by stimulating the release of dopamine from striatal dopaminergic nerve terminals and inhibiting its pre-synaptic reuptake. This agent may also exert some anticholinergic effect through inhibition of N-methyl-D-aspartic acid (NMDA) receptor-mediated stimulation of acetylcholine, resulting in antihyperalgesia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amantadine Hydrochloride","conceptCode":"C28818","definition":"The hydrochloride salt of amantadine, a synthetic tricyclic amine with antiviral, antiparkinsonian, and antihyperalgesic activities. Amantadine appears to exert its antiviral effect against the influenza A virus by interfering with the function of the transmembrane domain of the viral M2 protein, thereby preventing the release of infectious viral nucleic acids into host cells; furthermore, this agent prevents virus assembly during virus replication. Amantadine exerts its antiparkinsonian effects by stimulating the release of dopamine from striatal dopaminergic nerve terminals and inhibiting its pre-synaptic reuptake. This agent may also exert some anticholinergic effect through inhibition of N-methyl-D-aspartic acid (NMDA) receptor-mediated stimulation of acetylcholine, resulting in antihyperalgesia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F48F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"TAYLORT","dateModified":"2018-05-15","changeDescription":"5/15/18 tt added concept definition.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-762E-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Amikacin","valueDescription":"Amikacin Sulfate","ValueMeaning":{"publicId":"2576912","version":"1","preferredName":"Amikacin Sulfate","longName":"2576912","preferredDefinition":"A broad-spectrum antibiotic derived from kanamycin. It is reno- and ototoxic like the other aminoglycoside antibiotics. (MeSH)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amikacin Sulfate","conceptCode":"C230","definition":"The sulfate salt of amikacin, a broad-spectrum semi-synthetic aminoglycoside antibiotic, derived from kanamycin with antimicrobial property. Amikacin irreversibly binds to the bacterial 30S ribosomal subunit, specifically in contact with 16S rRNA and S12 protein within the 30S subunit. This leads to interference with translational initiation complex and misreading of mRNA, thereby hampering protein synthesis and resulting in bactericidal effect. This agent is usually used in short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F97D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-09","modifiedBy":"ONEDATA","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7638-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Amiloride","valueDescription":"Amiloride","ValueMeaning":{"publicId":"2576920","version":"1","preferredName":"Amiloride","longName":"2576920","preferredDefinition":"A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with diuretics to spare potassium loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amiloride","conceptCode":"C0002502","definition":"A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with diuretics to spare potassium loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705)","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F985-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7642-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Aminoglutethimide","valueDescription":"Aminoglutethimide","ValueMeaning":{"publicId":"2576921","version":"1","preferredName":"Aminoglutethimide","longName":"2576921","preferredDefinition":"A synthetic derivative of the sedative and anticonvulsant glutethimide with anti-steroid properties.  Originally used as an anticonvulsant, aminoglutethimide also blocks adrenal steroidogenesis by inhibiting the enzymatic conversion of cholesterol to pregnenolone.  In addition, this agent blocks the peripheral aromatization of androgenic precursors to estrogens.  Aminoglutethimide does not suppress ovarian estrogen production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aminoglutethimide","conceptCode":"C233","definition":"A synthetic derivative of the sedative and anticonvulsant glutethimide with anti-steroid properties.  Originally used as an anticonvulsant, aminoglutethimide also blocks adrenal steroidogenesis by inhibiting the enzymatic conversion of cholesterol to pregnenolone.  In addition, this agent blocks the peripheral aromatization of androgenic precursors to estrogens.  Aminoglutethimide does not suppress ovarian estrogen production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F986-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-764C-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Amiodarone","valueDescription":"Amiodarone Hydrochloride","ValueMeaning":{"publicId":"2576913","version":"1","preferredName":"Amiodarone Hydrochloride","longName":"2576913","preferredDefinition":"An iodine-rich benzofuran derivative with antianginal and antiarrhythmic activity.  Amiodarone blocks the calcium, potassium and sodium channels, resulting in prolonged cardiac action potential and refracatory period.  In addition, amiodarone exerts a noncompetitive alpha- and beta-adrenergic inhibition which is partially responsible for the negative dromotropic effects. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amiodarone Hydrochloride","conceptCode":"C236","definition":"The hydrochloride salt of an iodine-rich benzofuran derivative with antiarrhythmic and vasodilatory activities. As a class III antiarrhythmic agent, amiodarone blocks the myocardial calcium, potassium and sodium channels in cardiac tissue, resulting in prolongation of the cardiac action potential and refractory period. In addition, this agent inhibits alpha- and beta-adrenergic receptors, resulting in a reduction in sympathetic stimulation of the heart, a negative chronotropic effect, and a decrease in myocardial oxygen demands. Amiodarone may cause vasodilation by stimulation of the release of nitric oxide and cyclooxygenase-dependent relaxing endothelial factors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F97E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-09","modifiedBy":"ONEDATA","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7656-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Amisulpride","valueDescription":"Amisulpride","ValueMeaning":{"publicId":"2576000","version":"1","preferredName":"Amisulpride","longName":"2576000","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"amisulpride","conceptCode":"C0103045","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F5ED-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7660-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Amitriptyline","valueDescription":"Amitriptyline Hydrochloride","ValueMeaning":{"publicId":"2576914","version":"1","preferredName":"Amitriptyline Hydrochloride","longName":"2576914","preferredDefinition":"The hydrochloride salt of the tricyclic dibenzocycloheptadiene amitriptyline with antidepressant and antinociceptive activities. Amitriptyline inhibits the re-uptake of norepinephrine and serotonin by the presynaptic neuronal membrane in the central nervous system (CNS), thereby increasing the synaptic concentration of norepinephrine and serotonin. Due to constant stimulation to these receptors, amitriptyline may produce a downregulation of adrenergic and serotonin receptors, which may contribute to the antidepressant activity. In the CNS the antinociceptive activity of this agent may involve high affinity binding to and inhibition of N-methyl-D-aspartate (NMDA) receptors and/or the enhancement of the action of serotonin at the spinal terminals of an opioid-mediated intrinsic analgesia system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amitriptyline Hydrochloride","conceptCode":"C28819","definition":"The hydrochloride salt of the tricyclic dibenzocycloheptadiene amitriptyline with antidepressant and antinociceptive activities. Amitriptyline inhibits the re-uptake of norepinephrine and serotonin by the presynaptic neuronal membrane in the central nervous system (CNS), thereby increasing the synaptic concentration of norepinephrine and serotonin. Due to constant stimulation to these receptors, amitriptyline may produce a downregulation of adrenergic and serotonin receptors, which may contribute to the antidepressant activity. In the CNS the antinociceptive activity of this agent may involve high affinity binding to and inhibition of N-methyl-D-aspartate (NMDA) receptors and/or the enhancement of the action of serotonin at the spinal terminals of an opioid-mediated intrinsic analgesia system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F97F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-09","modifiedBy":"TAYLORT","dateModified":"2018-05-15","changeDescription":"5/15/18 tt added concept definition.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-766A-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Amlodipine Besylate","valueDescription":"Amlodipine Besylate","ValueMeaning":{"publicId":"2576922","version":"1","preferredName":"Amlodipine Besylate","longName":"2576922","preferredDefinition":"A dihydropyridine calcium channel blocking agent. Amlodipine besylate inhibits the influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility.  This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in some multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. Amlodipine besylate exhibits a longer half-life in vivo compared to other dihydropyridine calcium channel blocking agents. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amlodipine Besylate","conceptCode":"C28820","definition":"The besylate salt of amlodipine, a synthetic dihydropyridine with antihypertensive and antianginal effects. Amlodipine inhibits the influx of extracellular calcium ions into myocardial and peripheral vascular smooth muscle cells, thereby preventing vascular and myocardial contraction. This results in a dilatation of the main coronary and systemic arteries, decreased myocardial contractility, increased blood flow and oxygen delivery to the myocardial tissue, and decreased total peripheral resistance. This agent may also modulate multi-drug resistance (MDR) activity through inhibition of the p-glycoprotein efflux pump.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F987-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7674-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ammonium lactate","valueDescription":"Ammonium lactate","ValueMeaning":{"publicId":"2576923","version":"1","preferredName":"Ammonium lactate","longName":"2576923","preferredDefinition":"An organic salt of ammonium (lactic acid neutralized with ammonium hydroxide), topical moisturizing Ammonium Lactate can be applied as a humectant in ichthyosis vulgaris and xerosis. Available as cream or lotion, this agent moisturizes the skin and breaks up the scales. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ammonium Lactate","conceptCode":"C28821","definition":"An organic salt of ammonium (lactic acid neutralized with ammonium hydroxide), topical moisturizing Ammonium Lactate can be applied as a humectant in ichthyosis vulgaris and xerosis. Available as cream or lotion, this agent moisturizes the skin and breaks up the scales. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F988-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-767E-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Amoxicillin","valueDescription":"Amoxicillin","ValueMeaning":{"publicId":"2576924","version":"1","preferredName":"Amoxicillin","longName":"2576924","preferredDefinition":"A broad-spectrum semisynthetic antibiotic, similar to ampicillin but more resistance to gastric acids, that inhibits bacterial cell wall synthesis by binding to penicillin binding proteins and inhibiting peptidoglycan synthesis, a critical component of bacterial cell walls. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amoxicillin","conceptCode":"C237","definition":"A broad-spectrum, semisynthetic aminopenicillin antibiotic with bactericidal activity. Amoxicillin binds to and inactivates penicillin-binding protein (PBP) 1A located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall and causes cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F989-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7688-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Amoxicillin/Clavulonate Potassium","valueDescription":"Amoxicillin-Clavulanate Potassium","ValueMeaning":{"publicId":"2576915","version":"1","preferredName":"Amoxicillin-Clavulanate Potassium","longName":"2576915","preferredDefinition":"A fixed-ratio combination of amoxicillin trihydrate (see AMOXICILLIN), an aminopenicillin, and potassium clavulanate (see CLAVULANIC ACID), a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amoxicillin-Clavulanate Potassium","conceptCode":"C0054066","definition":"A fixed-ratio combination of amoxicillin trihydrate (see AMOXICILLIN), an aminopenicillin, and potassium clavulanate (see CLAVULANIC ACID), a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F980-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-09","modifiedBy":"ONEDATA","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7692-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Albumin","valueDescription":"ALBUMIN","ValueMeaning":{"publicId":"2561870","version":"1","preferredName":"ALBUMIN","longName":"2561870","preferredDefinition":"ALBUMIN","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Albumin","conceptCode":"C214","definition":"A family of globular proteins found in many plant and animal tissues that tend to bind a wide variety of ligands.  Albumin is the main protein in blood plasma.  Low serum levels occur in conditions associated with malnutrition, inflammation and liver and kidney diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BEBB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-22","endDate":null,"createdBy":"JASUR","dateCreated":"2002-07-22","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-769C-18F7-E053-F662850A60B1","beginDate":"2005-08-24","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Amphetamine","valueDescription":"Amphetamine Sulfate","ValueMeaning":{"publicId":"2576916","version":"1","preferredName":"Amphetamine Sulfate","longName":"2576916","preferredDefinition":"A synthetic substance related to natural sympathomimetic amines. Amphetamine appears to exert its central nervous system (CNS) and peripheral effects indirectly by inducing the release of biogenic amines from their storage sites in nerve terminals. This agent is a commonly abused psychostimulant drug, which may be snorted, taken orally, smoked, or injected.  Amphetamine induces psychologic dependence which is manifested by elevated mood, increased wakefulness, concentration, physical performance and a feeling of well-being. With sustained use, the effects of tachycardia and enhanced alertness diminish while psychotoxic effects such as hallucinations and delusions may occur. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amphetamine Sulfate","conceptCode":"C28822","definition":"The sulfate salt form of amphetamine, a synthetic substance related to natural sympathomimetic amines. Amphetamine appears to exert its central nervous system (CNS) and peripheral effects indirectly by inducing the release of biogenic amines from their storage sites in nerve terminals. This agent is a commonly abused psychostimulant drug, which may be snorted, taken orally, smoked, or injected.  Amphetamine induces psychologic dependence which is manifested by elevated mood, increased wakefulness, concentration, physical performance and a feeling of well-being. With sustained use, the effects of tachycardia and enhanced alertness diminish while psychotoxic effects such as hallucinations and delusions may occur. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F981-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-09","modifiedBy":"ONEDATA","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-76A6-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Benzoyl Peroxide","valueDescription":"Benzoyl Peroxide","ValueMeaning":{"publicId":"3082304","version":"1","preferredName":"Benzoyl Peroxide","longName":"3082304","preferredDefinition":"A peroxide with antibacterial, irritant, keratolytic, comedolytic, and anti-inflammatory activity. Upon topical application, benzoyl peroxide decomposes to release oxygen which is lethal to the bacteria Proprionibacterium acnes. Due to its irritant effect, benzoyl peroxide increases turnover rate of epithelial cells, thereby peeling the skin and promoting the resolution of comedones. Benzoyl peroxide is used in the treatment of acne vulgaris.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benzoyl Peroxide","conceptCode":"C47411","definition":"A peroxide with antibacterial, irritant, keratolytic, comedolytic, and anti-inflammatory activity. Upon topical application, benzoyl peroxide decomposes to release oxygen which is lethal to the bacteria Proprionibacterium acnes. Due to its irritant effect, benzoyl peroxide increases turnover rate of epithelial cells, thereby peeling the skin and promoting the resolution of comedones. Benzoyl peroxide is used in the treatment of acne vulgaris.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"85DFCF3B-F5DD-0FA4-E040-BB89AD43119F","latestVersionIndicator":"Yes","beginDate":"2010-05-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-05-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8D09-18F7-E053-F662850A60B1","beginDate":"2010-05-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Omega-3-6-9","valueDescription":"Omega-3-6-9 Fatty Acid","ValueMeaning":{"publicId":"3084630","version":"1","preferredName":"Omega-3-6-9 Fatty Acid","longName":"3084630","preferredDefinition":"Omega-3-6-9 Fatty Acid","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"864493CC-B971-B703-E040-BB89AD4320FB","latestVersionIndicator":"Yes","beginDate":"2010-05-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-05-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8D13-18F7-E053-F662850A60B1","beginDate":"2010-05-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Omega-9","valueDescription":"Omega-9 Fatty Acid","ValueMeaning":{"publicId":"3084631","version":"1","preferredName":"Omega-9 Fatty Acid","longName":"3084631","preferredDefinition":"Omega-9 Fatty Acid","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"864493CC-B994-B703-E040-BB89AD4320FB","latestVersionIndicator":"Yes","beginDate":"2010-05-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-05-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8D1D-18F7-E053-F662850A60B1","beginDate":"2010-05-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Omega-3","valueDescription":"Omega-3 Fatty Acid","ValueMeaning":{"publicId":"3084633","version":"1","preferredName":"Omega-3 Fatty Acid","longName":"3084633","preferredDefinition":"Any fatty acid that contains an unsaturated bond originating from the 3rd carbon from the methyl end. Omega-3 fatty acids do not occur naturally with chain lengths shorter than 16 carbon units.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Omega-3 Fatty Acid","conceptCode":"C493","definition":"Any fatty acid that contains an unsaturated bond originating from the 3rd carbon from the methyl end. Omega-3 fatty acids do not occur naturally with chain lengths shorter than 16 carbon units.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"864493CC-B9BA-B703-E040-BB89AD4320FB","latestVersionIndicator":"Yes","beginDate":"2010-05-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-05-10","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8D27-18F7-E053-F662850A60B1","beginDate":"2010-05-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Omega-6","valueDescription":"Omega-6 Fatty Acid","ValueMeaning":{"publicId":"3084635","version":"1","preferredName":"Omega-6 Fatty Acid","longName":"3084635","preferredDefinition":"Essential fatty acids obtained from food sources that are necessary for normal biological functions, as well as growth and development.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Omega-6 Fatty Acid","conceptCode":"C2563","definition":"Essential fatty acids obtained from food sources that are necessary for normal biological functions, as well as growth and development.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"864493CC-B9E0-B703-E040-BB89AD4320FB","latestVersionIndicator":"Yes","beginDate":"2010-05-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-05-10","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8D31-18F7-E053-F662850A60B1","beginDate":"2010-05-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Guanfacine","valueDescription":"Guanfacine","ValueMeaning":{"publicId":"3089822","version":"1","preferredName":"Guanfacine","longName":"3089822","preferredDefinition":"A centrally acting adrenergic agonist with non-stimulant and antihypertensive property. Guanfacine selectively stimulates alpha-2 adrenergic receptors in the central nervous system, thereby resulting in inhibition of sympathetic nervous system outflow. Used alone or in combination with other drugs, this agent causes reduction of peripheral and renal vascular resistance, and lowers both systolic and diastolic blood pressure and heart rate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Guanfacine","conceptCode":"C61779","definition":"A centrally acting adrenergic agonist with non-stimulant and antihypertensive property. Guanfacine selectively stimulates alpha-2 adrenergic receptors in the central nervous system, thereby resulting in inhibition of sympathetic nervous system outflow. Used alone or in combination with other drugs, this agent causes reduction of peripheral and renal vascular resistance, and lowers both systolic and diastolic blood pressure and heart rate.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87081A39-D875-A8DE-E040-BB89AD43310A","latestVersionIndicator":"Yes","beginDate":"2010-05-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-05-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8D3B-18F7-E053-F662850A60B1","beginDate":"2010-05-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Minoxidil","valueDescription":"Minoxidil","ValueMeaning":{"publicId":"3128718","version":"1","preferredName":"Minoxidil","longName":"3128718","preferredDefinition":"An orally administered vasodilator with hair growth stimulatory and antihypertensive effects. Minoxidil is converted into its active metabolite minoxidil sulphate by sulphotransferase enzymes. Minoxidil sulphate exerts its antihypertensive effect by opening of plasma membrane adenosine triphosphate (ATP)-sensitive potassium channels (KATP channels), thereby directly and rapidly relaxing arteriolar smooth muscle and subsequent reduction of elevated systolic and diastolic blood pressure by decreasing peripheral vascular resistance. This agent's hair growth stimulatory effect may be mediated through its vasodilatory activity, thereby increasing cutaneous blood flow, or due to its direct stimulatory effect on hair follicle cells and forcing them from their resting phase into their active growth phase.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Minoxidil","conceptCode":"C47623","definition":"An orally administered vasodilator with hair growth stimulatory and antihypertensive effects. Minoxidil is converted into its active metabolite minoxidil sulphate by sulphotransferase enzymes. Minoxidil sulphate exerts its antihypertensive effect by opening of plasma membrane adenosine triphosphate (ATP)-sensitive potassium channels (KATP channels), thereby directly and rapidly relaxing arteriolar smooth muscle and subsequent reduction of elevated systolic and diastolic blood pressure by decreasing peripheral vascular resistance. This agent's hair growth stimulatory effect may be mediated through its vasodilatory activity, thereby increasing cutaneous blood flow, or due to its direct stimulatory effect on hair follicle cells and forcing them from their resting phase into their active growth phase.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1661F-BE1D-44DA-E040-BB89AD43109F","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8D45-18F7-E053-F662850A60B1","beginDate":"2010-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Aluminum Sulfate","valueDescription":"Aluminum Sulfate","ValueMeaning":{"publicId":"3128721","version":"1","preferredName":"Aluminum Sulfate","longName":"3128721","preferredDefinition":"An aluminum salt of sulfuric acid, an industrial chemical used in many industrial applications. In purification of drinking water, aluminum sulfate acts as a flocculating agent which causes impurities to coagulate and sediment, so that they are easily removed by filtration. It is also used as a mordant in textile dyeing and paper manufacture.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aluminum Sulfate","conceptCode":"C75770","definition":"An aluminum salt of sulfuric acid, an industrial chemical used in many industrial applications. In purification of drinking water, aluminum sulfate acts as a flocculating agent which causes impurities to coagulate and sediment, so that they are easily removed by filtration. It is also used as a mordant in textile dyeing and paper manufacture.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1661F-BE6B-44DA-E040-BB89AD43109F","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"TAYLORT","dateModified":"2018-05-15","changeDescription":"5/15/18 tt added concept definition.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8D4F-18F7-E053-F662850A60B1","beginDate":"2010-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Alosetron HCL (Lotronex)","valueDescription":"Alosetron","ValueMeaning":{"publicId":"3128723","version":"1","preferredName":"Alosetron","longName":"3128723","preferredDefinition":"A potent and selective 5-HT3 receptor antagonist. Alosetron blocks the actions of serotonin at 5-HT3 sites in the peripheral nervous system, particularly on enteric and nociceptive sensory neurons, thereby affecting the regulation of visceral pain, decreasing gastrointestinal contraction and motility, and decreasing gastrointestinal secretions. This agent is used to treat diarrhea-predominant irritable bowel syndrome in women.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alosetron","conceptCode":"C73100","definition":"A potent and selective 5-HT3 receptor antagonist. Alosetron blocks the actions of serotonin at 5-HT3 sites in the peripheral nervous system, particularly on enteric and nociceptive sensory neurons, thereby affecting the regulation of visceral pain, decreasing gastrointestinal contraction and motility, and decreasing gastrointestinal secretions. This agent is used to treat diarrhea-predominant irritable bowel syndrome in women.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1661F-BE91-44DA-E040-BB89AD43109F","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"TAYLORT","dateModified":"2018-05-15","changeDescription":"5/15/18 tt added concept definition.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8D59-18F7-E053-F662850A60B1","beginDate":"2010-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Alfuzosin HCL","valueDescription":"Alfuzosin","ValueMeaning":{"publicId":"3128725","version":"1","preferredName":"Alfuzosin","longName":"3128725","preferredDefinition":"A synthetic quinazoline compound with smooth muscle relaxing activity. Alfuzosin selectively binds to and antagonizes alpha-1-adrenergic receptors in smooth muscle of the bladder neck and prostate, thereby relaxing the smooth muscle and decreasing the obstruction and urethral resistance seen with benign prostate hyperplasia (BPH) and prostate cancer. This agent also blocks alpha-1-adrenergic receptors in peripheral vascular smooth muscle, which leads to vasodilatation and a subsequent decrease in peripheral vascular resistance.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alfuzosin","conceptCode":"C61627","definition":"A synthetic quinazoline compound with smooth muscle relaxing activity. Alfuzosin selectively binds to and antagonizes alpha-1-adrenergic receptors in smooth muscle of the bladder neck and prostate, thereby relaxing the smooth muscle and decreasing the obstruction and urethral resistance seen with benign prostate hyperplasia (BPH) and prostate cancer. This agent also blocks alpha-1-adrenergic receptors in peripheral vascular smooth muscle, which leads to vasodilatation and a subsequent decrease in peripheral vascular resistance.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1661F-BEB7-44DA-E040-BB89AD43109F","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8D63-18F7-E053-F662850A60B1","beginDate":"2010-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Acetylcysteine","valueDescription":"Acetylcysteine","ValueMeaning":{"publicId":"3128727","version":"1","preferredName":"Acetylcysteine","longName":"3128727","preferredDefinition":"A synthetic N-acetyl derivative of the endogenous amino acid L-cysteine, a precursor of the antioxidant enzyme glutathione.  Acetylcysteine regenerates liver stores of glutathione. This agent also reduces disulfide bonds in mucoproteins, resulting in liquification of mucus.  Some evidence suggests that acetylcysteine may exert an anti-apoptotic effect due to its antioxidant activity, possibly preventing cancer cell development or growth.  In addition, acetylcysteine has inhibited viral stimulation by reactive oxygen intermediates, thereby producing antiviral activity in HIV patients. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acetylcysteine","conceptCode":"C200","definition":"A synthetic N-acetyl derivative and prodrug of the endogenous amino acid L-cysteine, a precursor of the antioxidant glutathione (GSH), with mucolytic, antioxidant, and potential cytoprotective, cancer-preventive, and anti-inflammatory activities.  Upon administration, acetylcysteine exerts its mucolytic activity by reducing disulfide bonds in mucoproteins, resulting in liquification of mucus and reducing its viscosity. It is also used for the treatment of acetaminophen overdose as it can restore the depleted GSH reserves in the hepatocytes during the process of detoxification.  The antioxidant activity is attributed to the ability of GSH to scavenge reactive oxygen species (ROS), thereby preventing ROS-mediated cell damage, decreasing oxidative stress, protecting cells against the damaging effects of free radicals and preventing apoptosis in these cells. In addition, this may inhibit tumor cell proliferation, progression and survival, in susceptible tumor cells that rely on ROS-mediated signaling for their proliferation and malignant behavior. Under certain circumstances, acetylcysteine is able to induce apoptosis in susceptible cells, including certain tumor cells, via the intrinsic mitochondria-dependent pathway but not involving endoplasmic reticulum stress. Also, acetylcysteine may also be able to degrade Notch2, thereby preventing proliferation, migration, and invasion in Notch2-overexpressing glioblastoma cells. In addition, acetylcysteine may inhibit viral stimulation by reactive oxygen intermediates, thereby producing antiviral activity in HIV patients. Acetylcysteine also possesses anti-inflammatory activity through modulation of the nuclear factor-kappa B (NF-kB) pathway and the modulation of cytokine synthesis.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1661F-BEDD-44DA-E040-BB89AD43109F","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8D6D-18F7-E053-F662850A60B1","beginDate":"2010-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Acepromazine","valueDescription":"Acepromazine","ValueMeaning":{"publicId":"3128729","version":"1","preferredName":"Acepromazine","longName":"3128729","preferredDefinition":"A phenothiazine derivative with depressant effect on the central nervous system. Acepromazine acts as a dopamine receptor antagonist in the CNS, thereby causing sedation, muscular relaxation and a reduction in spontaneous activity. Its fast-acting neuroleptic effect with low toxicity is of particular value in veterinary medicine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acepromazine","conceptCode":"C77568","definition":"A phenothiazine derivative with depressant effect on the central nervous system. Acepromazine acts as a dopamine receptor antagonist in the CNS, thereby causing sedation, muscular relaxation and a reduction in spontaneous activity. Its fast-acting neuroleptic effect with low toxicity is of particular value in veterinary medicine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1661F-BF03-44DA-E040-BB89AD43109F","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"TAYLORT","dateModified":"2018-05-15","changeDescription":"5/15/18 tt added concept definition.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8D77-18F7-E053-F662850A60B1","beginDate":"2010-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"5-Fluorouracil","valueDescription":"Fluorouracil","ValueMeaning":{"publicId":"2561703","version":"1","preferredName":"Fluorouracil","longName":"2561703","preferredDefinition":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity.  Fluorouracil and its metabolites possess a number of different mechanisms of action.  In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth.  Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), a necessary constituent of DNA.  Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both the processing and functions of RNA. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluorouracil","conceptCode":"C505","definition":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BE14-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-08","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-08","modifiedBy":"REEVESD","dateModified":"2009-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8D81-18F7-E053-F662850A60B1","beginDate":"2010-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Venlafaxine HCL","valueDescription":"Venlafaxine","ValueMeaning":{"publicId":"3128731","version":"1","preferredName":"Venlafaxine","longName":"3128731","preferredDefinition":"A synthetic phenethylamine bicyclic derivative with antidepressant activity. Venlafaxine and its active metabolite, O-desmethylvenlafaxine (ODV), are potent inhibitors of neuronal serotonin and norepinephrine reuptake and weak dopamine reuptake inhibitors.  This agent may reduce hormone-related vasomotor symptoms. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Venlafaxine","conceptCode":"C1278","definition":"A synthetic phenethylamine bicyclic derivative with antidepressant activity. Venlafaxine and its active metabolite, O-desmethylvenlafaxine (ODV), are potent inhibitors of neuronal serotonin and norepinephrine reuptake and weak dopamine reuptake inhibitors.  This agent may reduce hormone-related vasomotor symptoms. (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1D25C-1D7F-C451-E040-BB89AD4301E4","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8D8B-18F7-E053-F662850A60B1","beginDate":"2010-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Vasopressin","valueDescription":"Vasopressin","ValueMeaning":{"publicId":"3128733","version":"1","preferredName":"Vasopressin","longName":"3128733","preferredDefinition":"This protein is processed from a precursor protein consisting of arginine vasopressin and two associated proteins, neurophysin II and a glycopeptide, copeptin. Arginine vasopressin is a posterior pituitary hormone which is synthesized in the supraoptic nucleus and paraventricular nucleus of the hypothalamus. Along with its carrier protein, neurophysin II, it is packaged into neurosecretory vesicles and transported axonally to the nerve endings in the neurohypophysis where it is either stored or secreted into the bloodstream. It has a direct antidiuretic action on the kidney, and also causes vasoconstriction of the peripheral vessels. This hormone can contract smooth muscle during parturition and lactation. It is also involved in cognition, tolerance, adaptation and complex sexual and maternal behaviour, as well as in the regulation of water excretion and cardiovascular functions. (LocusLink)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Arginine-Vasopressin","conceptCode":"C2285","definition":"Arginine-vasopressin (9 aa, ~1 kDa) is encoded by the human AVP gene. This protein is involved in peripheral blood vessel vasoconstriction and antidiuretic action in the kidney.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1D25C-1DA5-C451-E040-BB89AD4301E4","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8D95-18F7-E053-F662850A60B1","beginDate":"2010-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Verapamil","valueDescription":"Verapamil","ValueMeaning":{"publicId":"3128735","version":"1","preferredName":"Verapamil","longName":"3128735","preferredDefinition":"A phenylalkylamine calcium channel blocking agent. Verapamil inhibits the transmembrane influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility.  This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in some multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Verapamil","conceptCode":"C928","definition":"A phenylalkylamine calcium channel blocking agent. Verapamil inhibits the transmembrane influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility.  This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in some multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1D25C-1DCB-C451-E040-BB89AD4301E4","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8D9F-18F7-E053-F662850A60B1","beginDate":"2010-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Vitamin B Complex","valueDescription":"Vitamin B Complex","ValueMeaning":{"publicId":"3128737","version":"1","preferredName":"Vitamin B Complex","longName":"3128737","preferredDefinition":"A compound containing several or all of the B-vitamins, including thiamine, riboflavin, niacin (nicotinic acid), niacinamide (nicotinamide), the vitamin B6 group (including pyridoxine, pyridoxal, pyridoxamine), biotin, pantothenic acid, folic acid, possibly para-aminobenzoic.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vitamin B Complex","conceptCode":"C940","definition":"A compound containing several or all of the B-vitamins, including thiamine, riboflavin, niacin (nicotinic acid), niacinamide (nicotinamide), the vitamin B6 group (including pyridoxine, pyridoxal, pyridoxamine), biotin, pantothenic acid, folic acid, possibly para-aminobenzoic.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1D25C-1DF1-C451-E040-BB89AD4301E4","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8DA9-18F7-E053-F662850A60B1","beginDate":"2010-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Vitamin D","valueDescription":"Vitamin D","ValueMeaning":{"publicId":"3128738","version":"1","preferredName":"Vitamin D","longName":"3128738","preferredDefinition":"Vitamin D. The vitamin that mediates intestinal calcium absorption, bone calcium metabolism, and probably muscle activity. It usually acts as a hormone precursor, requiring 2 stages of metabolism before reaching actual hormonal form. It is isolated from fish liver oils and used in the treatment and prevention of rickets.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"D Vitamin","conceptCode":"C941","definition":"A family of lipo-soluble steroids important to the absorption, metabolism, and function of calcium and phosphorus and the growth and development of bone and tooth enamel. Found naturally in animal tissues, cholecalciferol (vitamin D3) is formed in the skin when ultraviolet light activates cholesterol conversion into vitamin D3. Ultraviolet irradiation of ergosterol (plant vitamin D) forms ergocalciferol (vitamin D2). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1D25C-1E16-C451-E040-BB89AD4301E4","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8DB3-18F7-E053-F662850A60B1","beginDate":"2010-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Voriconazole","valueDescription":"Voriconazole","ValueMeaning":{"publicId":"2575726","version":"1","preferredName":"Voriconazole","longName":"2575726","preferredDefinition":"A synthetic triazole with antifungal activity. Voriconazole selectively inhibits 14-alpha-lanosterol demethylation in fungi, preventing the production of ergosterol, an essential constituent of the fungal cell membrane, and resulting in fungal cell lysis. (NCI04).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Voriconazole","conceptCode":"C1707","definition":"A synthetic triazole with antifungal activity. Voriconazole selectively inhibits 14-alpha-lanosterol demethylation in fungi, preventing the production of ergosterol, an essential constituent of the fungal cell membrane, and resulting in fungal cell lysis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4DB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"COOPERM","dateModified":"2017-05-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8DBD-18F7-E053-F662850A60B1","beginDate":"2010-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lisdexamfetamine","valueDescription":"Lisdexamfetamine","ValueMeaning":{"publicId":"3124278","version":"1","preferredName":"Lisdexamfetamine","longName":"3124278v1.00","preferredDefinition":"A prodrug of the d-isomer of amphetamine, a non-catecholamine sympathomimetic amine with central nervous system (CNS) stimulating activity. Upon administration, lisdexamphetamine is converted to dextroamphetamine through cleavage of the lysine group. Dextroamphetamine acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from its storage sites in nerve terminals in the CNS, and inhibits their uptake within the mesocorticolimbic system, a major component of the brain reward system, resulting in measurable behavioral changes such as euphoria, mental alertness and excitement and appetite suppression. As a CNS stimulant, this agent may increase blood pressure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lisdexamfetamine","conceptCode":"C75114","definition":"A prodrug of the d-isomer of amphetamine, a non-catecholamine sympathomimetic amine with central nervous system (CNS) stimulating activity. Upon administration, lisdexamphetamine is converted to dextroamphetamine through cleavage of the lysine group. Dextroamphetamine acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from its storage sites in nerve terminals in the CNS, and inhibits their uptake within the mesocorticolimbic system, a major component of the brain reward system, resulting in measurable behavioral changes such as euphoria, mental alertness and excitement and appetite suppression. As a CNS stimulant, this agent may increase blood pressure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C0EAA9F-D61F-4F99-E040-BB89AD435CFD","latestVersionIndicator":"Yes","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"CLOHNES","dateModified":"2023-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8DC7-18F7-E053-F662850A60B1","beginDate":"2010-07-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Warfarin","valueDescription":"Warfarin","ValueMeaning":{"publicId":"2573141","version":"1","preferredName":"Warfarin","longName":"2573141v1.00","preferredDefinition":"A synthetic anticoagulant. Warfarin inhibits the regeneration of vitamin K1 epoxide and so the synthesis of vitamin K dependent clotting factors, which include Factors II, VII, IX and X, and the anticoagulant proteins C and S. This inhibition results in a sequential depression of Factors VII, IX, X and II activities. Vitamin K is an essential cofactor for the post ribosomal synthesis of the vitamin K dependent clotting factors. The vitamin promotes the biosynthesis of gamma-carboxyglutamic acid residues in these proteins which are essential for biological activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Warfarin","conceptCode":"C945","definition":"A synthetic anticoagulant. Warfarin inhibits the regeneration of vitamin K1 epoxide and so the synthesis of vitamin K dependent clotting factors, which include Factors II, VII, IX and X, and the anticoagulant proteins C and S. This inhibition results in a sequential depression of Factors VII, IX, X and II activities. Vitamin K is an essential cofactor for the post ribosomal synthesis of the vitamin K dependent clotting factors. The vitamin promotes the biosynthesis of gamma-carboxyglutamic acid residues in these proteins which are essential for biological activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EAC2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-02-09","modifiedBy":"CLOHNES","dateModified":"2023-08-04","changeDescription":null,"administrativeNotes":"8/4/23 Added missing concepts per cleanup activities cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8DD1-18F7-E053-F662850A60B1","beginDate":"2010-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Zaleplon","valueDescription":"Zaleplon","ValueMeaning":{"publicId":"3128740","version":"1","preferredName":"Zaleplon","longName":"3128740","preferredDefinition":"A nonbenzodiazepine from the pyrazolopyrimidine class with hypnotic, sedative, anxiolytic, and muscle relaxant properties. Zaleplon interacts with the gamma-aminobutyric acid (GABA) -A receptor, thereby affecting the chloride channel ionophore complex and potentiating the inhibitory effects of GABA. In addition, zaleplon binds selectively to the brain omega-1 receptor situated on the alpha subunit of the GABA-A/chloride ion channel receptor complex and potentiates t-butyl-bicyclophosphorothionate (TBPS) binding.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zaleplon","conceptCode":"C29551","definition":"A nonbenzodiazepine from the pyrazolopyrimidine class with hypnotic, sedative, anxiolytic, and muscle relaxant properties. Zaleplon interacts with the gamma-aminobutyric acid (GABA) -A receptor, thereby affecting the chloride channel ionophore complex and potentiating the inhibitory effects of GABA. In addition, zaleplon binds selectively to the brain omega-1 receptor situated on the alpha subunit of the GABA-A/chloride ion channel receptor complex and potentiates t-butyl-bicyclophosphorothionate (TBPS) binding.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1D25C-1E50-C451-E040-BB89AD4301E4","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8DDB-18F7-E053-F662850A60B1","beginDate":"2010-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Zidovudine","valueDescription":"Zidovudine","ValueMeaning":{"publicId":"3128742","version":"1","preferredName":"Zidovudine","longName":"3128742","preferredDefinition":"A synthetic dideoxynucleoside. After intracellular phosphorylation to its active metabolite, zidovudine inhibits DNA polymerase, resulting in the inhibition of DNA replication and cell death. This agent also decreases levels of available pyrimidines. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zidovudine","conceptCode":"C947","definition":"A synthetic dideoxynucleoside. After intracellular phosphorylation to its active metabolite, zidovudine inhibits DNA polymerase, resulting in the inhibition of DNA replication and cell death. This agent also decreases levels of available pyrimidines. (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1D25C-1E76-C451-E040-BB89AD4301E4","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8DE5-18F7-E053-F662850A60B1","beginDate":"2010-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Zinc","valueDescription":"Zinc","ValueMeaning":{"publicId":"3128744","version":"1","preferredName":"Zinc","longName":"3128744","preferredDefinition":"An element with atomic symbol Zn, atomic number 30, and atomic weight 65.39.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zinc","conceptCode":"C948","definition":"An element with atomic symbol Zn, atomic number 30, and atomic weight 65.39.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1D25C-1E9C-C451-E040-BB89AD4301E4","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8DEF-18F7-E053-F662850A60B1","beginDate":"2010-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Zinc Oxide","valueDescription":"Zinc Oxide","ValueMeaning":{"publicId":"3128746","version":"1","preferredName":"Zinc Oxide","longName":"3128746","preferredDefinition":"A mild astringent and topical protectant with some antiseptic action. It is also used in bandages, pastes, ointments, dental cements, and as a sunblock.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zinc Oxide","conceptCode":"C949","definition":"A mild astringent and topical protectant with some antiseptic action. It is also used in bandages, pastes, ointments, dental cements, and as a sunblock.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1D25C-1EC2-C451-E040-BB89AD4301E4","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8DF9-18F7-E053-F662850A60B1","beginDate":"2010-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Zinc Undecylenate","valueDescription":"Zinc Undecylenate","ValueMeaning":{"publicId":"3128748","version":"1","preferredName":"Zinc Undecylenate","longName":"3128748","preferredDefinition":"A natural or synthetic fungistatic fatty acid, antifungal Zinc Undecylenate is used topically in creams against fungal infections, eczemas, ringworm, and other cutaneous conditions. The zinc provides an astringent action, reducing rawness and irritation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zinc Undecylenate","conceptCode":"C29552","definition":"A natural or synthetic fungistatic fatty acid, antifungal Zinc Undecylenate is used topically in creams against fungal infections, eczemas, ringworm, and other cutaneous conditions. The zinc provides an astringent action, reducing rawness and irritation. (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1D25C-1EE8-C451-E040-BB89AD4301E4","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8E03-18F7-E053-F662850A60B1","beginDate":"2010-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Zinc Sulfate","valueDescription":"Zinc Sulfate","ValueMeaning":{"publicId":"3128750","version":"1","preferredName":"Zinc Sulfate","longName":"3128750","preferredDefinition":"A salt of the essential trace metal zinc. Zinc is involved in tissue repair and is an important constituent of some proteins, including those involved in taste and smell. Zinc sulfate supplementation may prevent radiation-induced aguesia. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zinc Sulfate","conceptCode":"C1280","definition":"A salt of the essential trace metal zinc. Zinc is involved in tissue repair and is an important constituent of some proteins, including those involved in taste and smell. Zinc sulfate supplementation may prevent radiation-induced aguesia. (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1D25C-1F0E-C451-E040-BB89AD4301E4","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8E0D-18F7-E053-F662850A60B1","beginDate":"2010-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Zoledronate","valueDescription":"Zoledronate","ValueMeaning":{"publicId":"2576643","version":"1","preferredName":"Zoledronate","longName":"2576643","preferredDefinition":"A drug that belongs to the family of drugs called bisphosphonates. It is used to prevent bone fractures and reduce bone pain in people who have cancer that has spread to the bone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zoledronic Acid","conceptCode":"C1699","definition":"A synthetic imidazole bisphosphonate analog of pyrophosphate with anti-bone-resorption activity. A third-generation bisphosphonate, zoledronic acid binds to hydroxyapatite crystals in the bone matrix, slowing their dissolution and inhibiting the formation and aggregation of these crystals. This agent also inhibits farnesyl pyrophosphate synthase, an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids, donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which are important in the process of osteoclast turnover. Decreased bone turnover and stabilization of the bone matrix contribute to the analgesic effect of zoledronic acid with respect to painful osteoblastic lesions. The agent also reduces serum calcium concentrations associated with hypercalcemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F870-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8E17-18F7-E053-F662850A60B1","beginDate":"2010-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Azathioprine","valueDescription":"Azathioprine","ValueMeaning":{"publicId":"3128751","version":"1","preferredName":"Azathioprine","longName":"3128751","preferredDefinition":"A purine analogue with cytotoxic and immunosuppressive activity. Azathioprine is a prodrug that is converted by hepatic xanthine oxidase to its active metabolite 6-mercaptopurine (6-MP). 6-MP is further metabolized by hypoxanthine-guanine phosphoribosyltransferase (HGPRT) into 6-thioguanosine-5'-phosphate (6-thio-GMP) and 6-thioinosine monophosphate (6-thio-IMP), both inhibit nucleotide conversions and de novo purine synthesis. This leads to inhibition of DNA, RNA, and protein synthesis. As a result, cell proliferation may be inhibited, particularly in lymphocytes and leukocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Azathioprine","conceptCode":"C290","definition":"A purine analogue with cytotoxic and immunosuppressive activity. Azathioprine is a prodrug that is converted by hepatic xanthine oxidase to its active metabolite 6-mercaptopurine (6-MP). 6-MP is further metabolized by hypoxanthine-guanine phosphoribosyltransferase (HGPRT) into 6-thioguanosine-5'-phosphate (6-thio-GMP) and 6-thioinosine monophosphate (6-thio-IMP), both inhibit nucleotide conversions and de novo purine synthesis. This leads to inhibition of DNA, RNA, and protein synthesis. As a result, cell proliferation may be inhibited, particularly in lymphocytes and leukocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1D25C-1F3C-C451-E040-BB89AD4301E4","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8E21-18F7-E053-F662850A60B1","beginDate":"2010-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Atracurium Besylate","valueDescription":"Atracurium Besylate","ValueMeaning":{"publicId":"3128752","version":"1","preferredName":"Atracurium Besylate","longName":"3128752","preferredDefinition":"A synthetic dibenzensulfonate derivative muscle relaxant, Atracurium Besylate acts as a non-depolarizing neuromuscular blocking agent, with short to intermediary duration of action and no significant cardiovascular effects. Not dependent on kidney function for elimination, it provides clinical advantages over other non-depolarizing, neuromuscular blocking agents. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atracurium Besylate","conceptCode":"C28839","definition":"A synthetic dibenzensulfonate derivative muscle relaxant, Atracurium Besylate acts as a non-depolarizing neuromuscular blocking agent, with short to intermediary duration of action and no significant cardiovascular effects. Not dependent on kidney function for elimination, it provides clinical advantages over other non-depolarizing, neuromuscular blocking agents. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1D25C-1F61-C451-E040-BB89AD4301E4","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8E2B-18F7-E053-F662850A60B1","beginDate":"2010-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Arthro-7","valueDescription":"Arthro-7","ValueMeaning":{"publicId":"2576007","version":"1","preferredName":"Arthro-7","longName":"2576007","preferredDefinition":"Arthro-7","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F5F4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2005-08-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8E35-18F7-E053-F662850A60B1","beginDate":"2010-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Aminocaproic Acid","valueDescription":"Aminocaproic Acid","ValueMeaning":{"publicId":"3128754","version":"1","preferredName":"Aminocaproic Acid","longName":"3128754","preferredDefinition":"A synthetic lysine derivative with antifibrinolytic activity. Aminocaproic acid competitively inhibits activation of plasminogen, thereby reducing conversion of plasminogen to plasmin (fibrinolysin), an enzyme that degrades fibrin clots as well as fibrinogen and other plasma proteins including the procoagulant factors V and VIII. Aminocaproic acid competitively reduces the conversion of plasminogen to plasmin by plasminogen activators. It directly inhibits proteolytic activity of plasmin, but higher doses are required than are needed to reduce plasmin formation. Aminocaproic acid is used in the treatment of hemorrhage and prophylactically against hemorrhage, including hyperfibrinolysis-induced hemorrhage and postsurgical hemorrhage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aminocaproic Acid","conceptCode":"C47391","definition":"A synthetic lysine derivative with antifibrinolytic activity. Aminocaproic acid competitively inhibits activation of plasminogen, thereby reducing conversion of plasminogen to plasmin (fibrinolysin), an enzyme that degrades fibrin clots as well as fibrinogen and other plasma proteins including the procoagulant factors V and VIII. Aminocaproic acid competitively reduces the conversion of plasminogen to plasmin by plasminogen activators. It directly inhibits proteolytic activity of plasmin, but higher doses are required than are needed to reduce plasmin formation. Aminocaproic acid is used in the treatment of hemorrhage and prophylactically against hemorrhage, including hyperfibrinolysis-induced hemorrhage and postsurgical hemorrhage.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1D25C-1F92-C451-E040-BB89AD4301E4","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8E3F-18F7-E053-F662850A60B1","beginDate":"2010-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Zolmitriptan","valueDescription":"Zolmitriptan","ValueMeaning":{"publicId":"3128756","version":"1","preferredName":"Zolmitriptan","longName":"3128756","preferredDefinition":"A member of the triptan class agents with anti-migraine property. Zolmitriptan selectively binds to and activates serotonin (5-HT) 1B expressed in intracranial arteries and 5_HT 1D receptors located on peripheral trigeminal sensory nerve terminals in the meninges and central terminals in brain stem sensory nuclei. Receptor binding results in constriction of cranial vessels, reduction of the vessel pulsation and inhibition of nociceptive transmission, thereby providing relief of migraine headaches. Zolmitriptan may also relief migraine headaches by inhibition pro-inflammatory neuropeptide release.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zolmitriptan","conceptCode":"C47789","definition":"A member of the triptan class of agents with anti-migraine properties. Zolmitriptan selectively binds to and activates serotonin (5-HT) 1B receptors expressed in intracranial arteries and 5-HT 1D receptors located on peripheral trigeminal sensory nerve terminals in the meninges and central terminals in brainstem sensory nuclei. Receptor binding results in constriction of cranial vessels, reduction of vessel pulsation and inhibition of nociceptive transmission, thereby providing relief of migraine headaches. Zolmitriptan may also relieve migraine headaches by inhibition of pro-inflammatory neuropeptide release.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1D25C-1FB8-C451-E040-BB89AD4301E4","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8E49-18F7-E053-F662850A60B1","beginDate":"2010-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Zolpidem Tartrate","valueDescription":"Zolpidem Tartrate","ValueMeaning":{"publicId":"3128758","version":"1","preferredName":"Zolpidem Tartrate","longName":"3128758","preferredDefinition":"The tartrate salt of an imidazopyridine with non-benzodiazepine benzodiazepine-receptor agonist and sedative-hypnotic activities. Zolpidem binds selectively to the alpha 1 subunit of the omega-1 (BZ1) receptor of the gamma-aminobutyric acid type A (GABA-A ) receptor-chloride ionophore complex, thereby opening neuronal chloride channels, hyperpolarizing neuronal cell membranes, and inhibiting neuronal firing. In contrast, benzodiazepines non-selectively bind to and activate all omega receptor subtypes, exhibiting anticonvulsant and myorelaxant activities in addition to a sedative-hypnotic activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zolpidem Tartrate","conceptCode":"C29553","definition":"The tartrate salt of an imidazopyridine with non-benzodiazepine benzodiazepine-receptor agonist and sedative-hypnotic activities. Zolpidem binds selectively to the alpha 1 subunit of the omega-1 (BZ1) receptor of the gamma-aminobutyric acid type A (GABA-A) receptor-chloride ionophore complex, thereby opening neuronal chloride channels, hyperpolarizing neuronal cell membranes, and inhibiting neuronal firing. In contrast, benzodiazepines non-selectively bind to and activate all omega receptor subtypes, exhibiting anticonvulsant and myorelaxant activities in addition to a sedative-hypnotic activity.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1D25C-1FDE-C451-E040-BB89AD4301E4","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8E53-18F7-E053-F662850A60B1","beginDate":"2010-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Frovatriptan Succinate","valueDescription":"Frovatriptan Succinate (Frova)","ValueMeaning":{"publicId":"3143937","version":"1","preferredName":"Frovatriptan Succinate (Frova)","longName":"3143937","preferredDefinition":"The succinate salt form of frovatriptan, a synthetic triptan with serotonin (5-HT) receptor agonist activity. Frovatriptan succinate binds selectively and with high affinity to 5-HT 1B and presynaptic 5-HT 1D receptors in the extracerebral and intracranial arteries. This leads to an inhibition of serotonin activity and results in vasoconstriction of the painfully dilated blood vessels during migraine attack. Frovatriptan succinate is indicated for the acute treatment of migraine. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Frovatriptan Succinate","conceptCode":"C47544","definition":"The succinate salt form of frovatriptan, a synthetic triptan with serotonin (5-HT) receptor agonist activity. Frovatriptan succinate binds selectively and with high affinity to 5-HT 1B and presynaptic 5-HT 1D receptors in the extracerebral and intracranial arteries. This leads to an inhibition of serotonin activity and results in vasoconstriction of the painfully dilated blood vessels during migraine attack. Frovatriptan succinate is indicated for the acute treatment of migraine. (NCI05)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9167E85F-657D-A82C-E040-BB89AD433534","latestVersionIndicator":"Yes","beginDate":"2010-09-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8E5D-18F7-E053-F662850A60B1","beginDate":"2010-09-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Flurandrenolide","valueDescription":"Flurandrenolide","ValueMeaning":{"publicId":"3145498","version":"1","preferredName":"Flurandrenolide","longName":"3145498","preferredDefinition":"A synthetic glucocorticoid with anti-inflammatory and anti-allergic properties. Flurandrenolide exerts its effects by interacting with specific cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. The synthesis of certain anti-inflammatory proteins is induced while the synthesis of certain inflammatory mediators is inhibited. As a result, there is an overall reduction in chronic inflammation and autoimmune reactions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Flurandrenolide","conceptCode":"C47537","definition":"A synthetic glucocorticoid with anti-inflammatory and anti-allergic properties. Flurandrenolide exerts its effects by interacting with specific cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. The synthesis of certain anti-inflammatory proteins is induced while the synthesis of certain inflammatory mediators is inhibited. As a result, there is an overall reduction in chronic inflammation and autoimmune reactions.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91BE9EE9-89AD-F4E8-E040-BB89AD434FF3","latestVersionIndicator":"Yes","beginDate":"2010-10-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-10-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8E67-18F7-E053-F662850A60B1","beginDate":"2010-10-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"MedActive","valueDescription":"MedActive Oral Product","ValueMeaning":{"publicId":"3182317","version":"1","preferredName":"MedActive Oral Product","longName":"3182317","preferredDefinition":"Proprietary, over-the-counter products containing stannous flouride and Spilanthes extract for relief of dry mouth symptoms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MedActive Oral Product","conceptCode":"C95197","definition":"Proprietary, over-the-counter products containing stannous fluoride and Spilanthes extract for the relief of dry mouth symptoms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9975C44B-F420-7B68-E040-BB89AD430BD5","latestVersionIndicator":"Yes","beginDate":"2011-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8E71-18F7-E053-F662850A60B1","beginDate":"2011-01-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Hypromellose","valueDescription":"Hypromellose","ValueMeaning":{"publicId":"3228377","version":"1","preferredName":"Hypromellose","longName":"3228377","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hypromelloses","conceptCode":"C80902","definition":"A semisynthetic, inert, viscoelastic polymer. It is used as an ophthalmic lubricant and as an excipient in oral medications.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A160434C-66B0-A92B-E040-BB89AD43423D","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8E7B-18F7-E053-F662850A60B1","beginDate":"2011-04-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Imatinib","valueDescription":"Imatinib","ValueMeaning":{"publicId":"3228378","version":"1","preferredName":"Imatinib","longName":"3228378","preferredDefinition":"An antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that contain the Philadelphia chromosome.  Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF)/c-kit; the SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor (GIST).  This agent inhibits proliferation and induces apoptosis in cells that overexpress these oncoproteins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Imatinib","conceptCode":"C62035","definition":"An antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that contain the Philadelphia chromosome.  Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF)/c-kit; the SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor (GIST).  This agent inhibits proliferation and induces apoptosis in cells that overexpress these oncoproteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A160434C-66D5-A92B-E040-BB89AD43423D","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8E85-18F7-E053-F662850A60B1","beginDate":"2011-04-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Tranexamic Acid","valueDescription":"Tranexamic Acid","ValueMeaning":{"publicId":"3228380","version":"1","preferredName":"Tranexamic Acid","longName":"3228380","preferredDefinition":"A synthetic derivative of the amino acid lysine with antifibrinolytic activity. With strong affinity for the five lysine-binding sites of plasminogen, tranexamic acid competitively inhibits the activation of plasminogen to plasmin, resulting in inhibition of fibrinolysis; at higher concentrations, this agent noncompetitively inhibits plasmin. This agent has a longer half-life, is approximately ten times more potent, and is less toxic than aminocaproic acid, which possesses similar mechanisms of action.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tranexamic Acid","conceptCode":"C47765","definition":"A synthetic derivative of the amino acid lysine with antifibrinolytic activity. With strong affinity for the five lysine-binding sites of plasminogen, tranexamic acid competitively inhibits the activation of plasminogen to plasmin, resulting in inhibition of fibrinolysis; at higher concentrations, this agent noncompetitively inhibits plasmin. This agent has a longer half-life, is approximately ten times more potent, and is less toxic than aminocaproic acid, which possesses similar mechanisms of action.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A160434C-66FB-A92B-E040-BB89AD43423D","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8E8F-18F7-E053-F662850A60B1","beginDate":"2011-04-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Leucogen","valueDescription":"Leucogen (2-(2-Ethoxy-2-oxo-1-phenylethyl)-1,3-thiazolidine-4-carboxylic acid; 2-thiazolidineacetic acid, 4-carboxy-alpha-phenyl-, alpha-ethyl ester,  (C14H17NO4S)","ValueMeaning":{"publicId":"3654625","version":"1","preferredName":"Leucogen (2-(2-Ethoxy-2-oxo-1-phenylethyl)-1,3-thiazolidine-4-carboxylic acid; 2-thiazolidineacetic acid, 4-carboxy-alpha-phenyl-, alpha-ethyl ester,  (C14H17NO4S)","longName":"3654625","preferredDefinition":"2-(2-Ethoxy-2-oxo-1-phenylethyl)-1,3-thiazolidine-4-carboxylic acid; 2-thiazolidineacetic acid, 4-carboxy-alpha-phenyl-, alpha-ethyl ester,  (C14H17NO4S)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D40B41CA-B872-71CF-E040-BB89AD434508","latestVersionIndicator":"Yes","beginDate":"2013-01-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-01-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8E99-18F7-E053-F662850A60B1","beginDate":"2013-01-24","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Budesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol (Symbicort)","valueDescription":"Budesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol","ValueMeaning":{"publicId":"3238485","version":"1","preferredName":"Budesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol","longName":"3238485","preferredDefinition":"An inhalation aerosol formulation containing budesonide and the fumarate dihydrate salt of formoterol with anti-inflammatory and bronchial smooth muscle-relaxing activities. The synthetic corticosteroid steroid budesonide binds to intracellular glucocorticosteroid receptors (GRs), exhibiting inhibitory activities against multiple cell types and mediators associated with allergic inflammation. The long-acting beta-adrenergic receptor agonist formoterol selectively binds to beta-2 adrenergic receptors in bronchial smooth muscle, activating intracellular adenyl cyclase, an enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP); increased intracellular cAMP result in the relaxation of bronchial smooth muscle and inhibition of the cellular release of mediators of immediate hypersensitivity, especially from mast cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Budesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol","conceptCode":"C71534","definition":"An inhalation aerosol formulation containing budesonide and the fumarate dihydrate salt of formoterol with anti-inflammatory and bronchial smooth muscle-relaxing activities. The synthetic corticosteroid steroid budesonide binds to intracellular glucocorticosteroid receptors (GRs), exhibiting inhibitory activities against multiple cell types and mediators associated with allergic inflammation. The long-acting beta-adrenergic receptor agonist formoterol selectively binds to beta-2 adrenergic receptors in bronchial smooth muscle, activating intracellular adenyl cyclase, an enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP); increased intracellular cAMP result in the relaxation of bronchial smooth muscle and inhibition of the cellular release of mediators of immediate hypersensitivity, especially from mast cells.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A41DC8A8-EBF2-0F50-E040-BB89AD436610","latestVersionIndicator":"Yes","beginDate":"2011-05-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8EA3-18F7-E053-F662850A60B1","beginDate":"2011-05-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Eltrombopag","valueDescription":"Eltrombopag","ValueMeaning":{"publicId":"3173720","version":"1","preferredName":"Eltrombopag","longName":"3173720","preferredDefinition":"An orally active thrombopoietin receptor agonist with megakaryopoiesis stimulating activity. Eltrombopag binds to and stimulates the platelet thrombopoietin receptor (TPO-R or CD110), a member of the hematopoietin receptor superfamily. Activation of TPO-R leads to the proliferation and differentiation of megakaryocytes, thereby increasing the production of blood platelets.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eltrombopag","conceptCode":"C71634","definition":"An orally active thrombopoietin receptor agonist with megakaryopoiesis stimulating activity. Eltrombopag binds to and stimulates the platelet thrombopoietin receptor (TPO-R or CD110), a member of the hematopoietin receptor superfamily. Activation of TPO-R leads to the proliferation and differentiation of megakaryocytes, thereby increasing the production of blood platelets.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97EE67EB-72DA-3463-E040-BB89AD4305CD","latestVersionIndicator":"Yes","beginDate":"2010-12-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8EAD-18F7-E053-F662850A60B1","beginDate":"2010-12-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Rasburicase","valueDescription":"Rasburicase","ValueMeaning":{"publicId":"3173722","version":"1","preferredName":"Rasburicase","longName":"3173722","preferredDefinition":"A recombinant urate oxidase enzyme isolated from a genetically-modified strain of Saccharomyces cerevisiae.  Urate oxidase catalyzes the oxidation of uric acid to the excretable metabolite allantoin, a molecule that is 5-10 times more water-soluble than uric acid.  An enzyme that occurs endogenously in most mammals, urate oxidase is not found in humans. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rasburicase","conceptCode":"C2404","definition":"A recombinant urate oxidase enzyme isolated from a genetically-modified strain of Saccharomyces cerevisiae.  Urate oxidase catalyzes the oxidation of uric acid to the excretable metabolite allantoin, a molecule that is 5-10 times more water-soluble than uric acid.  An enzyme that occurs endogenously in most mammals, urate oxidase is not found in humans. (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97EE67EB-7300-3463-E040-BB89AD4305CD","latestVersionIndicator":"Yes","beginDate":"2010-12-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8EB7-18F7-E053-F662850A60B1","beginDate":"2010-12-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Prasugrel","valueDescription":"Prasugrel","ValueMeaning":{"publicId":"3162838","version":"1","preferredName":"Prasugrel","longName":"3162838","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prasugrel","conceptCode":"C81566","definition":"An orally bioavailable thienopyridine, with antiplatelet activity. Upon oral administration, the active metabolite of prasugrel targets and irreversibly binds to the platelet receptor for adenosine diphosphate (ADP), thereby blocking the binding of ADP to its receptor. This inhibits ADP-mediated activation of the glycoprotein complex GPIIb/IIIa, fibrinogen binding to platelets and platelet adhesion and aggregation. This results in increased bleeding time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"960B81F9-3F78-4863-E040-BB89AD430D1A","latestVersionIndicator":"Yes","beginDate":"2010-11-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-11-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8EC1-18F7-E053-F662850A60B1","beginDate":"2010-11-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Enalaprilat","valueDescription":"Enalaprilat","ValueMeaning":{"publicId":"3242021","version":"1","preferredName":"Enalaprilat","longName":"3242021","preferredDefinition":"The active metabolite of the pro-drug enalapril, a dicarboxylate-containing angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. Enalaprilat prevents the conversion of angiotensin I into angiotensin II by inhibiting ACE, thereby leading to decreased vasopressor activity and resulting in vasodilation. This agent also decreases aldosterone secretion by the adrenal cortex, which leads to an increase in natriuresis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Enalaprilat","conceptCode":"C47510","definition":"The active metabolite of the pro-drug enalapril, a dicarboxylate-containing angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. Enalaprilat prevents the conversion of angiotensin I into angiotensin II by inhibiting ACE, thereby leading to decreased vasopressor activity and resulting in vasodilation. This agent also decreases aldosterone secretion by the adrenal cortex, which leads to an increase in natriuresis.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A4A96C4C-1A0C-F5E2-E040-BB89AD437436","latestVersionIndicator":"Yes","beginDate":"2011-06-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-06-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8ECB-18F7-E053-F662850A60B1","beginDate":"2011-06-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Romiplostim","valueDescription":"Romiplostim","ValueMeaning":{"publicId":"3228298","version":"1","preferredName":"Romiplostim","longName":"3228298","preferredDefinition":"A recombinant protein with megakaryopoiesis stimulating activity. Romiplostim mimics endogenous thrombopoietin (TPO), directly binding to and activating the platelet thrombopoietin receptor (TpoR, Mpl, or CD110 antigen), a cytokine receptor belonging to the hematopoietin receptor superfamily. Activation of TpoR stimulates the proliferation and differentiation of megakaryocytes, resulting in an increase in the production of blood platelets.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Romiplostim","conceptCode":"C52183","definition":"A recombinant protein with megakaryopoiesis stimulating activity. Romiplostim mimics endogenous thrombopoietin (TPO), directly binding to and activating the platelet thrombopoietin receptor (TpoR, Mpl, or CD110 antigen), a cytokine receptor belonging to the hematopoietin receptor superfamily. Activation of TpoR stimulates the proliferation and differentiation of megakaryocytes, resulting in an increase in the production of blood platelets.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A15930B7-34BA-8C0F-E040-BB89AD43469C","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8ED5-18F7-E053-F662850A60B1","beginDate":"2011-04-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Imiquimod","valueDescription":"Imiquimod","ValueMeaning":{"publicId":"3228300","version":"1","preferredName":"Imiquimod","longName":"3228300","preferredDefinition":"A synthetic agent with immune response modifying activity. As an immune response modifier (IRM), imiquimod stimulates cytokine production, especially interferon production, and exhibits antitumor activity, particularly against cutaneous cancers. Imiquimod's proapoptotic activity appears to be related to Bcl-2 overexpression in susceptible tumor cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Imiquimod","conceptCode":"C1431","definition":"A synthetic agent with immune response modifying activity. As an immune response modifier (IRM), imiquimod stimulates cytokine production, especially interferon production, and exhibits antitumor activity, particularly against cutaneous cancers. Imiquimod's proapoptotic activity appears to be related to Bcl-2 overexpression in susceptible tumor cells. (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A15930B7-34E0-8C0F-E040-BB89AD43469C","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8EDF-18F7-E053-F662850A60B1","beginDate":"2011-04-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Sevelamer Carbonate","valueDescription":"Sevelamer Carbonate","ValueMeaning":{"publicId":"3228302","version":"1","preferredName":"Sevelamer Carbonate","longName":"3228302","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sevelamer Carbonate","conceptCode":"C78122","definition":"No Value Exists","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A15930B7-3506-8C0F-E040-BB89AD43469C","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8EE9-18F7-E053-F662850A60B1","beginDate":"2011-04-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lacosamide","valueDescription":"Lacosamide","ValueMeaning":{"publicId":"3232363","version":"1","preferredName":"Lacosamide","longName":"3232363v1.00","preferredDefinition":"A functionalized amino acid compound specifically synthesized as an anticonvulsive drug to use as add-on therapy for partial-onset seizures with antinociceptive and neuroprotective activities. Lacosamide selectively enhances slow inactivation of voltage-gated sodium channels without affecting fast inactivation, thereby stabilizing hyperexcitabe neuronal membranes. Furthermore, this agent binds to collapsin response mediator protein 2 (CRMP2; DPYSL2), a cytosolic phosphoprotein expressed in most tissues. In the nervous system, CRMP2 acts as a mediator of growth cone collapse as well as modifies axon number, length, and neuronal polarity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lacosamide","conceptCode":"C83859","definition":"A functionalized amino acid compound specifically synthesized as an anticonvulsive drug to use as add-on therapy for partial-onset seizures with antinociceptive and neuroprotective activities. Lacosamide selectively enhances slow inactivation of voltage-gated sodium channels without affecting fast inactivation, thereby stabilizing hyperexcitabe neuronal membranes. Furthermore, this agent binds to collapsin response mediator protein 2 (CRMP2; DPYSL2), a cytosolic phosphoprotein expressed in most tissues. In the nervous system, CRMP2 acts as a mediator of growth cone collapse as well as modifies axon number, length, and neuronal polarity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A1F2CCF0-7030-F4FA-E040-BB89AD434EDB","latestVersionIndicator":"Yes","beginDate":"2011-04-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-27","modifiedBy":"KUMMEROA","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8EF3-18F7-E053-F662850A60B1","beginDate":"2011-04-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Amphotericin B","valueDescription":"Amphotercin B","ValueMeaning":{"publicId":"2576917","version":"1","preferredName":"Amphotercin B","longName":"2576917","preferredDefinition":"A macrolide antifungal antibiotic produced by Streptomyces nodosus that binds to ergosterol altering cell membrane integrity with subsequent cell death. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amphotericin B","conceptCode":"C238","definition":"A polyene antifungal antibiotic produced by Streptomyces nodosus, with antifungal activity. Amphotericin B binds to ergosterol, an essential component of the fungal cell membrane, thereby causing depolarization of the membrane and altering cell membrane permeability. This leads to leakage of important intracellular components, cell rupture, and eventually cell death. This agent may also induce oxidative damage in fungal cells and has been reported to stimulate host immune cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F982-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-09","modifiedBy":"ONEDATA","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-76B0-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Amphotericin B Liposomal","valueDescription":"Amphotericin B Liposomal","ValueMeaning":{"publicId":"2576925","version":"1","preferredName":"Amphotericin B Liposomal","longName":"2576925","preferredDefinition":"Liposome encapsulated macrolide antifungal antibiotic amphotericin B.  Amphotericin B binds to ergosterol altering cell membrane integrity with subsequent cell death.  In addition, the liposomal form has decreased side effects of conventional Amphotericin. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amphotericin B Liposomal","conceptCode":"C1738","definition":"Liposome encapsulated macrolide antifungal antibiotic amphotericin B.  Amphotericin B binds to ergosterol altering cell membrane integrity with subsequent cell death.  In addition, the liposomal form has decreased side effects of conventional Amphotericin. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F98A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-76BA-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ampicillin","valueDescription":"Ampicillin","ValueMeaning":{"publicId":"2576926","version":"1","preferredName":"Ampicillin","longName":"2576926","preferredDefinition":"A broad-spectrum semisynthetic derivative of aminopenicillin that inhibits bacterial cell wall synthesis by binding to penicillin binding proteins and inhibiting peptidoglycan synthesis, a critical component of bacterial cell wall. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ampicillin","conceptCode":"C239","definition":"A broad-spectrum, semi-synthetic, beta-lactam penicillin antibiotic with bactericidal activity. Ampicillin binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall and causes cell lysis. Ampicillin is stable against hydrolysis by a variety of beta-lactamases, therefore, can be used in wide range of gram-positive and -negative infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F98B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-76C4-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ampicillin Sodium/Sulbactam Sodium","valueDescription":"Ampicillin Sodium/Sulbactam Sodium","ValueMeaning":{"publicId":"2575654","version":"1","preferredName":"Ampicillin Sodium/Sulbactam Sodium","longName":"2575654","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sultamicillin","conceptCode":"C28823","definition":"A combination formulation of the sodium salts of the antibiotic ampicillin and the beta-lactamase inhibitor sulbactam with antibacterial activity. Ampicillin, a broad-spectrum, semisynthetic penicillin, binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall, thereby interfering with the cross-linking of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. As a result, the cell wall is weakened and the cell lyses. The sulbactam component irreversibly binds to bacterial beta-lactamase at or near its active site, thereby interfering with substrate binding and inhibiting bacterial metabolism of penicillin and cephalosporin beta-lactam antibiotics, effectively extending their antibiotic spectrum to include many beta-lactam-resistant bacteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F493-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-76CE-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Amprenavir","valueDescription":"Amprenavir","ValueMeaning":{"publicId":"2576927","version":"1","preferredName":"Amprenavir","longName":"2576927","preferredDefinition":"A synthetic antiviral agent.  As a derivative of hydroxyethylamine sulfonamide, amprenavir selectively binds to and inhibits human immunodeficiency virus (HIV) protease, thereby preventing cleavage of the gag-pol viral polyprotein and resulting in the release of immature, noninfectious virions. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amprenavir","conceptCode":"C28824","definition":"A synthetic derivative of hydroxyethylamine sulfonamide that selectively binds to and inhibits human immunodeficiency virus (HIV) protease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F98C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-76D8-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Anagrelide","valueDescription":"Anagrelide","ValueMeaning":{"publicId":"2576928","version":"1","preferredName":"Anagrelide","longName":"2576928","preferredDefinition":"A synthetic quinazoline derivative, Anagrelide reduces platelet production through a decrease in megakaryocyte maturation. Anagrelide inhibits cyclic AMP phosphodiesterase, as well as ADP- and collagen-induced platelet aggregation. At therapeutic doses, it does not influence white cell counts or coagulation parameters. Anagrelide is used for treatment of essential thrombocythemia to reduce elevated platelet counts and the risk of thrombosis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anagrelide","conceptCode":"C28825","definition":"A synthetic quinazoline derivative, Anagrelide reduces platelet production through a decrease in megakaryocyte maturation. Anagrelide inhibits cyclic AMP phosphodiesterase, as well as ADP- and collagen-induced platelet aggregation. At therapeutic doses, it does not influence white cell counts or coagulation parameters. Anagrelide is used for treatment of essential thrombocythemia to reduce elevated platelet counts and the risk of thrombosis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F98D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-76E2-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Anastrozole","valueDescription":"ANASTROZOLE","ValueMeaning":{"publicId":"2561407","version":"1","preferredName":"ANASTROZOLE","longName":"2561407","preferredDefinition":"ANASTROZOLE","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anastrozole","conceptCode":"C1607","definition":"A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure.  As a third-generation aromatase inhibitor, anastrozole selectively binds to and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.  In estrogen-dependent breast cancers, ananstrozole may inhibit tumor growth. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BCEC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-02","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-76EC-18F7-E053-F662850A60B1","beginDate":"2005-08-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fexofenadine HCL","valueDescription":"Fexofenadine Hydrochloride","ValueMeaning":{"publicId":"2576853","version":"1","preferredName":"Fexofenadine Hydrochloride","longName":"2576853","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fexofenadine Hydrochloride","conceptCode":"C29050","definition":"The hydrochloride salt form of fexofenadine, a carboxylated metabolic derivative of terfenadine and second generation, long-lasting selective histamine H1 receptor antagonist, with antihistaminic activity. Upon administration, fexofenadine competitively binds of peripheral H1-receptors in the gastrointestinal (GI) tract, blood vessels, and bronchial smooth muscle. This prevents binding of histamine to peripheral H1-receptors and prevents their activation. This prevents a histamine-mediated allergic reaction. Fexofenadine does not cross the blood-brain-barrier (BBB).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F942-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-76F6-18F7-E053-F662850A60B1","beginDate":"2005-11-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fexofenadine HCL/Pseudoephedrine HCL","valueDescription":"Fexofenadine hydrochloride+pseudoephedrine hydrochloride","ValueMeaning":{"publicId":"2576943","version":"1","preferredName":"Fexofenadine hydrochloride+pseudoephedrine hydrochloride","longName":"2576943","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fexofenadine hydrochloride+pseudoephedrine hydrochloride","conceptCode":"CL311591","definition":"No value exists.","evsSource":"NCI_META_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F99C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-10","modifiedBy":"ONEDATA","dateModified":"2005-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7700-18F7-E053-F662850A60B1","beginDate":"2005-11-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Filgrastim","valueDescription":"Filgrastim","ValueMeaning":{"publicId":"2576855","version":"1","preferredName":"Filgrastim","longName":"2576855","preferredDefinition":"A colony-stimulating factor that stimulates the production of neutrophils (a type of white blood cell). It is a cytokine that belongs to the family of drugs called hematopoietic (blood-forming) agents. Also called granulocyte colony-stimulating factor (G-CSF).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Filgrastim","conceptCode":"C1474","definition":"A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F944-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-770A-18F7-E053-F662850A60B1","beginDate":"2005-11-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Finasteride","valueDescription":"Finasteride","ValueMeaning":{"publicId":"2576856","version":"1","preferredName":"Finasteride","longName":"2576856","preferredDefinition":"A synthetic azasteroid compound.  Finasteride binds to and inhibits 5-alpha-reductase, thereby interfering with the enzymatic conversion of testosterone to 5-dihydrotestosterone, ultimately interfering with prostate growth. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Finasteride","conceptCode":"C1099","definition":"A synthetic 4-azasteroid compound. Finasteride competitively binds to and inhibits steroid type II 5-alpha-reductase in the prostate gland, liver, and skin, thereby interfering with the enzymatic conversion of testosterone to 5-dihydrotestosterone (DHT) and reducing serum DHT levels. The reduction in serum DHT levels results in diminished stimulation of androgen receptors in the nuclei of prostate cells and, so, diminished prostate cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F945-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7714-18F7-E053-F662850A60B1","beginDate":"2005-11-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fioricet","valueDescription":"Fioricet","ValueMeaning":{"publicId":"2576857","version":"1","preferredName":"Fioricet","longName":"2576857","preferredDefinition":"A combination preparation of acetaminophen, butalbital, and caffeine. Acetaminophen exerts antipyretic and analgesic activities by inhibiting prostaglandin synthesis. Butalbital, a barbiturate with an intermediate duration of action, depresses the central nervous system and exerts sedative activity. Caffeine is a central nervous system stimulant and causes constriction of dilated cerebral blood vessels. This combination is used for the relief and treatment of migraine and tension headaches.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acetaminophen/Butalbital/Caffeine","conceptCode":"C29051","definition":"A combination preparation of acetaminophen, butalbital, and caffeine. Acetaminophen exerts antipyretic and analgesic activities by inhibiting prostaglandin synthesis. Butalbital, a barbiturate with an intermediate duration of action, depresses the central nervous system and exerts sedative activity. Caffeine is a central nervous system stimulant and causes constriction of dilated cerebral blood vessels. This combination is used for the relief and treatment of migraine and tension headaches.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F946-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"TAYLORT","dateModified":"2018-05-15","changeDescription":"5/15/18 tt added concept definition.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-771E-18F7-E053-F662850A60B1","beginDate":"2005-11-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fish Oil","valueDescription":"Fish Oil","ValueMeaning":{"publicId":"2576858","version":"1","preferredName":"Fish Oil","longName":"2576858","preferredDefinition":"Oils high in unsaturated fats extracted from the bodies of fish or fish parts, especially the livers. Those from the liver are usually high in vitamin A. The oils are used as dietary supplements, in soaps and detergents, as protective coatings, and as a base for other food products such as vegetable shortenings.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fish Oil","conceptCode":"C497","definition":"An oil derived from the tissues of oily fish. Fish oil is considered valuable due to its high content of omega-3 fatty acids eicosapentanoic acid and docosahexaenoic acid. Such fatty acids are not actually produced in fish, but are accumulated from phytoplankton which produce omega-3 fatty acids.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F947-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"REEVESD","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7728-18F7-E053-F662850A60B1","beginDate":"2005-11-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Flavopiridol","valueDescription":"Flavopiridol","ValueMeaning":{"publicId":"2576859","version":"1","preferredName":"Flavopiridol","longName":"2576859","preferredDefinition":"A synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, flavopiridol induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (cdk) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis.  This agent is also a competitive inhibitor of adenosine triphosphate activity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alvocidib Hydrochloride","conceptCode":"C1571","definition":"A synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (CDKs) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis. This agent is also a competitive inhibitor of adenosine triphosphate activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F948-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7732-18F7-E053-F662850A60B1","beginDate":"2005-11-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Flax Oil","valueDescription":"Flax Seed Oil","ValueMeaning":{"publicId":"2569634","version":"1","preferredName":"Flax Seed Oil","longName":"2569634","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Flax Seed Oil","conceptCode":"C1170277","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DD0F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-05-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-05-20","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-773C-18F7-E053-F662850A60B1","beginDate":"2005-11-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fleets Phospho-Soda","valueDescription":"Fleets Phospho-Soda","ValueMeaning":{"publicId":"2576860","version":"1","preferredName":"Fleets Phospho-Soda","longName":"2576860","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sodium Phosphate/Sodium Biphosphate Laxative","conceptCode":"C29052","definition":"An oral hyperosmotic saline laxative containing sodium biphosphate and sodium phosphate. Sodium phosphate/sodium biphosphate oral laxative promotes retention of water in the bowel, thereby increasing stool water content and volume, which results in increased gastrointestinal motility and stool transit time and evacuation of colonic contents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F949-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7746-18F7-E053-F662850A60B1","beginDate":"2005-11-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Flucinolone","valueDescription":"Flucinolone","ValueMeaning":{"publicId":"2576861","version":"1","preferredName":"Flucinolone","longName":"2576861v1.00","preferredDefinition":"A synthetic glucocorticoid with anti-inflammatory and antipruritic activities. Fluocinolone binds the glucocorticoid receptor, followed by translocation of the ligand-receptor complex to the nucleus and transcription activation of genes containing glucocorticoid-responsive elements. Lipocortin-1 is one factor induced by fluocinolone that interacts with and inhibits cytosolic phospholipase 2 alpha, thereby preventing phospholipase translocation to the perinuclear membrane and subsequent release and conversion of arachidonic acid to inflammatory prostaglandins. In addition, MAPK phosphatase 1 is induced, thereby preventing the triggering of the MAPK cascade resulting in pro-inflammatory effects via Jun N-terminal kinase and c-Jun. Finally, fluocinolone binds to and inhibits nuclear factor kappa-B directly, resulting in inhibition of cyclooxygenase 2 transcription and subsequent prostaglandin synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluocinolone","conceptCode":"C29053","definition":"A synthetic glucocorticoid with anti-inflammatory and antipruritic activities. Fluocinolone binds the glucocorticoid receptor, followed by translocation of the ligand-receptor complex to the nucleus and transcription activation of genes containing glucocorticoid-responsive elements. Lipocortin-1 is one factor induced by fluocinolone that interacts with and inhibits cytosolic phospholipase 2 alpha, thereby preventing phospholipase translocation to the perinuclear membrane and subsequent release and conversion of arachidonic acid to inflammatory prostaglandins. In addition, MAPK phosphatase 1 is induced, thereby preventing the triggering of the MAPK cascade resulting in pro-inflammatory effects via Jun N-terminal kinase and c-Jun. Finally, fluocinolone binds to and inhibits nuclear factor kappa-B directly, resulting in inhibition of cyclooxygenase 2 transcription and subsequent prostaglandin synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F94A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7750-18F7-E053-F662850A60B1","beginDate":"2005-11-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fluconazole","valueDescription":"Fluconazole","ValueMeaning":{"publicId":"2576944","version":"1","preferredName":"Fluconazole","longName":"2576944","preferredDefinition":"A synthetic triazole with antifungal activity. Fluconazole preferentially inhibits fungal cytochrome P-450 sterol C-14 alpha-demethylation, resulting in the accumulation of fungal 14 alpha-methyl sterols, the loss of normal fungal sterols, and fungistatic activity. Mammalian cell demethylation is much less sensitive to fluconazole inhibition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluconazole","conceptCode":"C500","definition":"A synthetic triazole with antifungal activity. Fluconazole preferentially inhibits fungal cytochrome P-450 sterol C-14 alpha-demethylation, resulting in the accumulation of fungal 14 alpha-methyl sterols, the loss of normal fungal sterols, and fungistatic activity. Mammalian cell demethylation is much less sensitive to fluconazole inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F99D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2005-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-775A-18F7-E053-F662850A60B1","beginDate":"2005-11-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fludarabine","valueDescription":"Fludarabine","ValueMeaning":{"publicId":"2568535","version":"1","preferredName":"Fludarabine","longName":"2568535","preferredDefinition":"A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fludarabine","conceptCode":"C1094","definition":"A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8C4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"REEVESD","dateModified":"2005-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7764-18F7-E053-F662850A60B1","beginDate":"2005-11-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fludrocortisone","valueDescription":"Fludrocortisone Acetate","ValueMeaning":{"publicId":"2576862","version":"1","preferredName":"Fludrocortisone Acetate","longName":"2576862","preferredDefinition":"A synthetic corticosteroid. It is used to replace steroid hormones normally produced by the adrenal gland.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fludrocortisone Acetate","conceptCode":"C1103","definition":"The acetate salt of a synthetic fluorinated corticosteroid with antiinflammatory and antiallergic activities. As a glucocorticoid-receptor agonist, fludrocortisone binds to cytoplasmic receptors, translocates to the nucleus, and subsequently initiates the transcription of glucocorticoid-responsive genes such as lipocortins to inhibit phospholipase A2 (PLA2). Inhibition of PLA2 activity prevents the release of arachidonic acid, a precursor of eicosanoids such as prostaglandins and leukotrienes; eicosanoids are important mediators in the pro-inflammatory response mechanism. As a mineralocorticoid-receptor agonist, this agent stimulates Na+ reabsorption and water retention and K+ and H+ secretion in the distal tubules and collecting ducts of the kidney.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F94B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-776E-18F7-E053-F662850A60B1","beginDate":"2005-11-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Flunisolide","valueDescription":"Flunisolide","ValueMeaning":{"publicId":"2576863","version":"1","preferredName":"Flunisolide","longName":"2576863","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Flunisolide","conceptCode":"C29054","definition":"A synthetic corticosteroid with antiinflammatory and antiallergic properties. Flunisolide is a glucocorticoid receptor agonist that binds to cytoplasmic glucocorticoid receptors and subsequently translocates to the nucleus where it initiates the transcription of glucocorticoid-responsive genes such as lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both are potent mediators of inflammation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F94C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7778-18F7-E053-F662850A60B1","beginDate":"2005-11-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fluocinolone Acetonide","valueDescription":"Fluocinolone Acetonide","ValueMeaning":{"publicId":"2576864","version":"1","preferredName":"Fluocinolone Acetonide","longName":"2576864","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluocinolone Acetonide","conceptCode":"C29055","definition":"The acetonide salt form of fluocinolone, a synthetic fluorinated corticosteroid with antiinflammatory, antipruritic and vasoconstrictive properties. Fluocinolone is a glucocorticoid receptor agonist that binds to cytoplasmic glucocorticoid receptors and subsequently translocates to the nucleus where it initiates the transcription of glucocorticoid-responsive genes such as lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both are potent mediators of inflammation. Fluocinolone exerts its vasoconstrictive effect through inhibition of nitric oxide synthase, thereby blocking nitric oxide production and effectively diminishing the effect of nitric oxide on vascular smooth muscles leading to reduced blood flow.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F94D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7782-18F7-E053-F662850A60B1","beginDate":"2005-11-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fluocinonide","valueDescription":"Fluocinonide","ValueMeaning":{"publicId":"2576865","version":"1","preferredName":"Fluocinonide","longName":"2576865v1.00","preferredDefinition":"A synthetic glucocorticoid and derivative of fluocinolone acetonide with anti-inflammatory and antipruritic activities. Fluocinonide binds the glucocorticoid receptor, followed by translocation of the ligand-receptor complex to the nucleus and transcription activation of genes containing glucocorticoid-responsive elements. Lipocortin-1 is one factor induced by fluocinonide that interacts and inhibits cytosolic phospholipase 2 alpha, thereby preventing phospholipase translocation to the perinuclear membrane and subsequent release and conversion of arachidonic acid to inflammatory prostaglandins. In addition, MAPK phosphatase 1 is induced, thereby preventing the triggering of the MAPK cascade resulting in pro-inflammatory effects via Jun N-terminal kinase and c-Jun. Finally, fluocinonide binds to and inhibits nuclear factor kappa-B directly, resulting in inhibition of cyclooxygenase 2 transcription and subsequent prostaglandin synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluocinonide","conceptCode":"C29056","definition":"A synthetic glucocorticoid and derivative of fluocinolone acetonide with anti-inflammatory and antipruritic activities. Fluocinonide binds the glucocorticoid receptor, followed by translocation of the ligand-receptor complex to the nucleus and transcription activation of genes containing glucocorticoid-responsive elements. Lipocortin-1 is one factor induced by fluocinonide that interacts and inhibits cytosolic phospholipase 2 alpha, thereby preventing phospholipase translocation to the perinuclear membrane and subsequent release and conversion of arachidonic acid to inflammatory prostaglandins. In addition, MAPK phosphatase 1 is induced, thereby preventing the triggering of the MAPK cascade resulting in pro-inflammatory effects via Jun N-terminal kinase and c-Jun. Finally, fluocinonide binds to and inhibits nuclear factor kappa-B directly, resulting in inhibition of cyclooxygenase 2 transcription and subsequent prostaglandin synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F94E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-778C-18F7-E053-F662850A60B1","beginDate":"2005-11-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fluorometholone","valueDescription":"Fluorometholone","ValueMeaning":{"publicId":"2576866","version":"1","preferredName":"Fluorometholone","longName":"2576866","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluorometholone","conceptCode":"C29058","definition":"A synthetic glucocorticoid with anti-inflammatory and anti-allergic properties. Fluorometholone exerts its effects by interacting with cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. The synthesis of certain anti-inflammatory proteins is induced while the synthesis of certain inflammatory mediators is inhibited. As a result, there is an overall reduction in chronic inflammation and autoimmune reactions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F94F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7796-18F7-E053-F662850A60B1","beginDate":"2005-11-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fluoxamine","valueDescription":"Fluvoxamine Maleate","ValueMeaning":{"publicId":"2576875","version":"1","preferredName":"Fluvoxamine Maleate","longName":"2576875","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluvoxamine Maleate","conceptCode":"C29063","definition":"The maleate salt form of fluvoxamine, a 2-aminoethyl oxime ether of aralkylketones, with antidepressant, antiobsessive-compulsive, and antibulimic activities. Fluvoxamine blocks serotonin reuptake by inhibiting the serotonin reuptake pump of the presynaptic neuronal membrane leading to an increase of serotonin levels within the synaptic cleft. This results in facilitated serotonergic transmission and decreased serotonin turnover leading to antidepressant and antiobsessive-compulsive effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F958-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-77A0-18F7-E053-F662850A60B1","beginDate":"2005-11-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fluoxetine HCL","valueDescription":"Fluoxetine Hydrochloride","ValueMeaning":{"publicId":"2576868","version":"1","preferredName":"Fluoxetine Hydrochloride","longName":"2576868","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluoxetine Hydrochloride","conceptCode":"C2829","definition":"The hydrochloride salt form of fluoxetine, a diphenhydramine derivative and selective serotonin reuptake inhibitor with antidepressant, anti-anxiety, antiobsessional and antibulimic activity and with potential immunomodulating activity. Upon administration, fluoxetine binds to the presynaptic serotonin (5-HT) receptor resulting in negative allosteric modulation of the receptor complex, thereby blocking recycling of serotonin by the presynaptic receptor. Inhibition of serotonin reuptake by fluoxetine enhances serotonergic function through serotonin accumulation in the synaptic space, resulting in long-term desensitization and downregulation of 5-HT receptors, preventing 5-HT-mediated signaling and leading to antidepressant, anti-anxiety, antiobsessional and antibulimic effects. In addition, fluoxetine may inhibit the expression of pro-inflammatory cytokines, including interleukin-6 (IL-6). This may prevent IL-6-mediated inflammation and cytokine storm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F951-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"REEVESD","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-77AA-18F7-E053-F662850A60B1","beginDate":"2005-11-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Calcitonin","valueDescription":"Calcitonin","ValueMeaning":{"publicId":"2563590","version":"1","preferredName":"Calcitonin","longName":"2563590","preferredDefinition":"This gene is involved in the regulation of bone incorporation and blood calcium and phosphate levels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CALCA Gene","conceptCode":"C38189","definition":"This gene is involved in the regulation of bone incorporation and blood calcium and phosphate levels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C573-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-12-04","endDate":null,"createdBy":"CVALMONT","dateCreated":"2002-12-04","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-77B4-18F7-E053-F662850A60B1","beginDate":"2005-08-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Calcium","valueDescription":"CALCIUM","ValueMeaning":{"publicId":"2562501","version":"1","preferredName":"CALCIUM","longName":"2562501v1.00","preferredDefinition":"An element with atomic symbol Ca, atomic number 20, and atomic weight 40.08.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Calcium","conceptCode":"C331","definition":"An element with atomic symbol Ca, atomic number 20, and atomic weight 40.08.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C132-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-10-02","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-10-02","modifiedBy":"CLOHNES","dateModified":"2023-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-77BE-18F7-E053-F662850A60B1","beginDate":"2005-08-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Capecitabine","valueDescription":"CAPECITABINE","ValueMeaning":{"publicId":"2561705","version":"1","preferredName":"CAPECITABINE","longName":"2561705v1.00","preferredDefinition":"A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Capecitabine","conceptCode":"C1794","definition":"A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BE16-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-08","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-08","modifiedBy":"CLOHNES","dateModified":"2023-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-77C8-18F7-E053-F662850A60B1","beginDate":"2005-08-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cream","valueDescription":"Cream","ValueMeaning":{"publicId":"2567677","version":"1","preferredName":"Cream","longName":"2567677","preferredDefinition":"A semisolid emulsion of either the oil-in-water or the water-in-oil type, ordinarily intended for topical use.|On-line Medical Dictionary\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cream Dosage Form","conceptCode":"C28944","definition":"A semi-solid composed of an emulsion of lipids, hydrocarbons, waxes, or polyols in water.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D56A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"REEVESD","dateModified":"2006-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-77D2-18F7-E053-F662850A60B1","beginDate":"2005-08-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cholecalciferol","valueDescription":"Cholecalciferol","ValueMeaning":{"publicId":"3237531","version":"1","preferredName":"Cholecalciferol","longName":"3237531","preferredDefinition":"A steroid hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role in maintaining blood calcium and phosphorus levels and mineralization of bone. The activated form of cholecalciferol binds to vitamin D receptors and modulates gene expression. This leads to an increase in serum calcium concentrations by increasing intestinal absorption of phosphorus and calcium, promoting distal renal tubular reabsorption of calcium and increasing osteoclastic resorption.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cholecalciferol","conceptCode":"C48194","definition":"A steroid hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role in maintaining blood calcium and phosphorus levels and mineralization of bone. The activated form of cholecalciferol binds to vitamin D receptors and modulates gene expression. This leads to an increase in serum calcium concentrations by increasing intestinal absorption of phosphorus and calcium, promoting distal renal tubular reabsorption of calcium and increasing osteoclastic resorption.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3F86C65-82A9-B0DA-E040-BB89AD435E50","latestVersionIndicator":"Yes","beginDate":"2011-05-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-23","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8EFD-18F7-E053-F662850A60B1","beginDate":"2011-05-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"StemEnhance","valueDescription":"StemEnhance","ValueMeaning":{"publicId":"3206297","version":"1","preferredName":"StemEnhance","longName":"3206297","preferredDefinition":"Proprietary all-natural supplement documented to support the release of \r\nadult stem cells from bone marrow.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F0FB3FD-E49C-ECEB-E040-BB89AD43714B","latestVersionIndicator":"Yes","beginDate":"2011-03-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-03-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8F07-18F7-E053-F662850A60B1","beginDate":"2011-03-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Stemflo","valueDescription":"Stemflo","ValueMeaning":{"publicId":"3206298","version":"1","preferredName":"Stemflo","longName":"3206298","preferredDefinition":"Proprietary blend of herbs and natural ingredients to support blood flow; includes Fibrinerase, Mangosteen, Berry extract, Cat's Claw, Rehmannia, and Curcumin","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F0FB3FD-E4BF-ECEB-E040-BB89AD43714B","latestVersionIndicator":"Yes","beginDate":"2011-03-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-03-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8F11-18F7-E053-F662850A60B1","beginDate":"2011-03-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Trifluridine","valueDescription":"Trifluridine","ValueMeaning":{"publicId":"3203290","version":"1","preferredName":"Trifluridine","longName":"3203290","preferredDefinition":"A fluorinated thymidine analog with potential antineoplastic activity. Trifluridine is incorporated into DNA and inhibits thymidylate synthase, resulting in inhibition of DNA synthesis, inhibition of protein synthesis, and apoptosis. This agent also exhibits antiviral activity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trifluridine","conceptCode":"C905","definition":"A fluorinated thymidine analog with potential antineoplastic activity. Trifluridine is incorporated into DNA and inhibits thymidylate synthase, resulting in inhibition of DNA synthesis, inhibition of protein synthesis, and apoptosis. This agent also exhibits antiviral activity. (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E8654C5-9B06-1C49-E040-BB89AD432E7C","latestVersionIndicator":"Yes","beginDate":"2011-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-03-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8F1B-18F7-E053-F662850A60B1","beginDate":"2011-03-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Azor","valueDescription":"Azor (Amlodipine/Olmesartan)","ValueMeaning":{"publicId":"3205721","version":"1","preferredName":"Azor (Amlodipine/Olmesartan)","longName":"3205721","preferredDefinition":"A combination of Amlodipine and Olmesartan use to treat hypertension.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9EFD7B87-C122-51DF-E040-BB89AD436BE5","latestVersionIndicator":"Yes","beginDate":"2011-03-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-03-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8F25-18F7-E053-F662850A60B1","beginDate":"2011-03-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Halothane","valueDescription":"Halothane","ValueMeaning":{"publicId":"3282273","version":"1","preferredName":"Halothane","longName":"3282273","preferredDefinition":"A nonflammable, halogenated, hydrocarbon and general inhalation anesthetic. Although the exact mechanism of action is unknown, halothane provides relatively rapid induction of anesthesia by depressing the central nervous system, thereby producing a reversible loss of consciousness and sensation. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Halothane","conceptCode":"C47554","definition":"A nonflammable, halogenated, hydrocarbon and general inhalation anesthetic. Although the exact mechanism of action is unknown, halothane provides relatively rapid induction of anesthesia by depressing the central nervous system, thereby producing a reversible loss of consciousness and sensation. (NCI05)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD6089D2-67E4-AE7F-E040-BB89AD432A6C","latestVersionIndicator":"Yes","beginDate":"2011-09-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8F2F-18F7-E053-F662850A60B1","beginDate":"2011-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Gefitinib","valueDescription":"Gefitinib","ValueMeaning":{"publicId":"3237466","version":"1","preferredName":"Gefitinib","longName":"3237466","preferredDefinition":"An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gefitinib","conceptCode":"C1855","definition":"An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis. (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3F78E39-65BC-13D6-E040-BB89AD432B2B","latestVersionIndicator":"Yes","beginDate":"2011-05-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-05-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8F39-18F7-E053-F662850A60B1","beginDate":"2011-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fosphenytoin Sodium","valueDescription":"Fosphenytoin Sodium","ValueMeaning":{"publicId":"3282275","version":"1","preferredName":"Fosphenytoin Sodium","longName":"3282275","preferredDefinition":"The sodium salt form of fosphenytoin, a prodrug that is hydrolyzed to the anticonvulsant phenytoin upon parental administration. Phenytoin exerts its effect most likely through an enhancement of sodium efflux from neurons in the motor cortex. This leads to a suppression of excessive neuronal firing and spread of seizure activity. Other physiologic effects from actions of phenytoin include modulation of the voltage-dependent calcium channels of neurons, inhibition of calcium flux across neuronal membranes and enhancement of sodium-potassium ATPase activity of neurons and glial cells. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fosphenytoin Sodium","conceptCode":"C47543","definition":"The sodium salt form of fosphenytoin, a prodrug that is hydrolyzed to the anticonvulsant phenytoin upon parental administration. Phenytoin exerts its effect most likely through an enhancement of sodium efflux from neurons in the motor cortex. This leads to a suppression of excessive neuronal firing and spread of seizure activity. Other physiologic effects from actions of phenytoin include modulation of the voltage-dependent calcium channels of neurons, inhibition of calcium flux across neuronal membranes and enhancement of sodium-potassium ATPase activity of neurons and glial cells. (NCI05)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD6089D2-6814-AE7F-E040-BB89AD432A6C","latestVersionIndicator":"Yes","beginDate":"2011-09-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8F43-18F7-E053-F662850A60B1","beginDate":"2011-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fosamprenavir Calcium","valueDescription":"Fosamprenavir Calcium","ValueMeaning":{"publicId":"3282277","version":"1","preferredName":"Fosamprenavir Calcium","longName":"3282277","preferredDefinition":"The calcium salt form of fosamprenavir, prodrug of amprenavir, and a human immunodeficiency virus (HIV) protease inhibitor with antiviral property. Fosamprenavir is converted to amprenavir by cellular phosphatases in the epithelial cells of the intestine. Then amprenavir binds to the active site of HIV-1 protease, thereby preventing the proteolytic cleavage of viral Gag-Pol polypeptide into individual functional proteins, thereby leading to the formation of immature non-infectious viral particles.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fosamprenavir Calcium","conceptCode":"C61771","definition":"The calcium salt form of fosamprenavir, prodrug of amprenavir, and a human immunodeficiency virus (HIV) protease inhibitor with antiviral property. Fosamprenavir is converted to amprenavir by cellular phosphatases in the epithelial cells of the intestine. Then amprenavir binds to the active site of HIV-1 protease, thereby preventing the proteolytic cleavage of viral Gag-Pol polypeptide into individual functional proteins, thereby leading to the formation of immature non-infectious viral particles.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD6089D2-683A-AE7F-E040-BB89AD432A6C","latestVersionIndicator":"Yes","beginDate":"2011-09-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8F4D-18F7-E053-F662850A60B1","beginDate":"2011-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Follicle Stimulating Hormone/Luteinizing Hormone","valueDescription":"Follicle Stimulating Hormone/Luteinizing Hormone","ValueMeaning":{"publicId":"2576877","version":"1","preferredName":"Follicle Stimulating Hormone/Luteinizing Hormone","longName":"2576877","preferredDefinition":"Follicle Stimulating Hormone/Luteinizing Hormone","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F95A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"REEVESD","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8F57-18F7-E053-F662850A60B1","beginDate":"2011-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fluorescein Sodium","valueDescription":"Fluorescein Sodium Injection","ValueMeaning":{"publicId":"3282279","version":"1","preferredName":"Fluorescein Sodium Injection","longName":"3282279","preferredDefinition":"An injectable form of the sodium salt of the fluorophore fluorescein. Fluorescein responds to electromagnetic radiation between the wavelengths of 465-490 nm and fluoresces, emitting light at wavelengths of 520-530 nm that can be detected visually.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluorescein Sodium Injection","conceptCode":"C82405","definition":"An injectable form of the sodium salt of the fluorophore fluorescein. Fluorescein responds to electromagnetic radiation between the wavelengths of 465-490 nm and fluoresces, emitting light at wavelengths of 520-530 nm that can be detected visually.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD6089D2-686B-AE7F-E040-BB89AD432A6C","latestVersionIndicator":"Yes","beginDate":"2011-09-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8F61-18F7-E053-F662850A60B1","beginDate":"2011-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Floxacillin","valueDescription":"Floxacillin","ValueMeaning":{"publicId":"3282281","version":"1","preferredName":"Floxacillin","longName":"3282281","preferredDefinition":"A narrow-spectrum, semisynthetic isoxazolyl penicillin with antibacterial activity. Floxacillin binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall, eventually causing cell lysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Flucloxacillin","conceptCode":"C80591","definition":"A narrow-spectrum, semisynthetic isoxazolyl penicillin with antibacterial activity. Floxacillin binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall, eventually causing cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD6089D2-6891-AE7F-E040-BB89AD432A6C","latestVersionIndicator":"Yes","beginDate":"2011-09-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8F6B-18F7-E053-F662850A60B1","beginDate":"2011-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Flebogamma","valueDescription":"Therapeutic Immune Globulin","ValueMeaning":{"publicId":"3282282","version":"1","preferredName":"Therapeutic Immune Globulin","longName":"3282282","preferredDefinition":"A preparation of plasma proteins derived from the pooled plasma of adult donors. Largely comprised of IgG antibodies, therapeutic immune globulin provides passive immunization by increasing the recipient's serum levels of circulating antibodies. IgG antibodies have multiple functions, including binding to and neutralizing bacterial toxins; opsonization of pathogens; activation of complement; and suppression of pathogenic cytokines and phagocytes through binding to CD5, interleukin-1a (IL-1a), interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and T-cell receptors.  Therapeutic immune globulin may diminish pathogenic mechanisms in some autoimmune diseases by binding to and inhibiting the activity of autoantibodies. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Immune Globulin","conceptCode":"C2701","definition":"A preparation of plasma proteins derived from the pooled plasma of adult donors. Largely comprised of IgG antibodies, therapeutic immune globulin provides passive immunization by increasing the recipient's serum levels of circulating antibodies. IgG antibodies have multiple functions, including binding to and neutralizing bacterial toxins; opsonization of pathogens; activation of complement; and suppression of pathogenic cytokines and phagocytes through binding to CD5, interleukin-1a (IL-1a), interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and T-cell receptors. Therapeutic immune globulin may diminish pathogenic mechanisms in some autoimmune diseases by binding to and inhibiting the activity of autoantibodies. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD6089D2-68B4-AE7F-E040-BB89AD432A6C","latestVersionIndicator":"Yes","beginDate":"2011-09-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8F75-18F7-E053-F662850A60B1","beginDate":"2011-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fiorinal","valueDescription":"Fiorinal (Aspirin, Butalbital, Caffeine)","ValueMeaning":{"publicId":"3282283","version":"1","preferredName":"Fiorinal (Aspirin, Butalbital, Caffeine)","longName":"3282283","preferredDefinition":"Fiorinal (Aspirin, Butalbital, Caffeine)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD6089D2-68D7-AE7F-E040-BB89AD432A6C","latestVersionIndicator":"Yes","beginDate":"2011-09-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8F7F-18F7-E053-F662850A60B1","beginDate":"2011-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ferrous Fumarate","valueDescription":"Ferrous Fumarate","ValueMeaning":{"publicId":"3282285","version":"1","preferredName":"Ferrous Fumarate","longName":"3282285","preferredDefinition":"The fumarate salt form of the mineral iron. Administration of ferrous fumarate results in elevation of serum iron concentration, which is then assimilated into hemoglobin, required for the transport of oxygen, or trapped in the reticuloendothelial cells for storage. This agent is used as a dietary supplement, and to prevent or treat iron deficiency related syndromes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ferrous Fumarate","conceptCode":"C61763","definition":"The fumarate salt form of the mineral iron. Administration of ferrous fumarate results in elevation of serum iron concentration, which is then assimilated into hemoglobin, required for the transport of oxygen, or trapped in the reticuloendothelial cells for storage. This agent is used as a dietary supplement, and to prevent or treat iron deficiency related syndromes.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD6089D2-68FD-AE7F-E040-BB89AD432A6C","latestVersionIndicator":"Yes","beginDate":"2011-09-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8F89-18F7-E053-F662850A60B1","beginDate":"2011-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Exenatide","valueDescription":"Exenatide","ValueMeaning":{"publicId":"3282287","version":"1","preferredName":"Exenatide","longName":"3282287","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Exenatide","conceptCode":"C65611","definition":"A 39 amino acid peptide and synthetic version of exendin-4, a hormone found in the saliva of the venomous lizard Gila monster, with insulin secretagogue and antihyperglycemic activity. Exenatide is administered subcutaneously and mimics human glucagon-like peptide-1 (GLP-1). Compared to GLP-1, exenatide has a longer half-life of 2.4 hours.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD6089D2-6923-AE7F-E040-BB89AD432A6C","latestVersionIndicator":"Yes","beginDate":"2011-09-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8F93-18F7-E053-F662850A60B1","beginDate":"2011-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Irbesartan-Hydrochlorothiazide","valueDescription":"Irbesartan-Hydrochlorothiazide","ValueMeaning":{"publicId":"3282288","version":"1","preferredName":"Irbesartan-Hydrochlorothiazide","longName":"3282288","preferredDefinition":"Irbesartan-Hydrochlorothiazide","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD6089D2-6947-AE7F-E040-BB89AD432A6C","latestVersionIndicator":"Yes","beginDate":"2011-09-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8F9D-18F7-E053-F662850A60B1","beginDate":"2011-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Insulin Detemir","valueDescription":"Insulin Detemir","ValueMeaning":{"publicId":"3282290","version":"1","preferredName":"Insulin Detemir","longName":"3282290","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Insulin Detemir","conceptCode":"C65920","definition":"A long-lasting, recombinant version of human insulin. It is an insulin analogue with myristic acid bound to the lysine at position B29 and a deletion of B30.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD6089D2-696D-AE7F-E040-BB89AD432A6C","latestVersionIndicator":"Yes","beginDate":"2011-09-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8FA7-18F7-E053-F662850A60B1","beginDate":"2011-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Immune Globulin 10%","valueDescription":"Immune Globulin/Zidovudine","ValueMeaning":{"publicId":"3282292","version":"1","preferredName":"Immune Globulin/Zidovudine","longName":"3282292","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune Globulin/Zidovudine","conceptCode":"C15479","definition":"A combination of agents containing immune globulin and zidovudine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD6089D2-6993-AE7F-E040-BB89AD432A6C","latestVersionIndicator":"Yes","beginDate":"2011-09-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8FB1-18F7-E053-F662850A60B1","beginDate":"2011-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ibadronate Sodium","valueDescription":"Ibadronate Sodium","ValueMeaning":{"publicId":"3282293","version":"1","preferredName":"Ibadronate Sodium","longName":"3282293v1.00","preferredDefinition":"The sodium salt form of ibandronic acid, a synthetic nitrogen-containing bisphosphonate. Ibandronic acid inhibits farnesyl pyrophosphate synthase, resulting in a reduction in geranylgeranyl GTPase signaling proteins and apoptosis of osteoclasts. This agent increases bone mineral density, decreases bone remodeling, inhibits osteoclast-mediated bone resorption, and reduces metastases-related and corticosteroid-related bone pain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ibandronate Sodium","conceptCode":"C1670","definition":"The sodium salt form of ibandronic acid, a synthetic nitrogen-containing bisphosphonate. Ibandronic acid inhibits farnesyl pyrophosphate synthase, resulting in a reduction in geranylgeranyl GTPase signaling proteins and apoptosis of osteoclasts. This agent increases bone mineral density, decreases bone remodeling, inhibits osteoclast-mediated bone resorption, and reduces metastases-related and corticosteroid-related bone pain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD6089D2-69B6-AE7F-E040-BB89AD432A6C","latestVersionIndicator":"Yes","beginDate":"2011-09-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-20","modifiedBy":"CLOHNES","dateModified":"2023-08-04","changeDescription":null,"administrativeNotes":"8/4/23 Added missing concept per cleanup activities cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8FBB-18F7-E053-F662850A60B1","beginDate":"2011-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Hyaluronic Acid","valueDescription":"Hyaluronic Acid","ValueMeaning":{"publicId":"3282295","version":"1","preferredName":"Hyaluronic Acid","longName":"3282295","preferredDefinition":"A glucosaminoglycan consisting of D-glucuronic acid and N-acetyl-D-glucosamine disaccharide units that is a component of connective tissue, skin, vitreous humour, umbilical cord, synovial fluid and the capsule of certain microorganisms contributing to adhesion, elasticity, and viscosity of extracellular substances.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hyaluronic Acid","conceptCode":"C549","definition":"A glucosaminoglycan consisting of D-glucuronic acid and N-acetyl-D-glucosamine disaccharide units that is a component of connective tissue, skin, vitreous humour, umbilical cord, synovial fluid and the capsule of certain microorganisms contributing to adhesion, elasticity, and viscosity of extracellular substances.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD6089D2-69DC-AE7F-E040-BB89AD432A6C","latestVersionIndicator":"Yes","beginDate":"2011-09-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-20","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8FC5-18F7-E053-F662850A60B1","beginDate":"2011-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Homotropine Hydroromide","valueDescription":"Homotropine Hydroromide","ValueMeaning":{"publicId":"3282296","version":"1","preferredName":"Homotropine Hydroromide","longName":"3282296","preferredDefinition":"Homotropine Hydroromide","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD6089D2-69FF-AE7F-E040-BB89AD432A6C","latestVersionIndicator":"Yes","beginDate":"2011-09-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8FCF-18F7-E053-F662850A60B1","beginDate":"2011-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Hexachlorophene","valueDescription":"Hexachlorophene","ValueMeaning":{"publicId":"3282298","version":"1","preferredName":"Hexachlorophene","longName":"3282298","preferredDefinition":"A chlorinated bisphenol antiseptic agent with bacteriostatic activity. Hexachlorophene is used topically in soaps, creams and dermatological preparations and is active against gram-positive organisms, but much less effective against gram-negative organisms. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hexachlorophene","conceptCode":"C47556","definition":"A chlorinated bisphenol antiseptic agent with bacteriostatic activity. Hexachlorophene is used topically in soaps, creams and dermatological preparations and is active against gram-positive organisms, but much less effective against gram-negative organisms. (NCI05)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD6089D2-6A25-AE7F-E040-BB89AD432A6C","latestVersionIndicator":"Yes","beginDate":"2011-09-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8FD9-18F7-E053-F662850A60B1","beginDate":"2011-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Hetastarch/Sodium Chloride","valueDescription":"Hetastarch","ValueMeaning":{"publicId":"3188879","version":"1","preferredName":"Hetastarch","longName":"3188879","preferredDefinition":"A plasma volume expander.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hetastarch","conceptCode":"C559","definition":"A synthetic, nonionic hydroxyethyl derivative of starch used as a plasma expander when prepared in an isotonic solution. Upon intravenous administration, hydroxyethyl starch colloid increases blood volume and thus improves circulation. This agent is almost exclusively excreted by the kidneys and is potentially nephrotoxic.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B7A3828-EB85-316D-E040-BB89AD432EE5","latestVersionIndicator":"Yes","beginDate":"2011-02-04","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-02-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8FE3-18F7-E053-F662850A60B1","beginDate":"2011-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Herbal supplement, NOS","valueDescription":"Herbal Supplement","ValueMeaning":{"publicId":"3282300","version":"1","preferredName":"Herbal Supplement","longName":"3282300","preferredDefinition":"A product made from a plant that is thought to be useful in treating disease or staying healthy. Herbal supplements are taken by mouth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Herbal Supplement","conceptCode":"C93221","definition":"A product made from a plant that is thought to be useful in treating disease or staying healthy. Herbal supplements are taken by mouth.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD6089D2-6A60-AE7F-E040-BB89AD432A6C","latestVersionIndicator":"Yes","beginDate":"2011-09-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8FED-18F7-E053-F662850A60B1","beginDate":"2011-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Buprepinorphine HCL","valueDescription":"Buprepinorphine Hydrochloride","ValueMeaning":{"publicId":"3269964","version":"1","preferredName":"Buprepinorphine Hydrochloride","longName":"3269964","preferredDefinition":"Buprepinorphine Hydrochloride","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC49B0C5-5F31-C986-E040-BB89AD432719","latestVersionIndicator":"Yes","beginDate":"2011-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-8FF7-18F7-E053-F662850A60B1","beginDate":"2011-09-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Biotene Toothpaste","valueDescription":"Biotene Toothpaste","ValueMeaning":{"publicId":"3269965","version":"1","preferredName":"Biotene Toothpaste","longName":"3269965","preferredDefinition":"Biotene Toothpaste","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC49B0C5-5F54-C986-E040-BB89AD432719","latestVersionIndicator":"Yes","beginDate":"2011-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9001-18F7-E053-F662850A60B1","beginDate":"2011-09-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Barley Grain","valueDescription":"Barley Grain","ValueMeaning":{"publicId":"3269966","version":"1","preferredName":"Barley Grain","longName":"3269966","preferredDefinition":"Barley Grain","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC49B0C5-5F77-C986-E040-BB89AD432719","latestVersionIndicator":"Yes","beginDate":"2011-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-900B-18F7-E053-F662850A60B1","beginDate":"2011-09-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Azelastine HCL","valueDescription":"Azelastine Hydrochloride","ValueMeaning":{"publicId":"3269968","version":"1","preferredName":"Azelastine Hydrochloride","longName":"3269968","preferredDefinition":"The hydrochloride salt form of azelastine, a phthalazinone derivative with antihistaminergic activity. Azelastine hydrochloride competes with histamine for the H1 receptor, thereby diminishing the actions of histamine on effector cells and decreasing the histamine-mediated symptoms of allergic reaction, such as bronchoconstriction, vasodilation, increased capillary permeability and spasmodic contractions of gastrointestinal smooth muscle.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Azelastine Hydrochloride","conceptCode":"C47408","definition":"The hydrochloride salt form of azelastine, a phthalazinone derivative with antihistaminergic activity. Azelastine hydrochloride competes with histamine for the H1 receptor, thereby diminishing the actions of histamine on effector cells and decreasing the histamine-mediated symptoms of allergic reaction, such as bronchoconstriction, vasodilation, increased capillary permeability and spasmodic contractions of gastrointestinal smooth muscle.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC49B0C5-5F9D-C986-E040-BB89AD432719","latestVersionIndicator":"Yes","beginDate":"2011-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9015-18F7-E053-F662850A60B1","beginDate":"2011-09-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Atripla","valueDescription":"Emtricitabine/tenofovir/efavirenz","ValueMeaning":{"publicId":"3269969","version":"1","preferredName":"Emtricitabine/tenofovir/efavirenz","longName":"3269969v1.00","preferredDefinition":"A fixed combination of efavirenz, a non-nucleoside reverse transcriptase (RT) inhibitor (NNRTI); emtricitabine, a nucleoside RT inhibitor (NRTI) analog of cytidine; and tenofovir disoproxil fumarate, an NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, efavirenz, emtricitabine, and tenofovir disoproxil fumarate inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate","conceptCode":"C157403","definition":"A fixed combination of efavirenz, a non-nucleoside reverse transcriptase (RT) inhibitor (NNRTI); emtricitabine, a nucleoside RT inhibitor (NRTI) analog of cytidine; and tenofovir disoproxil fumarate, an NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, efavirenz, emtricitabine, and tenofovir disoproxil fumarate inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC49B0C5-5FC0-C986-E040-BB89AD432719","latestVersionIndicator":"Yes","beginDate":"2011-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-06","modifiedBy":"CLOHNES","dateModified":"2023-08-04","changeDescription":null,"administrativeNotes":"8/4/23 Added missing concept per cleanup activities cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-901F-18F7-E053-F662850A60B1","beginDate":"2011-09-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Arthro Joint Complex","valueDescription":"Arthro Joint Complex","ValueMeaning":{"publicId":"2576006","version":"1","preferredName":"Arthro Joint Complex","longName":"2576006","preferredDefinition":"Arthro Joint Complex","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F5F3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2005-08-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9029-18F7-E053-F662850A60B1","beginDate":"2011-09-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Analgesic Balm","valueDescription":"Analgesic Balm","ValueMeaning":{"publicId":"3269970","version":"1","preferredName":"Analgesic Balm","longName":"3269970","preferredDefinition":"Analgesic Balm","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC49B0C5-5FEE-C986-E040-BB89AD432719","latestVersionIndicator":"Yes","beginDate":"2011-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9033-18F7-E053-F662850A60B1","beginDate":"2011-09-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Alpha-Lipoic Acid","valueDescription":"Alpha-Lipoic Acid","ValueMeaning":{"publicId":"3179560","version":"1","preferredName":"Alpha-Lipoic Acid","longName":"3179560","preferredDefinition":"A naturally occurring micronutrient, synthesized in small amounts by plants and animals (including humans), with antioxidant and potential chemopreventive activities. Alpha-lipoic acid acts as a free radical scavenger and assists in repairing oxidative damage and regenerates endogenous antioxidants, including vitamins C and E and glutathione. This agent also promotes glutathione synthesis. In addition, alpha-lipoic acid exerts metal chelating capacities and functions as a cofactor in various mitochondrial enzyme complexes involved in the decarboxylation of alpha-keto acids.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alpha-Lipoic Acid","conceptCode":"C61595","definition":"A naturally occurring micronutrient, synthesized in small amounts by plants and animals (including humans), with antioxidant and potential chemopreventive activities. Alpha-lipoic acid acts as a free radical scavenger and assists in repairing oxidative damage and regenerates endogenous antioxidants, including vitamins C and E and glutathione. This agent also promotes glutathione synthesis. In addition, alpha-lipoic acid exerts metal chelating capacities and functions as a cofactor in various mitochondrial enzyme complexes involved in the decarboxylation of alpha-keto acids.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"98A38FE3-E06F-444C-E040-BB89AD4311E5","latestVersionIndicator":"Yes","beginDate":"2010-12-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-903D-18F7-E053-F662850A60B1","beginDate":"2011-09-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Mouthwash","valueDescription":"Mouthwash Dosage Form","ValueMeaning":{"publicId":"2579085","version":"1","preferredName":"Mouthwash Dosage Form","longName":"2579085","preferredDefinition":"A solution or suspension intended for oral administration, for its deodorizing or antiseptic effects in the oral cavity. Usually, the mouthwash is swished around the mouth and expelled.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mouthwash Dosage Form","conceptCode":"C29269","definition":"A solution or suspension intended for oral administration, for its deodorizing or antiseptic effects in the oral cavity. Usually, the mouthwash is swished around the mouth and expelled.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-01FA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-05-03","modifiedBy":"COOPERM","dateModified":"2017-01-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9047-18F7-E053-F662850A60B1","beginDate":"2011-10-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Potassium Iodide","valueDescription":"Potassium Iodide","ValueMeaning":{"publicId":"3293799","version":"1","preferredName":"Potassium Iodide","longName":"3293799","preferredDefinition":"A metal halide composed of potassium and iodide with thyroid protecting and expectorant properties. Potassium iodide can block absorption of radioactive iodine by the thyroid gland through flooding the thyroid with non-radioactive iodine and preventing intake of radioactive molecules, thereby protecting the thyroid from cancer causing radiation. In addition, this agent acts as an expectorant by increasing secretion of respiratory fluids resulting in decreased mucus viscosity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Potassium Iodide","conceptCode":"C47680","definition":"A metal halide composed of potassium and iodide with thyroid protecting and expectorant properties. Potassium iodide can block absorption of radioactive iodine by the thyroid gland through flooding the thyroid with non-radioactive iodine and preventing intake of radioactive molecules, thereby protecting the thyroid from cancer causing radiation. In addition, this agent acts as an expectorant by increasing secretion of respiratory fluids resulting in decreased mucus viscosity.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF0C3CCE-D7C1-E20C-E040-BB89AD433BC3","latestVersionIndicator":"Yes","beginDate":"2011-10-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9051-18F7-E053-F662850A60B1","beginDate":"2011-10-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Gadopentetate Dimeglumine","valueDescription":"Gadopentetate Dimeglumine","ValueMeaning":{"publicId":"3293801","version":"1","preferredName":"Gadopentetate Dimeglumine","longName":"3293801","preferredDefinition":"A gadolinium complex of diethylenetriamine pentaacetic acid with ionic paramagnetic properties. Gadopentetate dimeglumine may provide contrast enhancement during magnetic resonance imaging (MRI) of intracranial lesions with abnormal vascularity or of abnormalities in the blood-brain barrier (BBB). (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gadopentetate Dimeglumine","conceptCode":"C2588","definition":"A gadolinium complex of diethylenetriamine pentaacetic acid with ionic paramagnetic properties. Gadopentetate dimeglumine may provide contrast enhancement during magnetic resonance imaging (MRI) of intracranial lesions with abnormal vascularity or of abnormalities in the blood-brain barrier (BBB). (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF0C3CCE-D7E7-E20C-E040-BB89AD433BC3","latestVersionIndicator":"Yes","beginDate":"2011-10-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-905B-18F7-E053-F662850A60B1","beginDate":"2011-10-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Noscapine","valueDescription":"Noscapine","ValueMeaning":{"publicId":"3293803","version":"1","preferredName":"Noscapine","longName":"3293803","preferredDefinition":"A phthalide isoquinoline non-narcotic alkaloid derived from the opium poppy Papaver somniferum, with mild analgesic, antitussive, and potential antineoplastic activities. Noscapine exerts its antitussive effects through the activation of sigma opioid receptors. This agent appears to exert its antimitotic effect by binding to tubulin, resulting in a disruption of microtubule assembly dynamics and subsequently, the inhibition of mitosis and tumor cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Noscapine","conceptCode":"C80589","definition":"A phthalide isoquinoline non-narcotic alkaloid derived from the opium poppy Papaver somniferum, with mild analgesic, antitussive, and potential antineoplastic activities. Noscapine exerts its antitussive effects through the activation of sigma opioid receptors. This agent appears to exert its antimitotic effect by binding to tubulin, resulting in a disruption of microtubule assembly dynamics and subsequently, the inhibition of mitosis and tumor cell death.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF0C3CCE-D80E-E20C-E040-BB89AD433BC3","latestVersionIndicator":"Yes","beginDate":"2011-10-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9065-18F7-E053-F662850A60B1","beginDate":"2011-10-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Psoralen","valueDescription":"Psoralen","ValueMeaning":{"publicId":"3293804","version":"1","preferredName":"Psoralen","longName":"3293804","preferredDefinition":"A furocoumarin that intercalates with DNA, inhibiting DNA synthesis and cell division.  Psoralen is used in Photochemotherapy or PUVA (Psoralen with high-intensity long-wavelength UVA irradiation). (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Psoralen","conceptCode":"C2586","definition":"A furocoumarin that intercalates with DNA, inhibiting DNA synthesis and cell division. Psoralen is used in Photochemotherapy with high-intensity long-wavelength UVA irradiation. Psoralens are tricyclic furocumarins and have a strong tendency to intercalate with DNA base pairs. Irradiation of nucleic acids in the presence of psoralen with long wave UV (~360 nm) results in the 2+2 cyclo- addition of either of its two photoreactive sites with 5,6-carbon bonds of pyrimidines resulting in crosslinking double-stranded nucleic acids.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF0C3CCE-D831-E20C-E040-BB89AD433BC3","latestVersionIndicator":"Yes","beginDate":"2011-10-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-906F-18F7-E053-F662850A60B1","beginDate":"2011-10-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Mycostatin","valueDescription":"Nystatin","ValueMeaning":{"publicId":"2575695","version":"1","preferredName":"Nystatin","longName":"2575695","preferredDefinition":"Macrolide antifungal antibiotic complex produced by Streptomyces noursei, S. aureus, and other Streptomyces species. The biologically active components of the complex are nystatin A1, A2, and A3.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nystatin","conceptCode":"C710","definition":"A polyene macrolide antibiotic, with antifungal activity. Upon administration, nystatin binds to sterols in the fungal plasma membrane, thereby increasing membrane permeability. This leads to leakage of important intracellular components, cell rupture, and eventually fungal cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4BC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9079-18F7-E053-F662850A60B1","beginDate":"2011-10-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Moxifloxacin HCL","valueDescription":"Moxifloxacin Hydrochloride","ValueMeaning":{"publicId":"3293874","version":"1","preferredName":"Moxifloxacin Hydrochloride","longName":"3293874","preferredDefinition":"The hydrochloride salt of a fluoroquinolone antibacterial antibiotic. Moxifloxacin binds to and inhibits the bacterial enzymes DNA gyrase (topoisomerase II) and topoisomerase IV, resulting in inhibition of DNA replication and repair and cell death in sensitive bacterial species.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Moxifloxacin Hydrochloride","conceptCode":"C38696","definition":"The hydrochloride salt of a fluoroquinolone antibacterial antibiotic. Moxifloxacin binds to and inhibits the bacterial enzymes DNA gyrase (topoisomerase II) and topoisomerase IV, resulting in inhibition of DNA replication and repair and cell death in sensitive bacterial species.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF2094A8-27F1-843F-E040-BB89AD436D8E","latestVersionIndicator":"Yes","beginDate":"2011-10-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9083-18F7-E053-F662850A60B1","beginDate":"2011-10-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Betamethasone Dipropionate 0.05%","valueDescription":"Betamethasone Dipropionate 0.05% (Diprolene, Diprolene AF, Maxivate, Diprosone)","ValueMeaning":{"publicId":"3257118","version":"1","preferredName":"Betamethasone Dipropionate 0.05% (Diprolene, Diprolene AF, Maxivate, Diprosone)","longName":"3257118","preferredDefinition":"The 17,21-dipropionate ester of betamethasone, a synthetic glucocorticoid with metabolic, immunosuppressive and anti-inflammatory actions. Betamethasone dipropionate binds to specific intracellular glucocorticoid receptors and subsequently binds to DNA to modify gene expression. The synthesis of certain anti-inflammatory proteins is induced while the synthesis of certain inflammatory mediators is inhibited.  As a result, there is an overall reduction in chronic inflammation and autoimmune reactions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Betamethasone Dipropionate","conceptCode":"C47963","definition":"The 17,21-dipropionate ester of betamethasone, a synthetic glucocorticoid with metabolic, immunosuppressive and anti-inflammatory actions. Betamethasone dipropionate binds to specific intracellular glucocorticoid receptors and subsequently binds to DNA to modify gene expression. The synthesis of certain anti-inflammatory proteins is induced while the synthesis of certain inflammatory mediators is inhibited.  As a result, there is an overall reduction in chronic inflammation and autoimmune reactions.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8E45D77-3D7D-FD86-E040-BB89AD43052F","latestVersionIndicator":"Yes","beginDate":"2011-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-908D-18F7-E053-F662850A60B1","beginDate":"2011-07-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Betamethasone Valerate 0.01%","valueDescription":"Betamethasone Valerate 0.01% Lotion (Valisone)","ValueMeaning":{"publicId":"3257120","version":"1","preferredName":"Betamethasone Valerate 0.01% Lotion (Valisone)","longName":"3257120","preferredDefinition":"A liquid preparation for bathing the skin, or an injured or diseased part, either for a medicinal purpose, or for improving its appearance. (On-line Medical Dictionary): The 17-valerate ester of betamethasone, a synthetic glucocorticoid with metabolic, immunosuppressive and anti-inflammatory actions. Betamethasone valerate binds to specific intracellular glucocorticoid receptors and subsequently binds to DNA to modify gene expression. The synthesis of certain anti-inflammatory proteins is induced while the synthesis of certain inflammatory mediators is inhibited. As a result, there is an overall reduction in chronic inflammation and autoimmune reactions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lotion Dosage Form","conceptCode":"C29167","definition":"A semi-solid composed of an oil in water emulsion, with lower viscosity than cream or gel.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Betamethasone Valerate","conceptCode":"C47962","definition":"The 17-valerate ester of betamethasone, a synthetic glucocorticoid with metabolic, immunosuppressive and anti-inflammatory actions. Betamethasone valerate binds to specific intracellular glucocorticoid receptors and subsequently binds to DNA to modify gene expression. The synthesis of certain anti-inflammatory proteins is induced while the synthesis of certain inflammatory mediators is inhibited. As a result, there is an overall reduction in chronic inflammation and autoimmune reactions.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8E45D77-3DAB-FD86-E040-BB89AD43052F","latestVersionIndicator":"Yes","beginDate":"2011-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9097-18F7-E053-F662850A60B1","beginDate":"2011-07-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fluticasone Propionate 0.005%","valueDescription":"Fluticasone Proprionate 0.005% (Cutivate)","ValueMeaning":{"publicId":"3257575","version":"1","preferredName":"Fluticasone Proprionate 0.005% (Cutivate)","longName":"3257575","preferredDefinition":"A number with no fractional part.::0.005%: The propionate salt form of fluticasone, a synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, antiinflammatory and antipruritic effects. Binding and activation of the glucocorticoid receptor results in the activation of lipocortin that in turn inhibits cytosolic phospholipase A2, which triggers cascade of reactions involved in synthesis of inflammatory mediators, such as prostaglandins and leukotrienes. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leads to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Fluticasone Propionate","conceptCode":"C29061","definition":"The propionate salt form of fluticasone, a synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, antiinflammatory and antipruritic effects. Binding and activation of the glucocorticoid receptor results in the activation of lipocortin that in turn inhibits cytosolic phospholipase A2, which triggers cascade of reactions involved in synthesis of inflammatory mediators, such as prostaglandins and leukotrienes. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leads to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8EA5DCE-91E6-385A-E040-BB89AD436355","latestVersionIndicator":"Yes","beginDate":"2011-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-90A1-18F7-E053-F662850A60B1","beginDate":"2011-07-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Clobetasol Proprionate 0.05%","valueDescription":"Clobetasol Propionate 0.05% (Temovate)","ValueMeaning":{"publicId":"2576057","version":"1","preferredName":"Clobetasol Propionate 0.05% (Temovate)","longName":"2576057","preferredDefinition":"The propionate salt form of clobetasol, a topical synthetic corticosteroid with anti-inflammatory, anti-pruritic, and vasoconstrictive properties. Clobetasol propionate exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators. Specifically, clobetasol propionate appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from membrane phospholipids by phospholipase A2.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clobetasol Propionate","conceptCode":"C28934","definition":"The propionate salt form of clobetasol, a topical synthetic corticosteroid with anti-inflammatory, anti-pruritic, and vasoconstrictive properties. Clobetasol propionate exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators. Specifically, clobetasol propionate appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from membrane phospholipids by phospholipase A2.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F626-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2011-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-90AB-18F7-E053-F662850A60B1","beginDate":"2011-07-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Desonide 0.05%","valueDescription":"Desonide 0.05% (Tridesilon)","ValueMeaning":{"publicId":"3257138","version":"1","preferredName":"Desonide 0.05% (Tridesilon)","longName":"3257138","preferredDefinition":"A synthetic glucocorticosteroid for topical use, with anti-inflammatory activity. Desonide binds to glucocorticoid receptors in the cytoplasm, and the ligand-receptor complex is translocated as a homodimer into the nucleus, where transcription activation via glucocorticoid response elements within glucocorticoid-responsive genes occur. This agent induces transcription of genes coding for anti-inflammatory proteins, including lipocortin-1, interleukin-10, interleukin-1 receptor antagonist and neutral endopeptidase. Increased synthesis of lipocortin-1 has an inhibitory effect on phospholipase A2, which in turn inhibits the release arachidonic acid, thereby controlling the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Desonide","conceptCode":"C61702","definition":"A synthetic glucocorticosteroid for topical use, with anti-inflammatory activity. Desonide binds to glucocorticoid receptors in the cytoplasm, and the ligand-receptor complex is translocated as a homodimer into the nucleus, where transcription activation via glucocorticoid response elements within glucocorticoid-responsive genes occur. This agent induces transcription of genes coding for anti-inflammatory proteins, including lipocortin-1, interleukin-10, interleukin-1 receptor antagonist and neutral endopeptidase. Increased synthesis of lipocortin-1 has an inhibitory effect on phospholipase A2, which in turn inhibits the release arachidonic acid, thereby controlling the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8E4F3E1-0D2F-C4A3-E040-BB89AD436510","latestVersionIndicator":"Yes","beginDate":"2011-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-90B5-18F7-E053-F662850A60B1","beginDate":"2011-07-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Halcinonide 0,1%","valueDescription":"Halcinonide 0.1% (Halog)","ValueMeaning":{"publicId":"3257258","version":"1","preferredName":"Halcinonide 0.1% (Halog)","longName":"3257258","preferredDefinition":"A topical, synthetic glucocorticoid with anti-inflammatory and anti-allergic properties. Halcinonide exerts its effect by interacting with specific intracellular receptors, and the ligand-receptor complex subsequently modulates gene expressions via the typical glucocorticoid signalling pathway. This results in the synthesis of certain anti-inflammatory proteins as well as in synthesis inhibition of certain inflammatory mediators. Consequently, an overall reduction in chronic inflammation and autoimmune reactions are accomplished. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Halcinonide","conceptCode":"C47552","definition":"A topical, synthetic glucocorticoid with anti-inflammatory and anti-allergic properties. Halcinonide exerts its effect by interacting with specific intracellular receptors, and the ligand-receptor complex subsequently modulates gene expressions via the typical glucocorticoid signalling pathway. This results in the synthesis of certain anti-inflammatory proteins as well as in synthesis inhibition of certain inflammatory mediators. Consequently, an overall reduction in chronic inflammation and autoimmune reactions are accomplished. (NCI05)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8EA5DCE-918B-385A-E040-BB89AD436355","latestVersionIndicator":"Yes","beginDate":"2011-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-90BF-18F7-E053-F662850A60B1","beginDate":"2011-07-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fluocinonode 0.05%","valueDescription":"Fluocinonode 0.05% (Fluonex, Lidex, Lidex-E, Lonide, Lyderm)","ValueMeaning":{"publicId":"3257259","version":"1","preferredName":"Fluocinonode 0.05% (Fluonex, Lidex, Lidex-E, Lonide, Lyderm)","longName":"3257259","preferredDefinition":"Fluocinonode 0.05%","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8EA5DCE-91AE-385A-E040-BB89AD436355","latestVersionIndicator":"Yes","beginDate":"2011-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-90C9-18F7-E053-F662850A60B1","beginDate":"2011-07-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fluticasone Propionate 0.05%","valueDescription":"Fluticasone Propionate 0.05% (Cutivate)","ValueMeaning":{"publicId":"3257576","version":"1","preferredName":"Fluticasone Propionate 0.05% (Cutivate)","longName":"3257576","preferredDefinition":"A number with no fractional part.::0.05%: The propionate salt form of fluticasone, a synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, antiinflammatory and antipruritic effects. Binding and activation of the glucocorticoid receptor results in the activation of lipocortin that in turn inhibits cytosolic phospholipase A2, which triggers cascade of reactions involved in synthesis of inflammatory mediators, such as prostaglandins and leukotrienes. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leads to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Fluticasone Propionate","conceptCode":"C29061","definition":"The propionate salt form of fluticasone, a synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, antiinflammatory and antipruritic effects. Binding and activation of the glucocorticoid receptor results in the activation of lipocortin that in turn inhibits cytosolic phospholipase A2, which triggers cascade of reactions involved in synthesis of inflammatory mediators, such as prostaglandins and leukotrienes. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leads to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8EA5DCE-9213-385A-E040-BB89AD436355","latestVersionIndicator":"Yes","beginDate":"2011-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-90D3-18F7-E053-F662850A60B1","beginDate":"2011-07-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Triamcinolone Acetonide 0.1%","valueDescription":"Triamcinolone Acetonide 0.1% (Aristocort A, Aristocort, Kenalog)","ValueMeaning":{"publicId":"3257579","version":"1","preferredName":"Triamcinolone Acetonide 0.1% (Aristocort A, Aristocort, Kenalog)","longName":"3257579","preferredDefinition":"A number with no fractional part.::0.1%: The acetonide salt form of triamcinolone, a synthetic glucocorticosteroid with immunosuppressive and anti-inflammatory activity. Triamcinolone acetonide binds to specific cytosolic glucocorticoid receptors and subsequently interacts with glucocorticoid receptor response element on DNA and alters gene expression. This results in an induction of the synthesis of certain anti-inflammatory proteins while inhibiting the synthesis of certain inflammatory mediators. Consequently, an overall reduction in chronic inflammation and autoimmune reactions are accomplished.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Triamcinolone Acetonide","conceptCode":"C48027","definition":"The acetonide salt form of triamcinolone, a synthetic glucocorticosteroid with immunosuppressive and anti-inflammatory activity. Triamcinolone acetonide binds to specific cytosolic glucocorticoid receptors and subsequently interacts with glucocorticoid receptor response element on DNA and alters gene expression. This results in an induction of the synthesis of certain anti-inflammatory proteins while inhibiting the synthesis of certain inflammatory mediators. Consequently, an overall reduction in chronic inflammation and autoimmune reactions are accomplished.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8EB450A-8CD2-6148-E040-BB89AD431193","latestVersionIndicator":"Yes","beginDate":"2011-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-90DD-18F7-E053-F662850A60B1","beginDate":"2011-07-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Triamcinolone Acetonide 0.025%","valueDescription":"Triamcinolone Acetonide 0.025% (Kenalog)","ValueMeaning":{"publicId":"3257580","version":"1","preferredName":"Triamcinolone Acetonide 0.025% (Kenalog)","longName":"3257580","preferredDefinition":"A number with no fractional part.::0.025%: The acetonide salt form of triamcinolone, a synthetic glucocorticosteroid with immunosuppressive and anti-inflammatory activity. Triamcinolone acetonide binds to specific cytosolic glucocorticoid receptors and subsequently interacts with glucocorticoid receptor response element on DNA and alters gene expression. This results in an induction of the synthesis of certain anti-inflammatory proteins while inhibiting the synthesis of certain inflammatory mediators. Consequently, an overall reduction in chronic inflammation and autoimmune reactions are accomplished.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Triamcinolone Acetonide","conceptCode":"C48027","definition":"The acetonide salt form of triamcinolone, a synthetic glucocorticosteroid with immunosuppressive and anti-inflammatory activity. Triamcinolone acetonide binds to specific cytosolic glucocorticoid receptors and subsequently interacts with glucocorticoid receptor response element on DNA and alters gene expression. This results in an induction of the synthesis of certain anti-inflammatory proteins while inhibiting the synthesis of certain inflammatory mediators. Consequently, an overall reduction in chronic inflammation and autoimmune reactions are accomplished.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8EB450A-8D04-6148-E040-BB89AD431193","latestVersionIndicator":"Yes","beginDate":"2011-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-90E7-18F7-E053-F662850A60B1","beginDate":"2011-07-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ergotamine Tartrate/Caffeine","valueDescription":"Caffeine + ergotamine tartrate","ValueMeaning":{"publicId":"2576820","version":"1","preferredName":"Caffeine + ergotamine tartrate","longName":"2576820","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Caffeine + ergotamine tartrate","conceptCode":"CL310688","definition":"No value exists.","evsSource":"NCI_META_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F921-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-799E-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cyclosporine","valueDescription":"Cyclosporine","ValueMeaning":{"publicId":"2567427","version":"1","preferredName":"Cyclosporine","longName":"2567427","preferredDefinition":"11-residue cyclic peptide produced by certain fungi which has antifungal and T cell specific immunosuppressive properties.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclosporine","conceptCode":"C406","definition":"A natural cyclic polypeptide immunosuppressant isolated from the fungus Beauveria nivea. The exact mechanism of action of cyclosporine is not known but may involve binding to the cellular protein cytophilin, resulting in inhibition of the enzyme calcineurin. This agent appears to specifically and reversibly inhibit immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited with T-helper cells as the primary target. Cyclosporine also inhibits lymphokine production and release. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D470-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-77DC-18F7-E053-F662850A60B1","beginDate":"2005-08-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Didanosine","valueDescription":"Didanosine","ValueMeaning":{"publicId":"2576104","version":"1","preferredName":"Didanosine","longName":"2576104","preferredDefinition":"A synthetic nucleoside analogue of deoxyadenosine in which the 3' hydroxyl on the ribose moiety is replaced by a hydrogen atom. In vivo, didanosine is converted to the active triphosphate form, which is incorporated into DNA. The absence of the 3' hydroxyl inhibits DNA elongation because phosphodiester bonds cannot be made with the substituted hydrogen. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Didanosine","conceptCode":"C431","definition":"A nucleoside reverse transcriptase inhibitor analog of adenosine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F655-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2008-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-77E6-18F7-E053-F662850A60B1","beginDate":"2005-08-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cortisporin","valueDescription":"Cortisporin","ValueMeaning":{"publicId":"2576781","version":"1","preferredName":"Cortisporin","longName":"2576781","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cortisporin","conceptCode":"C0056395","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F8FA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-77F0-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"ddI","valueDescription":"Didanosine","ValueMeaning":{"publicId":"2576104","version":"1","preferredName":"Didanosine","longName":"2576104","preferredDefinition":"A synthetic nucleoside analogue of deoxyadenosine in which the 3' hydroxyl on the ribose moiety is replaced by a hydrogen atom. In vivo, didanosine is converted to the active triphosphate form, which is incorporated into DNA. The absence of the 3' hydroxyl inhibits DNA elongation because phosphodiester bonds cannot be made with the substituted hydrogen. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Didanosine","conceptCode":"C431","definition":"A nucleoside reverse transcriptase inhibitor analog of adenosine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F655-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2008-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-77FA-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"ddC","valueDescription":"Zalcitabine","ValueMeaning":{"publicId":"2576782","version":"1","preferredName":"Zalcitabine","longName":"2576782","preferredDefinition":"A synthetic dideoxynucleoside. After intracellular phosphorylation to its active metabolite, zalcitabine preferentially inhibits the gamma form of DNA polymerase present in tumor cell mitochondria, resulting in the inhibition of tumor cell mitochondrial DNA replication and tumor cell death. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zalcitabine","conceptCode":"C430","definition":"A synthetic dideoxynucleoside. After intracellular phosphorylation to its active metabolite, zalcitabine preferentially inhibits the gamma form of DNA polymerase present in tumor cell mitochondria, resulting in the inhibition of tumor cell mitochondrial DNA replication and tumor cell death. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F8FB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7804-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Deoxycoformycin","valueDescription":"2-Deoxycoformycin (Pentostatin)","ValueMeaning":{"publicId":"2576783","version":"1","preferredName":"2-Deoxycoformycin (Pentostatin)","longName":"2576783","preferredDefinition":"An anticancer drug that belongs to the family of drugs called antimetabolites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pentostatin","conceptCode":"C732","definition":"A purine nucleotide analogue antibiotic isolated from the bacterium Streptomyces antibioticus. Also known as 2'-deoxycoformycin, pentostatin binds to and inhibits adenine deaminase (ADA), an enzyme essential to purine metabolism; ADA activity is greatest in cells of the lymphoid system with T-cells having higher activity than B-cells and T-cell malignancies higher ADA activity than B-cell malignancies. Pentostatin inhibition of ADA appears to result in elevated intracellular levels of dATP which may block DNA synthesis through the inhibition of ribonucleotide reductase. This agent may also inhibit RNA synthesis and may selectively deplete CD26+ lymphocytes. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F8FC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"REEVESD","dateModified":"2012-02-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-780E-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Dipyridamole","valueDescription":"dipyridamole","ValueMeaning":{"publicId":"2573139","version":"1","preferredName":"dipyridamole","longName":"2573139","preferredDefinition":"A drug that prevents blood cell clumping and enhances the effectiveness of fluorouracil and other chemotherapeutic agents.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dipyridamole","conceptCode":"C445","definition":"A synthetic agent derivative of pyrimido-pyrimidine, with antiplatelet properties.  Dipyridamole inhibits adenosine uptake by platelets and endothelial cells, triggering an accumulation of cyclic adenosine monophosphate (cAMP), and inhibiting the stimulation of platelet aggregation by agents such as platelet activating factor and collagen. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EAC0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-02-09","modifiedBy":"REEVESD","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7818-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Disopyramide Phosphate","valueDescription":"Disopyramide Phosphate","ValueMeaning":{"publicId":"2576784","version":"1","preferredName":"Disopyramide Phosphate","longName":"2576784","preferredDefinition":"A class Ia antiarrhythmic agent with cardiac depressant properties. Disopyramide phosphate exerts its actions by blocking both sodium and potassium channels in cardiac membrane during phase 0 of the action potential. This slows the impulse conduction through the AV node and prolongs the duration of the action potential of normal cardiac cells in atrial and ventricular tissues. Disopyramide prolongs the QT interval and causes a widening of the QRS complex. It also posesses some anticholinergic and local anaesthetic properties. Disopyramide phosphate is used in the treatment of supraventricular tachycardia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disopyramide Phosphate","conceptCode":"C47497","definition":"A class Ia antiarrhythmic agent with cardiac depressant properties. Disopyramide phosphate exerts its actions by blocking both sodium and potassium channels in cardiac membrane during phase 0 of the action potential. This slows the impulse conduction through the AV node and prolongs the duration of the action potential of normal cardiac cells in atrial and ventricular tissues. Disopyramide prolongs the QT interval and causes a widening of the QRS complex. It also possesses some anticholinergic and local anaesthetic properties. Disopyramide phosphate is used in the treatment of supraventricular tachycardia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F8FD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7822-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Divalproex Sodium","valueDescription":"Divalproex Sodium","ValueMeaning":{"publicId":"2576785","version":"1","preferredName":"Divalproex Sodium","longName":"2576785v1.00","preferredDefinition":"A stable coordination compound comprised of sodium valproate and valproic acid with anticonvulsant and antiepileptic activities. Divalproex dissociates to the valproate ion in the gastrointestinal tract. This agent binds to and inhibits gamma-aminobutyric acid (GABA) transaminase and its anticonvulsant activity may be exerted by increasing brain concentration of GABA and by inhibiting enzymes that catabolize GABA or block the reuptake of GABA into glia and nerve endings. Divalproex may also work by suppressing repetitive neuronal firing through inhibition of voltage-sensitive sodium channels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Divalproex Sodium","conceptCode":"C28996","definition":"A stable coordination compound comprised of sodium valproate and valproic acid with anticonvulsant and antiepileptic activities. Divalproex dissociates to the valproate ion in the gastrointestinal tract. This agent binds to and inhibits gamma-aminobutyric acid (GABA) transaminase and its anticonvulsant activity may be exerted by increasing brain concentration of GABA and by inhibiting enzymes that catabolize GABA or block the reuptake of GABA into glia and nerve endings. Divalproex may also work by suppressing repetitive neuronal firing through inhibition of voltage-sensitive sodium channels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F8FE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"CLOHNES","dateModified":"2023-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-782C-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Dobutamine HCL","valueDescription":"Dobutamine Hydrochloride","ValueMeaning":{"publicId":"2576786","version":"1","preferredName":"Dobutamine Hydrochloride","longName":"2576786v1.00","preferredDefinition":"The hydrochloride salt form of dobutamine, a synthetic catecholamine with direct inotropic activity. Dobutamine hydrochloride, mimics the effects of dopamine and stimulates beta-1 adrenergic receptors located in the myocardium. This leads to an increase in heart rate and force and results in an increase in cardiac output.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dobutamine Hydrochloride","conceptCode":"C28997","definition":"The hydrochloride salt form of dobutamine, a synthetic catecholamine with direct inotropic activity. Dobutamine hydrochloride, mimics the effects of dopamine and stimulates beta-1 adrenergic receptors located in the myocardium. This leads to an increase in heart rate and force and results in an increase in cardiac output.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F8FF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"CLOHNES","dateModified":"2023-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7836-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Docosahexaenoic Acid","valueDescription":"Docosahexaenoic Acid (All-Z Isomer)","ValueMeaning":{"publicId":"2576787","version":"1","preferredName":"Docosahexaenoic Acid (All-Z Isomer)","longName":"2576787","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Docosahexaenoic Acid (All-Z Isomer)","conceptCode":"C0887328","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F900-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7840-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Docusate Calcium","valueDescription":"Docusate Calcium","ValueMeaning":{"publicId":"2576788","version":"1","preferredName":"Docusate Calcium","longName":"2576788","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Docusate Calcium","conceptCode":"C28999","definition":"The calcium salt of docusate, a dioctyl salt and an emollient laxative with stool-softening activity. Docusate decreases surface tension and emulsification of fecal matter and allows water to penetrate and mix with stool. As a result, it softens the stool.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F901-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-784A-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Docusate Sodium","valueDescription":"Docusate Sodium","ValueMeaning":{"publicId":"2576789","version":"1","preferredName":"Docusate Sodium","longName":"2576789","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Docusate Sodium","conceptCode":"C29000","definition":"The sodium salt of docusate, a dioctyl salt and an emollient laxative with stool-softening activity. Docusate decreases surface tension and emulsification of fecal matter and allows water to penetrate and mix with stool. As a result, it softens the stool.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F902-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7854-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Dolasetron","valueDescription":"Dolasetron Mesylate","ValueMeaning":{"publicId":"2576790","version":"1","preferredName":"Dolasetron Mesylate","longName":"2576790","preferredDefinition":"An indole derivative with antiemetic activity.  As a selective serotonin receptor antagonist, dolasetron mesylate competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dolasetron Mesylate","conceptCode":"C1153","definition":"An indole derivative with antiemetic activity.  As a selective serotonin receptor antagonist, dolasetron mesylate competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F903-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-785E-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Domeboro Solution","valueDescription":"Domeboro Solution","ValueMeaning":{"publicId":"2576791","version":"1","preferredName":"Domeboro Solution","longName":"2576791","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Domeboro Solution","conceptCode":"C29001","definition":"A aluminum solution with astringent, antibacterial, and antifungal properties. Domeboro solution is a commercial preparation of modified Burow's solution, (5% aluminum acetate) by Bayer.  Aluminum sulfate, the active ingredient of Domeboro, is attributed for this agent's bacteriostatic effect. Domeboro is used most often to cleanse irritated skin and soothe inflammation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F904-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7868-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Domperidone","valueDescription":"Domperidone","ValueMeaning":{"publicId":"2576792","version":"1","preferredName":"Domperidone","longName":"2576792","preferredDefinition":"A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Domperidone","conceptCode":"C454","definition":"A peripheral-specific antagonist of the dopamine receptor D2 (D2R), with antiemetic, gastrokinetic and galactagogue activities. Following administration, domperidone binds to D2R expressed by peripheral neurons; this inhibits dopamine binding and D2R-mediated signaling. Inhibition of peripheral D2R signaling prevents or relieves various gastrointestinal (GI) symptoms, such as nausea and vomiting, and may help relief reflux and symptoms of a variety of other upper GI disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F905-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7872-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Donnatol","valueDescription":"Donnatol","ValueMeaning":{"publicId":"2576793","version":"1","preferredName":"Donnatol","longName":"2576793","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Donnatal","conceptCode":"C29002","definition":"A combination agent, comprised of belladonna alkaloids and Phenobarbital, with gastrointestinal anticholinergic activity. The belladonna alkaloids produce an anticholinergic effect by the competitive inhibition of acetylcholine at the parasympathetic neuro-effector junction, and the barbiturates produce a sedative effect probably as a result of their inhibition of synaptic neurotransmitters in the central nervous system (CNS).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F906-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-787C-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Dopamine","valueDescription":"Dopamine Hydrochloride","ValueMeaning":{"publicId":"2576794","version":"1","preferredName":"Dopamine Hydrochloride","longName":"2576794","preferredDefinition":"One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from tyrosine and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dopamine Hydrochloride","conceptCode":"C455","definition":"The hydrochloride salt form of dopamine, a monoamine compound with positive inotropic activity. Dopamine is a naturally occurring catecholamine formed by decarboxylation of dehydroxyphenylalanine and a precursor of norepinephrine and epinephrine. Dopamine binds to alpha-1- and beta-1- adrenergic receptors. Mediated through myocardial beta-1-adrenergic receptors, dopamine increase heart rate and force, thereby increasing cardiac output. Alpha-1-adrenergic receptor stimulation on vascular smooth muscle, leads to vasoconstriction and results in an increase in systemic vascular resistance. Stimulation of dopaminergic receptors in renal vasculature, leads to renal blood vessel dilation, and an increase in glomerular filtration rate, renal blood flow, sodium excretion, and urine output.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F907-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7886-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Dorzolamide Sodium","valueDescription":"Dorzolamide Sodium","ValueMeaning":{"publicId":"2576795","version":"1","preferredName":"Dorzolamide Sodium","longName":"2576795","preferredDefinition":"The sodium salt of Dorzolamide.  An inhibitor of carbonic anhydrase, a zinc-containing enzyme that catalyzes the rapid conversion of carbon dioxide and water into carbonic acid, protons and bicarbonate ions.  Distributed throughout many cells and tissues, various carbonic anhydrases play important roles in mineral and metabolic homeostasis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dorzolamide Sodium","conceptCode":"C29004","definition":"The sodium salt of Dorzolamide.  An inhibitor of carbonic anhydrase, a zinc-containing enzyme that catalyzes the rapid conversion of carbon dioxide and water into carbonic acid, protons and bicarbonate ions.  Distributed throughout many cells and tissues, various carbonic anhydrases play important roles in mineral and metabolic homeostasis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F908-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7890-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Doxazosin Mesylate","valueDescription":"Doxazosin Mesylate","ValueMeaning":{"publicId":"2576796","version":"1","preferredName":"Doxazosin Mesylate","longName":"2576796","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxazosin Mesylate","conceptCode":"C29005","definition":"The mesylate salt form of doxazosin, a quinazoline compound with smooth muscle relaxing activity. Doxazosin mesylate selectively antagonizes alpha-1-adrenergic receptors in smooth muscle of the bladder neck and prostate, thereby relaxing the smooth muscle and decreasing the obstruction and urethral resistance seen with benign prostate hyperplasia (BPH). This may improve BPH symptoms. This agent also blocks alpha-1-adrenergic receptors in peripheral vascular smooth muscle, which leads to vasodilatation and a subsequent decrease in peripheral vascular resistance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F909-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-789A-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Doxepin HCL","valueDescription":"Doxepin Hydrochloride","ValueMeaning":{"publicId":"2576797","version":"1","preferredName":"Doxepin Hydrochloride","longName":"2576797","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxepin Hydrochloride","conceptCode":"C29006","definition":"A dibenzoxepin derivative and tricyclic antidepressant with antipruritic and sedative activities. Doxepin blocks the reuptake of norepinephrine and serotonin into presynaptic terminals thereby prolonging the availability of the monoaminergic neurotransmitters within the synaptic cleft and enhancing their action leading to sedative effects. Doxepin also has antagonistic effects on histamine (H1 and H2), 5-HT2, alpha-1 adrenergic, and muscarinic receptors. The antipruritic effect of this agent is the result mediated through inhibition of histamine receptors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F90A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-78A4-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Doxycline Hyclate","valueDescription":"Doxycycline Hyclate","ValueMeaning":{"publicId":"2575681","version":"1","preferredName":"Doxycycline Hyclate","longName":"2575681","preferredDefinition":"Doxycycline in the monohydrate complex with ethanol form exhibiting antimicrobial activity.  Doxycycline blocks binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis.  In addition, this agent has exhibited inhibition of collagenase activity. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxycycline Hyclate","conceptCode":"C29007","definition":"The hyclate salt form of doxycycline, a synthetic, broad-spectrum tetracycline antibiotic exhibiting antimicrobial activity. Doxycycline hyclate binds reversibly to the 30S ribosomal subunit, possibly to the 50S ribosomal subunit as well, thereby blocking the binding of aminoacyl-tRNA to the mRNA-ribosome complex. This leads to an inhibition of protein synthesis. In addition, this agent has exhibited inhibition of collagenase activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4AE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-78AE-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Doxycycline Calcium","valueDescription":"Doxycycline Calcium","ValueMeaning":{"publicId":"2575679","version":"1","preferredName":"Doxycycline Calcium","longName":"2575679","preferredDefinition":"The calcium salt form of doxycycline exhibiting antimicrobial activity.  Doxycycline blocks binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis.  In addition, this agent has exhibited inhibition of collagenase activity. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxycycline Calcium","conceptCode":"C29008","definition":"The calcium salt form of doxycycline exhibiting antimicrobial activity.  Doxycycline blocks binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis.  In addition, this agent has exhibited inhibition of collagenase activity. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4AC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-78B8-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Doxycycline HCL","valueDescription":"Doxycycline Hydrochloride","ValueMeaning":{"publicId":"2576798","version":"1","preferredName":"Doxycycline Hydrochloride","longName":"2576798","preferredDefinition":"The hydrochloride salt form of doxycycline exhibiting antimicrobial activity.  Doxycycline blocks binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis.  In addition, this agent has exhibited inhibition of collagenase activity. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxycycline Hydrochloride","conceptCode":"C29010","definition":"The hydrochloride salt form of doxycycline exhibiting antimicrobial activity.  Doxycycline blocks binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis.  In addition, this agent has exhibited inhibition of collagenase activity. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F90B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-78C2-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Doxycycline Monohydrate","valueDescription":"Doxycycline Monohydrate","ValueMeaning":{"publicId":"2576802","version":"1","preferredName":"Doxycycline Monohydrate","longName":"2576802","preferredDefinition":"The monohydrate form of doxycycline exhibiting antimicrobial activity. Doxycycline blocks binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis. In addition, this agent has exhibited inhibition of collagenase activity. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxycycline Monohydrate","conceptCode":"C0700451","definition":"The monohydrate form of doxycycline exhibiting antimicrobial activity. Doxycycline blocks binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis. In addition, this agent has exhibited inhibition of collagenase activity. (NCI)","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F90F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-78CC-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Dronabinol","valueDescription":"Dronabinol","ValueMeaning":{"publicId":"2576799","version":"1","preferredName":"Dronabinol","longName":"2576799","preferredDefinition":"A synthetic form of delta-9-tetrahydrocannabinol, a psychoactive substance found in Cannabis sativa.  Dronabinol acts directly on the appetite and vomiting control centers in the brain to stimulate appetite and prevent emesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dronabinol","conceptCode":"C867","definition":"An isomer of tetrahydrocannabinol (THC) that is the main and most active isomer found in the Cannabis sativa L. plant, with potential anti-emetic, analgesic and appetite stimulating activities. Upon administration, dronabinol, also called delta-9-THC, targets and binds to cannabinoid receptors (CBRs) located in the central nervous system (CNS). Dronabinol acts directly on the appetite and vomiting control centers in the brain to stimulate appetite and prevent emesis. In addition, this agent induces analgesia. Urine levels may be used as a marker to determine the exposure to certain preparations containing parts of the cannabis plant, such as marijuana.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F90C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-78D6-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Droperidol","valueDescription":"Droperidol","ValueMeaning":{"publicId":"2576800","version":"1","preferredName":"Droperidol","longName":"2576800","preferredDefinition":"A butyrophenone with general properties similar to those of HALOPERIDOL. It is used in conjunction with an opioid analgesic such as FENTANYL to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Droperidol","conceptCode":"C458","definition":"A butyrophenone with anti-emetic, sedative and anti-anxiety properties. Although the exact mechanism through which droperidol exerts its effects is unknown, droperidol may block dopamine receptors in the chemoreceptor trigger zone (CTZ), which may lead to its anti-emetic effect. This agent may also bind to postsynaptic gamma-aminobutyric acid (GABA) receptors in the central nervous system (CNS), which increases the inhibitory effect of GABA and leads to sedative and anti-anxiety activities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F90D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-78E0-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Drops","valueDescription":"Drops: C29012","ValueMeaning":{"publicId":"2576801","version":"1","preferredName":"Drops: C29012","longName":"2576801","preferredDefinition":"A popular term for a medicine taken in doses measured by drops. (from On-line Medical Dictionary)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Drop Dosage Form","conceptCode":"C29012","definition":"A substance intended for administration in a drop-wise fashion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F90E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-78EA-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Duloxetine HCL","valueDescription":"duloxetine hydrochloride","ValueMeaning":{"publicId":"2576803","version":"1","preferredName":"duloxetine hydrochloride","longName":"2576803","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"duloxetine hydrochloride","conceptCode":"C1505020","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F910-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-78F4-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Duratec","valueDescription":"Duratec","ValueMeaning":{"publicId":"2576804","version":"1","preferredName":"Duratec","longName":"2576804","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Duratec","conceptCode":"C29014","definition":"No value exists.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F911-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-78FE-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"DuraVent/DA","valueDescription":"DuraVent DA","ValueMeaning":{"publicId":"2576805","version":"1","preferredName":"DuraVent DA","longName":"2576805","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chlorpheniramine/Methscopolamine/Phenylephrine Tablet Formulation","conceptCode":"C29013","definition":"A commercial combination preparation, by Biovail Pharmaceuticals, containing chlorpheniramine maleate, phenylephrine hydrochloride and methscopolamine nitrate used to relieve symptoms of cold and flu. Chlorpheniramine maleate, an antihistamine, blocks the effects of histamine, thereby preventing symptoms such as sneezing and itchy, watery eyes, runny nose and itchy throat. Phenylephrine hydrochloride, a sympathomimetic agent, acts as a decongestant by inducing blood vessels constriction mediated via alpha-adrenergic receptors, thereby reducing blood flow and decreasing swelling which prevents nasal and sinus congestion. Methscopolamine nitrate, an anticholinergic agent, may reduce fluid secretions and provides a drying effect in nose, eyes and chest.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F912-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7908-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Dutasteride","valueDescription":"Dutasteride","ValueMeaning":{"publicId":"2576806","version":"1","preferredName":"Dutasteride","longName":"2576806","preferredDefinition":"A synthetic 4-azasteroid compound. Dutasteride competitively and specificly inhibits both 5-alpha-reductase 1 and 2 isoenzymes that convert testosterone to dihydrotestosterone. The type 2 isoenzyme is primarily active in the reproductive tissues, while the type 1 isoenzyme is also responsible for conversion of testosterone in the skin and liver. Inhibition of 5-alpha reductase leads to a reduction of dihydrotestosterone formation and subsequently prevents the enlargement of the prostate gland. Dutasteride is used in the treatment of benign prostatic hyperplasia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dutasteride","conceptCode":"C47503","definition":"A synthetic 4-azasteroid compound. Dutasteride competitively and specifically binds to isoenzymes 1 and 2 of 5 alpha-reductase, forming stable enzyme complexes and inhibiting the conversion of testosterone to 5 alpha-dihydrotestosterone (DHT); the reduction in DHT activity may mitigate or prevent enlargement of the prostate gland. The type 2 5 alpha-reductase isoenzyme is primarily active in the reproductive tissues, while the type 1 isoenzyme is also active in skin and the liver.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F913-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7912-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Echinacea","valueDescription":"Echinacea <Asteraceae>","ValueMeaning":{"publicId":"2576807","version":"1","preferredName":"Echinacea <Asteraceae>","longName":"2576807","preferredDefinition":"A genus of perennial herbs used topically and internally. It contains echinacoside, GLYCOSIDES; INULIN; isobutyl amides, resin, and SESQUITERPENES.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Echinacea <Asteraceae>","conceptCode":"C1095869","definition":"A genus of perennial herbs used topically and internally. It contains echinacoside, GLYCOSIDES; INULIN; isobutyl amides, resin, and SESQUITERPENES.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F914-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-791C-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Efavirenz","valueDescription":"(DMP-266) Efavirenz","ValueMeaning":{"publicId":"2576812","version":"1","preferredName":"(DMP-266) Efavirenz","longName":"2576812","preferredDefinition":"A synthetic non-nucleoside reverse transcriptase (RT) inhibitor with antiviral properties.  Efavirenz binds directly to the human immunodeficiency virus type 1 (HIV-1) RT, an RNA-dependent DNA polymerase, blocking its function in viral DNA replication.  In combination with other antiretroviral drugs, this agent has been shown to significantly reduce HIV viral loads, therefore retarding or preventing damage to the immune system, and reducing the risk of developing AIDS.  Efavirenz induces activity of the cytochrome P450 system, thereby accelerating its own metabolism. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Efavirenz","conceptCode":"C29027","definition":"A synthetic non-nucleoside reverse transcriptase (RT) inhibitor with antiviral activity. Efavirenz binds directly to the human immunodeficiency virus type 1 (HIV-1) RT, an RNA-dependent DNA polymerase, blocking its function in viral DNA replication. In combination with other antiretroviral drugs, this agent has been shown to significantly reduce HIV viral load, retarding or preventing damage to the immune system and reducing the risk of developing AIDS. Efavirenz induces activity of the cytochrome P450 system, accelerating its own metabolism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F919-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2012-02-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7926-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Eletriptan Hydrobromide","valueDescription":"Eletriptan Hydrobromide","ValueMeaning":{"publicId":"2576808","version":"1","preferredName":"Eletriptan Hydrobromide","longName":"2576808","preferredDefinition":"A triptan with specific affinity for the 5-hydroxytriptamine1B/1D receptor. Eletriptan hydrobromide binds to and acts at serotonin 5-HT1B receptors located on intracranial blood vessels which leads to vasoconstriction. This drug may also exerts its effects by binding to and activating 5-HT 1D receptors on sensory nerve endings in the trigeminal system, which results in the inhibition of pro-inflammatory neuropeptide release. Eletriptan hydrobromide is used to relieve pain in nerve endings and associated symptoms caused by migraine headaches.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eletriptan Hydrobromide","conceptCode":"C47508","definition":"A triptan with specific affinity for the 5-hydroxytriptamine1B/1D receptor. Eletriptan hydrobromide binds to and acts at serotonin 5-HT1B receptors located on intracranial blood vessels which leads to vasoconstriction. This drug may also exerts its effects by binding to and activating 5-HT 1D receptors on sensory nerve endings in the trigeminal system, which results in the inhibition of pro-inflammatory neuropeptide release. Eletriptan hydrobromide is used to relieve pain or symptoms associated with migraine headaches.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F915-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7930-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"EMLA","valueDescription":"Eutectic Mixture of Local Anesthetics","ValueMeaning":{"publicId":"2576809","version":"1","preferredName":"Eutectic Mixture of Local Anesthetics","longName":"2576809","preferredDefinition":"A topical anesthetic cream, containing lidocaine 2.5% and prilocaine 2.5%, that provides neuralgia pain relief by causing loss of cutaneous sensation through reversible blockade of conduction in nerve fibers. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eutectic Mixture of Local Anesthetics","conceptCode":"C1081","definition":"A topical anesthetic cream, containing lidocaine 2.5% and prilocaine 2.5%, that provides neuralgia pain relief by causing loss of cutaneous sensation through reversible blockade of conduction in nerve fibers. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F916-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-793A-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Enalapril Maleate","valueDescription":"Enalapril Maleate","ValueMeaning":{"publicId":"2576810","version":"1","preferredName":"Enalapril Maleate","longName":"2576810","preferredDefinition":"An antihypertensive agent that can also be used to slow or prevent the progression of heart disease in people with childhood cancer treated with drugs that may be harmful to the heart.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Enalapril Maleate","conceptCode":"C468","definition":"The maleate salt form of enalapril, a dicarbocyl-containing peptide and angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. As a prodrug, enalapril is converted by de-esterification into its active form enalaprilat. Enalaprilat competitively binds to and inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the potent vasoconstrictive actions of angiotensin II and results in vasodilation. Enalapril also decreases angiotensin II-induced aldosterone secretion by the adrenal cortex, which leads to an increase in sodium excretion and subsequently increases water outflow.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F917-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7944-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Enema","valueDescription":"Enema","ValueMeaning":{"publicId":"2576811","version":"1","preferredName":"Enema","longName":"2576811","preferredDefinition":"The injection of a liquid through the anus into the large bowel.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Enema","conceptCode":"C28289","definition":"The injection of a liquid through the anus into the large bowel.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F918-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-794E-18F7-E053-F662850A60B1","beginDate":"2005-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Dyclonine","valueDescription":"Dyclonine","ValueMeaning":{"publicId":"2576813","version":"1","preferredName":"Dyclonine","longName":"2576813","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dyclonine","conceptCode":"C29015","definition":"An unclassified compound with local anesthetic effect. Dyclonine reversibly binds to activated sodium channels on the neuronal membrane, thereby decreasing the neuronal membrane's permeability to sodium ions, leading to an increased threshold for excitation. This reversibly stabilizes the membrane and inhibits depolarization, leading to the failure of a propagated action potential and subsequent conduction blockade. This results in a transient and reversible loss of sensation in a localized area of the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F91A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7958-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Enoxaparin Sodium","valueDescription":"Enoxaparin","ValueMeaning":{"publicId":"2576814","version":"1","preferredName":"Enoxaparin","longName":"2576814","preferredDefinition":"A drug used to prevent blood clots.  It belongs to the family of drugs called anticoagulants.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Enoxaparin","conceptCode":"C1452","definition":"A low molecular weight, synthetic heparin. As an anticoagulant/antithrombotic agent, enoxaprin's mechanism of action is similar to that of heparin, although it exhibits a higher ratio of anti-Factor Xa to anti-Factor IIa activity. This agent also has anti-inflammatory properties, inhibiting monocyte adhesion to tumor necrosis factor alpha- or lipopolysaccharide-activated endothelial cells.  Compared to unfractionated heparins, the use of enoxaparin is associated with lower incidences of osteoporosis and heparin-induced thrombocytopenia. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F91B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7962-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Entex","valueDescription":"Entex","ValueMeaning":{"publicId":"2576815","version":"1","preferredName":"Entex","longName":"2576815","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Entex","conceptCode":"C29028","definition":"A commercial combination preparation containing guaifenesin and phenylephrine hydrochloride with expectorant and decongestant activities. Guaifenesin works by drawing water into respiratory tracts, thereby reducing adhesiveness and surface tension of mucus as well as increasing hydration of mucus. This reduces the viscosity of mucus and makes the cough more productive. Phenylephrine hydrochloride, a direct-acting sympathicomimetic amine, activates alpha-adrenergic receptors in the nasal mucosa thereby causing vasoconstriction, reduces swelling of nasal mucous membranes and decreases nasal and sinus congestion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F91C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-796C-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Epinephrine","valueDescription":"Epinephrine","ValueMeaning":{"publicId":"2576816","version":"1","preferredName":"Epinephrine","longName":"2576816","preferredDefinition":"The active sympathomimetic hormone from the adrenal medulla in most species. It stimulates both the alpha- and beta- adrenergic systems, causes systemic vasoconstriction and gastrointestinal relaxation, stimulates the heart, and dilates bronchi and cerebral vessels. It is used in asthma and cardiac failure and to delay absorption of local anesthetics.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epinephrine","conceptCode":"C2292","definition":"The active sympathomimetic hormone from the adrenal medulla in most species. It stimulates both the alpha- and beta- adrenergic systems, causes systemic vasoconstriction and gastrointestinal relaxation, stimulates the heart, and dilates bronchi and cerebral vessels. It is used in asthma and cardiac failure and to delay absorption of local anesthetics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F91D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7976-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Epoetin Alfa","valueDescription":"Epoetin Alfa","ValueMeaning":{"publicId":"2576817","version":"1","preferredName":"Epoetin Alfa","longName":"2576817","preferredDefinition":"A colony-stimulating factor that is made in the laboratory. It increases the production of red blood cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epoetin Alfa","conceptCode":"C2695","definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine human erythropoietin (EPO). Produced primarily by cells of the peritubular capillary endothelium of the kidney in response to hypoxia, circulating EPO binds to EPO receptors on the surface of committed erythroid progenitors in the bone marrow resulting in their replication and maturation into functional erythrocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F91E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7980-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Eptifibatide","valueDescription":"Eptifibatide","ValueMeaning":{"publicId":"2576818","version":"1","preferredName":"Eptifibatide","longName":"2576818","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eptifibatide","conceptCode":"C47516","definition":"A cyclical heptapeptide with anticoagulant activity. Eptifibatide selectively and reversibly binds to and blocks the platelet glycoprotein IIb/IIIa receptor. This prevents the binding of fibrinogen, von Willebrand factor, and other adhesive ligands and leads to an inhibition of platelet aggregation and prevents thrombus development.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F91F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-798A-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ergocalciferol","valueDescription":"Ergocalciferol","ValueMeaning":{"publicId":"2576819","version":"1","preferredName":"Ergocalciferol","longName":"2576819","preferredDefinition":"Vitamin D2, a fat-soluble vitamin important for many biochemical processes including the absorption and metabolism of calcium and phosphorus.  In vivo, ergocalciferol is formed after sun (ultraviolet) irradiation of plant-derived ergosterol, another form of vitamin D. Ergocalciferol is the form of vitamin D usually found in vitamin supplements. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ergocalciferol","conceptCode":"C29029","definition":"Vitamin D2, a fat-soluble vitamin important for many biochemical processes including the absorption and metabolism of calcium and phosphorus.  In vivo, ergocalciferol is formed after sun (ultraviolet) irradiation of plant-derived ergosterol, another form of vitamin D. Ergocalciferol is the form of vitamin D usually found in vitamin supplements. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F920-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7994-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fluocinolone Acetonide 0.01%","valueDescription":"Fluocinolone Acetonide 0.01% (Synalar)","ValueMeaning":{"publicId":"3257582","version":"1","preferredName":"Fluocinolone Acetonide 0.01% (Synalar)","longName":"3257582","preferredDefinition":"A number with no fractional part.::0.01%: The acetonide salt form of fluocinolone, a synthetic fluorinated corticosteroid with antiinflammatory, antipruritic and vasoconstrictive properties. Fluocinolone is a glucocorticoid receptor agonist that binds to cytoplasmic glucocorticoid receptors and subsequently translocates to the nucleus where it initiates the transcription of glucocorticoid-responsive genes such as lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both are potent mediators of inflammation. Fluocinolone exerts its vasoconstrictive effect through inhibition of nitric oxide synthase, thereby blocking nitric oxide production and effectively diminishing the effect of nitric oxide on vascular smooth muscles leading to reduced blood flow.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Fluocinolone Acetonide","conceptCode":"C29055","definition":"The acetonide salt form of fluocinolone, a synthetic fluorinated corticosteroid with antiinflammatory, antipruritic and vasoconstrictive properties. Fluocinolone is a glucocorticoid receptor agonist that binds to cytoplasmic glucocorticoid receptors and subsequently translocates to the nucleus where it initiates the transcription of glucocorticoid-responsive genes such as lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both are potent mediators of inflammation. Fluocinolone exerts its vasoconstrictive effect through inhibition of nitric oxide synthase, thereby blocking nitric oxide production and effectively diminishing the effect of nitric oxide on vascular smooth muscles leading to reduced blood flow.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8EB450A-8D34-6148-E040-BB89AD431193","latestVersionIndicator":"Yes","beginDate":"2011-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-90F1-18F7-E053-F662850A60B1","beginDate":"2011-07-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fluocinolone Acetonide 0.025%","valueDescription":"Fluocinolone Acetonide 0.025% (Synalar)","ValueMeaning":{"publicId":"3257583","version":"1","preferredName":"Fluocinolone Acetonide 0.025% (Synalar)","longName":"3257583","preferredDefinition":"A number with no fractional part.::0.025%: The acetonide salt form of fluocinolone, a synthetic fluorinated corticosteroid with antiinflammatory, antipruritic and vasoconstrictive properties. Fluocinolone is a glucocorticoid receptor agonist that binds to cytoplasmic glucocorticoid receptors and subsequently translocates to the nucleus where it initiates the transcription of glucocorticoid-responsive genes such as lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both are potent mediators of inflammation. Fluocinolone exerts its vasoconstrictive effect through inhibition of nitric oxide synthase, thereby blocking nitric oxide production and effectively diminishing the effect of nitric oxide on vascular smooth muscles leading to reduced blood flow.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Fluocinolone Acetonide","conceptCode":"C29055","definition":"The acetonide salt form of fluocinolone, a synthetic fluorinated corticosteroid with antiinflammatory, antipruritic and vasoconstrictive properties. Fluocinolone is a glucocorticoid receptor agonist that binds to cytoplasmic glucocorticoid receptors and subsequently translocates to the nucleus where it initiates the transcription of glucocorticoid-responsive genes such as lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both are potent mediators of inflammation. Fluocinolone exerts its vasoconstrictive effect through inhibition of nitric oxide synthase, thereby blocking nitric oxide production and effectively diminishing the effect of nitric oxide on vascular smooth muscles leading to reduced blood flow.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8EB450A-8D5A-6148-E040-BB89AD431193","latestVersionIndicator":"Yes","beginDate":"2011-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-90FB-18F7-E053-F662850A60B1","beginDate":"2011-07-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Moexipril HCL","valueDescription":"Moexipril Hydrochloride","ValueMeaning":{"publicId":"3293876","version":"1","preferredName":"Moexipril Hydrochloride","longName":"3293876","preferredDefinition":"The hydrochloride salt form of moexipril, a prodrug and non-sulfhydryl angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Moexipril hydrochloride is hydrolized into its active form moexiprilat, which competitively inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the actions of the potent vasoconstrictor angiotensin II and leads to vasodilatation. It also prevents angiotensin II-induced aldosterone secretion by the adrenal cortex, thereby promoting diuresis and natriuresis. Moexipril hydrochloride also directly suppresses renin release.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Moexipril Hydrochloride","conceptCode":"C29267","definition":"The hydrochloride salt form of moexipril, a prodrug and non-sulfhydryl angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Moexipril hydrochloride is hydrolized into its active form moexiprilat, which competitively inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the actions of the potent vasoconstrictor angiotensin II and leads to vasodilatation. It also prevents angiotensin II-induced aldosterone secretion by the adrenal cortex, thereby promoting diuresis and natriuresis. Moexipril hydrochloride also directly suppresses renin release.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF2094A8-282C-843F-E040-BB89AD436D8E","latestVersionIndicator":"Yes","beginDate":"2011-10-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9105-18F7-E053-F662850A60B1","beginDate":"2011-10-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Miscellaneous topical agent","valueDescription":"Miscellaneous Topical Agent","ValueMeaning":{"publicId":"3293877","version":"1","preferredName":"Miscellaneous Topical Agent","longName":"3293877","preferredDefinition":"Diverse, mixed, consisting of an assortment of different kinds.: On the surface of the body.: An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Miscellaneous","conceptCode":"C69023","definition":"Diverse, mixed, consisting of an assortment of different kinds.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Topical","conceptCode":"C13344","definition":"On the surface of the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF2094A8-2853-843F-E040-BB89AD436D8E","latestVersionIndicator":"Yes","beginDate":"2011-10-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-910F-18F7-E053-F662850A60B1","beginDate":"2011-10-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Nalbuphine (Nubain)","valueDescription":"Nalbuphine","ValueMeaning":{"publicId":"3293879","version":"1","preferredName":"Nalbuphine","longName":"3293879","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nalbuphine","conceptCode":"C61854","definition":"A synthetic mixed opioid agonist-antagonist with analgesic properties. Although its exact mechanism has not been fully delineated, it is hypothesized that upon administration, nalbuphine binds to kappa receptors in the central nervous system (CNS), thereby inhibiting the release of neurotransmitters that mediate pain, such as substance P. Additionally, nalbuphine exerts post-synaptic inhibitory effects on interneurons and output neurons of the spinothalamic tract, responsible for transporting nociceptive information. Compared to other opioid agents that stimulate mu receptors, nalbuphine antagonizes mu receptors, thereby potentially producing less intense respiratory depression.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF2094A8-287A-843F-E040-BB89AD436D8E","latestVersionIndicator":"Yes","beginDate":"2011-10-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9119-18F7-E053-F662850A60B1","beginDate":"2011-10-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Nafcillin","valueDescription":"Nafcillin","ValueMeaning":{"publicId":"2575691","version":"1","preferredName":"Nafcillin","longName":"2575691","preferredDefinition":"A semi-synthetic naphthalene and beta-lactam antibiotic with antibacterial activity. Nafcillin inhibits bacterial wall synthesis by a mechanism of action similar to penicillin. Penicillinase-resistant Nafcillin is used to treat infections caused by penicillin-resistant strains of Staphylococci. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nafcillin","conceptCode":"C62053","definition":"A semi-synthetic naphthalene and beta-lactam antibiotic with antibacterial activity. Nafcillin inhibits bacterial wall synthesis by a mechanism of action similar to penicillin. Penicillinase-resistant Nafcillin is used to treat infections caused by penicillin-resistant strains of Staphylococci. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4B8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9123-18F7-E053-F662850A60B1","beginDate":"2011-10-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cetuximab (Erbitux)","valueDescription":"Cetuximab","ValueMeaning":{"publicId":"2574309","version":"1","preferredName":"Cetuximab","longName":"2574309","preferredDefinition":"A monoclonal antibody specific for the epidermal growth factor receptor (EGFR), a tyrosine kinase that triggers cell division.  Cetuximab binds to and inhibits EGFRs, which are overexpressed on the cell surfaces of many types of tumors.  This agent blocks the tumor growth, invasion, and metastasis associated with the overexpression of cell-surface EGFRs. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cetuximab","conceptCode":"C1723","definition":"A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EF52-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-02","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-02","modifiedBy":"REEVESD","dateModified":"2006-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-912D-18F7-E053-F662850A60B1","beginDate":"2011-09-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Carprofen","valueDescription":"Carprofen","ValueMeaning":{"publicId":"3270054","version":"1","preferredName":"Carprofen","longName":"3270054v1.00","preferredDefinition":"A propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic activities, used exclusively in veterinary medicine. Carprofen inhibits the activity of the enzymes cyclo-oxygenase (COX) I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. This inhibits the formation of prostaglandins, by prostaglandin synthase, that are involved in pain, inflammation and fever. Ibuprofen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carprofen","conceptCode":"C65290","definition":"A propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic activities, used exclusively in veterinary medicine. Carprofen inhibits the activity of the enzymes cyclo-oxygenase (COX) I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. This inhibits the formation of prostaglandins, by prostaglandin synthase, that are involved in pain, inflammation and fever. Ibuprofen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC4C5286-90F3-648A-E040-BB89AD434035","latestVersionIndicator":"Yes","beginDate":"2011-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9137-18F7-E053-F662850A60B1","beginDate":"2011-09-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Carbamide Peroxide","valueDescription":"Carbamide Peroxide","ValueMeaning":{"publicId":"3270056","version":"1","preferredName":"Carbamide Peroxide","longName":"3270056v1.00","preferredDefinition":"An agent composed of urea and hydrogen peroxide. As an earwax removal agent, carbamide peroxide releases, upon administration into the ear, oxygen and causes foaming which helps soften, loosen and remove excessive earwax. It is also used as a disinfectant and in dentistry for its teeth whitening effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carbamide Peroxide","conceptCode":"C77033","definition":"An agent composed of urea and hydrogen peroxide. As an earwax removal agent, carbamide peroxide releases, upon administration into the ear, oxygen and causes foaming which helps soften, loosen and remove excessive earwax. It is also used as a disinfectant and in dentistry for its teeth whitening effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC4C5286-9119-648A-E040-BB89AD434035","latestVersionIndicator":"Yes","beginDate":"2011-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-06","modifiedBy":"CLOHNES","dateModified":"2023-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9141-18F7-E053-F662850A60B1","beginDate":"2011-09-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Calmol-4","valueDescription":"Calmol-4","ValueMeaning":{"publicId":"3270057","version":"1","preferredName":"Calmol-4","longName":"3270057","preferredDefinition":"Calmol-4","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC4C5286-913C-648A-E040-BB89AD434035","latestVersionIndicator":"Yes","beginDate":"2011-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-914B-18F7-E053-F662850A60B1","beginDate":"2011-09-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Butorphanol Tartrate","valueDescription":"Butorphanol Tartrate","ValueMeaning":{"publicId":"3270059","version":"1","preferredName":"Butorphanol Tartrate","longName":"3270059","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Butorphanol Tartrate","conceptCode":"C61658","definition":"No Value Exists","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC4C5286-9162-648A-E040-BB89AD434035","latestVersionIndicator":"Yes","beginDate":"2011-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9155-18F7-E053-F662850A60B1","beginDate":"2011-09-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Burow's Solution","valueDescription":"Burow's Solution","ValueMeaning":{"publicId":"3270060","version":"1","preferredName":"Burow's Solution","longName":"3270060v1.00","preferredDefinition":"A aluminum solution with astringent, antibacterial, and antifungal properties. Domeboro solution is a commercial preparation of modified Burow's solution, (5% aluminum acetate) by Bayer.  Aluminum sulfate, the active ingredient of Domeboro, is attributed for this agent's bacteriostatic effect. Domeboro is used most often to cleanse irritated skin and soothe inflammation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Domeboro Solution","conceptCode":"C29001","definition":"A aluminum solution with astringent, antibacterial, and antifungal properties. Domeboro solution is a commercial preparation of modified Burow's solution, (5% aluminum acetate) by Bayer.  Aluminum sulfate, the active ingredient of Domeboro, is attributed for this agent's bacteriostatic effect. Domeboro is used most often to cleanse irritated skin and soothe inflammation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC4C5286-9185-648A-E040-BB89AD434035","latestVersionIndicator":"Yes","beginDate":"2011-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-06","modifiedBy":"CLOHNES","dateModified":"2023-08-04","changeDescription":null,"administrativeNotes":"8/4/23 Added missing concept per cleanup activities cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-915F-18F7-E053-F662850A60B1","beginDate":"2011-09-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Hydrocortisone Butyrate 0.1%","valueDescription":"Hydrocortisone Butyrate 0.1% (Locoid)","ValueMeaning":{"publicId":"3257739","version":"1","preferredName":"Hydrocortisone Butyrate 0.1% (Locoid)","longName":"3257739","preferredDefinition":"A number with no fractional part.::0.1%: The butyrate salt form of hydrocortisone, a synthetic glucocorticoid receptor agonist with antiinflammatory, antipruritic and vasoconstrictive effects. Binding and activation of the glucocorticoid receptor results in the activation of lipocortin that in turn inhibits cytosolic phospholipase A2. Lack of phospholipase A2 prevents the release of arachidonic acid, precursor for inflammatory mediator prostaglandins and leukotrienes, from the cell membrane. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leading to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Hydrocortisone Butyrate","conceptCode":"C48022","definition":"The butyrate salt form of hydrocortisone, a synthetic glucocorticoid receptor agonist with antiinflammatory, antipruritic and vasoconstrictive effects. Binding and activation of the glucocorticoid receptor results in the activation of lipocortin that in turn inhibits cytosolic phospholipase A2. Lack of phospholipase A2 prevents the release of arachidonic acid, precursor for inflammatory mediator prostaglandins and leukotrienes, from the cell membrane. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leading to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A9143574-AAF9-0172-E040-BB89AD437AEF","latestVersionIndicator":"Yes","beginDate":"2011-07-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9169-18F7-E053-F662850A60B1","beginDate":"2011-07-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Hydrocortisone Acetate 1%","valueDescription":"Hydrocortisone Acetate 1% (Hytone)","ValueMeaning":{"publicId":"3257745","version":"1","preferredName":"Hydrocortisone Acetate 1% (Hytone)","longName":"3257745","preferredDefinition":"A number with no fractional part.::1%: The synthetic acetate salt form of hydrocortisone, a corticosteroid with anti-inflammatory and immunosuppressive properties. Hydrocortisone acetate initially binds to the cytoplasmic glucocorticoid receptor; then the receptor-ligand complex is translocated to the nucleus where it initiates the transcription of genes encoding for anti-inflammatory mediators, such as cytokines and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Hydrocortisone Acetate","conceptCode":"C61785","definition":"The synthetic acetate ester form of hydrocortisone, a corticosteroid with anti-inflammatory and immunosuppressive properties. Hydrocortisone acetate initially binds to the cytoplasmic glucocorticoid receptor; then the receptor-ligand complex is translocated to the nucleus where it initiates the transcription of genes encoding for anti-inflammatory mediators, such as cytokines and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A9143574-ABC4-0172-E040-BB89AD437AEF","latestVersionIndicator":"Yes","beginDate":"2011-07-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9173-18F7-E053-F662850A60B1","beginDate":"2011-07-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Hydrocortisone Valerate 0.1%","valueDescription":"Hydrocortisone Valerate 0.1% (Westcort)","ValueMeaning":{"publicId":"3257742","version":"1","preferredName":"Hydrocortisone Valerate 0.1% (Westcort)","longName":"3257742","preferredDefinition":"A number with no fractional part.::0.1%: The valerate salt form of hydrocortisone, a synthetic glucocorticoid receptor agonist with antiinflammatory, antipruritic and vasoconstrictive effects. Binding and activation of the glucocorticoid receptor results in the activation of lipocortin that in turn inhibits cytosolic phospholipase A2. Lack of phospholipase A2 prevents the release of arachidonic acid, precursor for inflammatory mediator prostaglandins and leukotrienes, from the cell membrane. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leads to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Hydrocortisone Valerate","conceptCode":"C48024","definition":"The valerate salt form of hydrocortisone, a synthetic glucocorticoid receptor agonist with antiinflammatory, antipruritic and vasoconstrictive effects. Binding and activation of the glucocorticoid receptor results in the activation of lipocortin that in turn inhibits cytosolic phospholipase A2. Lack of phospholipase A2 prevents the release of arachidonic acid, precursor for inflammatory mediator prostaglandins and leukotrienes, from the cell membrane. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leads to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A9143574-AB67-0172-E040-BB89AD437AEF","latestVersionIndicator":"Yes","beginDate":"2011-07-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-917D-18F7-E053-F662850A60B1","beginDate":"2011-07-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Hydrocortisone Acetate 2.5%","valueDescription":"Hydrocortisone Acetate 2.5% (Hytone)","ValueMeaning":{"publicId":"3257744","version":"1","preferredName":"Hydrocortisone Acetate 2.5% (Hytone)","longName":"3257744","preferredDefinition":"A number with no fractional part.::2.5%: The synthetic acetate salt form of hydrocortisone, a corticosteroid with anti-inflammatory and immunosuppressive properties. Hydrocortisone acetate initially binds to the cytoplasmic glucocorticoid receptor; then the receptor-ligand complex is translocated to the nucleus where it initiates the transcription of genes encoding for anti-inflammatory mediators, such as cytokines and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Hydrocortisone Acetate","conceptCode":"C61785","definition":"The synthetic acetate ester form of hydrocortisone, a corticosteroid with anti-inflammatory and immunosuppressive properties. Hydrocortisone acetate initially binds to the cytoplasmic glucocorticoid receptor; then the receptor-ligand complex is translocated to the nucleus where it initiates the transcription of genes encoding for anti-inflammatory mediators, such as cytokines and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A9143574-AB95-0172-E040-BB89AD437AEF","latestVersionIndicator":"Yes","beginDate":"2011-07-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9187-18F7-E053-F662850A60B1","beginDate":"2011-07-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Tacrolimus","valueDescription":"Tacrolimus (Prograf, Protopic Ointment, Advagraf)","ValueMeaning":{"publicId":"2775673","version":"1","preferredName":"Tacrolimus (Prograf, Protopic Ointment, Advagraf)","longName":"2775673","preferredDefinition":"A drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tacrolimus","conceptCode":"C1311","definition":"A macrolide isolated from Streptomyces tsukubaensis. Tacrolimus binds to the FKBP-12 protein and forms a complex with calcium-dependent proteins, thereby inhibiting calcineurin phosphatase activity and resulting in decreased cytokine production. This agent exhibits potent immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation. Tacrolimus possesses similar immunosuppressive properties to cyclosporine, but is more potent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54FB5BE0-01E0-7379-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-08-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9191-18F7-E053-F662850A60B1","beginDate":"2011-07-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Pimecrolimus","valueDescription":"Pimecrolimus (Elidel Cream)","ValueMeaning":{"publicId":"3258237","version":"1","preferredName":"Pimecrolimus (Elidel Cream)","longName":"3258237","preferredDefinition":"A 33-epi-chloro-derivative of the ascomycin macrolactam with immunosuppressant property. Pimecrolimus binds to the receptor macrophilin-12 (FKBP-12) forming a complex that blocks the calcium-dependent signal transduction cascade mediated by calcineurin. Via dephosphorylation, calcineurin is the enzyme responsible for activating nuclear factor of activated T-cells (NF-AT), a T cell transcriptional regulatory factor. As a consequence, the synthesis and release of Th1- (T helper 1) and Th2- (T helper 2) type cytokines, and other inflammatory mediators from T-cells and mast cells are blocked and the expression of signals essential for the activation of inflammatory T-lymphocytes is inhibited. However, pimecrolimus mode of action is cell-selective and does not affect Langerhans' cells/dendritic cells and primary fibroblasts.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pimecrolimus","conceptCode":"C47671","definition":"A 33-epi-chloro-derivative of the ascomycin macrolactam with immunosuppressant property. Pimecrolimus binds to the receptor macrophilin-12 (FKBP-12) forming a complex that blocks the calcium-dependent signal transduction cascade mediated by calcineurin. Via dephosphorylation, calcineurin is the enzyme responsible for activating nuclear factor of activated T-cells (NF-AT), a T cell transcriptional regulatory factor. As a consequence, the synthesis and release of Th1- (T helper 1) and Th2- (T helper 2) type cytokines, and other inflammatory mediators from T-cells and mast cells are blocked and the expression of signals essential for the activation of inflammatory T-lymphocytes is inhibited. However, pimecrolimus mode of action is cell-selective and does not affect Langerhans' cells/dendritic cells and primary fibroblasts.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A9207C79-A66A-0C05-E040-BB89AD43035E","latestVersionIndicator":"Yes","beginDate":"2011-07-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-919B-18F7-E053-F662850A60B1","beginDate":"2011-07-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Flumethasone Pivalate","valueDescription":"Flumethasone Pivalate 0.03% (Locorten)","ValueMeaning":{"publicId":"3258239","version":"1","preferredName":"Flumethasone Pivalate 0.03% (Locorten)","longName":"3258239","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Flumethasone Pivalate","conceptCode":"C65718","definition":"No Value Exists","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A9207C79-A697-0C05-E040-BB89AD43035E","latestVersionIndicator":"Yes","beginDate":"2011-07-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-91A5-18F7-E053-F662850A60B1","beginDate":"2011-07-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cinnarizine","valueDescription":"Cinnarizine","ValueMeaning":{"publicId":"3259718","version":"1","preferredName":"Cinnarizine","longName":"3259718","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cinnarizine","conceptCode":"C76060","definition":"No Value Exists","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A996FD79-16B3-8516-E040-BB89AD436038","latestVersionIndicator":"Yes","beginDate":"2011-08-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-08-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-91AF-18F7-E053-F662850A60B1","beginDate":"2011-08-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Metaxalone","valueDescription":"Metaxalone","ValueMeaning":{"publicId":"2923336","version":"1","preferredName":"Metaxalone","longName":"2923336","preferredDefinition":"An oxazolidinone with centrally-acting skeletal muscle relaxant properties. Although the exact mechanism through which metaxalone exerts its effect is largely unknown, it might be due to general central nervous system (CNS) depression. Metaxalone has no direct effect on the contractile mechanisms of striated muscle, the motor end plate, or the nerve fiber.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metaxalone","conceptCode":"C47606","definition":"An oxazolidinone with centrally-acting skeletal muscle relaxant properties. Although the exact mechanism through which metaxalone exerts its effect is largely unknown, it might be due to general central nervous system (CNS) depression. Metaxalone has no direct effect on the contractile mechanisms of striated muscle, the motor end plate, or the nerve fiber.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6FB34A35-F6F6-0250-E040-BB89AD4308FF","latestVersionIndicator":"Yes","beginDate":"2009-07-27","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-07-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-91B9-18F7-E053-F662850A60B1","beginDate":"2011-09-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"MedOral dry mouth treatment","valueDescription":"MedOral dry mouth treatment","ValueMeaning":{"publicId":"3282738","version":"1","preferredName":"MedOral dry mouth treatment","longName":"3282738","preferredDefinition":"MedOral dry mouth treatment","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD7A7C31-1715-1CA5-E040-BB89AD434D37","latestVersionIndicator":"Yes","beginDate":"2011-09-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-91C3-18F7-E053-F662850A60B1","beginDate":"2011-09-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Maropitant Citrate","valueDescription":"Maropitant Citrate","ValueMeaning":{"publicId":"3282740","version":"1","preferredName":"Maropitant Citrate","longName":"3282740","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Maropitant Citrate","conceptCode":"C78028","definition":"A neurokinin receptor antagonist with antiemetic activity. This agent is approved for veterinary use only.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD7A7C31-173B-1CA5-E040-BB89AD434D37","latestVersionIndicator":"Yes","beginDate":"2011-09-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-91CD-18F7-E053-F662850A60B1","beginDate":"2011-09-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"MSM w/Glucosamine","valueDescription":"MSM/Glucosamine","ValueMeaning":{"publicId":"3282742","version":"1","preferredName":"MSM/Glucosamine","longName":"3282742","preferredDefinition":"A combination preparation of glucosamine, a hexosamine sugar polymer, and methyl sulfonyl methane (MSM), a derivative of dimethyl sulphoxide, with anti-arthritic and anti-inflammatory activities. The mechanism of action has not yet been fully elucidated but addition of glucosamine to chondrocytes results in inhibition of proteoglycan catabolism. Glucosamine inhibits interleukin-1-induced production of inflammatory mediators (nitric oxide, prostaglandin E2), and inhibit aggrecanase activity, which results in preservation of proteoglycan and chondrocytes. Other studies have also shown glucosamine to reduce the generation of reactive oxygen species by macrophages, and inhibit lysosomal enzymes. MSM has been suggested to exert its analgesic effect by inhibiting pain impulses along type C nerve fibers, reducing inflammation and muscle spasms, as well as promoting blood flow, thereby promoting the healing of cartilage lesions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MSM/Glucosamine","conceptCode":"C29234","definition":"A combination preparation of glucosamine, a hexosamine sugar polymer, and methyl sulfonyl methane (MSM), a derivative of dimethyl sulphoxide, with anti-arthritic and anti-inflammatory activities. The mechanism of action has not yet been fully elucidated but addition of glucosamine to chondrocytes results in inhibition of proteoglycan catabolism. Glucosamine inhibits interleukin-1-induced production of inflammatory mediators (nitric oxide, prostaglandin E2), and inhibit aggrecanase activity, which results in preservation of proteoglycan and chondrocytes. Other studies have also shown glucosamine to reduce the generation of reactive oxygen species by macrophages, and inhibit lysosomal enzymes. MSM has been suggested to exert its analgesic effect by inhibiting pain impulses along type C nerve fibers, reducing inflammation and muscle spasms, as well as promoting blood flow, thereby promoting the healing of cartilage lesions.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD7A7C31-1761-1CA5-E040-BB89AD434D37","latestVersionIndicator":"Yes","beginDate":"2011-09-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-91D7-18F7-E053-F662850A60B1","beginDate":"2011-09-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"MS Contin","valueDescription":"Morphine Sulfate Sustained-Release Tablet","ValueMeaning":{"publicId":"3282744","version":"1","preferredName":"Morphine Sulfate Sustained-Release Tablet","longName":"3282744","preferredDefinition":"A sustained-release tablet formulation containing the sulfate salt of the opiate alkaloid morphine with analgesic activity. Morphine binds to and activates the mu-opioid receptors in the central nervous system (CNS), thereby mimicking the effects of the endogenous opioids. Binding of morphine to opioid receptors stimulates exchange of GTP for GDP, inhibits adenylate cyclase, and decreases intracellular cAMP. This inhibits the release of various nociceptive neurotransmitters, such as substance P, gamma-aminobutyric acid (GABA), dopamine, acetylcholine, noradrenaline, vasopressin, and somatostatin. In addition, morphine closes N-type voltage-gated calcium channels and opens calcium-dependent inwardly rectifying potassium channels, which results in hyperpolarization of neuronal membranes and a reduction in neuronal excitability, and subsequently, analgesia and sedation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Morphine Sulfate Sustained-Release Tablet","conceptCode":"C84853","definition":"A sustained-release tablet formulation containing the sulfate salt of the opiate alkaloid morphine with analgesic activity. Morphine binds to and activates the mu-opioid receptors in the central nervous system (CNS), thereby mimicking the effects of the endogenous opioids. Binding of morphine to opioid receptors stimulates exchange of GTP for GDP, inhibits adenylate cyclase, and decreases intracellular cAMP. This inhibits the release of various nociceptive neurotransmitters, such as substance P, gamma-aminobutyric acid (GABA), dopamine, acetylcholine, noradrenaline, vasopressin, and somatostatin. In addition, morphine closes N-type voltage-gated calcium channels and opens calcium-dependent inwardly rectifying potassium channels, which results in hyperpolarization of neuronal membranes and a reduction in neuronal excitability, and subsequently, analgesia and sedation.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD7A7C31-1787-1CA5-E040-BB89AD434D37","latestVersionIndicator":"Yes","beginDate":"2011-09-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-91E1-18F7-E053-F662850A60B1","beginDate":"2011-09-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"MK-0158 (Raltegravir)","valueDescription":"Raltegravir","ValueMeaning":{"publicId":"3282746","version":"1","preferredName":"Raltegravir","longName":"3282746v1.00","preferredDefinition":"A small molecule with activity against human immunodeficiency virus (HIV). Raltegravir is an integrase inhibitor that blocks the integration of the viral genome into the host DNA, a critical step in the pathogenesis of HIV.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Raltegravir","conceptCode":"C72837","definition":"A small molecule with activity against human immunodeficiency virus (HIV). Raltegravir is an integrase inhibitor that blocks the integration of the viral genome into the host DNA, a critical step in the pathogenesis of HIV.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD7A7C31-17AD-1CA5-E040-BB89AD434D37","latestVersionIndicator":"Yes","beginDate":"2011-09-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-21","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-91EB-18F7-E053-F662850A60B1","beginDate":"2011-09-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lunesta (Eszopiclone)","valueDescription":"Eszopiclone","ValueMeaning":{"publicId":"3282748","version":"1","preferredName":"Eszopiclone","longName":"3282748","preferredDefinition":"A nonbenzodiazepine, cyclopyrrolone and active stereoisomer of zopiclone with hypnotic and sedative activity and without significant anxiolytic activity. Although the exact mechanism of action remains to be fully elucidated, eszopiclone is able to bind to and activate the omega-1 subtype of the alpha subunit of the gamma-aminobutyric acid-benzodiazepine GABA receptor complex (GABA-A), a chloride ionophore complex in the central nervous system (CNS). This leads to the opening of chloride channels, causing hyperpolarization, inhibition of neuronal firing, and enhancement of the inhibitory effect of GABA. This eventually leads to a hypnotic effect and allows for an induction of sleep.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eszopiclone","conceptCode":"C65545","definition":"A nonbenzodiazepine, cyclopyrrolone and active stereoisomer of zopiclone with hypnotic and sedative activity and without significant anxiolytic activity. Although the exact mechanism of action remains to be fully elucidated, eszopiclone is able to bind to and activate the omega-1 subtype of the alpha subunit of the gamma-aminobutyric acid-benzodiazepine GABA receptor complex (GABA-A), a chloride ionophore complex in the central nervous system (CNS). This leads to the opening of chloride channels, causing hyperpolarization, inhibition of neuronal firing, and enhancement of the inhibitory effect of GABA. This eventually leads to a hypnotic effect and allows for an induction of sleep.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD7A7C31-17D3-1CA5-E040-BB89AD434D37","latestVersionIndicator":"Yes","beginDate":"2011-09-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-91F5-18F7-E053-F662850A60B1","beginDate":"2011-09-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Hydrochlorothiazide/Telmisartan","valueDescription":"Hydrochlorothiazide Telmisartan","ValueMeaning":{"publicId":"3285608","version":"1","preferredName":"Hydrochlorothiazide Telmisartan","longName":"3285608","preferredDefinition":"The hydrogenated derivative of chlorothiazide, a thiazide diuretic with antihypertensive and anti-urolithic effects. This agent binds to the electroneutral Na-K-Cl cotransporter (NKCC) and thereby impairs Na+, K+ and Cl- reabsorption on the luminal membrane of the early segment in the distal convoluted tubule in the kidney. This leads to an increase in urinary excretion of sodium, chloride, potassium, bicarbonate and water subsequently reducing plasma and extracellular fluid volume leading to a reduction in blood pressure. Hydrochlorothiazide also decreases urinary calcium and uric acid excretion by direct action on the distal tubule.: A benzimidazole derivative and a non-peptide angiotensin II receptor antagonist with antihypertensive property. Telmisartan selectively antagonizes angiotensin II binding to the AT1 subtype receptor, located in vascular smooth muscle and adrenal gland. The antagonism results in vasodilation and inhibits the angiotensin II-mediated aldosterone production, which in turn leading to a decrease in sodium and water as well as an increase in potassium excretion leading to a subsequent reduction in blood pressure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydrochlorothiazide","conceptCode":"C29098","definition":"A short acting thiazide diuretic. Hydrochlorothiazide (HCTZ) is widely used to treat hypertension and edema. This agent's metabolite appears to preferentially bind to and accumulate in red blood cells. This agent is primarily excreted by the kidneys.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Telmisartan","conceptCode":"C47746","definition":"A benzimidazole derivative and a non-peptide angiotensin II receptor antagonist with antihypertensive property. Telmisartan selectively antagonizes angiotensin II binding to the AT1 subtype receptor, located in vascular smooth muscle and adrenal gland. The antagonism results in vasodilation and inhibits the angiotensin II-mediated aldosterone production, which in turn leading to a decrease in sodium and water as well as an increase in potassium excretion leading to a subsequent reduction in blood pressure.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ADED2CCF-E6BA-BB8C-E040-BB89AD43405D","latestVersionIndicator":"Yes","beginDate":"2011-09-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-91FF-18F7-E053-F662850A60B1","beginDate":"2011-09-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Insulin Glulisine","valueDescription":"Insulin Glulisine","ValueMeaning":{"publicId":"3287379","version":"1","preferredName":"Insulin Glulisine","longName":"3287379","preferredDefinition":"A drug used to control the amount of sugar in the blood of patients with diabetes mellitus. It is a form of the hormone insulin that is made in the laboratory. Insulin glulisine gets into the blood faster than insulin when it is injected under the skin before or shortly after a meal. It is a type of therapeutic insulin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Insulin Glulisine","conceptCode":"C65921","definition":"A drug used to control the amount of sugar in the blood of patients with diabetes mellitus. It is a form of the hormone insulin that is made in the laboratory. Insulin glulisine gets into the blood faster than insulin when it is injected under the skin before or shortly after a meal. It is a type of therapeutic insulin.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE15165B-E836-06CC-E040-BB89AD437EFC","latestVersionIndicator":"Yes","beginDate":"2011-09-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9209-18F7-E053-F662850A60B1","beginDate":"2011-09-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Denosumab","valueDescription":"Denosumab","ValueMeaning":{"publicId":"3241060","version":"1","preferredName":"Denosumab","longName":"3241060","preferredDefinition":"A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity. Denosumab specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces, resulting in inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Denosumab","conceptCode":"C61313","definition":"A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity. Denosumab specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces, resulting in inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A443510D-A108-C5AF-E040-BB89AD435D96","latestVersionIndicator":"Yes","beginDate":"2011-05-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9213-18F7-E053-F662850A60B1","beginDate":"2011-09-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"IgG","valueDescription":"IgG","ValueMeaning":{"publicId":"2658037","version":"1","preferredName":"IgG","longName":"2658037","preferredDefinition":"An immunoglobulin isotype (subclass) that characterizes secondary immune responses.  This isotype is further broken down into several smaller subclasses (IgG1, IgG2a, IgG2b, IgG3 in the mouse; IgG1-4 in the human), and each subclass is differentially synthesized and secreted into the serum upon differential immune stimuli.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IgG","conceptCode":"C568","definition":"An immunoglobulin isotype (subclass) that characterizes secondary immune responses.  This isotype is further broken down into several smaller subclasses (IgG1, IgG2a, IgG2b, IgG3 in the mouse; IgG1-4 in the human), and each subclass is differentially synthesized and secreted into the serum upon differential immune stimuli.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3356EC85-90C0-2A59-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-20","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2007-06-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-921D-18F7-E053-F662850A60B1","beginDate":"2011-09-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Midodrine HCL","valueDescription":"Midodrine Hydrochloride","ValueMeaning":{"publicId":"3293860","version":"1","preferredName":"Midodrine Hydrochloride","longName":"3293860","preferredDefinition":"The hydrochloride salt form of midodrine, a direct-acting prodrug and sympathomimetic agent with antihypotensive properties. Midodrine is converted to its active metabolite, desglymidodrine by deglycination reaction. Desglymidodrine selectively binds to and activates alpha-1-adrenergic receptors of the arteriolar and venous vasculature. This causes smooth muscle contraction and leads to an elevation of blood pressure. Desglymidodrine diffuses poorly across the blood-brain barrier, and is therefore not associated with effects on the central nervous system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Midodrine Hydrochloride","conceptCode":"C47620","definition":"The hydrochloride salt form of midodrine, a direct-acting prodrug and sympathomimetic agent with antihypotensive properties. Midodrine is converted to its active metabolite, desglymidodrine by deglycination reaction. Desglymidodrine selectively binds to and activates alpha-1-adrenergic receptors of the arteriolar and venous vasculature. This causes smooth muscle contraction and leads to an elevation of blood pressure. Desglymidodrine diffuses poorly across the blood-brain barrier, and is therefore not associated with effects on the central nervous system.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF1FC92F-6E23-7AF0-E040-BB89AD430313","latestVersionIndicator":"Yes","beginDate":"2011-10-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9227-18F7-E053-F662850A60B1","beginDate":"2011-10-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Midazolam","valueDescription":"Midazolam","ValueMeaning":{"publicId":"3293862","version":"1","preferredName":"Midazolam","longName":"3293862","preferredDefinition":"A short-acting benzodiazepine derivative with an imidazole structure and with anxiolytic, amnestic, hypnotic, anticonvulsant and sedative properties. Midazolam exerts its effect by binding to the benzodiazepine receptor at the gamma-aminobutyric acid (GABA) receptor-chloride ionophore complex in the central nervous system (CNS). This leads to an increase in the opening of chloride channels, membrane hyperpolarization and increases the inhibitory effect of GABA in the CNS. Midazolam may also interfere with the reuptake of GABA, thereby causing accumulation of GABA in the synaptic cleft.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Midazolam","conceptCode":"C62049","definition":"A short-acting benzodiazepine derivative with an imidazole structure and with anxiolytic, amnestic, hypnotic, anticonvulsant and sedative properties. Midazolam exerts its effect by binding to the benzodiazepine receptor at the gamma-aminobutyric acid (GABA) receptor-chloride ionophore complex in the central nervous system (CNS). This leads to an increase in the opening of chloride channels, membrane hyperpolarization and increases the inhibitory effect of GABA in the CNS. Midazolam may also interfere with the reuptake of GABA, thereby causing accumulation of GABA in the synaptic cleft.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF1FC92F-6E49-7AF0-E040-BB89AD430313","latestVersionIndicator":"Yes","beginDate":"2011-10-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9231-18F7-E053-F662850A60B1","beginDate":"2011-10-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Miconazole","valueDescription":"Miconazole","ValueMeaning":{"publicId":"2575690","version":"1","preferredName":"Miconazole","longName":"2575690","preferredDefinition":"An antifungal synthetic derivative of imidazole and used in the treatment of candidal skin infections, Miconazole selectively affects the integrity of fungal cell membranes, high in ergosterol content and different in composition from mammalian cells membranes. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Miconazole","conceptCode":"C62048","definition":"An antifungal synthetic derivative of imidazole and used in the treatment of candidal skin infections, Miconazole selectively affects the integrity of fungal cell membranes, high in ergosterol content and different in composition from mammalian cells membranes. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4B7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-923B-18F7-E053-F662850A60B1","beginDate":"2011-10-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Micafungin Sodium","valueDescription":"Micafungin Sodium","ValueMeaning":{"publicId":"3293864","version":"1","preferredName":"Micafungin Sodium","longName":"3293864","preferredDefinition":"The sodium salt form of micafungin, a semi-synthetic echinocandin derived from a natural product of the fungus Coleophoma empetri with antifungal activity. Micafungin, like other cyclic lipopeptides, noncompetitively inhibits the fungal specific enzyme 1,3-beta-D-glucan synthase, an enzyme essential for the synthesis of the important fungal cell wall component 1,3-beta-D-glucan. By preventing the synthesis of 1,3-beta-D-glucan, the cell wall is weakened which leads to osmotic lysis and eventually fungal cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Micafungin Sodium","conceptCode":"C66145","definition":"The sodium salt form of micafungin, a semi-synthetic echinocandin derived from a natural product of the fungus Coleophoma empetri with antifungal activity. Micafungin, like other cyclic lipopeptides, noncompetitively inhibits the fungal specific enzyme 1,3-beta-D-glucan synthase, an enzyme essential for the synthesis of the important fungal cell wall component 1,3-beta-D-glucan. By preventing the synthesis of 1,3-beta-D-glucan, the cell wall is weakened which leads to osmotic lysis and eventually fungal cell death.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF1FC92F-6E79-7AF0-E040-BB89AD430313","latestVersionIndicator":"Yes","beginDate":"2011-10-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9245-18F7-E053-F662850A60B1","beginDate":"2011-10-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Methenamine/Methylene Blue/Benzoic/Phenysal/Atropine/Hyoscyamine","valueDescription":"Methenamine/Methylene Blue/Benzoic/Phenysal/Atropine/Hyoscyamine","ValueMeaning":{"publicId":"3293865","version":"1","preferredName":"Methenamine/Methylene Blue/Benzoic/Phenysal/Atropine/Hyoscyamine","longName":"3293865","preferredDefinition":"Methenamine/Methylene Blue/Benzoic/Phenysal/Atropine/Hyoscyamine","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF1FC92F-6E9C-7AF0-E040-BB89AD430313","latestVersionIndicator":"Yes","beginDate":"2011-10-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-924F-18F7-E053-F662850A60B1","beginDate":"2011-10-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Minocycline HCL","valueDescription":"Minocycline Hydrochloride","ValueMeaning":{"publicId":"3293867","version":"1","preferredName":"Minocycline Hydrochloride","longName":"3293867","preferredDefinition":"The hydrochloride salt of minocycline, a broad spectrum long-acting derivative of the antibiotic tetracycline, with antibacterial and anti-inflammatory activities. Minocycline binds to the bacterial 30S ribosomal subunit and interferes with the binding of tRNA to the ribosomal complex, thereby inhibiting protein translation in bacteria. In addition, minocycline inhibits the inflammatory enzyme 5-lipoxygenase (5LOX) and may impede T cell-microglia interactions; both activities may contribute to minocycline's neuroprotective effects. 5LOX catalyzes the synthesis of inflammatory mediators such as prostaglandins and leukotrienes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Minocycline Hydrochloride","conceptCode":"C47622","definition":"The hydrochloride salt of minocycline, a broad spectrum long-acting derivative of the antibiotic tetracycline, with antibacterial and anti-inflammatory activities. Minocycline binds to the bacterial 30S ribosomal subunit and interferes with the binding of tRNA to the ribosomal complex, thereby inhibiting protein translation in bacteria. In addition, minocycline inhibits the inflammatory enzyme 5-lipoxygenase (5LOX) and may impede T cell-microglia interactions; both activities may contribute to minocycline's neuroprotective effects. 5LOX catalyzes the synthesis of inflammatory mediators such as prostaglandins and leukotrienes.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF1FC92F-6F1B-7AF0-E040-BB89AD430313","latestVersionIndicator":"Yes","beginDate":"2011-10-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9259-18F7-E053-F662850A60B1","beginDate":"2011-10-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Milk of Magnesia","valueDescription":"Magnesium Hydroxide","ValueMeaning":{"publicId":"2578256","version":"1","preferredName":"Magnesium Hydroxide","longName":"2578256","preferredDefinition":"A solution of magnesium hydroxide with antacid and laxative properties. Milk of magnesium exerts its antacid activity in low doses such that all hydroxide ions that enter the stomach are used to neutralize stomach acid. This agent exerts its laxative effect in higher doses so that hydroxide ions are able to move from the stomach to the intestines where they attract and retain water, thereby increasing intestinal movement (peristalsis) and inducing the urge to defecate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Magnesium Hydroxide","conceptCode":"C29262","definition":"A solution of magnesium hydroxide with antacid and laxative properties. Milk of magnesium exerts its antacid activity in low doses such that all hydroxide ions that enter the stomach are used to neutralize stomach acid. This agent exerts its laxative effect in higher doses so that hydroxide ions are able to move from the stomach to the intestines where they attract and retain water, thereby increasing intestinal movement (peristalsis) and inducing the urge to defecate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEBD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9263-18F7-E053-F662850A60B1","beginDate":"2011-10-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Midrin","valueDescription":"Dichloralphenazone Acetaminophen Isometheptene","ValueMeaning":{"publicId":"3293870","version":"1","preferredName":"Dichloralphenazone Acetaminophen Isometheptene","longName":"3293870","preferredDefinition":"No Value Exists: A drug that reduces pain and fever (but not inflammation).  It belongs to the family of drugs called analgesics.: No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dichloralphenazone","conceptCode":"C87204","definition":"No Value Exists","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Acetaminophen","conceptCode":"C198","definition":"A p-aminophenol derivative with analgesic and antipyretic activities. Although the exact mechanism through which acetaminophen exert its effects has yet to be fully determined, acetaminophen may inhibit the nitric oxide (NO) pathway mediated by a variety of neurotransmitter receptors including N-methyl-D-aspartate (NMDA) and substance P, resulting in elevation of the pain threshold. The antipyretic activity may result from inhibition of prostaglandin synthesis and release in the central nervous system (CNS) and prostaglandin-mediated effects on the heat-regulating center in the anterior hypothalamus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Isometheptene","conceptCode":"C75929","definition":"No Value Exists","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF1FC92F-6F58-7AF0-E040-BB89AD430313","latestVersionIndicator":"Yes","beginDate":"2011-10-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-926D-18F7-E053-F662850A60B1","beginDate":"2011-10-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Midol PMS","valueDescription":"Midol PMS","ValueMeaning":{"publicId":"3293871","version":"1","preferredName":"Midol PMS","longName":"3293871v1.00","preferredDefinition":"A combination preparation containing pyrilamine, pamabron and acetaminophen. Pyrilamine is an ethylenediamine antihistamine that blocks H1 receptors and exerts local anesthetic, sedative and mild analgesic activity. Pamabrom, a xanthine derivate, is a mild diuretic that helps the body to excrete excess fluid. Acetaminophen possesses analgesic and antipyretic effects. This preparation is used for the relief of premenstrual and menstrual symptoms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pyrilamine/Pamabrom/Acetaminophen","conceptCode":"C29259","definition":"A combination preparation containing pyrilamine, pamabron and acetaminophen. Pyrilamine is an ethylenediamine antihistamine that blocks H1 receptors and exerts local anesthetic, sedative and mild analgesic activity. Pamabrom, a xanthine derivate, is a mild diuretic that helps the body to excrete excess fluid. Acetaminophen possesses analgesic and antipyretic effects. This preparation is used for the relief of premenstrual and menstrual symptoms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF1FC92F-6F7B-7AF0-E040-BB89AD430313","latestVersionIndicator":"Yes","beginDate":"2011-10-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-12","modifiedBy":"CLOHNES","dateModified":"2023-08-04","changeDescription":null,"administrativeNotes":"8/4/23 Added missing concept per cleanup activities cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9277-18F7-E053-F662850A60B1","beginDate":"2011-10-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Midol Menstrual","valueDescription":"Midol Menstrual","ValueMeaning":{"publicId":"3293872","version":"1","preferredName":"Midol Menstrual","longName":"3293872v1.00","preferredDefinition":"A combination preparation containing pyrilamine, caffeine and acetaminophen. Pyrilamine is an ethylenediamine antihistamine that blocks H1 receptors and exerts local anesthetic, sedative and mild analgesic activities. Caffeine is a central nervous system stimulant. Acetaminophen possesses analgesic and antipyretic effects. This preparation is used for the relief of premenstrual and menstrual symptoms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pyrilamine/Caffeine/Acetaminophen","conceptCode":"C29258","definition":"A combination preparation containing pyrilamine, caffeine and acetaminophen. Pyrilamine is an ethylenediamine antihistamine that blocks H1 receptors and exerts local anesthetic, sedative and mild analgesic activities. Caffeine is a central nervous system stimulant. Acetaminophen possesses analgesic and antipyretic effects. This preparation is used for the relief of premenstrual and menstrual symptoms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF1FC92F-6F9E-7AF0-E040-BB89AD430313","latestVersionIndicator":"Yes","beginDate":"2011-10-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-12","modifiedBy":"CLOHNES","dateModified":"2023-08-04","changeDescription":null,"administrativeNotes":"8/4/23 Added missing concept per cleanup activities cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9281-18F7-E053-F662850A60B1","beginDate":"2011-10-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Desoximetasone 0.25%","valueDescription":"Desoximetasone 0.25% (Topicort)","ValueMeaning":{"publicId":"3257144","version":"1","preferredName":"Desoximetasone 0.25% (Topicort)","longName":"3257144","preferredDefinition":"A number with no fractional part.::0.25%: A synthetic glucocorticoid receptor agonist with metabolic, anti-inflammatory and immunosuppressive activity. Desoximetasone activates specific intracellular receptors, which bind to distinct sites on DNA to modify gene transcription. This results in an induction of the synthesis of anti-inflammatory proteins and suppression of the synthesis of inflammatory mediators. This leads to an overall reduction in chronic inflammation and autoimmune reactions. Desoximetasone is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Desoximetasone","conceptCode":"C47477","definition":"A synthetic glucocorticoid receptor agonist with metabolic, anti-inflammatory and immunosuppressive activity. Desoximetasone activates specific intracellular receptors, which bind to distinct sites on DNA to modify gene transcription. This results in an induction of the synthesis of anti-inflammatory proteins and suppression of the synthesis of inflammatory mediators. This leads to an overall reduction in chronic inflammation and autoimmune reactions. Desoximetasone is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8E5F174-7BED-0BD1-E040-BB89AD430295","latestVersionIndicator":"Yes","beginDate":"2011-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-928B-18F7-E053-F662850A60B1","beginDate":"2011-07-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Arginine","valueDescription":"Arginine","ValueMeaning":{"publicId":"3256941","version":"1","preferredName":"Arginine","longName":"3256941","preferredDefinition":"An essential amino acid in juvenile humans, Arginine is a complex amino acid, often found at active site in proteins and enzymes due to its amine-containing side chain. Arginine may prevent or treat heart and circulatory diseases, combat fatigue, and stimulate the immune system. It also boosts production of nitric oxide, relaxing blood vessels, and treating angina and other cardiovascular problems. Arginine is also an important intermediate in the urea cycle and in detoxification of nitrogenous wastes. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Arginine","conceptCode":"C62008","definition":"An essential amino acid in juvenile humans, Arginine is a complex amino acid, often found at active site in proteins and enzymes due to its amine-containing side chain. Arginine may prevent or treat heart and circulatory diseases, combat fatigue, and stimulate the immune system. It also boosts production of nitric oxide, relaxing blood vessels, and treating angina and other cardiovascular problems. Arginine is also an important intermediate in the urea cycle and in detoxification of nitrogenous wastes. (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A896758E-4FC7-97BE-E040-BB89AD435115","latestVersionIndicator":"Yes","beginDate":"2011-07-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-21","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9295-18F7-E053-F662850A60B1","beginDate":"2011-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Halobetasol Propionate 0.05%","valueDescription":"Halobetasol Propionate 0.05% (Ultravate)","ValueMeaning":{"publicId":"3257254","version":"1","preferredName":"Halobetasol Propionate 0.05% (Ultravate)","longName":"3257254","preferredDefinition":"The propionate salt form of halobetasol, a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictor activities. Halobetasol, a topical steroid, diffuses across cell membranes to interact with cytoplasmic corticosteroid receptors located in both the dermal and intradermal cells, thereby activating gene expression of anti-inflammatory proteins mediated via corticosteroid receptor response element. Specifically, this agent induces phospholipase A2 inhibitory proteins, which inhibit the release of arachidonic acid, thereby inhibiting the biosynthesis of potent mediators of inflammation, such as prostaglandins and leukotrienes. As a result, halobetasol reduces edema, erythema, and pruritus through its cutaneous effects on vascular dilation and permeability.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Halobetasol Propionate","conceptCode":"C47553","definition":"The propionate salt form of halobetasol, a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictor activities. Halobetasol, a topical steroid, diffuses across cell membranes to interact with cytoplasmic corticosteroid receptors located in both the dermal and intradermal cells, thereby activating gene expression of anti-inflammatory proteins mediated via corticosteroid receptor response element. Specifically, this agent induces phospholipase A2 inhibitory proteins, which inhibit the release of arachidonic acid, thereby inhibiting the biosynthesis of potent mediators of inflammation, such as prostaglandins and leukotrienes. As a result, halobetasol reduces edema, erythema, and pruritus through its cutaneous effects on vascular dilation and permeability.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8E92492-A086-08BA-E040-BB89AD43497B","latestVersionIndicator":"Yes","beginDate":"2011-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-929F-18F7-E053-F662850A60B1","beginDate":"2011-07-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Amcinonide 0.1%","valueDescription":"Amcinonide 0.1% (Cyclocort)","ValueMeaning":{"publicId":"3257256","version":"1","preferredName":"Amcinonide 0.1% (Cyclocort)","longName":"3257256","preferredDefinition":"A synthetic glucocorticoid receptor agonist that mimics the metabolic, anti-inflammatory, and immunosuppressive activity of the natural glucocorticoids. Amcinonide interacts with specific corticosteroid receptors and was internalized, which leads to binding of DNA and modification of gene expression. This results in synthesis of anti-inflammatory mediators while inhibiting synthesis of inflammatory mediators. Consequently, an overall reduction in chronic inflammation and autoimmune reactions are achieved.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amcinonide","conceptCode":"C47389","definition":"A synthetic glucocorticoid receptor agonist that mimics the metabolic, anti-inflammatory, and immunosuppressive activity of the natural glucocorticoids. Amcinonide interacts with specific corticosteroid receptors and was internalized, which leads to binding of DNA and modification of gene expression. This results in synthesis of anti-inflammatory mediators while inhibiting synthesis of inflammatory mediators. Consequently, an overall reduction in chronic inflammation and autoimmune reactions are achieved.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8E92492-A0B3-08BA-E040-BB89AD43497B","latestVersionIndicator":"Yes","beginDate":"2011-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-92A9-18F7-E053-F662850A60B1","beginDate":"2011-07-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Sevelamer","valueDescription":"Sevelamer","ValueMeaning":{"publicId":"3260567","version":"1","preferredName":"Sevelamer","longName":"3260567","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sevelamer","conceptCode":"C84172","definition":"A non-absorbable polymeric amine and phosphate binding agent that can be used to prevent hyperphosphatemia. Upon oral administration, the amine groups in sevelamer become protonated in the intestines and bind to the dietary phosphate groups in the gastrointestinal (GI) tract, thereby preventing the absorption of phosphate and controlling phosphate plasma levels. In addition, sevelamer, as a phosphate binder, can be used to prevent the absorption of the radionuclide phosphorus P 32 (P-32).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A9BAC718-E246-E556-E040-BB89AD43121D","latestVersionIndicator":"Yes","beginDate":"2011-08-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-08-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-92B3-18F7-E053-F662850A60B1","beginDate":"2011-08-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Desoximetasone 0.05%","valueDescription":"Desoximetasone 0.05% (Topicort, Topicort LP)","ValueMeaning":{"publicId":"3257140","version":"1","preferredName":"Desoximetasone 0.05% (Topicort, Topicort LP)","longName":"3257140","preferredDefinition":"A number with no fractional part.::0.05%: A synthetic glucocorticoid receptor agonist with metabolic, anti-inflammatory and immunosuppressive activity. Desoximetasone activates specific intracellular receptors, which bind to distinct sites on DNA to modify gene transcription. This results in an induction of the synthesis of anti-inflammatory proteins and suppression of the synthesis of inflammatory mediators. This leads to an overall reduction in chronic inflammation and autoimmune reactions. Desoximetasone is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Desoximetasone","conceptCode":"C47477","definition":"A synthetic glucocorticoid receptor agonist with metabolic, anti-inflammatory and immunosuppressive activity. Desoximetasone activates specific intracellular receptors, which bind to distinct sites on DNA to modify gene transcription. This results in an induction of the synthesis of anti-inflammatory proteins and suppression of the synthesis of inflammatory mediators. This leads to an overall reduction in chronic inflammation and autoimmune reactions. Desoximetasone is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8E57270-9FB5-D9E4-E040-BB89AD432AB9","latestVersionIndicator":"Yes","beginDate":"2011-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-92BD-18F7-E053-F662850A60B1","beginDate":"2011-07-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Betamethasone Valerate 0.1%","valueDescription":"Betamethasone Valerate 0.1% ","ValueMeaning":{"publicId":"3257141","version":"1","preferredName":"Betamethasone Valerate 0.1% ","longName":"3257141","preferredDefinition":"A number with no fractional part.::0.01%: The 17-valerate ester of betamethasone, a synthetic glucocorticoid with metabolic, immunosuppressive and anti-inflammatory actions. Betamethasone valerate binds to specific intracellular glucocorticoid receptors and subsequently binds to DNA to modify gene expression. The synthesis of certain anti-inflammatory proteins is induced while the synthesis of certain inflammatory mediators is inhibited. As a result, there is an overall reduction in chronic inflammation and autoimmune reactions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Betamethasone Valerate","conceptCode":"C47962","definition":"The 17-valerate ester of betamethasone, a synthetic glucocorticoid with metabolic, immunosuppressive and anti-inflammatory actions. Betamethasone valerate binds to specific intracellular glucocorticoid receptors and subsequently binds to DNA to modify gene expression. The synthesis of certain anti-inflammatory proteins is induced while the synthesis of certain inflammatory mediators is inhibited. As a result, there is an overall reduction in chronic inflammation and autoimmune reactions.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8E57270-9FDD-D9E4-E040-BB89AD432AB9","latestVersionIndicator":"Yes","beginDate":"2011-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-92C7-18F7-E053-F662850A60B1","beginDate":"2011-07-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Diflorasone Diacetate 0.05%","valueDescription":"Diflorasone Diacetate 0.05% (Psorcon, Florone, Maxiflor)","ValueMeaning":{"publicId":"3257143","version":"1","preferredName":"Diflorasone Diacetate 0.05% (Psorcon, Florone, Maxiflor)","longName":"3257143","preferredDefinition":"The acetate salt form of diflorasone, a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties. Like other glucocorticoids, diflorasone enters the cell by diffusion across the cell membrane and binds to the glucocorticoid receptor (GR) in the cytoplasm. The receptor complex subsequently translocates to the nucleus and activates or represses genes by interacting with short, palindromic DNA sequences called glucocorticoid response element (GRE). Gene activation leads to the exertion of anti-inflammatory effects, e.g. upregulation of IkappaB, while gene repression inhibits production of pro-inflammatory cytokines such as interleukin-1 (IL-1), IL-2 and IL-6, thereby preventing activation of cytotoxic T-lymphocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diflorasone Diacetate","conceptCode":"C47488","definition":"The acetate salt form of diflorasone, a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties. Like other glucocorticoids, diflorasone enters the cell by diffusion across the cell membrane and binds to the glucocorticoid receptor (GR) in the cytoplasm. The receptor complex subsequently translocates to the nucleus and activates or represses genes by interacting with short, palindromic DNA sequences called glucocorticoid response element (GRE). Gene activation leads to the exertion of anti-inflammatory effects, e.g. upregulation of IkappaB, while gene repression inhibits production of pro-inflammatory cytokines such as interleukin-1 (IL-1), IL-2 and IL-6, thereby preventing activation of cytotoxic T-lymphocytes.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8E57270-A010-D9E4-E040-BB89AD432AB9","latestVersionIndicator":"Yes","beginDate":"2011-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-92D1-18F7-E053-F662850A60B1","beginDate":"2011-07-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Alclometasone Dipropionate 0.05%","valueDescription":"Alclometasone Dipropionate 0.05% (Aclovate)","ValueMeaning":{"publicId":"3257586","version":"1","preferredName":"Alclometasone Dipropionate 0.05% (Aclovate)","longName":"3257586","preferredDefinition":"A number with no fractional part.::0.05%: The dipropionate salt form of alclometasone, a synthetic corticosteroid with low to medium potency. Alclometasone dipropionate is a glucocorticoid receptor agonist that mimics the metabolic, anti-inflammatory, immunosuppressive, antipruritic, and vasoconstrictive effects of natural glucocorticoids. This drug interacts with specific intracellular receptors and binds to DNA to modify gene expression. This results in an induction of synthesis of certain proteins while inhibiting the synthesis of others. Alclometasone dipropionate is used for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Alclometasone Dipropionate","conceptCode":"C47385","definition":"The dipropionate salt form of alclometasone, a synthetic corticosteroid with low to medium potency. Alclometasone dipropionate is a glucocorticoid receptor agonist that mimics the metabolic, anti-inflammatory, immunosuppressive, antipruritic, and vasoconstrictive effects of natural glucocorticoids. This drug interacts with specific intracellular receptors and binds to DNA to modify gene expression. This results in an induction of synthesis of certain proteins while inhibiting the synthesis of others. Alclometasone dipropionate is used for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. (NCI05)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8EBE4A6-35FC-683B-E040-BB89AD4367F4","latestVersionIndicator":"Yes","beginDate":"2011-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-92DB-18F7-E053-F662850A60B1","beginDate":"2011-07-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Erythromycin","valueDescription":"Erythromycin","ValueMeaning":{"publicId":"2576825","version":"1","preferredName":"Erythromycin","longName":"2576825","preferredDefinition":"A bacteriostatic antibiotic substance produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Erythromycin","conceptCode":"C476","definition":"A broad-spectrum, macrolide antibiotic with antibacterial activity. Erythromycin diffuses through the bacterial cell membrane and reversibly binds to the 50S subunit of the bacterial ribosome. This prevents bacterial protein synthesis. Erythromycin may be bacteriostatic or bactericidal in action, depending on the concentration of the drug at the site of infection and the susceptibility of the organism involved.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F926-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-79A8-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Erythromycin Stearate","valueDescription":"Erythromycin Stearate","ValueMeaning":{"publicId":"2576821","version":"1","preferredName":"Erythromycin Stearate","longName":"2576821","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Erythromycin Stearate","conceptCode":"C47989","definition":"The stearate salt form of erythromycin, a broad-spectrum, topical macrolide antibiotic with antibacterial activity. Erythromycin stearate diffuses through the bacterial cell membrane and reversibly binds to the 50S subunit of the bacterial ribosome. This prevents bacterial protein synthesis. Erythromycin stearate may be bacteriostatic or bactericidal in action, depending on the concentration of the drug at the site of infection and the susceptibility of the organism involved.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F922-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-79B2-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Escitalopram Oxalate","valueDescription":"Escitalopram Oxalate","ValueMeaning":{"publicId":"2576822","version":"1","preferredName":"Escitalopram Oxalate","longName":"2576822","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Escitalopram Oxalate","conceptCode":"C47518","definition":"The oxalate salt of escitalopram, a pure S-enantiomer of the racemic bicyclic phthalane derivative citalopram, with antidepressant activity. As a selective serotonin reuptake inhibitor (SSRI), escitalopram blocks the reuptake of serotonin by neurons in the central nervous system (CNS), thereby potentiating CNS serotonergic activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F923-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-79BC-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Esomeprazole Magnesium","valueDescription":"Esomeprazole Magnesium","ValueMeaning":{"publicId":"2576823","version":"1","preferredName":"Esomeprazole Magnesium","longName":"2576823","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Esomeprazole Magnesium","conceptCode":"C29032","definition":"The magnesium salt of esomeprazole, the S-isomer of omeprazole, with gastric proton pump inhibitor activity. In the acidic compartment of parietal cells, esomeprazole is protonated and converted into the active achiral sulphenamide; the active sulphenamide forms one or more covalent disulfide bonds with the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase), thereby inhibiting its activity and the parietal cell secretion of H+ ions into the gastric lumen, the final step in gastric acid production. H+/K+ ATPase is an integral membrane protein of the gastric parietal cell.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F924-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-79C6-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Essential Amino Acids","valueDescription":"Essential Amino Acid","ValueMeaning":{"publicId":"2576824","version":"1","preferredName":"Essential Amino Acid","longName":"2576824","preferredDefinition":"Amino acids that are not synthesized by the human body in amounts sufficient to carry out physiological functions. They are obtained from dietary foodstuffs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Essential Amino Acid","conceptCode":"C0002525","definition":"Amino acids that are not synthesized by the human body in amounts sufficient to carry out physiological functions. They are obtained from dietary foodstuffs.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F925-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-79D0-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Estrogen","valueDescription":"Estrogen","ValueMeaning":{"publicId":"2563598","version":"1","preferredName":"Estrogen","longName":"2563598","preferredDefinition":"A class of sex hormones associated with the development and maintenance of secondary female sex characteristics and control of the cyclical changes in the reproductive cycle. They are also required for pregnancy maintenance and have an anabolic effect on protein metabolism and water retention.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Estrogen","conceptCode":"C2293","definition":"A class of sex hormones associated with the development and maintenance of secondary female sex characteristics and control of the cyclical changes in the reproductive cycle. They are also required for pregnancy maintenance and have an anabolic effect on protein metabolism and water retention.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C57B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-12-04","endDate":null,"createdBy":"CVALMONT","dateCreated":"2002-12-04","modifiedBy":"COOPERM","dateModified":"2016-08-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-79DA-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Estradiol","valueDescription":"Estradiol","ValueMeaning":{"publicId":"2576827","version":"1","preferredName":"Estradiol","longName":"2576827","preferredDefinition":"Estradiol (E2). beta-estradiol; 17 beta-estradiol; 1,3,5(10)-estratriene-3,17 beta-diol; the most potent naturally occurring estrogen in mammals, formed by the ovary, placenta, testis, and possibly the adrenal cortex; therapeutic indications for estradiol are those typical of an estrogen. alpha-Estradiol, (17 alpha-estradiol), exhibits considerably less biologic activity. Estradiol is used in the treatment of menstrual disorders, menopause problems, etc. SYN estrogenic hormone, oestradiol.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Estradiol","conceptCode":"C2295","definition":"The most potent form of the naturally occurring steroid sex hormone in humans, produced by ovary, placenta, testis, and in small amount by adrenal cortex. Estradiol binds to a specific intracellular estrogen receptor located in female organs, breasts, hypothalamus and pituitary. The receptor-ligand complex promotes gene expression necessary for the maintenance of fertility and secondary sexual characteristics in females. In addition, estradiol exhibits mild anabolic and metabolic properties, and increases blood coagulability. Estradiol, the principal intracellular human estrogen, is substantially more active at the cellular level than its metabolites, estrone and estriol.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F928-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-79E4-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Etanercept","valueDescription":"Etanercept","ValueMeaning":{"publicId":"2567429","version":"1","preferredName":"Etanercept","longName":"2567429","preferredDefinition":"A dimeric fusion protein comprised of a recombinant form of the extracellular ligand-binding portion of the human 75-kilodalton tumor necrosis factor receptor linked to the Fc portion of human immunoglobulin G1 (IgG1).  Clinical Use: Juvenile Arthritis, Psoriatic Arthritis, and Rheumatoid Arthritis.  Clinical Trial: Bone Marrow Transplant and Adjuvant use for Caner-related Anorexia, Cachexia, and Stomatitis.(NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etanercept","conceptCode":"C2381","definition":"A recombinant soluble dimeric fusion protein consisting of the extracellular ligand-binding region of recombinant human tumor necrosis factor (rhTNF) receptor attached to the constant (Fc) region of human immunoglobulin G (FcIgG). The receptor moiety of etanercept binds to circulating TNF (2 molecules of TNF per receptor) and inhibits its attachment to endogenous TNF cell surface receptors, thereby rendering TNF inactive and inhibiting TNF-mediated mechanisms of inflammation. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D472-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-79EE-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ethacrymic Acid","valueDescription":"Ethacrynic Acid","ValueMeaning":{"publicId":"2576829","version":"1","preferredName":"Ethacrynic Acid","longName":"2576829","preferredDefinition":"A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ethacrynic Acid","conceptCode":"C0014963","definition":"A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F92A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-79F8-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ethambutol HCL","valueDescription":"Ethambutol Hydrochloride","ValueMeaning":{"publicId":"2575682","version":"1","preferredName":"Ethambutol Hydrochloride","longName":"2575682","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ethambutol Hydrochloride","conceptCode":"C29033","definition":"The hydrochloride salt form of ethambutol, an ethylenediamine derivative with antibacterial activity, specifically effective against mycobacteria. Although the exact mechanism of action of ethambutol hydrochloride is unknown, ethambutol hydrochloride inhibits the transfer of mycolic acids into the cell wall of bacteria, which impedes bacterial cell growth. This agent may also interfere with RNA synthesis or inhibit other cell metabolism, thereby preventing cell multiplication and causing cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4AF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7A02-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ethinyl Estradiol","valueDescription":"Ethinyl Estradiol","ValueMeaning":{"publicId":"2576830","version":"1","preferredName":"Ethinyl Estradiol","longName":"2576830","preferredDefinition":"A semisynthetic estrogen. Ethinyl estradiol binds to the estrogen receptor complex and enters the nucleus, activating DNA transcription of genes involved in estrogenic cellular responses. This agent also inhibits 5-alpha reductase in epididymal tissue, which lowers testosterone levels and may delay progression of prostatic cancer. In addition to its antineoplastic effects, ethinyl estradiol protects against osteoporosis. In animal models, short-term therapy with this agent has been shown to provide long-term protection against breast cancer, mimicking the antitumor effects of pregnancy. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ethinyl Estradiol","conceptCode":"C486","definition":"A semisynthetic estrogen. Ethinyl estradiol binds to the estrogen receptor complex and enters the nucleus, activating DNA transcription of genes involved in estrogenic cellular responses. This agent also inhibits 5-alpha reductase in epididymal tissue, which lowers testosterone levels and may delay progression of prostatic cancer. In addition to its antineoplastic effects, ethinyl estradiol protects against osteoporosis. In animal models, short-term therapy with this agent has been shown to provide long-term protection against breast cancer, mimicking the antitumor effects of pregnancy. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F92B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7A0C-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ethinyl Estradiol/Ethynodiol Diacetate","valueDescription":"Ethinyl Estradiol/Ethynodiol Diacetate","ValueMeaning":{"publicId":"2576831","version":"1","preferredName":"Ethinyl Estradiol/Ethynodiol Diacetate","longName":"2576831","preferredDefinition":"Ethinyl Estradiol/Ethynodiol Diacetate","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F92C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"REEVESD","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7A16-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ethinyl Estradiol/Levonorgestrel","valueDescription":"Ethinyl Estradiol/Levonorgestrel","ValueMeaning":{"publicId":"2576832","version":"1","preferredName":"Ethinyl Estradiol/Levonorgestrel","longName":"2576832","preferredDefinition":"A combination of two Steroid sex hormones, an estrogen and a progestin, used for contraceptive purposes. Estradiol, the endogenous counterpart of ethinyl estradiol (EE), is the principal, most potent estrogen hormone produced by the ovaries and is vital to the maintenance of fertility and secondary sexual characteristics in females. Levonorgestrel is a synthetic progestogen. This drug combination prevents or delays ovulation and causes a variety of hormonal changes. Ethinyl estradiol inhibits the release of follicle stimulating hormone (FSH), thus suppressing the development of ovarian follicle; levonorgestrel inhibits the release of luteinizing hormone (LH), thus preventing ovulation. This combination of agents alters the endometrium in such a way as to discourage implantation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ethinyl Estradiol/Levonorgestrel","conceptCode":"C0717761","definition":"A combination of two Steroid sex hormones, an estrogen and a progestin, used for contraceptive purposes. Estradiol, the endogenous counterpart of ethinyl estradiol (EE), is the principal, most potent estrogen hormone produced by the ovaries and is vital to the maintenance of fertility and secondary sexual characteristics in females. Levonorgestrel is a synthetic progestogen. This drug combination prevents or delays ovulation and causes a variety of hormonal changes. Ethinyl estradiol inhibits the release of follicle stimulating hormone (FSH), thus suppressing the development of ovarian follicle; levonorgestrel inhibits the release of luteinizing hormone (LH), thus preventing ovulation. This combination of agents alters the endometrium in such a way as to discourage implantation. (NCI04)","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F92D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7A20-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ethinyl Estradiol/Norethindrone","valueDescription":"Ethinyl Estradiol/Norethindrone","ValueMeaning":{"publicId":"2576833","version":"1","preferredName":"Ethinyl Estradiol/Norethindrone","longName":"2576833","preferredDefinition":"A combination of two steroid sex hormones, an estrogen and a progestin, used for contraceptive purposes.  Estradiol, the endogenous counterpart of ethinyl estradiol (EE), is the principal, most potent estrogen hormone produced by the ovaries and is vital to the maintenance of fertility and secondary sexual characteristics in females.  Norethindrone is a synthetic progestogen.  This drug combination prevents or delays ovulation and causes a variety of hormonal changes.  Ethinyl estradiol inhibits the release of follicle stimulating hormone (FSH), thus suppressing the development of ovarian follicle; norethindrone levonorgestrel inhibits the release of luteinizing hormone (LH), thus preventing ovulation.  This combination of agents alters the endometrium in such a way as to discourage implantation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ethinyl Estradiol/Norethindrone","conceptCode":"C29035","definition":"An oral contraceptive formulation containing the semisynthetic estrogen, ethinyl estradiol, combined with the synthetic progestin, norethindrone, with estrogenic and progestogenic activities, respectively. Ethinyl estradiol binds to and activates intracellular estrogen receptors found in the reproductive tract and other estrogen-responsive tissues. The activated complex enters the nucleus, binds to the estrogen response elements on DNA, activates the transcription of genes involved in the maintenance of the female reproductive system, inhibits the release of follicle stimulating hormone (FSH) from the anterior pituitary, and suppresses the development of the ovarian follicle. Norethindrone binds to intracellular progesterone receptors in progesterone-responsive tissues, such as the pituitary and those found in the reproductive system, and the activated ligand/receptor complex interacts with specific progesterone response elements on DNA, which results in the alteration in protein synthesis, the inhibition of ovulation, an increase in cervical mucus production, the induction of the secretory phase of the endometrial cycle, and the inhibition of luteinizing hormone (LH) release. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system and alters the structure of the endometrium to discourage implantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F92E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7A2A-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ethinyl Estradiol/Norethindrone Acetate","valueDescription":"Ethinyl Estradiol/Norethindrone: C1260235","ValueMeaning":{"publicId":"2576834","version":"1","preferredName":"Ethinyl Estradiol/Norethindrone: C1260235","longName":"2576834","preferredDefinition":"A combination of two Steroid sex hormones, an estrogen and a progestin, used for contraceptive purposes. Estradiol, the endogenous counterpart of ethinyl estradiol (EE), is the principal, most potent estrogen hormone produced by the ovaries and is vital to the maintenance of fertility and secondary sexual characteristics in females. Norethindrone is a synthetic progestogen. This drug combination prevents or delays ovulation and causes a variety of hormonal changes. Ethinyl estradiol inhibits the release of follicle stimulating hormone (FSH), thus suppressing the development of ovarian follicle; norethindrone levonorgestrel inhibits the release of luteinizing hormone (LH), thus preventing ovulation. This combination of agents alters the endometrium in such a way as to discourage implantation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ethinyl Estradiol/Norethindrone","conceptCode":"C1260235","definition":"A combination of two Steroid sex hormones, an estrogen and a progestin, used for contraceptive purposes. Estradiol, the endogenous counterpart of ethinyl estradiol (EE), is the principal, most potent estrogen hormone produced by the ovaries and is vital to the maintenance of fertility and secondary sexual characteristics in females. Norethindrone is a synthetic progestogen. This drug combination prevents or delays ovulation and causes a variety of hormonal changes. Ethinyl estradiol inhibits the release of follicle stimulating hormone (FSH), thus suppressing the development of ovarian follicle; norethindrone levonorgestrel inhibits the release of luteinizing hormone (LH), thus preventing ovulation. This combination of agents alters the endometrium in such a way as to discourage implantation. (NCI04)","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F92F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7A34-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cytarabine","valueDescription":"Cytarabine (Ara C, Cytosine Arabinoside)","ValueMeaning":{"publicId":"2960387","version":"1","preferredName":"Cytarabine (Ara C, Cytosine Arabinoside)","longName":"2960387","preferredDefinition":"An anticancer drug that belongs to the family of drugs called antimetabolites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytarabine","conceptCode":"C408","definition":"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"780B7F9B-CE25-2E47-E040-BB89AD431007","latestVersionIndicator":"Yes","beginDate":"2009-11-10","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-92E5-18F7-E053-F662850A60B1","beginDate":"2011-09-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Colistimethate Sodium","valueDescription":"Colistimethate Sodium","ValueMeaning":{"publicId":"3270474","version":"1","preferredName":"Colistimethate Sodium","longName":"3270474","preferredDefinition":"The sodium salt of colistimethate, a broad-spectrum polymyxin antibiotic against most aerobic Gram-negative bacteria except Proteus bacteria. Colistimethate sodium contains the pentasodium salt of the penta(methanesulfonic acid) derivative of colistin A as the major component and a small proportion of the petasodium salt of the pentamethanesulfonate derivative of colistin B. Colistins are cyclic polypeptides produced from Bacillus colistinus or B. polymyxa and function as a surfactant which penetrates into and disrupts the bacterial cell membrane, thereby resulting in bactericidal effect.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Colistimethate Sodium","conceptCode":"C65349","definition":"The sodium salt of colistimethate, a broad-spectrum polymyxin antibiotic against most aerobic Gram-negative bacteria except Proteus bacteria. Colistimethate sodium contains the pentasodium salt of the penta(methanesulfonic acid) derivative of colistin A as the major component and a small proportion of the petasodium salt of the pentamethanesulfonate derivative of colistin B. Colistins are cyclic polypeptides produced from Bacillus colistinus or B. polymyxa and function as a surfactant which penetrates into and disrupts the bacterial cell membrane, thereby resulting in bactericidal effect.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC7520C3-675A-A135-E040-BB89AD436B61","latestVersionIndicator":"Yes","beginDate":"2011-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-92EF-18F7-E053-F662850A60B1","beginDate":"2011-09-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Coagulation Factor Viia","valueDescription":"Factor Viia Human","ValueMeaning":{"publicId":"3270476","version":"1","preferredName":"Factor Viia Human","longName":"3270476","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Coagulation Factor VIIa Human","conceptCode":"C90854","definition":"A recombinant form of activated human blood coagulation factor VII that promotes hemostasis by activating the extrinsic pathway of the coagulation cascade.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC7520C3-6780-A135-E040-BB89AD436B61","latestVersionIndicator":"Yes","beginDate":"2011-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-92F9-18F7-E053-F662850A60B1","beginDate":"2011-09-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cilostazol","valueDescription":"Cilostazol","ValueMeaning":{"publicId":"3270478","version":"1","preferredName":"Cilostazol","longName":"3270478","preferredDefinition":"A quinolinone derivative and cellular phosphodiesterase inhibitor, more specific for phosphodiesterase III (PDE III). Although the exact mechanism of action of is unknown, cilostazol and its metabolites appears to inhibit PDE III activity, thereby suppressing cyclic adenosine monophosphate (cAMP) degradation. This results in an increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cilostazol","conceptCode":"C1051","definition":"A quinolinone derivative and cellular phosphodiesterase inhibitor, more specific for phosphodiesterase III (PDE III). Although the exact mechanism of action of is unknown, cilostazol and its metabolites appears to inhibit PDE III activity, thereby suppressing cyclic adenosine monophosphate (cAMP) degradation. This results in an increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC7520C3-67A6-A135-E040-BB89AD436B61","latestVersionIndicator":"Yes","beginDate":"2011-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9303-18F7-E053-F662850A60B1","beginDate":"2011-09-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cevimelline HCL","valueDescription":"Cevimelline HCL","ValueMeaning":{"publicId":"2576044","version":"1","preferredName":"Cevimelline HCL","longName":"2576044v1.00","preferredDefinition":"A cholinergic analogue with glandular secretion stimulatory activity. Cevimeline binds to and activates muscarinic receptors, thereby increasing the secretions in exocrine salivary and sweat glands. This cholinergic agonist also increases the tone of smooth muscle in the gastrointestinal and urinary tracts. Cevimeline is being studied as a treatment for dry mouth caused by radiation therapy to the head and neck.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cevimeline Hydrochloride","conceptCode":"C1337","definition":"A cholinergic analogue with glandular secretion stimulatory activity. Cevimeline binds to and activates muscarinic receptors, thereby increasing the secretions in exocrine salivary and sweat glands. This cholinergic agonist also increases the tone of smooth muscle in the gastrointestinal and urinary tracts. Cevimeline is being studied as a treatment for dry mouth caused by radiation therapy to the head and neck.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F619-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"CLOHNES","dateModified":"2023-08-04","changeDescription":null,"administrativeNotes":"8/4/23 Added missing concepts per cleanup activities cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-930D-18F7-E053-F662850A60B1","beginDate":"2011-09-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cytarabine","valueDescription":"Cytarabine","ValueMeaning":{"publicId":"3270479","version":"1","preferredName":"Cytarabine","longName":"3270479","preferredDefinition":"An anticancer drug that belongs to the family of drugs called antimetabolites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytarabine","conceptCode":"C408","definition":"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC7520C3-67D4-A135-E040-BB89AD436B61","latestVersionIndicator":"Yes","beginDate":"2011-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9317-18F7-E053-F662850A60B1","beginDate":"2011-09-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Dexmedetomidine HCL  (Precedex)","valueDescription":"Dexmedetomidine Hydrochloride","ValueMeaning":{"publicId":"3270582","version":"1","preferredName":"Dexmedetomidine Hydrochloride","longName":"3270582","preferredDefinition":"The hydrochloride salt form of dexmedetomidine, an imidazole derivate and active d-isomer of medetomidine with analgesic, anxiolytic and sedative activities. Dexmedetomidine selectively binds to and activates presynaptic alpha-2 adrenoceptors located in the brain, thereby inhibiting the release of norepinephrine from synaptic vesicles. This leads to an inhibition of postsynaptic activation of adrenoceptors, which inhibits sympathetic activity, thereby leading to analgesia, sedation and anxiolysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dexmedetomidine Hydrochloride","conceptCode":"C72738","definition":"The hydrochloride salt form of dexmedetomidine, an imidazole derivate and active d-isomer of medetomidine with analgesic, anxiolytic and sedative activities. Dexmedetomidine selectively binds to and activates presynaptic alpha-2 adrenoceptors located in the brain, thereby inhibiting the release of norepinephrine from synaptic vesicles. This leads to an inhibition of postsynaptic activation of adrenoceptors, which inhibits sympathetic activity, thereby leading to analgesia, sedation and anxiolysis.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC834724-A485-7DCC-E040-BB89AD43610C","latestVersionIndicator":"Yes","beginDate":"2011-09-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9321-18F7-E053-F662850A60B1","beginDate":"2011-09-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Dermeze","valueDescription":"Dermeze","ValueMeaning":{"publicId":"3270583","version":"1","preferredName":"Dermeze","longName":"3270583","preferredDefinition":"Dermeze","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC834724-A4A8-7DCC-E040-BB89AD43610C","latestVersionIndicator":"Yes","beginDate":"2011-09-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-932B-18F7-E053-F662850A60B1","beginDate":"2011-09-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Derecoxib","valueDescription":"Derecoxib","ValueMeaning":{"publicId":"3270584","version":"1","preferredName":"Derecoxib","longName":"3270584","preferredDefinition":"Derecoxib","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC834724-A4CB-7DCC-E040-BB89AD43610C","latestVersionIndicator":"Yes","beginDate":"2011-09-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9335-18F7-E053-F662850A60B1","beginDate":"2011-09-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Dantrolene Sodium","valueDescription":"Dantrolene Sodium","ValueMeaning":{"publicId":"3270586","version":"1","preferredName":"Dantrolene Sodium","longName":"3270586","preferredDefinition":"The sodium salt form of dantrolene, a hydantoin derivative and direct-acting skeletal muscle relaxant. Dantrolene depresses excitation-contraction coupling in skeletal muscle by binding to the ryanodine receptor 1, and decreasing intracellular calcium concentration. Ryanodine receptors mediate the release of calcium from the sarcoplasmic reticulum, an essential step in muscle contraction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dantrolene Sodium","conceptCode":"C61698","definition":"The sodium salt form of dantrolene, a hydantoin derivative and direct-acting skeletal muscle relaxant. Dantrolene depresses excitation-contraction coupling in skeletal muscle by binding to the ryanodine receptor 1, and decreasing intracellular calcium concentration. Ryanodine receptors mediate the release of calcium from the sarcoplasmic reticulum, an essential step in muscle contraction.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC834724-A4F1-7DCC-E040-BB89AD43610C","latestVersionIndicator":"Yes","beginDate":"2011-09-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-933F-18F7-E053-F662850A60B1","beginDate":"2011-09-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Darunavir","valueDescription":"Darunavir","ValueMeaning":{"publicId":"3270588","version":"1","preferredName":"Darunavir","longName":"3270588v1.00","preferredDefinition":"A human immunodeficiency virus type 1 (HIV-1) protease nonpeptidic inhibitor, with activity against HIV. Upon oral administration, darunavir selectively targets and binds to the active site of HIV-1 protease, and inhibits the dimerization and catalytic activity of HIV-1 protease. This inhibits the proteolytic cleavage of viral Gag and Gag-Pol polyproteins in HIV-infected cells. This inhibition leads to the production of immature, non-infectious viral proteins that are unable to form mature virions, and prevents HIV replication.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Darunavir","conceptCode":"C65364","definition":"A human immunodeficiency virus type 1 (HIV-1) protease nonpeptidic inhibitor, with activity against HIV. Upon oral administration, darunavir selectively targets and binds to the active site of HIV-1 protease, and inhibits the dimerization and catalytic activity of HIV-1 protease. This inhibits the proteolytic cleavage of viral Gag and Gag-Pol polyproteins in HIV-infected cells. This inhibition leads to the production of immature, non-infectious viral proteins that are unable to form mature virions, and prevents HIV replication.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC834724-A517-7DCC-E040-BB89AD43610C","latestVersionIndicator":"Yes","beginDate":"2011-09-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-09","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9349-18F7-E053-F662850A60B1","beginDate":"2011-09-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Drotrecogin Alfa","valueDescription":"Drotrecogin Alfa (Activated)","ValueMeaning":{"publicId":"3270598","version":"1","preferredName":"Drotrecogin Alfa (Activated)","longName":"3270598","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Drotrecogin Alfa (Activated)","conceptCode":"C80267","definition":"A recombinant form of human protein C with anti-thrombotic, anti-inflammatory, and profibrinolytic properties.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC834724-A57B-7DCC-E040-BB89AD43610C","latestVersionIndicator":"Yes","beginDate":"2011-09-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9353-18F7-E053-F662850A60B1","beginDate":"2011-09-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Donepezil HCL (Aricept)","valueDescription":"Donepezil Hydrochloride","ValueMeaning":{"publicId":"3270600","version":"1","preferredName":"Donepezil Hydrochloride","longName":"3270600","preferredDefinition":"The hydrochloride salt of a piperidine derivative with neurocognitive-enhancing activity. Donepezil reversibly inhibits acetylcholinesterase, thereby blocking the hydrolysis of the neurotransmitter acetylcholine and, consequently, increasing its activity.  This agent may improve neurocognitive function in Alzheimer's disease, reduce sedation associated with opioid treatment of cancer pain, and improve neurocognitive function in patients who have received radiation therapy for primary brain tumors or brain metastases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Donepezil Hydrochloride","conceptCode":"C2603","definition":"The hydrochloride salt of a piperidine derivative with neurocognitive-enhancing activity. Donepezil reversibly inhibits acetylcholinesterase, thereby blocking the hydrolysis of the neurotransmitter acetylcholine and, consequently, increasing its activity.  This agent may improve neurocognitive function in Alzheimer's disease, reduce sedation associated with opioid treatment of cancer pain, and improve neurocognitive function in patients who have received radiation therapy for primary brain tumors or brain metastases.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC834724-A5A1-7DCC-E040-BB89AD43610C","latestVersionIndicator":"Yes","beginDate":"2011-09-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-935D-18F7-E053-F662850A60B1","beginDate":"2011-09-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Docosanol","valueDescription":"Docosanol","ValueMeaning":{"publicId":"3270602","version":"1","preferredName":"Docosanol","longName":"3270602","preferredDefinition":"A saturated 22-carbon aliphatic alcohol with antiviral activity. Docosanol has a distinct mechanism of action and inhibits fusion between the plasma membrane and the herpes simplex virus envelope, thereby preventing viral entry into cells and subsequent viral activity and replication. Docosanol is used topically in the treatment of recurrent herpes simplex labialis episodes and relieves associated pain and may help heal sores faster.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Docosanol","conceptCode":"C47498","definition":"A saturated 22-carbon aliphatic alcohol with antiviral activity. Docosanol has a distinct mechanism of action and inhibits fusion between the plasma membrane and the herpes simplex virus envelope, thereby preventing viral entry into cells and subsequent viral activity and replication. Docosanol is used topically in the treatment of recurrent herpes simplex labialis episodes and relieves associated pain and may help heal sores faster.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC834724-A5C7-7DCC-E040-BB89AD43610C","latestVersionIndicator":"Yes","beginDate":"2011-09-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-09","modifiedBy":"TAYLORT","dateModified":"2020-01-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9367-18F7-E053-F662850A60B1","beginDate":"2011-09-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Diphenhydramine HCL","valueDescription":"Diphenhydramine Hydrochloride","ValueMeaning":{"publicId":"2577858","version":"1","preferredName":"Diphenhydramine Hydrochloride","longName":"2577858","preferredDefinition":"No Value Exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diphenhydramine Hydrochloride","conceptCode":"C300","definition":"The hydrochloride salt form of diphenhydramine, an ethanolamine and first-generation histamine antagonist with anti-allergic activity. Diphenhydramine hydrochloride competitively blocks H1receptors, thereby preventing the actions of histamine on bronchial smooth muscle, capillaries, and gastrointestinal (GI) smooth muscle. This prevents histamine-induced bronchoconstriction, vasodilation, increased capillary permeability, and GI smooth muscle spasms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD2F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9371-18F7-E053-F662850A60B1","beginDate":"2011-09-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Digestive Enzyme, NOS","valueDescription":"Digestion Enzyme","ValueMeaning":{"publicId":"3270603","version":"1","preferredName":"Digestion Enzyme","longName":"3270603","preferredDefinition":"The process or act of converting food into chemical substances that can be absorbed and assimilated.: A protein that speeds up chemical reactions in the body.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Digestion","conceptCode":"C16503","definition":"The process or act of converting food into chemical substances that can be absorbed and assimilated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Enzyme","conceptCode":"C16554","definition":"Molecules that catalyze a chemical reaction. They are usually proteins, although catalytic RNA and DNA molecules have been identified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC834724-A5F7-7DCC-E040-BB89AD43610C","latestVersionIndicator":"Yes","beginDate":"2011-09-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-937B-18F7-E053-F662850A60B1","beginDate":"2011-09-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Dextrose Solution","valueDescription":"Dextrose Oral Solution","ValueMeaning":{"publicId":"3270604","version":"1","preferredName":"Dextrose Oral Solution","longName":"3270604","preferredDefinition":"Dextrose Oral Solution","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC834724-A61A-7DCC-E040-BB89AD43610C","latestVersionIndicator":"Yes","beginDate":"2011-09-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9385-18F7-E053-F662850A60B1","beginDate":"2011-09-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Estazolam","valueDescription":"Estazolam","ValueMeaning":{"publicId":"3282239","version":"1","preferredName":"Estazolam","longName":"3282239","preferredDefinition":"A triazolo-benzodiazepine with anxiolytic, anticonvulsant, hypnotic, and muscle relaxant properties. Estazolam binds to the gamma-aminobutyric acid (GABA) receptor at a site distinct from the inhibitory neurotransmitter GABA binding site in the limbic system of the central nervous system (CNS). This binding leads to an opening of the chloride channels, which allows the flow of chloride ions into the neuron, hyperpolarizes the neuronal membrane, inhibits neuronal firing, and leads to a decrease in neuronal excitability.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Estazolam","conceptCode":"C47520","definition":"A triazolo-benzodiazepine with anxiolytic, anticonvulsant, hypnotic, and muscle relaxant properties. Estazolam binds to the gamma-aminobutyric acid (GABA) receptor at a site distinct from the inhibitory neurotransmitter GABA binding site in the limbic system of the central nervous system (CNS). This binding leads to an opening of the chloride channels, which allows the flow of chloride ions into the neuron, hyperpolarizes the neuronal membrane, inhibits neuronal firing, and leads to a decrease in neuronal excitability.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD607BC4-7244-F151-E040-BB89AD435BE2","latestVersionIndicator":"Yes","beginDate":"2011-09-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-938F-18F7-E053-F662850A60B1","beginDate":"2011-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Esmolol HCL","valueDescription":"Esmolol Hydrochloride","ValueMeaning":{"publicId":"3282241","version":"1","preferredName":"Esmolol Hydrochloride","longName":"3282241","preferredDefinition":"The hydrochloride salt form of esmolol, a short and rapid-acting beta adrenergic antagonist belonging to the class II anti-arrhythmic drugs and devoid of intrinsic sympathomimetic activity. Esmolol hydrochloride competitively blocks beta-1 adrenergic receptors in cardiac muscle and reduces the contractility and cardiac rate of heart muscle, thereby decreasing cardiac output and myocardial oxygen demands. This agent also decreases sympathetic output centrally and blocks renin secretion. At higher doses, esmolol hydrochloride also blocks beta-2 receptors located in bronchial and vascular smooth muscle, thereby leading to smooth muscle relaxation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Esmolol Hydrochloride","conceptCode":"C47519","definition":"The hydrochloride salt form of esmolol, a short and rapid-acting beta adrenergic antagonist belonging to the class II anti-arrhythmic drugs and devoid of intrinsic sympathomimetic activity. Esmolol hydrochloride competitively blocks beta-1 adrenergic receptors in cardiac muscle and reduces the contractility and cardiac rate of heart muscle, thereby decreasing cardiac output and myocardial oxygen demands. This agent also decreases sympathetic output centrally and blocks renin secretion. At higher doses, esmolol hydrochloride also blocks beta-2 receptors located in bronchial and vascular smooth muscle, thereby leading to smooth muscle relaxation.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD607BC4-726A-F151-E040-BB89AD435BE2","latestVersionIndicator":"Yes","beginDate":"2011-09-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9399-18F7-E053-F662850A60B1","beginDate":"2011-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ertapenem","valueDescription":"Ertapenem","ValueMeaning":{"publicId":"3243440","version":"1","preferredName":"Ertapenem","longName":"3243440","preferredDefinition":"A 1-beta-methyl carbapenem and broad-spectrum beta-lactam antibiotic with bactericidal property. Ertapenem binds to penicillin binding proteins (PBPs) located on the bacterial cell wall, in particular PBPs 2 and 3, thereby inhibiting the final transpeptidation step in the synthesis of peptidoglycan, an essential component of the bacterial cell wall. Inhibition results in a weakening and subsequent lysis of the cell wall leading to cell death of Gram-positive and Gram-negative aerobic and anaerobic pathogens. This agent is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, cephalosporinases and extended-spectrum beta-lactamases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ertapenem","conceptCode":"C61752","definition":"A 1-beta-methyl carbapenem and broad-spectrum beta-lactam antibiotic with bactericidal property. Ertapenem binds to penicillin binding proteins (PBPs) located on the bacterial cell wall, in particular PBPs 2 and 3, thereby inhibiting the final transpeptidation step in the synthesis of peptidoglycan, an essential component of the bacterial cell wall. Inhibition results in a weakening and subsequent lysis of the cell wall leading to cell death of Gram-positive and Gram-negative aerobic and anaerobic pathogens. This agent is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, cephalosporinases and extended-spectrum beta-lactamases.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A55A32E7-322F-D7C0-E040-BB89AD437508","latestVersionIndicator":"Yes","beginDate":"2011-06-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-06-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-93A3-18F7-E053-F662850A60B1","beginDate":"2011-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Erlotinib","valueDescription":"Erlotinib","ValueMeaning":{"publicId":"3237464","version":"1","preferredName":"Erlotinib","longName":"3237464","preferredDefinition":"A quinazoline derivative with antineoplastic properties.  Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Erlotinib","conceptCode":"C65530","definition":"A quinazoline derivative with antineoplastic properties.  Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3F78E39-6596-13D6-E040-BB89AD432B2B","latestVersionIndicator":"Yes","beginDate":"2011-05-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-05-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-93AD-18F7-E053-F662850A60B1","beginDate":"2011-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Epzicom","valueDescription":"Epzicom","ValueMeaning":{"publicId":"3282242","version":"1","preferredName":"Epzicom","longName":"3282242v1.00","preferredDefinition":"A fixed combination of abacavir sulfate, a nucleoside reverse transcriptase inhibitor (NRTI) analog of guanosine and lamivudine, an NRTI analog of cytidine, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, abacavir and lamivudine are phosphorylated into active metabolites that compete for incorporation into viral DNA. These metabolites inhibit the HIV reverse transcriptase (RT) enzyme competitively and act as a chain terminator of DNA synthesis. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abacavir Sulfate/Lamivudine","conceptCode":"C157405","definition":"A fixed combination of abacavir sulfate, a nucleoside reverse transcriptase inhibitor (NRTI) analog of guanosine and lamivudine, an NRTI analog of cytidine, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, abacavir and lamivudine are phosphorylated into active metabolites that compete for incorporation into viral DNA. These metabolites inhibit the HIV reverse transcriptase (RT) enzyme competitively and act as a chain terminator of DNA synthesis. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD607BC4-72A1-F151-E040-BB89AD435BE2","latestVersionIndicator":"Yes","beginDate":"2011-09-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-20","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-93B7-18F7-E053-F662850A60B1","beginDate":"2011-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Eprosartan Mesylate","valueDescription":"Eprosartan Mesylate","ValueMeaning":{"publicId":"3282244","version":"1","preferredName":"Eprosartan Mesylate","longName":"3282244","preferredDefinition":"The mesylate salt form of eprosartan, a non-biphenyl, non-tetrazole, nonpeptide angiotensin II antagonist with antihypertensive activity. Eprosartan mesylate antagonizes angiotensin II type I receptors in tissues such as vascular smooth muscle and the adrenal gland. This prevents angiotensin II-induced vasoconstriction and prevents angiotensin II-mediated stimulation of aldosterone secretion by the adrenal cortex, which decreases the excretion of sodium and water and increases the excretion of potassium.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eprosartan Mesylate","conceptCode":"C47515","definition":"The mesylate salt form of eprosartan, a non-biphenyl, non-tetrazole, nonpeptide angiotensin II antagonist with antihypertensive activity. Eprosartan mesylate antagonizes angiotensin II type I receptors in tissues such as vascular smooth muscle and the adrenal gland. This prevents angiotensin II-induced vasoconstriction and prevents angiotensin II-mediated stimulation of aldosterone secretion by the adrenal cortex, which decreases the excretion of sodium and water and increases the excretion of potassium.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD607BC4-72C7-F151-E040-BB89AD435BE2","latestVersionIndicator":"Yes","beginDate":"2011-09-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-93C1-18F7-E053-F662850A60B1","beginDate":"2011-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Entecavir","valueDescription":"Entecavir","ValueMeaning":{"publicId":"3282246","version":"1","preferredName":"Entecavir","longName":"3282246","preferredDefinition":"A synthetic analog of 2-deoxyguanosine with antiviral activity against hepatitis B virus (HBV).  Entecavir is activated in vivo to a 5-triphosphate metabolite. In turn, the triphosphate form competes with the natural substrate deoxyguanosine triphosphate (dGTP) for incorporation into viral DNA. The incorporation of the activated triphosphate metabolite of entecavir inhibits the reverse transcriptase (RT) viral RNA-dependent HBV DNA polymerase and, so, the replication of viral DNA and transcription.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Entecavir","conceptCode":"C65513","definition":"A synthetic analog of 2-deoxyguanosine with antiviral activity against hepatitis B virus (HBV).  Entecavir is activated in vivo to a 5-triphosphate metabolite. In turn, the triphosphate form competes with the natural substrate deoxyguanosine triphosphate (dGTP) for incorporation into viral DNA. The incorporation of the activated triphosphate metabolite of entecavir inhibits the reverse transcriptase (RT) viral RNA-dependent HBV DNA polymerase and, so, the replication of viral DNA and transcription.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD607BC4-72ED-F151-E040-BB89AD435BE2","latestVersionIndicator":"Yes","beginDate":"2011-09-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-93CB-18F7-E053-F662850A60B1","beginDate":"2011-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Enrofloxacin","valueDescription":"Enrofloxacin","ValueMeaning":{"publicId":"3282248","version":"1","preferredName":"Enrofloxacin","longName":"3282248","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Enrofloxacin","conceptCode":"C72660","definition":"No Value Exists","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD607BC4-7313-F151-E040-BB89AD435BE2","latestVersionIndicator":"Yes","beginDate":"2011-09-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-93D5-18F7-E053-F662850A60B1","beginDate":"2011-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Emtricitabine/Tenofovir Disoproxil Fumarate","valueDescription":"Emtricitabine/Tenofovir Disoproxil Fumarate","ValueMeaning":{"publicId":"3282249","version":"1","preferredName":"Emtricitabine/Tenofovir Disoproxil Fumarate","longName":"3282249","preferredDefinition":"Emtricitabine/Tenofovir Disoproxil Fumarate","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD607BC4-7336-F151-E040-BB89AD435BE2","latestVersionIndicator":"Yes","beginDate":"2011-09-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-93DF-18F7-E053-F662850A60B1","beginDate":"2011-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Emtricitabine","valueDescription":"Emtricitabine","ValueMeaning":{"publicId":"3282251","version":"1","preferredName":"Emtricitabine","longName":"3282251","preferredDefinition":"A synthetic fluoro derivative of thiacytidine with potent antiviral activity. Emtricitabine is phosphorylated to form emtricitabine 5'-triphosphate within the cell. This metabolite inhibits the activity of human immunodeficiency virus (HIV) reverse transcriptase both by competing with the natural substrate deoxycytidine 5'-triphosphate and by incorporation into viral DNA causing a termination of DNA chain elongation (due to the lack of the essential 3'-OH group).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Emtricitabine","conceptCode":"C47509","definition":"A synthetic fluoro derivative of thiacytidine with potent antiviral activity. Emtricitabine is phosphorylated to form emtricitabine 5'-triphosphate within the cell. This metabolite inhibits the activity of human immunodeficiency virus (HIV) reverse transcriptase both by competing with the natural substrate deoxycytidine 5'-triphosphate and by incorporation into viral DNA causing a termination of DNA chain elongation (due to the lack of the essential 3'-OH group).","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD607BC4-735C-F151-E040-BB89AD435BE2","latestVersionIndicator":"Yes","beginDate":"2011-09-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-93E9-18F7-E053-F662850A60B1","beginDate":"2011-09-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lubiprostone","valueDescription":"Lubiprostone","ValueMeaning":{"publicId":"3282722","version":"1","preferredName":"Lubiprostone","longName":"3282722","preferredDefinition":"A bicyclic fatty acid derived from prostaglandin E1 and a chloride channel activator with laxative activity. Upon intake, lubiprostone specifically binds to and activates the type 2 chloride channel (ClC-2) in the apical membrane of the gastrointestinal epithelium. This produces an efflux of chloride ions, thereby drawing water into the gastrointestinal lumen. The resulting increased amounts of intestinal fluid soften the stool, increase motility, and improve bowel movements.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lubiprostone","conceptCode":"C66040","definition":"A bicyclic fatty acid derived from prostaglandin E1 and a chloride channel activator with laxative activity. Upon intake, lubiprostone specifically binds to and activates the type 2 chloride channel (ClC-2) in the apical membrane of the gastrointestinal epithelium. This produces an efflux of chloride ions, thereby drawing water into the gastrointestinal lumen. The resulting increased amounts of intestinal fluid soften the stool, increase motility, and improve bowel movements.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD7A5918-D696-456E-E040-BB89AD433590","latestVersionIndicator":"Yes","beginDate":"2011-09-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-93F3-18F7-E053-F662850A60B1","beginDate":"2011-09-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Loteprednol Etabonate","valueDescription":"Loteprednol Etabonate","ValueMeaning":{"publicId":"3282724","version":"1","preferredName":"Loteprednol Etabonate","longName":"3282724","preferredDefinition":"The etabonate salt form of loteprednol, an ophthalmic analog of the corticosteroid prednisolone with anti-inflammatory activity. Loteprednol etabonate exerts its effect by interacting with specific intracellular receptors and subsequently binds to DNA to modify gene expression. This results in an induction of the synthesis of certain anti-inflammatory proteins while inhibiting the synthesis of certain inflammatory mediators. Loteprednol etabonate specifically induces phospholipase A2 inhibitory proteins (collectively called lipocortins), which inhibit the release of arachidonic acid, thereby inhibiting the biosynthesis of potent mediators of inflammation, such as prostaglandins and leukotrienes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Loteprednol Etabonate","conceptCode":"C47589","definition":"The etabonate salt form of loteprednol, an ophthalmic analog of the corticosteroid prednisolone with anti-inflammatory activity. Loteprednol etabonate exerts its effect by interacting with specific intracellular receptors and subsequently binds to DNA to modify gene expression. This results in an induction of the synthesis of certain anti-inflammatory proteins while inhibiting the synthesis of certain inflammatory mediators. Loteprednol etabonate specifically induces phospholipase A2 inhibitory proteins (collectively called lipocortins), which inhibit the release of arachidonic acid, thereby inhibiting the biosynthesis of potent mediators of inflammation, such as prostaglandins and leukotrienes.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD7A5918-D6BC-456E-E040-BB89AD433590","latestVersionIndicator":"Yes","beginDate":"2011-09-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-93FD-18F7-E053-F662850A60B1","beginDate":"2011-09-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Loracarbef","valueDescription":"Loracarbef","ValueMeaning":{"publicId":"3282726","version":"1","preferredName":"Loracarbef","longName":"3282726","preferredDefinition":"A semi-synthetic, broad-spectrum, beta-lactamase resistant, second-generation cephalosporin antibiotic derived from cephasporium. The bactericidal activity of loracarbef results from the inhibition of bacterial cell wall synthesis through interference with the cross-linking of peptidoglycan units. This results in a reduction of cell wall stability and causes cell lysis. Loracarbef is more active against a variety of gram-negative organisms but less active against gram-positive pathogens compared to first-generation agents.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Loracarbef","conceptCode":"C47588","definition":"A semi-synthetic, broad-spectrum, beta-lactamase resistant, second-generation cephalosporin antibiotic derived from cephasporium. The bactericidal activity of loracarbef results from the inhibition of bacterial cell wall synthesis through interference with the cross-linking of peptidoglycan units. This results in a reduction of cell wall stability and causes cell lysis. Loracarbef is more active against a variety of gram-negative organisms but less active against gram-positive pathogens compared to first-generation agents.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD7A5918-D6E2-456E-E040-BB89AD433590","latestVersionIndicator":"Yes","beginDate":"2011-09-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9407-18F7-E053-F662850A60B1","beginDate":"2011-09-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lidobenalox Solution","valueDescription":"Solution Lidobenalox","ValueMeaning":{"publicId":"3282727","version":"1","preferredName":"Solution Lidobenalox","longName":"3282727","preferredDefinition":"A homogeneous mixture of two or more substances; frequently (but not necessarily) a liquid solution.: An oral suspension of viscous lidocaine, diphenhydramine (Benadryl) and aluminum and magnesium hydroxides (Maalox). This agent possesses anesthetic, antihistamine, and antacid properties. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Solution","conceptCode":"C70830","definition":"A homogeneous mixture of two or more substances; frequently (but not necessarily) a liquid solution.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Lidobenalox","conceptCode":"C29155","definition":"An oral suspension of viscous lidocaine, diphenhydramine (Benadryl) and aluminum and magnesium hydroxides (Maalox). This agent possesses anesthetic, antihistamine, and antacid properties. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD7A5918-D708-456E-E040-BB89AD433590","latestVersionIndicator":"Yes","beginDate":"2011-09-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9411-18F7-E053-F662850A60B1","beginDate":"2011-09-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Levocarnitine","valueDescription":"Levocarnitine","ValueMeaning":{"publicId":"2578224","version":"1","preferredName":"Levocarnitine","longName":"2578224","preferredDefinition":"An amino acid derivative.  Levocarnitine facilitates long-chain fatty acid entry into mitochondria, delivering substrate for oxidation and subsequent energy production. Fatty acids are utilized as an energy substrate in all tissues except the brain. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Levocarnitine","conceptCode":"C26657","definition":"An amino acid derivative.  Levocarnitine facilitates long-chain fatty acid entry into mitochondria, delivering substrate for oxidation and subsequent energy production. Fatty acids are utilized as an energy substrate in all tissues except the brain. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE9D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-941B-18F7-E053-F662850A60B1","beginDate":"2011-09-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"L-Carnitine","valueDescription":"Carnitine","ValueMeaning":{"publicId":"3282729","version":"1","preferredName":"Carnitine","longName":"3282729","preferredDefinition":"An amino acid derivative.  Carnitine facilitates long-chain fatty acid entry into mitochondria, delivering substrate for oxidation and subsequent energy production. Fatty acids are utilized as an energy substrate in all tissues except the brain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carnitine","conceptCode":"C82599","definition":"An amino acid derivative.  Carnitine facilitates long-chain fatty acid entry into mitochondria, delivering substrate for oxidation and subsequent energy production. Fatty acids are utilized as an energy substrate in all tissues except the brain.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD7A5918-D742-456E-E040-BB89AD433590","latestVersionIndicator":"Yes","beginDate":"2011-09-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9425-18F7-E053-F662850A60B1","beginDate":"2011-09-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"K-Phos Neutral","valueDescription":"Potassium Phosphate/Sodium Phosphate","ValueMeaning":{"publicId":"3282731","version":"1","preferredName":"Potassium Phosphate/Sodium Phosphate","longName":"3282731","preferredDefinition":"A combination preparation containing potassium phosphate and sodium phosphate used for electrolyte-replacement purposes, dietary supplementation and to acidify urine. Phosphate, a predominant intracellular anion, plays an important role in energy storage, osteoblastic and osteoclastic activities, regulating serum calcium concentrations and numerous cellular phosphate-transfer reactions. Potassium phosphate and sodium phosphate are used to acidify the urine and lower the urinary calcium concentration. This may reduce rash and odor caused by ammonium in the urine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Potassium Phosphate/Sodium Phosphate","conceptCode":"C29288","definition":"A combination preparation containing potassium phosphate and sodium phosphate used for electrolyte-replacement purposes, dietary supplementation and to acidify urine. Phosphate, a predominant intracellular anion, plays an important role in energy storage, osteoblastic and osteoclastic activities, regulating serum calcium concentrations and numerous cellular phosphate-transfer reactions. Potassium phosphate and sodium phosphate are used to acidify the urine and lower the urinary calcium concentration. This may reduce rash and odor caused by ammonium in the urine.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD7A5918-D768-456E-E040-BB89AD433590","latestVersionIndicator":"Yes","beginDate":"2011-09-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-942F-18F7-E053-F662850A60B1","beginDate":"2011-09-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Isosorbide Mononitrate","valueDescription":"Isosorbide Mononitrate","ValueMeaning":{"publicId":"3282733","version":"1","preferredName":"Isosorbide Mononitrate","longName":"3282733","preferredDefinition":"The mononitrate salt form of isosorbide, an organic nitrate with vasodilator activity. Isosorbide mononitrate relaxes vascular smooth muscle by formation of the free radical nitric oxide (NO), which is identical to the endothelium-derived relaxing factor (EDRF). NO activates guanylyl cyclase, thereby increasing the synthesis of cGMP within smooth muscle, resulting in dephosphorylation of light chain myosin and relaxation of peripheral arteries and veins. In addition, isosorbide mononitrate relaxes coronary arteries, thereby increasing the blood circulation through the ischemic area. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Isosorbide Mononitrate","conceptCode":"C47575","definition":"The mononitrate salt form of isosorbide, an organic nitrate with vasodilator activity. Isosorbide mononitrate relaxes vascular smooth muscle by formation of the free radical nitric oxide (NO), which is identical to the endothelium-derived relaxing factor (EDRF). NO activates guanylyl cyclase, thereby increasing the synthesis of cGMP within smooth muscle, resulting in dephosphorylation of light chain myosin and relaxation of peripheral arteries and veins. In addition, isosorbide mononitrate relaxes coronary arteries, thereby increasing the blood circulation through the ischemic area. (NCI05)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD7A5918-D78E-456E-E040-BB89AD433590","latestVersionIndicator":"Yes","beginDate":"2011-09-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9439-18F7-E053-F662850A60B1","beginDate":"2011-09-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Isoflurane","valueDescription":"Isoflurane","ValueMeaning":{"publicId":"3282735","version":"1","preferredName":"Isoflurane","longName":"3282735","preferredDefinition":"A fluorinated ether with general anesthetic and muscle relaxant activities. Although the exact mechanism of action has not been established, inhaled isoflurane, appears to act on the lipid matrix of the neuronal cell membrane, which results in disruption of neuronal transmission. This agent enhances the release of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), thereby increasing the activity of the inhibitory neurotransmitter on synaptic transmission. Isoflurane may also both inhibit glutamatergic excitatory transmission by increasing glutamate re-uptake, and potentiate glycine receptor activity, which decreases motor function. In addition, isoflurane may alter certain pro- and anti-inflammatory cytokines, including interleukin-6 and -10 (IL-6, IL-10), possibly through the activation of the nuclear factor kappa B (NF-KB) pathway, which may affect immune responses during surgery. \r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Isoflurane","conceptCode":"C65978","definition":"A fluorinated ether with general anesthetic and muscle relaxant activities. Although the exact mechanism of action has not been established, inhaled isoflurane, appears to act on the lipid matrix of the neuronal cell membrane, which results in disruption of neuronal transmission. This agent enhances the release of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), thereby increasing the activity of the inhibitory neurotransmitter on synaptic transmission. Isoflurane may also both inhibit glutamatergic excitatory transmission by increasing glutamate re-uptake, and potentiate glycine receptor activity, which decreases motor function. In addition, isoflurane may alter certain pro- and anti-inflammatory cytokines, including interleukin-6 and -10 (IL-6, IL-10), possibly through the activation of the nuclear factor kappa B (NF-KB) pathway, which may affect immune responses during surgery.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD7A5918-D7B4-456E-E040-BB89AD433590","latestVersionIndicator":"Yes","beginDate":"2011-09-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-21","modifiedBy":"TAYLORT","dateModified":"2019-08-09","changeDescription":"8/9/19 tt associated concept with definition.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9443-18F7-E053-F662850A60B1","beginDate":"2011-09-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Iron Sucrose Complex","valueDescription":"Iron Sucrose","ValueMeaning":{"publicId":"3282737","version":"1","preferredName":"Iron Sucrose","longName":"3282737","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Iron Sucrose","conceptCode":"C65963","definition":"A sterile aqueous complex of polynuclear iron (III)-hydroxide in sucrose for intravenous use. Following intravenous administration, iron sucrose is dissociated by the reticuloendothelial system into iron and sucrose; the sucrose component is eliminated mainly by urinary excretion. Iron sucrose can be administered with or without erythropoietin to raise hemoglobin levels and may be used in cases of oral iron therapy intolerance or ineffectiveness. Hypersensitivity reactions are less common with iron sucrose compared to other parenteral iron products, such as iron dextran.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD7A5918-D7DA-456E-E040-BB89AD433590","latestVersionIndicator":"Yes","beginDate":"2011-09-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-944D-18F7-E053-F662850A60B1","beginDate":"2011-09-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Metyrosine","valueDescription":"Metyrosine","ValueMeaning":{"publicId":"3434558","version":"1","preferredName":"Metyrosine","longName":"3434558","preferredDefinition":"A methylated tyrosine, a catecholamine synthesis antagonist with antihypertensive property. Metyrosine competitively inhibits tyrosine 3-monooxygenase, an enzyme that activates molecular oxygen to catalyze the hydroxylation of tyrosine to dihydroxyphenylalanine (Dopa), an intermediate to catecholamine (dopamine, norepinephrine, and epinephrine) production. This agent reduces the elevated levels of catecholamines associated with pheochromocytoma, thereby preventing hypertension.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metyrosine","conceptCode":"C998","definition":"A methylated tyrosine, a catecholamine synthesis antagonist with antihypertensive property. Metyrosine competitively inhibits tyrosine 3-monooxygenase, an enzyme that activates molecular oxygen to catalyze the hydroxylation of tyrosine to dihydroxyphenylalanine (Dopa), an intermediate to catecholamine (dopamine, norepinephrine, and epinephrine) production. This agent reduces the elevated levels of catecholamines associated with pheochromocytoma, thereby preventing hypertension.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD3F6081-6556-1C16-E040-BB89AD431E82","latestVersionIndicator":"Yes","beginDate":"2012-04-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9457-18F7-E053-F662850A60B1","beginDate":"2012-04-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Tropisetron HCL","valueDescription":"Tropisetron Hydrochloride","ValueMeaning":{"publicId":"3402740","version":"1","preferredName":"Tropisetron Hydrochloride","longName":"3402740","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tropisetron Hydrochloride","conceptCode":"C95284","definition":"The hydrochloride salt form of tropisetron, a selective, competitive serotonin 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist, with antinauseant and antiemetic activities. Tropisetron competitively binds to and blocks the action of serotonin at 5HT3 receptors peripherally on vagus nerve terminals located in the gastrointestinal (GI) tract as well as centrally in the chemoreceptor trigger zone (CTZ) of the area postrema of the central nervous system (CNS). This results in the suppression of chemotherapy- and radiotherapy-induced nausea and vomiting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA86E320-4504-0A45-E040-BB89AD435A21","latestVersionIndicator":"Yes","beginDate":"2012-03-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-03-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9461-18F7-E053-F662850A60B1","beginDate":"2012-03-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Denileukin","valueDescription":"Denileukin Diftitox","ValueMeaning":{"publicId":"2577847","version":"1","preferredName":"Denileukin Diftitox","longName":"2577847","preferredDefinition":"A cytotoxic recombinant protein consisting of interleukin-2 (IL-2) protein sequences fused to diphtheria toxin. The IL-2 protein sequence moiety of denileukin difitox directs the cytocidal action of diphtheria toxin to cells that express IL-2 receptors. After the toxin moiety is internalized into target IL-2 receptor-expressing cells, its catalytic domain catalyzes the transfer of the ADP-ribose moiety of NAD to a posttranslationally modified histidine residue of elongation factor 2 (EF-2), called diphthamine. This covalent modification inactivates EF-2 and disrupts polypeptide chain elongation, resulting in cell death. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Denileukin Diftitox","conceptCode":"C1476","definition":"A cytotoxic recombinant fusion protein consisting of the human cytokine interleukin-2 (IL-2) fused to diphtheria toxin fragments A and B, containing both the catalytic and translocation domains, with potential antineoplastic activity. Upon administration, the IL-2 moiety of denileukin difitox targets and binds to IL-2 receptors. After internalization by IL-2 receptor-expressing cells via endocytosis, denileukin difitox is proteolytically cleaved. This releases the catalytic domain of the toxin moiety, which catalyzes the transfer of the ADP-ribose moiety of NAD to a diphthamide residue of elongation factor 2 (EF-2). This covalent modification inactivates EF-2 and disrupts polypeptide chain elongation, resulting in an inhibition of translation and cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD24-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"ONEDATA","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-946B-18F7-E053-F662850A60B1","beginDate":"2006-02-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Autologous Serum","valueDescription":"Autologous Serum","ValueMeaning":{"publicId":"3344917","version":"1","preferredName":"Autologous Serum","longName":"3344917","preferredDefinition":"(aw-TAHL-o-gus) Taken from an individual's own tissues, cells, or DNA.: The clear liquid part of the blood that remains after blood cells and clotting proteins have been removed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Autologous","conceptCode":"C28000","definition":"Taken from an individual's own tissues, cells, or DNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Serum","conceptCode":"C13325","definition":"The clear portion of the blood that remains after the removal of the blood cells and the clotting proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B5DBB36F-D2A1-D946-E040-BB89AD437163","latestVersionIndicator":"Yes","beginDate":"2012-01-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-01-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9475-18F7-E053-F662850A60B1","beginDate":"2012-01-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Dasatinib","valueDescription":"Dasatinib","ValueMeaning":{"publicId":"2737464","version":"1","preferredName":"Dasatinib","longName":"2737464","preferredDefinition":"An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases.  Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dasatinib","conceptCode":"C38713","definition":"An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases.  Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with a variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"497238FA-C312-26E6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-947F-18F7-E053-F662850A60B1","beginDate":"2012-01-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Olanzapine","valueDescription":"Olanzapine","ValueMeaning":{"publicId":"3304318","version":"1","preferredName":"Olanzapine","longName":"3304318","preferredDefinition":"A synthetic derivative of thienobenzodiazepine with antipsychotic, antinausea, and antiemetic activities. As a selective monoaminergic antagonist, olanzapine binds with high affinity binding to the following receptors: serotoninergic, dopaminergic, muscarinic M1-5, histamine H1, and alpha-1-adrenergic receptors; it binds weakly to gamma-aminobutyric acid type A, benzodiazepine, and beta-adrenergic receptors. The antinausea and antiemetic effects of this agent appear to be due to the blockade of 5-HT2 and 5-HT3 receptors for serotonin. Although its exact mechanism of action in schizophrenia is unknown, it has been proposed that olanzapine's antipsychotic activity is mediated through antagonism to dopamine D2 receptors with rapid ligand-receptor dissociation kinetics that help to minimize extrapyramidal symptoms (EPS). Olanzapine may also stimulate appetite.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Olanzapine","conceptCode":"C47639","definition":"A synthetic derivative of thienobenzodiazepine with antipsychotic, antinausea, and antiemetic activities. As a selective monoaminergic antagonist, olanzapine binds with high affinity binding to the following receptors: serotoninergic, dopaminergic, muscarinic M1-5, histamine H1, and alpha-1-adrenergic receptors; it binds weakly to gamma-aminobutyric acid type A, benzodiazepine, and beta-adrenergic receptors. The antinausea and antiemetic effects of this agent appear to be due to the blockade of 5-HT2 and 5-HT3 receptors for serotonin. Although its exact mechanism of action in schizophrenia is unknown, it has been proposed that olanzapine's antipsychotic activity is mediated through antagonism to dopamine D2 receptors with rapid ligand-receptor dissociation kinetics that help to minimize extrapyramidal symptoms (EPS). Olanzapine may also stimulate appetite.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1D487B9-D1F1-491E-E040-BB89AD432EE4","latestVersionIndicator":"Yes","beginDate":"2011-11-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-11-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9489-18F7-E053-F662850A60B1","beginDate":"2011-11-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Nefludan","valueDescription":"Nefludan","ValueMeaning":{"publicId":"3335019","version":"1","preferredName":"Nefludan","longName":"3335019","preferredDefinition":"Nefludan","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B43B6E2B-6148-FD19-E040-BB89AD437374","latestVersionIndicator":"Yes","beginDate":"2011-12-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9493-18F7-E053-F662850A60B1","beginDate":"2011-12-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Nefazadone HCL","valueDescription":"Nefazodone Hydrochloride","ValueMeaning":{"publicId":"3335021","version":"1","preferredName":"Nefazodone Hydrochloride","longName":"3335021","preferredDefinition":"A synthetic derivative of phenylpiperazine and chemically unrelated to selective serotonin reuptake inhibitors, tricyclics, tetracyclics, or monoamine oxidase inhibitors (MAOI), antidepressant Nefazadone Hydrochloride antagonizes central 5-HT2 receptors and inhibits reuptake of serotonin and norepinephrine. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nefazodone Hydrochloride","conceptCode":"C29283","definition":"A synthetic derivative of phenylpiperazine and chemically unrelated to selective serotonin reuptake inhibitors, tricyclics, tetracyclics, or monoamine oxidase inhibitors (MAOI), antidepressant Nefazadone Hydrochloride antagonizes central 5-HT2 receptors and inhibits reuptake of serotonin and norepinephrine. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B43B6E2B-616E-FD19-E040-BB89AD437374","latestVersionIndicator":"Yes","beginDate":"2011-12-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-949D-18F7-E053-F662850A60B1","beginDate":"2011-12-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Naratriptan","valueDescription":"Naratriptan","ValueMeaning":{"publicId":"3335023","version":"1","preferredName":"Naratriptan","longName":"3335023","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Naratriptan","conceptCode":"C61857","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B43B6E2B-6194-FD19-E040-BB89AD437374","latestVersionIndicator":"Yes","beginDate":"2011-12-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-94A7-18F7-E053-F662850A60B1","beginDate":"2011-12-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Naphazoline HCL","valueDescription":"Naphazoline Hydrochloride","ValueMeaning":{"publicId":"3335025","version":"1","preferredName":"Naphazoline Hydrochloride","longName":"3335025","preferredDefinition":"The hydrochloride salt form of naphazoline, an imidazole derivative and a direct-acting sympathomimetic amine with vasoconstrictive properties. Upon ocular administration, naphazoline hydrochloride exerts its effect by acting on alpha-adrenergic receptors in the arterioles of the conjunctiva to produce vasoconstriction, resulting in decreased conjunctival congestion and diminished itching, irritation and redness.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Naphazoline Hydrochloride","conceptCode":"C47632","definition":"The hydrochloride salt form of naphazoline, an imidazole derivative and a direct-acting sympathomimetic amine with vasoconstrictive properties. Upon ocular administration, naphazoline hydrochloride exerts its effect by acting on alpha-adrenergic receptors in the arterioles of the conjunctiva to produce vasoconstriction, resulting in decreased conjunctival congestion and diminished itching, irritation and redness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B43B6E2B-61BA-FD19-E040-BB89AD437374","latestVersionIndicator":"Yes","beginDate":"2011-12-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-94B1-18F7-E053-F662850A60B1","beginDate":"2011-12-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Naltrexone HCL","valueDescription":"Naltrexone Hydrochloride","ValueMeaning":{"publicId":"3335027","version":"1","preferredName":"Naltrexone Hydrochloride","longName":"3335027","preferredDefinition":"The hydrochloride salt of naltrexone, a noroxymorphone derivative with competitive opioid antagonistic activity. Naltrexone and its metabolite 6-beta-naltrexol reverse the effects of opioids by binding to various opioid receptors in the central nervous system CNS), including the mu-, kappa- and gamma-opioid receptors; opioid effects of analgesia, euphoria, sedation, respiratory depression, miosis, bradycardia, and physical dependence are inhibited. Naltrexone is longer-acting and more potent compared to naloxone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Naltrexone Hydrochloride","conceptCode":"C679","definition":"The hydrochloride salt of naltrexone, a noroxymorphone derivative with competitive opioid antagonistic activity. Naltrexone and its metabolite 6-beta-naltrexol reverse the effects of opioids by binding to various opioid receptors in the central nervous system CNS), including the mu-, kappa- and gamma-opioid receptors; opioid effects of analgesia, euphoria, sedation, respiratory depression, miosis, bradycardia, and physical dependence are inhibited. Naltrexone is longer-acting and more potent compared to naloxone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B43B6E2B-61E0-FD19-E040-BB89AD437374","latestVersionIndicator":"Yes","beginDate":"2011-12-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-94BB-18F7-E053-F662850A60B1","beginDate":"2011-12-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Naloxone","valueDescription":"Naloxone","ValueMeaning":{"publicId":"3335029","version":"1","preferredName":"Naloxone","longName":"3335029","preferredDefinition":"A thebaine derivate with competitive opioid antagonistic properties. Naloxone reverses the effects of opioid analgesics by binding to the opioid receptors in the CNS, and inhibiting the typical actions of opioid analgesics, including analgesia, euphoria, sedation, respiratory depression, miosis, bradycardia, and physical dependence. Naloxone binds to mu-opioid receptors with a high affinity, and a lesser degree to kappa- and gamma-opioid receptors in the CNS.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Naloxone","conceptCode":"C62054","definition":"A thebaine derivate with competitive opioid antagonistic properties. Naloxone reverses the effects of opioid analgesics by binding to the opioid receptors in the CNS, and inhibiting the typical actions of opioid analgesics, including analgesia, euphoria, sedation, respiratory depression, miosis, bradycardia, and physical dependence. Naloxone binds to mu-opioid receptors with a high affinity, and a lesser degree to kappa- and gamma-opioid receptors in the CNS.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B43B6E2B-6206-FD19-E040-BB89AD437374","latestVersionIndicator":"Yes","beginDate":"2011-12-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-94C5-18F7-E053-F662850A60B1","beginDate":"2011-12-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Nicardipine HCL","valueDescription":"Nicardipine Hydrochloride","ValueMeaning":{"publicId":"3335075","version":"1","preferredName":"Nicardipine Hydrochloride","longName":"3335075","preferredDefinition":"The hydrochloride salt form of nicardipine, a synthetic derivative of nitrophenyl-pyridine and potent calcium channel blocker, Nicardipine (Nifedipine Family) blocks calcium ions from certain cell walls and inhibits contraction of coronary and peripheral arteries, resulting in lowered oxygen requirements for heart muscle and decreased arterial contraction and spasm. It is used clinically as a cerebral and coronary vasodilator. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nicardipine Hydrochloride","conceptCode":"C29840","definition":"The hydrochloride salt form of nicardipine, a synthetic derivative of nitrophenyl-pyridine and potent calcium channel blocker, Nicardipine (Nifedipine Family) blocks calcium ions from certain cell walls and inhibits contraction of coronary and peripheral arteries, resulting in lowered oxygen requirements for heart muscle and decreased arterial contraction and spasm. It is used clinically as a cerebral and coronary vasodilator. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B43BE7C1-EB63-6A5C-E040-BB89AD437808","latestVersionIndicator":"Yes","beginDate":"2011-12-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-94CF-18F7-E053-F662850A60B1","beginDate":"2011-12-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ethinyl Estradiol/Norgestrel","valueDescription":"Ethinyl Estradiol/Norgestrel","ValueMeaning":{"publicId":"2576835","version":"1","preferredName":"Ethinyl Estradiol/Norgestrel","longName":"2576835","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ethinyl Estradiol/Norgestrel","conceptCode":"C12162","definition":"A combination of two steroid sex hormones, the semisynthetic estrogen ethinyl estradiol and the synthetic progestogen norgestrel, with contraceptive activity.  The combination of ethinyl estradiol with norgestrel suppresses the hypothalamic-pituitary system, leading to an inhibition of the release of follicle stimulating hormone (FSH), thus suppressing the development of ovarian follicles. The release of luteinizing hormone (LH) is also inhibited, thus preventing ovulation. In addition, thickening of the cervical mucus and the endometrium is promoted, thereby altering the endometrium in such a way as to discourage implantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F930-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7A3E-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Etodolac","valueDescription":"Etodolac","ValueMeaning":{"publicId":"2576836","version":"1","preferredName":"Etodolac","longName":"2576836","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etodolac","conceptCode":"C47526","definition":"A pyranocarboxylic acid and non-steroidal anti-inflammatory drug (NSAID) with antipyretic and analgesic activities. Etodolac inhibits the activity of cyclooxygenase I and II, thereby preventing the formation of prostaglandin which is involved in the induction of pain, fever, and inflammation. It also inhibits platelet aggregation by blocking platelet cyclooxygenase and the subsequent formation of thromboxane A2.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F931-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7A48-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Etomidate","valueDescription":"Etomidate","ValueMeaning":{"publicId":"2576837","version":"1","preferredName":"Etomidate","longName":"2576837","preferredDefinition":"An imidazole derivative with short-acting sedative, hypnotic, and general anesthetic properties. Etomidate appears to have gamma-aminobutyric acid (GABA) like effects, mediated through GABA-A receptor. The action enhances the inhibitory effect of GABA on the central nervous system by causing chloride channel opening events which leads to membrane hyperpolarization.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etomidate","conceptCode":"C47527","definition":"An imidazole derivative with short-acting sedative, hypnotic, and general anesthetic properties. Etomidate appears to have gamma-aminobutyric acid (GABA) like effects, mediated through GABA-A receptor. The action enhances the inhibitory effect of GABA on the central nervous system by causing chloride channel opening events which leads to membrane hyperpolarization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"COOPERM","dateModified":"2019-08-06","changeDescription":"Updated concept definition. mc 8.6.19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7A52-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Eucerin","valueDescription":"Eucerin","ValueMeaning":{"publicId":"2576838","version":"1","preferredName":"Eucerin","longName":"2576838","preferredDefinition":"A moisturizing skincare formulation used for various skin conditions including dry skin conditions associated with eczema, psoriasis, chapped or chafed skin. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eucerin","conceptCode":"C1425","definition":"A moisturizing skincare formulation used for various skin conditions including dry skin conditions associated with eczema, psoriasis, chapped or chafed skin. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F933-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7A5C-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Evening Primrose Oil","valueDescription":"evening primrose oil","ValueMeaning":{"publicId":"2576839","version":"1","preferredName":"evening primrose oil","longName":"2576839","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"evening primrose oil","conceptCode":"C0700602","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F934-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7A66-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Excedrin","valueDescription":"Excedrin","ValueMeaning":{"publicId":"2576840","version":"1","preferredName":"Excedrin","longName":"2576840","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acetaminophen/Aspirin/Caffeine","conceptCode":"C29038","definition":"A commercial combination preparation by Novartis containing acetaminophen, aspirin, and caffeine with analgesic activity. Acetaminophen exerts antipyretic and analgesic activities by inhibiting prostaglandin synthesis while aspirin, a salicylate, inhibits cyclooxygenases (COX) with anti-inflammatory, antipyretic and analgesic properties. Caffeine is a central nervous system stimulant and causes constriction of dilated cerebral blood vessels. Excedrin is used for the relief and treatment of migraine and tension headaches.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F935-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7A70-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Exemestane","valueDescription":"Exemestane","ValueMeaning":{"publicId":"2563643","version":"1","preferredName":"Exemestane","longName":"2563643","preferredDefinition":"A synthetic androgen analogue.  Exemestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Exemestane","conceptCode":"C1097","definition":"An irreversible steroidal aromatase inhibitor, with antiestrogen and antineoplastic activities. Upon oral administration, exemestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the peripheral aromatization of androgens, including androstenedione and testosterone, to estrogens. This lowers estrogen levels in the blood circulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C5A8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-12-05","endDate":null,"createdBy":"CVALMONT","dateCreated":"2002-12-05","modifiedBy":"COOPERM","dateModified":"2016-08-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7A7A-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ex-Lax","valueDescription":"Ex-Lax","ValueMeaning":{"publicId":"2576841","version":"1","preferredName":"Ex-Lax","longName":"2576841","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ex-Lax","conceptCode":"C29037","definition":"A commercial preparation, by Novartis, with laxative activity. Ex-Lax contains anthraquinone glycosides sennosides, extracted from senna leaves. Sennosides irritate the lining of the intestine wall, thereby causing increased intestinal muscle contractions that lead to vigorous bowel movement and relief constipation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F936-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7A84-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ezetimibe","valueDescription":"Ezetimibe","ValueMeaning":{"publicId":"2576842","version":"1","preferredName":"Ezetimibe","longName":"2576842","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ezetimibe","conceptCode":"C47529","definition":"An azetidinone derivative and a cholesterol absorption inhibitor with lipid-lowering activity. Ezetimibe appears to interact physically with cholesterol transporters at the brush border of the small intestine and inhibits the intestinal absorption of cholesterol and related phytosterols. As a result, ezetimibe causes a decrease in the level of blood cholesterol or an increase in the clearance of cholesterol from the bloodstream. Overall, the following effects observed are a reduction of hepatic cholesterol stores and a reduction of total cholesterol, LDL cholesterol, and other triglycerides in the blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F937-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"GDEEN","dateModified":"2024-02-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7A8E-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Famciclovir","valueDescription":"Famciclovir","ValueMeaning":{"publicId":"2575683","version":"1","preferredName":"Famciclovir","longName":"2575683","preferredDefinition":"A diacetyl 6-deoxy prodrug analog of the antiviral agent penciclovir.  Orally administered, famciclovir in vivo is converted to penciclovir triphosphate, which is active against the Herpes viruses, including herpes simplex 1 and 2 and varicella-zoster.  This agent inhibits the replication of viral DNA by interfering competitively with DNA polymerase. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Famciclovir","conceptCode":"C29044","definition":"A diacetyl 6-deoxy prodrug analog of the antiviral agent penciclovir.  Orally administered, famciclovir in vivo is converted to penciclovir triphosphate, which is active against the Herpes viruses, including herpes simplex 1 and 2 and varicella-zoster.  This agent inhibits the replication of viral DNA by interfering competitively with DNA polymerase. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4B0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7A98-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Famotidine","valueDescription":"Famotidine","ValueMeaning":{"publicId":"2576843","version":"1","preferredName":"Famotidine","longName":"2576843v1.00","preferredDefinition":"A propanimidamide and histamine H2-receptor antagonist with antacid activity. As a competitive inhibitor of histamine H2-receptors located on the basolateral membrane of the parietal cell, famotidine reduces basal and nocturnal gastric acid secretion, resulting in a reduction in gastric volume, acidity, and amount of gastric acid released in response to various stimuli.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Famotidine","conceptCode":"C29045","definition":"A propanimidamide and histamine H2-receptor antagonist with antacid activity. As a competitive inhibitor of histamine H2-receptors located on the basolateral membrane of the parietal cell, famotidine reduces basal and nocturnal gastric acid secretion, resulting in a reduction in gastric volume, acidity, and amount of gastric acid released in response to various stimuli.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F938-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"KUMMEROA","dateModified":"2023-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7AA2-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fat Emulsion","valueDescription":"Fat Emulsion","ValueMeaning":{"publicId":"2576845","version":"1","preferredName":"Fat Emulsion","longName":"2576845","preferredDefinition":"A liquid composed of two immiscible substances, typically some form of fat and water. In parenteral nutrition, a fat emulsion may contain phospholipids, triglycerides and essential fatty acids (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fat Emulsion","conceptCode":"C2575","definition":"A liquid composed of two immiscible substances, typically some form of fat and water. In parenteral nutrition, a fat emulsion may contain phospholipids, triglycerides and essential fatty acids (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F93A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7AAC-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fazarabine","valueDescription":"Fazarabine","ValueMeaning":{"publicId":"2576848","version":"1","preferredName":"Fazarabine","longName":"2576848","preferredDefinition":"An orally-active pyrimidine analogue of an aza-substituted cytidine in which the ribose moiety is replaced by an arabinose sugar. Similar in action to cytarabine, fazarabine is phosphorylated by deoxycytidine kinase to a triphosphate form which competes with thymidine for incorporation into DNA; its incorporation into DNA inhibits DNA synthesis, resulting in tumor cell death and tumor necrosis. The presence of deoxycytidine kinase in a tumor is a determinant of tumor sensitivity to this drug. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fazarabine","conceptCode":"C1096","definition":"An orally-active pyrimidine analogue of an aza-substituted cytidine in which the ribose moiety is replaced by an arabinose sugar. Similar in action to cytarabine, fazarabine is phosphorylated by deoxycytidine kinase to a triphosphate form which competes with thymidine for incorporation into DNA; its incorporation into DNA inhibits DNA synthesis, resulting in tumor cell death and tumor necrosis. The presence of deoxycytidine kinase in a tumor is a determinant of tumor sensitivity to this drug. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F93D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7AB6-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Felodipine","valueDescription":"Felodipine","ValueMeaning":{"publicId":"2576849","version":"1","preferredName":"Felodipine","longName":"2576849","preferredDefinition":"A dihydropyridine calcium channel blocking agent. Felodipine inhibits the influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility. This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in some multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Felodipine","conceptCode":"C29046","definition":"A dihydropyridine calcium channel blocking agent. Felodipine inhibits the influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility. This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in some multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F93E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7AC0-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fenofibrate","valueDescription":"fenofibrate","ValueMeaning":{"publicId":"2573147","version":"1","preferredName":"fenofibrate","longName":"2573147v1.00","preferredDefinition":"A synthetic phenoxy-isobutyric acid derivate and prodrug with antihyperlipidemic activity. Fenofibrate is hydrolyzed in vivo to its active metabolite fenofibric acid that binds to and activates peroxisome proliferator activated receptor alpha (PPARalpha), resulting in the activation of lipoprotein lipase and reduction of the production of apoprotein C-III, an inhibitor of lipoprotein lipase activity. Increased lipolysis and a fall in plasma triglycerides, in turn, leads to the modification of the small, dense low density lipoporotein (LDL) particles into larger particles that are catabolized more rapidly due to a greater affinity for cholesterol receptors. In addition, activation of PPARalpha also increases the synthesis of apoproteins A-I, A-II, and high density lipoprotein (HDL)-cholesterol. Overall, fenofibrate reduces total cholesterol, LDL cholesterol, apolipoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) while increasing HDL cholesterol.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fenofibrate","conceptCode":"C29047","definition":"A synthetic phenoxy-isobutyric acid derivate and prodrug with antihyperlipidemic activity. Fenofibrate is hydrolyzed in vivo to its active metabolite fenofibric acid that binds to and activates peroxisome proliferator activated receptor alpha (PPARalpha), resulting in the activation of lipoprotein lipase and reduction of the production of apoprotein C-III, an inhibitor of lipoprotein lipase activity. Increased lipolysis and a fall in plasma triglycerides, in turn, leads to the modification of the small, dense low density lipoporotein (LDL) particles into larger particles that are catabolized more rapidly due to a greater affinity for cholesterol receptors. In addition, activation of PPARalpha also increases the synthesis of apoproteins A-I, A-II, and high density lipoprotein (HDL)-cholesterol. Overall, fenofibrate reduces total cholesterol, LDL cholesterol, apolipoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) while increasing HDL cholesterol.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EAC8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-02-09","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7ACA-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fentanyl","valueDescription":"Fentanyl","ValueMeaning":{"publicId":"2576850","version":"1","preferredName":"Fentanyl","longName":"2576850","preferredDefinition":"A narcotic opioid drug that is used in the treatment of pain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fentanyl","conceptCode":"C494","definition":"A synthetic, lipophilic phenylpiperidine opioid agonist with analgesic and anesthetic properties. Fentanyl selectively binds to and activates the mu-receptor in the central nervous system (CNS) thereby mimicking the effects of endogenous opiates. Activation of the mu-subtype opioid receptor stimulates the exchange of GTP for GDP on the G-protein complex and subsequently inhibits adenylate cyclase. This causes a decrease in intracellular cAMP which inhibits cAMP-mediated calcium influx into the cell via the calcium channels and thereby results in hyperpolarization and reduced neuronal excitability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F93F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7AD4-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ferrous Gluconate","valueDescription":"Ferrous Gluconate","ValueMeaning":{"publicId":"2576851","version":"1","preferredName":"Ferrous Gluconate","longName":"2576851","preferredDefinition":"A form of mineral iron for oral administration, Ferrous Gluconate is absorbed in the stomach and small intestine and combines with apoferritin to form ferritin, which is stored in the liver, spleen, red bone marrow, and intestinal mucosa. Important in transport of oxygen by hemoglobin to the tissues, iron is also found in myoglobin, transferrin, and ferritin, and is as a component of many enzymes such as catalase, peroxidase, and cytochromes. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ferrous Gluconate","conceptCode":"C29048","definition":"A form of mineral iron for oral administration, Ferrous Gluconate is absorbed in the stomach and small intestine and combines with apoferritin to form ferritin, which is stored in the liver, spleen, red bone marrow, and intestinal mucosa. Important in transport of oxygen by hemoglobin to the tissues, iron is also found in myoglobin, transferrin, and ferritin, and is as a component of many enzymes such as catalase, peroxidase, and cytochromes. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F940-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7ADE-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ferrous Sulfate","valueDescription":"Ferrous Sulfate","ValueMeaning":{"publicId":"2576852","version":"1","preferredName":"Ferrous Sulfate","longName":"2576852","preferredDefinition":"A sulfate salt of mineral iron formulated for oral administration and used as a dietary supplement, Ferrous Sulfate is absorbed in the stomach and small intestine and combines with apoferritin to form ferritin, which is stored in the liver, spleen, red bone marrow, and intestinal mucosa. Important in transport of oxygen by hemoglobin to the tissues, iron is also found in myoglobin, transferrin, and ferritin, and is as a component of many enzymes such as catalase, peroxidase, and cytochromes. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ferrous Sulfate","conceptCode":"C29049","definition":"A sulfate salt of mineral iron formulated for oral administration and used as a dietary supplement, ferrous sulfate is absorbed in the stomach and small intestine and combines with apoferritin to form ferritin, which is stored in the liver, spleen, red bone marrow, and intestinal mucosa. Important in transport of oxygen by hemoglobin to the tissues, iron is also found in myoglobin, transferrin, and ferritin, and is a component of many enzymes such as catalase, peroxidase, and cytochromes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F941-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7AE8-18F7-E053-F662850A60B1","beginDate":"2005-11-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"3TC","valueDescription":"3TC (Lamivudine)","ValueMeaning":{"publicId":"2576885","version":"1","preferredName":"3TC (Lamivudine)","longName":"2576885","preferredDefinition":"A synthetic nucleoside analogue with activity against hepatitis B virus (HBV) and HIV. Intracellularly, lamivudine is phosphorylated to its active metabolites, lamiduvine triphosphate (L-TP) and lamiduvine monophosphate (L-MP).  In HIV, L-TP inhibits HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleoside analogue into viral DNA.  In HBV, incorporation of L-MP into viral DNA by HBV polymerase results in DNA chain termination. L-TP is a weak inhibitor of mammalian DNA polymerases alpha and beta, and mitochondrial DNA polymerase. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lamivudine","conceptCode":"C1471","definition":"A synthetic nucleoside analogue with activity against hepatitis B virus (HBV) and HIV. Intracellularly, lamivudine is phosphorylated to its active metabolites, lamiduvine triphosphate (L-TP) and lamiduvine monophosphate (L-MP).  In HIV, L-TP inhibits HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleoside analogue into viral DNA.  In HBV, incorporation of L-MP into viral DNA by HBV polymerase results in DNA chain termination. L-TP is a weak inhibitor of mammalian DNA polymerases alpha and beta, and mitochondrial DNA polymerase. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F962-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-09","modifiedBy":"REEVESD","dateModified":"2010-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7AF2-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"9-AC","valueDescription":"Aminocamptothecin","ValueMeaning":{"publicId":"2576886","version":"1","preferredName":"Aminocamptothecin","longName":"2576886","preferredDefinition":"A water-insoluble camptothecin derivative.  Aminocamptothecin binds to the nuclear enzyme topoisomerase I, thereby inhibiting repair of single-strand DNA breakages.  Because the terminal lactone ring of aminocamptothecin required for the agent's antitumor activity spontaneously opens under physiological conditions to an inactive carboxy form, the drug must be administered over an extended period of time to achieve effective cytotoxicity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aminocamptothecin","conceptCode":"C1488","definition":"A water-insoluble camptothecin derivative.  Aminocamptothecin binds to the nuclear enzyme topoisomerase I, thereby inhibiting repair of single-strand DNA breakages.  Because the terminal lactone ring of aminocamptothecin required for the agent's antitumor activity spontaneously opens under physiological conditions to an inactive carboxy form, the drug must be administered over an extended period of time to achieve effective cytotoxicity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F963-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-09","modifiedBy":"ONEDATA","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7AFC-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"A&D Ointment","valueDescription":"A and D Ointment","ValueMeaning":{"publicId":"2576887","version":"1","preferredName":"A and D Ointment","longName":"2576887","preferredDefinition":"A topical preparation containing fat-soluble vitamins A and D usually in a lanolin-petrolatum base, A and D Ointment promotes healing of minor burns, rashes, sunburn, skin irritations, and acne; and prevents diaper rash. Vitamin A is essential for diverse cellular functions, immune system functions, and maintenance of mucous membranes, while vitamin D regulates calcium and phosphorous metabolism. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"A and D Ointment","conceptCode":"C28794","definition":"A topical preparation containing fat-soluble vitamins A and D usually in a lanolin-petrolatum base, A and D Ointment promotes healing of minor burns, rashes, sunburn, skin irritations, and acne; and prevents diaper rash. Vitamin A is essential for diverse cellular functions, immune system functions, and maintenance of mucous membranes, while vitamin D regulates calcium and phosphorous metabolism. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F964-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-09","modifiedBy":"ONEDATA","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7B06-18F7-E053-F662850A60B1","beginDate":"2005-11-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fluoxymesterone","valueDescription":"Fluoxymesterone","ValueMeaning":{"publicId":"2576869","version":"1","preferredName":"Fluoxymesterone","longName":"2576869","preferredDefinition":"An anabolic steroid that has been used in the treatment of male hypogonadism, delayed puberty in males, and in the treatment of breast neoplasms in women.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluoxymesterone","conceptCode":"C507","definition":"A halogenated derivative of 17-alpha-methyltestosterone.  Similar to testosterone, fluoxymesterone binds to and activates specific nuclear receptors, resulting in an increase in protein anabolism, a decrease in amino acid catabolism, and retention of nitrogen, potassium, and phosphorus.  This agent also may competitively inhibit prolactin receptors and estrogen receptors, thereby inhibiting the growth of hormone-dependent tumor lines. Fluoxymesterone is approximately five times more potent than methyltestosterone. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F952-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7B11-18F7-E053-F662850A60B1","beginDate":"2006-02-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Flurazepam","valueDescription":"Flurazepam Hydrochloride","ValueMeaning":{"publicId":"2576870","version":"1","preferredName":"Flurazepam Hydrochloride","longName":"2576870","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Flurazepam Hydrochloride","conceptCode":"C29060","definition":"The hydrochloride salt form of flurazepam, a member of the benzodiazepines and a long-acting depressor of the central nervous system (CNS) with sedative and hypnotic effects. Flurazepam binds to a specific site on the benzodiazepine-gamma-aminobutyric acid (GABA)-A-chloride ionophore receptor complex located on the neuronal membrane. Binding causes an allosteric modification of the receptor thereby enhancing the affinity of GABA to the receptor leading to an increase in the frequency of chloride-channel opening events, which leads to an increase in chloride ion conductance, neuronal hyperpolarization, inhibition of the action potential, and a decrease in neuronal excitability. By modulating binding of the GABA inhibitory neurotransmitter to GABA-A receptors in the ascending reticular activating system, flurazepam blocks arousal of the cortical and limbic system, thereby exerting its sedative and hypnotic effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F953-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7B1B-18F7-E053-F662850A60B1","beginDate":"2006-02-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Flurbiprofen","valueDescription":"Flurbiprofen","ValueMeaning":{"publicId":"2576871","version":"1","preferredName":"Flurbiprofen","longName":"2576871","preferredDefinition":"An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting carbonic anhydrase.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Flurbiprofen","conceptCode":"C508","definition":"A derivative of propionic acid, and a phenylalkanoic acid derivative of non-steroidal antiinflammatory drugs (NSAIDs) with analgesic, antiinflammatory and antipyretic effects. Flurbiprofen non-selectively binds to and inhibits cyclooxygenase (COX). This results in a reduction of arachidonic acid conversion into prostaglandins that are involved in the regulation of pain, inflammation and fever. This NSAID also inhibits carbonic anhydrase, thereby reducing the production of hydrogen and bicarbonate ions. Upon ocular administration, flurbiprofen may reduce bicarbonate ion concentrations leading to a decrease in the production of aqueous humor, thereby lowering intraocular pressure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F954-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7B25-18F7-E053-F662850A60B1","beginDate":"2006-02-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Flutamide","valueDescription":"FLUTAMIDE","ValueMeaning":{"publicId":"2561412","version":"1","preferredName":"FLUTAMIDE","longName":"2561412","preferredDefinition":"FLUTAMIDE","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Flutamide","conceptCode":"C509","definition":"A toluidine derivative and a nonsteroidal antiandrogen that is structurally related to bicalutamide and nilutamide. Flutamide and its more potent active metabolite 2-hydroxyflutamide competitively block dihydrotestosterone binding at androgen receptors, forming inactive complexes which cannot translocate into the cell nucleus. Formation of inactive receptors inhibits androgen-dependent DNA and protein synthesis, resulting in tumor cell growth arrest or transient tumor regression. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BCF1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-02","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7B2F-18F7-E053-F662850A60B1","beginDate":"2006-02-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fluticasone Propionate","valueDescription":"Fluticasone Propionate","ValueMeaning":{"publicId":"2576872","version":"1","preferredName":"Fluticasone Propionate","longName":"2576872","preferredDefinition":"The propionate salt form of fluticasone, a synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, antiinflammatory and antipruritic effects. Binding and activation of the glucocorticoid receptor results in the activation of lipocortin that in turn inhibits cytosolic phospholipase A2, which triggers cascade of reactions involved in synthesis of inflammatory mediators, such as prostaglandins and leukotrienes. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leads to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluticasone Propionate","conceptCode":"C29061","definition":"The propionate salt form of fluticasone, a synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, antiinflammatory and antipruritic effects. Binding and activation of the glucocorticoid receptor results in the activation of lipocortin that in turn inhibits cytosolic phospholipase A2, which triggers cascade of reactions involved in synthesis of inflammatory mediators, such as prostaglandins and leukotrienes. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leads to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F955-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"REEVESD","dateModified":"2011-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7B39-18F7-E053-F662850A60B1","beginDate":"2006-02-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fluticasone Propionate/Salmeterol","valueDescription":"fluticasone propionate - salmeterol combination","ValueMeaning":{"publicId":"2577873","version":"1","preferredName":"fluticasone propionate - salmeterol combination","longName":"2577873","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"fluticasone propionate - salmeterol combination","conceptCode":"C1176242","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD3E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-22","modifiedBy":"ONEDATA","dateModified":"2006-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7B43-18F7-E053-F662850A60B1","beginDate":"2006-02-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fluvastatin Sodium","valueDescription":"Fluvastatin Sodium","ValueMeaning":{"publicId":"2576874","version":"1","preferredName":"Fluvastatin Sodium","longName":"2576874","preferredDefinition":"A synthetic lipid-lowering agent.  Formulated as as a sodium salt, fluvastatin sodium competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis.  Fluvastatin lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by the suppression of MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluvastatin Sodium","conceptCode":"C29062","definition":"The sodium salt of a synthetic lipid-lowering agent with potential antineoplastic activity. Fluvastatin competitively inhibits hepatic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses through the suppression of MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. Through the inhibition of mevalonate synthesis, statins, like fluvastatin, have been shown to inhibit the production of dolichol, geranylpyrophosphate (GPP) and farnesylpyrophosphate (FPP) and the isoprenylation of the intracellular G-proteins Ras and Rho, which may result in antiangiogenic, apoptotic, and antimetastatic effects in susceptible tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F957-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7B4D-18F7-E053-F662850A60B1","beginDate":"2006-02-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Nifabutin","valueDescription":"Nifabutin","ValueMeaning":{"publicId":"3335071","version":"1","preferredName":"Nifabutin","longName":"3335071","preferredDefinition":"Nifabutin","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B43BE7C1-EB17-6A5C-E040-BB89AD437808","latestVersionIndicator":"Yes","beginDate":"2011-12-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-94D9-18F7-E053-F662850A60B1","beginDate":"2011-12-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Nicotinamide Adenine Dinucleotide","valueDescription":"Nadide","ValueMeaning":{"publicId":"3335073","version":"1","preferredName":"Nadide","longName":"3335073","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nadide","conceptCode":"C87339","definition":"A dinucleotide of adenine and nicotinamide. It has coenzyme activity in redox reactions and also acts as a donor of ADP-ribose moieties.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B43BE7C1-EB3D-6A5C-E040-BB89AD437808","latestVersionIndicator":"Yes","beginDate":"2011-12-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-94E3-18F7-E053-F662850A60B1","beginDate":"2011-12-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Neutra-phos","valueDescription":"Potassium Phosphate/Sodium Phosphate","ValueMeaning":{"publicId":"3282731","version":"1","preferredName":"Potassium Phosphate/Sodium Phosphate","longName":"3282731","preferredDefinition":"A combination preparation containing potassium phosphate and sodium phosphate used for electrolyte-replacement purposes, dietary supplementation and to acidify urine. Phosphate, a predominant intracellular anion, plays an important role in energy storage, osteoblastic and osteoclastic activities, regulating serum calcium concentrations and numerous cellular phosphate-transfer reactions. Potassium phosphate and sodium phosphate are used to acidify the urine and lower the urinary calcium concentration. This may reduce rash and odor caused by ammonium in the urine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Potassium Phosphate/Sodium Phosphate","conceptCode":"C29288","definition":"A combination preparation containing potassium phosphate and sodium phosphate used for electrolyte-replacement purposes, dietary supplementation and to acidify urine. Phosphate, a predominant intracellular anion, plays an important role in energy storage, osteoblastic and osteoclastic activities, regulating serum calcium concentrations and numerous cellular phosphate-transfer reactions. Potassium phosphate and sodium phosphate are used to acidify the urine and lower the urinary calcium concentration. This may reduce rash and odor caused by ammonium in the urine.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD7A5918-D768-456E-E040-BB89AD433590","latestVersionIndicator":"Yes","beginDate":"2011-09-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-94ED-18F7-E053-F662850A60B1","beginDate":"2011-12-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Nesiritide","valueDescription":"Nesiritide","ValueMeaning":{"publicId":"3335077","version":"1","preferredName":"Nesiritide","longName":"3335077","preferredDefinition":"A recombinant version of the cardiac neurohormone, human B-type natriuretic peptide (hBNP) produced by the ventricular myocardium. Nesiritide binds to natriuretic peptide receptors on vascular smooth muscle and endothelial cells, through which it triggers guanylate cyclase dependent signal transduction resulting in increase of intracellular concentrations of cGMP. This leads to smooth muscle cell relaxation causing arterial and venous dilatation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nesiritide","conceptCode":"C47636","definition":"A recombinant version of the cardiac neurohormone, human B-type natriuretic peptide (hBNP) produced by the ventricular myocardium. Nesiritide binds to natriuretic peptide receptors on vascular smooth muscle and endothelial cells, through which it triggers guanylate cyclase dependent signal transduction resulting in increase of intracellular concentrations of cGMP. This leads to smooth muscle cell relaxation causing arterial and venous dilatation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B43BE7C1-EB9D-6A5C-E040-BB89AD437808","latestVersionIndicator":"Yes","beginDate":"2011-12-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-94F7-18F7-E053-F662850A60B1","beginDate":"2011-12-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Neostigmine","valueDescription":"Neostigmine","ValueMeaning":{"publicId":"3335079","version":"1","preferredName":"Neostigmine","longName":"3335079","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neostigmine","conceptCode":"C75024","definition":"A parasympathomimetic agent that acts as a reversible acetylcholinesterase inhibitor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B43BE7C1-EBC3-6A5C-E040-BB89AD437808","latestVersionIndicator":"Yes","beginDate":"2011-12-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9501-18F7-E053-F662850A60B1","beginDate":"2011-12-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Neosporin","valueDescription":"Neosporin","ValueMeaning":{"publicId":"3335081","version":"1","preferredName":"Neosporin","longName":"3335081","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neosporin","conceptCode":"C0068536","definition":"No Value Exists","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B43BE7C1-EBE9-6A5C-E040-BB89AD437808","latestVersionIndicator":"Yes","beginDate":"2011-12-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-950B-18F7-E053-F662850A60B1","beginDate":"2011-12-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Neomycin/Polymyxin","valueDescription":"Polymyxin Antibiotic","ValueMeaning":{"publicId":"3335083","version":"1","preferredName":"Polymyxin Antibiotic","longName":"3335083","preferredDefinition":"Any of the polymyxin antibiotics, cyclic peptides with long hydrophobic ends, obtained from Bacillus polymyxa strains. Polymyxin antibiotics exert their antimicrobial effect through their cationic detergent actions on cell membranes. Specifically, they bind to the negatively charged site in the lipopolysaccharide (LPS) layer of the bacterial cell membrane via electrostatic affinity with the positively charged amino groups in the cyclic peptide portion of the polymyxin antibiotic. Subsequently, the fatty acid portion of the polymyxin antibiotic dissolves in the hydrophobic region of the bacterial cell membrane. This results in an alteration in cell membrane structure, an increase in permeability for water and other molecules and disruption of cell wall integrity. This leads to bacterial cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polymyxin Antibiotic","conceptCode":"C78160","definition":"Any of the polymyxin antibiotics, cyclic peptides with long hydrophobic ends, obtained from Bacillus polymyxa strains. Polymyxin antibiotics exert their antimicrobial effect through their cationic detergent actions on cell membranes. Specifically, they bind to the negatively charged site in the lipopolysaccharide (LPS) layer of the bacterial cell membrane via electrostatic affinity with the positively charged amino groups in the cyclic peptide portion of the polymyxin antibiotic. Subsequently, the fatty acid portion of the polymyxin antibiotic dissolves in the hydrophobic region of the bacterial cell membrane. This results in an alteration in cell membrane structure, an increase in permeability for water and other molecules and disruption of cell wall integrity. This leads to bacterial cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B43BE7C1-EC0F-6A5C-E040-BB89AD437808","latestVersionIndicator":"Yes","beginDate":"2011-12-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9515-18F7-E053-F662850A60B1","beginDate":"2011-12-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Nystatin","valueDescription":"Nystatin","ValueMeaning":{"publicId":"2575695","version":"1","preferredName":"Nystatin","longName":"2575695","preferredDefinition":"Macrolide antifungal antibiotic complex produced by Streptomyces noursei, S. aureus, and other Streptomyces species. The biologically active components of the complex are nystatin A1, A2, and A3.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nystatin","conceptCode":"C710","definition":"A polyene macrolide antibiotic, with antifungal activity. Upon administration, nystatin binds to sterols in the fungal plasma membrane, thereby increasing membrane permeability. This leads to leakage of important intracellular components, cell rupture, and eventually fungal cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4BC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-951F-18F7-E053-F662850A60B1","beginDate":"2011-12-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Nyquil","valueDescription":"Nyquil","ValueMeaning":{"publicId":"3335129","version":"1","preferredName":"Nyquil","longName":"3335129","preferredDefinition":"A commercial combination preparation, by Vicks, containing acetaminophen, dextromethorphan hydrobromide and doxylamine succinate used to relieve symptoms of cold and flu. Acetaminophen exerts analgesic and antipyretic actions by inhibiting prostaglandin synthesis. Dextromethorphan exerts antitussive activity by raising the threshold for coughing in the cough center. Doxylamine succinate, an antihistamine, blocks the effects of histamine, thereby treating symptoms such as sneezing, itchy, watery eyes, runny nose, itchy throat and causes drowsiness.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nyquil","conceptCode":"C29296","definition":"A commercial combination preparation, by Vicks, containing acetaminophen, dextromethorphan hydrobromide and doxylamine succinate used to relieve symptoms of cold and flu. Acetaminophen exerts analgesic and antipyretic actions by inhibiting prostaglandin synthesis. Dextromethorphan exerts antitussive activity by raising the threshold for coughing in the cough center. Doxylamine succinate, an antihistamine, blocks the effects of histamine, thereby treating symptoms such as sneezing, itchy, watery eyes, runny nose, itchy throat and causes drowsiness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B43BE7C1-EC40-6A5C-E040-BB89AD437808","latestVersionIndicator":"Yes","beginDate":"2011-12-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9529-18F7-E053-F662850A60B1","beginDate":"2011-12-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Nutritional Supplement","valueDescription":"Supplements","ValueMeaning":{"publicId":"3335130","version":"1","preferredName":"Supplements/Vitamins","longName":"3335130v1.00","preferredDefinition":"Oral preparations containing dietary ingredient(s) intended to supplement the diet.  Dietary ingredients include vitamins, minerals, herbs, amino acids, extracts and metabolites._Used to indicate that either or both of two items or options may be valid._A group of organic food substances found in animals and plants in small quantities. They must be supplied in diet or dietary supplement and are essential for normal metabolism.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dietary Supplement","conceptCode":"C1505","definition":"Oral preparations containing dietary ingredient(s) intended to supplement the diet.  Dietary ingredients include vitamins, minerals, herbs, amino acids, extracts and metabolites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And/Or","conceptCode":"C48928","definition":"Used to indicate that either or both of two items or options may be valid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Vitamin","conceptCode":"C944","definition":"A group of organic food substances found in animals and plants in small quantities. They must be supplied in diet or dietary supplement and are essential for normal metabolism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B43BE7C1-EC63-6A5C-E040-BB89AD437808","latestVersionIndicator":"Yes","beginDate":"2011-12-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-16","modifiedBy":"LISU","dateModified":"2023-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9533-18F7-E053-F662850A60B1","beginDate":"2011-12-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Nortriptyline HCL","valueDescription":"Nortriptyline Hydrochloride","ValueMeaning":{"publicId":"3335132","version":"1","preferredName":"Nortriptyline Hydrochloride","longName":"3335132","preferredDefinition":"The hydrochloride salt form of nortriptyline, a tricyclic antidepressant agent used for short-term treatment of various forms of depression. Nortriptyline blocks the norepinephrine presynaptic receptors, thereby blocking the reuptake of this neurotransmitter and raising the concentration in the synaptic cleft in the CNS. Nortriptyline also binds to alpha-adrenergic, histaminergic and cholinergic receptors. Long-term treatment with nortriptyline produces a downregulation of adrenergic receptors due to the increased stimulation of these receptors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nortriptyline Hydrochloride","conceptCode":"C704","definition":"The hydrochloride salt form of nortriptyline, a tricyclic antidepressant agent used for short-term treatment of various forms of depression. Nortriptyline blocks the norepinephrine presynaptic receptors, thereby blocking the reuptake of this neurotransmitter and raising the concentration in the synaptic cleft in the CNS. Nortriptyline also binds to alpha-adrenergic, histaminergic and cholinergic receptors. Long-term treatment with nortriptyline produces a downregulation of adrenergic receptors due to the increased stimulation of these receptors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B43BE7C1-EC89-6A5C-E040-BB89AD437808","latestVersionIndicator":"Yes","beginDate":"2011-12-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-953D-18F7-E053-F662850A60B1","beginDate":"2011-12-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Normal Saline","valueDescription":"Saline","ValueMeaning":{"publicId":"2636972","version":"1","preferredName":"Saline","longName":"2636972","preferredDefinition":"A solution of salt and water. Saline usually refers to normal or physiological saline, which is an aqueous solution containing 0.9% sodium chloride.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Saline","conceptCode":"C821","definition":"A solution of salt and water. Saline usually refers to normal or physiological saline, which is an aqueous solution containing 0.9% sodium chloride.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"300DDB40-932F-448E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-05-09","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-05-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9547-18F7-E053-F662850A60B1","beginDate":"2011-12-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Norepinephrine","valueDescription":"Norepinephrine","ValueMeaning":{"publicId":"3335134","version":"1","preferredName":"Norepinephrine","longName":"3335134","preferredDefinition":"A synthetic phenylethylamine that mimics the sympathomimetic actions of the endogenous norepinephrine. Norepinephrine acts directly on the alpha- and beta-adrenergic receptors. Clinically, norepinephrine is used as a peripheral vasoconstrictor that causes constriction of arterial and venous beds via its alpha-adrenergic action. It is also used as a potent inotropic and chronotropic stimulator of the heart mediated through its beta-1 adrenergic action.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Norepinephrine, DL-","conceptCode":"C62098","definition":"A synthetic phenylethylamine that mimics the sympathomimetic actions of the endogenous norepinephrine. Norepinephrine acts directly on the alpha- and beta-adrenergic receptors. Clinically, norepinephrine is used as a peripheral vasoconstrictor that causes constriction of arterial and venous beds via its alpha-adrenergic action. It is also used as a potent inotropic and chronotropic stimulator of the heart mediated through its beta-1 adrenergic action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B43BE7C1-ECC4-6A5C-E040-BB89AD437808","latestVersionIndicator":"Yes","beginDate":"2011-12-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9551-18F7-E053-F662850A60B1","beginDate":"2011-12-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Nizatidine","valueDescription":"Nizatidine","ValueMeaning":{"publicId":"3335136","version":"1","preferredName":"Nizatidine","longName":"3335136","preferredDefinition":"A competitive and reversible histamine H2-receptor antagonist with antacid activity. Nizatidine inhibits the histamine H2-receptors located on the basolateral membrane of the gastric parietal cell, thereby reducing basal and nocturnal gastric acid secretion, resulting in a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nizatidine","conceptCode":"C29295","definition":"A competitive and reversible histamine H2-receptor antagonist with antacid activity. Nizatidine inhibits the histamine H2-receptors located on the basolateral membrane of the gastric parietal cell, thereby reducing basal and nocturnal gastric acid secretion, resulting in a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B43BE7C1-ECEA-6A5C-E040-BB89AD437808","latestVersionIndicator":"Yes","beginDate":"2011-12-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-955B-18F7-E053-F662850A60B1","beginDate":"2011-12-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Nitroglycerin","valueDescription":"Nitroglycerin","ValueMeaning":{"publicId":"3335138","version":"1","preferredName":"Nitroglycerin","longName":"3335138","preferredDefinition":"An organic nitrate with vasodilator activity. Nitroglycerin is converted into nitric oxide (NO) in smooth muscle and activates guanylyl cyclase, thereby increasing cGMP concentration, and resulting in smooth muscle relaxation. Dilatation of the veins results in decreased venous return to the heart, thereby decreasing left ventricular volume (reduced preload) and decreasing myocardial oxygen requirements. Arteriolar relaxation reduces arteriolar resistance (reduced afterload), thereby decreasing myocardial oxygen demands. In addition, nitroglycerine causes coronary artery dilatation, thereby improving myocardial blood distribution.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nitroglycerin","conceptCode":"C29294","definition":"An organic nitrate with vasodilator activity. Nitroglycerin is converted into nitric oxide (NO) in smooth muscle and activates guanylyl cyclase, thereby increasing cGMP concentration, and resulting in smooth muscle relaxation. Dilatation of the veins results in decreased venous return to the heart, thereby decreasing left ventricular volume (reduced preload) and decreasing myocardial oxygen requirements. Arteriolar relaxation reduces arteriolar resistance (reduced afterload), thereby decreasing myocardial oxygen demands. In addition, nitroglycerine causes coronary artery dilatation, thereby improving myocardial blood distribution.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B43BE7C1-ED10-6A5C-E040-BB89AD437808","latestVersionIndicator":"Yes","beginDate":"2011-12-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9565-18F7-E053-F662850A60B1","beginDate":"2011-12-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Nitrofurantoin","valueDescription":"Nitrofurantoin","ValueMeaning":{"publicId":"2575694","version":"1","preferredName":"Nitrofurantoin","longName":"2575694","preferredDefinition":"A synthetic derivative of imidazolidinedione, Nitrofurantoin inhibits bacterial DNA, RNA, and cell wall protein synthesis. Activated by bacterial flavoproteins to intermediates that inactivate bacterial ribosomal proteins, Nitrofurantoin is used prophylactically as a urinary anti-infective agent against most gram-positive and gram-negative organisms and for long-term suppression of infections. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nitrofurantoin","conceptCode":"C29293","definition":"A synthetic derivative of imidazolidinedione, Nitrofurantoin inhibits bacterial DNA, RNA, and cell wall protein synthesis. Activated by bacterial flavoproteins to intermediates that inactivate bacterial ribosomal proteins, Nitrofurantoin is used prophylactically as a urinary anti-infective agent against most gram-positive and gram-negative organisms and for long-term suppression of infections. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4BB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-956F-18F7-E053-F662850A60B1","beginDate":"2011-12-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Nisoldipine SR","valueDescription":"Sustained Release Dosage Form Nisoldipine","ValueMeaning":{"publicId":"3335141","version":"1","preferredName":"Sustained Release Dosage Form Nisoldipine","longName":"3335141","preferredDefinition":"A dosage form designed to release active and/or inert ingredient(s) slowly so as to achieve a constant circulating concentration of the ingredient over a period of time.: A dihydropyridine calcium channel blocking agent. Nisoldipine inhibits the transmembrane influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility. This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in some multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sustained Release Dosage Form","conceptCode":"C42672","definition":"A dosage form designed to release active and/or inert ingredient(s) slowly so as to achieve a constant circulating concentration of the ingredient over a period of time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Nisoldipine","conceptCode":"C29291","definition":"A dihydropyridine calcium channel blocking agent. Nisoldipine inhibits the transmembrane influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, causing dilatation of the main coronary and systemic arteries and decreasing myocardial contractility. This agent also inhibits the drug efflux pump P-glycoprotein which is overexpressed in some multi-drug resistant tumors and may improve the efficacy of some antineoplastic agents. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B43BE7C1-ED42-6A5C-E040-BB89AD437808","latestVersionIndicator":"Yes","beginDate":"2011-12-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9579-18F7-E053-F662850A60B1","beginDate":"2011-12-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Nilutamide","valueDescription":"Nilutamide","ValueMeaning":{"publicId":"3335142","version":"1","preferredName":"Nilutamide","longName":"3335142","preferredDefinition":"A drug that blocks the effects of male hormones in the body.  It belongs to the family of drugs called antiandrogens.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nilutamide","conceptCode":"C1173","definition":"A synthetic, nonsteroidal agent with antiandrogenic properties. Nilutamide preferentially binds to androgen receptors and blocks androgen receptor activation by testosterone and other androgens; this agent may inhibit androgen-dependent growth of normal and neoplastic prostate cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B43BE7C1-ED69-6A5C-E040-BB89AD437808","latestVersionIndicator":"Yes","beginDate":"2011-12-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9583-18F7-E053-F662850A60B1","beginDate":"2011-12-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cyclosporine Ophthalmic Emulsion (Restasis)","valueDescription":"Cyclosporine Ophthalmic Emulsion","ValueMeaning":{"publicId":"3564172","version":"1","preferredName":"Cyclosporine Ophthalmic Emulsion","longName":"3564172","preferredDefinition":"An topical ophthalmic formulation containing cyclosporine, an undecapeptide produced by the fungus Beauveria nivea, with immunosuppressant and anti-inflammatory activities. The exact therapeutic mechanism of action of cyclosporine is not known but may involve binding to the cellular protein cytophilin, resulting in inhibition of the enzyme calcineurin. This agent appears to specifically and reversibly inhibit immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited with T-helper cells as the primary target. Cyclosporine also inhibits lymphokine production and release.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclosporine Ophthalmic Emulsion","conceptCode":"C80051","definition":"An topical ophthalmic formulation containing cyclosporine, an undecapeptide produced by the fungus Beauveria nivea, with immunosuppressant and anti-inflammatory activities. The exact therapeutic mechanism of action of cyclosporine is not known but may involve binding to the cellular protein cytophilin, resulting in inhibition of the enzyme calcineurin. This agent appears to specifically and reversibly inhibit immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited with T-helper cells as the primary target. Cyclosporine also inhibits lymphokine production and release.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7DE3983-D865-00EE-E040-BB89AD432ACB","latestVersionIndicator":"Yes","beginDate":"2012-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-958D-18F7-E053-F662850A60B1","beginDate":"2012-08-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Plerixafor","valueDescription":"Plerixafor","ValueMeaning":{"publicId":"3631680","version":"1","preferredName":"Plerixafor","longName":"3631680","preferredDefinition":"A bicyclam with hematopoietic stem cell-mobilizing activity. Plerixafor blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plerixafor","conceptCode":"C1777","definition":"A bicyclam with hematopoietic stem cell-mobilizing activity. Plerixafor blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFB802C2-BC50-449B-E040-BB89AD4358D4","latestVersionIndicator":"Yes","beginDate":"2012-11-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-11-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9597-18F7-E053-F662850A60B1","beginDate":"2012-11-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ranolazine","valueDescription":"Ranolazine","ValueMeaning":{"publicId":"3631682","version":"1","preferredName":"Ranolazine","longName":"3631682v1.00","preferredDefinition":"An orally available, piperazine derivative with anti-anginal and potential antineoplastic activities. Ranolazine's mechanism of action for its anti-ischemic effects has yet to be fully elucidated but may involve the alteration of the trans-cellular late sodium current in the ischemic myocyte. By preventing the rise of intracellular sodium levels, ranolazine may affect the transport activity of sodium-dependent calcium channels and prevent the calcium overload during myocardial ischemia, thereby preventing cellular injury. Ranolazine's potential antineoplastic effect may depend on its inhibitory effect on fatty acid oxidation, which may sensitize tumor cells to apoptosis and decrease tumor cell proliferation; fatty acid oxidation provides energy and promotes tumor cell proliferation and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ranolazine","conceptCode":"C66507","definition":"An orally available, piperazine derivative with anti-anginal and potential antineoplastic activities. Ranolazine's mechanism of action for its anti-ischemic effects has yet to be fully elucidated but may involve the alteration of the trans-cellular late sodium current in the ischemic myocyte. By preventing the rise of intracellular sodium levels, ranolazine may affect the transport activity of sodium-dependent calcium channels and prevent the calcium overload during myocardial ischemia, thereby preventing cellular injury. Ranolazine's potential antineoplastic effect may depend on its inhibitory effect on fatty acid oxidation, which may sensitize tumor cells to apoptosis and decrease tumor cell proliferation; fatty acid oxidation provides energy and promotes tumor cell proliferation and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFB802C2-BC76-449B-E040-BB89AD4358D4","latestVersionIndicator":"Yes","beginDate":"2012-11-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-11-30","modifiedBy":"KUMMEROA","dateModified":"2023-08-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-95A1-18F7-E053-F662850A60B1","beginDate":"2012-11-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ranibizumab","valueDescription":"Ranibizumab","ValueMeaning":{"publicId":"3631684","version":"1","preferredName":"Ranibizumab","longName":"3631684","preferredDefinition":"A second-generation, recombinant humanized IgG1 kappa monoclonal antibody fragment directed against human vascular endothelial growth factor (VEGF) alpha. Ranibizumab binds to VEGF alpha and inhibits VEGF alpha binding to its receptors, VEGFR1 and VEGFR2, thereby preventing the growth and maintenance of tumor blood vessels. The molecular weight of this agent (48 kD) is much smaller than the molecular weight of bevacizumab (MW ~149 kD), allowing complete penetration of the retina and the subretinal space following intravitreal injection. In contrast to other anti-VEGF aptamers such as pegaptanib, ranibizumab has a high specificity and affinity for all soluble human isoforms of VEGF.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ranibizumab","conceptCode":"C67562","definition":"A second-generation, recombinant humanized IgG1 kappa monoclonal antibody fragment directed against human vascular endothelial growth factor (VEGF) alpha. Ranibizumab binds to VEGF alpha and inhibits VEGF alpha binding to its receptors, VEGFR1 and VEGFR2, thereby preventing the growth and maintenance of tumor blood vessels. The molecular weight of this agent (48 kD) is much smaller than the molecular weight of bevacizumab (MW ~149 kD), allowing complete penetration of the retina and the subretinal space following intravitreal injection. In contrast to other anti-VEGF aptamers such as pegaptanib, ranibizumab has a high specificity and affinity for all soluble human isoforms of VEGF.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFB802C2-BC9C-449B-E040-BB89AD4358D4","latestVersionIndicator":"Yes","beginDate":"2012-11-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-11-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-95AB-18F7-E053-F662850A60B1","beginDate":"2012-11-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Silodosin","valueDescription":"Silodosin","ValueMeaning":{"publicId":"3444458","version":"1","preferredName":"Silodosin","longName":"3444458","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Silodosin","conceptCode":"C81372","definition":"An orally available, alpha-1 adrenoreceptor (alpha-1a) selective antagonist that can be used to relieve symptoms of benign prostate hyperplasia (BPH). Upon administration, silodosin selectively binds alpha-1a receptors located in the human prostate and bladder with high affinity and blocks signaling pathways mediated by alpha-1a. Blockade of these receptors causes smooth muscle relaxation, lowers intraurethral pressure, and results in improved urine flow and a reduction in the symptoms of BPH, such as difficulty with urinating, painful urination, urinary frequency and incomplete bladder emptying. In addition, silodosin may be used to improve lower urinary tract symptoms, which can occur after receiving radiation therapy for prostate cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEE697DE-0E2D-E3C7-E040-BB89AD43655E","latestVersionIndicator":"Yes","beginDate":"2012-04-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-95B5-18F7-E053-F662850A60B1","beginDate":"2012-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Saxagliptin","valueDescription":"Saxagliptin","ValueMeaning":{"publicId":"3461718","version":"1","preferredName":"Saxagliptin","longName":"3461718","preferredDefinition":"A potent, selective and competitive, cyanopyrrolidine-based, orally bioavailable inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. Saxagliptin is metabolized into an, although less potent, active mono-hydroxy metabolite.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Saxagliptin","conceptCode":"C75983","definition":"A potent, selective and competitive, cyanopyrrolidine-based, orally bioavailable inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. Saxagliptin is metabolized into an, although less potent, active mono-hydroxy metabolite.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C03D20CE-A9A2-F0B2-E040-BB89AD4303B8","latestVersionIndicator":"Yes","beginDate":"2012-05-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-95BF-18F7-E053-F662850A60B1","beginDate":"2012-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fosaprepitant","valueDescription":"Fosaprepitant","ValueMeaning":{"publicId":"3460078","version":"1","preferredName":"Fosaprepitant","longName":"3460078","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fosaprepitant","conceptCode":"C72787","definition":"A water-soluble, N-phosphorylated prodrug of the substance P (SP; neurokinin 1 (NK1)) antagonist aprepitant, with antiemetic activity. Upon intravenous administration and rapid conversion to aprepitant, this agent selectively binds to and blocks the human substance P receptors in the central nervous system (CNS). This inhibits receptor binding of the endogenous substance P and prevents substance P-induced emesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BFC2CD9D-19E7-9786-E040-BB89AD4324CC","latestVersionIndicator":"Yes","beginDate":"2012-05-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-95C9-18F7-E053-F662850A60B1","beginDate":"2012-05-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Arformoterol Tartrate","valueDescription":"Arformoterol Tartrate","ValueMeaning":{"publicId":"3564162","version":"1","preferredName":"Arformoterol Tartrate","longName":"3564162","preferredDefinition":"The tartrate salt of arformoterol, the (R,R)-enantiomer of formoterol and a long-acting beta-2 adrenergic agonist with bronchodilator activity. Arformoterol selectively binds to and activates beta-2 adrenergic receptors in bronchiolar smooth muscle, thereby causing stimulation of adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increased intracellular cAMP levels cause relaxation of bronchial smooth muscle and lead to an inhibition of release of inflammatory mediators from mast cells. This may eventually lead to an improvement of airway function.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Arformoterol Tartrate","conceptCode":"C65240","definition":"The tartrate salt of arformoterol, the (R,R)-enantiomer of formoterol and a long-acting beta-2 adrenergic agonist with bronchodilator activity. Arformoterol selectively binds to and activates beta-2 adrenergic receptors in bronchiolar smooth muscle, thereby causing stimulation of adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increased intracellular cAMP levels cause relaxation of bronchial smooth muscle and lead to an inhibition of release of inflammatory mediators from mast cells. This may eventually lead to an improvement of airway function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7DBA78C-8BA8-5111-E040-BB89AD4317C1","latestVersionIndicator":"Yes","beginDate":"2012-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-95D3-18F7-E053-F662850A60B1","beginDate":"2012-08-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Treximet","valueDescription":"Sumatriptan Naproxen","ValueMeaning":{"publicId":"3453411","version":"1","preferredName":"Sumatriptan Naproxen","longName":"3453411","preferredDefinition":"A sulfonamide triptan with vasoconstrictor activity. Sumatriptan selectively binds to and activates serotonin 5-HT1D receptors in the central nervous system (CNS), thereby constricting cerebral blood vessels. This may lead to a relief in pain from vascular headaches. Sumatriptan may also relieve vascular headaches by decreasing the release of vasoactive neuropeptides from perivascular trigeminal axons in the dura mater during a migraine, by reducing extravasation of plasma proteins, and by decreasing the release of other mediators of inflammation from the trigeminal nerve.: A propionic acid derivative and a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Naproxen inhibits the activity of the enzymes cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. The resulting decrease in prostaglandin synthesis is responsible for the therapeutic effects of naproxen. Naproxen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sumatriptan","conceptCode":"C1240","definition":"A sulfonamide triptan with vasoconstrictor activity. Sumatriptan selectively binds to and activates serotonin 5-HT1D receptors in the central nervous system (CNS), thereby constricting cerebral blood vessels. This may lead to a relief in pain from vascular headaches. Sumatriptan may also relieve vascular headaches by decreasing the release of vasoactive neuropeptides from perivascular trigeminal axons in the dura mater during a migraine, by reducing extravasation of plasma proteins, and by decreasing the release of other mediators of inflammation from the trigeminal nerve.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Naproxen","conceptCode":"C680","definition":"A propionic acid derivative and a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Naproxen inhibits the activity of the enzymes cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. The resulting decrease in prostaglandin synthesis is responsible for the therapeutic effects of naproxen. Naproxen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF8D06EE-42F1-B55B-E040-BB89AD434169","latestVersionIndicator":"Yes","beginDate":"2012-05-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-05-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-95DD-18F7-E053-F662850A60B1","beginDate":"2012-05-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Pulmicort","valueDescription":"Inhalation Formulation Budesonide","ValueMeaning":{"publicId":"3641129","version":"1","preferredName":"Inhalation Formulation Budesonide","longName":"3641129","preferredDefinition":"Administration of a substance in the form of a gas, aerosol, or fine powder via the respiratory tract, usually by oral or nasal inhalation, for local or systemic effect.: A glucocorticoid used in the management of asthma, the treatment of various skin disorders, and allergic rhinitis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inhalation Route of Administration","conceptCode":"C38216","definition":"Administration of a substance in the form of a gas, aerosol, or fine powder via the respiratory tract, usually by oral or nasal inhalation, for local or systemic effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Budesonide","conceptCode":"C1027","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. Upon administration, budesonide binds to intracellular glucocorticoid receptors (GRs) and induces the expression of glucocorticoid-responsive genes that encode for anti-inflammatory mediators, such as certain anti-inflammatory cytokines, including interleukin 10 (IL-10), and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both mediators of inflammation. In addition, budesonide prevents the release of pro-inflammatory cytokines from epithelial cells and macrophages, including interleukin 6 (IL-6), IL-8, interferon-beta (IFNb), and inhibits nuclear factor kappa-B (NF-kB) activation thereby decreasing NF-kB-mediated inflammation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D0ACE02E-B3F4-E452-E040-BB89AD436E23","latestVersionIndicator":"Yes","beginDate":"2012-12-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-12-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-95E7-18F7-E053-F662850A60B1","beginDate":"2012-12-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Clofazimine","valueDescription":"Clofazimine","ValueMeaning":{"publicId":"3378890","version":"1","preferredName":"Clofazimine","longName":"3378890","preferredDefinition":"A phenazine dye with anti-mycobacterial and anti-inflammatory activity. The exact mechanism through which clofazime exerts its effect is unknown.  However, it binds preferentially to mycobacterial DNA, thereby inhibiting DNA replication and cell growth. Clofazimine has a slow bactericidal effect on Mycobacterium leprae and is active against various other Mycobacteria.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clofazimine","conceptCode":"C47456","definition":"A phenazine dye with anti-mycobacterial and anti-inflammatory activities. The exact mechanism through which clofazimine exerts its effect is unknown.  However, it binds preferentially to mycobacterial DNA, thereby inhibiting DNA replication and cell growth. Clofazimine has a slow bactericidal effect on Mycobacterium leprae and is active against various other Mycobacteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90729CF-40B2-B0E0-E040-BB89AD436B58","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-95F1-18F7-E053-F662850A60B1","beginDate":"2013-05-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Clobazam","valueDescription":"Clobazam","ValueMeaning":{"publicId":"3680999","version":"1","preferredName":"Clobazam","longName":"3680999v1.00","preferredDefinition":"A 1,5-benzodiazepine and partial gamma-aminobutyric acid (GABA) receptor agonist, with anxiolytic, sedative, and anticonvulsant activities. Clobazam binds to a specific site, distinct from the inhibitory neurotransmitter GABA binding site, on the benzodiazepine-GABA-A-chloride ionophore receptor complex located in the central nervous system (CNS). This binding causes an allosteric modification of the receptor and enhances the affinity of GABA to the receptor leading to an increase in the opening of chloride-channels. This leads to an increase in chloride ion conductance, neuronal hyperpolarization, inhibition of the action potential and a decrease in neuronal excitability.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clobazam","conceptCode":"C81615","definition":"A 1,5-benzodiazepine and partial gamma-aminobutyric acid (GABA) receptor agonist, with anxiolytic, sedative, and anticonvulsant activities. Clobazam binds to a specific site, distinct from the inhibitory neurotransmitter GABA binding site, on the benzodiazepine-GABA-A-chloride ionophore receptor complex located in the central nervous system (CNS). This binding causes an allosteric modification of the receptor and enhances the affinity of GABA to the receptor leading to an increase in the opening of chloride-channels. This leads to an increase in chloride ion conductance, neuronal hyperpolarization, inhibition of the action potential and a decrease in neuronal excitability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D510745F-508C-1FFA-E040-BB89AD4306DC","latestVersionIndicator":"Yes","beginDate":"2013-02-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-02-06","modifiedBy":"KUMMEROA","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-95FB-18F7-E053-F662850A60B1","beginDate":"2013-02-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ambroxol","valueDescription":"Ambroxol","ValueMeaning":{"publicId":"3690092","version":"1","preferredName":"Ambroxol","longName":"3690092","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ambroxol","conceptCode":"C74262","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D68C2697-3D53-5AFE-E040-BB89AD431E18","latestVersionIndicator":"Yes","beginDate":"2013-02-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-02-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9605-18F7-E053-F662850A60B1","beginDate":"2013-02-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cefixime","valueDescription":"Cefixime","ValueMeaning":{"publicId":"3690094","version":"1","preferredName":"Cefixime","longName":"3690094","preferredDefinition":"A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cefixime","conceptCode":"C1100","definition":"A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D68C2697-3D79-5AFE-E040-BB89AD431E18","latestVersionIndicator":"Yes","beginDate":"2013-02-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-02-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-960F-18F7-E053-F662850A60B1","beginDate":"2013-02-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Dexlansoprazole","valueDescription":"Dexlansoprazole","ValueMeaning":{"publicId":"3690096","version":"1","preferredName":"Dexlansoprazole","longName":"3690096","preferredDefinition":"The R-isomer of lansoprazole and a substituted benzimidazole prodrug with selective and irreversible proton pump inhibitor activity. As a weak base, dexlansoprazole accumulates in the acidic environment of the secretory canaliculus of the gastric parietal cell where it is converted to an active sulfenamide form that binds to cysteine sulfhydryl groups on the luminal aspect of the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase), thereby inhibiting the pump's activity and the parietal cell secretion of H+ ions into the gastric lumen, the final step in gastric acid production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dexlansoprazole","conceptCode":"C73192","definition":"The R-isomer of lansoprazole and a substituted benzimidazole prodrug with selective and irreversible proton pump inhibitor activity. As a weak base, dexlansoprazole accumulates in the acidic environment of the secretory canaliculus of the gastric parietal cell where it is converted to an active sulfenamide form that binds to cysteine sulfhydryl groups on the luminal aspect of the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase), thereby inhibiting the pump's activity and the parietal cell secretion of H+ ions into the gastric lumen, the final step in gastric acid production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D68C2697-3DA0-5AFE-E040-BB89AD431E18","latestVersionIndicator":"Yes","beginDate":"2013-02-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-02-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9619-18F7-E053-F662850A60B1","beginDate":"2013-02-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Betaxolol","valueDescription":"Betaxolol","ValueMeaning":{"publicId":"3690098","version":"1","preferredName":"Betaxolol","longName":"3690098","preferredDefinition":"A racemic mixture and selective beta-1 adrenergic receptor antagonist with antihypertensive and anti-glaucoma activities and devoid of intrinsic sympathomimetic activity. Betaxolol selectively and competitively binds to and blocks beta-1 adrenergic receptors in the heart, thereby decreasing cardiac contractility and rate. This leads to a reduction in cardiac output and lowers blood pressure. When applied topically in the eye, this agent reduces aqueous humor secretion and lowers the intraocular pressure (IOP). In addition, betaxolol prevents the release of renin, a hormone secreted by the kidneys that causes constriction of blood vessels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Betaxolol","conceptCode":"C61652","definition":"A racemic mixture and selective beta-1 adrenergic receptor antagonist with antihypertensive and anti-glaucoma activities and devoid of intrinsic sympathomimetic activity. Betaxolol selectively and competitively binds to and blocks beta-1 adrenergic receptors in the heart, thereby decreasing cardiac contractility and rate. This leads to a reduction in cardiac output and lowers blood pressure. When applied topically in the eye, this agent reduces aqueous humor secretion and lowers the intraocular pressure (IOP). In addition, betaxolol prevents the release of renin, a hormone secreted by the kidneys that causes constriction of blood vessels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D68C2697-3DC6-5AFE-E040-BB89AD431E18","latestVersionIndicator":"Yes","beginDate":"2013-02-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-02-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9623-18F7-E053-F662850A60B1","beginDate":"2013-02-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Astaxanthin","valueDescription":"Astaxanthin","ValueMeaning":{"publicId":"3690100","version":"1","preferredName":"Astaxanthin","longName":"3690100","preferredDefinition":"Carotenoid having a chemical structure similar to beta-carotene with hydroxyl groups at the number 3 and 3' carbon atoms and carbonyl (C=O) functions at the number 4 and 4' carbon atoms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Astaxanthin","conceptCode":"C63653","definition":"A natural and synthetic xanthophyll and nonprovitamin A carotenoid, with potential antioxidant, anti-inflammatory and antineoplastic activities. Upon administration, astaxanthin may act as an antioxidant and reduce oxidative stress, thereby preventing protein and lipid oxidation and DNA damage. By decreasing the production of reactive oxygen species (ROS) and free radicals, it may also prevent ROS-induced activation of nuclear factor-kappa B (NF-kB) transcription factor and the production of inflammatory cytokines such as interleukin-1beta (IL-1b), IL-6 and tumor necrosis factor-alpha (TNF-a). In addition, astaxanthin may inhibit cyclooxygenase-1 (COX-1) and nitric oxide (NO) activities, thereby reducing inflammation. Oxidative stress and inflammation play key roles in the pathogenesis of many diseases, including cardiovascular, neurological, autoimmune and neoplastic diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D68C2697-3DEC-5AFE-E040-BB89AD431E18","latestVersionIndicator":"Yes","beginDate":"2013-02-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-02-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-962D-18F7-E053-F662850A60B1","beginDate":"2013-02-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Gaviscon","valueDescription":"Gaviscon","ValueMeaning":{"publicId":"3690101","version":"1","preferredName":"Gaviscon","longName":"3690101","preferredDefinition":"Gaviscon","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D68C2697-3E0F-5AFE-E040-BB89AD431E18","latestVersionIndicator":"Yes","beginDate":"2013-02-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-02-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9637-18F7-E053-F662850A60B1","beginDate":"2013-02-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Glatiramer Acetate","valueDescription":"Glatiramer Acetate","ValueMeaning":{"publicId":"3640459","version":"1","preferredName":"Glatiramer Acetate","longName":"3640459","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glatiramer Acetate","conceptCode":"C65805","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D094D3FB-1860-9B9C-E040-BB89AD43042A","latestVersionIndicator":"Yes","beginDate":"2012-12-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-12-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9641-18F7-E053-F662850A60B1","beginDate":"2012-12-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Berbamine HCL","valueDescription":"Berbamine Hydrochloride","ValueMeaning":{"publicId":"3654561","version":"1","preferredName":"Berbamine Hydrochloride","longName":"3654561","preferredDefinition":"Berbamine Hydrochloride","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D3FA6A93-9BED-64AF-E040-BB89AD4342AF","latestVersionIndicator":"Yes","beginDate":"2013-01-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-01-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-964B-18F7-E053-F662850A60B1","beginDate":"2013-01-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Acetyl-L-Carnitine","valueDescription":"Acetyl-L-Carnitine","ValueMeaning":{"publicId":"3703292","version":"1","preferredName":"Acetyl-L-Carnitine","longName":"3703292","preferredDefinition":"A form of the natural substance carnitine that is being studied as a way to prevent tissue damage caused by chemotherapy. Carnitine is made in muscle and liver tissue and is found in certain foods, such as meat, poultry, fish, and some dairy products. It is used by many cells in the body to make energy from fat.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acetyl-L-Carnitine Hydrochloride","conceptCode":"C61624","definition":"A nutritional supplement composed of the hydrochloride salt form of the acetylated form of the endogenously produced L-carnitine, with potential neuroprotective, cognitive-enhancing, anti-depressive and immunomodulating activities. L-carnitine is responsible for the transport of fatty acids into the mitochondria for breakdown. It may also relieve peripheral neuropathy induced by chemotherapy, diabetes or other diseases. In addition, acetyl-L-carnitine may modulate the immune response by increasing T-lymphocytes maturation and may downregulate pro-inflammatory cytokines in response to viruses, such as SARS-CoV-2.  It may also disrupt the ACE2 signaling pathway and inhibit the production of reactive oxygen species (ROS).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D8BCFC94-CAEE-23A9-E040-BB89AD433C8B","latestVersionIndicator":"Yes","beginDate":"2013-03-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9655-18F7-E053-F662850A60B1","beginDate":"2013-03-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Dabigatran Etexilate Mesylate (Pradaxa)","valueDescription":"Dabigatran Etexilate Mesylate","ValueMeaning":{"publicId":"3703312","version":"1","preferredName":"Dabigatran Etexilate Mesylate","longName":"3703312","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dabigatran Etexilate Mesylate","conceptCode":"C90702","definition":"An orally available mesylate salt form of the etexilate prodrug of dabigatran, a benzimidazole and direct thrombin inhibitor with anticoagulant activity. Upon administration, dabigatran etexilate is hydrolyzed by esterases and is converted into dabigatran. Dabigatran reversibly binds to and inhibits the activity of thrombin, a serine protease that converts fibrinogen into fibrin. This disrupts the coagulation cascade and inhibits the formation of blood clots.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D8BCFC94-CB1B-23A9-E040-BB89AD433C8B","latestVersionIndicator":"Yes","beginDate":"2013-03-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-965F-18F7-E053-F662850A60B1","beginDate":"2013-03-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Brimonidine Tartrate (Alphagan-P)","valueDescription":"Brimonidine Tartrate","ValueMeaning":{"publicId":"3703314","version":"1","preferredName":"Brimonidine Tartrate","longName":"3703314","preferredDefinition":"The tartrate salt form of brimonidine, an imidazole derivative and a selective alpha-2 adrenergic receptor agonist. Upon ocular administration, brimonidine tartrate acts on the blood vessels causing them to constrict which leads to a decrease in the production of aqueous humor. Brimonidine tartrate also enhances the outflow of aqueous humor. This drug is used in the treatment of glaucoma to reduce intraocular pressure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brimonidine Tartrate","conceptCode":"C47419","definition":"The tartrate salt form of brimonidine, an imidazole derivative and a selective alpha-2 adrenergic receptor agonist. Upon ocular administration, brimonidine tartrate acts on the blood vessels causing them to constrict which leads to a decrease in the production of aqueous humor. Brimonidine tartrate also enhances the outflow of aqueous humor. This drug is used in the treatment of glaucoma to reduce intraocular pressure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D8BCFC94-CB41-23A9-E040-BB89AD433C8B","latestVersionIndicator":"Yes","beginDate":"2013-03-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9669-18F7-E053-F662850A60B1","beginDate":"2013-03-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Hydrochlorothiazide","valueDescription":"Hydrochlorothiazide","ValueMeaning":{"publicId":"3775356","version":"1","preferredName":"Hydrochlorothiazide","longName":"3775356","preferredDefinition":"The hydrogenated derivative of chlorothiazide, a thiazide diuretic with antihypertensive and anti-urolithic effects. This agent binds to the electroneutral Na-K-Cl cotransporter (NKCC) and thereby impairs Na+, K+ and Cl- reabsorption on the luminal membrane of the early segment in the distal convoluted tubule in the kidney. This leads to an increase in urinary excretion of sodium, chloride, potassium, bicarbonate and water subsequently reducing plasma and extracellular fluid volume leading to a reduction in blood pressure. Hydrochlorothiazide also decreases urinary calcium and uric acid excretion by direct action on the distal tubule.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydrochlorothiazide","conceptCode":"C29098","definition":"A short acting thiazide diuretic. Hydrochlorothiazide (HCTZ) is widely used to treat hypertension and edema. This agent's metabolite appears to preferentially bind to and accumulate in red blood cells. This agent is primarily excreted by the kidneys.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE6B3ED1-9E4E-50C6-E040-BB89AD436688","latestVersionIndicator":"Yes","beginDate":"2013-06-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9673-18F7-E053-F662850A60B1","beginDate":"2013-06-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Prazosin HCL","valueDescription":"Prazosin Hydrochloride","ValueMeaning":{"publicId":"3788432","version":"1","preferredName":"Prazosin Hydrochloride","longName":"3788432","preferredDefinition":"A synthetic piperazine derivative with hypotensive antiadrenergic properties, Prazosin Hydrochloride reduces peripheral resistance and relaxes vascular smooth muscles as a selective adrenergic alpha-1 antagonist by a mechanism not completely known. It is used in the treatment of heart failure, hypertension, pheochromocytoma, Raynaud's syndrome, prostatic hypertrophy, and urinary retention. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prazosin Hydrochloride","conceptCode":"C1507","definition":"A synthetic piperazine derivative with hypotensive antiadrenergic properties, Prazosin Hydrochloride reduces peripheral resistance and relaxes vascular smooth muscles as a selective adrenergic alpha-1 antagonist by a mechanism not completely known. It is used in the treatment of heart failure, hypertension, pheochromocytoma, Raynaud's syndrome, prostatic hypertrophy, and urinary retention. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF80FBD4-2B81-8703-E040-BB89AD4365B4","latestVersionIndicator":"Yes","beginDate":"2013-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-967D-18F7-E053-F662850A60B1","beginDate":"2013-06-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Eplerenone","valueDescription":"Eplerenone","ValueMeaning":{"publicId":"3813152","version":"1","preferredName":"Eplerenone","longName":"3813152","preferredDefinition":"A selective aldosterone receptor antagonist. Eplerenone binds to the mineralocorticoid receptor and blocks the binding of aldosterone, thereby decreasing sodium resorption and subsequently increasing water outflow. This leads to a decrease in blood pressure. Eplerenone is used in the treatment of hypertension and congestive heart failure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eplerenone","conceptCode":"C47513","definition":"A selective aldosterone receptor antagonist. Eplerenone binds to the mineralocorticoid receptor and blocks the binding of aldosterone, thereby decreasing sodium resorption and subsequently increasing water outflow. This leads to a decrease in blood pressure. Eplerenone is used in the treatment of hypertension and congestive heart failure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E1D91D2E-47D4-CFB6-E040-BB89AD434693","latestVersionIndicator":"Yes","beginDate":"2013-07-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-07-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9687-18F7-E053-F662850A60B1","beginDate":"2013-07-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Artificial Tears","valueDescription":"Carboxymethylcellulose Sodium-containing Eye Drop","ValueMeaning":{"publicId":"3777004","version":"1","preferredName":"Carboxymethylcellulose Sodium-containing Eye Drop","longName":"3777004","preferredDefinition":"An eye drop solution containing the sodium salt form of carboxymethylcellulose (CMC) used as artificial tears. Upon application of the drops into the eye, carboxymethylcellulose sodium lubricates the eye and prevents or relieves dryness and irritation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboxymethylcellulose Sodium-containing Eye Drop","conceptCode":"C106410","definition":"An eye drop solution containing the sodium salt form of carboxymethylcellulose (CMC) used as artificial tears. Upon application of the drops into the eye, carboxymethylcellulose sodium lubricates the eye and prevents or relieves dryness and irritation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DECE2246-538B-B502-E040-BB89AD4311C4","latestVersionIndicator":"Yes","beginDate":"2013-06-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-10","modifiedBy":"GDEEN","dateModified":"2022-12-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9691-18F7-E053-F662850A60B1","beginDate":"2013-06-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Amlodipine/Valsartan (Exforge)","valueDescription":"Amlodipine Valsartan Agent","ValueMeaning":{"publicId":"3693073","version":"1","preferredName":"Amlodipine Valsartan Agent","longName":"3693073","preferredDefinition":"A synthetic dihydropyridine and a calcium channel blocker with antihypertensive and antianginal properties. Amlodipine inhibits the influx of extracellular calcium ions into myocardial and peripheral vascular smooth muscle cells, thereby preventing vascular and myocardial contraction. This results in a dilatation of the main coronary and systemic arteries, decreased myocardial contractility, increased blood flow and oxygen delivery to the myocardial tissue, and decreased total peripheral resistance. This agent may also modulate multi-drug response (MDR) activity through inhibition of the p-glycoprotein efflux pump.: An orally active nonpeptide triazole-derived antagonist of angiotensin (AT) II with antihypertensive properties. Valsartan selectively and competitively blocks the binding of angiotensin II to the AT1 subtype receptor in vascular smooth muscle and the adrenal gland, preventing AT II-mediated vasoconstriction, aldosterone synthesis and secretion, and renal reabsorption of sodium, and resulting in vasodilation, increased excretion of sodium and water, a reduction in plasma volume, and a reduction in blood pressure.: An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amlodipine","conceptCode":"C61635","definition":"A synthetic dihydropyridine and a calcium channel blocker with antihypertensive and antianginal properties. Amlodipine inhibits the influx of extracellular calcium ions into myocardial and peripheral vascular smooth muscle cells, thereby preventing vascular and myocardial contraction. This results in a dilatation of the main coronary and systemic arteries, decreased myocardial contractility, increased blood flow and oxygen delivery to the myocardial tissue, and decreased total peripheral resistance. This agent may also modulate multi-drug resistance (MDR) activity through inhibition of the p-glycoprotein efflux pump.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Valsartan","conceptCode":"C47781","definition":"An orally active nonpeptide triazole-derived antagonist of angiotensin (AT) II with antihypertensive properties. Valsartan selectively and competitively blocks the binding of angiotensin II to the AT1 subtype receptor in vascular smooth muscle and the adrenal gland, preventing AT II-mediated vasoconstriction, aldosterone synthesis and secretion, and renal reabsorption of sodium, and resulting in vasodilation, increased excretion of sodium and water, a reduction in plasma volume, and a reduction in blood pressure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D7327E13-E0E4-AC03-E040-BB89AD431BB7","latestVersionIndicator":"Yes","beginDate":"2013-03-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-03-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-969B-18F7-E053-F662850A60B1","beginDate":"2013-03-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Nepafenac","valueDescription":"Nepafenac","ValueMeaning":{"publicId":"3813672","version":"1","preferredName":"Nepafenac","longName":"3813672","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nepafenac","conceptCode":"C66228","definition":"A topical nonsteroidal anti-inflammatory drug that is used in eye drops for the treatment of eye pain and swelling.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E22CB539-3A4C-765C-E040-BB89AD431F51","latestVersionIndicator":"Yes","beginDate":"2013-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-96A5-18F7-E053-F662850A60B1","beginDate":"2013-07-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Clorazepate","valueDescription":"Clorazepate Dipotassium","ValueMeaning":{"publicId":"3813674","version":"1","preferredName":"Clorazepate Dipotassium","longName":"3813674","preferredDefinition":"A benzodiazepine with anxiolytic, sedative, hypnotic, and anticonvulsant properties. Clorazepate dipotassium exerts its effect by de-activating the nervous system through potentiation of the inhibitory effect of gamma-aminobutyric acid (GABA) on the GABA-A receptors by binding to a site that is distinct from the GABA binding site. Its inhibitory effect is caused by an increase in GABA-mediated chloride channel opening events, leading to hyperpolarization and synaptic inhibition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clorazepate Dipotassium","conceptCode":"C47459","definition":"A benzodiazepine with anxiolytic, sedative, hypnotic, and anticonvulsant properties. Clorazepate dipotassium exerts its effect by de-activating the nervous system through potentiation of the inhibitory effect of gamma-aminobutyric acid (GABA) on the GABA-A receptors by binding to a site that is distinct from the GABA binding site. Its inhibitory effect is caused by an increase in GABA-mediated chloride channel opening events, leading to hyperpolarization and synaptic inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E22CB539-3A73-765C-E040-BB89AD431F51","latestVersionIndicator":"Yes","beginDate":"2013-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-96AF-18F7-E053-F662850A60B1","beginDate":"2013-07-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lisinopril/Hydrochlorothiazide (Zestoretic; Prinizide)","valueDescription":"Lisinopril/Hydrochlorothiazide (Zestoretic; Prinizide)","ValueMeaning":{"publicId":"3775412","version":"1","preferredName":"Lisinopril/Hydrochlorothiazide (Zestoretic; Prinizide)","longName":"3775412","preferredDefinition":"A synthetic peptide derivate and long-acting angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. Lisinopril specifically and competitively inhibits angiotensin-converting enzyme thereby decreasing the formation of the potent vasoconstrictor angiotensin II. This leads to a diminished vasopressor activity. In addition, angiotensin II-stimulated aldosterone secretion by adrenal cortex is decreased which results in a decrease of sodium and water retention and an increase of serum potassium.: The hydrogenated derivative of chlorothiazide, a thiazide diuretic with antihypertensive and anti-urolithic effects. This agent binds to the electroneutral Na-K-Cl cotransporter (NKCC) and thereby impairs Na+, K+ and Cl- reabsorption on the luminal membrane of the early segment in the distal convoluted tubule in the kidney. This leads to an increase in urinary excretion of sodium, chloride, potassium, bicarbonate and water subsequently reducing plasma and extracellular fluid volume leading to a reduction in blood pressure. Hydrochlorothiazide also decreases urinary calcium and uric acid excretion by direct action on the distal tubule.: The act or process of developing or preparing a mixture of ingredients to create a desired end drug product, such as a specific flavor, aroma, or polymer; or the desired final drug product itself; also, a listing of the ingredients and composition of the dosage form.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lisinopril","conceptCode":"C29159","definition":"An orally bioavailable, long-acting angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. Lisinopril, a synthetic peptide derivative, specifically and competitively inhibits ACE, which results in a decrease in the production of the potent vasoconstrictor angiotensin II and, so, diminished vasopressor activity. In addition, angiotensin II-stimulated aldosterone secretion by the adrenal cortex is decreased which results in a decrease in sodium and water retention and an increase in serum potassium.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Hydrochlorothiazide","conceptCode":"C29098","definition":"A short acting thiazide diuretic. Hydrochlorothiazide (HCTZ) is widely used to treat hypertension and edema. This agent's metabolite appears to preferentially bind to and accumulate in red blood cells. This agent is primarily excreted by the kidneys.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Drug Formulation Process","conceptCode":"C15653","definition":"The act or process of developing or preparing a mixture of ingredients to create a desired end drug product, such as a specific flavor, aroma, or polymer; or the desired final drug product itself; also, a listing of the ingredients and composition of the dosage form.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE6F63E2-570A-1683-E040-BB89AD430425","latestVersionIndicator":"Yes","beginDate":"2013-06-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-96B9-18F7-E053-F662850A60B1","beginDate":"2013-06-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Armodafinil","valueDescription":"Armodafinil","ValueMeaning":{"publicId":"3729834","version":"1","preferredName":"Armodafinil","longName":"3729834","preferredDefinition":"The R-enantiomer of the racemic synthetic agent modafinil with central nervous system (CNS) stimulant and wakefulness-promoting activities. Although the exact mechanism of action has yet to be fully elucidated, armodafinil appears to inhibit the reuptake of dopamine by binding to the dopamine-reuptake pump, which leads to an increase in extracellular dopamine levels in some brain regions. This agent does not bind to or inhibit several receptors and enzymes that may be involved in sleep/wake regulation and is not a direct- or indirect-acting dopamine receptor agonist. Armodafinil has a longer half-life than modafinil.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Armodafinil","conceptCode":"C65241","definition":"The R-enantiomer of the racemic synthetic agent modafinil with central nervous system (CNS) stimulant and wakefulness-promoting activities. Although the exact mechanism of action has yet to be fully elucidated, armodafinil appears to inhibit the reuptake of dopamine by binding to the dopamine-reuptake pump, which leads to an increase in extracellular dopamine levels in some brain regions. This agent does not bind to or inhibit several receptors and enzymes that may be involved in sleep/wake regulation and is not a direct- or indirect-acting dopamine receptor agonist. Armodafinil has a longer half-life than modafinil.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB321644-EB53-7538-E040-BB89AD4353DB","latestVersionIndicator":"Yes","beginDate":"2013-04-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-04-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-96C3-18F7-E053-F662850A60B1","beginDate":"2013-04-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fluvoxamine Maleate","valueDescription":"Fluvoxamine Maleate","ValueMeaning":{"publicId":"2576875","version":"1","preferredName":"Fluvoxamine Maleate","longName":"2576875","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluvoxamine Maleate","conceptCode":"C29063","definition":"The maleate salt form of fluvoxamine, a 2-aminoethyl oxime ether of aralkylketones, with antidepressant, antiobsessive-compulsive, and antibulimic activities. Fluvoxamine blocks serotonin reuptake by inhibiting the serotonin reuptake pump of the presynaptic neuronal membrane leading to an increase of serotonin levels within the synaptic cleft. This results in facilitated serotonergic transmission and decreased serotonin turnover leading to antidepressant and antiobsessive-compulsive effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F958-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7B57-18F7-E053-F662850A60B1","beginDate":"2006-02-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Folic Acid","valueDescription":"Folic Acid","ValueMeaning":{"publicId":"2569629","version":"1","preferredName":"Folic Acid","longName":"2569629","preferredDefinition":"A collective term for pteroylglutamic acids and their oligoglutamic acid conjugates. As a natural water-soluble substance, folic acid is involved in carbon transfer reactions of amino acid metabolism, in addition to purine and pyrimidine synthesis, and is essential for hematopoiesis and red blood cell production. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Folic Acid","conceptCode":"C510","definition":"A collective term for pteroylglutamic acids and their oligoglutamic acid conjugates. As a natural water-soluble substance, folic acid is involved in carbon transfer reactions of amino acid metabolism, in addition to purine and pyrimidine synthesis, and is essential for hematopoiesis and red blood cell production. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DD0A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-05-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-05-20","modifiedBy":"ONEDATA_WA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7B61-18F7-E053-F662850A60B1","beginDate":"2006-02-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Folinic Acid","valueDescription":"Leucovorin Calcium","ValueMeaning":{"publicId":"2576876","version":"1","preferredName":"Leucovorin Calcium","longName":"2576876","preferredDefinition":"An active metabolite of folic acid (also called folinic acid and citrovorum factor), which does not require metabolism by dihydrofolate reductase, the molecular target of folate antagonist-type chemotherapeutic drugs.  Leucovorin calcium counteracts the toxic effects of these medications, 'rescuing' the patient while permitting the antitumor activity of the folate antagonist. This agent also potentiates the effects of fluorouracil and its derivatives by stabilizing the binding of the drug's metabolite to its target enzyme, thus prolonging drug activity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leucovorin Calcium","conceptCode":"C607","definition":"An active metabolite of folic acid (also called folinic acid and citrovorum factor), which does not require metabolism by dihydrofolate reductase, the molecular target of folate antagonist-type chemotherapeutic drugs.  Leucovorin calcium counteracts the toxic effects of these medications, 'rescuing' the patient while permitting the antitumor activity of the folate antagonist. This agent also potentiates the effects of fluorouracil and its derivatives by stabilizing the binding of the drug's metabolite to its target enzyme, thus prolonging drug activity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F959-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7B6B-18F7-E053-F662850A60B1","beginDate":"2006-02-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fondaparinux","valueDescription":"fondaparinux","ValueMeaning":{"publicId":"2577874","version":"1","preferredName":"fondaparinux","longName":"2577874v1.00","preferredDefinition":"A synthetic glucopyranoside with antithrombotic activity. Fondaparinux selectively binds to antithrombin III, thereby potentiating the innate neutralization of activated factor X (Factor Xa) by antithrombin. Neutralization of Factor Xa inhibits its activity and interrupts the blood coagulation cascade, thereby preventing thrombin formation and thrombus development.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fondaparinux","conceptCode":"C73142","definition":"A synthetic glucopyranoside with antithrombotic activity. Fondaparinux selectively binds to antithrombin III, thereby potentiating the innate neutralization of activated factor X (Factor Xa) by antithrombin. Neutralization of Factor Xa inhibits its activity and interrupts the blood coagulation cascade, thereby preventing thrombin formation and thrombus development.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD3F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-22","modifiedBy":"KUMMEROA","dateModified":"2023-09-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7B75-18F7-E053-F662850A60B1","beginDate":"2006-02-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Flecainide","valueDescription":"Flecainide","ValueMeaning":{"publicId":"3729832","version":"1","preferredName":"Flecainide","longName":"3729832","preferredDefinition":"A synthetic agent derived from trifluoroethoxy-benzamide exhibiting antiarrhythmic and local anesthetic activity. As a class Ic antiarrhythmic that blocks sodium channels, flecainide depresses polarization phase 0 and decreases the induction velocity of the His-Purkinje system. It also decreases phase 4 slope and increases the depolarization threshold. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Flecainide","conceptCode":"C62029","definition":"A synthetic agent derived from trifluoroethoxy-benzamide exhibiting antiarrhythmic and local anesthetic activity. As a class Ic antiarrhythmic that blocks sodium channels, flecainide depresses polarization phase 0 and decreases the induction velocity of the His-Purkinje system. It also decreases phase 4 slope and increases the depolarization threshold. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB321644-EB2D-7538-E040-BB89AD4353DB","latestVersionIndicator":"Yes","beginDate":"2013-04-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-04-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-96CD-18F7-E053-F662850A60B1","beginDate":"2013-04-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Vilazodone","valueDescription":"Vilazodone","ValueMeaning":{"publicId":"3729836","version":"1","preferredName":"Vilazodone","longName":"3729836","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vilazodone","conceptCode":"C90716","definition":"A selective serotonin (5-HT) reuptake inhibitor (SSRI) and a 5-HT-1A receptor partial agonist, with antidepressant and anti-anxiety activities. Vilazodone inhibits the reuptake of serotonin from the synaptic cleft while stimulating the release of 5-HT into the synaptic cleft. This increases the concentration of 5-HT in the synaptic cleft and potentiates serotonergic neurotransmission in the central nervous system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB321644-EB79-7538-E040-BB89AD4353DB","latestVersionIndicator":"Yes","beginDate":"2013-04-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-04-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-96D7-18F7-E053-F662850A60B1","beginDate":"2013-04-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fesoterodine Fumarate","valueDescription":"Fesoterodine Fumarate","ValueMeaning":{"publicId":"3926150","version":"1","preferredName":"Fesoterodine Fumarate","longName":"3926150","preferredDefinition":"The fumarate salt form of fesoterodine, a competitive muscarinic receptor antagonist with muscle relaxant and urinary antispasmodic properties. Fesoterodine is rapidly hydrolyzed in vivo into its active metabolite 5-hydroxy methyl tolterodine, which binds and inhibits muscarinic receptors on the bladder detrusor muscle, thereby preventing bladder contractions or spasms caused by acetylcholine. This results in the relaxation of bladder smooth muscle and greater bladder capacity, in addition to a reduction in involuntary muscle contractions and involuntary loss of urine. The active metabolite does not interact with alpha-adrenergic, serotonergic, histaminergic and excitatory amino acid receptors and is eliminated via renal excretion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fesoterodine Fumarate","conceptCode":"C72779","definition":"The fumarate salt form of fesoterodine, a competitive muscarinic receptor antagonist with muscle relaxant and urinary antispasmodic properties. Fesoterodine is rapidly hydrolyzed in vivo into its active metabolite 5-hydroxy methyl tolterodine, which binds and inhibits muscarinic receptors on the bladder detrusor muscle, thereby preventing bladder contractions or spasms caused by acetylcholine. This results in the relaxation of bladder smooth muscle and greater bladder capacity, in addition to a reduction in involuntary muscle contractions and involuntary loss of urine. The active metabolite does not interact with alpha-adrenergic, serotonergic, histaminergic and excitatory amino acid receptors and is eliminated via renal excretion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9572018-9D0D-3743-E040-BB89AD43170D","latestVersionIndicator":"Yes","beginDate":"2013-10-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-10-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-96E1-18F7-E053-F662850A60B1","beginDate":"2013-10-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Trihexyphenidyl","valueDescription":"Trihexyphenidyl Hydrochloride","ValueMeaning":{"publicId":"3835823","version":"1","preferredName":"Trihexyphenidyl Hydrochloride","longName":"3835823","preferredDefinition":"The hydrochloride salt form of trihexyphenidyl, a synthetic, substituted piperidine with parasympatholytic activity used mostly in Parkinson's disease. Trihexyphenidyl hydrochloride antagonizes activities of acetylcholine via muscarinic receptors. This balances the cholinergic and dopaminergic activity in the basal ganglia leading to an improvement of classic Parkinson symptoms such as rigidity and tremor. In addition, trihexyphenidyl hydrochloride exerts a direct antispasmodic effect on smooth muscle.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trihexyphenidyl Hydrochloride","conceptCode":"C47771","definition":"The hydrochloride salt form of trihexyphenidyl, a synthetic, substituted piperidine with parasympatholytic activity used mostly in Parkinson's disease. Trihexyphenidyl hydrochloride antagonizes activities of acetylcholine via muscarinic receptors. This balances the cholinergic and dopaminergic activity in the basal ganglia leading to an improvement of classic Parkinson symptoms such as rigidity and tremor. In addition, trihexyphenidyl hydrochloride exerts a direct antispasmodic effect on smooth muscle.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E2E72669-F8D2-E72F-E040-BB89AD436C77","latestVersionIndicator":"Yes","beginDate":"2013-08-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-08-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-96EB-18F7-E053-F662850A60B1","beginDate":"2013-08-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Rivastigmine Tartrate","valueDescription":"Rivastigmine Tartrate","ValueMeaning":{"publicId":"3856592","version":"1","preferredName":"Rivastigmine Tartrate","longName":"3856592","preferredDefinition":"The tartrate salt form of rivastigmine, a phenylcarbamate derivative exhibiting cognitive stimulating property. Although the mechanism of action has not been fully elucidated, rivastigmine tartrate may bind reversibly to cholinesterase, thereby decreasing the breakdown of acetylcholine and enhancing cholinergic function.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rivastigmine Tartrate","conceptCode":"C47707","definition":"The tartrate salt form of rivastigmine, a phenylcarbamate derivative exhibiting cognitive stimulating property. Although the mechanism of action has not been fully elucidated, rivastigmine tartrate may bind reversibly to cholinesterase, thereby decreasing the breakdown of acetylcholine and enhancing cholinergic function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E4164DC7-4786-D69B-E040-BB89AD431DE9","latestVersionIndicator":"Yes","beginDate":"2013-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-96FF-18F7-E053-F662850A60B1","beginDate":"2013-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Azilsartan Medoxomil","valueDescription":"Azilsartan Medoxomil","ValueMeaning":{"publicId":"3856594","version":"1","preferredName":"Azilsartan Medoxomil","longName":"3856594","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Azilsartan Medoxomil","conceptCode":"C75110","definition":"A medoxomil prodrug of azilsartan, an angiotensin II receptor antagonist with antihypertensive activity. Upon hydrolysis, azilsartan selectively and competitively binds to the AT1 subtype angiotensin II receptor and blocks the binding of angiotensin II to the receptor, thus promoting vasodilatation and counteracting the effects of aldosterone. Converted from angiotensin I by angiotensin-converting enzyme (ACE), angiotensin II stimulates the adrenal cortex to synthesize and secrete aldosterone, decreasing sodium excretion and increasing potassium excretion, and acts as a vasoconstrictor in vascular smooth muscle.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E4164DC7-47AC-D69B-E040-BB89AD431DE9","latestVersionIndicator":"Yes","beginDate":"2013-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9709-18F7-E053-F662850A60B1","beginDate":"2013-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Aminophylline","valueDescription":"Aminophylline","ValueMeaning":{"publicId":"3896162","version":"1","preferredName":"Aminophylline","longName":"3896162","preferredDefinition":"A methylxanthine and derivative of theophylline. Aminophylline relaxes smooth muscles, particularly bronchial muscles. This xanthine most likely exerts its effect by inhibiting cAMP or cGMP phosphodiesterases, thereby increasing levels of the second messenger cAMP or cGMP intracellularly. Other mode of actions include an adenosine antagonistic effect on the activity of CD4 lymphocytes and mediator release from mast cells thereby decreasing lung sensitivity to allergens and other substances that cause inflammation. Aminophylline also acts as a CNS stimulant and exerts a positive chronotropic and inotropic effect on the heart.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aminophylline","conceptCode":"C47393","definition":"A methylxanthine and derivative of theophylline. Aminophylline relaxes smooth muscles, particularly bronchial muscles. This xanthine most likely exerts its effect by inhibiting cAMP or cGMP phosphodiesterases, thereby increasing levels of the second messenger cAMP or cGMP intracellularly. Other mode of actions include an adenosine antagonistic effect on the activity of CD4 lymphocytes and mediator release from mast cells thereby decreasing lung sensitivity to allergens and other substances that cause inflammation. Aminophylline also acts as a CNS stimulant and exerts a positive chronotropic and inotropic effect on the heart.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E64364A0-92C3-41BB-E040-BB89AD4328F8","latestVersionIndicator":"Yes","beginDate":"2013-09-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9713-18F7-E053-F662850A60B1","beginDate":"2013-09-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Nateglinide","valueDescription":"Nateglinide","ValueMeaning":{"publicId":"3896164","version":"1","preferredName":"Nateglinide","longName":"3896164","preferredDefinition":"A phenylalanine derivative of the meglitinide class of agents with hypoglycemic activity. Nateglinide, compared to repaglitinide, binds with a higher affinity to the SUR1 subunit and with a faster onset of action and a shorter duration of action. This agent is metabolized by the cytochrome P450 isoenzyme CYP2C9, and, to a lesser extent, by CYP3A4. The parent drug and metabolites are mainly excreted in the urine and its half-life is about 1.5 hours.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nateglinide","conceptCode":"C61858","definition":"A phenylalanine derivative of the meglitinide class of agents with hypoglycemic activity. Nateglinide, compared to repaglitinide, binds with a higher affinity to the SUR1 subunit and with a faster onset of action and a shorter duration of action. This agent is metabolized by the cytochrome P450 isoenzyme CYP2C9, and, to a lesser extent, by CYP3A4. The parent drug and metabolites are mainly excreted in the urine and its half-life is about 1.5 hours.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E64364A0-92E9-41BB-E040-BB89AD4328F8","latestVersionIndicator":"Yes","beginDate":"2013-09-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-971D-18F7-E053-F662850A60B1","beginDate":"2013-09-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Succinylcholine Chloride","valueDescription":"Succinylcholine Chloride","ValueMeaning":{"publicId":"3896166","version":"1","preferredName":"Succinylcholine Chloride","longName":"3896166","preferredDefinition":"The chloride salt form of succinylcholine, a quaternary ammonium compound and depolarizing agent with short-term muscle relaxant properties. Succinylcholine chloride binds to nicotinic receptors at the neuromuscular junction and opening the ligand-gated channels in the same way as acetylcholine, resulting in depolarization and inhibition of neuromuscular transmission. Depolarization may be prolonged due to succinylcholine's resistance to acetylcholinesterases thereby leading to disorganized muscle contraction followed by skeletal muscle relaxation and flaccid paralysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Succinylcholine Chloride","conceptCode":"C47730","definition":"The chloride salt form of succinylcholine, a quaternary ammonium compound and depolarizing agent with short-term muscle relaxant properties. Succinylcholine chloride binds to nicotinic receptors at the neuromuscular junction and opening the ligand-gated channels in the same way as acetylcholine, resulting in depolarization and inhibition of neuromuscular transmission. Depolarization may be prolonged due to succinylcholine's resistance to acetylcholinesterases thereby leading to disorganized muscle contraction followed by skeletal muscle relaxation and flaccid paralysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E64364A0-930F-41BB-E040-BB89AD4328F8","latestVersionIndicator":"Yes","beginDate":"2013-09-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9727-18F7-E053-F662850A60B1","beginDate":"2013-09-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Tafluprost","valueDescription":"Tafluprost","ValueMeaning":{"publicId":"3896168","version":"1","preferredName":"Tafluprost","longName":"3896168","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tafluprost","conceptCode":"C87385","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E64364A0-9335-41BB-E040-BB89AD4328F8","latestVersionIndicator":"Yes","beginDate":"2013-09-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9731-18F7-E053-F662850A60B1","beginDate":"2013-09-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Cyclophosphamide","valueDescription":"Cyclophosphamide","ValueMeaning":{"publicId":"2757911","version":"1","preferredName":"Cyclophosphamide","longName":"2757911","preferredDefinition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F5148FD-83F7-3F65-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-06-10","modifiedBy":"KUMMEROA","dateModified":"2022-09-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-973B-18F7-E053-F662850A60B1","beginDate":"2013-12-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Mefloquine","valueDescription":"Mefloquine","ValueMeaning":{"publicId":"4144094","version":"1","preferredName":"Mefloquine","longName":"4144094","preferredDefinition":"A quinolinemethanol derivative with antimalarial, anti-inflammatory, and potential chemosensitization and radiosensitization activities. Although the exact mechanism remains to be elucidated, mefloquine, a weak base, preferentially accumulates in lysosomes and disrupts lysosomal function and integrity, thereby leading to host cell death. Similar to chloroquine, the chemosensitizing and radiosensitizing activities of this agent may be related to its inhibition of autophagocytosis, a cellular mechanism involving lysosomal degradation that minimizes the production of reactive oxygen species (ROS) related to tumor reoxygenation and tumor exposure to chemotherapeutic agents and radiation. Compared to chloroquine, mefloquine has better blood-brain-barrier (BBB) penetration.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mefloquine","conceptCode":"C61827","definition":"A quinolinemethanol derivative with antimalarial, anti-inflammatory, and potential chemosensitization and radiosensitization activities. Although the exact mechanism remains to be elucidated, mefloquine, a weak base, preferentially accumulates in lysosomes and disrupts lysosomal function and integrity, thereby leading to host cell death. Similar to chloroquine, the chemosensitizing and radiosensitizing activities of this agent may be related to its inhibition of autophagocytosis, a cellular mechanism involving lysosomal degradation that minimizes the production of reactive oxygen species (ROS) related to tumor reoxygenation and tumor exposure to chemotherapeutic agents and radiation. Compared to chloroquine, mefloquine has better blood-brain-barrier (BBB) penetration.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F1D7010F-7A75-24D9-E040-BB89AD437B67","latestVersionIndicator":"Yes","beginDate":"2014-02-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-02-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9745-18F7-E053-F662850A60B1","beginDate":"2014-02-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Pomalidomide","valueDescription":"Pomalidomide","ValueMeaning":{"publicId":"3944871","version":"1","preferredName":"Pomalidomide","longName":"3944871","preferredDefinition":"An orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). In addition, pomalidomide may inhibit tumor angiogenesis, promote cell cycle arrest in susceptible tumor cell populations, and stimulate erythropoeisis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pomalidomide","conceptCode":"C72560","definition":"An orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). In addition, pomalidomide may inhibit tumor angiogenesis, promote cell cycle arrest in susceptible tumor cell populations, and stimulate erythropoeisis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA60336B-F055-AE12-E040-BB89AD435C63","latestVersionIndicator":"Yes","beginDate":"2013-11-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-11-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-974F-18F7-E053-F662850A60B1","beginDate":"2013-11-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Basiliximab","valueDescription":"Basiliximab","ValueMeaning":{"publicId":"3944873","version":"1","preferredName":"Basiliximab","longName":"3944873","preferredDefinition":"A recombinant, chimeric, human-murine monoclonal antibody directed against the alpha subunit of the interleukin-2 receptor (IL-2R alpha) with immunosuppressant activity. Basiliximab selectively binds to and blocks IL-2R alpha, expressed on the surface of activated T-lymphocytes, thereby preventing interleukin-2 binding and inhibiting the interleukin-2-mediated activation of lymphocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Basiliximab","conceptCode":"C52186","definition":"A recombinant, chimeric, human-murine monoclonal antibody directed against the alpha subunit of the interleukin-2 receptor (IL-2R alpha) with immunosuppressant activity. Basiliximab selectively binds to and blocks IL-2R alpha, expressed on the surface of activated T-lymphocytes, thereby preventing interleukin-2 binding and inhibiting the interleukin-2-mediated activation of lymphocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA60336B-F07B-AE12-E040-BB89AD435C63","latestVersionIndicator":"Yes","beginDate":"2013-11-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-11-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9759-18F7-E053-F662850A60B1","beginDate":"2013-11-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Methoxsalen","valueDescription":"Methoxsalen","ValueMeaning":{"publicId":"3944875","version":"1","preferredName":"Methoxsalen","longName":"3944875","preferredDefinition":"A naturally occurring substance isolated from the seeds of the plant Ammi majus with photoactivating properties.  As a member of the family of compounds known as psoralens or furocoumarins, methoxsalen's exact mechanism of action is unknown; upon photoactivation, methoxsalen has been observed to bind covalently to and crosslink DNA. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methoxsalen","conceptCode":"C643","definition":"A naturally occurring substance isolated from the seeds of the plant Ammi majus with photoactivating properties.  As a member of the family of compounds known as psoralens or furocoumarins, methoxsalen's exact mechanism of action is unknown; upon photoactivation, methoxsalen has been observed to bind covalently to and crosslink DNA. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA60336B-F0A1-AE12-E040-BB89AD435C63","latestVersionIndicator":"Yes","beginDate":"2013-11-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-11-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9763-18F7-E053-F662850A60B1","beginDate":"2013-11-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Desonide","valueDescription":"Desonide","ValueMeaning":{"publicId":"3944876","version":"1","preferredName":"Desonide","longName":"3944876","preferredDefinition":"A synthetic glucocorticosteroid for topical use, with anti-inflammatory activity. Desonide binds to glucocorticoid receptors in the cytoplasm, and the ligand-receptor complex is translocated as a homodimer into the nucleus, where transcription activation via glucocorticoid response elements within glucocorticoid-responsive genes occur. This agent induces transcription of genes coding for anti-inflammatory proteins, including lipocortin-1, interleukin-10, interleukin-1 receptor antagonist and neutral endopeptidase. Increased synthesis of lipocortin-1 has an inhibitory effect on phospholipase A2, which in turn inhibits the release arachidonic acid, thereby controlling the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Desonide","conceptCode":"C61702","definition":"A synthetic glucocorticosteroid for topical use, with anti-inflammatory activity. Desonide binds to glucocorticoid receptors in the cytoplasm, and the ligand-receptor complex is translocated as a homodimer into the nucleus, where transcription activation via glucocorticoid response elements within glucocorticoid-responsive genes occur. This agent induces transcription of genes coding for anti-inflammatory proteins, including lipocortin-1, interleukin-10, interleukin-1 receptor antagonist and neutral endopeptidase. Increased synthesis of lipocortin-1 has an inhibitory effect on phospholipase A2, which in turn inhibits the release arachidonic acid, thereby controlling the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA60336B-F0C4-AE12-E040-BB89AD435C63","latestVersionIndicator":"Yes","beginDate":"2013-11-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-11-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-976D-18F7-E053-F662850A60B1","beginDate":"2013-11-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Palifermin","valueDescription":"Palifermin","ValueMeaning":{"publicId":"2769629","version":"1","preferredName":"Palifermin","longName":"2769629","preferredDefinition":"A recombinant form of the endogenous human keratinocyte growth factor with cell growth promoting activity. Palifermin acts in the manner similar to the endogenous keratinocyte growth factor that binds to keratinocyte growth factor receptors on the epithelial cell surface in the lining of mouth and gastrointestinal tract. This results in stimulation of epithelial cell proliferation, differentiation and upregulation of cytoprotective mechanisms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Palifermin","conceptCode":"C2455","definition":"A recombinant form of the endogenous human keratinocyte growth factor with cell growth promoting activity. Palifermin acts in the manner similar to the endogenous keratinocyte growth factor that binds to keratinocyte growth factor receptors on the epithelial cell surface in the lining of mouth and gastrointestinal tract. This results in stimulation of epithelial cell proliferation, differentiation and upregulation of cytoprotective mechanisms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"53415CE1-9809-4013-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CZECHS","dateCreated":"2008-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9777-18F7-E053-F662850A60B1","beginDate":"2013-11-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Nitazoxanide","valueDescription":"Nitazoxanide","ValueMeaning":{"publicId":"3944878","version":"1","preferredName":"Nitazoxanide","longName":"3944878","preferredDefinition":"A synthetic benzamide with antiprotozoal activity. Nitazoxanide exerts its antiprotozoal activity by interfering with the pyruvate ferredoxin/flavodoxin oxidoreductase dependent electron transfer reaction, which is essential to anaerobic energy metabolism. PFOR enzyme reduces nitazoxanide, thereby impairing the energy metabolism. However, interference with the PFOR enzyme-dependent electron transfer reaction may not be the only pathway by which nitazoxanide exhibits antiprotozoal activity. Nitazoxanide is active against Giardia lamblia and Cryptosporidium parvum.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nitazoxanide","conceptCode":"C47637","definition":"A synthetic benzamide with antiprotozoal activity. Nitazoxanide exerts its antiprotozoal activity by interfering with the pyruvate ferredoxin/flavodoxin oxidoreductase dependent electron transfer reaction, which is essential to anaerobic energy metabolism. PFOR enzyme reduces nitazoxanide, thereby impairing the energy metabolism. However, interference with the PFOR enzyme-dependent electron transfer reaction may not be the only pathway by which nitazoxanide exhibits antiprotozoal activity. Nitazoxanide is active against Giardia lamblia and Cryptosporidium parvum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA60336B-F0FE-AE12-E040-BB89AD435C63","latestVersionIndicator":"Yes","beginDate":"2013-11-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-11-04","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9781-18F7-E053-F662850A60B1","beginDate":"2013-11-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine","valueDescription":"Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine","ValueMeaning":{"publicId":"3944880","version":"1","preferredName":"Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine","longName":"3944880","preferredDefinition":"A non-infectious recombinant, quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid (L1) protein of human papillomavirus (HPV) types 6, 11, 16, and 18 with immunoprophylactic activity. L1 proteins are produced by separate fermentations in recombinant Saccharomyces cerevisiae, self-assembled into VLPs, and adsorbed onto amorphous aluminium hydroxyphosphate sulfate adjuvant following purification. The immunoprophylactic efficacy of L1 VLP vaccines, such as quadrivalent human papillomavirus (types 6,11,16,18) recombinant vaccine, appear to be mediated by the development of humoral immune responses. HPV Types 16 and 18 account for approximately 70% of cervical cancers and HPV Types 6 and 11 account for approximately 90% of genital warts.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine","conceptCode":"C61087","definition":"A non-infectious recombinant, quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid (L1) protein of human papillomavirus (HPV) types 6, 11, 16, and 18 with immunoprophylactic activity. L1 proteins are produced by separate fermentations in recombinant Saccharomyces cerevisiae, self-assembled into VLPs, and adsorbed onto amorphous aluminium hydroxyphosphate sulfate adjuvant following purification. The immunoprophylactic efficacy of L1 VLP vaccines, such as quadrivalent human papillomavirus (types 6,11,16,18) recombinant vaccine, appear to be mediated by the development of humoral immune responses. HPV Types 16 and 18 account for approximately 70% of cervical cancers and HPV Types 6 and 11 account for approximately 90% of genital warts.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA60336B-F124-AE12-E040-BB89AD435C63","latestVersionIndicator":"Yes","beginDate":"2013-11-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-11-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-978B-18F7-E053-F662850A60B1","beginDate":"2013-11-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lenalidomide","valueDescription":"Lenalidomide","ValueMeaning":{"publicId":"3379210","version":"1","preferredName":"Lenalidomide","longName":"3379210","preferredDefinition":"A thalidomide analog with potential antineoplastic activity.  Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis.  This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lenalidomide","conceptCode":"C2668","definition":"A thalidomide analog with potential antineoplastic activity.  Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis.  This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B918227F-B2FA-6EA7-E040-BB89AD434A76","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9795-18F7-E053-F662850A60B1","beginDate":"2013-11-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Xerese","valueDescription":"Xerese (Acyclovir/Hydrocortisone Cream)","ValueMeaning":{"publicId":"3947775","version":"1","preferredName":"Xerese (Acyclovir/Hydrocortisone Cream)","longName":"3947775","preferredDefinition":"A synthetic analog of the purine nucleoside, guanosine, with potent antiviral activity against herpes simplex viruses type 1 and 2, varicella-zoster virus and other viruses.  After conversion in vitro to the active metabolite acyclovir triphosphate, acyclovir competitively inhibits viral DNA polymerase, incorporates into and terminates the growing viral DNA chain, and inactivates viral DNA polymerase. The greater antiviral activity of acyclovir against HSV compared to VZV is due to its more efficient phosphorylation by the thymidine kinase of HSV. (NCI04): A hormone made by the adrenal cortex (the outer layer of the adrenal gland). It helps the body use glucose (a sugar), protein, and fats. Cortisol made in the laboratory is called hydrocortisone. It is used to treat many conditions, including inflammation, allergies, and some cancers. Cortisol is a type of glucocorticoid hormone.: A semisolid emulsion of either the oil-in-water or the water-in-oil type, ordinarily intended for topical use. (On-line Medical Dictionary)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acyclovir","conceptCode":"C205","definition":"A synthetic analog of the purine nucleoside, guanosine, with potent antiviral activity against herpes simplex viruses type 1 and 2, varicella-zoster virus and other viruses of the herpesvirus family. After conversion in vivo to the active metabolite acyclovir triphosphate by viral thymidine kinase, acyclovir competitively inhibits viral DNA polymerase by incorporating into the growing viral DNA chain and terminating further polymerization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cortisol","conceptCode":"C2290","definition":"A hormone made by the adrenal cortex (the outer layer of the adrenal gland). It helps the body use glucose (a sugar), protein, and fats. Cortisol made in the laboratory is called hydrocortisone. It is used to treat many conditions, including inflammation, allergies, and some cancers. Cortisol is a type of glucocorticoid hormone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cream Dosage Form","conceptCode":"C28944","definition":"A semi-solid composed of an emulsion of lipids, hydrocarbons, waxes, or polyols in water.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA9C47AB-B5F9-7564-E040-BB89AD437320","latestVersionIndicator":"Yes","beginDate":"2013-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-11-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-979F-18F7-E053-F662850A60B1","beginDate":"2013-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Anti-Thymocyte Globulin","valueDescription":"Anti-Thymocyte Globulin","ValueMeaning":{"publicId":"3253646","version":"1","preferredName":"Anti-Thymocyte Globulin","longName":"3253646","preferredDefinition":"Purified gamma globulin, with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-Thymocyte Globulin","conceptCode":"C278","definition":"Purified gamma globulin, with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A81EFF99-7AB2-7C87-E040-BB89AD430597","latestVersionIndicator":"Yes","beginDate":"2011-07-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-07-15","modifiedBy":"KUMMEROA","dateModified":"2022-06-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-97A9-18F7-E053-F662850A60B1","beginDate":"2013-11-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Rivaroxaban","valueDescription":"Rivaroxaban","ValueMeaning":{"publicId":"4179700","version":"1","preferredName":"Rivaroxaban","longName":"4179700","preferredDefinition":"An orally bioavailable oxazolidinone derivative and direct inhibitor of the coagulation factor Xa with anticoagulant activity. Upon oral administration, rivaroxaban selectively binds to both free factor Xa and factor Xa bound in the prothrombinase complex. This interferes with the conversion of prothrombin (factor II) to thrombin and eventually prevents the formation of cross-linked fibrin clots. Rivaroxaban does not affect existing thrombin levels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rivaroxaban","conceptCode":"C77995","definition":"An orally bioavailable oxazolidinone derivative and direct inhibitor of the coagulation factor Xa with anticoagulant activity. Upon oral administration, rivaroxaban selectively binds to both free factor Xa and factor Xa bound in the prothrombinase complex. This interferes with the conversion of prothrombin (factor II) to thrombin and eventually prevents the formation of cross-linked fibrin clots. Rivaroxaban does not affect existing thrombin levels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3657FD8-9265-1168-E040-BB89AD4356DB","latestVersionIndicator":"Yes","beginDate":"2014-02-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-02-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-97B3-18F7-E053-F662850A60B1","beginDate":"2014-02-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Trandolapril","valueDescription":"Trandolapril","ValueMeaning":{"publicId":"4308492","version":"1","preferredName":"Trandolapril","longName":"4308492","preferredDefinition":"A non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. As a prodrug, trandolapril is converted by de-esterification in the liver into its active form trandolaprilat. Trandolaprilat competitively binds to and inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the potent vasoconstrictive actions of angiotensin II and results in vasodilation. Trandolaprilat also decreases angiotensin II-induced aldosterone secretion by the adrenal cortex, which leads to an increase in sodium excretion and subsequently increases water outflow.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trandolapril","conceptCode":"C61978","definition":"A non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. As a prodrug, trandolapril is converted by de-esterification in the liver into its active form trandolaprilat. Trandolaprilat competitively binds to and inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the potent vasoconstrictive actions of angiotensin II and results in vasodilation. Trandolaprilat also decreases angiotensin II-induced aldosterone secretion by the adrenal cortex, which leads to an increase in sodium excretion and subsequently increases water outflow.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95C1211-E5FB-7DEE-E040-BB89AD432385","latestVersionIndicator":"Yes","beginDate":"2014-05-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-05-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-97BD-18F7-E053-F662850A60B1","beginDate":"2014-05-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Marijuana","valueDescription":"Marijuana","ValueMeaning":{"publicId":"2579325","version":"1","preferredName":"Marijuana","longName":"2579325","preferredDefinition":"Any part of, or extract from, the female hemp plant Cannabis sativa.  Marijuana contains cannabinoids, substances with hallucinogenic, psychoactive, and addictive properties.  This agent has potential use for treating cancer pain and cachexia. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Marijuana","conceptCode":"C26659","definition":"Any part of, or extract from, the female hemp plant Cannabis sativa.  Marijuana contains cannabinoids, substances with hallucinogenic, psychoactive, and addictive properties.  This agent has potential use for treating cancer pain and cachexia. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-02EA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-97C7-18F7-E053-F662850A60B1","beginDate":"2014-08-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Carboxyamidotriazole Orotate","valueDescription":"Carboxyamidotriazole Orotate","ValueMeaning":{"publicId":"3564178","version":"1","preferredName":"Carboxyamidotriazole Orotate","longName":"3564178","preferredDefinition":"The orotate salt form of carboxyamidotriazole (CAI), an orally bioavailable small molecule with potential antiangiogenic and antiproliferative activities. Carboxyamidotriazole binds to and inhibits non-voltage-operated calcium channels, blocking both Ca2+ influx into cells and Ca2+ release from intracellular stores, resulting in the disruption of calcium channel-mediated signal transduction. CAI inhibits PI3 activity and vascular endothelial growth factor (VEGF) signaling. This may inhibit endothelial proliferation, tumor cell growth, invasion and metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboxyamidotriazole Orotate","conceptCode":"C91090","definition":"The orotate salt form of carboxyamidotriazole (CAI), an orally bioavailable small molecule with potential antiangiogenic and antiproliferative activities. Carboxyamidotriazole binds to and inhibits non-voltage-operated calcium channels, blocking both Ca2+ influx into cells and Ca2+ release from intracellular stores, resulting in the disruption of calcium channel-mediated signal transduction. CAI inhibits PI3 activity and vascular endothelial growth factor (VEGF) signaling. This may inhibit endothelial proliferation, tumor cell growth, invasion and metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7DE3983-D915-00EE-E040-BB89AD432ACB","latestVersionIndicator":"Yes","beginDate":"2012-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-97D1-18F7-E053-F662850A60B1","beginDate":"2014-08-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Jiaogulan","valueDescription":"Gynostemma pentaphyllum Supplement","ValueMeaning":{"publicId":"4461468","version":"1","preferredName":"Gynostemma pentaphyllum Supplement","longName":"4461468","preferredDefinition":"A traditional Chinese medicine (TCM) derived from the plant Gynostemma pentaphyllum, an herbaceous climbing vine found in southern China and Southeast Asia, with potential antioxidant activity. Gynostemma pentaphyllum intake has also been used for its adaptogenic effect, to decrease cholesterol and high blood pressure, to strengthen the immune system, and to increase stamina and to improve memory.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gynostemma pentaphyllum Supplement","conceptCode":"C117275","definition":"A traditional Chinese medicine (TCM) derived from the plant Gynostemma pentaphyllum, an herbaceous climbing vine found in southern China and Southeast Asia, with potential antioxidant activity. Gynostemma pentaphyllum intake has also been used for its adaptogenic effect, to decrease cholesterol and high blood pressure, to strengthen the immune system, and to increase stamina and to improve memory.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0177B18A-002C-2EDB-E050-BB89AD433270","latestVersionIndicator":"Yes","beginDate":"2014-08-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-08-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-97DB-18F7-E053-F662850A60B1","beginDate":"2014-08-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Benazepril/Hydrochlorothiazide","valueDescription":"Benazepril/Hydrochlorothiazide","ValueMeaning":{"publicId":"4461469","version":"1","preferredName":"Benazepril/Hydrochlorothiazide","longName":"4461469","preferredDefinition":"A combination preparation of the synthetic angiotensin-converting enzyme (ACE) inhibitor prodrug benazepril and the thiazide diuretic hydrochlorothiazide, with antihypertensive activity. Benazepril is de-esterified by the liver into its active form benazeprilat, which competitively inhibits ACE. ACE inhibition prevents the formation of angiotensin II, and blocks angiotensin II-mediated activities, including vasoconstriction and stimulation of synthesis and secretion of aldosterone, which leads to an increase in sodium excretion and increases water outflow. Hydrochlorothiazide inhibits electrolyte reabsorption via binding to the Na-Cl cotransporter on the renal distal tubules, thereby increasing excretion of sodium, potassium, chloride, bicarbonate and water. Together, these agents lead to a reduction in blood pressure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benazepril/Hydrochlorothiazide","conceptCode":"C117276","definition":"A combination preparation of the synthetic angiotensin-converting enzyme (ACE) inhibitor prodrug benazepril and the thiazide diuretic hydrochlorothiazide, with antihypertensive activity. Benazepril is de-esterified by the liver into its active form benazeprilat, which competitively inhibits ACE. ACE inhibition prevents the formation of angiotensin II, and blocks angiotensin II-mediated activities, including vasoconstriction and stimulation of synthesis and secretion of aldosterone, which leads to an increase in sodium excretion and increases water outflow. Hydrochlorothiazide inhibits electrolyte reabsorption via binding to the Na-Cl cotransporter on the renal distal tubules, thereby increasing excretion of sodium, potassium, chloride, bicarbonate and water. Together, these agents lead to a reduction in blood pressure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0177B18A-0051-2EDB-E050-BB89AD433270","latestVersionIndicator":"Yes","beginDate":"2014-08-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-08-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-97E5-18F7-E053-F662850A60B1","beginDate":"2014-08-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Atenolol/Chlorthalidone","valueDescription":"Atenolol/Chlorthalidone","ValueMeaning":{"publicId":"4461470","version":"1","preferredName":"Atenolol/Chlorthalidone","longName":"4461470","preferredDefinition":"A combination preparation composed of the adrenergic beta-1 receptor antagonist atenolol and thiazide-like diuretic chlorthalidone, with anti-hypertensive activity. Atenolol selectively binds to beta-1 adrenergic receptors in the heart and vascular smooth muscle, thereby inhibiting sympathetic stimulation. This results in a decrease in cardiac rate and muscle contractility, thereby reducing cardiac output. As a diuretic, chlorthalidone directly inhibits sodium and chloride reabsorption on the luminal membrane of the early segment in the distal convoluted tubule (DCT) in the kidney. This leads to an increase in sodium, chloride, bicarbonate, and potassium secretion and results in the excretion of water. Together, these agents lead to a reduction in blood pressure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atenolol/Chlorthalidone","conceptCode":"C117274","definition":"A combination preparation composed of the adrenergic beta-1 receptor antagonist atenolol and thiazide-like diuretic chlorthalidone, with anti-hypertensive activity. Atenolol selectively binds to beta-1 adrenergic receptors in the heart and vascular smooth muscle, thereby inhibiting sympathetic stimulation. This results in a decrease in cardiac rate and muscle contractility, thereby reducing cardiac output. As a diuretic, chlorthalidone directly inhibits sodium and chloride reabsorption on the luminal membrane of the early segment in the distal convoluted tubule (DCT) in the kidney. This leads to an increase in sodium, chloride, bicarbonate, and potassium secretion and results in the excretion of water. Together, these agents lead to a reduction in blood pressure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0177B18A-0076-2EDB-E050-BB89AD433270","latestVersionIndicator":"Yes","beginDate":"2014-08-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-08-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-97EF-18F7-E053-F662850A60B1","beginDate":"2014-08-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Tocilizumab","valueDescription":"Tocilizumab","ValueMeaning":{"publicId":"4618052","version":"1","preferredName":"Tocilizumab","longName":"4618052","preferredDefinition":"A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity. Tocilizumab targets and binds to both the soluble form of IL-6R (sIL-6R) and the membrane-bound form (mIL-6R), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. Il-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders and certain types of cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tocilizumab","conceptCode":"C84217","definition":"A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity. Tocilizumab targets and binds to both the soluble form of IL-6R (sIL-6R) and the membrane-bound form (mIL-6R), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. IL-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders, certain types of cancers and possibly various other inflammatory conditions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0953B289-65BB-6299-E050-BB89AD4328C8","latestVersionIndicator":"Yes","beginDate":"2014-12-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-12-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-97F9-18F7-E053-F662850A60B1","beginDate":"2014-12-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Memantine","valueDescription":"Memantine","ValueMeaning":{"publicId":"4599972","version":"1","preferredName":"Memantine","longName":"4599972","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Memantine","conceptCode":"C73269","definition":"A low-affinity, voltage-dependent, noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist. Memantine binds to and inhibits cation channels of glutamanergic NMDA receptors located in the central nervous system (CNS), preventing the prolonged influx of calcium ions and the associated neuronal excitotoxicity, and thereby potentially enhancing cognitive function. Memantine is also a 5-hydroxytryptamine type 3 (5HT3) receptor and nicotinic receptor antagonist.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"08391E69-9B09-0735-E050-BB89AD4304D6","latestVersionIndicator":"Yes","beginDate":"2014-11-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-11-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9803-18F7-E053-F662850A60B1","beginDate":"2014-11-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Temazepam","valueDescription":"Temazepam","ValueMeaning":{"publicId":"4640872","version":"1","preferredName":"Temazepam","longName":"4640872","preferredDefinition":"A benzodiazepine derivative with antidepressant, sedative, hypnotic and anticonvulsant properties. Temazepam potentiates the inhibitory activities of gamma-aminobutyric acid (GABA) by binding to the GABA receptor, located in the limbic, neocortical and mesencephalic reticular system. This increases the frequency of chloride channel opening events, allowing the flow of chloride ions into the neuron leading to membrane hyperpolarization and decreases neuronal excitability.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Temazepam","conceptCode":"C29488","definition":"A benzodiazepine derivative with antidepressant, sedative, hypnotic and anticonvulsant properties. Temazepam potentiates the inhibitory activities of gamma-aminobutyric acid (GABA) by binding to the GABA receptor, located in the limbic, neocortical and mesencephalic reticular system. This increases the frequency of chloride channel opening events, allowing the flow of chloride ions into the neuron leading to membrane hyperpolarization and decreases neuronal excitability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0A7E4D2D-35DA-F298-E050-BB89AD4309D6","latestVersionIndicator":"Yes","beginDate":"2014-12-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-12-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-980D-18F7-E053-F662850A60B1","beginDate":"2014-12-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Pamabrom","valueDescription":"Pamabrom","ValueMeaning":{"publicId":"4640874","version":"1","preferredName":"Pamabrom","longName":"4640874","preferredDefinition":"A mixture containing 2-amino-2-methyl-1-propanol and 8-bromotheophylline (a methylxanthine) in a 1:1 ratio, with mild diuretic activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pamabrom","conceptCode":"C81076","definition":"A mixture containing 2-amino-2-methyl-1-propanol and 8-bromotheophylline (a methylxanthine) in a 1:1 ratio, with mild diuretic activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0A7E4D2D-3600-F298-E050-BB89AD4309D6","latestVersionIndicator":"Yes","beginDate":"2014-12-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-12-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9817-18F7-E053-F662850A60B1","beginDate":"2014-12-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Iron","valueDescription":"Dietary Iron","ValueMeaning":{"publicId":"4640876","version":"1","preferredName":"Dietary Iron","longName":"4640876","preferredDefinition":"Forms of the element iron found in foods.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dietary Iron","conceptCode":"C68256","definition":"Forms of the element iron found in foods.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0A7E4D2D-3626-F298-E050-BB89AD4309D6","latestVersionIndicator":"Yes","beginDate":"2014-12-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-12-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9821-18F7-E053-F662850A60B1","beginDate":"2014-12-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Prednisone","valueDescription":"Prednisone","ValueMeaning":{"publicId":"2568547","version":"1","preferredName":"Prednisone","longName":"2568547","preferredDefinition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prednisone","conceptCode":"C770","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8D0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"ALAIS","dateModified":"2007-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-982B-18F7-E053-F662850A60B1","beginDate":"2014-12-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Prochlorperazine","valueDescription":"Prochlorperazine","ValueMeaning":{"publicId":"4640878","version":"1","preferredName":"Prochlorperazine","longName":"4640878","preferredDefinition":"A synthetic propylpiperazine derivative of phenothiazine with antiemetic, antipsychotic, antihistaminic, and anticholinergic activities.  Prochlorperazine antagonizes the dopamine D2-receptor in the chemoreceptor trigger zone (CTZ) of the brain and may prevent chemotherapy-induced emesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prochlorperazine","conceptCode":"C774","definition":"A synthetic propylpiperazine derivative of phenothiazine with antiemetic, antipsychotic, antihistaminic, and anticholinergic activities.  Prochlorperazine antagonizes the dopamine D2-receptor in the chemoreceptor trigger zone (CTZ) of the brain and may prevent chemotherapy-induced emesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0A7E4D2D-3656-F298-E050-BB89AD4309D6","latestVersionIndicator":"Yes","beginDate":"2014-12-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-12-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9835-18F7-E053-F662850A60B1","beginDate":"2014-12-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Potassium Chloride","valueDescription":"Potassium Chloride","ValueMeaning":{"publicId":"4640880","version":"1","preferredName":"Potassium Chloride","longName":"4640880","preferredDefinition":"A metal halide composed of potassium and chloride. Potassium maintains intracellular tonicity, is required for nerve conduction, cardiac, skeletal and smooth muscle contraction, production of energy, the synthesis of nucleic acids, maintenance of blood pressure and normal renal function. This agent has potential antihypertensive effects and when taken as a nutritional supplement may prevent hypokalemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Potassium Chloride","conceptCode":"C47679","definition":"A metal halide composed of potassium and chloride. Potassium maintains intracellular tonicity, is required for nerve conduction, cardiac, skeletal and smooth muscle contraction, production of energy, the synthesis of nucleic acids, maintenance of blood pressure and normal renal function. This agent has potential antihypertensive effects and when taken as a nutritional supplement may prevent hypokalemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0A7E4D2D-367C-F298-E050-BB89AD4309D6","latestVersionIndicator":"Yes","beginDate":"2014-12-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-12-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-983F-18F7-E053-F662850A60B1","beginDate":"2014-12-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Omeprazole","valueDescription":"Omeprazole","ValueMeaning":{"publicId":"4640882","version":"1","preferredName":"Omeprazole","longName":"4640882","preferredDefinition":"A benzimidazole with selective and irreversible proton pump inhibition activity. Omeprazole forms a stable disulfide bond with the sulfhydryl group of the hydrogen-potassium (H+ - K+) ATPase found on the secretory surface of parietal cells, thereby inhibiting the final transport of hydrogen ions (via exchange with potassium ions) into the gastric lumen and suppressing gastric acid secretion. This agent exhibits no anticholinergic activities and does not antagonize histamine H2 receptors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Omeprazole","conceptCode":"C716","definition":"A benzimidazole with selective and irreversible proton pump inhibition activity. Omeprazole forms a stable disulfide bond with the sulfhydryl group of the hydrogen-potassium (H+ - K+) ATPase found on the secretory surface of parietal cells, thereby inhibiting the final transport of hydrogen ions (via exchange with potassium ions) into the gastric lumen and suppressing gastric acid secretion. This agent exhibits no anticholinergic activities and does not antagonize histamine H2 receptors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0A7E4D2D-36A2-F298-E050-BB89AD4309D6","latestVersionIndicator":"Yes","beginDate":"2014-12-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-12-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9849-18F7-E053-F662850A60B1","beginDate":"2014-12-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ondansetron","valueDescription":"Ondansetron","ValueMeaning":{"publicId":"4640883","version":"1","preferredName":"Ondansetron","longName":"4640883","preferredDefinition":"A carbazole derivative with antiemetic activity.  As a selective serotonin receptor antagonist, ondansetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ondansetron","conceptCode":"C1119","definition":"A carbazole derivative with antiemetic activity.  As a selective serotonin receptor antagonist, ondansetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0A7E4D2D-36C7-F298-E050-BB89AD4309D6","latestVersionIndicator":"Yes","beginDate":"2014-12-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-12-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9853-18F7-E053-F662850A60B1","beginDate":"2014-12-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Tramadol","valueDescription":"Tramadol","ValueMeaning":{"publicId":"3380229","version":"1","preferredName":"Tramadol","longName":"3380229","preferredDefinition":"A synthetic codeine analogue, Tramadol has central analgesic properties with effects similar to opioids, such as morphine and codeine, acting on specific opioid receptors. Used as a narcotic analgesic for severe pain, it can be addictive and weakly inhibits norepinephrine and serotonin reuptake. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tramadol","conceptCode":"C29507","definition":"A synthetic codeine analogue, Tramadol has central analgesic properties with effects similar to opioids, such as morphine and codeine, acting on specific opioid receptors. Used as a narcotic analgesic for severe pain, it can be addictive and weakly inhibits norepinephrine and serotonin reuptake. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97B8401-15B8-113F-E040-BB89AD431AAC","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-985D-18F7-E053-F662850A60B1","beginDate":"2014-12-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Sumatriptan","valueDescription":"Sumatriptan","ValueMeaning":{"publicId":"4640884","version":"1","preferredName":"Sumatriptan","longName":"4640884","preferredDefinition":"A sulfonamide triptan with vasoconstrictor activity. Sumatriptan selectively binds to and activates serotonin 5-HT1D receptors in the central nervous system (CNS), thereby constricting cerebral blood vessels. This may lead to a relief in pain from vascular headaches. Sumatriptan may also relieve vascular headaches by decreasing the release of vasoactive neuropeptides from perivascular trigeminal axons in the dura mater during a migraine, by reducing extravasation of plasma proteins, and by decreasing the release of other mediators of inflammation from the trigeminal nerve.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sumatriptan","conceptCode":"C1240","definition":"A sulfonamide triptan with vasoconstrictor activity. Sumatriptan selectively binds to and activates serotonin 5-HT1D receptors in the central nervous system (CNS), thereby constricting cerebral blood vessels. This may lead to a relief in pain from vascular headaches. Sumatriptan may also relieve vascular headaches by decreasing the release of vasoactive neuropeptides from perivascular trigeminal axons in the dura mater during a migraine, by reducing extravasation of plasma proteins, and by decreasing the release of other mediators of inflammation from the trigeminal nerve.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0A7E4D2D-36F6-F298-E050-BB89AD4309D6","latestVersionIndicator":"Yes","beginDate":"2014-12-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-12-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9867-18F7-E053-F662850A60B1","beginDate":"2014-12-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Vitamin E","valueDescription":"Vitamin E Compound","ValueMeaning":{"publicId":"4804371","version":"1","preferredName":"Vitamin E Compound","longName":"4804371","preferredDefinition":"A fat-soluble vitamin which is primarily a chain-breaking antioxidant that prevents the propagation of lipid peroxidation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vitamin E Compound","conceptCode":"C942","definition":"A natural fat-soluble antioxidant with potential chemopreventive activity. Also known as tocopherol, vitamin E ameliorates free-radical damage to biological membranes, protecting polyunsaturated fatty acids (PUFA) within membrane phospholipids and within circulating lipoproteins. Peroxyl radicals react 1000-fold faster with vitamin E than with PUFA.  In the case of oxygen free radical-mediated tumorigenesis, vitamin E may be chemopreventive. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"14D48A7B-0E48-07D2-E050-BB89AD436B74","latestVersionIndicator":"Yes","beginDate":"2015-04-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-04-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9871-18F7-E053-F662850A60B1","beginDate":"2015-04-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Sildenafil","valueDescription":"Sildenafil","ValueMeaning":{"publicId":"4804373","version":"1","preferredName":"Sildenafil","longName":"4804373","preferredDefinition":"A drug used to treat erectile dysfunction. Sildenafil relaxes the smooth muscle of the penis to allow increased blood flow and erection. It is a type of phosphodiesterase inhibitor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sildenafil","conceptCode":"C61940","definition":"An orally bioavailable pyrazolopyrimidinone derivative structurally related to zaprinast, with vasodilating and potential anti-inflammatory activities. Upon oral administration, sildenafil selectively targets and inhibits cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), thereby inhibiting the PDE5-mediated degradation of cGMP found in smooth muscle and increasing cGMP availability. This results in prolonged smooth muscle relaxation in the corpus cavernosum of the penis, thereby causing vasodilation, blood engorgement and a prolonged penile erection.  In the smooth muscle of the pulmonary vasculature, the increase in cGMP results in smooth muscle relaxation, vasodilation of the pulmonary vascular bed, relieving pulmonary hypertension and increasing blood flow in the lungs. In addition, sildenafil may reduce airway inflammation and mucus production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"14D48A7B-0E6E-07D2-E050-BB89AD436B74","latestVersionIndicator":"Yes","beginDate":"2015-04-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-04-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-987B-18F7-E053-F662850A60B1","beginDate":"2015-04-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Trazodone","valueDescription":"Trazodone","ValueMeaning":{"publicId":"4804375","version":"1","preferredName":"Trazodone","longName":"4804375","preferredDefinition":"A synthetic triazolopyridine derivative, antidepressant and sedative Trazodone acts as a serotonin uptake inhibitor, chemically unrelated to tricyclic, tetracyclic, or other antidepressants. It is effective in patients with schizoaffective disorders; major depressive disorders; and depressive disorders associated with insomnia and anxiety. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trazodone","conceptCode":"C29510","definition":"A synthetic triazolopyridine derivative, antidepressant and sedative Trazodone acts as a serotonin uptake inhibitor, chemically unrelated to tricyclic, tetracyclic, or other antidepressants. It is effective in patients with schizoaffective disorders; major depressive disorders; and depressive disorders associated with insomnia and anxiety. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"14D48A7B-0E94-07D2-E050-BB89AD436B74","latestVersionIndicator":"Yes","beginDate":"2015-04-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-04-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9885-18F7-E053-F662850A60B1","beginDate":"2015-04-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Oxycodone","valueDescription":"Oxycodone","ValueMeaning":{"publicId":"4804377","version":"1","preferredName":"Oxycodone","longName":"4804377","preferredDefinition":"A semi-synthetic, morphine-like opioid alkaloid with analgesic activity. Oxycodone exerts its analgesic activity by binding to the mu-receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opioids. Binding of the opiate receptor stimulates the exchange of GTP for GDP on the G-protein complex and inhibits adenylate cyclase, thereby preventing cAMP production. Subsequently, the release of nociceptive neurotransmitters, such as substance P, gamma-aminobutyric acid (GABA), dopamine, acetylcholine, and noradrenaline, is inhibited. Oxycodone also inhibits the release of vasopressin, somatostatin, insulin, and glucagon. In addition, oxycodone closes N-type voltage-gated calcium channels and opens G-protein-coupled inwardly rectifying potassium channels resulting in hyperpolarization and reduction of neuronal excitability.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oxycodone","conceptCode":"C29309","definition":"A semi-synthetic, morphine-like opioid alkaloid with analgesic activity. Oxycodone exerts its analgesic activity by binding to the mu-receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opioids. Binding of the opiate receptor stimulates the exchange of GTP for GDP on the G-protein complex and inhibits adenylate cyclase, thereby preventing cAMP production. Subsequently, the release of nociceptive neurotransmitters, such as substance P, gamma-aminobutyric acid (GABA), dopamine, acetylcholine, and noradrenaline, is inhibited. Oxycodone also inhibits the release of vasopressin, somatostatin, insulin, and glucagon. In addition, oxycodone closes N-type voltage-gated calcium channels and opens G-protein-coupled inwardly rectifying potassium channels resulting in hyperpolarization and reduction of neuronal excitability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"14D48A7B-0EBA-07D2-E050-BB89AD436B74","latestVersionIndicator":"Yes","beginDate":"2015-04-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-04-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-988F-18F7-E053-F662850A60B1","beginDate":"2015-04-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Acetaminophen/Codeine (Tylenol #4)","valueDescription":"Acetaminophen 300 mg/Codeine 60 mg","ValueMeaning":{"publicId":"4804378","version":"1","preferredName":"Acetaminophen 300 mg/Codeine 60 mg","longName":"4804378","preferredDefinition":"A synthetic p-aminophenol derivative combined with codeine, with anti-inflammatory and analgesic activites. Acetaminophen with codeine is used against inflammatory conditions, fever, and pain. Codeine is an opium alkaloid with analgesic properties. Acetaminophen appears to inhibit prostaglandin biosynthesis in the central nervous system and less in peripheral tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acetaminophen/Codeine","conceptCode":"C28807","definition":"A synthetic p-aminophenol derivative combined with codeine, with anti-inflammatory and analgesic activites. Acetaminophen with codeine is used against inflammatory conditions, fever, and pain. Codeine is an opium alkaloid with analgesic properties. Acetaminophen appears to inhibit prostaglandin biosynthesis in the central nervous system and less in peripheral tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"14D48A7B-0EDD-07D2-E050-BB89AD436B74","latestVersionIndicator":"Yes","beginDate":"2015-04-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-04-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9899-18F7-E053-F662850A60B1","beginDate":"2015-04-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Acetaminophen/Codeine (Tylenol #2)","valueDescription":"Acetaminophen 300 mg/Codeine 15 mg","ValueMeaning":{"publicId":"4804379","version":"1","preferredName":"Acetaminophen 300 mg/Codeine 15 mg","longName":"4804379","preferredDefinition":"A synthetic p-aminophenol derivative combined with codeine, with anti-inflammatory and analgesic activites. Acetaminophen with codeine is used against inflammatory conditions, fever, and pain. Codeine is an opium alkaloid with analgesic properties. Acetaminophen appears to inhibit prostaglandin biosynthesis in the central nervous system and less in peripheral tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acetaminophen/Codeine","conceptCode":"C28807","definition":"A synthetic p-aminophenol derivative combined with codeine, with anti-inflammatory and analgesic activites. Acetaminophen with codeine is used against inflammatory conditions, fever, and pain. Codeine is an opium alkaloid with analgesic properties. Acetaminophen appears to inhibit prostaglandin biosynthesis in the central nervous system and less in peripheral tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"14D48A7B-0F00-07D2-E050-BB89AD436B74","latestVersionIndicator":"Yes","beginDate":"2015-04-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-04-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-98A3-18F7-E053-F662850A60B1","beginDate":"2015-04-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Polyethylene Glycol 3350","valueDescription":"Polyethylene Glycol 3350","ValueMeaning":{"publicId":"4863732","version":"1","preferredName":"Polyethylene Glycol 3350","longName":"4863732","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polyethylene Glycol 3350","conceptCode":"C80131","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"18523D7B-5898-BB92-E050-BB89AD433FDA","latestVersionIndicator":"Yes","beginDate":"2015-06-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-06-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-98AD-18F7-E053-F662850A60B1","beginDate":"2015-06-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Sennosides","valueDescription":"Sennosides","ValueMeaning":{"publicId":"4863734","version":"1","preferredName":"Sennosides","longName":"4863734","preferredDefinition":"Anthraquinone glycosides found in senna plant, usually referring to the sennosides A and B, with laxative activity. Sennosides act on and irritate the lining of the intestine wall, thereby causing increased intestinal muscle contractions leading to vigorous bowel movement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sennosides","conceptCode":"C29448","definition":"Anthraquinone glycosides found in senna plant, usually referring to the sennosides A and B, with laxative activity. Sennosides act on and irritate the lining of the intestine wall, thereby causing increased intestinal muscle contractions leading to vigorous bowel movement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"18523D7B-58BE-BB92-E050-BB89AD433FDA","latestVersionIndicator":"Yes","beginDate":"2015-06-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-06-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-98B7-18F7-E053-F662850A60B1","beginDate":"2015-06-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Formoterol Fumarate","valueDescription":"Formoterol Fumarate","ValueMeaning":{"publicId":"2576878","version":"1","preferredName":"Formoterol Fumarate","longName":"2576878","preferredDefinition":"The fumarate salt form of formoterol, a long-acting and selective sympathomimetic beta-receptor agonist with bronchodilator activity. Formoterol fumarate binds beta 2 adrenergic receptors in bronchial smooth muscle and stimulates intracellular adenyl cyclase, thereby increasing the production of cyclic adenosine monophosphate (cAMP). Increased cAMP levels cause relaxation of bronchial smooth muscle, improve mucociliary clearance and reduce mediator substance release in inflammatory cells, especially from mast cells. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Formoterol Fumarate","conceptCode":"C47540","definition":"The fumarate salt form of formoterol, a long-acting and selective sympathomimetic beta-receptor agonist with bronchodilator activity. Formoterol fumarate binds beta 2 adrenergic receptors in bronchial smooth muscle and stimulates intracellular adenyl cyclase, thereby increasing the production of cyclic adenosine monophosphate (cAMP). Increased cAMP levels cause relaxation of bronchial smooth muscle, improve mucociliary clearance and reduce mediator substance release in inflammatory cells, especially from mast cells. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F95B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7B7F-18F7-E053-F662850A60B1","beginDate":"2006-02-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Foscarnet","valueDescription":"Foscarnet Sodium","ValueMeaning":{"publicId":"2577879","version":"1","preferredName":"Foscarnet Sodium","longName":"2577879","preferredDefinition":"A synthetic organic analogue of inorganic pyrophosphate with antiviral properties.  Foscarnet (trisodium phosphonoformate) selectively blocks the pyrophosphate binding site of virus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases.  Because this agent crosses the blood brain barrier, it may be used in the treatment of viral infections of the CNS.  (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Foscarnet Sodium","conceptCode":"C1193","definition":"The trisodium salt of a synthetic organic analogue of inorganic pyrophosphate with antiviral activity. Foscarnet selectively blocks the pyrophosphate binding site of herpesvirus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases. This agent does not require phosphorylation by thymidine kinase (TK) or other kinases and therefore is active in vitro against herpes simplex virus (HSV) TK deficient mutants and cytomegalovirus (CMV) UL97 mutants. Because foscarnet crosses the blood brain barrier, it may be used in the treatment of viral infections of the CNS.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD44-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"KUMMEROA","dateModified":"2022-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7B89-18F7-E053-F662850A60B1","beginDate":"2006-02-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fosinopril","valueDescription":"Fosinopril Sodium: C47542","ValueMeaning":{"publicId":"2577875","version":"1","preferredName":"Fosinopril Sodium: C47542","longName":"2577875","preferredDefinition":"The sodium salt of fosinopril, a phosphinic acid-containing angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. Fosinopril sodium is an ester prodrug that is hydrolysed by esterases to its active metabolite fosinoprilat. Fosinoprilat specifically and competitively inhibits angiotensin-converting enzyme thereby decreasing the formation of the potent vasoconstrictor angiotensin II, resulting in diminished vasopressor activity. In addition, angiotensin II-mediated aldosterone secretion by adrenal cortex is decreased, which results in a decrease of sodium retention and an increase of serum potassium. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fosinopril Sodium","conceptCode":"C47542","definition":"The sodium salt of fosinopril, a phosphinic acid-containing angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. Fosinopril sodium is an ester prodrug that is hydrolysed by esterases to its active metabolite fosinoprilat. Fosinoprilat specifically and competitively inhibits angiotensin-converting enzyme thereby decreasing the formation of the potent vasoconstrictor angiotensin II, resulting in diminished vasopressor activity. In addition, angiotensin II-mediated aldosterone secretion by adrenal cortex is decreased, which results in a decrease of sodium retention and an increase of serum potassium. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD40-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-22","modifiedBy":"ONEDATA","dateModified":"2006-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7B93-18F7-E053-F662850A60B1","beginDate":"2006-02-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fulvestrant","valueDescription":"Fulvestrant","ValueMeaning":{"publicId":"2575943","version":"1","preferredName":"Fulvestrant","longName":"2575943","preferredDefinition":"A synthetic estrogen receptor antagonist.  Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fulvestrant","conceptCode":"C1379","definition":"A synthetic estrogen receptor antagonist.  Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F5B4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-08-15","modifiedBy":"REEVESD","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7B9D-18F7-E053-F662850A60B1","beginDate":"2006-02-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Furosemide","valueDescription":"Furosemide","ValueMeaning":{"publicId":"2576880","version":"1","preferredName":"Furosemide","longName":"2576880","preferredDefinition":"A sulfamyl saluretic and diuretic. It has a fast onset and short duration of action and is used in edema and chronic renal insufficiency.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Furosemide","conceptCode":"C515","definition":"A sulfamoylanthranilic acid derivative, also known as frusemide, and potent loop diuretic. Furosemide is widely used to treat hypertension and edema. This agent is highly bound to albumin and is largely excreted unchanged in the urine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F95D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7BA7-18F7-E053-F662850A60B1","beginDate":"2006-02-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Gabapentin","valueDescription":"Gabapentin","ValueMeaning":{"publicId":"2576881","version":"1","preferredName":"Gabapentin","longName":"2576881","preferredDefinition":"A substance that is being studied as a treatment for relieving hot flashes in women with breast cancer.  It belongs to the family of drugs called anticonvulsants.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gabapentin","conceptCode":"C1108","definition":"A synthetic analogue of the neurotransmitter gamma-aminobutyric acid with anticonvulsant activity. Although its exact mechanism of action is unknown, gabapentin appears to inhibit excitatory neuron activity. This agent also exhibits analgesic properties. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F95E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7BB1-18F7-E053-F662850A60B1","beginDate":"2006-02-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Gamma Globulin","valueDescription":"Gamma Globulin","ValueMeaning":{"publicId":"2576882","version":"1","preferredName":"Gamma Globulin","longName":"2576882","preferredDefinition":"A type of globulin in plasma that in electrically charged solutions exhibits slowest colloidal mobility after that of the alpha and beta globulins. All immunoglobulins belong to this group of serum protein.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gamma Globulin","conceptCode":"C16601","definition":"A type of globulin in plasma that in electrically charged solutions exhibits slowest colloidal mobility after that of the alpha and beta globulins. All immunoglobulins belong to this group of serum protein.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F95F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7BBB-18F7-E053-F662850A60B1","beginDate":"2006-02-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ganciclovir","valueDescription":"Ganciclovir","ValueMeaning":{"publicId":"2575684","version":"1","preferredName":"Ganciclovir","longName":"2575684","preferredDefinition":"A synthetic guanine derivative with antiviral activity.  As the active metabolite of ganciclovir, ganciclovir-5-triphosphate (ganciclovir-TP) appears to inhibit viral DNA synthesis by competitive inhibition of viral DNA polymerases and incorporation into viral DNA, resulting in eventual termination of viral DNA elongation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ganciclovir","conceptCode":"C517","definition":"A synthetic guanine derivative with antiviral activity.  As the active metabolite of ganciclovir, ganciclovir-5-triphosphate (ganciclovir-TP) appears to inhibit viral DNA synthesis by competitive inhibition of viral DNA polymerases and incorporation into viral DNA, resulting in eventual termination of viral DNA elongation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4B1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7BC5-18F7-E053-F662850A60B1","beginDate":"2006-02-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Garcinia Cambogia","valueDescription":"Garcinia cambogia preparation","ValueMeaning":{"publicId":"2576883","version":"1","preferredName":"Garcinia cambogia preparation","longName":"2576883","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Garcinia cambogia preparation","conceptCode":"C0795610","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F960-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7BCF-18F7-E053-F662850A60B1","beginDate":"2006-02-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Garlic Extract","valueDescription":"Garlic Extract","ValueMeaning":{"publicId":"2576884","version":"1","preferredName":"Garlic Extract","longName":"2576884","preferredDefinition":"The alcoholic extract of the bulb or whole garlic plant Allium sativum (Liliaceae) with potential antineoplastic activity. The garlic plant has long been considered a beneficial plant for health and has been used as an antihelmintic, a rubefacient, an anti-infective, and an antihypertensive. Fresh or aged, garlic extracts contain compounds such as diallyl and allyl propyl disulfides with potent antioxidant, cholesterol-lowering properties; regular ingestion may be preventative for atherosclerosis and cardiovascular diseases. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Garlic Extract","conceptCode":"C29069","definition":"The alcoholic extract of the bulb or whole garlic plant Allium sativum (Liliaceae) with potential antineoplastic activity. The garlic plant has long been considered a beneficial plant for health and has been used as an antihelmintic, a rubefacient, an anti-infective, and an antihypertensive. Fresh or aged, garlic extracts contain compounds such as diallyl and allyl propyl disulfides with potent antioxidant, cholesterol-lowering properties; regular ingestion may be preventative for atherosclerosis and cardiovascular diseases. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F961-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7BD9-18F7-E053-F662850A60B1","beginDate":"2006-02-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Gatifloxacin","valueDescription":"Gatifloxacin","ValueMeaning":{"publicId":"2577880","version":"1","preferredName":"Gatifloxacin","longName":"2577880","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gatifloxacin","conceptCode":"C29070","definition":"A synthetic 8-methoxyfluoroquinolone with antibacterial activity against a wide range of gram-negative and gram-positive microorganisms. Gatifloxacin exerts its effect through inhibition of DNA gyrase, an enzyme involved in DNA replication, transcription and repair, and inhibition of topoisomerase IV, an enzyme involved in partitioning of chromosomal DNA during bacterial cell division.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD45-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7BE3-18F7-E053-F662850A60B1","beginDate":"2006-02-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"G-CSF","valueDescription":"Colony Stimulating Factor 3","ValueMeaning":{"publicId":"2577876","version":"1","preferredName":"Colony Stimulating Factor 3","longName":"2577876","preferredDefinition":"Colony Stimulating Factor 3, encoded by the CSF3 gene, is a cytokine that controls the production, differentiation, and function of granulocytes. The active protein is found extracellularly. Three transcript variants encoding three different protein isoforms have been found for this gene. (From LocusLink)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Colony Stimulating Factor 3","conceptCode":"CL101592","definition":"Colony Stimulating Factor 3, encoded by the CSF3 gene, is a cytokine that controls the production, differentiation, and function of granulocytes. The active protein is found extracellularly. Three transcript variants encoding three different protein isoforms have been found for this gene. (From LocusLink)","evsSource":"NCI_META_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD41-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-22","modifiedBy":"ONEDATA","dateModified":"2006-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7BED-18F7-E053-F662850A60B1","beginDate":"2006-02-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"GM-CSF","valueDescription":"GM-CSF","ValueMeaning":{"publicId":"2576458","version":"1","preferredName":"GM-CSF","longName":"2576458","preferredDefinition":"Granulocyte-macrophage colony-stimulating factor. A colony-stimulating factor that stimulates the production of white blood cells, especially granulocytes and macrophages, and cells (in the bone marrow) that are precursors of platelets. It is a cytokine that belongs to the family of drugs called hematopoietic (blood-forming) agents. Also called sargramostim.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Granulocyte-Macrophage Colony-Stimulating Factor","conceptCode":"C1288","definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous glycoprotein cytokine growth factor granulocyte-macrophage colony stimulating factor (GM-CSF). Therapeutic GM-CSF induces the clonal expansion and differentiation of progenitor blood cells and stimulates the cytotoxicity of monocytes and neutrophils, thereby restoring immune function and host antitumor immune responses and stimulating engraftment of transplanted bone marrow tissue. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F7B7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-10-07","modifiedBy":"SHIDED","dateModified":"2013-05-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7BF7-18F7-E053-F662850A60B1","beginDate":"2006-02-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Gelclair","valueDescription":"Gelclair","ValueMeaning":{"publicId":"2577877","version":"1","preferredName":"Gelclair","longName":"2577877","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gelclair","conceptCode":"C1098961","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD42-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-22","modifiedBy":"ONEDATA","dateModified":"2006-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7C01-18F7-E053-F662850A60B1","beginDate":"2006-02-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Gemfibrozil","valueDescription":"gemfibrozil","ValueMeaning":{"publicId":"2573148","version":"1","preferredName":"gemfibrozil","longName":"2573148v1.00","preferredDefinition":"A fibric acid derivative with hypolipidemic effects. Gemfibrozil interacts with peroxisome proliferator-activated receptors (PPARalpha) resulting in PPARalpha-mediated stimulation of fatty acid oxidation and an increase in lipoprotein lipase (LPL) synthesis. This enhances triglyceride-rich lipoprotein clearance and reduces the expression of apolipoprotein C-III (apoC-III). The reduction in hepatic production of apoC-III results in subsequent reduction of serum levels of very-low-density-lipoprotein cholesterol (VLDL-C). In addition, gemfibrozil-mediated PPARalpha stimulation of apoA-I and apoA-II expression results in an increase in high-density lipoprotein cholesterol (HDL-C).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gemfibrozil","conceptCode":"C29071","definition":"A fibric acid derivative with hypolipidemic effects. Gemfibrozil interacts with peroxisome proliferator-activated receptors (PPARalpha) resulting in PPARalpha-mediated stimulation of fatty acid oxidation and an increase in lipoprotein lipase (LPL) synthesis. This enhances triglyceride-rich lipoprotein clearance and reduces the expression of apolipoprotein C-III (apoC-III). The reduction in hepatic production of apoC-III results in subsequent reduction of serum levels of very-low-density-lipoprotein cholesterol (VLDL-C). In addition, gemfibrozil-mediated PPARalpha stimulation of apoA-I and apoA-II expression results in an increase in high-density lipoprotein cholesterol (HDL-C).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EAC9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-02-09","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7C0B-18F7-E053-F662850A60B1","beginDate":"2006-02-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Gentamicin","valueDescription":"Gentamicin","ValueMeaning":{"publicId":"2577881","version":"1","preferredName":"Gentamicin","longName":"2577881","preferredDefinition":"A complex of three different closely related aminoglycoside sulfates, Gentamicins C1, C2, and C1(subA), obtained from Micromonospora purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit protein synthesis (TRANSLATION (GENETICS)).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gentamicin","conceptCode":"C519","definition":"A broad-spectrum aminoglycoside antibiotic produced by fermentation of Micromonospora purpurea or M. echinospora. Gentamicin is an antibiotic complex consisting of four major (C1, C1a, C2, and C2a) and several minor components. This agent irreversibly binds to the bacterial 30S ribosomal subunit. Specifically, this antibiotic is lodged between 16S rRNA and S12 protein within the 30S subunit. This leads to interference with translational initiation complex, misreading of mRNA, thereby hampering protein synthesis and resulting in bactericidal effect. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD46-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7C15-18F7-E053-F662850A60B1","beginDate":"2006-02-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Gingko","valueDescription":"Ginkgo","ValueMeaning":{"publicId":"2577878","version":"1","preferredName":"Ginkgo","longName":"2577878","preferredDefinition":"A substance derived from the plant Ginkgo biloba. Ginkgo biloba leaf extract contains potent anti-oxidants and substances believed to improve blood flow to the brain and peripheral tissues. Ginkgo biloba exocarp polysaccharides (GBEP) can inhibit proliferation and induce apoptosis and differentiation of tumor cells. As a medicinal herb, ginkgo requires standardization for medicinal use; typically, a 50:1 extract of ginkgo leaf is used in ginkgo supplements. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ginkgo","conceptCode":"C0772125","definition":"A substance derived from the plant Ginkgo biloba. Ginkgo biloba leaf extract contains potent anti-oxidants and substances believed to improve blood flow to the brain and peripheral tissues. Ginkgo biloba exocarp polysaccharides (GBEP) can inhibit proliferation and induce apoptosis and differentiation of tumor cells. As a medicinal herb, ginkgo requires standardization for medicinal use; typically, a 50:1 extract of ginkgo leaf is used in ginkgo supplements. (NCI04)","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD43-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-22","modifiedBy":"ONEDATA","dateModified":"2006-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7C1F-18F7-E053-F662850A60B1","beginDate":"2006-02-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Iodine","valueDescription":"Iodine","ValueMeaning":{"publicId":"2578182","version":"1","preferredName":"Iodine","longName":"2578182","preferredDefinition":"An element that is necessary for the body to make thyroid hormone.  It is found in shellfish and iodized salt.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Iodine","conceptCode":"C594","definition":"An element with atomic symbol I, atomic number 53, and atomic weight of 126.90.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE73-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"DWARZEL","dateModified":"2006-08-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7C29-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Hydrocortisone","valueDescription":"Therapeutic Hydrocortisone","ValueMeaning":{"publicId":"2578183","version":"1","preferredName":"Therapeutic Hydrocortisone","longName":"2578183","preferredDefinition":"A synthetic or semisynthetic analog of natural hydrocortisone hormone produced by the adrenal glands with primary glucocorticoid and minor mineralocorticoid effects. As a glucocorticoid receptor agonist, hydrocortisone promotes protein catabolism, gluconeogenesis, capillary wall stability, renal excretion of calcium, and suppresses immune and inflammatory responses. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Hydrocortisone","conceptCode":"C555","definition":"A synthetic or semisynthetic analog of natural hydrocortisone hormone produced by the adrenal glands with primary glucocorticoid and minor mineralocorticoid effects. As a glucocorticoid receptor agonist, hydrocortisone promotes protein catabolism, gluconeogenesis, capillary wall stability, renal excretion of calcium, and suppresses immune and inflammatory responses. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE74-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7C33-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Hydroxypropyl Methylcellulose D","valueDescription":"Hydroxypropyl Methylcellulose D","ValueMeaning":{"publicId":"2578184","version":"1","preferredName":"Hydroxypropyl Methylcellulose D","longName":"2578184","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydroxypropyl Methylcellulose D","conceptCode":"C29102","definition":"A semisynthetic, high viscosity polymer used as a food additive which may have the ability to lower total cholesterol and low-density lipoprotein cholesterol (LDL-C).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE75-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7C3D-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Hydroxyzine HCL","valueDescription":"Hydroxyzine Hydrochloride","ValueMeaning":{"publicId":"2578185","version":"1","preferredName":"Hydroxyzine Hydrochloride","longName":"2578185","preferredDefinition":"The hydrochloride salt form of hydroxyzine, a piperazine histamine H1-receptor antagonist with anti-allergic, antispasmodic, sedative, anti-emetic and anti-anxiety properties. Hydroxyzine hydrochloride blocks the H1 histamine receptor and prevents the symptoms that are caused by histamine activity on capillaries, bronchial smooth muscle, and gastrointestinal smooth muscle, including vasodilatation, increased capillary permeability, bronchoconstriction, and spasmodic contraction of gastrointestinal smooth muscle. In addition, hydroxyzine hydrochloride crosses the blood-brain barrier and acts on the histamine H1-receptors in the central nervous system. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydroxyzine Hydrochloride","conceptCode":"C0684229","definition":"The hydrochloride salt form of hydroxyzine, a piperazine histamine H1-receptor antagonist with anti-allergic, antispasmodic, sedative, anti-emetic and anti-anxiety properties. Hydroxyzine hydrochloride blocks the H1 histamine receptor and prevents the symptoms that are caused by histamine activity on capillaries, bronchial smooth muscle, and gastrointestinal smooth muscle, including vasodilatation, increased capillary permeability, bronchoconstriction, and spasmodic contraction of gastrointestinal smooth muscle. In addition, hydroxyzine hydrochloride crosses the blood-brain barrier and acts on the histamine H1-receptors in the central nervous system. (NCI05)","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE76-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7C47-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ibutilide","valueDescription":"Ibutilide Fumarate","ValueMeaning":{"publicId":"2578186","version":"1","preferredName":"Ibutilide Fumarate","longName":"2578186","preferredDefinition":"The fumarate salt form of ibutilide, a class III antiarrhythmic agent. Ibutilide exerts its effect by activating a slow, inward, predominately sodium current rather than by blocking outward potassium currents. This results in prolongation of atrial and ventricular action potential duration and refractory periods. Ibutilide slightly decreases the sinus rate and atrioventricular (AV) conduction and produces a dose-related prolongation of the QT interval. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ibutilide Fumarate","conceptCode":"C0644117","definition":"The fumarate salt form of ibutilide, a class III antiarrhythmic agent. Ibutilide exerts its effect by activating a slow, inward, predominately sodium current rather than by blocking outward potassium currents. This results in prolongation of atrial and ventricular action potential duration and refractory periods. Ibutilide slightly decreases the sinus rate and atrioventricular (AV) conduction and produces a dose-related prolongation of the QT interval. (NCI05)","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE77-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7C51-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"IL-1","valueDescription":"Interleukin-1","ValueMeaning":{"publicId":"2578187","version":"1","preferredName":"Interleukin-1","longName":"2578187","preferredDefinition":"Human interleukin-1 protein (271 aa, 31 kD precursor) is encoded by the human interleukin-1 (IL1) gene. This soluble protein is produced primarily by monocytes and macrophages. It activates and potentiates T-lymphocyte responses to mitogens or antigens. This protein is also capable of replacing macrophage requirements for T-cell activation","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interleukin-1","conceptCode":"C20506","definition":"Interleukin-1 (endogenous pyrogen), produced primarily by monocytes, is an important pro-inflammatory cytokine that mediates the acute phase host response.  The biologic activities of IL1 are properties of a protein derived from a larger precursor.  Inflammation causes induction of COX2, leading to release of prostanoids, which sensitize peripheral nociceptor terminals and produce local pain hypersensitivity.  Inflammation also generates sensitivity in neighboring tissue, muscle and joint pain, fever, lethargy, and anorexia.  COX2 induction in regions of the CNS is mediated by IL1B.  Interleukin-1-beta also stimulates bone resorption.  IL1RN is a competitive inhibitor of IL1B.  Mature IL1-beta levels are a sensitive and specific indicator of caspase-1 activation.  (from OMIM 147720 and NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE78-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7C5B-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"IL-2","valueDescription":"Interleukin-2","ValueMeaning":{"publicId":"2578198","version":"1","preferredName":"Interleukin-2","longName":"2578198","preferredDefinition":"Encoded by human IL2 Gene, Interleukin-2 is a secreted cytokine important for proliferation of T and B lymphocytes. The receptor of this cytokine is a heterotrimeric protein complex whose gamma chain is also shared by interleukin 4 (IL4) and interleukin 7 (IL7). IL2 expression in mature thymocytes is monoallelic, which represents an unusual regulatory mode for controlling expression of a single gene. Targeted disruption of a similar gene in mice leads to ulcerative colitis-like disease, which suggests an essential role in the immune response to antigenic stimuli. (From LocusLink)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interleukin-2","conceptCode":"C20507","definition":"Interleukin-2 (153 aa, ~18 kDa) is encoded by the human IL2 gene. This protein is involved in T-cell proliferation, leukocyte stimulation and immune responses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE83-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"REEVESD","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7C65-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"IL12","valueDescription":"Interleukin-12","ValueMeaning":{"publicId":"2578188","version":"1","preferredName":"Interleukin-12","longName":"2578188","preferredDefinition":"Exhibiting a broad range of biological activities on T and natural killer cells, Interleukin-12 is a disulfide-bonded heterodimeric cytokine composed of a 35-kD IL12A subunit (IL-6 Superfamily) and a 40-kDa IL12B subunit (Type I Cytokine Receptor 3 Family). IL12 stimulates T-cell-independent production of IFN-gamma by PBMCs, enhances NK cell lytic activity, acts as a growth factor for T- and NK-cells, and is important for Th1 and Th2 cell differentiation. Lymphocyte responses to IL12 require NOS2A and are mediated by STAT4 activator of transcription. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interleukin-12","conceptCode":"C20514","definition":"Exhibiting a broad range of biological activities on T and natural killer cells, Interleukin-12 is a disulfide-bonded heterodimeric cytokine composed of a 35-kD IL12A subunit (IL-6 Superfamily) and a 40-kDa IL12B subunit (Type I Cytokine Receptor 3 Family). IL12 stimulates T-cell-independent production of IFN-gamma by PBMCs, enhances NK cell lytic activity, acts as a growth factor for T- and NK-cells, and is important for Th1 and Th2 cell differentiation. Lymphocyte responses to IL12 require NOS2A and are mediated by STAT4 activator of transcription. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE79-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7C6F-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"IL-3","valueDescription":"Interleukin-3","ValueMeaning":{"publicId":"2578189","version":"1","preferredName":"Interleukin-3","longName":"2578189","preferredDefinition":"Human interleukin-3 (152 aa, 17 kDa precursor) is encoded by the human interleukin-3 (IL3) gene. This protein is a potent growth-promoting cytokine that enhances the ability of the immune system to fight tumor cells. IL-3 supports proliferation of many hematopoietic cell types. It is involved in cell growth, differentiation and apoptosis in addition to possessing neurotrophic activity. Abnormalities in this protein may be associated with neurologic disorders.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interleukin-3","conceptCode":"C20439","definition":"Interleukin-3 (152 aa, ~17 kDa) is encoded by the human IL3 gene. This protein plays a role in neurotrophic activity and the proliferation of several types of hematopoietic lineage cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE7A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7C79-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"IL-6","valueDescription":"Interleukin-6","ValueMeaning":{"publicId":"2578190","version":"1","preferredName":"Interleukin-6","longName":"2578190","preferredDefinition":"Interleukin-6 (IL-6), a glycoprotein produced by activated T-cells and a variety of other cells, induces the production of IgM by B-cells and can be used to replace feeder cells for the growth and maintenance of B-cell hybridomas in vitro.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interleukin-6","conceptCode":"C20451","definition":"Interleukin-6 (212 aa, ~24 kDa) is encoded by the human IL6 gene. This protein is involved in signaling affecting a wide variety of cell types including monocytes, lymphocytes, hepatocytes and nerve cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE7B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7C83-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Imipenem/Cilastatin","valueDescription":"Imipenem-Cilastatin Sodium","ValueMeaning":{"publicId":"2578191","version":"1","preferredName":"Imipenem-Cilastatin Sodium","longName":"2578191","preferredDefinition":"A combination antibiotic containing Imipenem, a broad spectrum beta-lactam antibiotic, and Cilastatin Sodium, an agent that reduces metabolism of Imipenem by inhibiting dehydropeptidase, used in treating severe infections caused by multiresistant organisms.(NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Imipenem-Cilastatin Sodium","conceptCode":"C2338","definition":"A parenteral antibiotic preparation containing imipenem and cilastatin sodium with bactericidal activity. Imipenem, a broad spectrum beta-lactam antibiotic, binds to penicillin-binding proteins (PBP) on the inner membrane of the bacterial cell wall, thereby interfering with the cross-linkage of peptidoglycan chains critical for bacterial cell wall strength and rigidity. Cilastatin sodium is added to reduce breakdown of imipenem by kidney dehydropeptidase.  This agent is effective against both gram positive and negative bacteria and is often used in treating severe infections caused by multiresistant organisms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE7C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7C8D-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Imipramine","valueDescription":"Imipramine Hydrochloride","ValueMeaning":{"publicId":"2578192","version":"1","preferredName":"Imipramine Hydrochloride","longName":"2578192","preferredDefinition":"A synthetic tricyclic derivative, antidepressant Imipramine enhances monoamine neurotransmission in certain areas of the brain. It also induces sedation through histamine 1 receptor blockage; hypotension through beta-adrenergic blockage; and diverse parasympatholytic effects. Imipramine has less sedative effect than other members of its therapeutic family. It is used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Imipramine Hydrochloride","conceptCode":"C29116","definition":"The hydrochloride salt form of imipramine, a synthetic tricyclic derivative, antidepressant Imipramine enhances monoamine neurotransmission in certain areas of the brain. It also induces sedation through histamine 1 receptor blockage; hypotension through beta-adrenergic blockage; and diverse parasympatholytic effects. Imipramine has less sedative effect than other members of its therapeutic family. It is used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE7D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7C97-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Indinavir","valueDescription":"Indinavir Sulfate","ValueMeaning":{"publicId":"2578193","version":"1","preferredName":"Indinavir Sulfate","longName":"2578193","preferredDefinition":"A synthetic antiviral agent. Indinavir selectively inhibits human immunodeficiency virus (HIV) protease, an essential enzyme for replication and maturation of viral particles. HIV protease inhibition prevents the normal cleavage of gag-pol viral polyproteins, resulting in the release of immature, noninfectious virions and protection of healthy host cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indinavir Sulfate","conceptCode":"C1662","definition":"A synthetic antiviral agent. Indinavir selectively binds to the active site of human immunodeficiency virus (HIV) protease and inhibits its activity, preventing the protease-mediated cleavage of gag-pol viral polyproteins; as a result immature, noninfectious virions are produced.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE7E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7CA1-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Indomethicin","valueDescription":"Indomethacin","ValueMeaning":{"publicId":"2578194","version":"1","preferredName":"Indomethacin","longName":"2578194","preferredDefinition":"A synthetic nonsteroidal indole derivative with anti-inflammatory activity and chemopreventive properties. As a nonsteroidal anti-inflammatory drug (NSAID), indomethacin inhibits the enzyme cyclooxygenase, thereby preventing cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines. This agent also may inhibit the expression of multidrug-resistant protein type 1, resulting in increased efficacies of some antineoplastic agents in treating multi-drug resistant tumors. In addition, indomethacin activates phosphatases that inhibit the migration and proliferation of cancer cells and downregulates survivin, which may result in tumor cell apoptosis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indomethacin","conceptCode":"C576","definition":"A synthetic nonsteroidal indole derivative with anti-inflammatory activity and chemopreventive properties. As a nonsteroidal anti-inflammatory drug (NSAID), indomethacin inhibits the enzyme cyclooxygenase, thereby preventing cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines. This agent also may inhibit the expression of multidrug-resistant protein type 1, resulting in increased efficacies of some antineoplastic agents in treating multi-drug resistant tumors. In addition, indomethacin activates phosphatases that inhibit the migration and proliferation of cancer cells and downregulates survivin, which may result in tumor cell apoptosis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE7F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7CAB-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Influenza Vaccine","valueDescription":"Influenza Vaccines","ValueMeaning":{"publicId":"2578195","version":"1","preferredName":"Influenza Vaccines","longName":"2578195","preferredDefinition":"Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed or attenuated vaccines. The composition of the vaccines are changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The vaccine is usually bivalent or trivalent, containing one or two INFLUENZAVIRUS A strains and one INFLUENZAVIRUS B strain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Influenza Vaccines","conceptCode":"C0021403","definition":"Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed or attenuated vaccines. The composition of the vaccines are changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The vaccine is usually bivalent or trivalent, containing one or two INFLUENZAVIRUS A strains and one INFLUENZAVIRUS B strain.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE80-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7CB5-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Insulin, Glargine","valueDescription":"Insulin Glargine Recombinant","ValueMeaning":{"publicId":"2578196","version":"1","preferredName":"Insulin Glargine Recombinant","longName":"2578196v1.00","preferredDefinition":"A recombinant human insulin analog with long-acting, blood glucose-lowering activity. Insulin glargine, like regular types of human insulin, regulates glucose metabolism by binding to insulin receptors on muscle and fat cells, thereby facilitating the cellular uptake of glucose. This lowers blood glucose levels. At the same time, insulin glargine inhibits the liver's conversion of stored glycogen into glucose, which also contributes to lower blood glucose levels. Insulin glargine also inhibits lipolysis in adipose tissue, inhibits proteolysis, and enhances protein synthesis. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Insulin Glargine","conceptCode":"C47564","definition":"A recombinant human insulin analog with long-acting, blood glucose-lowering activity. Insulin glargine, like regular types of human insulin, regulates glucose metabolism by binding to insulin receptors on muscle and fat cells, thereby facilitating the cellular uptake of glucose. This lowers blood glucose levels. At the same time, insulin glargine inhibits the liver's conversion of stored glycogen into glucose, which also contributes to lower blood glucose levels. Insulin glargine also inhibits lipolysis in adipose tissue, inhibits proteolysis, and enhances protein synthesis. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE81-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"CLOHNES","dateModified":"2023-09-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7CBF-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Iron Dextran","valueDescription":"Iron Dextran Complex","ValueMeaning":{"publicId":"2578197","version":"1","preferredName":"Iron Dextran Complex","longName":"2578197v1.00","preferredDefinition":"A colloidal solution containing ferric oxyhydroxide complexed with polymerized dextran, used as a form of parenteral iron-replacement therapy. Upon administration and absorption, the iron dextran complex is removed from plasma by the reticuloendothelial system which cleaves it into the components iron and dextran; ferric iron subsequently binds to transferrin or is stored as hemosiderin or ferritin. Transferrin-bound iron is transported in the plasma to the liver, spleen and bone marrow, where is it is incorporated into hemoglobin (Hgb) and to muscle where it is incorporated into myoglobin (Mb). Use of this agent circumvents the gastrointestinal adverse effects commonly encountered with the use of orally administered iron salt preparations. Because of cross-reactivity with antibodies targeted against polysaccharides similar to dextran, anaphylactic reactions may occur with this type of iron formulation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Iron Dextran Complex","conceptCode":"C44394","definition":"A colloidal solution containing ferric oxyhydroxide complexed with polymerized dextran, used as a form of parenteral iron-replacement therapy. Upon administration and absorption, the iron dextran complex is removed from plasma by the reticuloendothelial system which cleaves it into the components iron and dextran; ferric iron subsequently binds to transferrin or is stored as hemosiderin or ferritin. Transferrin-bound iron is transported in the plasma to the liver, spleen and bone marrow, where is it is incorporated into hemoglobin (Hgb) and to muscle where it is incorporated into myoglobin (Mb). Use of this agent circumvents the gastrointestinal adverse effects commonly encountered with the use of orally administered iron salt preparations. Because of cross-reactivity with antibodies targeted against polysaccharides similar to dextran, anaphylactic reactions may occur with this type of iron formulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE82-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"CLOHNES","dateModified":"2023-09-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7CC9-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Isoniazid","valueDescription":"Isoniazid","ValueMeaning":{"publicId":"2578203","version":"1","preferredName":"Isoniazid","longName":"2578203","preferredDefinition":"A synthetic derivative of nicotinic acid with anti-mycobacterial properties.  Although its mechanism of action is still unclear, isoniazid appears to block the synthesis of mycolic acids, major components of the mycobacterial cell wall. This agent is only active against actively growing mycobacteria because, as a pro-drug, it requires activation in susceptible mycobacterial species. Isoniazid also interferes with mycobacterial metabolism of vitamin B6.  Resistance occurs due to decreased bacterial wall penetration. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Isoniazid","conceptCode":"C600","definition":"A synthetic derivative of nicotinic acid with anti-mycobacterial properties.  Although its mechanism of action is still unclear, isoniazid appears to block the synthesis of mycolic acids, major components of the mycobacterial cell wall. This agent is only active against actively growing mycobacteria because, as a pro-drug, it requires activation in susceptible mycobacterial species. Isoniazid also interferes with mycobacterial metabolism of vitamin B6.  Resistance occurs due to decreased bacterial wall penetration. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE88-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7CD3-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Isoproterenol Hydrochloride","valueDescription":"Isoproterenol Hydrochloride","ValueMeaning":{"publicId":"2578204","version":"1","preferredName":"Isoproterenol Hydrochloride","longName":"2578204","preferredDefinition":"A synthetic catechol compound and potent beta adrenergic agonist with peripheral vasodilator, bronchodilator, and cardiac stimulating properties. Isoproterenol exerts its effect on the beta1-receptors in the myocardium, thereby increasing heart rate and cardiac output. In addition, isoproterenol acts on beta2-receptors in bronchiolar and vascular smooth muscle, thereby causing smooth muscle relaxation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Isoproterenol Hydrochloride","conceptCode":"C29133","definition":"The hydrochloride salt form of isoproterenol, a synthetic catechol compound and potent beta adrenergic agonist with peripheral vasodilator, bronchodilator, and cardiac stimulating properties. Isoproterenol exerts its effect on the beta-1 adrenergic receptors in the myocardium, thereby increasing heart rate and cardiac output. In addition, isoproterenol acts on beta-2 adrenergic receptors in bronchiolar and vascular smooth muscle, thereby causing smooth muscle relaxation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE89-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7CDD-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Isosorbide Dinitrate","valueDescription":"Isosorbide Dinitrate","ValueMeaning":{"publicId":"2578205","version":"1","preferredName":"Isosorbide Dinitrate","longName":"2578205","preferredDefinition":"The dinitrate salt form of isosorbide, an organic nitrate with vasodilator activity. Isosorbide dinitrate relaxes vascular smooth muscle by formation of the free radical nitric oxide (NO), which is identical to the endothelium-derived relaxing factor (EDRF). NO activates guanylyl cyclase, thereby increasing the synthesis of cGMP within smooth muscle, resulting in dephosphorylation of light chain myosin and relaxation of peripheral arteries and veins. In addition, isosorbide dinitrate relaxes coronary arteries, thereby increasing the blood circulation through the ischemic area. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Isosorbide Dinitrate","conceptCode":"C29134","definition":"The dinitrate salt form of isosorbide, an organic nitrate with vasodilator activity. Isosorbide dinitrate relaxes vascular smooth muscle by formation of the free radical nitric oxide (NO), which is identical to the endothelium-derived relaxing factor (EDRF). NO activates guanylyl cyclase, thereby increasing the synthesis of cGMP within smooth muscle, resulting in dephosphorylation of light chain myosin and relaxation of peripheral arteries and veins. In addition, isosorbide dinitrate relaxes coronary arteries, thereby increasing the blood circulation through the ischemic area. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE8A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7CE7-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Isotretinoin","valueDescription":"13-cis Retinoic Acid","ValueMeaning":{"publicId":"2578199","version":"1","preferredName":"13-cis Retinoic Acid","longName":"2578199","preferredDefinition":"A topical dermatologic agent that is used in the treatment of acne vulgaris and several other skin diseases. The drug has teratogenic and other adverse effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Isotretinoin","conceptCode":"C603","definition":"A naturally-occurring retinoic acid with potential antineoplastic activity. Isotretinoin binds to and activates nuclear retinoic acid receptors (RARs); activated RARs serve as transcription factors that promote cell differentiation and apoptosis. This agent also exhibits immunomodulatory and anti-inflammatory responses and inhibits ornithine decarboxylase, thereby decreasing polyamine synthesis and keratinization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE84-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7CF1-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Isradipine","valueDescription":"Isradipine","ValueMeaning":{"publicId":"2578200","version":"1","preferredName":"Isradipine","longName":"2578200","preferredDefinition":"A dihydropyridine calcium channel blockers with antihypertensive and vasodilator activity. Isradipine blocks the calcium entry through the calcium ion channels of coronary and peripheral vascular smooth muscle, thereby dilating coronary arteries and peripheral arterioles. This increases oxygen delivery due to an increased blood flow and reduces oxygen requirements due to decrease in total peripheral resistance. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Isradipine","conceptCode":"C47577","definition":"A dihydropyridine calcium channel blockers with antihypertensive and vasodilator activities. Isradipine blocks the calcium entry through the calcium ion channels of coronary and peripheral vascular smooth muscle, thereby dilating coronary arteries and peripheral arterioles. This increases oxygen delivery due to an increased blood flow and reduces oxygen requirements due to decrease in total peripheral resistance. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE85-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7CFB-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Itraconazole","valueDescription":"Itraconazole","ValueMeaning":{"publicId":"2578206","version":"1","preferredName":"Itraconazole","longName":"2578206","preferredDefinition":"A synthetic triazole agent with antimycotic properties. Formulated for both topical and systemic use, itraconazole preferentially inhibits fugal cytochrome P450 enzymes, resulting in a decrease in fungal ergosterol synthesis.  Because of its low toxicity profile, this agent can be used for long-term maintenance treatment of chronic fungal infections. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Itraconazole","conceptCode":"C1138","definition":"A synthetic triazole agent with antimycotic properties. Formulated for both topical and systemic use, itraconazole preferentially inhibits fungal cytochrome P450 enzymes, resulting in a decrease in fungal ergosterol synthesis.  Because of its low toxicity profile, this agent can be used for long-term maintenance treatment of chronic fungal infections. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE8B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7D05-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"IV Fluid","valueDescription":"IV Fluid","ValueMeaning":{"publicId":"2578207","version":"1","preferredName":"IV Fluid","longName":"2578207","preferredDefinition":"A sterile liquid preparation infused into a vein.  IV fluid is prescribed as a replacement of fluid, electrolytes, calories, vitamins, and other nutritional substances.  In addition, IV fluids are used to administer blood products and medications such as chemotherapy.  Examples of IV fluids include Normal Saline, Ringers Solution, and Lactated Ringers Solution. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IV Fluid","conceptCode":"C29107","definition":"A sterile liquid preparation infused into a vein.  IV fluid is prescribed as a replacement of fluid, electrolytes, calories, vitamins, and other nutritional substances.  In addition, IV fluids are used to administer blood products and medications such as chemotherapy.  Examples of IV fluids include Normal Saline, Ringers Solution, and Lactated Ringers Solution. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE8C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7D0F-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ivermectin","valueDescription":"Ivermectin","ValueMeaning":{"publicId":"2578208","version":"1","preferredName":"Ivermectin","longName":"2578208","preferredDefinition":"A macrocyclic lactone derived from Streptomyces avermitilis with antiparasitic activity. Ivermectin exerts its anthelmintic effect via activating glutamate-gated chloride channels expressed on nematode neurons and pharyngeal muscle cells. Distinct from the channel opening induced by endogenous glutamate transmitter, ivermectin-activated channels open very slowly but essentially irreversibly. As a result, neurons or muscle cells remain at either hyperpolarisation or depolarization state, thereby resulting in paralysis and death of the parasites. Ivermectin does not readily pass the mammal blood-brain barrier to the central nervous system where glutamate-gated chloride channels locate, hence the hosts are relatively resistant to the effects of this agent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ivermectin","conceptCode":"C61796","definition":"An orally bioavailable macrocyclic lactone derived from Streptomyces avermitilis, with antiparasitic and potential anti-viral activities. Upon administration, ivermectin exerts its anthelmintic effect through binding and activating glutamate-gated chloride channels (GluCls) expressed on nematode neurons and pharyngeal muscle cells. This causes increased permeability of chloride ions, causing a state of hyperpolarization and results in the paralysis and death of the parasite. Ivermectin may exerts its antiviral effect, including its potential activity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), by binding to the importin (IMP) alpha/beta1 heterodimer, which is responsible for the nuclear import of viral proteins such as the integrase (IN) protein. This inhibits nuclear import of host and viral proteins and may inhibit viral replication.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE8D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"REEVESD","dateModified":"2008-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7D19-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"EyePromise EZ Tears","valueDescription":"EyePromise EZ Tears","ValueMeaning":{"publicId":"5039956","version":"1","preferredName":"EyePromise EZ Tears","longName":"5039956","preferredDefinition":"EyePromise EZ Tears is the brand name of a vitamin-containing soft gel formulation that is indicated to treat symptoms associated with dry eyes.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"233F048B-7B23-7571-E050-BB89AD43473A","latestVersionIndicator":"Yes","beginDate":"2015-10-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-10-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-98C1-18F7-E053-F662850A60B1","beginDate":"2015-10-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Tropicamide Ophthalmic Solution","valueDescription":"Tropicamide","ValueMeaning":{"publicId":"4934734","version":"1","preferredName":"Tropicamide","longName":"4934734","preferredDefinition":"A synthetic muscarinic antagonist with actions similar to atropine and with an anticholinergic property. Upon ocular administration, tropicamide binds to and blocks the muscarinic receptors in the sphincter and ciliary muscle in the eye.  This inhibits the responses from cholinergic stimulation, producing dilation of the pupil and paralysis of the ciliary muscle. Tropicamide is a diagnostic agent and is used to produce short-duration mydriasis and cycloplegia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tropicamide","conceptCode":"C47776","definition":"A synthetic muscarinic antagonist with actions similar to atropine and with an anticholinergic property. Upon ocular administration, tropicamide binds to and blocks the muscarinic receptors in the sphincter and ciliary muscle in the eye.  This inhibits the responses from cholinergic stimulation, producing dilation of the pupil and paralysis of the ciliary muscle. Tropicamide is a diagnostic agent and is used to produce short-duration mydriasis and cycloplegia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1C95F791-730B-0539-E050-BB89AD433951","latestVersionIndicator":"Yes","beginDate":"2015-08-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-08-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-98CB-18F7-E053-F662850A60B1","beginDate":"2015-08-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Loxapine Succinate","valueDescription":"Loxapine Succinate","ValueMeaning":{"publicId":"5037632","version":"1","preferredName":"Loxapine Succinate","longName":"5037632","preferredDefinition":"The succinate salt form of loxapine, a tricyclic dibenzoxazepine antipsychotic agent with antiemetic, sedative, anticholinergic, and antiadrenergic actions. Loxapine succinate exerts its actions by blocking the dopamine receptors at postsynaptic receptor sites in the limbic system, cortical system and basal ganglia, thereby reducing the hallucinations and delusions that are associated with schizophrenia. This agent also exerts extrapyramidal side effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Loxapine Succinate","conceptCode":"C47590","definition":"The succinate salt form of loxapine, a tricyclic dibenzoxazepine antipsychotic agent with antiemetic, sedative, anticholinergic, and antiadrenergic actions. Loxapine succinate exerts its actions by blocking the dopamine receptors at postsynaptic receptor sites in the limbic system, cortical system and basal ganglia, thereby reducing the hallucinations and delusions that are associated with schizophrenia. This agent also exerts extrapyramidal side effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"22B50B64-FEF6-FDDF-E050-BB89AD430E1D","latestVersionIndicator":"Yes","beginDate":"2015-10-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-10-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-98D5-18F7-E053-F662850A60B1","beginDate":"2015-10-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Herbal Polysaccharide Saliva Substitute","valueDescription":"Herbal Polysaccharide Saliva Substitute","ValueMeaning":{"publicId":"5022332","version":"1","preferredName":"Herbal Polysaccharide Saliva Substitute","longName":"5022332","preferredDefinition":"A plant-based, proprietary formulation of saliva substitute with potential anti-xerostomia activity. Extracted from the plant called yerba santa (holy herb), herbal polysaccharide saliva substitute contains plant mucins, which is nearly identical to that of human mucous membranes. Upon direct application using the polysaccharide-containing spray, a protective film of moisture is deposited over the mucous membranes of the mouth and throat. The xylitol in this preparation protects against the formation of harmful oral flora and thus helps to prevent cavities. Moreover, this agent has shown a demineralization effect on dentin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Herbal Polysaccharide Saliva Substitute","conceptCode":"C95735","definition":"A plant-based, proprietary formulation of saliva substitute with potential anti-xerostomia activity. Extracted from the plant called yerba santa (holy herb), herbal polysaccharide saliva substitute contains plant mucins, which is nearly identical to that of human mucous membranes. Upon direct application using the polysaccharide-containing spray, a protective film of moisture is deposited over the mucous membranes of the mouth and throat. The xylitol in this preparation protects against the formation of harmful oral flora and thus helps to prevent cavities. Moreover, this agent has shown a demineralization effect on dentin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2055C609-E3D4-FB23-E050-BB89AD436F39","latestVersionIndicator":"Yes","beginDate":"2015-09-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-09-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-98DF-18F7-E053-F662850A60B1","beginDate":"2015-09-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Tranylcypromine Sulfate","valueDescription":"Tranylcypromine Sulfate","ValueMeaning":{"publicId":"5118533","version":"1","preferredName":"Tranylcypromine Sulfate","longName":"5118533","preferredDefinition":"The sulfate salt form of tranylcypromine, an orally bioavailable, nonselective, irreversible, non-hydrazine inhibitor of both monoamine oxidase (MAO) and lysine-specific demethylase 1 (LSD1/BHC110), with antidepressant and anxiolytic activities, and potential antineoplastic activities. Upon oral administration, tranylcypromine exerts its antidepressant and anxiolytic effects through the inhibition of MAO, an enzyme that catalyzes the breakdown of the monoamine neurotransmitters serotonin, norepinephrine, epinephrine and dopamine. This increases the concentrations and activity of these neurotransmitters. Tranylcypromine exerts its antineoplastic effect through the inhibition of LSD1. Inhibition of LSD1 prevents the transcription of LSD1 target genes. LSD1, a flavin-dependent monoamine oxidoreductase and a histone demethylase, is upregulated in a variety of cancers and plays a key role in tumor cell proliferation, migration, and invasion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tranylcypromine Sulfate","conceptCode":"C61980","definition":"The sulfate salt form of tranylcypromine, an orally bioavailable, nonselective, irreversible, non-hydrazine inhibitor of both monoamine oxidase (MAO) and lysine-specific demethylase 1 (LSD1/BHC110), with antidepressant and anxiolytic activities, and potential antineoplastic activities. Upon oral administration, tranylcypromine exerts its antidepressant and anxiolytic effects through the inhibition of MAO, an enzyme that catalyzes the breakdown of the monoamine neurotransmitters serotonin, norepinephrine, epinephrine and dopamine. This increases the concentrations and activity of these neurotransmitters. Tranylcypromine exerts its antineoplastic effect through the inhibition of LSD1. Inhibition of LSD1 prevents the transcription of LSD1 target genes. LSD1, a flavin-dependent monoamine oxidoreductase and a histone demethylase, is upregulated in a variety of cancers and plays a key role in tumor cell proliferation, migration, and invasion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2AE48541-AB71-A010-E050-BB89AD431501","latestVersionIndicator":"Yes","beginDate":"2016-02-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-02-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-98E9-18F7-E053-F662850A60B1","beginDate":"2016-02-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Oxiconazole Nitrate","valueDescription":"Oxiconazole Nitrate","ValueMeaning":{"publicId":"5085112","version":"1","preferredName":"Oxiconazole Nitrate","longName":"5085112","preferredDefinition":"The nitrate salt form of oxiconazole, a broad spectrum imidazole derivative with antifungal activity. Although the exact mechanism of action has yet to be fully elucidated, oxiconazole, like other azole antifungals, most likely inhibits the cytochrome P450-dependent demethylation of lanosterol. This prevents the synthesis of ergosterol which is a crucial component of fungal cell membrane. By disrupting fungal cell membrane synthesis and integrity, oxiconazole alters fungal cell membrane permeability, promotes loss of essential intracellular components and eventually inhibits fungal cell growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oxiconazole Nitrate","conceptCode":"C47644","definition":"The nitrate salt form of oxiconazole, a broad spectrum imidazole derivative with antifungal activity. Although the exact mechanism of action has yet to be fully elucidated, oxiconazole, like other azole antifungals, most likely inhibits the cytochrome P450-dependent demethylation of lanosterol. This prevents the synthesis of ergosterol which is a crucial component of fungal cell membrane. By disrupting fungal cell membrane synthesis and integrity, oxiconazole alters fungal cell membrane permeability, promotes loss of essential intracellular components and eventually inhibits fungal cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"26F7D9CA-994B-550C-E050-BB89AD4311BF","latestVersionIndicator":"Yes","beginDate":"2015-12-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-12-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-98F3-18F7-E053-F662850A60B1","beginDate":"2015-12-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Aluminum Hydroxide/Magnesium Hydroxide/Simethicone.","valueDescription":"Aluminum Hydroxide/Magnesium Hydroxide Simethicone Combination","ValueMeaning":{"publicId":"5026535","version":"1","preferredName":"Aluminum Hydroxide/Magnesium Hydroxide Simethicone Combination","longName":"5026535","preferredDefinition":"An oral suspension containing aluminum hydroxide and magnesium hydroxide, with antacid effects. Aluminum hydroxide and magnesium hydroxide neutralizes or reduces gastric acid, thereby relieving symptoms associated with indigestion, gastritis, and gastroesophageal disease (GERD). Combined with other liquid ingredients (such as lidocaine and diphenhydramine), this antacid provides relief for painful stomatitis, mucositis, and esophagitis associated with both chemotherapy and radiation therapy.: A mixture of polydimethylsiloxanes with antifoaming and anti-bloating effects. Simethicone reduces the surface tension of gas bubbles causing them to coalesce into larger bubbles that can be passed more easily by belching or flatulence.: A collection of things that have been assembled together to form a new whole.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aluminum Hydroxide/Magnesium Hydroxide","conceptCode":"C1149","definition":"An oral suspension containing aluminum hydroxide and magnesium hydroxide, with antacid effects. Aluminum hydroxide and magnesium hydroxide neutralizes or reduces gastric acid, thereby relieving symptoms associated with indigestion, gastritis, and gastroesophageal disease (GERD). Combined with other liquid ingredients (such as lidocaine and diphenhydramine), this antacid provides relief for painful stomatitis, mucositis, and esophagitis associated with both chemotherapy and radiation therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Simethicone","conceptCode":"C29453","definition":"A mixture of polydimethylsiloxanes with antifoaming and anti-bloating effects. Simethicone reduces the surface tension of gas bubbles causing them to coalesce into larger bubbles that can be passed more easily by belching or flatulence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Combination","conceptCode":"C61517","definition":"A collection of things that have been assembled together to form a new whole.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"20E2CCF0-ED62-0D47-E050-BB89AD434682","latestVersionIndicator":"Yes","beginDate":"2015-09-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-09-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-98FD-18F7-E053-F662850A60B1","beginDate":"2015-09-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Aclidinium Bromide","valueDescription":"Aclidinium Bromide","ValueMeaning":{"publicId":"5229557","version":"1","preferredName":"Aclidinium Bromide","longName":"5229557","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aclidinium Bromide","conceptCode":"C75999","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3103B130-D13F-2546-E050-BB89AD43403D","latestVersionIndicator":"Yes","beginDate":"2016-04-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-04-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9907-18F7-E053-F662850A60B1","beginDate":"2016-04-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Apixaban","valueDescription":"Apixaban","ValueMeaning":{"publicId":"5229559","version":"1","preferredName":"Apixaban","longName":"5229559","preferredDefinition":"An orally active inhibitor of coagulation factor Xa with anticoagulant activity. Apixaban directly inhibits factor Xa, thereby interfering with the conversion of prothrombin to thrombin and preventing formation of cross-linked fibrin clots.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Apixaban","conceptCode":"C61308","definition":"An orally active inhibitor of coagulation factor Xa with anticoagulant activity. Apixaban directly inhibits factor Xa, thereby interfering with the conversion of prothrombin to thrombin and preventing formation of cross-linked fibrin clots.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3103B130-D165-2546-E050-BB89AD43403D","latestVersionIndicator":"Yes","beginDate":"2016-04-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-04-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9911-18F7-E053-F662850A60B1","beginDate":"2016-04-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"L-methylfolate","valueDescription":"L-methylfolate","ValueMeaning":{"publicId":"5260858","version":"1","preferredName":"L-methylfolate","longName":"5260858","preferredDefinition":"A nutritional supplement containing the biologically active form of the B9 vitamin folate, 5-methyltetrahydrofolate (L-methylfolate), with potential antineoplastic activity. Upon administration, L-methylfolate is able to provide methyl groups allowing an increase in the level of DNA methylation in the promoter regions of certain tumor-promoting genes, thereby reversing the DNA hypomethylation of these genes and inactivating them. This may result in a decrease of both tumor cell proliferation and tumor progression. In addition, administration of L-methylfolate may sensitize tumor cells to the cytotoxic effects of other chemotherapeutic agents. Unlike folic acid, L-methylfolate is able to cross the blood brain barrier and could be beneficial in the treatment of brain tumors. DNA hypomethylation of certain genes leads to chromosome instability and contributes to tumor development.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"L-methylfolate","conceptCode":"C107240","definition":"A nutritional supplement containing the biologically active form of the B9 vitamin folate, 5-methyltetrahydrofolate (L-methylfolate), with potential antineoplastic activity. Upon administration, L-methylfolate is able to provide methyl groups allowing an increase in the level of DNA methylation in the promoter regions of certain tumor-promoting genes, thereby reversing the DNA hypomethylation of these genes and inactivating them. This may result in a decrease of both tumor cell proliferation and tumor progression. In addition, administration of L-methylfolate may sensitize tumor cells to the cytotoxic effects of other chemotherapeutic agents. Unlike folic acid, L-methylfolate is able to cross the blood brain barrier and could be beneficial in the treatment of brain tumors. DNA hypomethylation of certain genes leads to chromosome instability and contributes to tumor development.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32BBEB8A-62F7-445B-E050-BB89AD4334B3","latestVersionIndicator":"Yes","beginDate":"2016-05-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-991B-18F7-E053-F662850A60B1","beginDate":"2016-05-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Etoricoxib","valueDescription":"Etoricoxib","ValueMeaning":{"publicId":"5255766","version":"1","preferredName":"Etoricoxib","longName":"5255766","preferredDefinition":"A synthetic, nonsteroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic, and potential antineoplastic properties. Etoricoxib specifically binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in inhibition of the conversion of arachidonic acid into prostaglandins. Inhibition of COX-2 may induce apoptosis and inhibit tumor cell proliferation and angiogenesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etoricoxib","conceptCode":"C52188","definition":"A synthetic, nonsteroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic, and potential antineoplastic properties. Etoricoxib specifically binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in inhibition of the conversion of arachidonic acid into prostaglandins. Inhibition of COX-2 may induce apoptosis and inhibit tumor cell proliferation and angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32936C88-8CB3-BF10-E050-BB89AD436D35","latestVersionIndicator":"Yes","beginDate":"2016-05-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9925-18F7-E053-F662850A60B1","beginDate":"2016-05-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ciprofloxacin/Dexamethasone (Ciprodex)","valueDescription":"Ciprofloxacin Dexamethasone (Ciprodex)","ValueMeaning":{"publicId":"5498123","version":"1","preferredName":"Ciprofloxacin Dexamethasone (Ciprodex)","longName":"5498123","preferredDefinition":"A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication.  This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04): A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04): A drug product that contains one or more active and/or inactive ingredients; it is intended to treat, prevent or alleviate the symptoms of disease. This term does not refer to the individual ingredients that make up the product.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ciprofloxacin","conceptCode":"C375","definition":"A synthetic broad spectrum fluoroquinolone antibiotic. Ciprofloxacin binds to and inhibits bacterial DNA gyrase, an enzyme essential for DNA replication.  This agent is more active against Gram-negative bacteria than Gram-positive bacteria. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Dexamethasone","conceptCode":"C422","definition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Medication","conceptCode":"C459","definition":"A drug product that contains one or more active and/or inactive ingredients; it is intended to treat, prevent or alleviate the symptoms of disease. This term does not refer to the individual ingredients that make up the product.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3DFA455F-056C-5B69-E053-F662850A61BC","latestVersionIndicator":"Yes","beginDate":"2016-10-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-10-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-992F-18F7-E053-F662850A60B1","beginDate":"2016-10-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Triamcinolone","valueDescription":"Triamcinolone","ValueMeaning":{"publicId":"3305278","version":"1","preferredName":"Triamcinolone","longName":"3305278","preferredDefinition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. Upon cell entry, triamcinolone binds to and activates the glucocorticoid receptor, which leads to translocation of the ligand-receptor complex to the nucleus and induces expression of glucocorticoid-responsive genes such as lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both mediators of inflammation. In addition, pro-inflammatory cytokine production, including interleukin (IL)-1and IL-6, and the activation of cytotoxic T-lymphocytes is also inhibited. T-cells are prevented from making IL-2 and proliferating. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis through increasing Ikappa-B expression and curtailing activation of nuclear factor (NF)kappa-B.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Triamcinolone","conceptCode":"C901","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. Upon cell entry, triamcinolone binds to and activates the glucocorticoid receptor, which leads to translocation of the ligand-receptor complex to the nucleus and induces expression of glucocorticoid-responsive genes such as lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both mediators of inflammation. In addition, pro-inflammatory cytokine production, including interleukin (IL)-1and IL-6, and the activation of cytotoxic T-lymphocytes is also inhibited. T-cells are prevented from making IL-2 and proliferating. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis through increasing Ikappa-B expression and curtailing activation of nuclear factor (NF)kappa-B.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1F1A4B8-0D8C-8518-E040-BB89AD435A01","latestVersionIndicator":"Yes","beginDate":"2011-11-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9939-18F7-E053-F662850A60B1","beginDate":"2016-12-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Prednisolone","valueDescription":"Prednisolone","ValueMeaning":{"publicId":"3305273","version":"1","preferredName":"Prednisolone","longName":"3305273","preferredDefinition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisolone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prednisolone","conceptCode":"C769","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisolone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1F1A4B8-0CFE-8518-E040-BB89AD435A01","latestVersionIndicator":"Yes","beginDate":"2011-11-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9943-18F7-E053-F662850A60B1","beginDate":"2016-12-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Liotrix","valueDescription":"Liotrix","ValueMeaning":{"publicId":"3305292","version":"1","preferredName":"Liotrix","longName":"3305292","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liotrix","conceptCode":"C87251","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1F1F71A-7142-08C4-E040-BB89AD43052C","latestVersionIndicator":"Yes","beginDate":"2011-11-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-994D-18F7-E053-F662850A60B1","beginDate":"2016-12-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Liothyronine","valueDescription":"Liothyronine","ValueMeaning":{"publicId":"3305290","version":"1","preferredName":"Liothyronine","longName":"3305290","preferredDefinition":"A therapeutic formulation of the primary physiologically active form of endogenous thyroid hormone. In vivo, triiodothyronine enters the nucleus and binds to nuclear thyroid hormone receptors that subsequently bind to thyroid response elements (TREs) located in target genes. Receptor binding by triiodothyronine in combination with recruited coactivators results in maximal transcriptional activation after binding to TREs; in general, binding of thyroid hormone receptor alone to TREs leads to repression of gene transcription (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liothyronine","conceptCode":"C907","definition":"A therapeutic formulation of the primary physiologically active form of endogenous thyroid hormone. In vivo, triiodothyronine enters the nucleus and binds to nuclear thyroid hormone receptors that subsequently bind to thyroid response elements (TREs) located in target genes. Receptor binding by triiodothyronine in combination with recruited coactivators results in maximal transcriptional activation after binding to TREs; in general, binding of thyroid hormone receptor alone to TREs leads to repression of gene transcription (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1F1F71A-711C-08C4-E040-BB89AD43052C","latestVersionIndicator":"Yes","beginDate":"2011-11-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9957-18F7-E053-F662850A60B1","beginDate":"2016-12-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fluticasone","valueDescription":"Fluticasone","ValueMeaning":{"publicId":"5607318","version":"1","preferredName":"Fluticasone","longName":"5607318","preferredDefinition":"A synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, antiinflammatory and antipruritic effects. Fluticasone binds and activates glucocorticoid receptor, resulting in the activation of lipocortin. Lipocortin, in turn, inhibits cytosolic phospholipase A2, which triggers a cascade of reactions involved in the synthesis of inflammatory mediators, such as prostaglandins and leukotrienes. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leads to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluticasone","conceptCode":"C61767","definition":"A synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, antiinflammatory and antipruritic effects. Fluticasone binds and activates glucocorticoid receptor, resulting in the activation of lipocortin. Lipocortin, in turn, inhibits cytosolic phospholipase A2, which triggers a cascade of reactions involved in the synthesis of inflammatory mediators, such as prostaglandins and leukotrienes. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leads to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4401AFC3-14A3-48B8-E053-F662850A4449","latestVersionIndicator":"Yes","beginDate":"2016-12-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-12-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9961-18F7-E053-F662850A60B1","beginDate":"2016-12-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Therapeutic Testosterone","valueDescription":"Therapeutic Testosterone","ValueMeaning":{"publicId":"5608403","version":"1","preferredName":"Therapeutic Testosterone","longName":"5608403","preferredDefinition":"A synthetic form of the endogenous androgenic steroid testosterone. In vivo, testosterone is irreversibly converted to dihydrotestosterone (DHT) in target tissues by the enzyme 5-alpha reductase. Testosterone or DHT ligand-androgen receptor complexes act as transcription factor complexes, stimulating the expression of various responsive genes. DHT binds with higher affinity to androgen receptors than testosterone, activating gene expression more efficiently. In addition, testosterone is irreversibly converted to estradiol by the enzyme complex aromatase, particularly in the liver and adipose tissue. Testosterone and DHT promote the development and maintenance of male sex characteristics related to the internal and external genitalia, skeletal muscle, and hair follicles; estradiol promotes epiphyseal maturation and bone mineralization. Due to rapid metabolism by the liver, therapeutic testosterone is generally administered as an ester derivative.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Testosterone","conceptCode":"C862","definition":"A synthetic form of the endogenous androgenic steroid testosterone. In vivo, testosterone is irreversibly converted to dihydrotestosterone (DHT) in target tissues by the enzyme 5-alpha reductase. Testosterone or DHT ligand-androgen receptor complexes act as transcription factor complexes, stimulating the expression of various responsive genes. DHT binds with higher affinity to androgen receptors than testosterone, activating gene expression more efficiently. In addition, testosterone is irreversibly converted to estradiol by the enzyme complex aromatase, particularly in the liver and adipose tissue. Testosterone and DHT promote the development and maintenance of male sex characteristics related to the internal and external genitalia, skeletal muscle, and hair follicles; estradiol promotes epiphyseal maturation and bone mineralization. Due to rapid metabolism by the liver, therapeutic testosterone is generally administered as an ester derivative.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"441D4C30-4AD4-5D0E-E053-F662850A708E","latestVersionIndicator":"Yes","beginDate":"2016-12-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-12-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-996B-18F7-E053-F662850A60B1","beginDate":"2016-12-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Adalimumab","valueDescription":"Adalimumab","ValueMeaning":{"publicId":"5608404","version":"1","preferredName":"Adalimumab","longName":"5608404","preferredDefinition":"A recombinant, human IgG1 monoclonal antibody directed against tumor necrosis factor-alpha (TNF-alpha), with immunomodulating activity. Upon administration, adalimumab binds to TNF-alpha, thereby preventing its binding to the p55 and p75 TNF cell surface receptors and inhibiting TNF-mediated immune responses. TNF-alpha, a pro-inflammatory cytokine, is upregulated in various autoimmune diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adalimumab","conceptCode":"C65216","definition":"A recombinant, human IgG1 monoclonal antibody directed against tumor necrosis factor-alpha (TNF-alpha), with immunomodulating activity. Upon administration, adalimumab binds to TNF-alpha, thereby preventing its binding to the p55 and p75 TNF cell surface receptors and inhibiting TNF-mediated immune responses. TNF-alpha, a pro-inflammatory cytokine, is upregulated in various autoimmune diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"441D4C30-4AF9-5D0E-E053-F662850A708E","latestVersionIndicator":"Yes","beginDate":"2016-12-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-12-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9975-18F7-E053-F662850A60B1","beginDate":"2016-12-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Marizomib","valueDescription":"Marizomib","ValueMeaning":{"publicId":"5621726","version":"1","preferredName":"Marizomib","longName":"5621726","preferredDefinition":"A naturally-occurring salinosporamide, isolated from the marine actinomycete Salinospora tropica, with potential antineoplastic activity. Marizomib irreversibly binds to and inhibits the 20S catalytic core subunit of the proteasome by covalently modifying its active site threonine residues; inhibition of ubiquitin-proteasome mediated proteolysis results in an accumulation of poly-ubiquitinated proteins, which may result in the disruption of cellular processes, cell cycle arrest, the induction of apoptosis, and the inhibition of tumor growth and angiogenesis. This agent more may more potent and selective than the proteasome inhibitor bortezomib.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Marizomib","conceptCode":"C64634","definition":"A naturally-occurring salinosporamide, isolated from the marine actinomycete Salinospora tropica, with potential antineoplastic activity. Marizomib irreversibly binds to and inhibits the 20S catalytic core subunit of the proteasome by covalently modifying its active site threonine residues; inhibition of ubiquitin-proteasome mediated proteolysis results in an accumulation of poly-ubiquitinated proteins, which may result in the disruption of cellular processes, cell cycle arrest, the induction of apoptosis, and the inhibition of tumor growth and angiogenesis. This agent more may more potent and selective than the proteasome inhibitor bortezomib.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AECAE5-BC0F-28A7-E053-F662850AD609","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-997F-18F7-E053-F662850A60B1","beginDate":"2017-01-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Daratumumab","valueDescription":"Daratumumab","ValueMeaning":{"publicId":"5621727","version":"1","preferredName":"Daratumumab","longName":"5621727","preferredDefinition":"A fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. The binding of anti-CD38 monoclonal antibody to natural killer (NK) cells mimics the normal CD38-CD31 interaction on the NK cell surface. CD38 is also present on multiple myeloma (MM) cells and plasma leukemia cells; this agent may preferentially bind these cells, triggering antitumoral antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). CD38, a cell surface glycoprotein, is present on various immune cells and has been shown to regulate the cytotoxic response of activated NK cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Daratumumab","conceptCode":"C74007","definition":"A human immunoglobulin G1-kappa (IgG1k) monoclonal antibody directed against the cell surface glycoprotein CD38, with immunomodulating and antineoplastic activities. Upon administration, daratumumab targets and binds to CD38 expressed on tumor cells. This triggers direct cell killing, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cell mediated phagocytosis (ADCP) and antibody-mediated complement dependent cytotoxicity (CDC) in CD38-expressing tumor cells. In addition, binding to CD38 by daratumumab depletes CD38-expressing immunosuppressive regulatory T- and B-cells and myeloid-derived suppressor cells (MDSCs). CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AECAE5-BC32-28A7-E053-F662850AD609","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9989-18F7-E053-F662850A60B1","beginDate":"2017-01-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Elotuzumab","valueDescription":"Elotuzumab","ValueMeaning":{"publicId":"5621728","version":"1","preferredName":"Elotuzumab","longName":"5621728","preferredDefinition":"A humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity. Elotuzumab binds to the CS1 antigen, which may trigger antibody-dependent cellular cytotoxicity (ADCC) in cells expressing CS1. CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is highly expressed by multiple myeloma cells, but minimally expressed by normal cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Elotuzumab","conceptCode":"C66982","definition":"A humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity. Elotuzumab binds to the CS1 antigen, which may trigger antibody-dependent cellular cytotoxicity (ADCC) in cells expressing CS1. CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is highly expressed by multiple myeloma cells, but minimally expressed by normal cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AECAE5-BC55-28A7-E053-F662850AD609","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9993-18F7-E053-F662850A60B1","beginDate":"2017-01-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ruxolitinib","valueDescription":"Ruxolitinib","ValueMeaning":{"publicId":"5125106","version":"1","preferredName":"Ruxolitinib","longName":"5125106","preferredDefinition":"An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ruxolitinib","conceptCode":"C77888","definition":"An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C0D42D8-A87E-AEAF-E050-BB89AD430679","latestVersionIndicator":"Yes","beginDate":"2016-02-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-999D-18F7-E053-F662850A60B1","beginDate":"2017-01-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"IVIG","valueDescription":"Intravenous Route of Administration Immunoglobulin Therapy","ValueMeaning":{"publicId":"5621730","version":"1","preferredName":"Intravenous Route of Administration Immunoglobulin Therapy","longName":"5621730","preferredDefinition":"Administration within or into a vein or veins.: The use of immunoglobulins in the treatment of any disease or disorder.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intravenous Route of Administration","conceptCode":"C38276","definition":"Administration of a drug within or into a vein or veins. Introduction of the drug directly into venous circulation results in 100% bioavailability due to an absence of the absorption phase, provides a precise and continuous mode of drug therapy, especially for drugs with a narrow therapeutic index.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Immunoglobulin Therapy","conceptCode":"C62710","definition":"The use of immunoglobulins in the treatment of any disease or disorder.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AECAE5-BC90-28A7-E053-F662850AD609","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-99A7-18F7-E053-F662850A60B1","beginDate":"2017-01-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Insulin Aspart","valueDescription":"Insulin Aspart","ValueMeaning":{"publicId":"5623180","version":"1","preferredName":"Insulin Aspart","longName":"5623180","preferredDefinition":"A recombinant human insulin analog with rapid-acting, blood glucose-lowering activity. Insulin aspart, acting faster than regular human insulin, regulates glucose metabolism by binding to insulin receptors on muscle and fat cells, thereby facilitating the cellular uptake of glucose. This lowers blood glucose levels. At the same time, insulin aspart inhibits the liver's conversion of stored glycogen into glucose, which also contributes to lower blood glucose levels. Insulin aspart also inhibits lipolysis in adipose tissue, inhibits proteolysis, and enhances protein synthesis. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Insulin Aspart","conceptCode":"C47563","definition":"A recombinant human insulin analog with rapid-acting, blood glucose-lowering activity. Insulin aspart, acting faster than regular human insulin, regulates glucose metabolism by binding to insulin receptors on muscle and fat cells, thereby facilitating the cellular uptake of glucose. This lowers blood glucose levels. At the same time, insulin aspart inhibits the liver's conversion of stored glycogen into glucose, which also contributes to lower blood glucose levels. Insulin aspart also inhibits lipolysis in adipose tissue, inhibits proteolysis, and enhances protein synthesis. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45D6B528-6913-1647-E053-F662850A38DC","latestVersionIndicator":"Yes","beginDate":"2017-01-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-99B1-18F7-E053-F662850A60B1","beginDate":"2017-01-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Canagliflozin","valueDescription":"Canagliflozin","ValueMeaning":{"publicId":"5623182","version":"1","preferredName":"Canagliflozin","longName":"5623182","preferredDefinition":"A C-glucoside with a thiophene ring that is an orally available inhibitor of sodium-glucose transporter 2 (SGLT2) with antihyperglycemic activity. Canagliflozin is also able to reduce body weight and has a low risk for hypoglycemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Canagliflozin","conceptCode":"C91018","definition":"A C-glucoside with a thiophene ring that is an orally available inhibitor of sodium-glucose transporter 2 (SGLT2) with antihyperglycemic activity. Canagliflozin is also able to reduce body weight and has a low risk for hypoglycemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45D6B528-6939-1647-E053-F662850A38DC","latestVersionIndicator":"Yes","beginDate":"2017-01-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-99BB-18F7-E053-F662850A60B1","beginDate":"2017-01-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Tylenol Multi Symptom","valueDescription":"Acetaminophen-based Oral Cough and Cold Preparation","ValueMeaning":{"publicId":"5697159","version":"1","preferredName":"Acetaminophen-based Oral Cough and Cold Preparation","longName":"5697159","preferredDefinition":"Any of the commercial combination preparations, by Novartis, containing a combination of any of the following agents: the analgesic antipyretic acetaminophen, an antihistamine (chlorpheniramine maleate or brompheniramine maleate), the expectorant guaifenesin, the antitussive dextromethorphan maleate and/or the decongestant pseudoephedrine hydrochloride. Comtrex preparations are used to relieve symptoms of cold, cough and flu.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acetaminophen-based Oral Cough and Cold Preparation","conceptCode":"C28940","definition":"A combination preparation containing the analgesic acetaminophen and a combination of one or more of the following agents: an antihistamine (chlorpheniramine maleate or brompheniramine maleate), the expectorant guaifenesin, the antitussive dextromethorphan maleate and/or the decongestant pseudoephedrine hydrochloride or phenylephrine hydrochloride. These preparations are used to relieve symptoms of cold, cough and flu.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A13386C-3AB1-7A45-E053-F662850A481C","latestVersionIndicator":"Yes","beginDate":"2017-03-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-03-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-99C5-18F7-E053-F662850A60B1","beginDate":"2017-03-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Albendazole","valueDescription":"Albendazole","ValueMeaning":{"publicId":"5701697","version":"1","preferredName":"Albendazole","longName":"5701697","preferredDefinition":"A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Albendazole","conceptCode":"C47384","definition":"A broad-spectrum, synthetic benzimidazole-derivative anthelmintic. Albendazole interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. Albendazole is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. Albendazole may also be used to treat a variety of other roundworm infections. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A4D3A46-8D9A-2398-E053-F662850A2160","latestVersionIndicator":"Yes","beginDate":"2017-03-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-03-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-99CF-18F7-E053-F662850A60B1","beginDate":"2017-03-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Febuxostat","valueDescription":"Febuxostat (Uloric, Adenuric)","ValueMeaning":{"publicId":"5727117","version":"1","preferredName":"Febuxostat (Uloric, Adenuric)","longName":"5727117","preferredDefinition":"An orally available, non-purine inhibitor of xanthine oxidase with uric acid lowering activity. Upon oral administration, febuxostat selectively and noncompetitively inhibits the activity of xanthine oxidase, an enzyme that converts oxypurines, including hypoxanthine and xanthine, into uric acid. By inhibiting xanthine oxidase, uric acid production is reduced and serum uric acid levels are lowered. Febuxostat may provide protection against acute renal failure caused by the excessive release of uric acid that occurs upon massive tumor cell lysis resulting from the treatment of some malignancies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Febuxostat","conceptCode":"C65629","definition":"An orally available, non-purine inhibitor of xanthine oxidase with uric acid lowering activity. Upon oral administration, febuxostat selectively and noncompetitively inhibits the activity of xanthine oxidase, an enzyme that converts oxypurines, including hypoxanthine and xanthine, into uric acid. By inhibiting xanthine oxidase, uric acid production is reduced and serum uric acid levels are lowered. Febuxostat may provide protection against acute renal failure caused by the excessive release of uric acid that occurs upon massive tumor cell lysis resulting from the treatment of some malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4BD0FD29-90D1-356F-E053-F662850AA489","latestVersionIndicator":"Yes","beginDate":"2017-03-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-03-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-99D9-18F7-E053-F662850A60B1","beginDate":"2017-03-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Chloramphenicol","valueDescription":"Chloramphenicol","ValueMeaning":{"publicId":"3874336","version":"1","preferredName":"Chloramphenicol","longName":"3874336","preferredDefinition":"A semisynthetic, broad-spectrum antibiotic derived from Streptomyces venequelae with primarily bacteriostatic activity. Chloramphenicol diffuses through the bacterial cell wall and reversibly binds to the bacterial 50S ribosomal subunit. The binding interferes with peptidyl transferase activity, thereby prevents transfer of amino acids to the growing peptide chains and blocks peptide bond formation. As a result bacterial protein synthesis is blocked and impede bacterial cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chloramphenicol","conceptCode":"C363","definition":"A semisynthetic, broad-spectrum antibiotic derived from Streptomyces venequelae with primarily bacteriostatic activity. Chloramphenicol diffuses through the bacterial cell wall and reversibly binds to the bacterial 50S ribosomal subunit. The binding interferes with peptidyl transferase activity, thereby prevents transfer of amino acids to the growing peptide chains and blocks peptide bond formation. As a result bacterial protein synthesis is blocked and impede bacterial cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E591CA67-354A-9D51-E040-BB89AD4371CB","latestVersionIndicator":"Yes","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-99E3-18F7-E053-F662850A60B1","beginDate":"2017-06-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Firocoxib","valueDescription":"Firocoxib (Equioxx, Previcox)","ValueMeaning":{"publicId":"5886789","version":"1","preferredName":"Firocoxib (Equioxx, Previcox)","longName":"5886789","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Firocoxib","conceptCode":"C65686","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"52A2911D-B822-249F-E053-F662850A679C","latestVersionIndicator":"Yes","beginDate":"2017-06-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-06-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-99ED-18F7-E053-F662850A60B1","beginDate":"2017-06-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Dapagliflozin","valueDescription":"Dapagliflozin (Farxiga, Forxiga)","ValueMeaning":{"publicId":"5887261","version":"1","preferredName":"Dapagliflozin (Farxiga, Forxiga)","longName":"5887261","preferredDefinition":"A selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. Dapagliflozin selectively and potently inhibits SGLT2 compared to SGLT1, which is the cotransporter of glucose in the gut.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dapagliflozin","conceptCode":"C78126","definition":"A selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. Dapagliflozin selectively and potently inhibits SGLT2 compared to SGLT1, which is the cotransporter of glucose in the gut.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"52A27F77-F13C-201B-E053-F662850A3F7F","latestVersionIndicator":"Yes","beginDate":"2017-06-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-06-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-99F7-18F7-E053-F662850A60B1","beginDate":"2017-06-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Doxorubicin","valueDescription":"Doxorubicin","ValueMeaning":{"publicId":"2561008","version":"1","preferredName":"Doxorubicin","longName":"2561008","preferredDefinition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxorubicin","conceptCode":"C456","definition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BB5D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-04-11","endDate":null,"createdBy":"JASUR","dateCreated":"2002-04-11","modifiedBy":"CLOHNES","dateModified":"2022-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9A01-18F7-E053-F662850A60B1","beginDate":"2017-08-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Gemcitabine","valueDescription":"Gemcitabine","ValueMeaning":{"publicId":"5242658","version":"1","preferredName":"Gemcitabine","longName":"5242658","preferredDefinition":"The active ingredient in a drug that is used to treat pancreatic cancer that is advanced or has spread. It is also used with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine blocks the cell from making DNA and may kill cancer cells. It is a type of antimetabolite.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gemcitabine","conceptCode":"C66876","definition":"A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in \"masked termination\" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31F0A2DB-98BB-9ED8-E050-BB89AD436E03","latestVersionIndicator":"Yes","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9A0B-18F7-E053-F662850A60B1","beginDate":"2017-08-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Docetaxel","valueDescription":"Docetaxel","ValueMeaning":{"publicId":"2576637","version":"1","preferredName":"Docetaxel","longName":"2576637","preferredDefinition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Docetaxel","conceptCode":"C1526","definition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F86A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9A15-18F7-E053-F662850A60B1","beginDate":"2017-08-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Paclitaxel","valueDescription":"Paclitaxel","ValueMeaning":{"publicId":"2739551","version":"1","preferredName":"Paclitaxel","longName":"2739551","preferredDefinition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paclitaxel","conceptCode":"C1411","definition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A7528ED-0248-5EF5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9A1F-18F7-E053-F662850A60B1","beginDate":"2017-08-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Palbociclib","valueDescription":"PD-0332991","ValueMeaning":{"publicId":"3564160","version":"1","preferredName":"PD-0332991","longName":"3564160","preferredDefinition":"An orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. PD-0332991 selectively inhibits cyclin-dependent kinases (particularly Cdk4/cyclin D1 kinase), which may inhibit retinoblastoma (Rb) protein phosphorylation; inhibition of Rb phosphorylation prevents Rb-positive tumor cells from entering the S phase of the cell cycle (arrest in the G1 phase), resulting in suppression of DNA replication and decreased tumor cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Palbociclib","conceptCode":"C49176","definition":"An orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7DBA78C-8B81-5111-E040-BB89AD4317C1","latestVersionIndicator":"Yes","beginDate":"2012-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-22","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9A29-18F7-E053-F662850A60B1","beginDate":"2017-08-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Pertuzumab","valueDescription":"Pertuzumab","ValueMeaning":{"publicId":"3378887","version":"1","preferredName":"Pertuzumab","longName":"3378887","preferredDefinition":"A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pertuzumab","conceptCode":"C38692","definition":"A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90729CF-405F-B0E0-E040-BB89AD436B58","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9A33-18F7-E053-F662850A60B1","beginDate":"2017-08-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Insulin Degludec","valueDescription":"Insulin Degludec","ValueMeaning":{"publicId":"6046328","version":"1","preferredName":"Insulin Degludec","longName":"6046328v1.00","preferredDefinition":"A recombinant, long-acting analog of human insulin, with blood glucose-lowering activity. Upon subcutaneous injection, insulin degludec forms a multi-hexameric depot from which insulin monomers are slowly released into the systemic circulation. Insulin regulates glucose metabolism by binding to insulin receptors on muscle and fat cells, which stimulates the cellular uptake of glucose and lowers blood glucose levels. Insulin inhibits the liver's conversion of stored glycogen into glucose, which also contributes to lower blood glucose levels. In addition, insulin inhibits lipolysis in adipose tissue, inhibits proteolysis, and enhances protein synthesis. Insulin degludec doesn't contain the amino acid threonine that is found at position B30 in human insulin; additionally, the lysine at position B29 is conjugated to hexadecanedioic acid, which allows the formation of the multi-hexamers upon subcutaneous injection. The phenol and zinc present in the pharmaceutical formulation promote a di-hexameric state of insulin degludec.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Insulin Degludec","conceptCode":"C142979","definition":"A recombinant, long-acting analog of human insulin, with blood glucose-lowering activity. Upon subcutaneous injection, insulin degludec forms a multi-hexameric depot from which insulin monomers are slowly released into the systemic circulation. Insulin regulates glucose metabolism by binding to insulin receptors on muscle and fat cells, which stimulates the cellular uptake of glucose and lowers blood glucose levels. Insulin inhibits the liver's conversion of stored glycogen into glucose, which also contributes to lower blood glucose levels. In addition, insulin inhibits lipolysis in adipose tissue, inhibits proteolysis, and enhances protein synthesis. Insulin degludec doesn't contain the amino acid threonine that is found at position B30 in human insulin; additionally, the lysine at position B29 is conjugated to hexadecanedioic acid, which allows the formation of the multi-hexamers upon subcutaneous injection. The phenol and zinc present in the pharmaceutical formulation promote a di-hexameric state of insulin degludec.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"61D0F87D-1F46-739E-E053-F662850A43FA","latestVersionIndicator":"Yes","beginDate":"2018-01-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-01-02","modifiedBy":"CLOHNES","dateModified":"2023-08-04","changeDescription":null,"administrativeNotes":"8/4/23 Added missing concept per cleanup activities cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9A3D-18F7-E053-F662850A60B1","beginDate":"2018-01-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Mirabegron","valueDescription":"Mirabegron","ValueMeaning":{"publicId":"6046330","version":"1","preferredName":"Mirabegron","longName":"6046330","preferredDefinition":"An orally bioavailable agonist of the human beta-3 adrenergic receptor (ADRB3), with muscle relaxing, neuroprotective and potential antineoplastic activities.  Upon oral administration, mirabegron binds to and activates ADRB3, which leads to smooth muscle relaxation. Mirabegron also restores sympathetic stimulation in mesenchymal stem cell (MSC) niches, inhibits JAK2-mutated hematopoietic stem cell (HSC) expansion and blocks the progression of myeloproliferative neoplasms (MPNs). Lack of sympathetic stimulation of the MSC and HSC niche is associated with the development of MPNs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mirabegron","conceptCode":"C90633","definition":"An orally bioavailable agonist of the human beta-3 adrenergic receptor (ADRB3), with muscle relaxing, neuroprotective and potential antineoplastic activities.  Upon oral administration, mirabegron binds to and activates ADRB3, which leads to smooth muscle relaxation. Mirabegron also restores sympathetic stimulation in mesenchymal stem cell (MSC) niches, inhibits JAK2-mutated hematopoietic stem cell (HSC) expansion and blocks the progression of myeloproliferative neoplasms (MPNs). Lack of sympathetic stimulation of the MSC and HSC niche is associated with the development of MPNs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"61D0F87D-1F6C-739E-E053-F662850A43FA","latestVersionIndicator":"Yes","beginDate":"2018-01-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-01-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9A47-18F7-E053-F662850A60B1","beginDate":"2018-01-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ibrutinib","valueDescription":"Ibrutinib","ValueMeaning":{"publicId":"5588944","version":"1","preferredName":"Ibrutinib","longName":"5588944","preferredDefinition":"An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon oral administration, ibrutinib binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is required for B cell receptor signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies. The expression of BTK in tumor cells is also associated with increased proliferation and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ibrutinib","conceptCode":"C81934","definition":"An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon oral administration, ibrutinib binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is required for B cell receptor signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies. The expression of BTK in tumor cells is also associated with increased proliferation and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42B08557-93BA-6CD6-E053-F662850A558E","latestVersionIndicator":"Yes","beginDate":"2016-12-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-12-02","modifiedBy":"COOPERM","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9A51-18F7-E053-F662850A60B1","beginDate":"2018-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Dolutegravir","valueDescription":"Dolutegravir","ValueMeaning":{"publicId":"6199953","version":"1","preferredName":"Dolutegravir","longName":"6199953","preferredDefinition":"An orally bioavailable integrase strand-transfer inhibitor (INSTI), with activity against human immunodeficiency virus type 1 (HIV-1) infection. Upon oral administration, dolutegravir binds to the active site of integrase, an HIV enzyme that catalyzes the transfer of viral genetic material into human chromosomes. This prevents integrase from binding to retroviral deoxyribonucleic acid (DNA), and blocks the strand transfer step, which is essential for the HIV replication cycle. This prevents HIV-1 replication.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dolutegravir","conceptCode":"C121543","definition":"An orally bioavailable integrase strand-transfer inhibitor (INSTI), with activity against human immunodeficiency virus type 1 (HIV-1) infection. Upon oral administration, dolutegravir binds to the active site of integrase, an HIV enzyme that catalyzes the transfer of viral genetic material into human chromosomes. This prevents integrase from binding to retroviral deoxyribonucleic acid (DNA), and blocks the strand transfer step, which is essential for the HIV replication cycle. This prevents HIV-1 replication.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69FD98C0-8FB2-2C45-E053-F662850AF23F","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-04-16","modifiedBy":"ONEDATA","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9A5B-18F7-E053-F662850A60B1","beginDate":"2018-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fidaxomicin","valueDescription":"Fidaxomicin","ValueMeaning":{"publicId":"6199955","version":"1","preferredName":"Fidaxomicin","longName":"6199955","preferredDefinition":"A narrow-spectrum, 18-membered macrolide antibiotic isolated from the actinomycete Dactylosporangium aurantiacum subsp. hamdenensis with potential antibacterial activity. Although the exact mechanism of action has yet to be fully elucidated, fidaxomicin may bind to and inhibit bacterial DNA-dependent RNA polymerase, thereby inhibiting the initiation of bacterial RNA synthesis. When orally administered, this agent is minimally absorbed into the systemic circulation, acting locally in the gastrointestinal tract. Fidaxomicin appears to be active against pathogenic Gram-positive bacteria, such as clostridia, enterococci, and staphylococci, but does not appear to be active against other beneficial intestinal bacteria.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fidaxomicin","conceptCode":"C66979","definition":"A narrow-spectrum, 18-membered macrolide antibiotic isolated from the actinomycete Dactylosporangium aurantiacum subsp. hamdenensis with potential antibacterial activity. Although the exact mechanism of action has yet to be fully elucidated, fidaxomicin may bind to and inhibit bacterial DNA-dependent RNA polymerase, thereby inhibiting the initiation of bacterial RNA synthesis. When orally administered, this agent is minimally absorbed into the systemic circulation, acting locally in the gastrointestinal tract. Fidaxomicin appears to be active against pathogenic Gram-positive bacteria, such as clostridia, enterococci, and staphylococci, but does not appear to be active against other beneficial intestinal bacteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69FD98C0-8FDB-2C45-E053-F662850AF23F","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-04-16","modifiedBy":"ONEDATA","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9A65-18F7-E053-F662850A60B1","beginDate":"2018-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Isavuconazole","valueDescription":"Isavuconazole","ValueMeaning":{"publicId":"5073216","version":"1","preferredName":"Isavuconazole","longName":"5073216","preferredDefinition":"A water-soluble triazole prodrug with broad-spectrum antifungal activity. Isavuconazole is absorbed easily, given either orally or intravenously, and is hydrolyzed to its active moiety BAL4815 by plasma esterases. BAL4815 inhibits fungal cytochrome P450 lanosterol 14-alpha-demethylase (CYP51) that catalyzes the conversion of lanosterol to ergosterol, an important component of the fungal cell membrane. Enzyme inhibition by this agent leads to a decrease in ergosterol pool and therefore disturbs synthesis of fungal cell membrane, thereby increasing cell membrane permeability and promoting loss of essential intracellular elements. This ultimately causes fungal cell lysis and death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Isavuconazole","conceptCode":"C64543","definition":"A water-soluble triazole prodrug with broad-spectrum antifungal activity. Isavuconazole is absorbed easily, given either orally or intravenously, and is hydrolyzed to its active moiety BAL4815 by plasma esterases. BAL4815 inhibits fungal cytochrome P450 lanosterol 14-alpha-demethylase (CYP51) that catalyzes the conversion of lanosterol to ergosterol, an important component of the fungal cell membrane. Enzyme inhibition by this agent leads to a decrease in ergosterol pool and therefore disturbs synthesis of fungal cell membrane, thereby increasing cell membrane permeability and promoting loss of essential intracellular elements. This ultimately causes fungal cell lysis and death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"261938BC-02B2-DBF7-E050-BB89AD4347C5","latestVersionIndicator":"Yes","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"COOPERM","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9A6F-18F7-E053-F662850A60B1","beginDate":"2018-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ustekinumab","valueDescription":"Ustekinumab","ValueMeaning":{"publicId":"6199775","version":"1","preferredName":"Ustekinumab","longName":"6199775","preferredDefinition":"An orally available, human, IgG1kappa, monoclonal antibody directed against the p40 protein subunit of both interleukin-12 (IL-12) and IL-23, with immunomodulating activity. Upon administration, ustekinumab binds to the p40 subunit of IL-12 and IL-23, blocking the binding of IL-12 and IL-23 to their interleukin receptors. This inhibits IL-12- and IL-23-mediated signaling and inhibits differentiation of CD4 positive T-cells into Th1 and Th17 cells. This prevents Th1- and Th17-mediated responses and cytokine production. This may prevent graft versus host disease (GVHD). IL-12 and IL-23, cytokines that play a key role in the regulation of the immune system, are upregulated in immune-mediated inflammatory disorders. Both Th1 and Th17 cells play a crucial role in GVHD.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ustekinumab","conceptCode":"C84237","definition":"An orally available, human, IgG1kappa, monoclonal antibody directed against the p40 protein subunit of both interleukin-12 (IL-12) and IL-23, with immunomodulating activity. Upon administration, ustekinumab binds to the p40 subunit of IL-12 and IL-23, blocking the binding of IL-12 and IL-23 to their interleukin receptors. This inhibits IL-12- and IL-23-mediated signaling and inhibits differentiation of CD4 positive T-cells into Th1 and Th17 cells. This prevents Th1- and Th17-mediated responses and cytokine production. This may prevent graft versus host disease (GVHD). IL-12 and IL-23, cytokines that play a key role in the regulation of the immune system, are upregulated in immune-mediated inflammatory disorders. Both Th1 and Th17 cells play a crucial role in GVHD.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69FA0151-F978-2B31-E053-F662850A82BD","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-04-16","modifiedBy":"COOPERM","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9A79-18F7-E053-F662850A60B1","beginDate":"2018-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Linaclotide","valueDescription":"Linaclotide","ValueMeaning":{"publicId":"6199957","version":"1","preferredName":"Linaclotide","longName":"6199957","preferredDefinition":"A synthetic, fourteen amino acid peptide and agonist of intestinal guanylate cyclase type C (GC-C), which is structurally related to the guanylin peptide family, with secretagogue, analgesic and laxative activities.  Upon oral administration, linaclotide binds to and activates GC-C receptors located on the luminal surface of the intestinal epithelium. This increases the concentration of intracellular cyclic guanosine monophosphate (cGMP), which is derived from guanosine triphosphate (GTP). cGMP activates the cystic fibrosis transmembrane conductance regulator (CFTR) and stimulates the secretion of chloride and bicarbonate into the intestinal lumen. This promotes sodium excretion into the lumen and results in increased intestinal fluid secretion. This ultimately accelerates GI transit of intestinal contents, improves bowel movement and relieves constipation. Increased extracellular cGMP levels may also exert an antinociceptive effect, through an as of yet not fully elucidated mechanism, that may involve modulation of nociceptors found on colonic afferent pain fibers. Linaclotide is minimally absorbed from the GI tract.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Linaclotide","conceptCode":"C81001","definition":"A synthetic, fourteen amino acid peptide and agonist of intestinal guanylate cyclase type C (GC-C), which is structurally related to the guanylin peptide family, with secretagogue, analgesic and laxative activities.  Upon oral administration, linaclotide binds to and activates GC-C receptors located on the luminal surface of the intestinal epithelium. This increases the concentration of intracellular cyclic guanosine monophosphate (cGMP), which is derived from guanosine triphosphate (GTP). cGMP activates the cystic fibrosis transmembrane conductance regulator (CFTR) and stimulates the secretion of chloride and bicarbonate into the intestinal lumen. This promotes sodium excretion into the lumen and results in increased intestinal fluid secretion. This ultimately accelerates GI transit of intestinal contents, improves bowel movement and relieves constipation. Increased extracellular cGMP levels may also exert an antinociceptive effect, through an as of yet not fully elucidated mechanism, that may involve modulation of nociceptors found on colonic afferent pain fibers. Linaclotide is minimally absorbed from the GI tract.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69FD98C0-9017-2C45-E053-F662850AF23F","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-04-16","modifiedBy":"ONEDATA","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9A83-18F7-E053-F662850A60B1","beginDate":"2018-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Degarelix","valueDescription":"Degarelix","ValueMeaning":{"publicId":"3240855","version":"1","preferredName":"Degarelix","longName":"3240855","preferredDefinition":"A long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing testosterone production by interstitial (Leydig) cells in the testes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Degarelix","conceptCode":"C48385","definition":"A long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing testosterone production by interstitial (Leydig) cells in the testes.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A4302120-6A24-B554-E040-BB89AD4307C7","latestVersionIndicator":"Yes","beginDate":"2011-05-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-26","modifiedBy":"COOPERM","dateModified":"2019-03-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9A8D-18F7-E053-F662850A60B1","beginDate":"2019-03-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Empagliflozin","valueDescription":"Empagliflozin","ValueMeaning":{"publicId":"6661773","version":"1","preferredName":"Empagliflozin","longName":"6661773","preferredDefinition":"An orally available competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2; SLC5A2) with antihyperglycemic activity. Upon oral administration, empagliflozin selectively and potently inhibits SGLT2 in the kidneys, thereby suppressing the reabsorption of glucose in the proximal tubule. Inhibition of SGLT2 increases urinary glucose excretion by the kidneys, resulting in a reduction of plasma glucose levels in an insulin-independent manner. SGLT2, a transport protein exclusively expressed in the proximal renal tubules, mediates approximately 90% of renal glucose reabsorption from tubular fluid.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Empagliflozin","conceptCode":"C158136","definition":"An orally available competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2; SLC5A2) with antihyperglycemic activity. Upon oral administration, empagliflozin selectively and potently inhibits SGLT2 in the kidneys, thereby suppressing the reabsorption of glucose in the proximal tubule. Inhibition of SGLT2 increases urinary glucose excretion by the kidneys, resulting in a reduction of plasma glucose levels in an insulin-independent manner. Inhibition of SGLT2 in the kidneys also suppresses the renal reabsorption of 1,5-anhydroglucitol (1,5AG). This lowers serum 1,5AG and neutrophil 1,5-anhydroglucitol-6-phosphate (1,5AG6P) levels, which may improve neutropenia and neutrophil dysfunction in patients with glycogen storage disease type Ib (GSD Ib). SGLT2, a transport protein exclusively expressed in the proximal renal tubules, mediates approximately 90% of renal glucose reabsorption from tubular fluid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"835E4D2B-A158-6F05-E053-F662850A7125","latestVersionIndicator":"Yes","beginDate":"2019-03-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-03-05","modifiedBy":"COOPERM","dateModified":"2019-03-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9A97-18F7-E053-F662850A60B1","beginDate":"2019-03-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Hydrocortisone Acetate","valueDescription":"Hydrocortisone Acetate","ValueMeaning":{"publicId":"6661774","version":"1","preferredName":"Hydrocortisone Acetate","longName":"6661774","preferredDefinition":"The synthetic acetate salt form of hydrocortisone, a corticosteroid with anti-inflammatory and immunosuppressive properties. Hydrocortisone acetate initially binds to the cytoplasmic glucocorticoid receptor; then the receptor-ligand complex is translocated to the nucleus where it initiates the transcription of genes encoding for anti-inflammatory mediators, such as cytokines and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydrocortisone Acetate","conceptCode":"C61785","definition":"The synthetic acetate ester form of hydrocortisone, a corticosteroid with anti-inflammatory and immunosuppressive properties. Hydrocortisone acetate initially binds to the cytoplasmic glucocorticoid receptor; then the receptor-ligand complex is translocated to the nucleus where it initiates the transcription of genes encoding for anti-inflammatory mediators, such as cytokines and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"835E4D2B-A17D-6F05-E053-F662850A7125","latestVersionIndicator":"Yes","beginDate":"2019-03-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-03-05","modifiedBy":"ONEDATA","dateModified":"2019-03-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9AA1-18F7-E053-F662850A60B1","beginDate":"2019-03-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ceftazidime/Avibactam Sodium","valueDescription":"Ceftazidime/Avibactam Sodium","ValueMeaning":{"publicId":"6661776","version":"1","preferredName":"Ceftazidime/Avibactam Sodium","longName":"6661776","preferredDefinition":"A combination preparation containing the third-generation cephalosporin ceftazidime and the sodium salt form of avibactam, a non-beta-lactam beta-lactamase inhibitor, with antibiotic and beta-lactamase inhibiting activity, respectively. Upon administration, ceftazidime binds to essential penicillin-binding proteins (PBPs) and inhibits cell wall synthesis in certain bacteria. Avibactam binds to and inactivates beta-lactamases, thereby protecting ceftazidime from degradation and increasing ceftazidime's efficacy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ceftazidime/Avibactam Sodium","conceptCode":"C127836","definition":"A combination preparation containing the third-generation cephalosporin ceftazidime and the sodium salt form of avibactam, a non-beta-lactam beta-lactamase inhibitor, with antibiotic and beta-lactamase inhibiting activity, respectively. Upon administration, ceftazidime binds to essential penicillin-binding proteins (PBPs) and inhibits cell wall synthesis in certain bacteria. Avibactam binds to and inactivates beta-lactamases, thereby protecting ceftazidime from degradation and increasing ceftazidime's efficacy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"835E4D2B-A1A3-6F05-E053-F662850A7125","latestVersionIndicator":"Yes","beginDate":"2019-03-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-03-05","modifiedBy":"ONEDATA","dateModified":"2019-03-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9AAB-18F7-E053-F662850A60B1","beginDate":"2019-03-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Kaletra","valueDescription":"Lopinavir/Ritonavir","ValueMeaning":{"publicId":"2578201","version":"1","preferredName":"Lopinavir/Ritonavir","longName":"2578201","preferredDefinition":"A combination anti-HIV protease inhibitor from Abbott Laboratories.  Brand name is Kaletra.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lopinavir/Ritonavir","conceptCode":"C2096","definition":"A fixed combination of two protease inhibitors, lopinavir and ritonavir, used to treat human immunodeficiency virus (HIV) infection. The ritonavir in the combination drug increases the concentration and biological half-life of lopinavir but is not present in sufficient concentration to act as a protease inhibitor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE86-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7D23-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Kamillosan Sol","valueDescription":"ANISE OIL MISC. OIL","ValueMeaning":{"publicId":"2578202","version":"1","preferredName":"ANISE OIL MISC. OIL","longName":"2578202","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ANISE OIL MISC. OIL","conceptCode":"C0304095","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE87-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7D2D-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Kava","valueDescription":"Kava","ValueMeaning":{"publicId":"2578209","version":"1","preferredName":"Kava","longName":"2578209v1.00","preferredDefinition":"An herb native to islands in the South Pacific. Substances taken from the root have been used in some cultures to relieve stress, anxiety, tension, sleeplessness, and problems of menopause. Kava kava may increase the effect of alcohol and of certain drugs used to treat anxiety and depression. The U.S. Food and Drug Administration advises users that kava kava may cause severe liver damage. The scientific name is Piper methysticum.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Piper methysticum","conceptCode":"C72403","definition":"An herb native to islands in the South Pacific. Substances taken from the root have been used in some cultures to relieve stress, anxiety, tension, sleeplessness, and problems of menopause. Kava kava may increase the effect of alcohol and of certain drugs used to treat anxiety and depression. The U.S. Food and Drug Administration advises users that kava kava may cause severe liver damage. The scientific name is Piper methysticum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE8E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"CLOHNES","dateModified":"2023-09-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7D37-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ketoconazole","valueDescription":"Ketoconazole","ValueMeaning":{"publicId":"2578210","version":"1","preferredName":"Ketoconazole","longName":"2578210","preferredDefinition":"A synthetic derivative of phenylpiperazine with broad antifungal properties and potential antineoplastic activity.  Ketoconazole inhibits sterol 14-a-dimethylase, a microsomal cytochrome P450-dependent enzyme, thereby disrupting synthesis of ergosterol, an important component of the fungal cell wall. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ketoconazole","conceptCode":"C605","definition":"A synthetic derivative of phenylpiperazine with broad antifungal properties and potential antineoplastic activity.  Ketoconazole inhibits sterol 14-a-dimethylase, a microsomal cytochrome P450-dependent enzyme, thereby disrupting synthesis of ergosterol, an important component of the fungal cell wall. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE8F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7D41-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ketoprofen","valueDescription":"Ketoprofen","ValueMeaning":{"publicId":"2578211","version":"1","preferredName":"Ketoprofen","longName":"2578211","preferredDefinition":"A propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic effects. Ketoprofen inhibits the activity of the enzymes cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. The resulting decrease in prostaglandin synthesis, by prostaglandin synthase, is responsible for the therapeutic effects of ibuprofen. Ketoprofen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ketoprofen","conceptCode":"C47578","definition":"A propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic effects. Ketoprofen inhibits the activity of the enzymes cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. The resulting decrease in prostaglandin synthesis, by prostaglandin synthase, is responsible for the therapeutic effects of ibuprofen. Ketoprofen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE90-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7D4B-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ketorolac","valueDescription":"Ketorolac","ValueMeaning":{"publicId":"2578212","version":"1","preferredName":"Ketorolac","longName":"2578212","preferredDefinition":"A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ketorolac","conceptCode":"C1219","definition":"A synthetic pyrrolizine carboxylic acid derivative with anti-inflammatory, analgesic, and antipyretic activities. Ketorolac non-selective inhibits the enzymes cyclooxygenase 1 (COX-1) and COX-2. The inhibition of COX-2, up-regulated at sites of inflammation, prevents conversion of arachidonic acid to pro-inflammatory prostaglandins. The inhibition of COX-1 by this agent prevents the normal steady-state production of prostaglandins that play housekeeping roles in the protection of the gastrointestinal tract, the regulation of renal blood flow, and platelet aggregation. As a result, the inhibition of COX-1 may be associated with gastrointestinal toxicity, nephrotoxicity, and the inhibition of platelet aggregation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE91-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7D55-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Labetalol","valueDescription":"Labetalol","ValueMeaning":{"publicId":"2578213","version":"1","preferredName":"Labetalol","longName":"2578213","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Labetalol","conceptCode":"C29146","definition":"A third generation selective alpha-1-adrenergic antagonist and non-selective beta-adrenergic antagonist with vasodilatory and antihypertensive properties. Labetalol competitively binds to alpha-1-adrenergic receptors in vascular smooth muscle, thereby inhibiting the adrenergic stimulation of endothelial cell function and vasoconstriction in peripheral blood vessels. This agent also binds to beta-receptors in the bronchial and vascular smooth muscle, resulting in a decrease in adrenergic stimulation. The result is a decrease in resting and exercise heart rates, cardiac output, and in both systolic and diastolic blood pressure, thereby resulting in vasodilation, and negative chronotropic and inotropic cardiac effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE92-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7D5F-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lactobacillus","valueDescription":"Lactobacillus","ValueMeaning":{"publicId":"2567497","version":"1","preferredName":"Lactobacillus","longName":"2567497","preferredDefinition":"A genus of Gram-positive facultative anaerobic or microaerophilic bacteria in the phylum Firmicutes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lactobacillus","conceptCode":"C76352","definition":"A genus of Gram-positive facultative anaerobic or microaerophilic bacteria in the phylum Firmicutes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D4B6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-19","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7D69-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lactulose","valueDescription":"Lactulose","ValueMeaning":{"publicId":"2578214","version":"1","preferredName":"Lactulose","longName":"2578214","preferredDefinition":"A disaccharide (sugar) synthesized from fructose and galactose, Lactulose is used to treat constipation and some liver diseases. Nondigestible in mammals, lactulose passes unabsorbed down to the large intestine where resident bacteria consume it and produce lactic, acetic, and formic acids, which draw fluid into the bowel to soften the stool (laxative effect). Acidification of the colon contents attracts ammonia from the bloodstream, assisting stool excretion; helpful in liver failure when ammonia cannot be detoxified. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lactulose","conceptCode":"C29148","definition":"A disaccharide (sugar) synthesized from fructose and galactose, Lactulose is used to treat constipation and some liver diseases. Nondigestible in mammals, lactulose passes unabsorbed down to the large intestine where resident bacteria consume it and produce lactic, acetic, and formic acids, which draw fluid into the bowel to soften the stool (laxative effect). Acidification of the colon contents attracts ammonia from the bloodstream, assisting stool excretion; helpful in liver failure when ammonia cannot be detoxified. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE93-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7D73-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Laetrille","valueDescription":"Laetrille","ValueMeaning":{"publicId":"2578215","version":"1","preferredName":"Laetrille","longName":"2578215","preferredDefinition":"Originally, the name laetrile was the contraction of laevo-mandelonitrile glucoside, a cyanogenic glycoside found naturally in some plants.  Over the years the meaning of laetrile has changed.  There are now preparations called Laetrile where amygdalin is the major constituent.  Laetrile and amygdalin are often used interchangeably, but are different agents.  Cyanide and benzaldehyde are metabolites of both laetrile and amygdalin.  Both metabolites may possess antineoplastic properties.  Laetrile has been used as an anticancer treatment in humans worldwide, but scientific evidence does not support its effectiveness.  It is not approved for use in the United States. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Laetrile","conceptCode":"C29149","definition":"Originally, the name laetrile was the contraction of laevo-mandelonitrile glucoside, a cyanogenic glycoside found naturally in some plants.  Over the years the meaning of laetrile has changed.  There are now preparations called Laetrile where amygdalin is the major constituent.  Laetrile and amygdalin are often used interchangeably, but are different agents.  Cyanide and benzaldehyde are metabolites of both laetrile and amygdalin.  Both metabolites may possess antineoplastic properties.  Laetrile has been used as an anticancer treatment in humans worldwide, but scientific evidence does not support its effectiveness.  It is not approved for use in the United States. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE94-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7D7D-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lamivudine","valueDescription":"3TC (Lamivudine)","ValueMeaning":{"publicId":"2576885","version":"1","preferredName":"3TC (Lamivudine)","longName":"2576885","preferredDefinition":"A synthetic nucleoside analogue with activity against hepatitis B virus (HBV) and HIV. Intracellularly, lamivudine is phosphorylated to its active metabolites, lamiduvine triphosphate (L-TP) and lamiduvine monophosphate (L-MP).  In HIV, L-TP inhibits HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleoside analogue into viral DNA.  In HBV, incorporation of L-MP into viral DNA by HBV polymerase results in DNA chain termination. L-TP is a weak inhibitor of mammalian DNA polymerases alpha and beta, and mitochondrial DNA polymerase. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lamivudine","conceptCode":"C1471","definition":"A synthetic nucleoside analogue with activity against hepatitis B virus (HBV) and HIV. Intracellularly, lamivudine is phosphorylated to its active metabolites, lamiduvine triphosphate (L-TP) and lamiduvine monophosphate (L-MP).  In HIV, L-TP inhibits HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleoside analogue into viral DNA.  In HBV, incorporation of L-MP into viral DNA by HBV polymerase results in DNA chain termination. L-TP is a weak inhibitor of mammalian DNA polymerases alpha and beta, and mitochondrial DNA polymerase. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F962-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-09","modifiedBy":"REEVESD","dateModified":"2010-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7D87-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lamotrigine","valueDescription":"Lamotrigine","ValueMeaning":{"publicId":"2578216","version":"1","preferredName":"Lamotrigine","longName":"2578216","preferredDefinition":"A synthetic phenyltriazine with antiepileptic and analgesic properties.  Lamotrigine enhances the action of gamma-aminobutyric acid, an inhibitory neurotransmitter, which may result in a reduction of pain-related transmission of signals along nerve fibers. This agent may also inhibit voltage-gated sodium channels, suppress glutamate release, and inhibit serotonin reuptake. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lamotrigine","conceptCode":"C38703","definition":"A synthetic phenyltriazine with antiepileptic and analgesic properties.  Lamotrigine enhances the action of gamma-aminobutyric acid, an inhibitory neurotransmitter, which may result in a reduction of pain-related transmission of signals along nerve fibers. This agent may also inhibit voltage-gated sodium channels, suppress glutamate release, and inhibit serotonin reuptake. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE95-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7D91-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Glimepiride","valueDescription":"Glimepiride","ValueMeaning":{"publicId":"2577900","version":"1","preferredName":"Glimepiride","longName":"2577900","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glimepiride","conceptCode":"C29073","definition":"A long-acting, third-generation sulfonylurea with hypoglycemic activity. Compared to other generations of sulfonylurea compounds, glimepiride is very potent and has a longer duration of action. This agent is metabolized by CYP2C9 and shows peroxisome proliferator-activated receptor gamma (PPARgamma) agonistic activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD59-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-23","modifiedBy":"ONEDATA","dateModified":"2006-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7D9B-18F7-E053-F662850A60B1","beginDate":"2006-02-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Glipizide","valueDescription":"Glipizide","ValueMeaning":{"publicId":"2577901","version":"1","preferredName":"Glipizide","longName":"2577901","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glipizide","conceptCode":"C29074","definition":"A short-acting, second-generation sulfonylurea with hypoglycemic activity. Glipizide is rapidly absorbed, has a very quick onset of action and a short half-life. This agent is extensively metabolized in the liver and the metabolites as well as the unchanged form are excreted in the urine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD5A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-23","modifiedBy":"ONEDATA","dateModified":"2006-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7DA5-18F7-E053-F662850A60B1","beginDate":"2006-02-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Glucosamine Sulfate","valueDescription":"Glucosamine Sulfate","ValueMeaning":{"publicId":"2577902","version":"1","preferredName":"Glucosamine Sulfate","longName":"2577902","preferredDefinition":"An amino sugar (2-amino, 2-deoxyglucose) in cell membranes, Glucosamine Sulfate is believed to play a role in cartilage formation and repair. Long-term glucosamine sulfate treatment retards progression of knee osteoarthritis; the mechanism appears to involve glucosamine's role as an essential substrate for glycosaminoglycans and hyaluronic acid, needed for formation of the joint proteoglycan structural matrix. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glucosamine Sulfate","conceptCode":"C29075","definition":"An amino sugar (2-amino, 2-deoxyglucose) in cell membranes, Glucosamine Sulfate is believed to play a role in cartilage formation and repair. Long-term glucosamine sulfate treatment retards progression of knee osteoarthritis; the mechanism appears to involve glucosamine's role as an essential substrate for glycosaminoglycans and hyaluronic acid, needed for formation of the joint proteoglycan structural matrix. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD5B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-23","modifiedBy":"ONEDATA","dateModified":"2006-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7DAF-18F7-E053-F662850A60B1","beginDate":"2006-02-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lansoprazole","valueDescription":"Lansoprazole","ValueMeaning":{"publicId":"2578217","version":"1","preferredName":"Lansoprazole","longName":"2578217","preferredDefinition":"A substituted benzimidazole and selective and irreversible proton pump inhibitor. Lansoprazole is converted to active sulfenamide derivatives in the acidic environment of the gastric parietal cell. Lansoprazole sulfenamide binds to the gastric proton pump, H+/K+ ATPase, by forming a stable disulfide bond with the sulfhydryl group near the potassium-binding site on the luminal side. This inactivates ATPase, thereby decreasing the efflux and diminishing gastric acid secretion. Lansoprazole does not have anticholinergic or histamine H2 -receptor antagonistic properties.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lansoprazole","conceptCode":"C29150","definition":"A substituted benzimidazole prodrug with selective and irreversible proton pump inhibitor activity. Lansoprazole prodrug is converted to an active sulfonamide derivative in the acidic environment of the gastric parietal cell; the sulfonamide derivative binds to the gastric proton pump H+/K+ ATPase and forms a stable disulfide bond with the sulfhydryl group near the potassium-binding site on the luminal side, resulting in inactivation of the ATPase and a reduction in gastric acid secretion. This agent does not have anticholinergic or histamine H2 -receptor antagonistic properties.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE96-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7DB9-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Latanoprost","valueDescription":"Latanoprost","ValueMeaning":{"publicId":"2578218","version":"1","preferredName":"Latanoprost","longName":"2578218","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Latanoprost","conceptCode":"C29151","definition":"A prostaglandin F2alpha analogue and a prostanoid selective FP receptor agonist with an ocular hypertensive effect. Latanoprost increases uveoscleral outflow and thereby reduces intraocular pressure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE97-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7DC3-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Letrozole","valueDescription":"LETROZOLE","ValueMeaning":{"publicId":"2561408","version":"1","preferredName":"LETROZOLE","longName":"2561408","preferredDefinition":"LETROZOLE","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Letrozole","conceptCode":"C1527","definition":"A nonsteroidal inhibitor of estrogen synthesis with antineoplastic activity. As a third-generation aromatase inhibitor, letrozole selectively and reversibly inhibits aromatase, which may result in growth inhibition of estrogen-dependent breast cancer cells. Aromatase, a cytochrome P-450 enzyme localized to the endoplasmic reticulum of the cell and found in many tissues including those of the premenopausal ovary, liver, and breast, catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BCED-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-02","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7DCD-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Dornase Alfa","valueDescription":"Dornase Alfa","ValueMeaning":{"publicId":"6661778","version":"1","preferredName":"Dornase Alfa","longName":"6661778","preferredDefinition":"A recombinant human deoxyribonuclease I (rhDNAse) with selective DNA cleaving activity. Upon intrapleural administration, dornase alfa catalyzes the degradation of extracellular DNA in airway secretions, which can reduce their viscosity. Thus, dornase alfa may both promote the clearing of airway mucus and improve pulmonary function.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dornase Alfa","conceptCode":"C81664","definition":"A recombinant human deoxyribonuclease I (rhDNAse) with selective DNA cleaving activity. Upon intrapleural administration, dornase alfa catalyzes the degradation of extracellular DNA in airway secretions, which can reduce their viscosity. Thus, dornase alfa may both promote the clearing of airway mucus and improve pulmonary function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"835E4D2B-A1C9-6F05-E053-F662850A7125","latestVersionIndicator":"Yes","beginDate":"2019-03-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-03-05","modifiedBy":"COOPERM","dateModified":"2019-03-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9AB5-18F7-E053-F662850A60B1","beginDate":"2019-03-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Citric Acid Monohydrate","valueDescription":"Citric Acid Monohydrate","ValueMeaning":{"publicId":"6661779","version":"1","preferredName":"Citric Acid Monohydrate","longName":"6661779","preferredDefinition":"A tricarboxylic acid found in citrus fruits. Citric acid is used as an excipient in pharmaceutical preparations due to its antioxidant properties.  It maintains stability of active ingredients and is used as a preservative. It is also used as an acidulant to control pH and acts as an anticoagulant by chelating calcium in blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Citric Acid Monohydrate","conceptCode":"C47452","definition":"A tricarboxylic acid found in citrus fruits. Citric acid is used as an excipient in pharmaceutical preparations due to its antioxidant properties.  It maintains stability of active ingredients and is used as a preservative. It is also used as an acidulant to control pH and acts as an anticoagulant by chelating calcium in blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"835E4D2B-A1EC-6F05-E053-F662850A7125","latestVersionIndicator":"Yes","beginDate":"2019-03-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-03-05","modifiedBy":"ONEDATA","dateModified":"2019-03-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9ABF-18F7-E053-F662850A60B1","beginDate":"2019-03-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Naloxegol","valueDescription":"Naloxegol","ValueMeaning":{"publicId":"6661781","version":"1","preferredName":"Naloxegol","longName":"6661781","preferredDefinition":"A pegylated form of naloxone, a peripherally-acting mu-opioid receptor antagonist, that can be used to reduce opioid-induced symptoms. Upon administration, naloxegol binds to and blocks mu-opioid receptors in the peripheral nervous system. This prevents peripheral opioid receptor activation and abrogates opioid-induced side effects, such as opioid-induced constipation (OIC). Pegylation of naloxone reduces permeability across the blood-brain barrier (BBB) and prevents this agent from interfering with the analgesic activity of opioid receptor agonists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Naloxegol","conceptCode":"C97506","definition":"A pegylated form of naloxone, a peripherally-acting mu-opioid receptor antagonist, that can be used to reduce opioid-induced symptoms. Upon administration, naloxegol binds to and blocks mu-opioid receptors in the peripheral nervous system. This prevents peripheral opioid receptor activation and abrogates opioid-induced side effects, such as opioid-induced constipation (OIC). Pegylation of naloxone reduces permeability across the blood-brain barrier (BBB) and prevents this agent from interfering with the analgesic activity of opioid receptor agonists.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"835E4D2B-A212-6F05-E053-F662850A7125","latestVersionIndicator":"Yes","beginDate":"2019-03-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-03-05","modifiedBy":"ONEDATA","dateModified":"2019-03-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9AC9-18F7-E053-F662850A60B1","beginDate":"2019-03-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Letermovir","valueDescription":"Letermovir","ValueMeaning":{"publicId":"5073183","version":"1","preferredName":"Letermovir","longName":"5073183","preferredDefinition":"An orally bioavailable, non-nucleoside, 3,4-dihydroquinazolinyl acetic acid and inhibitor of the pUL56 subunit of the viral terminase complex of cytomegalovirus (CMV), with potential CMV-specific antiviral activity. Upon oral administration, letermovir binds to the pUL56 subunit of the viral terminase complex of CMV and prevents the cleavage of concatemeric DNA into monomeric genome length DNA. As this agent interferes with viral DNA processing and subsequent viral DNA packaging into procapsids, CMV replication is blocked and CMV infection is prevented.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Letermovir","conceptCode":"C115099","definition":"An orally bioavailable, non-nucleoside, 3,4-dihydroquinazolinyl acetic acid and inhibitor of the pUL56 subunit of the viral terminase complex of cytomegalovirus (CMV), with potential CMV-specific antiviral activity. Upon oral administration, letermovir binds to the pUL56 subunit of the viral terminase complex of CMV and prevents the cleavage of concatemeric DNA into monomeric genome length DNA. As this agent interferes with viral DNA processing and subsequent viral DNA packaging into procapsids, CMV replication is blocked and CMV infection is prevented.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"261938BC-01EC-DBF7-E050-BB89AD4347C5","latestVersionIndicator":"Yes","beginDate":"2015-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-04","modifiedBy":"COOPERM","dateModified":"2019-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9AD3-18F7-E053-F662850A60B1","beginDate":"2019-04-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Triptorelin Pamoate","valueDescription":"Triptorelin Pamoate","ValueMeaning":{"publicId":"6686955","version":"1","preferredName":"Triptorelin Pamoate","longName":"6686955","preferredDefinition":"The pamoate salt of triptorelin, a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH).  Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion after prolonged administration.  After chronic, continuous administration, a sustained decrease in LH, FSH and testicular and ovarian steroidogenesis is observed.  The serum testosterone concentration may fall to levels typically seen in surgically castrated men. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Triptorelin Pamoate","conceptCode":"C29523","definition":"The pamoate salt of triptorelin, a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH).  Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion after prolonged administration.  After chronic, continuous administration, a sustained decrease in LH, FSH and testicular and ovarian steroidogenesis is observed.  The serum testosterone concentration may fall to levels typically seen in surgically castrated men. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"85CF99BA-2E1B-5D80-E053-F662850A4E9A","latestVersionIndicator":"Yes","beginDate":"2019-04-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-05","modifiedBy":"ONEDATA","dateModified":"2019-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9ADD-18F7-E053-F662850A60B1","beginDate":"2019-04-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Trospium Chloride","valueDescription":"Trospium Chloride","ValueMeaning":{"publicId":"6686957","version":"1","preferredName":"Trospium Chloride","longName":"6686957","preferredDefinition":"The chloride salt form of trospium, a quaternary ammonium compound and antimuscarinic agent, with antispasmodic activity. Upon administration of trospium chloride, trospium targets and competitively binds to and blocks the muscarinic receptor on smooth muscle. This relaxes and prevents spasms of the smooth muscles, including the bladder.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trospium Chloride","conceptCode":"C61995","definition":"The chloride salt form of trospium, a quaternary ammonium compound and antimuscarinic agent, with antispasmodic activity. Upon administration of trospium chloride, trospium targets and competitively binds to and blocks the muscarinic receptor on smooth muscle. This relaxes and prevents spasms of the smooth muscles, including the bladder.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"85CF99BA-2E41-5D80-E053-F662850A4E9A","latestVersionIndicator":"Yes","beginDate":"2019-04-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-05","modifiedBy":"COOPERM","dateModified":"2019-04-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9AE7-18F7-E053-F662850A60B1","beginDate":"2019-04-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Difluprednate","valueDescription":"Difluprednate","ValueMeaning":{"publicId":"6686959","version":"1","preferredName":"Difluprednate","longName":"6686959","preferredDefinition":"A topical corticosteroid and prednisolone acetate derivative, with anti-inflammatory activity. Upon instillation into the eye, difluprednate binds to and activates the glucocorticoid receptor (GR). The receptor-ligand complex binds to promoter regions of certain genes and initiates RNA transcription. This results in an induction of synthesis of phospholipase A2 inhibitory proteins, thereby inhibiting the synthesis of arachidonic acid and preventing the synthesis of certain inflammatory mediators, such as prostaglandins and leukotrienes. This reduces ocular inflammation and pain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Difluprednate","conceptCode":"C80259","definition":"A topical corticosteroid and prednisolone acetate derivative, with anti-inflammatory activity. Upon instillation into the eye, difluprednate binds to and activates the glucocorticoid receptor (GR). The receptor-ligand complex binds to promoter regions of certain genes and initiates RNA transcription. This results in an induction of synthesis of phospholipase A2 inhibitory proteins, thereby inhibiting the synthesis of arachidonic acid and preventing the synthesis of certain inflammatory mediators, such as prostaglandins and leukotrienes. This reduces ocular inflammation and pain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"85CF99BA-2E71-5D80-E053-F662850A4E9A","latestVersionIndicator":"Yes","beginDate":"2019-04-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-05","modifiedBy":"COOPERM","dateModified":"2019-04-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9AF1-18F7-E053-F662850A60B1","beginDate":"2019-04-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Perindopril Erbumine","valueDescription":"Perindopril Erbumine","ValueMeaning":{"publicId":"6686961","version":"1","preferredName":"Perindopril Erbumine","longName":"6686961","preferredDefinition":"The tert-butylamine salt of perindopril, the ethyl ester of a non-sulfhydryl angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Upon hydrolysis, perindopril erbumine is converted to its active form perindoprilat, inhibiting ACE and the conversion of angiotensin I to angiotensin II; consequently, angiotensin II-mediated vasoconstriction and angiotensin II-stimulated aldosterone secretion from the adrenal cortex are inhibited and diuresis and natriuresis ensue.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Perindopril Erbumine","conceptCode":"C47666","definition":"The tert-butylamine salt of perindopril, the ethyl ester of a non-sulfhydryl angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Upon hydrolysis, perindopril erbumine is converted to its active form perindoprilat, inhibiting ACE and the conversion of angiotensin I to angiotensin II; consequently, angiotensin II-mediated vasoconstriction and angiotensin II-stimulated aldosterone secretion from the adrenal cortex are inhibited and diuresis and natriuresis ensue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"85CF99BA-2E97-5D80-E053-F662850A4E9A","latestVersionIndicator":"Yes","beginDate":"2019-04-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-05","modifiedBy":"ONEDATA","dateModified":"2019-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9AFB-18F7-E053-F662850A60B1","beginDate":"2019-04-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Nilotinib","valueDescription":"Nilotinib Hydrochloride Monohydrate","ValueMeaning":{"publicId":"6688536","version":"1","preferredName":"Nilotinib Hydrochloride Monohydrate","longName":"6688536","preferredDefinition":"The monohydrate monohydrochloride form of nilotinib, an orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance resulting from Bcr-Abl kinase mutations, upon administration, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl portion of the Bcr-Abl fusion protein, resulting in the inhibition of the constitutive kinase activity of Bcr-Abl protein. This inhibits the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. Nilotinib also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R; PDGFR), mast/stem cell growth factor receptor Kit (c-Kit), and, to a lesser extent, colony-stimulating factor 1 receptor (CSF-1R; CSF1R), and discoidin domain-containing receptor 1 (DDR1).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nilotinib Hydrochloride Monohydrate","conceptCode":"C95229","definition":"The monohydrate monohydrochloride form of nilotinib, an orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance resulting from Bcr-Abl kinase mutations, upon administration, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl portion of the Bcr-Abl fusion protein, resulting in the inhibition of the constitutive kinase activity of Bcr-Abl protein. This inhibits the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. Nilotinib also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R; PDGFR), mast/stem cell growth factor receptor Kit (c-Kit), and, to a lesser extent, colony-stimulating factor 1 receptor (CSF-1R; CSF1R), and discoidin domain-containing receptor 1 (DDR1).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"860CCE3A-0AF9-57F9-E053-F662850ACDA8","latestVersionIndicator":"Yes","beginDate":"2019-04-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-09","modifiedBy":"ONEDATA","dateModified":"2019-04-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9B05-18F7-E053-F662850A60B1","beginDate":"2019-04-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Doxylamine Succinate","valueDescription":"Doxylamine Succinate (Unisom)","ValueMeaning":{"publicId":"6941798","version":"1","preferredName":"Doxylamine Succinate (Unisom)","longName":"6941798","preferredDefinition":"A pyridine derivate histamine H1 antagonist with pronounced sedative properties. Doxylamine succinate competitively blocks the histamine H1 receptor and limits the typical allergic and anaphylactic responses, including bronchoconstriction, vasodilation, increased capillary permeability, and spasmodic contraction of gastrointestinal smooth muscle, caused by actions of histamine on bronchial and gastrointestinal smooth muscles, and on capillaries. This drug also prevents histamine-induced pain and itching of the skin and mucous membranes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxylamine Succinate","conceptCode":"C47501","definition":"A pyridine derivate histamine H1 antagonist with pronounced sedative properties. Doxylamine succinate competitively blocks the histamine H1 receptor and limits the typical allergic and anaphylactic responses, including bronchoconstriction, vasodilation, increased capillary permeability, and spasmodic contraction of gastrointestinal smooth muscle, caused by actions of histamine on bronchial and gastrointestinal smooth muscles, and on capillaries. This drug also prevents histamine-induced pain and itching of the skin and mucous membranes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"92C4010A-EF83-53AA-E053-F662850A93F7","latestVersionIndicator":"Yes","beginDate":"2019-09-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-09-17","modifiedBy":"COOPERM","dateModified":"2019-09-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9B0F-18F7-E053-F662850A60B1","beginDate":"2019-09-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ferumoxytol","valueDescription":"Ferumoxytol (Feraheme)","ValueMeaning":{"publicId":"6841514","version":"1","preferredName":"Ferumoxytol (Feraheme)","longName":"6841514","preferredDefinition":"A superparamagnetic iron oxide nanoparticle coated with a low molecular weight semi-synthetic carbohydrate, polyglucose sorbitol carboxymethyl ether, with potential anti-anemic and imaging properties. After intravenous administration, ferumoxytol replaces iron stores with fewer side effects compared to the use of oral iron.  In addition, this agent generates T1 relaxation, producing a magnetic field and enhancing T2 relaxation, thereby darkening contrast media-containing structures in magnetic resonance imaging (MRI). Due to small particle size, ferumoxytol remains in the intravasculature for a prolonged period and so may be used as a blood pool agent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ferumoxytol","conceptCode":"C87701","definition":"A superparamagnetic iron oxide nanoparticle coated with a low molecular weight semi-synthetic carbohydrate, polyglucose sorbitol carboxymethyl ether, with potential anti-anemic and imaging properties. After intravenous administration, ferumoxytol replaces iron stores with fewer side effects compared to the use of oral iron.  In addition, this agent generates T1 relaxation, producing a magnetic field and enhancing T2 relaxation, thereby darkening contrast media-containing structures in magnetic resonance imaging (MRI). Due to small particle size, ferumoxytol remains in the intravasculature for a prolonged period and so may be used as a blood pool agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8EF9DADB-7D21-24E4-E053-F662850AA580","latestVersionIndicator":"Yes","beginDate":"2019-07-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-31","modifiedBy":"COOPERM","dateModified":"2019-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9B19-18F7-E053-F662850A60B1","beginDate":"2019-07-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Aluminum Acetate","valueDescription":"Aluminum Acetate Topical Solution Dosage Form","ValueMeaning":{"publicId":"6846825","version":"1","preferredName":"Aluminum Acetate Topical Solution Dosage Form","longName":"6846825","preferredDefinition":"A topical astringent that is used as an antiseptic agent. Aluminum acetate is used to treat inflammation, itching, and stinging of the infected skin and promotes healing.: A solution intended for administration to a body surface.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aluminum Acetate","conceptCode":"C47387","definition":"A topical astringent that is used as an antiseptic agent. Aluminum acetate is used to treat inflammation, itching, and stinging of the infected skin and promotes healing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Topical Solution Dosage Form","conceptCode":"C64905","definition":"A solution intended for administration to a body surface.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F63A637-9344-69C7-E053-F662850AD19F","latestVersionIndicator":"Yes","beginDate":"2019-08-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9B23-18F7-E053-F662850A60B1","beginDate":"2019-08-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Fostair 100/6","valueDescription":"Fostair 100/6 (inhaler)","ValueMeaning":{"publicId":"6846826","version":"1","preferredName":"Fostair 100/6 (inhaler)","longName":"6846826","preferredDefinition":"Fostair 100/6 (inhaler)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F63A637-9369-69C7-E053-F662850AD19F","latestVersionIndicator":"Yes","beginDate":"2019-08-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9B2D-18F7-E053-F662850A60B1","beginDate":"2019-08-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"CBD","valueDescription":"Cannabidiol","ValueMeaning":{"publicId":"6846828","version":"1","preferredName":"Cannabidiol","longName":"6846828","preferredDefinition":"A phytocannabinoid derived from Cannabis species, which is devoid of psychoactive activity, with analgesic, anti-inflammatory, antineoplastic and chemopreventive activities. Upon administration, cannabidiol (CBD) exerts its anti-proliferative, anti-angiogenic and pro-apoptotic activity through various mechanisms, which likely do not involve signaling by cannabinoid receptor 1 (CB1), CB2, or vanilloid receptor 1. CBD stimulates endoplasmic reticulum (ER) stress and inhibits AKT/mTOR signaling, thereby activating autophagy and promoting apoptosis. In addition, CBD enhances the generation of reactive oxygen species (ROS), which further enhances apoptosis. This agent also upregulates the expression of intercellular adhesion molecule 1 (ICAM-1) and tissue inhibitor of matrix metalloproteinases-1 (TIMP1) and decreases the expression of inhibitor of DNA binding 1 (ID-1). This inhibits cancer cell invasiveness and metastasis. CBD may also activate the transient receptor potential vanilloid type 2 (TRPV2), which may increase the uptake of various cytotoxic agents in cancer cells. The analgesic effect of CBD is mediated through the binding of this agent to and activation of CB1.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cannabidiol","conceptCode":"C118452","definition":"A phytocannabinoid derived from Cannabis species, which is devoid of psychoactive activity, with analgesic, anti-inflammatory, antineoplastic and chemopreventive activities. Upon administration, cannabidiol (CBD) exerts its anti-proliferative, anti-angiogenic and pro-apoptotic activity through various mechanisms, which likely do not involve signaling by cannabinoid receptor 1 (CB1), CB2, or vanilloid receptor 1. CBD stimulates endoplasmic reticulum (ER) stress and inhibits AKT/mTOR signaling, thereby activating autophagy and promoting apoptosis. In addition, CBD enhances the generation of reactive oxygen species (ROS), which further enhances apoptosis. This agent also upregulates the expression of intercellular adhesion molecule 1 (ICAM-1) and tissue inhibitor of matrix metalloproteinases-1 (TIMP1) and decreases the expression of inhibitor of DNA binding 1 (ID-1). This inhibits cancer cell invasiveness and metastasis. CBD may also activate the transient receptor potential vanilloid type 2 (TRPV2), which may increase the uptake of various cytotoxic agents in cancer cells. The analgesic effect of CBD is mediated through the binding of this agent to and activation of CB1.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F63A637-938F-69C7-E053-F662850AD19F","latestVersionIndicator":"Yes","beginDate":"2019-08-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-05","modifiedBy":"TAYLORT","dateModified":"2020-01-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9B37-18F7-E053-F662850A60B1","beginDate":"2019-08-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Metformin / Sitagliptin","valueDescription":"Metformin And Sitagliptin","ValueMeaning":{"publicId":"6846830","version":"1","preferredName":"Metformin And Sitagliptin","longName":"6846830","preferredDefinition":"An agent belonging to the biguanide class of antidiabetics with antihyperglycemic activity. Metformin is associated with a very low incidence of lactic acidosis. This agent helps reduce LDL cholesterol and triglyceride levels, and is not associated with weight gain, and prevents the cardiovascular complications of diabetes. Metformin is not metabolized and is excreted unchanged by the kidneys.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: An orally available, competitive, beta-amino acid-derived inhibitor of dipeptidyl peptidase 4 (DDP-4) with hypoglycemic activity. Sitagliptin may cause an increased risk in the development of pancreatitis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metformin","conceptCode":"C61612","definition":"An agent belonging to the biguanide class of antidiabetics with antihyperglycemic activity. Metformin is associated with a very low incidence of lactic acidosis. This agent helps reduce LDL cholesterol and triglyceride levels, and is not associated with weight gain, and prevents the cardiovascular complications of diabetes. Metformin is not metabolized and is excreted unchanged by the kidneys.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Sitagliptin","conceptCode":"C73838","definition":"An orally available, competitive, beta-amino acid-derived inhibitor of dipeptidyl peptidase 4 (DDP-4) with hypoglycemic activity. Sitagliptin may cause an increased risk in the development of pancreatitis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F63A637-93B9-69C7-E053-F662850AD19F","latestVersionIndicator":"Yes","beginDate":"2019-08-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-05","modifiedBy":"ONEDATA","dateModified":"2019-08-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9B41-18F7-E053-F662850A60B1","beginDate":"2019-08-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Rimiducid","valueDescription":"Rimiducid","ValueMeaning":{"publicId":"6769545","version":"1","preferredName":"Rimiducid","longName":"6769545","preferredDefinition":"A lipid-permeable tacrolimus analogue with homodimerizing activity. Dimerizer drug AP1903 homodimerizes an analogue of human protein FKBP12 (Fv) which contains a single acid substitution (Phe36Val) so that AP1903 binds to wild-type FKBP12 with 1000-fold lower affinity. This agent is used to homodimerize the Fv-containing drug-binding domains of genetically engineered receptors such as the iCD40 receptor of the autologous dendritic cell vaccine BP-GMAX-CD1, resulting in receptor activation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rimiducid","conceptCode":"C82412","definition":"A lipid-permeable tacrolimus analogue with homodimerizing activity. Dimerizer drug AP1903 homodimerizes an analogue of human protein FKBP12 (Fv) which contains a single acid substitution (Phe36Val) so that AP1903 binds to wild-type FKBP12 with 1000-fold lower affinity. This agent is used to homodimerize the Fv-containing drug-binding domains of genetically engineered receptors such as the iCD40 receptor of the autologous dendritic cell vaccine BP-GMAX-CD1, resulting in receptor activation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"89A5495D-3008-09DC-E053-F662850AAB7D","latestVersionIndicator":"Yes","beginDate":"2019-05-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-05-24","modifiedBy":"ONEDATA","dateModified":"2019-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9B4B-18F7-E053-F662850A60B1","beginDate":"2019-05-24","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Menthol/Camphor Lotion","valueDescription":"Camphor/Menthol-based Formulation Lotion Dosage Form","ValueMeaning":{"publicId":"6856468","version":"1","preferredName":"Camphor/Menthol-based Formulation Lotion Dosage Form","longName":"6856468","preferredDefinition":"A combination preparation containing camphor and menthol with anti-pruritic activity. Camphor, a terpenoid extracted from camphor laurel (Cinnamonum camphora) tree, can be absorbed readily through the skin and produces a cooling feeling similar to that of menthol. This formulation is used to relieve itching and cools irritated skin due to sunburn, dry and itchy skin, poison ivy, poison oak, insect bites, minor cuts, burns and abrasions.: A semi-solid composed of an oil in water emulsion, with lower viscosity than cream or gel.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Camphor/Menthol-based Formulation","conceptCode":"C29445","definition":"A combination preparation containing camphor and menthol with anti-pruritic activity. Camphor, a terpenoid extracted from camphor laurel (Cinnamonum camphora) tree, can be absorbed readily through the skin and produces a cooling feeling similar to that of menthol. This formulation is used to relieve itching and cools irritated skin due to sunburn, dry and itchy skin, poison ivy, poison oak, insect bites, minor cuts, burns and abrasions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Lotion Dosage Form","conceptCode":"C29167","definition":"A semi-solid composed of an oil in water emulsion, with lower viscosity than cream or gel.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"903B32A6-B568-455E-E053-F662850AF244","latestVersionIndicator":"Yes","beginDate":"2019-08-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-08-16","modifiedBy":"ONEDATA","dateModified":"2019-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-9B55-18F7-E053-F662850A60B1","beginDate":"2019-08-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Leucovorin Calcium","valueDescription":"Leucovorin Calcium","ValueMeaning":{"publicId":"2576876","version":"1","preferredName":"Leucovorin Calcium","longName":"2576876","preferredDefinition":"An active metabolite of folic acid (also called folinic acid and citrovorum factor), which does not require metabolism by dihydrofolate reductase, the molecular target of folate antagonist-type chemotherapeutic drugs.  Leucovorin calcium counteracts the toxic effects of these medications, 'rescuing' the patient while permitting the antitumor activity of the folate antagonist. This agent also potentiates the effects of fluorouracil and its derivatives by stabilizing the binding of the drug's metabolite to its target enzyme, thus prolonging drug activity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leucovorin Calcium","conceptCode":"C607","definition":"An active metabolite of folic acid (also called folinic acid and citrovorum factor), which does not require metabolism by dihydrofolate reductase, the molecular target of folate antagonist-type chemotherapeutic drugs.  Leucovorin calcium counteracts the toxic effects of these medications, 'rescuing' the patient while permitting the antitumor activity of the folate antagonist. This agent also potentiates the effects of fluorouracil and its derivatives by stabilizing the binding of the drug's metabolite to its target enzyme, thus prolonging drug activity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F959-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7DD7-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Leuprolide Acetate","valueDescription":"Leuprolide Acetate","ValueMeaning":{"publicId":"2576645","version":"1","preferredName":"Leuprolide Acetate","longName":"2576645","preferredDefinition":"A synthetic nonapeptide analogue of gonadotropin-releasing hormone. Leuprolide binds to and activates gonadotropin-releasing hormone (GnRH) receptors. Continuous, prolonged administration of leuprolide in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. This agent reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leuprolide Acetate","conceptCode":"C1319","definition":"The acetate salt of a synthetic nonapeptide analogue of gonadotropin-releasing hormone. Leuprolide binds to and activates gonadotropin-releasing hormone (GnRH) receptors. Continuous, prolonged administration of leuprolide in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. This agent reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F872-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7DE1-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Levamisole","valueDescription":"Levamisole","ValueMeaning":{"publicId":"2578219","version":"1","preferredName":"Levamisole","longName":"2578219","preferredDefinition":"An anthelmintic drug. Co-administered with fluorouracil in the treatment of Dukes' stage C colon cancer, levamisole restores immune function through stimulating antibody formation, enhancing T-cell activity, and potentiating macrophage function. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Levamisole Hydrochloride","conceptCode":"C610","definition":"The hydrochloride salt of the synthetic imidazothiazole derivative levamisole with anthelminthic and immunomodulating activities. In immunosuppressed states, levamisole may restore immune function by: 1) stimulating antibody formation, 2) stimulating T-cell activation and proliferation, 3) potentiating monocyte and macrophage phagocytosis and chemotaxis and 4) increasing neutrophil mobility, adherence, and chemotaxis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE98-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7DEB-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Levarterenol Bitartrate","valueDescription":"Levarterenol Bitartrate","ValueMeaning":{"publicId":"2578220","version":"1","preferredName":"Levarterenol Bitartrate","longName":"2578220","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Levarterenol Bitartrate Anhydrous","conceptCode":"C29152","definition":"The anhydrous bitartrate salt form of levarterenol, the levorotatory isomer of norepinephrine with a vasoconstrictor effect. Levarterenol binds to alpha and beta-1 receptor sites of sympathetic effector cells, thereby causing vasoconstriction of the radial smooth muscle of the arteries, arterioles, and veins and increasing myocardial contractility, heart rate, automaticity, and artrioventricular (AV) conduction, respectively. Stimulation of the beta-2 adrenergic receptors causes bronchiolar and vascular smooth muscle dilatation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE99-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7DF5-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Levetiracetam","valueDescription":"Levetiracetam","ValueMeaning":{"publicId":"2578221","version":"1","preferredName":"Levetiracetam","longName":"2578221","preferredDefinition":"A pyrrolidine with antiepileptic activity. The exact mechanism through which levetiracetam exerts its effects is unknown but does not involve inhibitory and excitatory neurotransmitter activity. Stereoselective binding of levetiracetam was confined to synaptic plasma membranes in the central nervous system with no binding occurring in peripheral tissue. Levetiracetam inhibits burst firing without affecting normal neuronal excitability, which suggests that it may selectively prevent hyper-synchronization of epileptiform burst firing and propagation of seizure activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Levetiracetam","conceptCode":"C47581","definition":"A pyrrolidine with antiepileptic activity. The exact mechanism through which levetiracetam exerts its effects is unknown but does not involve inhibitory and excitatory neurotransmitter activity. Stereoselective binding of levetiracetam was confined to synaptic plasma membranes in the central nervous system with no binding occurring in peripheral tissue. Levetiracetam inhibits burst firing without affecting normal neuronal excitability, which suggests that it may selectively prevent hyper-synchronization of epileptiform burst firing and propagation of seizure activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE9A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7DFF-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Ketamine HCL","valueDescription":"Ketamine Hydrochloride","ValueMeaning":{"publicId":"2578222","version":"1","preferredName":"Ketamine Hydrochloride","longName":"2578222","preferredDefinition":"A synthetic nonbarbiturate anesthetic derivative of cyclohexanone, Ketamine Hydrochloride can block NMDA receptors (N-methyl-D-aspartate) and may interact with sigma receptors. Its mechanism of action is not well understood. Ketamine reduces pain perception, causes sedation, and distorts perceptions. It is used for induction of anesthesia. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ketamine Hydrochloride","conceptCode":"C29142","definition":"The hydrochloride salt of a synthetic derivative of cyclohexanone with analgesic and anesthetic activities. Although its mechanism of action is not well understood, ketamine appears to non-competitively block N-methyl-D-aspartate (NMDA) receptors and may interact with opioid mu receptors and sigma receptors, thereby reducing pain perception, inducing sedation, and producing dissociative anesthesia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE9B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7E09-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lactaid","valueDescription":"Lactase Enzyme","ValueMeaning":{"publicId":"2578223","version":"1","preferredName":"Lactase Enzyme","longName":"2578223","preferredDefinition":"Formulated in various oral forms for use in lactose intolerance, Lactase Enzyme (Lactaid) is a dietary supplement that breaks down lactose (milk sugar) in dairy foods. It prevents gas, diarrhea, and bloating caused by consumption from dairy foods in people that lack the natural lactase enzyme. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lactase","conceptCode":"C29147","definition":"Formulated in various oral forms for use in lactose intolerance, Lactase Enzyme (Lactaid) is a dietary supplement that breaks down lactose (milk sugar) in dairy foods. It prevents gas, diarrhea, and bloating caused by consumption from dairy foods in people that lack the natural lactase enzyme. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE9C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7E13-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"L-Carnitine","valueDescription":"Levocarnitine","ValueMeaning":{"publicId":"2578224","version":"1","preferredName":"Levocarnitine","longName":"2578224","preferredDefinition":"An amino acid derivative.  Levocarnitine facilitates long-chain fatty acid entry into mitochondria, delivering substrate for oxidation and subsequent energy production. Fatty acids are utilized as an energy substrate in all tissues except the brain. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Levocarnitine","conceptCode":"C26657","definition":"An amino acid derivative.  Levocarnitine facilitates long-chain fatty acid entry into mitochondria, delivering substrate for oxidation and subsequent energy production. Fatty acids are utilized as an energy substrate in all tissues except the brain. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE9D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7E1D-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lecithin","valueDescription":"Lecithin","ValueMeaning":{"publicId":"2578225","version":"1","preferredName":"Lecithin","longName":"2578225v1.00","preferredDefinition":"A phospholipid with a polar choline found in phosphoester linkage to diacylglycerol.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lecithin","conceptCode":"C68386","definition":"A phospholipid with a polar choline found in phosphoester linkage to diacylglycerol.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE9E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"CLOHNES","dateModified":"2023-08-04","changeDescription":null,"administrativeNotes":"8/4/23 Added missing concept per cleanup activites cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7E27-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Levalbuterol","valueDescription":"Levalbuterol","ValueMeaning":{"publicId":"2578226","version":"1","preferredName":"Levalbuterol","longName":"2578226v1.00","preferredDefinition":"A short-acting sympathomimetic beta-2 adrenergic receptor agonist with bronchodilator activity. Levalbuterol binds to beta-2 adrenergic receptors in bronchial smooth muscle and activates intracellular adenyl cyclase, an enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increased cAMP levels lead to the activation of protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in relaxation of bronchial smooth muscles. The increased cAMP concentrations also inhibit the release of inflammatory mediators, especially from mast cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Levalbuterol","conceptCode":"C74196","definition":"A short-acting sympathomimetic beta-2 adrenergic receptor agonist with bronchodilator activity. Levalbuterol binds to beta-2 adrenergic receptors in bronchial smooth muscle and activates intracellular adenyl cyclase, an enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increased cAMP levels lead to the activation of protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in relaxation of bronchial smooth muscles. The increased cAMP concentrations also inhibit the release of inflammatory mediators, especially from mast cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE9F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"CLOHNES","dateModified":"2023-09-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7E31-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Levofloxacin","valueDescription":"Levofloxacin","ValueMeaning":{"publicId":"2575687","version":"1","preferredName":"Levofloxacin","longName":"2575687","preferredDefinition":"A type of quinolone antibiotic. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Levofloxacin","conceptCode":"C1586","definition":"A broad-spectrum, third-generation fluoroquinolone antibiotic and optically active L-isomer of ofloxacin with antibacterial activity. Levofloxacin diffuses through the bacterial cell wall and acts by inhibiting DNA gyrase (bacterial topoisomerase II), an enzyme required for DNA replication, RNA transcription, and repair of bacterial DNA. Inhibition of DNA gyrase activity leads to blockage of bacterial cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4B4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7E3B-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Librax","valueDescription":"Librax","ValueMeaning":{"publicId":"2578232","version":"1","preferredName":"Librax","longName":"2578232","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Librax","conceptCode":"C0064956","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEA5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7E45-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lidobenalox","valueDescription":"Lidobenalox","ValueMeaning":{"publicId":"2578233","version":"1","preferredName":"Lidobenalox","longName":"2578233","preferredDefinition":"An oral suspension of viscous lidocaine, diphenhydramine (Benadryl) and aluminum and magnesium hydroxides (Maalox). This agent possesses anesthetic, antihistamine, and antacid properties. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lidobenalox","conceptCode":"C29155","definition":"An oral suspension of viscous lidocaine, diphenhydramine (Benadryl) and aluminum and magnesium hydroxides (Maalox). This agent possesses anesthetic, antihistamine, and antacid properties. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEA6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7E4F-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lidocaine Patch","valueDescription":"Lidocaine Patch","ValueMeaning":{"publicId":"2578234","version":"1","preferredName":"Lidocaine Patch","longName":"2578234","preferredDefinition":"A transdermal patch containing 5 percent lidocaine, that releases lidocaine into the body through the skin. It is used as a peripheral analgesic.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lidocaine Patch","conceptCode":"C29988","definition":"A transdermal patch containing a 5 percent aqueous base solution of the synthetic amide-type anesthetic lidocaine with analgesic activity. Upon topical application and transdermal delivery, the active ingredient lidocaine binds to and blocks voltage-gated sodium channels in the neuronal cell membrane; lidocaine-mediated stabilization of neuronal membranes inhibits the initiation and conduction of nerve impulses and produces a reversible local anesthesia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEA7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7E59-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lidocaine Topical","valueDescription":"Lidocaine Topical","ValueMeaning":{"publicId":"2578235","version":"1","preferredName":"Lidocaine Topical","longName":"2578235v1.00","preferredDefinition":"A synthetic aminoethylamide with local anesthetic activity applied topically to either the skin or mucous membranes. Lidocaine stabilizes the neuronal cell membrane by binding to and inhibiting voltage-gated sodium channels, thereby inhibiting the initiation and conduction of nerve impulses and producing a reversible loss of sensation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lidocaine Topical","conceptCode":"C29989","definition":"A synthetic aminoethylamide with local anesthetic activity applied topically to either the skin or mucous membranes. Lidocaine stabilizes the neuronal cell membrane by binding to and inhibiting voltage-gated sodium channels, thereby inhibiting the initiation and conduction of nerve impulses and producing a reversible loss of sensation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEA8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"CLOHNES","dateModified":"2023-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7E63-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lidocaine Oral Solution","valueDescription":"Lidocaine Oral Solution","ValueMeaning":{"publicId":"2578236","version":"1","preferredName":"Lidocaine Oral Solution","longName":"2578236v1.00","preferredDefinition":"A synthetic aminoethylamide with anesthetic activity applied topically to the mucous membranes in the mouth and/or throat. Lidocaine stabilizes the neuronal cell membrane by binding to and inhibiting voltage-gated sodium channels, thereby inhibiting the initiation and conduction of nerve impulses and producing a reversible loss of sensation. Lidocaine oral solution applied to specific areas in the mouth and/or throat is used to provide relief of pain and discomfort during dental procedures and due to irritated or inflamed mucous membranes of the mouth and pharynx.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lidocaine Oral Solution","conceptCode":"C29987","definition":"A synthetic aminoethylamide with anesthetic activity applied topically to the mucous membranes in the mouth and/or throat. Lidocaine stabilizes the neuronal cell membrane by binding to and inhibiting voltage-gated sodium channels, thereby inhibiting the initiation and conduction of nerve impulses and producing a reversible loss of sensation. Lidocaine oral solution applied to specific areas in the mouth and/or throat is used to provide relief of pain and discomfort during dental procedures and due to irritated or inflamed mucous membranes of the mouth and pharynx.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEA9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"CLOHNES","dateModified":"2023-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7E6D-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Linezolid","valueDescription":"Linezolid","ValueMeaning":{"publicId":"2578237","version":"1","preferredName":"Linezolid","longName":"2578237","preferredDefinition":"A synthetic oxazolidinone derivative, Linezolid selectively inhibits an early step in bacterial protein synthesis and affects blood pressure through monoamine oxidase inhibition. It is effective against Gram-positive organisms, including methicillin-resistant Staphylococcus aureus strains, coagulase-negative Staphylococci, vancomycin-resistant Enterococci, and penicillin-resistant Streptococcus pneumoniae strains. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Linezolid","conceptCode":"C29158","definition":"A synthetic oxazolidinone derivative, Linezolid selectively inhibits an early step in bacterial protein synthesis and affects blood pressure through monoamine oxidase inhibition. It is effective against Gram-positive organisms, including methicillin-resistant Staphylococcus aureus strains, coagulase-negative Staphylococci, vancomycin-resistant Enterococci, and penicillin-resistant Streptococcus pneumoniae strains. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEAA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7E77-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lipid","valueDescription":"Lipid","ValueMeaning":{"publicId":"2571047","version":"1","preferredName":"Lipid","longName":"2571047","preferredDefinition":"Lipids are fatty acid esters, an oily organic compound insoluble in water but soluble in organic solvents.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lipid","conceptCode":"C616","definition":"A class of hydrocarbon-containing organic compounds. Lipids are insoluble in water but soluble in nonpolar solvents and play important roles in living organisms: these roles include functioning as energy storage molecules, serving as structural components of cell membranes, and constituting important signaling molecules. Lipids can be subdivided into 2 groups: fatty acids and glycerides.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E294-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-07-09","endDate":null,"createdBy":"PWEST","dateCreated":"2004-07-09","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7E81-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lisinopril","valueDescription":"Lisinopril","ValueMeaning":{"publicId":"2578238","version":"1","preferredName":"Lisinopril","longName":"2578238","preferredDefinition":"A synthetic peptide derivate and long-acting angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. Lisinopril specifically and competitively inhibits angiotensin-converting enzyme thereby decreasing the formation of the potent vasoconstrictor angiotensin II. This leads to a diminished vasopressor activity. In addition, angiotensin II-stimulated aldosterone secretion by adrenal cortex is decreased which results in a decrease of sodium and water retention and an increase of serum potassium.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lisinopril","conceptCode":"C29159","definition":"An orally bioavailable, long-acting angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. Lisinopril, a synthetic peptide derivative, specifically and competitively inhibits ACE, which results in a decrease in the production of the potent vasoconstrictor angiotensin II and, so, diminished vasopressor activity. In addition, angiotensin II-stimulated aldosterone secretion by the adrenal cortex is decreased which results in a decrease in sodium and water retention and an increase in serum potassium.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEAB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7E8B-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lithium Carbonate","valueDescription":"Lithium Carbonate","ValueMeaning":{"publicId":"2578239","version":"1","preferredName":"Lithium Carbonate","longName":"2578239","preferredDefinition":"A lithium salt, classified as a mood-stabilizing agent. Lithium ion alters the metabolism of BIOGENIC MONOAMINES in the CENTRAL NERVOUS SYSTEM, and affects multiple neurotransmission systems.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lithium Carbonate","conceptCode":"C1318","definition":"The carbonate salt of lithium, a soft alkali metal, with antimanic and hematopoietic activities. Lithium interferes with transmembrane sodium exchange in nerve cells by affecting sodium, potassium-stimulated adenosine triphosphatase (Na+, K+-ATPase); alters the release of neurotransmitters; affects cyclic adenosine monophosphate (cAMP) concentrations; and blocks inositol metabolism resulting in depletion of cellular inositol and inhibition of phospholipase C-mediated signal transduction. The exact mechanism through which lithium exerts its mood-stabilizing effect has not been established. In addition, lithium stimulates granulocytopoiesis and appears to increase the level of pluripotent hematopoietic stem cells by stimulating the release of hematopoietic cytokines and/or directly acting on hematopoietic stem cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEAC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7E95-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lodoxamide Tromethamine","valueDescription":"Lodoxamide Tromethamine","ValueMeaning":{"publicId":"2578240","version":"1","preferredName":"Lodoxamide Tromethamine","longName":"2578240v1.00","preferredDefinition":"The tromethamide salt form of lodoxamide, a synthetic mast cell stabilizing compound with anti-inflammatory activity. Upon administration to the eye, lodoxamide tromethamide inhibits type I immediate hypersensitivity reaction by preventing the antigen-stimulated calcium influx into mast cells, thereby inhibiting release of histamine. Lodoxamide tromethamide also prevents the release of slow-reacting substances of anaphylaxis (SRS-A) and inhibits eosinophil chemotaxis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lodoxamide Tromethamine","conceptCode":"C29160","definition":"The tromethamide salt form of lodoxamide, a synthetic mast cell stabilizing compound with anti-inflammatory activity. Upon administration to the eye, lodoxamide tromethamide inhibits type I immediate hypersensitivity reaction by preventing the antigen-stimulated calcium influx into mast cells, thereby inhibiting release of histamine. Lodoxamide tromethamide also prevents the release of slow-reacting substances of anaphylaxis (SRS-A) and inhibits eosinophil chemotaxis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEAD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"CLOHNES","dateModified":"2023-09-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7E9F-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Loperamide","valueDescription":"Loperamide","ValueMeaning":{"publicId":"2578241","version":"1","preferredName":"Loperamide","longName":"2578241","preferredDefinition":"A synthetic agent chemically related to the opiates with anti-diarrheal properties.  Loperamide decreases gastro-intestinal motility by effects on the circular and longitudinal muscles of the intestine. Part of its anti-diarrheal effect may be due to a reduction of gastro-intestinal secretion produced by opioid receptor binding in the intestinal mucosa. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Loperamide","conceptCode":"C618","definition":"A synthetic agent chemically related to the opiates with anti-diarrheal properties.  Loperamide decreases gastro-intestinal motility by effects on the circular and longitudinal muscles of the intestine. Part of its anti-diarrheal effect may be due to a reduction of gastro-intestinal secretion produced by opioid receptor binding in the intestinal mucosa. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEAE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7EA9-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lopinavir","valueDescription":"Lopinavir","ValueMeaning":{"publicId":"2575688","version":"1","preferredName":"Lopinavir","longName":"2575688","preferredDefinition":"An anti-HIV protease inhibitor","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lopinavir","conceptCode":"C2095","definition":"A peptidomimetic HIV protease inhibitor that retains activity against HIV protease with the Val 82 mutation. Lopinavir is less affected by binding to serum proteins than the structurally-related drug ritonavir.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4B5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7EB3-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Loratadine","valueDescription":"Loratadine","ValueMeaning":{"publicId":"2578242","version":"1","preferredName":"Loratadine","longName":"2578242","preferredDefinition":"A piperidine histamine H1-receptor antagonist with anti-allergic properties and without sedative effects. Loratadine blocks the H1 histamine receptor and prevents the symptoms that are caused by histamine activity on capillaries, bronchial smooth muscle, and gastrointestinal smooth muscle, including vasodilatation, increased capillary permeability, bronchoconstriction, and spasmodic contraction of gastrointestinal smooth muscle. Loratadine does not cross the blood-brain barrier and does not cause central nervous system effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Loratadine","conceptCode":"C29162","definition":"A piperidine histamine H1-receptor antagonist with anti-allergic properties and without sedative effects. Loratadine blocks the H1 histamine receptor and prevents the symptoms that are caused by histamine activity on capillaries, bronchial smooth muscle, and gastrointestinal smooth muscle, including vasodilatation, increased capillary permeability, bronchoconstriction, and spasmodic contraction of gastrointestinal smooth muscle. Loratadine does not cross the blood-brain barrier and does not cause central nervous system effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEAF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7EBD-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Loratadine/Pseudoephedrine","valueDescription":"Loratadine/Pseudoephedrine","ValueMeaning":{"publicId":"2578243","version":"1","preferredName":"Loratadine/Pseudoephedrine","longName":"2578243v1.00","preferredDefinition":"An oral combination preparation containing the antihistamine loratidine and the indirect-acting sympathicomimetic agent pseudoephedrine, with anti-allergic and decongestant activities. Loratadine, a piperidine, blocks the H1-receptor thereby preventing the symptoms that are caused by histamine activity on capillaries, bronchial smooth muscle, and gastrointestinal smooth muscle, including vasodilatation, increased capillary permeability, bronchoconstriction, and spasmodic contraction of gastrointestinal smooth muscle. Pseudoephedrine displaces norepinephrine from storage vesicles in presynaptic neurons, thereby releasing norepinephrine into the neuronal synapses where it stimulates primarily alpha-adrenergic receptors in the nasal mucosa, thereby producing vasoconstriction, reduces swelling of nasal tissues and decreasing nasal and sinus congestion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Loratadine/Pseudoephedrine","conceptCode":"C29163","definition":"An oral combination preparation containing the antihistamine loratidine and the indirect-acting sympathicomimetic agent pseudoephedrine, with anti-allergic and decongestant activities. Loratadine, a piperidine, blocks the H1-receptor thereby preventing the symptoms that are caused by histamine activity on capillaries, bronchial smooth muscle, and gastrointestinal smooth muscle, including vasodilatation, increased capillary permeability, bronchoconstriction, and spasmodic contraction of gastrointestinal smooth muscle. Pseudoephedrine displaces norepinephrine from storage vesicles in presynaptic neurons, thereby releasing norepinephrine into the neuronal synapses where it stimulates primarily alpha-adrenergic receptors in the nasal mucosa, thereby producing vasoconstriction, reduces swelling of nasal tissues and decreasing nasal and sinus congestion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEB0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"CLOHNES","dateModified":"2023-09-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7EC7-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lorazepam","valueDescription":"Lorazepam","ValueMeaning":{"publicId":"2578244","version":"1","preferredName":"Lorazepam","longName":"2578244","preferredDefinition":"An anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lorazepam","conceptCode":"C619","definition":"A benzodiazepine with anxiolytic, anti-anxiety, anticonvulsant, anti-emetic and sedative properties. Lorazepam enhances the effect of the inhibitory neurotransmitter gamma-aminobutyric acid on the GABA receptors by binding to a site that is distinct from the GABA binding site in the central nervous system. This leads to an increase in chloride channel opening events, a facilitation of chloride ion conductance, membrane hyperpolarization, and eventually inhibition of the transmission of nerve signals, thereby decreasing nervous excitation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEB1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7ED1-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lorcet","valueDescription":"Hydrocodone/Acetaminophen","ValueMeaning":{"publicId":"2578164","version":"1","preferredName":"Hydrocodone/Acetaminophen","longName":"2578164v1.00","preferredDefinition":"A combination preparation of the analgesic acetaminophen and the semisynthetic opioid agonist hydrocodone with analgesic and antitussive activities. Acetaminophen exerts its analgesic activity by inhibiting prostaglandin synthesis while hydrocodone exerts its analgesic activity by binding to the mu-receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opioids.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydrocodone/Acetaminophen","conceptCode":"C29100","definition":"A combination preparation of the analgesic acetaminophen and the semisynthetic opioid agonist hydrocodone with analgesic and antitussive activities. Acetaminophen exerts its analgesic activity by inhibiting prostaglandin synthesis while hydrocodone exerts its analgesic activity by binding to the mu-receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opioids.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE61-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"CLOHNES","dateModified":"2023-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7EDB-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Levobunolol","valueDescription":"Levobunolol Hydrochloride","ValueMeaning":{"publicId":"2578227","version":"1","preferredName":"Levobunolol Hydrochloride","longName":"2578227","preferredDefinition":"A naphthalenone and non-cardioselective adrenergic beta-receptor antagonist with anti-glaucoma activity. Upon administration in the eye, levobunolol blocks beta-adrenergic receptors, thereby causing vasoconstriction. Levobunolol also decreases ciliary's body production of aqueous humor, leading to a decrease in aqueous humor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Levobunolol Hydrochloride","conceptCode":"C29153","definition":"The hydrochloride salt form of levobunolol, a naphthalenone and non-cardioselective adrenergic beta-receptor antagonist with anti-glaucoma activity. Upon administration in the eye, levobunolol blocks beta-adrenergic receptors, thereby causing vasoconstriction. Levobunolol also decreases ciliary's body production of aqueous humor, leading to a decrease in aqueous humor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEA0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7EE5-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Levodopa/Carbidopa","valueDescription":"Carbidopa / Levodopa Oral Tablet","ValueMeaning":{"publicId":"2578228","version":"1","preferredName":"Carbidopa / Levodopa Oral Tablet","longName":"2578228","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carbidopa / Levodopa Oral Tablet","conceptCode":"C1245308","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEA1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7EEF-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Levothyroxine","valueDescription":"Levothyroxine Sodium","ValueMeaning":{"publicId":"2578229","version":"1","preferredName":"Levothyroxine Sodium","longName":"2578229","preferredDefinition":"The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Levothyroxine Sodium","conceptCode":"C888","definition":"The sodium salt of levothyroxine, a synthetic levoisomer of thyroxine (T4) that is similar to the endogenous hormone produced by the thyroid gland. In peripheral tissues, levothyroxine is deiodinated by 5'-deiodinase to form triiodothyronine (T3). T3 enters the cell and binds to nuclear thyroid hormone receptors; the activated hormone-receptor complex in turn triggers gene expression and produces proteins required in the regulation of cellular respiration; thermogenesis; cellular growth and differentiation; and the metabolism of proteins, carbohydrates and lipids. T3 also exhibits cardiostimulatory effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEA2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7EF9-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lidocaine HCL","valueDescription":"Lidocaine Hydrochloride","ValueMeaning":{"publicId":"2578230","version":"1","preferredName":"Lidocaine Hydrochloride","longName":"2578230","preferredDefinition":"The hydrochloride salt from of lidocaine, an aminoethylamide and a prototypical member of the amide class anesthetics. Lidocaine interacts with voltage-gated Na+ channels in the nerve cell membrane and blocks the transient increase in permeability of excitable membranes to Na+. This prevents the generation and conduction of nerve impulses and produces a reversible loss of sensation. Lidocaine hydrochloride also exhibits class IB antiarrhythmic effects. The agent decreases the flow of sodium ions into myocardial tissue, especially on the Purkinje network, during phase 0 of the action potential, thereby decreasing depolarization, automaticity and excitability.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lidocaine Hydrochloride","conceptCode":"C48000","definition":"The hydrochloride salt form of lidocaine, an aminoethylamide and a prototypical member of the amide class anesthetics. Lidocaine interacts with voltage-gated Na+ channels in the nerve cell membrane and blocks the transient increase in permeability of excitable membranes to Na+. This prevents the generation and conduction of nerve impulses and produces a reversible loss of sensation. Lidocaine hydrochloride also exhibits class IB antiarrhythmic effects. The agent decreases the flow of sodium ions into myocardial tissue, especially on the Purkinje network, during phase 0 of the action potential, thereby decreasing depolarization, automaticity and excitability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEA3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7F03-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Lidocaine/Prilocaine","valueDescription":"Eutectic Mixture of Local Anesthetics","ValueMeaning":{"publicId":"2576809","version":"1","preferredName":"Eutectic Mixture of Local Anesthetics","longName":"2576809","preferredDefinition":"A topical anesthetic cream, containing lidocaine 2.5% and prilocaine 2.5%, that provides neuralgia pain relief by causing loss of cutaneous sensation through reversible blockade of conduction in nerve fibers. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eutectic Mixture of Local Anesthetics","conceptCode":"C1081","definition":"A topical anesthetic cream, containing lidocaine 2.5% and prilocaine 2.5%, that provides neuralgia pain relief by causing loss of cutaneous sensation through reversible blockade of conduction in nerve fibers. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F916-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7F0D-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Liothyronine Sodium","valueDescription":"Liothyronine Sodium","ValueMeaning":{"publicId":"2578231","version":"1","preferredName":"Liothyronine Sodium","longName":"2578231","preferredDefinition":"The sodium salt form of liothyronine, a synthetic thyroid hormone T3. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liothyronine Sodium","conceptCode":"C2581","definition":"The sodium salt form of liothyronine, a synthetic form of the levorotatory isomer of the naturally occurring thyroid hormone triiodothyronine (T3). Liothyronine sodium binds to nuclear thyroid receptors which then bind to thyroid hormone response elements of target genes. As a result, liothyronine sodium induces gene expression that is required for normal growth and development. Liothyronine sodium is more potent and has a more rapid action than thyroxine (T4).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEA4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7F17-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Losartan Potassium","valueDescription":"Losartan Potassium","ValueMeaning":{"publicId":"2578245","version":"1","preferredName":"Losartan Potassium","longName":"2578245","preferredDefinition":"The potassium salt form of losartan, a non-peptide angiotensin II antagonist with antihypertensive activity. Losartan potassium selectively and competitively blocks the binding of angiotensin II to the angiotensin I (AT1) receptor. Angiotensin II, formed from angiotensin I by angiotensin-converting enzyme (ACE), stimulates the adrenal cortex to synthesize and secrete aldosterone, which decreases the excretion of sodium and increases the excretion of potassium. Angiotensin II also acts as a vasoconstrictor in vascular smooth muscle. Losartan potassium, by blocking the binding of angiotensin II to the AT 1 receptor, promotes vasodilatation and decreases the effects of aldosterone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Losartan Potassium","conceptCode":"C29165","definition":"The potassium salt of losartan, a non-peptide angiotensin II receptor antagonist with antihypertensive activity. Losartan selectively and competitively binds to the angiotensin II receptor (type AT1) and blocks the binding of angiotensin II to the receptor, thus promoting vasodilatation and counteracting the effects of aldosterone. Converted from angiotensin I by angiotensin-converting enzyme (ACE), angiotensin II stimulates the adrenal cortex to synthesize and secrete aldosterone, decreasing sodium excretion and increasing potassium excretion, and acts as a vasoconstrictor in vascular smooth muscle.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEB2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7F21-18F7-E053-F662850A60B1","beginDate":"2006-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Glucosamine/Chondroitin","valueDescription":"chondroitin-glucosamine","ValueMeaning":{"publicId":"2577903","version":"1","preferredName":"chondroitin-glucosamine","longName":"2577903","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"chondroitin-glucosamine","conceptCode":"C0876712","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD5C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-23","modifiedBy":"ONEDATA","dateModified":"2006-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7F2B-18F7-E053-F662850A60B1","beginDate":"2006-02-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Glutamine/L-Glutamine","valueDescription":"Glutamine","ValueMeaning":{"publicId":"2577904","version":"1","preferredName":"Glutamine","longName":"2577904","preferredDefinition":"A nonessential amino acid. Glutamine can donate the ammonia on its side chain to the formation of urea (for eventual excretion by the kidneys) and to purines (necessary for the synthesis of nucleic acids). Glutamine may become a conditionally essential nutrient during certain catabolic states. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glutamine","conceptCode":"C522","definition":"A nonessential amino acid. Glutamine can donate the ammonia on its side chain to the formation of urea (for eventual excretion by the kidneys) and to purines (necessary for the synthesis of nucleic acids). Glutamic acid-to-glutamine conversion, in which an ammonia group is added to glutamic acid (catalyzed by glutamine synthase), is of central importance in the regulation of toxic levels of ammonia in the body. This agent is a substrate for the production of both excitatory and inhibitory neurotransmitters (glutamate and GABA) and is also an important source of energy for the nervous system. Glutamine may become a conditionally essential amino acid during certain catabolic states.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD5D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-23","modifiedBy":"ONEDATA_WA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7F35-18F7-E053-F662850A60B1","beginDate":"2006-02-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Glyburide","valueDescription":"Glyburide","ValueMeaning":{"publicId":"2577905","version":"1","preferredName":"Glyburide","longName":"2577905","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glyburide","conceptCode":"C29076","definition":"A sulfonamide urea derivative with antihyperglycemic activity that can potentially be used to decrease cerebral edema. Upon administration, glyburide binds to and blocks the sulfonylurea receptor type 1 (SUR1) subunit of the ATP-sensitive inwardly-rectifying potassium (K(ATP)) channels on the membranes of pancreatic beta cells. This prevents the inward current flow of positively charged potassium (K+) ions into the cell, and induces a calcium ion (Ca2+) influx through voltage-sensitive calcium channels, which triggers exocytosis of insulin-containing granules. In addition, glyburide also inhibits the SUR1-regulated nonselective cation (NC) Ca-ATP channel, melastatin 4 (transient receptor potential cation channel subfamily M member 4; (TRPM4)), thereby preventing capillary failure and brain swelling. SUR1-TRPM4 channels are formed by co-assembly of SUR1 with TRPM4 in neurons, astrocytes, and capillary endothelium during cerebral ischemia. Upon ischemia-induced ATP depletion, channels open which results in sodium influx, cytotoxic edema formation, capillary fragmentation and necrotic cell death. SUR1-TRPM4 is not expressed in normal, uninjured tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD5E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-23","modifiedBy":"ONEDATA","dateModified":"2006-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7F3F-18F7-E053-F662850A60B1","beginDate":"2006-02-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Glycerin","valueDescription":"Glycerin","ValueMeaning":{"publicId":"2577906","version":"1","preferredName":"Glycerin","longName":"2577906","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glycerin","conceptCode":"C29077","definition":"A trihydroxyalcohol with localized osmotic diuretic and laxative effects. Glycerin elevates the blood plasma osmolality thereby extracting water from tissues into interstitial fluid and plasma. This agent also prevents water reabsorption in the proximal tubule in the kidney leading to an increase in water and sodium excretion and a reduction in blood volume. Administered rectally, glycerin exerts a hyperosmotic laxative effect by attracting water into the rectum, thereby relieving constipation. In addition, glycerin is used as a solvent, humectant and vehicle in various pharmaceutical preparations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD5F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-23","modifiedBy":"ONEDATA","dateModified":"2006-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7F49-18F7-E053-F662850A60B1","beginDate":"2006-02-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Glycopyrrolate","valueDescription":"Glycopyrrolate","ValueMeaning":{"publicId":"2577907","version":"1","preferredName":"Glycopyrrolate","longName":"2577907","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glycopyrrolate","conceptCode":"C29078","definition":"A synthetic quaternary ammonium that is an anticholinergic agent with antispasmodic activity. Glycopyrrolate competitively binds to peripheral muscarinic receptors in the autonomic effector cells of, and inhibits cholinergic transmission in smooth muscle, cardiac muscle, the sinoatrial (SA) node, the atrioventricular (AV) node, exocrine glands and in the autonomic ganglia. Blockage of cholinergic transmission, in smooth muscle cells located in the gastrointestinal tract and the bladder, causes smooth muscle relaxation and prevents the occurrence of painful spasms. In addition, glycopyrrolate inhibits the release of gastric, pharyngeal, tracheal, and bronchial secretions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD60-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-23","modifiedBy":"ONEDATA","dateModified":"2006-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7F53-18F7-E053-F662850A60B1","beginDate":"2006-02-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Glyoktyl","valueDescription":"Glyoktyl","ValueMeaning":{"publicId":"2577908","version":"1","preferredName":"Glyoktyl","longName":"2577908","preferredDefinition":"A Danish brand name for a laxative product containing glycerin and docusate sodium.  As a hyperosmotic laxative, glycerin draws water into the bowel from surrounding tissues, thereby softening the stool and increasing bowel action.  Docusate sodium acts as a surface-active agent (emollient) that promotes the mixing of intestinal liquid and dry stool. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glyoktyl","conceptCode":"C29079","definition":"A Danish brand name for a laxative product containing glycerin and docusate sodium.  As a hyperosmotic laxative, glycerin draws water into the bowel from surrounding tissues, thereby softening the stool and increasing bowel action.  Docusate sodium acts as a surface-active agent (emollient) that promotes the mixing of intestinal liquid and dry stool. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD61-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-23","modifiedBy":"ONEDATA","dateModified":"2006-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7F5D-18F7-E053-F662850A60B1","beginDate":"2006-02-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Go LYTELY","valueDescription":"GoLYTELY","ValueMeaning":{"publicId":"2577909","version":"1","preferredName":"GoLYTELY","longName":"2577909","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"GoLYTELY","conceptCode":"C0061795","definition":"No value exists.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD62-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-23","modifiedBy":"ONEDATA","dateModified":"2006-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9768B702-7F67-18F7-E053-F662850A60B1","beginDate":"2006-02-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"ONEDATA","dateModified":"2019-11-15","deletedIndicator":"No"},{"value":"Oxytocin","valueDescription":"Oxytocin","ValueMeaning":{"publicId":"5380081","version":"1","preferredName":"Oxytocin","longName":"5380081","preferredDefinition":"Oxytocin (125 aa, ~13kDa) is encoded by the human OXT gene. This protein plays a role in smooth muscle contraction in both the mammary gland and uterus. Oxytocin also is involved in maternal-newborn bonding, cognition and many other psychological and physiological processes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oxytocin","conceptCode":"C2283","definition":"Oxytocin (9 aa, ~1 kDa) is encoded by the human OXT gene. This protein plays a role in smooth muscle contraction in both the mammary gland and uterus. Oxytocin also may also be involved in maternal-newborn bonding, cognition and many other psychological and physiological processes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3944D144-4F7D-77A6-E050-BB89AD43480C","latestVersionIndicator":"Yes","beginDate":"2016-08-04","endDate":null,"createdBy":"COLBERTM","dateCreated":"2016-08-04","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A21868-5853-4347-E053-F662850A6F62","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Oxymorphone","valueDescription":"Oxymorphone","ValueMeaning":{"publicId":"3379280","version":"1","preferredName":"Oxymorphone","longName":"3379280","preferredDefinition":"A semisynthetic narcotic analgesic related to hydromorphone and other opiates, Oxymorphone, hydroxy-dihydromorphinone, affects the central nervous system and smooth muscles by activation of specific opiate receptors. Similar to morphine, but more potent and without cough suppressant activity, it is used in treatment of moderate to severe pain, including obstetrical pain, or as an adjunct to anaesthesia. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oxymorphone","conceptCode":"C29314","definition":"A semisynthetic narcotic analgesic related to hydromorphone and other opiates, Oxymorphone, hydroxy-dihydromorphinone, affects the central nervous system and smooth muscles by activation of specific opiate receptors. Similar to morphine, but more potent and without cough suppressant activity, it is used in treatment of moderate to severe pain, including obstetrical pain, or as an adjunct to anaesthesia. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-C61C-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A21868-585E-4347-E053-F662850A6F62","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Oxymetazoline HCL","valueDescription":"Oxymetazoline Hydrochloride","ValueMeaning":{"publicId":"7060474","version":"1","preferredName":"Oxymetazoline Hydrochloride","longName":"7060474","preferredDefinition":"The hydrochloride salt form of oxymetazoline, an imidazole derivative with a direct acting sympathomimetic property. Oxymetazoline binds to and activates alpha-2 adrenergic receptors. Upon nasal or ocular administration, oxymetazoline constricts the arterioles in the nose and eye, resulting in decreased nasal and conjunctival congestion, respectively.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oxymetazoline Hydrochloride","conceptCode":"C29313","definition":"The hydrochloride salt form of oxymetazoline, an imidazole derivative with a direct acting sympathomimetic property. Oxymetazoline binds to and activates alpha-2 adrenergic receptors. Upon nasal or ocular administration, oxymetazoline constricts the arterioles in the nose and eye, resulting in decreased nasal and conjunctival congestion, respectively.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A21868-586B-4347-E053-F662850A6F62","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A21868-5884-4347-E053-F662850A6F62","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Oxycodone/Acetaminophen","valueDescription":"Oxycodone/Acetaminophen","ValueMeaning":{"publicId":"6287980","version":"1","preferredName":"Oxycodone/Acetaminophen","longName":"6287980","preferredDefinition":"A combination preparation of the analgesic and antipyretic acetaminophen and the semisynthetic opioid agonist oxycodone with analgesic and antitussive properties. Acetaminophen exerts its analgesic activity by inhibiting prostaglandin synthesis, while oxycodone exerts its analgesic activity by binding to the mu-receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opioids.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oxycodone/Acetaminophen","conceptCode":"C29311","definition":"A combination preparation of the analgesic and antipyretic acetaminophen and the semisynthetic opioid agonist oxycodone with analgesic and antitussive properties. Acetaminophen exerts its analgesic activity by inhibiting prostaglandin synthesis, while oxycodone exerts its analgesic activity by binding to the mu-receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opioids.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C430E2D-FA59-6D57-E053-F662850A02D6","latestVersionIndicator":"Yes","beginDate":"2018-05-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-15","modifiedBy":"COOPERM","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A21868-5898-4347-E053-F662850A6F62","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Oxycodone SR","valueDescription":"Sustained Release Dosage Form Oxycodone","ValueMeaning":{"publicId":"7060475","version":"1","preferredName":"Sustained Release Dosage Form Oxycodone","longName":"7060475","preferredDefinition":"A dosage form designed to release active and/or inert ingredient(s) slowly so as to achieve a constant circulating concentration of the ingredient over a period of time.: A semi-synthetic, morphine-like opioid alkaloid with analgesic activity. Oxycodone exerts its analgesic activity by binding to the mu-receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opioids. Binding of the opiate receptor stimulates the exchange of GTP for GDP on the G-protein complex and inhibits adenylate cyclase, thereby preventing cAMP production. Subsequently, the release of nociceptive neurotransmitters, such as substance P, gamma-aminobutyric acid (GABA), dopamine, acetylcholine, and noradrenaline, is inhibited. Oxycodone also inhibits the release of vasopressin, somatostatin, insulin, and glucagon. In addition, oxycodone closes N-type voltage-gated calcium channels and opens G-protein-coupled inwardly rectifying potassium channels resulting in hyperpolarization and reduction of neuronal excitability.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sustained Release Dosage Form","conceptCode":"C42672","definition":"A dosage form designed to release active and/or inert ingredient(s) slowly so as to achieve a constant circulating concentration of the ingredient over a period of time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Oxycodone","conceptCode":"C29309","definition":"A semi-synthetic, morphine-like opioid alkaloid with analgesic activity. Oxycodone exerts its analgesic activity by binding to the mu-receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opioids. Binding of the opiate receptor stimulates the exchange of GTP for GDP on the G-protein complex and inhibits adenylate cyclase, thereby preventing cAMP production. Subsequently, the release of nociceptive neurotransmitters, such as substance P, gamma-aminobutyric acid (GABA), dopamine, acetylcholine, and noradrenaline, is inhibited. Oxycodone also inhibits the release of vasopressin, somatostatin, insulin, and glucagon. In addition, oxycodone closes N-type voltage-gated calcium channels and opens G-protein-coupled inwardly rectifying potassium channels resulting in hyperpolarization and reduction of neuronal excitability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A21868-58A5-4347-E053-F662850A6F62","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A21868-58BE-4347-E053-F662850A6F62","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Oxycodone HCl","valueDescription":"Oxycodone Hydrochloride","ValueMeaning":{"publicId":"7060477","version":"1","preferredName":"Oxycodone Hydrochloride","longName":"7060477","preferredDefinition":"The hydrochloride salt of oxycodone, a methylether of oxymorphone and semisynthetic opioid agonist with analgesic and antitussive properties. Oxycodone binds to mu-receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opiates. In addition to analgesia and a depressive effect on the cough center in the medulla, this agent may cause euphoria, anxiolysis, miosis, sedation, physical dependence, constipation, and respiratory depression, depending on dosage and variations in individual metabolism.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oxycodone Hydrochloride","conceptCode":"C48010","definition":"The hydrochloride salt of oxycodone, a methylether of oxymorphone and semisynthetic opioid agonist with analgesic and antitussive properties. Oxycodone binds to mu-receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opiates. In addition to analgesia and a depressive effect on the cough center in the medulla, this agent may cause euphoria, anxiolysis, miosis, sedation, physical dependence, constipation, and respiratory depression, depending on dosage and variations in individual metabolism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A21868-58CB-4347-E053-F662850A6F62","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A21868-58E4-4347-E053-F662850A6F62","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Oxybutynin CL","valueDescription":"Oxybutynin Chloride","ValueMeaning":{"publicId":"7060479","version":"1","preferredName":"Oxybutynin Chloride","longName":"7060479","preferredDefinition":"The chloride salt form of oxybutynin, a tertiary amine and anticholinergic agent with antispasmodic activity. Oxybutynin chloride exerts its antimuscarinic effect on bladder smooth muscle by blocking muscarinic receptors in smooth muscle, thereby inhibiting acetylcholine binding. This results in a relaxation of bladder smooth muscle, a reduction of involuntary muscle contractions and delays the initial desire to void.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oxybutynin Chloride","conceptCode":"C73597","definition":"The chloride salt form of oxybutynin, a tertiary amine and anticholinergic agent with antispasmodic activity. Oxybutynin chloride exerts its antimuscarinic effect on bladder smooth muscle by blocking muscarinic receptors in smooth muscle, thereby inhibiting acetylcholine binding. This results in a relaxation of bladder smooth muscle, a reduction of involuntary muscle contractions and delays the initial desire to void.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A21868-58F1-4347-E053-F662850A6F62","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A21868-590A-4347-E053-F662850A6F62","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Oxcarbazepine","valueDescription":"Oxcarbazepine","ValueMeaning":{"publicId":"5625815","version":"1","preferredName":"Oxcarbazepine","longName":"5625815","preferredDefinition":"A dibenzazepine carboxamide derivative with an anticonvulsant property. As a prodrug, oxcarbazepine is converted to its active metabolite, 10-monohydroxy. Although the mechanism of action has not been fully elucidated, electrophysiological studies indicate this agent blocks voltage-gated sodium channels, thereby stabilizing hyper-excited neural membranes, inhibiting repetitive neuronal firing, and decreasing the propagation of synaptic impulses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oxcarbazepine","conceptCode":"C47643","definition":"A dibenzazepine carboxamide derivative with an anticonvulsant property. As a prodrug, oxcarbazepine is converted to its active metabolite, 10-monohydroxy. Although the mechanism of action has not been fully elucidated, electrophysiological studies indicate this agent blocks voltage-gated sodium channels, thereby stabilizing hyper-excited neural membranes, inhibiting repetitive neuronal firing, and decreasing the propagation of synaptic impulses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45D958C0-7DFD-5173-E053-F662850AAAF2","latestVersionIndicator":"Yes","beginDate":"2017-01-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-11","modifiedBy":"COOPERM","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A21868-591E-4347-E053-F662850A6F62","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Oxazepam","valueDescription":"Oxazepam","ValueMeaning":{"publicId":"7060481","version":"1","preferredName":"Oxazepam","longName":"7060481","preferredDefinition":"A synthetic benzodiazepine derivative with anxiolytic and sedative hypnotic properties. Although the mechanism of action has not been fully elucidated, oxazepam appears to enhance gamma-aminobutyric acid (GABA) receptor affinity for GABA, thereby prolonging synaptic actions of GABA.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oxazepam","conceptCode":"C47642","definition":"A synthetic benzodiazepine derivative with anxiolytic and sedative hypnotic properties. Although the mechanism of action has not been fully elucidated, oxazepam appears to enhance gamma-aminobutyric acid (GABA) receptor affinity for GABA, thereby prolonging synaptic actions of GABA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A21868-592C-4347-E053-F662850A6F62","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A21868-5945-4347-E053-F662850A6F62","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Oxaprozin","valueDescription":"Oxaprozin","ValueMeaning":{"publicId":"7060483","version":"1","preferredName":"Oxaprozin","longName":"7060483","preferredDefinition":"A nonsteroidal anti-inflammatory drug (NSAID) derivative of oxazole-propionic acid with analgesic and antipyretic properties.  As a first generation NSAID inhibitor, oxaprozin binds to and inactivates both isoforms of cyclooxygenase (COX-1 and-2), thereby blocking the conversion of arachidonic acid to pro-inflammatory prostaglandins.  When inhibiting COX-2, this agent may be effective in relieving pain and inflammation; when inhibiting COX-1, it may produce unacceptable gastrointestinal side effects. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oxaprozin","conceptCode":"C29307","definition":"A nonsteroidal anti-inflammatory drug (NSAID) derivative of oxazole-propionic acid with analgesic and antipyretic properties.  As a first generation NSAID inhibitor, oxaprozin binds to and inactivates both isoforms of cyclooxygenase (COX-1 and-2), thereby blocking the conversion of arachidonic acid to pro-inflammatory prostaglandins.  When inhibiting COX-2, this agent may be effective in relieving pain and inflammation; when inhibiting COX-1, it may produce unacceptable gastrointestinal side effects. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A21868-5952-4347-E053-F662850A6F62","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A21868-596B-4347-E053-F662850A6F62","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Oxandrolone","valueDescription":"Oxandrolone (Oxandrin)","ValueMeaning":{"publicId":"3076461","version":"1","preferredName":"Oxandrolone (Oxandrin)","longName":"3076461","preferredDefinition":"A synthetic, anabolic steroid hormone analog of testosterone. Similar to testosterone, oxandrolone binds to and activates specific nuclear receptors. This agent may be used for testosterone replacement therapy in hypogonadal men, in HIV-wasting syndrome, and in other conditions in order to increase nitrogen retention and fat-free muscle mass. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oxandrolone","conceptCode":"C29306","definition":"A synthetic, anabolic steroid hormone analog of testosterone. Similar to testosterone, oxandrolone binds to and activates specific nuclear receptors. This agent may be used for testosterone replacement therapy in hypogonadal men, in HIV-wasting syndrome, and in other conditions in order to increase nitrogen retention and fat-free muscle mass. (NCI04)","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"852693AD-C7A9-32F2-E040-BB89AD436CB9","latestVersionIndicator":"Yes","beginDate":"2010-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A21868-5975-4347-E053-F662850A6F62","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Oxacillin Sodium","valueDescription":"Oxacillin Sodium","ValueMeaning":{"publicId":"2575698","version":"1","preferredName":"Oxacillin Sodium","longName":"2575698","preferredDefinition":"The sodium salt form of oxacillin, a semisynthetic penicillinase-resistant and acid-stable penicillin with an antimicrobial activity. Oxacillin binds to penicillin-binding proteins in the bacterial cell wall, thereby blocking the synthesis of peptidoglycan, a critical component of the bacterial cell wall. This leads to inhibition of cell growth and causes cell lysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oxacillin Sodium","conceptCode":"C720","definition":"The sodium salt form of oxacillin, a semisynthetic penicillinase-resistant and acid-stable penicillin with an antimicrobial activity. Oxacillin binds to penicillin-binding proteins in the bacterial cell wall, thereby blocking the synthesis of peptidoglycan, a critical component of the bacterial cell wall. This leads to inhibition of cell growth and causes cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4BF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"REEVESD","dateModified":"2008-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A21868-597F-4347-E053-F662850A6F62","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Oseltamivir","valueDescription":"Oseltamivir","ValueMeaning":{"publicId":"5633395","version":"1","preferredName":"Oseltamivir","longName":"5633395","preferredDefinition":"A synthetic derivative prodrug of ethyl ester with antiviral activity. Osetamivir blocks neuraminidases on the surfaces of influenza viruses, interfering with host cell release of complete viral particles.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oseltamivir","conceptCode":"C62061","definition":"A synthetic derivative prodrug of ethyl ester with antiviral activity. Osetamivir blocks neuraminidases on the surfaces of influenza viruses, interfering with host cell release of complete viral particles.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46EDA67D-D79E-41DC-E053-F662850A0513","latestVersionIndicator":"Yes","beginDate":"2017-01-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-01-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A21868-5989-4347-E053-F662850A6F62","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Orthotricyclen","valueDescription":"Ethinyl Estradiol/Norgestimate","ValueMeaning":{"publicId":"7060485","version":"1","preferredName":"Ethinyl Estradiol/Norgestimate","longName":"7060485","preferredDefinition":"An oral preparation combination containing the semisynthetic estrogen ethinyl estradiol and the synthetic progestagen norgestimate with contraceptive activity. Ethinyl estradiol and norgestimate act by negative feed back mechanism at pituitary gland suppressing the release of gonadotropin hormones follicle stimulating hormone (FSH) and luteinizing hormone (LH). This combination inhibits ovulation and promotes the thickening of the cervical mucus and the endometrium. The combination of ethinyl estradiol and norgestimate may also be used in the treatment of acne.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ethinyl Estradiol/Norgestimate","conceptCode":"C29304","definition":"An oral preparation combination containing the semisynthetic estrogen ethinyl estradiol and the synthetic progestagen norgestimate with contraceptive activity. Ethinyl estradiol and norgestimate act by negative feed back mechanism at pituitary gland suppressing the release of gonadotropin hormones follicle stimulating hormone (FSH) and luteinizing hormone (LH). This combination inhibits ovulation and promotes the thickening of the cervical mucus and the endometrium. The combination of ethinyl estradiol and norgestimate may also be used in the treatment of acne.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A21868-5997-4347-E053-F662850A6F62","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A21868-59B0-4347-E053-F662850A6F62","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Orlistat","valueDescription":"Orlistat","ValueMeaning":{"publicId":"7060487","version":"1","preferredName":"Orlistat","longName":"7060487","preferredDefinition":"A reversible active-site inhibitor of gastrointestinal lipases.  Orlistat forms a covalent bond with the active serine site in gastric and pancreatic lipases, thereby inhibiting their activity and preventing dietary fat from being hydrolyzed and absorbed. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Orlistat","conceptCode":"C29303","definition":"A reversible active-site inhibitor of gastrointestinal lipases.  Orlistat forms a covalent bond with the active serine site in gastric and pancreatic lipases, thereby inhibiting their activity and preventing dietary fat from being hydrolyzed and absorbed. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A21868-59BD-4347-E053-F662850A6F62","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A21868-59D6-4347-E053-F662850A6F62","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Polyvinyl Alcohol","valueDescription":"Polyvinyl Alcohol","ValueMeaning":{"publicId":"7060575","version":"1","preferredName":"Polyvinyl Alcohol","longName":"7060575","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polyvinyl Alcohol","conceptCode":"C29370","definition":"A water-soluble synthetic polymer that is used for a wide variety of applications.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A24286-3838-5888-E053-F662850A1989","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"COOPERM","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A24286-3851-5888-E053-F662850A1989","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Polyethylene Oxide","valueDescription":"Polyethylene glycol","ValueMeaning":{"publicId":"2579249","version":"1","preferredName":"Polyethylene glycol","longName":"2579249","preferredDefinition":"A polymer made by joining molecules of ethylene oxide and water together in a repeating pattern. Polyethylene glycol can be a liquid or a waxy solid. In medicine, forms of polyethylene glycol can be used in ointments, in drugs or substances to make them stay in the body longer, or in laxatives.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polyethylene Glycol","conceptCode":"C762","definition":"A polymer made by joining molecules of ethylene oxide and water together in a repeating pattern. Polyethylene glycol can be a liquid or a waxy solid. In medicine, forms of polyethylene glycol can be used in ointments, in drugs or substances to make them stay in the body longer, or in laxatives.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-029E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-08","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-05-08","modifiedBy":"COOPERM","dateModified":"2019-11-18","changeDescription":"Added current NCIt concept and definition. mc 11/18/19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A24286-3865-5888-E053-F662850A1989","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Polycitra","valueDescription":"Citrate-containing Alkalinizing Agent","ValueMeaning":{"publicId":"7060577","version":"1","preferredName":"Citrate-containing Alkalinizing Agent","longName":"7060577","preferredDefinition":"A combination of sodium citrate and potassium citrate with alkalizing and antiurolithic effects. Polycitra is metabolized to bicarbonates, thereby increasing urinary pH by increasing the excretion of free bicarbonate ions. A rise in urinary pH increases the solubility of cystine in the urine and the ionization of uric acid to more soluble urate ion. In addition, increased urinary citrate and pH decreases calcium ion activity by increasing calcium complexation to dissociated anions and thus decreasing the saturation of calcium oxalate. By increasing the level of plasma bicarbonate this agent also buffers excess hydrogen ion concentration and raises blood pH, thereby reversing the clinical manifestations of acidosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Citrate-containing Alkalinizing Agent","conceptCode":"C29369","definition":"A combination of sodium citrate and potassium citrate with alkalizing and antiurolithic effects. Polycitra is metabolized to bicarbonates, thereby increasing urinary pH by increasing the excretion of free bicarbonate ions. A rise in urinary pH increases the solubility of cystine in the urine and the ionization of uric acid to more soluble urate ion. In addition, increased urinary citrate and pH decreases calcium ion activity by increasing calcium complexation to dissociated anions and thus decreasing the saturation of calcium oxalate. By increasing the level of plasma bicarbonate this agent also buffers excess hydrogen ion concentration and raises blood pH, thereby reversing the clinical manifestations of acidosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A24286-3873-5888-E053-F662850A1989","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A24286-388C-5888-E053-F662850A1989","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Policosanol","valueDescription":"Policosanol","ValueMeaning":{"publicId":"7060578","version":"1","preferredName":"Policosanol","longName":"7060578","preferredDefinition":"A chemical most often obtained from sugar cane. It can also be made from other plants, such as wheat. Policosanol is most commonly used for leg pain due to poor blood circulation (intermittent claudication).","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A24286-3896-5888-E053-F662850A1989","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A24286-38AF-5888-E053-F662850A1989","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Podofilox","valueDescription":"Podofilox","ValueMeaning":{"publicId":"7060580","version":"1","preferredName":"Podofilox","longName":"7060580","preferredDefinition":"A pure, stabilized form of podophyllin, in which only the biologically active portion of the compound is present.  Podophyllotoxin is a toxic, polycyclic antimitotic agent isolated primarily from the rhizome of the plant Podophyllum peltatum. This agent is formulated for topical applications. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Podofilox","conceptCode":"C29368","definition":"A pure, stabilized form of podophyllin, in which only the biologically active portion of the compound is present.  Podophyllotoxin is a toxic, polycyclic antimitotic agent isolated primarily from the rhizome of the plant Podophyllum peltatum. This agent is formulated for topical applications. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A24286-38BC-5888-E053-F662850A1989","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A24286-38D5-5888-E053-F662850A1989","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Pneumovax","valueDescription":"Pneumococcal Polyvalent Vaccine","ValueMeaning":{"publicId":"3828979","version":"1","preferredName":"Pneumococcal Polyvalent Vaccine","longName":"3828979","preferredDefinition":"An polyvalent vaccine used to prevent infection by the bacterium Streptococcus pneumoniae. Pneumococcal polyvalent vaccine contains highly purified capsular antigens from the 23 most prevalent or invasive pneumococcal types of Streptococcus pneumoniae to ensure cross-protection. Following vaccination, protective capsular type-specific antibody levels typically develop by the third week; serotype-specific antibody levels generally decline after 5-10 years.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pneumococcal Polyvalent Vaccine","conceptCode":"C1643","definition":"An polyvalent vaccine used to prevent infection by the bacterium Streptococcus pneumoniae. Pneumococcal polyvalent vaccine contains highly purified capsular antigens from the 23 most prevalent or invasive pneumococcal types of Streptococcus pneumoniae to ensure cross-protection. Following vaccination, protective capsular type-specific antibody levels typically develop by the third week; serotype-specific antibody levels generally decline after 5-10 years.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E2A8BB67-2DB2-B6D0-E040-BB89AD43093C","latestVersionIndicator":"Yes","beginDate":"2013-07-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2013-07-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A24286-38E9-5888-E053-F662850A1989","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Plasma","valueDescription":"Plasma","ValueMeaning":{"publicId":"2567156","version":"1","preferredName":"Plasma","longName":"2567156","preferredDefinition":"Plasma is the fluid (noncellular) portion of the circulating blood, as distinguished from the serum that is the fluid portion of the blood obtained by removal of the fibrin clot and blood cells after coagulation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plasma","conceptCode":"C13356","definition":"Plasma is the fluid (noncellular) portion of the circulating blood, as distinguished from the serum that is the fluid portion of the blood obtained by removal of the fibrin clot and blood cells after coagulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D361-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-10-30","endDate":null,"createdBy":"PFOWLER","dateCreated":"2003-10-30","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A24286-38F4-5888-E053-F662850A1989","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Piroxicam","valueDescription":"Piroxicam","ValueMeaning":{"publicId":"3379484","version":"1","preferredName":"Piroxicam","longName":"3379484","preferredDefinition":"A nonsteroidal oxicam derivative with anti-inflammatory, antipyretic and analgesic properties. As a non-selective, nonsteroidal anti-inflammatory drug (NSAID), piroxicam binds and chelates both isoforms of cyclooxygenases (COX1 and COX2), thereby stalling phospholipase A2 activity and conversion of arachidonic acid into prostaglandin precursors at the rate limiting cyclooxygenase enzyme step. This results in inhibition of prostaglandin biosynthesis. As a second, independent effect, piroxicam inhibits the activation of neutrophils thereby contributing to its overall anti-inflammatory effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Piroxicam","conceptCode":"C751","definition":"A nonsteroidal oxicam derivative with anti-inflammatory, antipyretic and analgesic properties. As a non-selective, nonsteroidal anti-inflammatory drug (NSAID), piroxicam binds and chelates both isoforms of cyclooxygenases (COX1 and COX2), thereby stalling phospholipase A2 activity and conversion of arachidonic acid into prostaglandin precursors at the rate limiting cyclooxygenase enzyme step. This results in inhibition of prostaglandin biosynthesis. As a second, independent effect, piroxicam inhibits the activation of neutrophils thereby contributing to its overall anti-inflammatory effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-25B4-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A24286-38FF-5888-E053-F662850A1989","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Piritrexim","valueDescription":"Piritrexim","ValueMeaning":{"publicId":"3379482","version":"1","preferredName":"Piritrexim","longName":"3379482","preferredDefinition":"A synthetic antifolate agent with antiparasitic, antipsoriatic and antitumor properties. Piritrexim inhibits the enzyme dihydrofolate reductase enzyme, thereby disrupting folate metabolism and DNA synthesis and cell division. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Piritrexim","conceptCode":"C1031","definition":"A synthetic antifolate agent with antiparasitic, antipsoriatic and antitumor properties. Piritrexim inhibits the enzyme dihydrofolate reductase enzyme, thereby disrupting folate metabolism and DNA synthesis and cell division. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-258E-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A24286-3909-5888-E053-F662850A1989","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Piperacillin Sodium/Tazobactam Sodium","valueDescription":"Piperacillin-Tazobactam","ValueMeaning":{"publicId":"2744249","version":"1","preferredName":"Piperacillin-Tazobactam","longName":"2744249","preferredDefinition":"A combination formulation of the antibiotic piperacillin and the beta-lactamase inhibitor tazobactam with antibacterial activity. Piperacillin, a broad-spectrum, semisynthetic penicillin, binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall, thereby interfering with the cross-linking of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. As a result, the cell wall is weakened and the cell lyses. Tazobactam, a penicillanic acid sulfone derivative, irreversibly binds to and inhibits bacterial beta-lactamase at or near its active site, thereby preventing the destruction of the beta-lactamase susceptible piperacillin by this bacterial enzyme.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Piperacillin-Tazobactam","conceptCode":"C1530","definition":"A combination formulation of the antibiotic piperacillin and the beta-lactamase inhibitor tazobactam with antibacterial activity. Piperacillin, a broad-spectrum, semisynthetic penicillin, binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall, thereby interfering with the cross-linking of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. As a result, the cell wall is weakened and the cell lyses. Tazobactam, a penicillanic acid sulfone derivative, irreversibly binds to and inhibits bacterial beta-lactamase at or near its active site, thereby preventing the destruction of the beta-lactamase susceptible piperacillin by this bacterial enzyme.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B8ED6E9-EAB6-3596-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-04-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A24286-3913-5888-E053-F662850A1989","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Piperacillin","valueDescription":"Piperacillin","ValueMeaning":{"publicId":"2575703","version":"1","preferredName":"Piperacillin","longName":"2575703","preferredDefinition":"A broad-spectrum semisynthetic, ampicillin-derived ureidopenicillin antibiotic. Piperacillin binds to penicillin binding proteins (PBP), the enzymes that catalyze the synthesis of peptidoglycan, a critical component of the bacterial cell wall. This blockade leads to the interruption of cell wall synthesis, consequently, leading to bacterial cell growth inhibition and cell lysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Piperacillin","conceptCode":"C62069","definition":"A broad-spectrum semisynthetic, ampicillin-derived ureidopenicillin antibiotic. Piperacillin binds to penicillin binding proteins (PBP), the enzymes that catalyze the synthesis of peptidoglycan, a critical component of the bacterial cell wall. This blockade leads to the interruption of cell wall synthesis, consequently, leading to bacterial cell growth inhibition and cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F4C4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"COOPERM","dateModified":"2019-11-18","changeDescription":"Added NCIt concept. mc 11/18/19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A24286-391D-5888-E053-F662850A1989","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Pioglitazone","valueDescription":"Pioglitazone","ValueMeaning":{"publicId":"3153632","version":"1","preferredName":"Pioglitazone","longName":"3153632","preferredDefinition":"An orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity. Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis. This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pioglitazone","conceptCode":"C71633","definition":"An orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity. Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis. This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93B0B207-3593-B370-E040-BB89AD431C0F","latestVersionIndicator":"Yes","beginDate":"2010-10-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-10-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A24286-3931-5888-E053-F662850A1989","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Pindolol","valueDescription":"Pindolol","ValueMeaning":{"publicId":"7060582","version":"1","preferredName":"Pindolol","longName":"7060582","preferredDefinition":"An aryloxypropanolamine derivative with antihypertensive property. Pindolol competitively binds to beta-adrenergic receptors, resulting in a decrease in beta-adrenergic activities, i.e., vasodilation, and negative chronotropic and inotropic effects. In addition, this agent blocks serotonin (5-HT) 1A receptors, thereby increasing the available serotonin in the brain. Increased serotonin levels augment the antidepressant action of selective serotonin reuptake inhibitors and monoamine oxidase inhibitors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pindolol","conceptCode":"C47673","definition":"An aryloxypropanolamine derivative with antihypertensive property. Pindolol competitively binds to beta-adrenergic receptors, resulting in a decrease in beta-adrenergic activities, i.e., vasodilation, and negative chronotropic and inotropic effects. In addition, this agent blocks serotonin (5-HT) 1A receptors, thereby increasing the available serotonin in the brain. Increased serotonin levels augment the antidepressant action of selective serotonin reuptake inhibitors and monoamine oxidase inhibitors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A24286-393F-5888-E053-F662850A1989","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A24286-3958-5888-E053-F662850A1989","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Pilocarpine","valueDescription":"Pilocarpine","ValueMeaning":{"publicId":"2575475","version":"1","preferredName":"Pilocarpine","longName":"2575475","preferredDefinition":"A natural alkaloid extracted from plants of the genus Pilocarpus with cholinergic agonist activity. As a cholinergic parasympathomimetic agent, pilocarpine predominantly binds to muscarinic receptors, thereby inducing exocrine gland secretion and stimulating smooth muscle in the bronchi, urinary tract, biliary tract, and intestinal tract. When applied topically to eyes, this agent stimulates the sphincter pupillae to contract, resulting in miosis; stimulates the ciliary muscle to contract, resulting in spasm of accommodation; and may cause a transitory rise in intraocular pressure followed by a more persistent fall due to opening of the trabecular meshwork and an increase in the outflow of aqueous humor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pilocarpine","conceptCode":"C62068","definition":"A natural alkaloid extracted from plants of the genus Pilocarpus with cholinergic agonist activity. As a cholinergic parasympathomimetic agent, pilocarpine predominantly binds to muscarinic receptors, thereby inducing exocrine gland secretion and stimulating smooth muscle in the bronchi, urinary tract, biliary tract, and intestinal tract. When applied topically to eyes, this agent stimulates the sphincter pupillae to contract, resulting in miosis; stimulates the ciliary muscle to contract, resulting in spasm of accommodation; and may cause a transitory rise in intraocular pressure followed by a more persistent fall due to opening of the trabecular meshwork and an increase in the outflow of aqueous humor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F3E0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-30","endDate":null,"createdBy":"PWEST","dateCreated":"2005-06-30","modifiedBy":"COOPERM","dateModified":"2019-11-18","changeDescription":"Added current NCIt definition. mc 11/18/19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97A24286-3962-5888-E053-F662850A1989","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","deletedIndicator":"No"},{"value":"Netarsudil","valueDescription":"Netarsudil","ValueMeaning":{"publicId":"7247373","version":"1","preferredName":"Netarsudil","longName":"7247373","preferredDefinition":"An amino-isoquinoline amide and inhibitor of Rho kinase (ROCK) and norepinephrine transporter (NET), with potential intraocular pressure (IOP)-lowering activity. Upon ocular administration, netarsudil inhibits ROCK and the Rho pathway, increases aqueous humor (AH) outflow via the trabecular pathway, and lowers IOP. In addition, netarsudil may lower IOP by decreasing episcleral venous pressure and decreasing the production of aqueous humor through inhibition of NET.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Netarsudil","conceptCode":"C170213","definition":"An amino-isoquinoline amide and inhibitor of Rho kinase (ROCK) and norepinephrine transporter (NET), with potential intraocular pressure (IOP)-lowering activity. Upon ocular administration, netarsudil inhibits ROCK and the Rho pathway, increases aqueous humor (AH) outflow via the trabecular pathway, and lowers IOP. In addition, netarsudil may lower IOP by decreasing episcleral venous pressure and decreasing the production of aqueous humor through inhibition of NET. ","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A36C8D6E-75F7-1EC3-E053-F662850A8FDB","latestVersionIndicator":"Yes","beginDate":"2020-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-04-16","modifiedBy":"COOPERM","dateModified":"2020-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A36C8D6E-7610-1EC3-E053-F662850A8FDB","beginDate":"2020-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-04-16","modifiedBy":"ONEDATA","dateModified":"2020-04-16","deletedIndicator":"No"},{"value":"Tapentadol","valueDescription":"Tapentadol","ValueMeaning":{"publicId":"7247375","version":"1","preferredName":"Tapentadol","longName":"7247375","preferredDefinition":"An orally available, synthetic benzenoid that acts as an agonist for the mu-opioid receptor (MOR) and inhibits the reuptake of noradrenaline, with potential anti-nociceptive activity. Upon oral administration, tapentadol binds to the MOR which enhances MOR-mediated signaling, interferes with the sensation of pain and results in an analgesic effect. Tapentadol also inhibits the reuptake of noradrenaline, which increases the levels of noradrenaline (NA), activates the inhibitory alpha-2 receptors and results in an analgesic effect.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tapentadol","conceptCode":"C72139","definition":"An orally available, synthetic benzenoid that acts as an agonist for the mu-opioid receptor (MOR) and inhibits the reuptake of noradrenaline, with potential anti-nociceptive activity. Upon oral administration, tapentadol binds to the MOR which enhances MOR-mediated signaling, interferes with the sensation of pain and results in an analgesic effect. Tapentadol also inhibits the reuptake of noradrenaline, which increases the levels of noradrenaline (NA), activates the inhibitory alpha-2 receptors and results in an analgesic effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A36C8D6E-761D-1EC3-E053-F662850A8FDB","latestVersionIndicator":"Yes","beginDate":"2020-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-04-16","modifiedBy":"COOPERM","dateModified":"2020-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A36C8D6E-7636-1EC3-E053-F662850A8FDB","beginDate":"2020-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-04-16","modifiedBy":"ONEDATA","dateModified":"2020-04-16","deletedIndicator":"No"},{"value":"Ceftaroline Fosamil","valueDescription":"Ceftaroline Fosamil","ValueMeaning":{"publicId":"7295348","version":"1","preferredName":"Ceftaroline Fosamil","longName":"7295348","preferredDefinition":"An N-phosphono prodrug of the fifth-generation cephalosporin derivative ceftaroline with antibacterial activity. Ceftaroline fosamil is hydrolyzed to the active form ceftaroline in vivo. Ceftaroline binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ceftaroline Fosamil","conceptCode":"C81034","definition":"An N-phosphono prodrug of the fifth-generation cephalosporin derivative ceftaroline with antibacterial activity. Ceftaroline fosamil is hydrolyzed to the active form ceftaroline in vivo. Ceftaroline binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A5A16EF7-9178-0714-E053-F662850AC2F8","latestVersionIndicator":"Yes","beginDate":"2020-05-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-05-14","modifiedBy":"GDEEN","dateModified":"2023-12-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A5A16EF7-9194-0714-E053-F662850AC2F8","beginDate":"2020-05-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-05-14","modifiedBy":"ONEDATA","dateModified":"2020-05-14","deletedIndicator":"No"},{"value":"HPV","valueDescription":"Recombinant Human Papillomavirus Nonavalent Vaccine","ValueMeaning":{"publicId":"7356947","version":"1","preferredName":"Recombinant Human Papillomavirus Nonavalent Vaccine","longName":"7356947","preferredDefinition":"A non-infectious, recombinant, nonavalent vaccine prepared from highly purified virus-like particles (VLPs) comprised of the major capsid (L1) proteins from human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, and 58, with active immunizing activity. Upon administration, the recombinant HPV nonavalent vaccine activates the immune system to produce antibodies against the 9 HPV types. This protects against HPV infection and HPV-related cancers. Altogether, HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 account for the majority of the HPV types that cause cervical, vulvar, vaginal and anal cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Human Papillomavirus Nonavalent Vaccine","conceptCode":"C119664","definition":"A non-infectious, recombinant, nonavalent vaccine prepared from highly purified virus-like particles (VLPs) comprised of the major capsid (L1) proteins from human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, and 58, with active immunizing activity. Upon administration, the recombinant HPV nonavalent vaccine activates the immune system to produce antibodies against the 9 HPV types. This protects against HPV infection and HPV-related cancers. Altogether, HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 account for the majority of the HPV types that cause cervical, vulvar, vaginal and anal cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA951CDB-D6FC-53FD-E053-4EBD850A3983","latestVersionIndicator":"Yes","beginDate":"2020-07-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-07-16","modifiedBy":"ONEDATA","dateModified":"2020-07-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA951CDB-D715-53FD-E053-4EBD850A3983","beginDate":"2020-07-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-07-16","modifiedBy":"ONEDATA","dateModified":"2020-07-16","deletedIndicator":"No"},{"value":"Meningococcal Group B vaccine","valueDescription":"Meningococcal Group B Vaccine","ValueMeaning":{"publicId":"7356948","version":"1","preferredName":"Meningococcal Group B Vaccine","longName":"7356948","preferredDefinition":"A vaccine containing recombinant bacterial proteins derived from the bacterium Neisseria meningitidis serogroup B, that is used to provide active immunization against and to prevent invasive disease caused by Neisseria meningitidis serogroup B. Upon intramuscular vaccination with meningococcal group B vaccine, the recombinant proteins activate the immune system to produce antibodies directed against the recombinant proteins. This provides active immunization and protection against invasive meningococcal disease by complement-mediated antibody-dependent killing of N. meningitidis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Meningococcal Group B Vaccine","conceptCode":"C173628","definition":"A vaccine containing recombinant bacterial proteins derived from the bacterium Neisseria meningitidis serogroup B, that is used to provide active immunization against and to prevent invasive disease caused by Neisseria meningitidis serogroup B. Upon intramuscular vaccination with meningococcal group B vaccine, the recombinant proteins activate the immune system to produce antibodies directed against the recombinant proteins. This provides active immunization and protection against invasive meningococcal disease by complement-mediated antibody-dependent killing of N. meningitidis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA951CDB-D71F-53FD-E053-4EBD850A3983","latestVersionIndicator":"Yes","beginDate":"2020-07-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-07-16","modifiedBy":"COOPERM","dateModified":"2020-07-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA951CDB-D738-53FD-E053-4EBD850A3983","beginDate":"2020-07-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-07-16","modifiedBy":"ONEDATA","dateModified":"2020-07-16","deletedIndicator":"No"},{"value":"Meningococcal, quadrivalent","valueDescription":"Meningococcal Conjugate Vaccine MCV4","ValueMeaning":{"publicId":"7356950","version":"1","preferredName":"Meningococcal Conjugate Vaccine MCV4","longName":"7356950","preferredDefinition":"A conjugate vaccine of meningococcal polysaccharide used for active immunization against invasive meningococcal disease caused by Neisseria meningiditis serogroups A, C, Y, and W-135.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Meningococcal Conjugate Vaccine MCV4","conceptCode":"C96391","definition":"A conjugate vaccine of meningococcal polysaccharide used for active immunization against invasive meningococcal disease caused by Neisseria meningiditis serogroups A, C, Y, and W-135.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA951CDB-D745-53FD-E053-4EBD850A3983","latestVersionIndicator":"Yes","beginDate":"2020-07-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-07-16","modifiedBy":"ONEDATA","dateModified":"2020-07-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA951CDB-D75E-53FD-E053-4EBD850A3983","beginDate":"2020-07-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-07-16","modifiedBy":"ONEDATA","dateModified":"2020-07-16","deletedIndicator":"No"},{"value":"VZV","valueDescription":"Varicella-Zoster Virus Strain Oka/Merck Live Antigen","ValueMeaning":{"publicId":"7356952","version":"1","preferredName":"Varicella-Zoster Virus Strain Oka/Merck Live Antigen","longName":"7356952","preferredDefinition":"A sterile, lyophilized preparation of the Oka/Merck strain of the live, attenuated varicella-zoster virus (VZV), that can be used to prevent varicella, commonly known as chickenpox, or herpes zoster (HZ), commonly known as shingles. Upon reconstitution and subcutaneous vaccination with the VZV strain Oka/Merck live antigen, this vaccine induces antigen-specific T-cell and B-cell immune responses against the VZV, thereby protecting against VZV infection.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Varicella-Zoster Virus Strain Oka/Merck Live Antigen","conceptCode":"C77799","definition":"A sterile, lyophilized preparation of the Oka/Merck strain of the live, attenuated varicella-zoster virus (VZV), that can be used to prevent varicella, commonly known as chickenpox, or herpes zoster (HZ), commonly known as shingles. Upon reconstitution and subcutaneous vaccination with the VZV strain Oka/Merck live antigen, this vaccine induces antigen-specific T-cell and B-cell immune responses against the VZV, thereby protecting against VZV infection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA951CDB-D76B-53FD-E053-4EBD850A3983","latestVersionIndicator":"Yes","beginDate":"2020-07-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-07-16","modifiedBy":"ONEDATA","dateModified":"2020-07-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA951CDB-D784-53FD-E053-4EBD850A3983","beginDate":"2020-07-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-07-16","modifiedBy":"ONEDATA","dateModified":"2020-07-16","deletedIndicator":"No"},{"value":"MMR","valueDescription":"Measles/Mumps/Rubella Vaccine","ValueMeaning":{"publicId":"3828981","version":"1","preferredName":"Measles/Mumps/Rubella Vaccine","longName":"3828981","preferredDefinition":"A trivalent vaccine containing live attenuated viruses that can cause measles, mumps and rubella. It is an injection administered subcutaneously in two separate doses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Measles/Mumps/Rubella Vaccine","conceptCode":"C96403","definition":"A trivalent vaccine containing live attenuated viruses that can cause measles, mumps and rubella. It is an injection administered subcutaneously in two separate doses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E2A8BB67-2DD8-B6D0-E040-BB89AD43093C","latestVersionIndicator":"Yes","beginDate":"2013-07-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2013-07-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA951CDB-D78E-53FD-E053-4EBD850A3983","beginDate":"2020-07-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-07-16","modifiedBy":"ONEDATA","dateModified":"2020-07-16","deletedIndicator":"No"},{"value":"IPV","valueDescription":"Inactivated Poliovirus Vaccine","ValueMeaning":{"publicId":"7356954","version":"1","preferredName":"Inactivated Poliovirus Vaccine","longName":"7356954","preferredDefinition":"A vaccine consisting of inactivated poliovirus (IPV) types 1,2 and 3, with active immunizing activity against poliomyelitis. Upon intramuscular vaccination, inactivated poliovirus vaccine (IPV) activates the immune system to develop antibodies against polioviruses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inactivated Poliovirus Vaccine","conceptCode":"C91715","definition":"A vaccine consisting of inactivated poliovirus (IPV) types 1,2 and 3, with active immunizing activity against poliomyelitis. Upon intramuscular vaccination, inactivated poliovirus vaccine (IPV) activates the immune system to develop antibodies against polioviruses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA951CDB-D79C-53FD-E053-4EBD850A3983","latestVersionIndicator":"Yes","beginDate":"2020-07-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-07-16","modifiedBy":"ONEDATA","dateModified":"2020-07-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA951CDB-D7B5-53FD-E053-4EBD850A3983","beginDate":"2020-07-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-07-16","modifiedBy":"ONEDATA","dateModified":"2020-07-16","deletedIndicator":"No"},{"value":"Hib conjugate","valueDescription":"Haemophilus Influenzae B Vaccine","ValueMeaning":{"publicId":"3828974","version":"1","preferredName":"Haemophilus Influenzae B Vaccine","longName":"3828974","preferredDefinition":"A vaccine against serotype b of the Gram-negative bacterium H. influenzae (Hib).  Hib vaccines contain polysaccharide-protein conjugate antigens that produce greater host immune responses than first-generation purified polysaccharide vaccine.  These vaccines may differ with regard to use of protein carriers, polysaccharides, diluents, and preservatives. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Haemophilus Influenzae B Vaccine","conceptCode":"C1126","definition":"A vaccine against serotype b of the Gram-negative bacterium H. influenzae (Hib). Hib vaccines contain polysaccharide-protein conjugate antigens that produce greater host immune responses than first-generation purified polysaccharide vaccine. These vaccines may differ with regard to use of protein carriers, polysaccharides, diluents, and preservatives.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E2A8BB67-2D43-B6D0-E040-BB89AD43093C","latestVersionIndicator":"Yes","beginDate":"2013-07-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2013-07-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA951CDB-D7C9-53FD-E053-4EBD850A3983","beginDate":"2020-07-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-07-16","modifiedBy":"ONEDATA","dateModified":"2020-07-16","deletedIndicator":"No"},{"value":"DTaP","valueDescription":"Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed","ValueMeaning":{"publicId":"7356955","version":"1","preferredName":"Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed","longName":"7356955","preferredDefinition":"A vaccine containing detoxified tetanus toxoid, detoxified diphtheria toxoid and acellular pertussis antigens, adsorbed on aluminum phosphate, with active immunizing activity against diphtheria, tetanus and pertussis. The acellular pertussis vaccine components, produced by Bordetella pertussis, are detoxified pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (PRN) and fimbriae types 2 and 3 (FIM). Intramuscular injection with this vaccine activates the immune system to develop antibodies against tetanus toxin, diphtheria toxin and B. pertussis antigens.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed","conceptCode":"C91717","definition":"A vaccine containing detoxified tetanus toxoid, detoxified diphtheria toxoid and acellular pertussis antigens, adsorbed on aluminum phosphate, with active immunizing activity against diphtheria, tetanus and pertussis. The acellular pertussis vaccine components, produced by Bordetella pertussis, are detoxified pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (PRN) and fimbriae types 2 and 3 (FIM). Intramuscular injection with this vaccine activates the immune system to develop antibodies against tetanus toxin, diphtheria toxin and B. pertussis antigens.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA951CDB-D7D4-53FD-E053-4EBD850A3983","latestVersionIndicator":"Yes","beginDate":"2020-07-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-07-16","modifiedBy":"ONEDATA","dateModified":"2020-07-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA951CDB-D7ED-53FD-E053-4EBD850A3983","beginDate":"2020-07-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-07-16","modifiedBy":"ONEDATA","dateModified":"2020-07-16","deletedIndicator":"No"},{"value":"Pneumococcal 13-valent conjugate","valueDescription":"Pneumococcal 13-valent Conjugate Vaccine","ValueMeaning":{"publicId":"7356956","version":"1","preferredName":"Pneumococcal 13-valent Conjugate Vaccine","longName":"7356956","preferredDefinition":"A pneumococcal conjugate vaccine containing 13 different strains of the bacterium Streptococcus pneumoniae, used in children and studied in immunocompromised patients for the prevention of pneumococcal disease. The pneumococcal 13-valent conjugate vaccine contains capsular antigen polysaccharides derived from the S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F that are individually conjugated to a nontoxic diphtheria cross-reactive material (CRM) carrier protein (CRM197). Upon vaccination, pneumococcal 13-valent conjugate vaccine induces active immunization against 13 different serotypes of S. pneumoniae and protects against pneumococcal disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pneumococcal 13-valent Conjugate Vaccine","conceptCode":"C97121","definition":"A pneumococcal conjugate vaccine containing 13 different strains of the bacterium Streptococcus pneumoniae, used in children and studied in immunocompromised patients for the prevention of pneumococcal disease. The pneumococcal 13-valent conjugate vaccine contains capsular antigen polysaccharides derived from the S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F that are individually conjugated to a nontoxic diphtheria cross-reactive material (CRM) carrier protein (CRM197). Upon vaccination, pneumococcal 13-valent conjugate vaccine induces active immunization against 13 different serotypes of S. pneumoniae and protects against pneumococcal disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA951CDB-D7F7-53FD-E053-4EBD850A3983","latestVersionIndicator":"Yes","beginDate":"2020-07-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-07-16","modifiedBy":"ONEDATA","dateModified":"2020-07-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA951CDB-D810-53FD-E053-4EBD850A3983","beginDate":"2020-07-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-07-16","modifiedBy":"ONEDATA","dateModified":"2020-07-16","deletedIndicator":"No"},{"value":"Umeclidinium","valueDescription":"Umeclidinium","ValueMeaning":{"publicId":"7449446","version":"1","preferredName":"Umeclidinium","longName":"7449446","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Umeclidinium","conceptCode":"C152796","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B08EEA7F-EDC4-56BA-E053-4EBD850AA8B6","latestVersionIndicator":"Yes","beginDate":"2020-09-30","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2020-09-30","modifiedBy":"ONEDATA","dateModified":"2020-09-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B08EEA7F-EDDD-56BA-E053-4EBD850AA8B6","beginDate":"2020-09-30","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2020-09-30","modifiedBy":"ONEDATA","dateModified":"2020-09-30","deletedIndicator":"No"},{"value":"Gentamicin Sulfate/Betamethasone Valerate/Clotrimazole Otic Ointment","valueDescription":"Gentamicin Sulfate/Betamethasone Valerate/Clotrimazole Otic Ointment (Otomax)","ValueMeaning":{"publicId":"7485304","version":"1","preferredName":"Gentamicin Sulfate/Betamethasone Valerate/Clotrimazole Otic Ointment (Otomax)","longName":"7485304","preferredDefinition":"An otic ointment formulation of the broad-spectrum aminoglycoside antibiotic gentamicin sulfate, the synthetic adrenocorticoid betamethasone valerate and the broad-spectrum antifungal agent clotrimazole, with antibacterial, anti-inflammatory, and antifungal activities. Upon otic administration, gentamicin sulfate/betamethasone valerate/clotrimazole otic ointment inhibits bacterial protein synthesis and replication, inhibits fungal sterols biosynthesis which leads to fungal cell leakage and fungal cell lysis, and inhibits the inflammatory response by preventing phospholipid release, inhibiting eosinophil activity, and decreasing pro-inflammatory cytokine production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gentamicin Sulfate/Betamethasone Valerate/Clotrimazole Otic Ointment","conceptCode":"C175558","definition":"An otic ointment formulation of the broad-spectrum aminoglycoside antibiotic gentamicin sulfate, the synthetic adrenocorticoid betamethasone valerate and the broad-spectrum antifungal agent clotrimazole, with antibacterial, anti-inflammatory, and antifungal activities. Upon otic administration, gentamicin sulfate/betamethasone valerate/clotrimazole otic ointment inhibits bacterial protein synthesis and replication, inhibits fungal sterols biosynthesis which leads to fungal cell leakage and fungal cell lysis, and inhibits the inflammatory response by preventing phospholipid release, inhibiting eosinophil activity, and decreasing pro-inflammatory cytokine production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFA5F8-5346-562C-E053-4EBD850A44BB","latestVersionIndicator":"Yes","beginDate":"2020-10-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-10-29","modifiedBy":"COOPERM","dateModified":"2020-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B2CFA5F8-535F-562C-E053-4EBD850A44BB","beginDate":"2020-10-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-10-29","modifiedBy":"ONEDATA","dateModified":"2020-10-29","deletedIndicator":"No"},{"value":"Polysulfated Glycosaminoglycan","valueDescription":"Polysulfated Glycosaminoglycan (Adequan Canine, PSGAG)","ValueMeaning":{"publicId":"7485295","version":"1","preferredName":"Polysulfated Glycosaminoglycan (Adequan Canine, PSGAG)","longName":"7485295","preferredDefinition":"A semi-synthetic glycosaminoglycan (GAG) prepared by extracting GAGs from bovine tracheal cartilage and consisting of mostly chondroitin sulfate, with anti-arthritic activities in animals including dogs. Upon administration, polysulfated GAG (PSGAG), a proteolytic enzyme inhibitor, may inhibit various processes that lead to the loss of cartilaginous mucopolysaccharides. This may include the inhibition of interleukin-1 (IL-1)-mediated inflammation and degradation of cartilage proteoglycans and collagen. PSGAG may also stimulate the synthesis of protein, collagen, proteoglycans, and hyaluronic acid, which may improve joint function.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polysulfated Glycosaminoglycan","conceptCode":"C175559","definition":"A semi-synthetic glycosaminoglycan (GAG) prepared by extracting GAGs from bovine tracheal cartilage and consisting of mostly chondroitin sulfate, with anti-arthritic activities in animals including dogs. Upon administration, polysulfated GAG (PSGAG), a proteolytic enzyme inhibitor, may inhibit various processes that lead to the loss of cartilaginous mucopolysaccharides. This may include the inhibition of interleukin-1 (IL-1)-mediated inflammation and degradation of cartilage proteoglycans and collagen. PSGAG may also stimulate the synthesis of protein, collagen, proteoglycans, and hyaluronic acid, which may improve joint function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CF8693-964B-1AF6-E053-4EBD850ADCE8","latestVersionIndicator":"Yes","beginDate":"2020-10-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-10-29","modifiedBy":"COOPERM","dateModified":"2020-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B2CFA5F8-5369-562C-E053-4EBD850A44BB","beginDate":"2020-10-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-10-29","modifiedBy":"ONEDATA","dateModified":"2020-10-29","deletedIndicator":"No"},{"value":"Praziquantel/Pyrantel Pamoate","valueDescription":"Praziquantel/Pyrantel Pamoate (Drontal))","ValueMeaning":{"publicId":"7485305","version":"1","preferredName":"Praziquantel/Pyrantel Pamoate (Drontal))","longName":"7485305","preferredDefinition":"A fixed combination of praziquantel and pyrantel pamoate, with anthelminthic activity. Upon administration, praziquantel increases the permeability of the tegument of susceptible worms, resulting in an influx and increase in intra-tegumental calcium leading to rapid contractions and paralysis of the worm's musculature. In addition, vacuolization of the tegumental syncytium and blebbing results in tegument disintegration, leads to antigen exposure and elicit host defense responses to the worm. This results in granulomas formation and phagocytosis. Pyrantel pamoate acts as a depolarizing neuromuscular blocking agent resulting in spastic paralysis of the helminths. The parasites are then eliminated through intestinal tract peristalsis of the host.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Praziquantel/Pyrantel Pamoate","conceptCode":"C175560","definition":"A fixed combination of praziquantel and pyrantel pamoate, with anthelminthic activity. Upon administration, praziquantel increases the permeability of the tegument of susceptible worms, resulting in an influx and increase in intra-tegumental calcium leading to rapid contractions and paralysis of the worm's musculature. In addition, vacuolization of the tegumental syncytium and blebbing results in tegument disintegration, leads to antigen exposure and elicit host defense responses to the worm. This results in granulomas formation and phagocytosis. Pyrantel pamoate acts as a depolarizing neuromuscular blocking agent resulting in spastic paralysis of the helminths. The parasites are then eliminated through intestinal tract peristalsis of the host.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFA5F8-5375-562C-E053-4EBD850A44BB","latestVersionIndicator":"Yes","beginDate":"2020-10-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-10-29","modifiedBy":"COOPERM","dateModified":"2020-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B2CFA5F8-538E-562C-E053-4EBD850A44BB","beginDate":"2020-10-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-10-29","modifiedBy":"ONEDATA","dateModified":"2020-10-29","deletedIndicator":"No"},{"value":"Alfaxalone","valueDescription":"Alfaxalone (Alfax)","ValueMeaning":{"publicId":"7485306","version":"1","preferredName":"Alfaxalone (Alfax)","longName":"7485306","preferredDefinition":"A synthetic neuroactive steroid, with anesthetic activity. Upon administration, alfaxalone binds to the gamma-aminobutyric acid (GABA)-A cell surface receptor, thereby enhancing the inhibitory actions of GABA-A in the brain. This leads to modulation of neuronal cell membrane chloride ion transport and induction and maintenance of anesthesia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alfaxalone","conceptCode":"C72161","definition":"A synthetic neuroactive steroid, with anesthetic activity. Upon administration, alfaxalone binds to the gamma-aminobutyric acid (GABA)-A cell surface receptor, thereby enhancing the inhibitory actions of GABA-A in the brain. This leads to modulation of neuronal cell membrane chloride ion transport and induction and maintenance of anesthesia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFA5F8-539A-562C-E053-4EBD850A44BB","latestVersionIndicator":"Yes","beginDate":"2020-10-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-10-29","modifiedBy":"COOPERM","dateModified":"2020-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B2CFA5F8-53B3-562C-E053-4EBD850A44BB","beginDate":"2020-10-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-10-29","modifiedBy":"ONEDATA","dateModified":"2020-10-29","deletedIndicator":"No"},{"value":"Dulaglutide","valueDescription":"Dulaglutide (Trulicity)","ValueMeaning":{"publicId":"7656770","version":"1","preferredName":"Dulaglutide (Trulicity)","longName":"7656770","preferredDefinition":"A glucagon-like peptide-1 (GLP-1) receptor agonist that is 90% homologous to native human GLP-1 (7-37) and is composed of a dipeptidyl peptidase-IV-protected GLP-1 analog covalently linked to a human immunoglobulin G4 (IgG4)-Fc heavy chain, with antihyperglycemic activity. Upon administration, dulaglutide binds to and activates GLP-1 receptors, thereby increasing intracellular cyclic AMP (cAMP) in pancreatic beta cells. This increases glucose-dependent insulin release. Dulaglutide also reduces the elevated glucagon secretion by inhibiting alpha cells of the pancreas and slows gastric emptying. Altogether this lowers the postprandial glucose level. GLP-1 is normally secreted by L cells of the gastrointestinal (GI) mucosa in response to a meal to normalize blood glucose levels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dulaglutide","conceptCode":"C169923","definition":"A glucagon-like peptide-1 (GLP-1) receptor agonist that is 90% homologous to native human GLP-1 (7-37) and is composed of a dipeptidyl peptidase-IV-protected GLP-1 analog covalently linked to a human immunoglobulin G4 (IgG4)-Fc heavy chain, with antihyperglycemic activity. Upon administration, dulaglutide binds to and activates GLP-1 receptors, thereby increasing intracellular cyclic AMP (cAMP) in pancreatic beta cells. This increases glucose-dependent insulin release. Dulaglutide also reduces the elevated glucagon secretion by inhibiting alpha cells of the pancreas and slows gastric emptying. Altogether this lowers the postprandial glucose level. GLP-1 is normally secreted by L cells of the gastrointestinal (GI) mucosa in response to a meal to normalize blood glucose levels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C228CEC8-D34E-0582-E053-4EBD850AA103","latestVersionIndicator":"Yes","beginDate":"2021-05-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-05-12","modifiedBy":"COOPERM","dateModified":"2021-05-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C228CEC8-D367-0582-E053-4EBD850AA103","beginDate":"2021-05-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-05-12","modifiedBy":"ONEDATA","dateModified":"2021-05-12","deletedIndicator":"No"},{"value":"Turmeric curcumin","valueDescription":"Curcumin (Curcuma Longa, Turmeric Root, Wild Curcuma)","ValueMeaning":{"publicId":"7675413","version":"1","preferredName":"Curcumin (Curcuma Longa, Turmeric Root, Wild Curcuma)","longName":"7675413","preferredDefinition":"A phytopolylphenol pigment isolated from the plant Curcuma longa, commonly known as turmeric, with a variety of pharmacologic properties.  Curcumin blocks the formation of reactive-oxygen species, possesses anti-inflammatory properties as a result of inhibition of cyclooxygenases (COX) and other enzymes involved in inflammation; and disrupts cell signal transduction by various mechanisms including inhibition of protein kinase C.  These effects may play a role in the agent's observed antineoplastic properties, which include inhibition of tumor cell proliferation and suppression of chemically induced carcinogenesis and tumor growth in animal models of cancer. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Curcumin","conceptCode":"C401","definition":"A phytopolylphenol pigment isolated from the plant Curcuma longa, commonly known as turmeric, with a variety of pharmacologic properties.  Curcumin blocks the formation of reactive-oxygen species, possesses anti-inflammatory properties as a result of inhibition of cyclooxygenases (COX) and other enzymes involved in inflammation; and disrupts cell signal transduction by various mechanisms including inhibition of protein kinase C.  These effects may play a role in the agent's observed antineoplastic properties, which include inhibition of tumor cell proliferation and suppression of chemically induced carcinogenesis and tumor growth in animal models of cancer. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C3F19B25-DA77-3503-E053-4EBD850A86CD","latestVersionIndicator":"Yes","beginDate":"2021-06-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-06-04","modifiedBy":"COOPERM","dateModified":"2021-06-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C3F19B25-DA90-3503-E053-4EBD850A86CD","beginDate":"2021-06-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-06-04","modifiedBy":"ONEDATA","dateModified":"2021-06-04","deletedIndicator":"No"},{"value":"Xylimelts","valueDescription":"Saliva substitute (Xylimelts)","ValueMeaning":{"publicId":"7675414","version":"1","preferredName":"Saliva substitute (Xylimelts)","longName":"7675414","preferredDefinition":"A medication containing xylitol and cellulose gum used to coat, lubricate and soothe the oral cavity and also help stimulate natural saliva flow to relieve dryness and pain, or discomfort that may be caused by certain disease conditions, medications, surgery, or chemotherapy and radiation treatments.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C3F19B25-DA9A-3503-E053-4EBD850A86CD","latestVersionIndicator":"Yes","beginDate":"2021-06-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-06-04","modifiedBy":"ONEDATA","dateModified":"2021-06-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C3F19B25-DAB3-3503-E053-4EBD850A86CD","beginDate":"2021-06-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-06-04","modifiedBy":"ONEDATA","dateModified":"2021-06-04","deletedIndicator":"No"},{"value":"Efinaconazole","valueDescription":"Efinaconazole (Jublia, Clenafin)","ValueMeaning":{"publicId":"7675416","version":"1","preferredName":"Efinaconazole (Jublia, Clenafin)","longName":"7675416","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Efinaconazole","conceptCode":"C97998","definition":"A triazole compound, with antifungal activity. Upon administration, efinaconazole targets, binds to and inhibits 14-alpha-demethylase, a cytochrome P450-dependent enzyme. Inhibition of 14-alpha-demethylase prevents the conversion of lanosterol to ergosterol, an important component of the fungal cell wall. Inhibition of ergosterol synthesis changes the fungal cell membrane composition and integrity, alters membrane permeability and eventually leads to fungal cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C3F19B25-DAC0-3503-E053-4EBD850A86CD","latestVersionIndicator":"Yes","beginDate":"2021-06-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-06-04","modifiedBy":"COOPERM","dateModified":"2021-06-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C3F19B25-DAD9-3503-E053-4EBD850A86CD","beginDate":"2021-06-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-06-04","modifiedBy":"ONEDATA","dateModified":"2021-06-04","deletedIndicator":"No"},{"value":"Iron polysaccharide complex","valueDescription":"Iron polysaccharide complex (Niferex, Ferrex)","ValueMeaning":{"publicId":"7675417","version":"1","preferredName":"Iron polysaccharide complex (Niferex, Ferrex)","longName":"7675417","preferredDefinition":"A medication used as an iron supplement to treat or prevent low blood levels of iron, such as those caused by anemia or pregnancy.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C3F19B25-DAE3-3503-E053-4EBD850A86CD","latestVersionIndicator":"Yes","beginDate":"2021-06-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-06-04","modifiedBy":"ONEDATA","dateModified":"2021-06-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C3F19B25-DAFC-3503-E053-4EBD850A86CD","beginDate":"2021-06-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-06-04","modifiedBy":"ONEDATA","dateModified":"2021-06-04","deletedIndicator":"No"},{"value":"Sodium Ferric Gluconate complex/Sucrose","valueDescription":"Sodium Ferric Gluconate Complex in Sucrose (Ferrlecit, Nulecit )","ValueMeaning":{"publicId":"7675419","version":"1","preferredName":"Sodium Ferric Gluconate Complex in Sucrose (Ferrlecit, Nulecit )","longName":"7675419","preferredDefinition":"A compound containing elemental iron as the sodium salt of a ferric ion carbohydrate complex in an alkaline aqueous solution with approximately 20% sucrose w/v in water for injection, used to replete the total body content of iron. Iron is critical for normal hemoglobin and myoglobin syntheses to maintain oxygen transport and various enzymatic processes, including the biosynthesis of deoxyribonucleotides catalyzed by ribonucleotide reductase (RNR).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sodium Ferric Gluconate Complex in Sucrose","conceptCode":"C78185","definition":"A compound containing elemental iron as the sodium salt of a ferric ion carbohydrate complex in an alkaline aqueous solution with approximately 20% sucrose w/v in water for injection, used to replete the total body content of iron. Iron is critical for normal hemoglobin and myoglobin syntheses to maintain oxygen transport and various enzymatic processes, including the biosynthesis of deoxyribonucleotides catalyzed by ribonucleotide reductase (RNR).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C3F19B25-DB09-3503-E053-4EBD850A86CD","latestVersionIndicator":"Yes","beginDate":"2021-06-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-06-04","modifiedBy":"COOPERM","dateModified":"2021-06-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C3F19B25-DB22-3503-E053-4EBD850A86CD","beginDate":"2021-06-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-06-04","modifiedBy":"ONEDATA","dateModified":"2021-06-04","deletedIndicator":"No"},{"value":"Collagenase topical ointment","valueDescription":"Collagenase Topical Ointment (Santyl, Collagenase)","ValueMeaning":{"publicId":"7675420","version":"1","preferredName":"Collagenase Topical Ointment (Santyl, Collagenase)","longName":"7675420","preferredDefinition":"A medication used to treat the symptoms of dermal ulcers.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C3F19B25-DB2C-3503-E053-4EBD850A86CD","latestVersionIndicator":"Yes","beginDate":"2021-06-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-06-04","modifiedBy":"ONEDATA","dateModified":"2021-06-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C3F19B25-DB45-3503-E053-4EBD850A86CD","beginDate":"2021-06-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-06-04","modifiedBy":"ONEDATA","dateModified":"2021-06-04","deletedIndicator":"No"},{"value":"Gentian violet","valueDescription":"Gentian Violet (Triple Dye, Kerr Triple Dye) ","ValueMeaning":{"publicId":"7675422","version":"1","preferredName":"Gentian Violet (Triple Dye, Kerr Triple Dye) ","longName":"7675422","preferredDefinition":"A blue, aniline-derived dye with antifungal and antimitotic properties. Gentian violet (GV) dissociates into positive (GV+) and negative ions (Cl-) that penetrate both gram-positive and gram-negative bacterial cells. The GV+ ions interact with negatively charged components of the bacterial cell wall including lipopolysaccharide, peptidoglycan and DNA. This agent is also a mutagen and mitotic poison. GV elicits a photodynamic action mediated by a free-radical mechanism. Furthermore, this agent dissipates the action potential on prokaryotic or eukaryotic membranes by inducing permeability, thereby leading to respiratory inhibition and subsequent cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gentian Violet","conceptCode":"C61776","definition":"A blue, aniline-derived dye with antifungal and antimitotic properties. Gentian violet (GV) dissociates into positive (GV+) and negative ions (Cl-) that penetrate both gram-positive and gram-negative bacterial cells. The GV+ ions interact with negatively charged components of the bacterial cell wall including lipopolysaccharide, peptidoglycan and DNA. This agent is also a mutagen and mitotic poison. GV elicits a photodynamic action mediated by a free-radical mechanism. Furthermore, this agent dissipates the action potential on prokaryotic or eukaryotic membranes by inducing permeability, thereby leading to respiratory inhibition and subsequent cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C3F19B25-DB52-3503-E053-4EBD850A86CD","latestVersionIndicator":"Yes","beginDate":"2021-06-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-06-04","modifiedBy":"COOPERM","dateModified":"2021-06-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C3F19B25-DB6B-3503-E053-4EBD850A86CD","beginDate":"2021-06-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-06-04","modifiedBy":"ONEDATA","dateModified":"2021-06-04","deletedIndicator":"No"},{"value":"Betahistine","valueDescription":"Betahistine","ValueMeaning":{"publicId":"7675427","version":"1","preferredName":"Betahistine","longName":"7675427","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Betahistine","conceptCode":"C83554","definition":"A histamine analog with weak histamine H1 agonistic and more potent histamine H3 antagonistic properties. Upon intranasal administration, betahistine binds to histamine H1 and H3 receptors and exerts its agonistic and antagonistic actions locally and centrally. This promotes cochlear, vestibular and cerebral blood flow, decreases neuronal firing in the vestibular nuclei and increases histamine synthesis and release in the brain which facilitates vestibular compensation. Increased blood flow around the inner ear reduces the amount of fluid in the inner ear and may alleviate vertigo, tinnitus, and hearing loss.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C3F30240-2339-5778-E053-4EBD850A3981","latestVersionIndicator":"Yes","beginDate":"2021-06-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-06-04","modifiedBy":"ONEDATA","dateModified":"2021-06-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C3F30240-2352-5778-E053-4EBD850A3981","beginDate":"2021-06-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-06-04","modifiedBy":"ONEDATA","dateModified":"2021-06-04","deletedIndicator":"No"},{"value":"Fusidic acid cream","valueDescription":"Cream Dosage Form Fusidic Acid","ValueMeaning":{"publicId":"7675429","version":"1","preferredName":"Cream Dosage Form Fusidic Acid","longName":"7675429","preferredDefinition":"A semi-solid composed of an emulsion of lipids, hydrocarbons, waxes, or polyols in water.: A bacteriostatic antibiotic derived from the fungus Fusidium coccineum and used as a topical medication to treat skin infections. Fusidic acid acts as a bacterial protein synthesis inhibitor by preventing the turnover of elongation factor G (EF-G) from the ribosome. Fusidic acid is effective primarily on gram-positive bacteria.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cream Dosage Form","conceptCode":"C28944","definition":"A semi-solid composed of an emulsion of lipids, hydrocarbons, waxes, or polyols in water.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Fusidic Acid","conceptCode":"C65793","definition":"A bacteriostatic antibiotic derived from the fungus Fusidium coccineum and used as a topical medication to treat skin infections. Fusidic acid acts as a bacterial protein synthesis inhibitor by preventing the turnover of elongation factor G (EF-G) from the ribosome. Fusidic acid is effective primarily on gram-positive bacteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C3F30240-2360-5778-E053-4EBD850A3981","latestVersionIndicator":"Yes","beginDate":"2021-06-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-06-04","modifiedBy":"ONEDATA","dateModified":"2021-06-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C3F30240-2379-5778-E053-4EBD850A3981","beginDate":"2021-06-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-06-04","modifiedBy":"ONEDATA","dateModified":"2021-06-04","deletedIndicator":"No"},{"value":"Botulinum Toxin Type A","valueDescription":"Botulinum Toxin Type A","ValueMeaning":{"publicId":"7675407","version":"1","preferredName":"Botulinum Toxin Type A","longName":"7675407","preferredDefinition":"An injectable formulation of a neurotoxin derived through the fermentation of the Hall strain of Clostridium botulinum type A with neuromuscular transmission inhibitory and analgesic activities. Upon injection into the affected muscle, the heavy chain portion of botulinum toxin type A (BTX-A) binds to the cell membrane of the motor nerve and is internalized via endocytosis. Upon entry, the light chain portion of the toxin is activated and cleaves the protein SNAP-25, thereby preventing the fusion of acetylcholine (ACh)-containing synaptic vesicles with the cell membrane and, so, the release of ACh into the neuromuscular junction; subsequent binding of ACH to motor end-plate nicotinic acid receptors and ACh-mediated muscle contraction are thus blocked. In addition to ACh, BTX-A may inhibit the release of neuropeptides, such as substance P and glutamate, which may contribute to its analgesic activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Botulinum Toxin Type A","conceptCode":"C82623","definition":"An injectable formulation of a neurotoxin derived through the fermentation of the Hall strain of Clostridium botulinum type A with neuromuscular transmission inhibitory and analgesic activities. Upon injection into the affected muscle, the heavy chain portion of botulinum toxin type A (BTX-A) binds to the cell membrane of the motor nerve and is internalized via endocytosis. Upon entry, the light chain portion of the toxin is activated and cleaves the protein SNAP-25, thereby preventing the fusion of acetylcholine (ACh)-containing synaptic vesicles with the cell membrane and, so, the release of ACh into the neuromuscular junction; subsequent binding of ACH to motor end-plate nicotinic acid receptors and ACh-mediated muscle contraction are thus blocked. In addition to ACh, BTX-A may inhibit the release of neuropeptides, such as substance P and glutamate, which may contribute to its analgesic activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C3F20DB8-E9DE-7FAB-E053-4EBD850A3C54","latestVersionIndicator":"Yes","beginDate":"2021-06-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-06-04","modifiedBy":"COOPERM","dateModified":"2021-06-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C3F20DB8-E9F7-7FAB-E053-4EBD850A3C54","beginDate":"2021-06-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-06-04","modifiedBy":"ONEDATA","dateModified":"2021-06-04","deletedIndicator":"No"},{"value":"Sugammadex","valueDescription":"Sugammadex (Bridion)","ValueMeaning":{"publicId":"7675408","version":"1","preferredName":"Sugammadex (Bridion)","longName":"7675408","preferredDefinition":"A medication for the reversal of neuromuscular blockade induced by rocuronium and vecuronium general anesthesia. It is the first selective relaxant binding agent (SRBA).","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C3F20DB8-EA01-7FAB-E053-4EBD850A3C54","latestVersionIndicator":"Yes","beginDate":"2021-06-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-06-04","modifiedBy":"ONEDATA","dateModified":"2021-06-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C3F20DB8-EA1A-7FAB-E053-4EBD850A3C54","beginDate":"2021-06-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-06-04","modifiedBy":"ONEDATA","dateModified":"2021-06-04","deletedIndicator":"No"},{"value":"Trulance","valueDescription":"Plecanatide","ValueMeaning":{"publicId":"7801835","version":"1","preferredName":"Plecanatide","longName":"7801835","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plecanatide","conceptCode":"C167027","definition":"An agonist of intestinal guanylate cyclase type C (GC-C) which is almost structurally identical to human uroguanylin, with laxative and anti-nociceptive activities.  Upon oral administration, plecanatide binds to and activates GC-C receptors located on endothelial cells on the luminal surface of the intestinal epithelium. This increases the concentration of intracellular cyclic guanosine monophosphate (cGMP). cGMP activates the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel and stimulates the secretion of chloride and bicarbonate into the intestinal lumen. This also promotes sodium excretion into the lumen and osmosis. The increased intestinal fluid secretion accelerates gastrointestinal transit of intestinal contents, improves bowel movement, softens stool, and relieves constipation. In addition, plecanatide exerts its anti-nociceptive effects by increasing the concentration of extracellular cGMP which inhibits the activity of pain-sensitive nerves, decreases muscle contractions and may relieve intestinal pain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFD5718E-4A97-07D0-E053-4EBD850A1DE3","latestVersionIndicator":"Yes","beginDate":"2021-11-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-11-02","modifiedBy":"ONEDATA","dateModified":"2021-11-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CFD5718E-4AB0-07D0-E053-4EBD850A1DE3","beginDate":"2021-11-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-11-02","modifiedBy":"ONEDATA","dateModified":"2021-11-02","deletedIndicator":"No"},{"value":"Alogliptin","valueDescription":"Alogliptin","ValueMeaning":{"publicId":"7801837","version":"1","preferredName":"Alogliptin","longName":"7801837","preferredDefinition":"A selective, orally bioavailable, pyrimidinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. In addition to its effect on glucose levels, alogliptin may inhibit inflammatory responses by preventing the toll-like receptor 4 (TLR-4)-mediated formation of proinflammatory cytokines.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alogliptin","conceptCode":"C76906","definition":"A selective, orally bioavailable, pyrimidinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. In addition to its effect on glucose levels, alogliptin may inhibit inflammatory responses by preventing the toll-like receptor 4 (TLR-4)-mediated formation of proinflammatory cytokines.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFD5718E-4ABD-07D0-E053-4EBD850A1DE3","latestVersionIndicator":"Yes","beginDate":"2021-11-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-11-02","modifiedBy":"ONEDATA","dateModified":"2021-11-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CFD5718E-4AD6-07D0-E053-4EBD850A1DE3","beginDate":"2021-11-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-11-02","modifiedBy":"ONEDATA","dateModified":"2021-11-02","deletedIndicator":"No"},{"value":"Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate","valueDescription":"Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate","ValueMeaning":{"publicId":"8024216","version":"1","preferredName":"Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate","longName":"8024216","preferredDefinition":"A fixed combination of elvitegravir, a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI); cobicistat, a cytochrome P450 3A (CYP3A) inhibitor; emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine; and tenofovir alafenamide fumarate, the fumarate salt form of the lipophilic phosphonamidate prodrug of tenofovir, a NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, elvitegravir inhibits the activity of integrase, an HIV-1 coded enzyme that is necessary for viral replication. Inhibition of integrase prevents the integration of HIV-1 DNA into host genomic DNA. Cobicistat inhibits CYP3A, thereby limiting the oxidative metabolism of elvitegravir and increases its systemic exposure. Emtricitabine and tenofovir inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate","conceptCode":"C157537","definition":"A fixed combination of elvitegravir, a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI); cobicistat, a cytochrome P450 3A (CYP3A) inhibitor; emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine; and tenofovir alafenamide fumarate, the fumarate salt form of the lipophilic phosphonamidate prodrug of tenofovir, a NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, elvitegravir inhibits the activity of integrase, an HIV-1 coded enzyme that is necessary for viral replication. Inhibition of integrase prevents the integration of HIV-1 DNA into host genomic DNA. Cobicistat inhibits CYP3A, thereby limiting the oxidative metabolism of elvitegravir and increases its systemic exposure. Emtricitabine and tenofovir inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D6FBE51D-09C0-33FD-E053-4EBD850A5B32","latestVersionIndicator":"Yes","beginDate":"2022-02-01","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2022-02-01","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D6FBE51D-09DD-33FD-E053-4EBD850A5B32","beginDate":"2022-02-01","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2022-02-01","modifiedBy":"ONEDATA","dateModified":"2022-02-01","deletedIndicator":"No"},{"value":"Risankizumab","valueDescription":"Risankizumab","ValueMeaning":{"publicId":"8127741","version":"1","preferredName":"Risankizumab","longName":"8127741","preferredDefinition":"A humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the p19 subunit of human interleukin 23 (IL-23) cytokine, with anti-inflammatory activity. Upon administration, risankizumab targets and binds to the p19 subunit of human IL-23, inhibiting the interaction of IL-23 with the IL-23 receptor complex. This inhibits IL-23/IL-23 receptor-mediated signaling and inhibits the release of pro-inflammatory cytokines and chemokines. IL-23 plays an important role in the development, maintenance and activation of Th17 cells, which produce pro-inflammatory cytokines including IL-17A, IL-17F, and IL-22. It is upregulated in various inflammatory and autoimmune diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Risankizumab","conceptCode":"C152227","definition":"A humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the p19 subunit of human interleukin 23 (IL-23) cytokine, with anti-inflammatory activity. Upon administration, risankizumab targets and binds to the p19 subunit of human IL-23, inhibiting the interaction of IL-23 with the IL-23 receptor complex. This inhibits IL-23/IL-23 receptor-mediated signaling and inhibits the release of pro-inflammatory cytokines and chemokines. IL-23 plays an important role in the development, maintenance and activation of Th17 cells, which produce pro-inflammatory cytokines including IL-17A, IL-17F, and IL-22. It is upregulated in various inflammatory and autoimmune diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB7234CD-A9EB-07C4-E053-4EBD850A7EDA","latestVersionIndicator":"Yes","beginDate":"2022-03-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-03-30","modifiedBy":"ONEDATA","dateModified":"2022-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DB7234CD-AA04-07C4-E053-4EBD850A7EDA","beginDate":"2022-03-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-03-30","modifiedBy":"ONEDATA","dateModified":"2022-03-30","deletedIndicator":"No"},{"value":"Orphenadrine","valueDescription":"Orphenadrine","ValueMeaning":{"publicId":"2923334","version":"1","preferredName":"Orphenadrine","longName":"2923334","preferredDefinition":"A muscarinic antagonist with muscle relaxant activity. Although the mechanism of action has not been determined, orphenadrine appears to block muscarinic acetylcholine receptors as well as N-methyl-D-aspartate (NMDA) receptors in the central nervous system (CNS). This may interfere with the transmission of nerve impulses from the spinal cord to the muscles and may help relax muscles. In addition, orphenadrine exerts antagonistic effects on histamine H1 receptors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Orphenadrine","conceptCode":"C61868","definition":"A muscarinic antagonist with muscle relaxant activity. Although the mechanism of action has not been determined, orphenadrine appears to block muscarinic acetylcholine receptors as well as N-methyl-D-aspartate (NMDA) receptors in the central nervous system (CNS). This may interfere with the transmission of nerve impulses from the spinal cord to the muscles and may help relax muscles. In addition, orphenadrine exerts antagonistic effects on histamine H1 receptors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6FB34A35-F6C6-0250-E040-BB89AD4308FF","latestVersionIndicator":"Yes","beginDate":"2009-07-27","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-07-27","modifiedBy":"KUMMEROA","dateModified":"2022-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DB7234CD-AA0E-07C4-E053-4EBD850A7EDA","beginDate":"2022-03-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-03-30","modifiedBy":"ONEDATA","dateModified":"2022-03-30","deletedIndicator":"No"},{"value":"Cilgavimab","valueDescription":"Cilgavimab","ValueMeaning":{"publicId":"8137607","version":"1","preferredName":"Cilgavimab","longName":"8137607","preferredDefinition":"A neutralizing human monoclonal antibody isolated from convalescent patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and directed against the spike (S) protein, that can potentially be used for passive immunization against Coronavirus disease 2019 (COVID-19). Upon administration, cilgavimab specifically targets and binds to the SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cilgavimab","conceptCode":"C177058","definition":"A neutralizing human monoclonal antibody isolated from convalescent patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and directed against the spike (S) protein, that can potentially be used for passive immunization against Coronavirus disease 2019 (COVID-19). Upon administration, cilgavimab specifically targets and binds to the SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DBD7662C-B16B-37A9-E053-4EBD850A53F2","latestVersionIndicator":"Yes","beginDate":"2022-04-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-04-04","modifiedBy":"ONEDATA","dateModified":"2022-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DBD7662C-B184-37A9-E053-4EBD850A53F2","beginDate":"2022-04-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-04-04","modifiedBy":"ONEDATA","dateModified":"2022-04-04","deletedIndicator":"No"},{"value":"Tixagevimab","valueDescription":"Tixagevimab","ValueMeaning":{"publicId":"8137609","version":"1","preferredName":"Tixagevimab","longName":"8137609","preferredDefinition":"A neutralizing human monoclonal antibody isolated from convalescent patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and directed against the spike (S) protein, that can potentially be used for passive immunization against Coronavirus disease 2019 (COVID-19). Upon administration, tixagevimab specifically targets and binds to the SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tixagevimab","conceptCode":"C177082","definition":"A neutralizing human monoclonal antibody isolated from convalescent patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and directed against the spike (S) protein, that can potentially be used for passive immunization against Coronavirus disease 2019 (COVID-19). Upon administration, tixagevimab specifically targets and binds to the SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DBD7662C-B191-37A9-E053-4EBD850A53F2","latestVersionIndicator":"Yes","beginDate":"2022-04-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-04-04","modifiedBy":"ONEDATA","dateModified":"2022-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DBD7662C-B1AA-37A9-E053-4EBD850A53F2","beginDate":"2022-04-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-04-04","modifiedBy":"ONEDATA","dateModified":"2022-04-04","deletedIndicator":"No"},{"value":"Lidocaine/Epinephrine","valueDescription":"Lidocaine/Epinephrine","ValueMeaning":{"publicId":"8127796","version":"1","preferredName":"Lidocaine/Epinephrine","longName":"8127796","preferredDefinition":"A combination agent composed of the hydrochloride salt form of lidocaine, an aminoethylamide and a prototypical member of the amide class of anesthetics, and the synthetic form of the naturally occurring sympathomimetic amine epinephrine, with local vasoconstricting and anesthetic activities. Upon local administration of lidocaine hydrochloride/epinephrine by injection, epinephrine binds to and stimulates vascular alpha-adrenergic receptors, thereby causing vasoconstriction. Lidocaine interacts with voltage-gated sodium (Na+) channels in the nerve cell membranes and blocks the transient increase in permeability of excitable membranes to Na+. This prevents the generation and conduction of nerve impulses and produces a reversible loss of sensation. By administering epinephrine, lidocaine's potential to disperse into the surrounding tissue is reduced, thereby increasing its local efficacy, and enhancing and prolonging the anesthetic effect.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lidocaine Hydrochloride/Epinephrine","conceptCode":"C186590","definition":"A combination agent composed of the hydrochloride salt form of lidocaine, an aminoethylamide and a prototypical member of the amide class of anesthetics, and the synthetic form of the naturally occurring sympathomimetic amine epinephrine, with local vasoconstricting and anesthetic activities. Upon local administration of lidocaine hydrochloride/epinephrine by injection, epinephrine binds to and stimulates vascular alpha-adrenergic receptors, thereby causing vasoconstriction. Lidocaine interacts with voltage-gated sodium (Na+) channels in the nerve cell membranes and blocks the transient increase in permeability of excitable membranes to Na+. This prevents the generation and conduction of nerve impulses and produces a reversible loss of sensation. By administering epinephrine, lidocaine's potential to disperse into the surrounding tissue is reduced, thereby increasing its local efficacy, and enhancing and prolonging the anesthetic effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB746421-3817-675B-E053-4EBD850A97F9","latestVersionIndicator":"Yes","beginDate":"2022-03-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-03-30","modifiedBy":"KUMMEROA","dateModified":"2022-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DB746421-3830-675B-E053-4EBD850A97F9","beginDate":"2022-03-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-03-30","modifiedBy":"ONEDATA","dateModified":"2022-03-30","deletedIndicator":"No"},{"value":"Abiraterone acetate","valueDescription":null,"ValueMeaning":{"publicId":"5425971","version":"1","preferredName":"Abiraterone Acetate","longName":"5425971","preferredDefinition":"An orally active acetate salt of the steroidal compound abiraterone with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abiraterone Acetate","conceptCode":"C68845","definition":"An orally active acetate ester form of the steroidal compound abiraterone with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A714DC5-A5C1-9607-E050-BB89AD43167A","latestVersionIndicator":"Yes","beginDate":"2016-08-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-19","modifiedBy":"GDEEN","dateModified":"2022-07-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E26DC616-38AF-67B5-E053-731AD00AD545","beginDate":"2022-07-06","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-07-06","modifiedBy":"GDEEN","dateModified":"2022-07-06","deletedIndicator":"No"},{"value":"Pomegranate (extract)","valueDescription":null,"ValueMeaning":{"publicId":"10571485","version":"1","preferredName":"Pomegranate Liquid Extract","longName":"10571485v1.00","preferredDefinition":"A liquid extract preparation derived from pomegranate (Punica granatum) seeds with antioxidant, and potential antineoplastic and chemopreventive activities. Pomegranate liquid extract contains flavonoids which may promote differentiation and apoptosis in tumor cells by down-regulating vascular endothelial growth factor (VEGF) and stimulating migration inhibitory factor (MIF), thus inhibiting angiogenesis. Pomegranate liquid extract flavanoids also scavenge reactive oxygen species (ROS) and, in some cell types, may prevent ROS-mediated cell injury and death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pomegranate Liquid Extract","conceptCode":"C78866","definition":"A liquid extract preparation derived from pomegranate (Punica granatum) seeds with antioxidant, and potential antineoplastic and chemopreventive activities. Pomegranate liquid extract contains flavonoids which may promote differentiation and apoptosis in tumor cells by down-regulating vascular endothelial growth factor (VEGF) and stimulating migration inhibitory factor (MIF), thus inhibiting angiogenesis. Pomegranate liquid extract flavanoids also scavenge reactive oxygen species (ROS) and, in some cell types, may prevent ROS-mediated cell injury and death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3B1B261-6DC8-1AB6-E053-731AD00AD1D1","latestVersionIndicator":"Yes","beginDate":"2022-07-13","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-07-13","modifiedBy":"GDEEN","dateModified":"2022-07-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E3B1B261-6DC9-1AB6-E053-731AD00AD1D1","beginDate":"2022-07-13","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-07-13","modifiedBy":"GDEEN","dateModified":"2022-07-13","deletedIndicator":"No"},{"value":"Polyvinylpyrrolidone/Hyaluronic Acid Gel","valueDescription":null,"ValueMeaning":{"publicId":"11127009","version":"1","preferredName":"Polyvinylpyrrolidone-Sodium Hyaluronate Gel","longName":"11127009v1.00","preferredDefinition":"An oral bioadherent gel containing polyvinylpyrrolidone (PVP) and sodium hyaluronate with muco-protective activity. Upon oral application, this gel adheres to the mucosal surface of the mouth and throat, forming a thin layer that acts as a barrier to protect exposed and sensitized nerve endings from the painful stimuli associated with eating, drinking, and talking.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polyvinylpyrrolidone-Sodium Hyaluronate Gel","conceptCode":"C61593","definition":"An oral bioadherent gel containing polyvinylpyrrolidone (PVP) and sodium hyaluronate with muco-protective activity. Upon oral application, this gel adheres to the mucosal surface of the mouth and throat, forming a thin layer that acts as a barrier to protect exposed and sensitized nerve endings from the painful stimuli associated with eating, drinking, and talking.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E6621BF2-DB4C-5CD7-E053-731AD00A5500","latestVersionIndicator":"Yes","beginDate":"2022-08-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-16","modifiedBy":"KUMMEROA","dateModified":"2022-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E6621BF2-DB4D-5CD7-E053-731AD00A5500","beginDate":"2022-08-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-16","modifiedBy":"KUMMEROA","dateModified":"2022-08-16","deletedIndicator":"No"},{"value":"Belumosudil","valueDescription":null,"ValueMeaning":{"publicId":"7614732","version":"1","preferredName":"Belumosudil","longName":"7614732","preferredDefinition":"An orally administered inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2; ROCK-II), with potential immunomodulating activity. Upon administration, belumosudil binds to and inhibits the serine/threonine kinase activity of ROCK2. This inhibits ROCK2-mediated signal transduction pathways and modulates various pro- and anti-inflammatory immune cell responses. ROCK2 is upregulated in various diseases, including various fibrotic, neurodegenerative and autoimmune diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Belumosudil","conceptCode":"C128786","definition":"An orally bioavailable inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2; ROCK-II), with potential immunomodulating activity. Upon oral administration, belumosudil binds to and inhibits the serine/threonine kinase activity of ROCK2. This inhibits ROCK2-mediated signal transduction pathways and modulates various pro- and anti-inflammatory immune cell responses through the regulation of signal transducer and activator of transcription 3 and 5 (STAT3/STAT5) phosphorylation. This downregulates pro-inflammatory Th17 cells and increases regulatory T (Treg) cells. Belumosudil also inhibits ROCK2-mediated fibrotic processes, including stress fiber formation, myofibroblast activation and pro-fibrotic gene transcription. ROCK2 is upregulated in various diseases, including various fibrotic, neurodegenerative and autoimmune diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE5F33BC-9A44-657F-E053-4EBD850AFD37","latestVersionIndicator":"Yes","beginDate":"2021-03-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-25","modifiedBy":"GDEEN","dateModified":"2022-09-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E9381459-BFB2-4825-E053-731AD00AFDBE","beginDate":"2022-09-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-09-21","modifiedBy":"GDEEN","dateModified":"2022-09-21","deletedIndicator":"No"},{"value":"Darunavir Ethanolate/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate","valueDescription":null,"ValueMeaning":{"publicId":"11289980","version":"1","preferredName":"Darunavir Ethanolate/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate","longName":"11289980v1.00","preferredDefinition":"A four-drug fixed combination of the ethanolate salt form of darunavir, a human immunodeficiency virus type 1 (HIV-1) protease nonpeptidic inhibitor; cobicistat, a cytochrome P450 3A (CYP3A) inhibitor; emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine; and tenofovir alafenamide fumarate, the fumarate salt form of the lipophilic phosphonamidate prodrug of tenofovir, a NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration of darunavir ethanolate/cobicistat/emtricitabine/tenofovir alafenamide fumarate, darunavir selectively targets and binds to the active site of HIV-1 protease and inhibits the dimerization and catalytic activity of HIV-1 protease. This inhibits the proteolytic cleavage of viral Gag and Gag-Pol polyproteins in HIV-infected cells. This inhibition leads to the production of immature, non-infectious viral proteins that are unable to form mature virions, and prevents HIV replication. Cobicistat inhibits CYP3A, thereby limiting the oxidative metabolism of darunavir and increases its systemic exposure. Emtricitabine and tenofovir alafenamide, after being converted in vivo to tenofovir, inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain and resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Darunavir Ethanolate/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate","conceptCode":"C173644","definition":"A four-drug fixed combination of the ethanolate salt form of darunavir, a human immunodeficiency virus type 1 (HIV-1) protease nonpeptidic inhibitor; cobicistat, a cytochrome P450 3A (CYP3A) inhibitor; emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine; and tenofovir alafenamide fumarate, the fumarate salt form of the lipophilic phosphonamidate prodrug of tenofovir, a NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration of darunavir ethanolate/cobicistat/emtricitabine/tenofovir alafenamide fumarate, darunavir selectively targets and binds to the active site of HIV-1 protease and inhibits the dimerization and catalytic activity of HIV-1 protease. This inhibits the proteolytic cleavage of viral Gag and Gag-Pol polyproteins in HIV-infected cells. This inhibition leads to the production of immature, non-infectious viral proteins that are unable to form mature virions, and prevents HIV replication. Cobicistat inhibits CYP3A, thereby limiting the oxidative metabolism of darunavir and increases its systemic exposure. Emtricitabine and tenofovir alafenamide, after being converted in vivo to tenofovir, inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain and resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9381459-BFAF-4825-E053-731AD00AFDBE","latestVersionIndicator":"Yes","beginDate":"2022-09-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-09-21","modifiedBy":"GDEEN","dateModified":"2022-09-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E9381459-BFB3-4825-E053-731AD00AFDBE","beginDate":"2022-09-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-09-21","modifiedBy":"GDEEN","dateModified":"2022-09-21","deletedIndicator":"No"},{"value":"Molnupiravir","valueDescription":null,"ValueMeaning":{"publicId":"8062014","version":"1","preferredName":"Molnupiravir","longName":"8062014","preferredDefinition":"An orally bioavailable prodrug of EIDD-1931, the synthetic ribonucleoside derivative N4-hydroxycytidine and ribonucleoside analog, with potential antiviral activity against a variety of RNA viruses. Upon oral administration, molnupiravir, being a prodrug, is metabolized into its active form EIDD-1931 and converted into its triphosphate (TP) form. The TP form of EIDD-1931 is incorporated into RNA and inhibits the action of viral RNA-dependent RNA polymerase. This results in the termination of RNA transcription and decreases viral RNA production, and viral RNA replication.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Molnupiravir","conceptCode":"C172633","definition":"An orally bioavailable prodrug of EIDD-1931, the synthetic ribonucleoside derivative N4-hydroxycytidine and ribonucleoside analog, with potential antiviral activity against a variety of RNA viruses. Upon oral administration, molnupiravir, being a prodrug, is metabolized into its active form EIDD-1931 and converted into its triphosphate (TP) form. The TP form of EIDD-1931 is incorporated into RNA and inhibits the action of viral RNA-dependent RNA polymerase. This results in the termination of RNA transcription and decreases viral RNA production, and viral RNA replication.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D918E1F9-3F95-4AB3-E053-4EBD850A5869","latestVersionIndicator":"Yes","beginDate":"2022-02-28","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-02-28","modifiedBy":"GDEEN","dateModified":"2022-09-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E9381459-BFB4-4825-E053-731AD00AFDBE","beginDate":"2022-09-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-09-21","modifiedBy":"GDEEN","dateModified":"2022-09-21","deletedIndicator":"No"},{"value":"Imipenem-Cilastatin-Relebactam","valueDescription":null,"ValueMeaning":{"publicId":"11289981","version":"1","preferredName":"Imipenem-Cilastatin-Relebactam","longName":"11289981v1.00","preferredDefinition":"A parenteral antibiotic preparation containing imipenem, cilastatin sodium and relebactam, with bactericidal activity. Imipenem, a broad spectrum beta-lactam carbapenem antibiotic, binds to and inactivates penicillin-binding proteins (PBP) on the inner membrane of the bacterial cell wall, thereby interfering with the cross-linkage of peptidoglycan chains critical for bacterial cell wall strength and rigidity. Cilastatin sodium, a renal dehydropeptidase inhibitor, reduces the breakdown of imipenem by renal dehydropeptidase. Relebactam, a beta-lactamase inhibitor, reduces the breakdown of imipenem by certain serine beta-lactamases among gram-negative bacteria. Imipenem is active against a wide range of gram-positive and gram-negative organisms, and the imipenem, cilastatin sodium and relebactam combination may be used to treat infections caused by resistant gram-negative bacteria.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Imipenem-Cilastatin-Relebactam","conceptCode":"C181013","definition":"A parenteral antibiotic preparation containing imipenem, cilastatin sodium and relebactam, with bactericidal activity. Imipenem, a broad spectrum beta-lactam carbapenem antibiotic, binds to and inactivates penicillin-binding proteins (PBP) on the inner membrane of the bacterial cell wall, thereby interfering with the cross-linkage of peptidoglycan chains critical for bacterial cell wall strength and rigidity. Cilastatin sodium, a renal dehydropeptidase inhibitor, reduces the breakdown of imipenem by renal dehydropeptidase. Relebactam, a beta-lactamase inhibitor, reduces the breakdown of imipenem by certain serine beta-lactamases among gram-negative bacteria. Imipenem is active against a wide range of gram-positive and gram-negative organisms, and the imipenem, cilastatin sodium and relebactam combination may be used to treat infections caused by resistant gram-negative bacteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9381459-BFB0-4825-E053-731AD00AFDBE","latestVersionIndicator":"Yes","beginDate":"2022-09-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-09-21","modifiedBy":"GDEEN","dateModified":"2022-09-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E9381459-BFB5-4825-E053-731AD00AFDBE","beginDate":"2022-09-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-09-21","modifiedBy":"GDEEN","dateModified":"2022-09-21","deletedIndicator":"No"},{"value":"Tedizolid","valueDescription":null,"ValueMeaning":{"publicId":"7094876","version":"1","preferredName":"Tedizolid","longName":"7094876","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tedizolid","conceptCode":"C84222","definition":"An antibacterial agent of the oxazolidinone class, that is used for the treatment of acute bacterial skin and skin structure infections caused by certain Gram-positive microorganisms. Upon intravenous administration, tedizolid targets and binds to the 50S subunit of the bacterial ribosome. This inhibits bacterial protein synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99EFE66B-C6A0-1CAA-E053-F662850A8AE0","latestVersionIndicator":"Yes","beginDate":"2019-12-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-12-17","modifiedBy":"GDEEN","dateModified":"2022-09-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E9381459-BFB6-4825-E053-731AD00AFDBE","beginDate":"2022-09-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-09-21","modifiedBy":"GDEEN","dateModified":"2022-09-21","deletedIndicator":"No"},{"value":"Meropenem Trihydrate/Vaborbactam","valueDescription":null,"ValueMeaning":{"publicId":"11289982","version":"1","preferredName":"Meropenem Trihydrate/Vaborbactam","longName":"11289982v1.00","preferredDefinition":"A fixed two-agent injectable combination of the trihydrate form of meropenem, a broad-spectrum synthetic beta-lactam carbapenem antibiotic, and vaborbactam, a cyclic boronic acid beta-lactamase inhibitor, with antibacterial activity against susceptible bacteria. Upon administration of meropenem trihydrate/vaborbactam, meropenem binds to and inactivates penicillin-binding proteins (PBPs) on the inner membrane of the bacterial cell wall, thereby interfering with the cross-linkage of peptidoglycan chains critical for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall and causes cell lysis. Vaborbactam binds to and inhibits beta-lactamase, thereby inhibiting the breakdown of meropenem, and increases the activity and therapeutic effect of meropenem.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Meropenem Trihydrate/Vaborbactam","conceptCode":"C189976","definition":"A fixed two-agent injectable combination of the trihydrate form of meropenem, a broad-spectrum synthetic beta-lactam carbapenem antibiotic, and vaborbactam, a cyclic boronic acid beta-lactamase inhibitor, with antibacterial activity against susceptible bacteria. Upon administration of meropenem trihydrate/vaborbactam, meropenem binds to and inactivates penicillin-binding proteins (PBPs) on the inner membrane of the bacterial cell wall, thereby interfering with the cross-linkage of peptidoglycan chains critical for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall and causes cell lysis. Vaborbactam binds to and inhibits beta-lactamase, thereby inhibiting the breakdown of meropenem, and increases the activity and therapeutic effect of meropenem.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9381459-BFB1-4825-E053-731AD00AFDBE","latestVersionIndicator":"Yes","beginDate":"2022-09-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-09-21","modifiedBy":"GDEEN","dateModified":"2022-09-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E9381459-BFB7-4825-E053-731AD00AFDBE","beginDate":"2022-09-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-09-21","modifiedBy":"GDEEN","dateModified":"2022-09-21","deletedIndicator":"No"},{"value":"Dolutegravir Sodium/Rilpivirine Hydrochloride","valueDescription":null,"ValueMeaning":{"publicId":"11289984","version":"1","preferredName":"Dolutegravir Sodium/Rilpivirine Hydrochloride","longName":"11289984v1.00","preferredDefinition":"A fixed two-agent combination of the sodium salt form of dolutegravir, a human immunodeficiency virus type 1 (HIV-1) integrase strand-transfer inhibitor (INSTI) and the hydrochloride salt form of rilpivirine, a non-nucleoside reverse transcriptase (RT) inhibitor (NNRTI), that may be used to treat HIV infection. Upon oral administration of dolutegravir sodium/rilpivirine hydrochloride, dolutegravir binds to the active site of integrase, an HIV enzyme that catalyzes the transfer of viral genetic material into human chromosomes. This prevents integrase from binding to retroviral deoxyribonucleic acid (DNA), and blocks the strand transfer step, which is essential for the HIV replication cycle. Rilpivirine binds to HIV RT, thereby blocking RNA and DNA-dependent DNA polymerase activities including viral replication, thereby further preventing HIV-1 replication.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dolutegravir Sodium/Rilpivirine Hydrochloride","conceptCode":"C189974","definition":"A fixed two-agent combination of the sodium salt form of dolutegravir, a human immunodeficiency virus type 1 (HIV-1) integrase strand-transfer inhibitor (INSTI and the hydrochloride salt form of rilpivirine, a non-nucleoside reverse transcriptase (RT) inhibitor (NNRTI), that may be used to treat HIV infection. Upon oral administration of dolutegravir sodium/rilpivirine hydrochloride, dolutegravir binds to the active site of integrase, an HIV enzyme that catalyzes the transfer of viral genetic material into human chromosomes. This prevents integrase from binding to retroviral deoxyribonucleic acid (DNA), and blocks the strand transfer step, which is essential for the HIV replication cycle. Rilpivirine binds to HIV RT, thereby blocking RNA and DNA-dependent DNA polymerase activities including viral replication, thereby further preventing HIV-1 replication.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9389882-E553-5E85-E053-731AD00A5B1E","latestVersionIndicator":"Yes","beginDate":"2022-09-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-09-21","modifiedBy":"GDEEN","dateModified":"2022-09-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E9389882-E554-5E85-E053-731AD00A5B1E","beginDate":"2022-09-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-09-21","modifiedBy":"GDEEN","dateModified":"2022-09-21","deletedIndicator":"No"},{"value":"Remdesivir","valueDescription":null,"ValueMeaning":{"publicId":"7850277","version":"1","preferredName":"Remdesivir","longName":"7850277","preferredDefinition":"A prodrug of an adenosine triphosphate (ATP) analog, with potential antiviral activity against a variety of RNA viruses. Upon administration, remdesivir, being a prodrug, is metabolized into its active form GS-441524. As an ATP analog, GS-441524 competes with ATP for incorporation into RNA and inhibits the action of viral RNA-dependent RNA polymerase. This results in the termination of RNA transcription and decreases viral RNA production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Remdesivir","conceptCode":"C152185","definition":"A prodrug of an adenosine triphosphate (ATP) analog, with potential antiviral activity against a variety of RNA viruses. Upon administration, remdesivir, being a prodrug, is metabolized into its active form GS-441524. As an ATP analog, GS-441524 competes with ATP for incorporation into RNA and inhibits the action of viral RNA-dependent RNA polymerase. This results in the termination of RNA transcription and decreases viral RNA production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2B8E3D6-7E97-4D8B-E053-4EBD850A5E4B","latestVersionIndicator":"Yes","beginDate":"2021-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-12-09","modifiedBy":"GDEEN","dateModified":"2022-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E947B1B2-909E-02A3-E053-731AD00A1F55","beginDate":"2022-09-22","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-09-22","modifiedBy":"GDEEN","dateModified":"2022-09-22","deletedIndicator":"No"},{"value":"Elderberry","valueDescription":null,"ValueMeaning":{"publicId":"11555879","version":"1","preferredName":"Sambucus ebulus","longName":"11555879v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sambucus ebulus","conceptCode":"C74320","definition":"No value exists.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ECE8721C-ECEA-2557-E053-731AD00A7F7C","latestVersionIndicator":"Yes","beginDate":"2022-11-07","endDate":null,"createdBy":"BMAESKE","dateCreated":"2022-11-07","modifiedBy":"BMAESKE","dateModified":"2022-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ECE8721C-ECEC-2557-E053-731AD00A7F7C","beginDate":"2022-11-07","endDate":null,"createdBy":"BMAESKE","dateCreated":"2022-11-07","modifiedBy":"BMAESKE","dateModified":"2022-11-07","deletedIndicator":"No"},{"value":"Dried yeast","valueDescription":null,"ValueMeaning":{"publicId":"11555880","version":"1","preferredName":"Yeast, Dried","longName":"11555880v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yeast","conceptCode":"C66676","definition":"No value exists.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ECE8721C-ECEB-2557-E053-731AD00A7F7C","latestVersionIndicator":"Yes","beginDate":"2022-11-07","endDate":null,"createdBy":"BMAESKE","dateCreated":"2022-11-07","modifiedBy":"BMAESKE","dateModified":"2022-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ECE8721C-ECED-2557-E053-731AD00A7F7C","beginDate":"2022-11-07","endDate":null,"createdBy":"BMAESKE","dateCreated":"2022-11-07","modifiedBy":"BMAESKE","dateModified":"2022-11-07","deletedIndicator":"No"},{"value":"Acetaminophen/Tramadol","valueDescription":null,"ValueMeaning":{"publicId":"12093849","version":"1","preferredName":"Acetaminophen/Tramadol (Tramacet)","longName":"12093849v1.00","preferredDefinition":"A combination preparation of the non-opiate, non-salicylate analgesic acetaminophen and the centrally acting synthetic opioid analgesic tramadol, with analgesic activity. Upon oral administration, acetaminophen exerts its analgesic activity by inhibiting prostaglandin synthesis, while tramadol exerts its analgesic activity by multiple mechanisms including the binding to the mu-opioid receptors in the central nervous system (CNS) and the weak inhibition of norepinephrine and serotonin reuptake.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acetaminophen/Tramadol","conceptCode":"C190844","definition":"A combination preparation of the non-opiate, non-salicylate analgesic acetaminophen and the centrally acting synthetic opioid analgesic tramadol, with analgesic activity. Upon oral administration, acetaminophen exerts its analgesic activity by inhibiting prostaglandin synthesis, while tramadol exerts its analgesic activity by multiple mechanisms including the binding to the mu-opioid receptors in the central nervous system (CNS) and the weak inhibition of norepinephrine and serotonin reuptake.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDB4E65C-0A64-0187-E053-731AD00A269E","latestVersionIndicator":"Yes","beginDate":"2022-11-17","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-11-17","modifiedBy":"GDEEN","dateModified":"2022-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDB4E65C-0A68-0187-E053-731AD00A269E","beginDate":"2022-11-17","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-11-17","modifiedBy":"GDEEN","dateModified":"2022-11-17","deletedIndicator":"No"},{"value":"Bintrafusp Alfa","valueDescription":null,"ValueMeaning":{"publicId":"7405919","version":"1","preferredName":"Bintrafusp Alfa","longName":"7405919","preferredDefinition":"A bifunctional fusion protein composed of avelumab, an anti-programmed death ligand 1 (PD-L1) human monoclonal antibody, bound to the soluble extracellular domain of human transforming growth factor beta (TGFbeta) receptor type II (TGFbetaRII), with potential antineoplastic and immune checkpoint modulating activities. Upon administration, the TGFbetaRII moiety of bintrafusp alfa binds to and neutralizes TGFbeta while the avelumab moiety simultaneously binds to PD-L1. This prevents TGFbeta- and PD-L1-mediated signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This inhibits tumor cell proliferation in susceptible tumor cells. TGFbeta and PD-L1 are both upregulated in certain types of cancers; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bintrafusp Alfa","conceptCode":"C124229","definition":"A bifunctional fusion protein composed of an anti-programmed death ligand 1 (PD-L1) human monoclonal antibody, bound to the soluble extracellular domain of human transforming growth factor beta (TGFbeta) receptor type II (TGFbetaRII), with potential antineoplastic and immune checkpoint modulating activities. Upon administration, bintrafusp alfa binds to and neutralizes activated TGFbeta and binds to PD-L1. This prevents TGFbeta- and PD-L1-mediated signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This inhibits tumor cell proliferation in susceptible tumor cells. TGFbeta and PD-L1 are both upregulated in certain types of cancers; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD63C989-8500-2DA7-E053-4EBD850A8CE1","latestVersionIndicator":"Yes","beginDate":"2020-08-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2020-08-21","modifiedBy":"GDEEN","dateModified":"2022-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDB4E65C-0A69-0187-E053-731AD00A269E","beginDate":"2022-11-17","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-11-17","modifiedBy":"GDEEN","dateModified":"2022-11-17","deletedIndicator":"No"},{"value":"Enclomiphene Citrate","valueDescription":null,"ValueMeaning":{"publicId":"12093850","version":"1","preferredName":"Enclomiphene Citrate (Androxal)","longName":"12093850v1.00","preferredDefinition":"The orally bioavailable citrate salt of enclomiphene, the trans-isomer of the nonsteroidal triphenylethylene compound clomiphene, with tissue-selective estrogenic and antiestrogenic activities. As a selective estrogen receptor modulator (SERM), enclomiphene binds to hypothalamic estrogen receptors, blocking the negative feedback of endogenous estrogens and stimulating the release of gonadotropin-releasing hormone (GnRH) from the hypothalamus; released GnRH subsequently stimulates the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary, resulting in ovulation. In addition, this agent may bind to estrogen receptors on breast cancer cells, resulting in the inhibition of estrogen-stimulated proliferation in susceptible cell populations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Enclomiphene Citrate","conceptCode":"C61745","definition":"The orally bioavailable citrate salt of enclomiphene, the trans-isomer of the nonsteroidal triphenylethylene compound clomiphene, with tissue-selective estrogenic and antiestrogenic activities. As a selective estrogen receptor modulator (SERM), enclomiphene binds to hypothalamic estrogen receptors, blocking the negative feedback of endogenous estrogens and stimulating the release of gonadotropin-releasing hormone (GnRH) from the hypothalamus; released GnRH subsequently stimulates the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary, resulting in ovulation. In addition, this agent may bind to estrogen receptors on breast cancer cells, resulting in the inhibition of estrogen-stimulated proliferation in susceptible cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDB4E65C-0A65-0187-E053-731AD00A269E","latestVersionIndicator":"Yes","beginDate":"2022-11-17","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-11-17","modifiedBy":"GDEEN","dateModified":"2022-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDB4E65C-0A6A-0187-E053-731AD00A269E","beginDate":"2022-11-17","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-11-17","modifiedBy":"GDEEN","dateModified":"2022-11-17","deletedIndicator":"No"},{"value":"Ibutamoren Mesylate","valueDescription":null,"ValueMeaning":{"publicId":"12093851","version":"1","preferredName":"Ibutamoren Mesylate (Nutrobal)","longName":"12093851v1.00","preferredDefinition":"The mesylate salt form of ibutamoren, an orally bioavailable, small molecule, non-peptide growth hormone secretagogue (GHS). Upon administration, ibutamoren promotes the release of growth hormone (GH) from the pituitary gland, thereby increasing plasma GH levels. This may counteract GH deficiency. GH plays an important role in many biological processes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ibutamoren Mesylate","conceptCode":"C97489","definition":"The mesylate salt form of ibutamoren, an orally bioavailable, small molecule, non-peptide growth hormone secretagogue (GHS). Upon administration, ibutamoren promotes the release of growth hormone (GH) from the pituitary gland, thereby increasing plasma GH levels. This may counteract GH deficiency. GH plays an important role in many biological processes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDB4E65C-0A66-0187-E053-731AD00A269E","latestVersionIndicator":"Yes","beginDate":"2022-11-17","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-11-17","modifiedBy":"GDEEN","dateModified":"2022-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDB4E65C-0A6B-0187-E053-731AD00A269E","beginDate":"2022-11-17","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-11-17","modifiedBy":"GDEEN","dateModified":"2022-11-17","deletedIndicator":"No"},{"value":"Methionine/Inositol/Choline Chloride/Cyanocobalamin Injection","valueDescription":null,"ValueMeaning":{"publicId":"12093852","version":"1","preferredName":"Methionine/Inositol/Choline Chloride/Cyanocobalamin Injection (Lipo-B (MIC) injection)","longName":"12093852v1.00","preferredDefinition":"An injectable preparation composed of the four ingredients methionine, inositol, choline chloride and cyanocobalamin, with potential lipotropic activity. Upon administration of methionine/inositol/choline chloride/cyanocobalamin injection, the active ingredients may exert lipotropic effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methionine/Inositol/Choline Chloride/Cyanocobalamin Injection","conceptCode":"C190845","definition":"An injectable preparation composed of the four ingredients methionine, inositol, choline chloride and cyanocobalamin, with potential lipotropic activity. Upon administration of methionine/inositol/choline chloride/cyanocobalamin injection, the active ingredients may exert lipotropic effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDB4E65C-0A67-0187-E053-731AD00A269E","latestVersionIndicator":"Yes","beginDate":"2022-11-17","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-11-17","modifiedBy":"GDEEN","dateModified":"2022-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDB4E65C-0A6C-0187-E053-731AD00A269E","beginDate":"2022-11-17","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-11-17","modifiedBy":"GDEEN","dateModified":"2022-11-17","deletedIndicator":"No"},{"value":"Nivolumab","valueDescription":null,"ValueMeaning":{"publicId":"4899197","version":"1","preferredName":"Receiving Nivolumab","longName":"4899197","preferredDefinition":"A fully human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1/PCD-1) with immunopotentiation activity. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands PD-L1 and PD-L2, resulting in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and effector function through the suppression of P13k/Akt pathway activation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nivolumab","conceptCode":"C68814","definition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1ADCA2DB-E931-C902-E050-BB89AD437CFF","latestVersionIndicator":"Yes","beginDate":"2015-07-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2015-07-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDB4E65C-0A6D-0187-E053-731AD00A269E","beginDate":"2022-11-17","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-11-17","modifiedBy":"GDEEN","dateModified":"2022-11-17","deletedIndicator":"No"},{"value":"Cobalamin","valueDescription":null,"ValueMeaning":{"publicId":"2577835","version":"1","preferredName":"Vitamin B12","longName":"2577835","preferredDefinition":"A cobalt-containing coordination compound produced by intestinal micro-organisms and found also in soil and water. Higher plants do not concentrate vitamin B 12 from the soil and so are a poor source of the substance as compared with animal tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cobalamin","conceptCode":"C939","definition":"An essential nutrient and natural water-soluble vitamin of the B-complex family that must combine with an intrinsic factor for absorption by the intestine, Vitamin B12 (cyanocobalamin) is necessary for hematopoiesis, neural metabolism, DNA and RNA production, and carbohydrate, fat, and protein metabolism. B12 improves iron functions in the metabolic cycle and assists folic acid in choline synthesis. B12 metabolism is interconnected with that of folic acid. Vitamin B12 deficiency causes pernicious anemia, megaloblastic anemia, and neurologic lesions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD18-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-21","modifiedBy":"GDEEN","dateModified":"2022-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDB57881-7FE9-1A7E-E053-731AD00A1DA3","beginDate":"2022-11-17","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-11-17","modifiedBy":"GDEEN","dateModified":"2022-11-17","deletedIndicator":"No"},{"value":"Copanlisib","valueDescription":null,"ValueMeaning":{"publicId":"12117784","version":"1","preferredName":"Copanlisib Hydrochloride (Aliqopa)","longName":"12117784v1.00","preferredDefinition":"The dihydrochloride salt form of copanlisib, a phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Copanlisib Hydrochloride","conceptCode":"C138994","definition":"The dihydrochloride salt form of copanlisib, a phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EEA771CA-4F81-4CFD-E053-731AD00A43EC","latestVersionIndicator":"Yes","beginDate":"2022-11-29","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-11-29","modifiedBy":"GDEEN","dateModified":"2022-11-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EEA783B7-6376-4FB3-E053-731AD00A9340","beginDate":"2022-11-29","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-11-29","modifiedBy":"GDEEN","dateModified":"2022-11-29","deletedIndicator":"No"},{"value":"Vortioxetine Hydrobromide","valueDescription":null,"ValueMeaning":{"publicId":"12127874","version":"1","preferredName":"Vortioxetine Hydrobromide (Trintellix)","longName":"12127874v1.00","preferredDefinition":"A hydrobromide salt form of vortioxetine, a serotonin (5-HT) modulator and stimulator (SMS), with antidepressant activity. Vortioxetine inhibits the reuptake of serotonin and norepinephrine from the synaptic cleft and acts variably as a serotonin receptor agonist (5-HT1A), partial agonist (5-HT1B) or antagonist (5-HT3, 5-HT1D and 5-HT7). It is not clear how this agent's purported multimodal mechanism of action contributes to its antidepressant effect; however, it is presumed to increase the synaptic availability of serotonin and norepinephrine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vortioxetine Hydrobromide","conceptCode":"C125653","definition":"A hydrobromide salt form of vortioxetine, a serotonin (5-HT) modulator and stimulator (SMS), with antidepressant activity. Vortioxetine inhibits the reuptake of serotonin and norepinephrine from the synaptic cleft and acts variably as a serotonin receptor agonist (5-HT1A), partial agonist (5-HT1B) or antagonist (5-HT3, 5-HT1D and 5-HT7). It is not clear how this agent's purported multimodal mechanism of action contributes to its antidepressant effect; however, it is presumed to increase the synaptic availability of serotonin and norepinephrine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EF354FFA-1174-5D37-E053-731AD00AFA66","latestVersionIndicator":"Yes","beginDate":"2022-12-06","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-12-06","modifiedBy":"GDEEN","dateModified":"2022-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EF3F52EE-F055-101A-E053-731AD00AEA6C","beginDate":"2022-12-07","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-12-07","modifiedBy":"GDEEN","dateModified":"2022-12-07","deletedIndicator":"No"},{"value":"Carboxymethylcellulose Sodium-containing Eye Drop","valueDescription":null,"ValueMeaning":{"publicId":"3777004","version":"1","preferredName":"Carboxymethylcellulose Sodium-containing Eye Drop","longName":"3777004","preferredDefinition":"An eye drop solution containing the sodium salt form of carboxymethylcellulose (CMC) used as artificial tears. Upon application of the drops into the eye, carboxymethylcellulose sodium lubricates the eye and prevents or relieves dryness and irritation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboxymethylcellulose Sodium-containing Eye Drop","conceptCode":"C106410","definition":"An eye drop solution containing the sodium salt form of carboxymethylcellulose (CMC) used as artificial tears. Upon application of the drops into the eye, carboxymethylcellulose sodium lubricates the eye and prevents or relieves dryness and irritation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DECE2246-538B-B502-E040-BB89AD4311C4","latestVersionIndicator":"Yes","beginDate":"2013-06-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-10","modifiedBy":"GDEEN","dateModified":"2022-12-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F032E55A-3C27-2E85-E053-731AD00A95DF","beginDate":"2022-12-19","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-12-19","modifiedBy":"GDEEN","dateModified":"2022-12-19","deletedIndicator":"No"},{"value":"Polyethylene Glycol 400/Propylene Glycol-containing Eye Drop","valueDescription":null,"ValueMeaning":{"publicId":"12173256","version":"1","preferredName":"Polyethylene Glycol 400/Propylene Glycol-containing Eye Drop (Systane)","longName":"12173256v1.00","preferredDefinition":"An eye drop solution containing polyethylene glycol (PEG) 400 and propylene glycol used for the relief of dry eye. Upon application of the drops into the eye, PEG 400 and propylene glycol lubricate the eye and relieve dryness and irritation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polyethylene Glycol 400/Propylene Glycol-containing Eye Drop","conceptCode":"C191779","definition":"An eye drop solution containing polyethylene glycol (PEG) 400 and propylene glycol used for the relief of dry eye. Upon application of the drops into the eye, PEG 400 and propylene glycol lubricate the eye and relieve dryness and irritation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F032E55A-3C26-2E85-E053-731AD00A95DF","latestVersionIndicator":"Yes","beginDate":"2022-12-19","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-12-19","modifiedBy":"GDEEN","dateModified":"2022-12-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F032E55A-3C28-2E85-E053-731AD00A95DF","beginDate":"2022-12-19","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-12-19","modifiedBy":"GDEEN","dateModified":"2022-12-19","deletedIndicator":"No"},{"value":"Mepivacaine Hydrochloride","valueDescription":null,"ValueMeaning":{"publicId":"12267130","version":"1","preferredName":"Mepivacaine Hydrochloride (Carbocaine)","longName":"12267130v1.00","preferredDefinition":"The hydrochloride salt form of mepivacaine, an amide derivative with local anesthetic properties.  At the injection site, mepivacaine hydrochloride acts by binding to specific membrane sodium ion channels in the neuronal cell membranes, thereby inhibiting sodium influx. This leads to a blockage of nerve impulse conduction and results in a loss of sensation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mepivacaine Hydrochloride","conceptCode":"C47602","definition":"The hydrochloride salt form of mepivacaine, an amide derivative with local anesthetic properties.  At the injection site, mepivacaine hydrochloride acts by binding to specific membrane sodium ion channels in the neuronal cell membranes, thereby inhibiting sodium influx. This leads to a blockage of nerve impulse conduction and results in a loss of sensation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F10F9205-BC32-2765-E053-731AD00A55C5","latestVersionIndicator":"Yes","beginDate":"2022-12-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-12-30","modifiedBy":"GDEEN","dateModified":"2022-12-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F10F9B29-F3F6-2836-E053-731AD00AB909","beginDate":"2022-12-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-12-30","modifiedBy":"GDEEN","dateModified":"2022-12-30","deletedIndicator":"No"},{"value":"Dronedarone Hydrochloride","valueDescription":null,"ValueMeaning":{"publicId":"12399014","version":"1","preferredName":"Dronedarone Hydrochloride","longName":"12399014v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dronedarone Hydrochloride","conceptCode":"C65486","definition":"The hydrochloride salt form of dronedarone, an orally bioavailable benzofuran derivative, with anti-arrhythmic activity. Upon oral administration, and although the exact mechanism of action through which dronedarone exerts its anti-arrhythmic effect has not been fully elucidated, it inhibits multiple voltage-gated ion channels, including sodium, potassium, and calcium ion channels, and restores the normal sinus rhythm and reduces heart rate in atrial fibrillation. It also non-competitively antagonizes adrenergic receptors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2900C2F-B833-39F8-E053-731AD00A559E","latestVersionIndicator":"Yes","beginDate":"2023-01-18","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-01-18","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F2900C2F-B834-39F8-E053-731AD00A559E","beginDate":"2023-01-18","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-01-18","modifiedBy":"GDEEN","dateModified":"2023-01-18","deletedIndicator":"No"},{"value":"Vedolizumab","valueDescription":null,"ValueMeaning":{"publicId":"8115529","version":"1","preferredName":"Vedolizumab","longName":"8115529v1.00","preferredDefinition":"A recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the human lymphocyte Peyer's patch adhesion molecule 1 (LPAM-1; alpha4beta7; a4b7), with immunomodulating, anti-inflammatory, and potential antineoplastic activities. Upon administration, vedolizumab selectively binds to integrin a4b7 and prevents the binding of a4b7, expressed on the surface of a subset of T-lymphocytes, to its natural ligand, mucosal addressin cell adhesion molecule-1 (MAdCAM-1), which is mainly expressed on the surface of gut endothelial cells. This prevents a4b7-mediated signaling, adhesion of lymphocytes to the endothelium and the migration of T-lymphocytes across the endothelium into inflamed gastrointestinal (GI) tissue. By preventing this infiltration to the affected area, inflammation is reduced. The human lymphocyte a4b7 integrin, plays a key role in gastrointestinal (GI) inflammation; it is overexpressed in certain types of cancer cells. The alpha4beta7/MAdCAM-1 signaling pathway plays a critical role in the homing of T-lymphocytes to intestinal tissue.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vedolizumab","conceptCode":"C95798","definition":"A recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the human lymphocyte Peyer's patch adhesion molecule 1 (LPAM-1; alpha4beta7; a4b7), with immunomodulating, anti-inflammatory, and potential antineoplastic activities. Upon administration, vedolizumab selectively binds to integrin a4b7 and prevents the binding of a4b7, expressed on the surface of a subset of T-lymphocytes, to its natural ligand, mucosal addressin cell adhesion molecule-1 (MAdCAM-1), which is mainly expressed on the surface of gut endothelial cells. This prevents a4b7-mediated signaling, adhesion of lymphocytes to the endothelium and the migration of T-lymphocytes across the endothelium into inflamed gastrointestinal (GI) tissue. By preventing this infiltration to the affected area, inflammation is reduced. The human lymphocyte a4b7 integrin, plays a key role in gastrointestinal (GI) inflammation; it is overexpressed in certain types of cancer cells. The alpha4beta7/MAdCAM-1 signaling pathway plays a critical role in the homing of T-lymphocytes to intestinal tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DAD1A896-3E8E-0376-E053-4EBD850A20B1","latestVersionIndicator":"Yes","beginDate":"2022-03-22","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-22","modifiedBy":"GDEEN","dateModified":"2023-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F4124297-3098-4E64-E053-731AD00AD87B","beginDate":"2023-02-06","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-06","modifiedBy":"GDEEN","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"Trametinib Dimethyl Sulfoxide","valueDescription":null,"ValueMeaning":{"publicId":"12564909","version":"1","preferredName":"Trametinib Dimethyl Sulfoxide","longName":"12564909v1.00","preferredDefinition":"A dimethyl sulfoxide (DMSO) solvated form of trametinib, an orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and 2, with potential antineoplastic activity. Upon oral administration, trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity serine/threonine and tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trametinib Dimethyl Sulfoxide","conceptCode":"C152711","definition":"A dimethyl sulfoxide (DMSO) solvated form of trametinib, an orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and 2, with potential antineoplastic activity. Upon oral administration, trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity serine/threonine and tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F49F7251-D8A2-3657-E053-731AD00A34EB","latestVersionIndicator":"Yes","beginDate":"2023-02-13","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-13","modifiedBy":"GDEEN","dateModified":"2023-02-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F49F7251-D8A3-3657-E053-731AD00A34EB","beginDate":"2023-02-13","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-13","modifiedBy":"GDEEN","dateModified":"2023-02-13","deletedIndicator":"No"},{"value":"COVID-19 Vaccine","valueDescription":null,"ValueMeaning":{"publicId":"7740207","version":"1","preferredName":"COVID-19 Vaccine","longName":"7740207","preferredDefinition":"Any vaccine that may prevent coronavirus disease-2019 (COVID-19) that is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"COVID-19 Vaccine","conceptCode":"C173023","definition":"Any vaccine that may prevent coronavirus disease-2019 (COVID-19) that is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C71BAD22-0445-14D8-E053-4EBD850A0409","latestVersionIndicator":"Yes","beginDate":"2021-07-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-07-14","modifiedBy":"ONEDATA","dateModified":"2021-07-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F4AE3FE4-D9F4-2999-E053-731AD00AB3F8","beginDate":"2023-02-14","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-14","modifiedBy":"GDEEN","dateModified":"2023-02-14","deletedIndicator":"No"},{"value":"Dofetilide","valueDescription":null,"ValueMeaning":{"publicId":"13314838","version":"1","preferredName":"Dofetilide (Tikosyn)","longName":"13314838v1.00","preferredDefinition":"A sulfonamide class III antiarrhythmic agent and potassium channel blocker. Dofetilide selectively blocks cardiac ion channels of the rapid component of the delayed rectifier potassium current Ikr. This antiarrhythmic agent prolongs cardiac action potential duration and effective refractory period due to delayed repolarization without affecting conduction velocity. This results in a normal sinus rhythm. Dofetilide is used in the treatment of atrial fibrillation and flutter.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dofetilide","conceptCode":"C47499","definition":"A sulfonamide class III antiarrhythmic agent and potassium channel blocker. Dofetilide selectively blocks cardiac ion channels of the rapid component of the delayed rectifier potassium current Ikr. This antiarrhythmic agent prolongs cardiac action potential duration and effective refractory period due to delayed repolarization without affecting conduction velocity. This results in a normal sinus rhythm. Dofetilide is used in the treatment of atrial fibrillation and flutter.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F89A9A30-A662-0203-E053-731AD00AAD9D","latestVersionIndicator":"Yes","beginDate":"2023-04-05","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-05","modifiedBy":"GDEEN","dateModified":"2023-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F89A9A30-A664-0203-E053-731AD00AAD9D","beginDate":"2023-04-05","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-05","modifiedBy":"GDEEN","dateModified":"2023-04-05","deletedIndicator":"No"},{"value":"Aryl Hydrocarbon Receptor Inhibitor IK-175","valueDescription":null,"ValueMeaning":{"publicId":"13314839","version":"1","preferredName":"Aryl Hydrocarbon Receptor Inhibitor IK-175","longName":"13314839v1.00","preferredDefinition":"An orally bioavailable selective inhibitor of the aryl hydrocarbon receptor (AhR; class E basic helix-loop-helix protein 76; bHLHe76), with potential immunomodulating and antineoplastic activities. Upon oral administration, AhR inhibitor IK-175 specifically targets and binds to AhR, inhibits AhR activation, prevents AhR-mediated signaling, and AhR-dependent tumor cell proliferation. Abrogation of AhR activation prevents the activation of immune-tolerant dendritic cells (DCs), regulatory T-cells (Tregs) and decreases suppressive cytokines in the tumor microenvironment (TME). It stimulates cytotoxic T-cell activation and expansion. This may restore the immune response against tumor cells. AhR, a member of the basic helix-loop-helix/Per-Arnt-Sim (bHLH/PAS) family of transcription factors, plays key roles in regulating immunity and cellular differentiation. It mediates the expression of multiple immune related and tumor cell signal transduction and proliferation genes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aryl Hydrocarbon Receptor Inhibitor IK-175","conceptCode":"C171151","definition":"An orally bioavailable selective inhibitor of the aryl hydrocarbon receptor (AhR; class E basic helix-loop-helix protein 76; bHLHe76), with potential immunomodulating and antineoplastic activities. Upon oral administration, AhR inhibitor IK-175 specifically targets and binds to AhR, inhibits AhR activation, prevents AhR-mediated signaling, and AhR-dependent tumor cell proliferation. Abrogation of AhR activation prevents the activation of immune-tolerant dendritic cells (DCs), regulatory T-cells (Tregs) and decreases suppressive cytokines in the tumor microenvironment (TME). It stimulates cytotoxic T-cell activation and expansion. This may restore the immune response against tumor cells. AhR, a member of the basic helix-loop-helix/Per-Arnt-Sim (bHLH/PAS) family of transcription factors, plays key roles in regulating immunity and cellular differentiation. It mediates the expression of multiple immune related and tumor cell signal transduction and proliferation genes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F89A9A30-A663-0203-E053-731AD00AAD9D","latestVersionIndicator":"Yes","beginDate":"2023-04-05","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-05","modifiedBy":"GDEEN","dateModified":"2023-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F89A9A30-A665-0203-E053-731AD00AAD9D","beginDate":"2023-04-05","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-05","modifiedBy":"GDEEN","dateModified":"2023-04-05","deletedIndicator":"No"},{"value":"Evolocumab","valueDescription":null,"ValueMeaning":{"publicId":"13526867","version":"1","preferredName":"Evolocumab","longName":"13526867v1.00","preferredDefinition":"A human immunoglobulin G2 (IgG2) monoclonal antibody directed against human proprotein convertase subtilisin/kexin type 9 (PCSK9), that can be used in the treatment of hypercholesterolemia. Upon administration, evolocumab targets, binds to and inhibits the activity of PCSK9. This prevents binding of PCSK9 to low-density lipoprotein receptor (LDLR) on hepatocytes and prevents its degradation. This increases LDLR on hepatocytes and increases the liver's ability to remove LDL cholesterol (LDL-C) from the blood, thereby lowering LDL-C levels. PCSK9 binds to LDLR on the surface of hepatocytes to promote LDLR degradation within the liver.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Evolocumab","conceptCode":"C174672","definition":"A human immunoglobulin G2 (IgG2) monoclonal antibody directed against human proprotein convertase subtilisin/kexin type 9 (PCSK9), that can be used in the treatment of hypercholesterolemia. Upon administration, evolocumab targets, binds to and inhibits the activity of PCSK9. This prevents binding of PCSK9 to low-density lipoprotein receptor (LDLR) on hepatocytes and prevents its degradation. This increases LDLR on hepatocytes and increases the liver's ability to remove LDL cholesterol (LDL-C) from the blood, thereby lowering LDL-C levels. PCSK9 binds to LDLR on the surface of hepatocytes to promote LDLR degradation within the liver.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FB322F82-DB81-2FB1-E053-731AD00A5A67","latestVersionIndicator":"Yes","beginDate":"2023-05-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-08","modifiedBy":"GDEEN","dateModified":"2023-05-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FB322F82-DB85-2FB1-E053-731AD00A5A67","beginDate":"2023-05-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-08","modifiedBy":"GDEEN","dateModified":"2023-05-08","deletedIndicator":"No"},{"value":"Ziv-Aflibercept","valueDescription":null,"ValueMeaning":{"publicId":"3880514","version":"1","preferredName":"Aflibercept","longName":"3880514v1.00","preferredDefinition":"A recombinant protein comprised of epitopes of the extracellular domains of human vascular endothelial growth factor receptors (VEGFR) fused to the constant region (Fc) of human IgG1 with potential antiangiogenic activity. Afilbercept, functioning as a soluble decoy receptor, binds to pro-angiogenic vascular endothelial growth factors (VEGFs), thereby preventing VEGFs from binding to their endogenous receptors. Disruption of the binding of VEGFs to their cellular receptors may result in the inhibition of tumor angiogenesis, metastasis, and ultimately tumor regression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ziv-Aflibercept","conceptCode":"C2682","definition":"A recombinant protein comprised of epitopes of the extracellular domains of human vascular endothelial growth factor receptors (VEGFR) fused to the constant region (Fc) of human IgG1 with potential antiangiogenic activity. Afilbercept, functioning as a soluble decoy receptor, binds to pro-angiogenic vascular endothelial growth factors (VEGFs), thereby preventing VEGFs from binding to their endogenous receptors. Disruption of the binding of VEGFs to their cellular receptors may result in the inhibition of tumor angiogenesis, metastasis, and ultimately tumor regression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5B6AC0C-2D46-A8F1-E040-BB89AD43573C","latestVersionIndicator":"Yes","beginDate":"2013-09-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-06","modifiedBy":"GDEEN","dateModified":"2023-05-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FB322F82-DB86-2FB1-E053-731AD00A5A67","beginDate":"2023-05-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-08","modifiedBy":"GDEEN","dateModified":"2023-05-08","deletedIndicator":"No"},{"value":"Tofacitinib Citrate","valueDescription":null,"ValueMeaning":{"publicId":"13526868","version":"1","preferredName":"Tofacitinib Citrate","longName":"13526868v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tofacitinib Citrate","conceptCode":"C95801","definition":"The citrate salt form of tofacitinib, an orally bioavailable inhibitor of Janus kinases (JAK), with immunomodulatory and anti-inflammatory activities. Upon oral administration, tofacitinib binds to JAK and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This may decrease the production of pro-inflammatory cytokines, such as interleukin (IL)-6, -7, -15, -21, interferon-alpha (IFN-a) and -beta (IFN-b), and may prevent both an inflammatory response and the inflammation-induced damage caused by certain immunological diseases. JAK kinases are intracellular enzymes involved in signaling pathways affecting hematopoiesis, immunity and inflammation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FB322F82-DB82-2FB1-E053-731AD00A5A67","latestVersionIndicator":"Yes","beginDate":"2023-05-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-08","modifiedBy":"GDEEN","dateModified":"2023-05-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FB322F82-DB87-2FB1-E053-731AD00A5A67","beginDate":"2023-05-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-08","modifiedBy":"GDEEN","dateModified":"2023-05-08","deletedIndicator":"No"},{"value":"Cariprazine hydrochloride","valueDescription":null,"ValueMeaning":{"publicId":"13526869","version":"1","preferredName":"Cariprazine hydrochloride","longName":"13526869v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cariprazine Hydrochloride","conceptCode":"C169827","definition":"The hydrochloride salt form of cariprazine, an orally bioavailable partial agonist of the dopamine D2 and D3 receptors, a partial agonist of the serotonin 1A (5-HT1A) receptor, and an antagonist of the serotonin 2A (5-HT2A) and 2B (5-HT2B) receptors, with antipsychotic activity. Although its exact mechanism of action in schizophrenia is unknown, it has been proposed that cariprazine's antipsychotic activity is mediated through a combination of agonist and antagonist activities at various dopamine and serotonin receptors, particularly through its partial agonist activity at central dopamine D2 and 5-HT1A receptors, and its antagonist activity at 5-HT2A receptor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FB322F82-DB83-2FB1-E053-731AD00A5A67","latestVersionIndicator":"Yes","beginDate":"2023-05-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-08","modifiedBy":"GDEEN","dateModified":"2023-05-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FB322F82-DB88-2FB1-E053-731AD00A5A67","beginDate":"2023-05-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-08","modifiedBy":"GDEEN","dateModified":"2023-05-08","deletedIndicator":"No"},{"value":"Bempedoic Acid/Ezetimibe","valueDescription":null,"ValueMeaning":{"publicId":"13526870","version":"1","preferredName":"Bempedoic Acid/Ezetimibe","longName":"13526870v1.00","preferredDefinition":"An orally bioavailable combination agent containing the prodrug bempedoic acid, an inhibitor of adenosine triphosphate-citrate lyase (ACL) and ezetimibe, a cholesterol absorption inhibitor, with lipid-lowering activity. Upon oral administration of bempedoic acid/ezetimibe, ezetimibe binds to the sterol transporter Niemann-Pick C1-Like 1 (NPC1L1) at the brush border of the small intestine and inhibits the intestinal absorption of biliary and dietary cholesterol and related phytosterols. This decreases blood cholesterol levels, decreases the delivery of intestinal cholesterol to the liver, reduces hepatic cholesterol stores and enhances the clearance of cholesterol from the bloodstream. Bempedoic acid is activated to its thioester form with coenzyme A (CoA) by the enzyme very long-chain acyl-CoA synthetase 1 (ACSVL1; SLC27A2) in the liver and inhibits ACL, thereby preventing the liver's biosynthesis of cholesterol. This lowers low-density lipoprotein cholesterol (LDL-C) levels. ACL is an enzyme upstream of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase in the cholesterol biosynthesis pathway.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bempedoic Acid/Ezetimibe","conceptCode":"C199227","definition":"An orally bioavailable combination agent containing the prodrug bempedoic acid, an inhibitor of adenosine triphosphate-citrate lyase (ACL) and ezetimibe, a cholesterol absorption inhibitor, with lipid-lowering activity. Upon oral administration of bempedoic acid/ezetimibe, ezetimibe binds to the sterol transporter Niemann-Pick C1-Like 1 (NPC1L1) at the brush border of the small intestine and inhibits the intestinal absorption of biliary and dietary cholesterol and related phytosterols. This decreases blood cholesterol levels, decreases the delivery of intestinal cholesterol to the liver, reduces hepatic cholesterol stores and enhances the clearance of cholesterol from the bloodstream. Bempedoic acid is activated to its thioester form with coenzyme A (CoA) by the enzyme very long-chain acyl-CoA synthetase 1 (ACSVL1; SLC27A2) in the liver and inhibits ACL, thereby preventing the liver's biosynthesis of cholesterol. This lowers low-density lipoprotein cholesterol (LDL-C) levels. ACL is an enzyme upstream of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase in the cholesterol biosynthesis pathway.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FB322F82-DB84-2FB1-E053-731AD00A5A67","latestVersionIndicator":"Yes","beginDate":"2023-05-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-08","modifiedBy":"GDEEN","dateModified":"2023-05-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FB322F82-DB89-2FB1-E053-731AD00A5A67","beginDate":"2023-05-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-08","modifiedBy":"GDEEN","dateModified":"2023-05-08","deletedIndicator":"No"},{"value":"Semaglutide","valueDescription":null,"ValueMeaning":{"publicId":"13552970","version":"1","preferredName":"Semaglutide (Ozempic)","longName":"13552970v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Semaglutide","conceptCode":"C152328","definition":"A glucagon-like peptide-1 (GLP-1) receptor agonist that is 94% homologous to human GLP-1 (7-37), with antihyperglycemic and appetite regulating activities. Upon administration, semaglutide binds to and activates GLP-1 receptor. In pancreatic beta cells, this increases glucose-dependent insulin release. Semaglutide also reduces the elevated glucagon secretion by inhibiting alpha cells of the pancreas and slows gastric emptying. Altogether this lowers the postprandial glucose level. In the brain, the binding to and activation of GLP-1 receptor suppresses appetite, which decreases caloric intake and lowers body weight. GLP-1 is normally secreted by L cells of the gastrointestinal (GI) mucosa in response to a meal to normalize blood glucose levels. It also plays an important role in the regulation of appetite and caloric intake.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FB48ADCD-1958-299D-E053-731AD00ACF88","latestVersionIndicator":"Yes","beginDate":"2023-05-09","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-09","modifiedBy":"GDEEN","dateModified":"2023-05-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FB48ADCD-195A-299D-E053-731AD00ACF88","beginDate":"2023-05-09","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-09","modifiedBy":"GDEEN","dateModified":"2023-05-09","deletedIndicator":"No"},{"value":"Eye Multivitamin","valueDescription":null,"ValueMeaning":{"publicId":"13552971","version":"1","preferredName":"Eye Multivitamin (Macuhealth)","longName":"13552971v1.00","preferredDefinition":"The organ of sight or vision._A dietary supplement containing all or most of the vitamins that may not be readily available in the diet. Vitamins may be classified according to their solubility either in lipids (vitamins A, D, E, K, F) or in water (vitamins C, B-complex). Present in minute amounts in various foods, vitamins are essential to maintaining normal metabolism and biochemical functions. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eye","conceptCode":"C12401","definition":"The organ of sight or vision.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Multivitamin","conceptCode":"C1654","definition":"A dietary supplement containing all or most of the vitamins that may not be readily available in the diet. Vitamins may be classified according to their solubility either in lipids (vitamins A, D, E, K, F) or in water (vitamins C, B-complex). Present in minute amounts in various foods, vitamins are essential to maintaining normal metabolism and biochemical functions. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FB48ADCD-1959-299D-E053-731AD00ACF88","latestVersionIndicator":"Yes","beginDate":"2023-05-09","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-09","modifiedBy":"GDEEN","dateModified":"2023-05-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FB48ADCD-195B-299D-E053-731AD00ACF88","beginDate":"2023-05-09","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-09","modifiedBy":"GDEEN","dateModified":"2023-05-09","deletedIndicator":"No"},{"value":"Eslicarbazepine acetate","valueDescription":null,"ValueMeaning":{"publicId":"13569525","version":"1","preferredName":"Eslicarbazepine Acetate","longName":"13569525v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eslicarbazepine Acetate","conceptCode":"C83697","definition":"No value exists.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FB73A3B5-A41F-3903-E053-731AD00A8622","latestVersionIndicator":"Yes","beginDate":"2023-05-11","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-11","modifiedBy":"GDEEN","dateModified":"2023-05-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FB73A3B5-A421-3903-E053-731AD00A8622","beginDate":"2023-05-11","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-11","modifiedBy":"GDEEN","dateModified":"2023-05-11","deletedIndicator":"No"},{"value":"Remegepant sulfate","valueDescription":null,"ValueMeaning":{"publicId":"13569526","version":"1","preferredName":"Rimegepant Sulfate","longName":"13569526v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rimegepant Sulfate","conceptCode":"C152221","definition":"No value exists.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FB73A3B5-A420-3903-E053-731AD00A8622","latestVersionIndicator":"Yes","beginDate":"2023-05-11","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-11","modifiedBy":"GDEEN","dateModified":"2023-05-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FB73A3B5-A422-3903-E053-731AD00A8622","beginDate":"2023-05-11","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-11","modifiedBy":"GDEEN","dateModified":"2023-05-11","deletedIndicator":"No"},{"value":"Parenteral Nutrition","valueDescription":null,"ValueMeaning":{"publicId":"4720934","version":"1","preferredName":"Total Parenteral Nutrition","longName":"4720934","preferredDefinition":"Total parenteral nutrition formulated for intravenous administration in patients who cannot eat or cannot get enough nutrients from the foods they eat.  It is a liquid mixture of proteins, carbohydrates, fats, vitamins, minerals and other nutrients.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Total Parenteral Nutrition","conceptCode":"C29484","definition":"Total parenteral nutrition formulated for intravenous administration in patients who cannot eat or cannot get enough nutrients from the foods they eat.  It is a liquid mixture of proteins, carbohydrates, fats, vitamins, minerals and other nutrients.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F72D1C8-50A6-14D6-E050-BB89AD43702D","latestVersionIndicator":"Yes","beginDate":"2015-02-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-02-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FC72F7D1-E84A-7429-E053-731AD00A9CD3","beginDate":"2023-05-24","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-24","modifiedBy":"GDEEN","dateModified":"2023-05-24","deletedIndicator":"No"},{"value":"Ubrogepant","valueDescription":null,"ValueMeaning":{"publicId":"13673419","version":"1","preferredName":"Ubrogepant (Ubrelvy)","longName":"13673419v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ubrogepant","conceptCode":"C152790","definition":"An orally bioavailable calcitonin gene-related peptide (CGRP) receptor antagonist that can be used in the acute treatment of migraines. Upon oral administration, ubrogepant targets, binds to and blocks the activity of CGRP receptor. This prevents CGRP-mediated signaling. By blocking the CGRP-mediated pathways, ubrogepant is able to ease migraine symptoms, especially migraine headache pain. CGRP-mediated signaling plays a key role in migraine pathogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC880DFD-F848-496B-E053-731AD00A5074","latestVersionIndicator":"Yes","beginDate":"2023-05-25","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-25","modifiedBy":"GDEEN","dateModified":"2023-05-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FC880DFD-F84A-496B-E053-731AD00A5074","beginDate":"2023-05-25","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-25","modifiedBy":"GDEEN","dateModified":"2023-05-25","deletedIndicator":"No"},{"value":"Iodine/Thuja occidentalis/Echinancea-based Homeopathic Formulation","valueDescription":null,"ValueMeaning":{"publicId":"13673420","version":"1","preferredName":"Iodine/Thuja occidentalis/Echinancea-based Homeopathic Formulation (ZymaDerm)","longName":"13673420v1.00","preferredDefinition":"A topical, homeopathic liquid formulation composed of iodine derived from kelp extract, Thuja occidentalis whole and unspecified Echinacea, with potential topical anti-viral, anti-inflammatory and immunomodulatory activities, that may potentially be used in the treatment of Molluscum contagiosum. Upon topical administration to the affected area(s), iodine/Thuja occidentalis/Echinacea-based homeopathic formulation may help as an aid in the treatment of Molluscum contagiosum.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Iodine/Thuja occidentalis/Echinancea-based Homeopathic Formulation","conceptCode":"C199450","definition":"A topical, homeopathic liquid formulation composed of iodine derived from kelp extract, Thuja occidentalis whole and unspecified Echinacea, with potential topical anti-viral, anti-inflammatory and immunomodulatory activities, that may potentially be used in the treatment of Molluscum contagiosum. Upon topical administration to the affected area(s), iodine/Thuja occidentalis/Echinacea-based homeopathic formulation may help as an aid in the treatment of Molluscum contagiosum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC880DFD-F849-496B-E053-731AD00A5074","latestVersionIndicator":"Yes","beginDate":"2023-05-25","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-25","modifiedBy":"GDEEN","dateModified":"2023-05-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FC880DFD-F84B-496B-E053-731AD00A5074","beginDate":"2023-05-25","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-25","modifiedBy":"GDEEN","dateModified":"2023-05-25","deletedIndicator":"No"},{"value":"Antifungal Cream","valueDescription":null,"ValueMeaning":{"publicId":"13950078","version":"1","preferredName":"Antifungal Agent Topical Cream Dosage Form","longName":"13950078v1.00","preferredDefinition":"Substances that treat systemic or topical infections caused by fungi. Antifungal agents kill or inhibit the growth of fungi, by various mechanisms. These mechanisms include inhibition of fungal mitosis, impairing synthesis or binding to ergosterol, inhibition of RNA or DNA synthesis, and interfering with other fungal metabolic processes._A cream intended for administration to a body surface.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antifungal Agent","conceptCode":"C514","definition":"Substances that treat systemic or topical infections caused by fungi. Antifungal agents kill or inhibit the growth of fungi, by various mechanisms. These mechanisms include inhibition of fungal mitosis, impairing synthesis or binding to ergosterol, inhibition of RNA or DNA synthesis, and interfering with other fungal metabolic processes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Topical Cream Dosage Form","conceptCode":"C91187","definition":"A cream intended for administration to a body surface.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE20A283-142B-7D78-E053-731AD00A65C2","latestVersionIndicator":"Yes","beginDate":"2023-06-14","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-06-14","modifiedBy":"GDEEN","dateModified":"2023-06-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FE20A283-142D-7D78-E053-731AD00A65C2","beginDate":"2023-06-14","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-06-14","modifiedBy":"GDEEN","dateModified":"2023-06-14","deletedIndicator":"No"},{"value":"Topical Cream","valueDescription":null,"ValueMeaning":{"publicId":"13950079","version":"1","preferredName":"Topical Cream Dosage Form","longName":"13950079v1.00","preferredDefinition":"A cream intended for administration to a body surface.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Topical Cream Dosage Form","conceptCode":"C91187","definition":"A cream intended for administration to a body surface.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE20A283-142C-7D78-E053-731AD00A65C2","latestVersionIndicator":"Yes","beginDate":"2023-06-14","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-06-14","modifiedBy":"GDEEN","dateModified":"2023-06-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FE20A283-142E-7D78-E053-731AD00A65C2","beginDate":"2023-06-14","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-06-14","modifiedBy":"GDEEN","dateModified":"2023-06-14","deletedIndicator":"No"},{"value":"Pembrolizumab","valueDescription":null,"ValueMeaning":{"publicId":"5076693","version":"1","preferredName":"Pembrolizumab","longName":"5076693v1.00","preferredDefinition":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pembrolizumab","conceptCode":"C106432","definition":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2653AD7D-EB81-5B33-E050-BB89AD437FF5","latestVersionIndicator":"Yes","beginDate":"2015-12-07","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FFC07829-F603-2007-E053-731AD00A4C95","beginDate":"2023-07-05","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-05","modifiedBy":"GDEEN","dateModified":"2023-07-05","deletedIndicator":"No"},{"value":"Eluxadoline","valueDescription":null,"ValueMeaning":{"publicId":"14019538","version":"1","preferredName":"Eluxadoline","longName":"14019538v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eluxadoline","conceptCode":"C166725","definition":"No value exists.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FFD6E96E-1A0B-2F23-E053-731AD00A0C88","latestVersionIndicator":"Yes","beginDate":"2023-07-06","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-06","modifiedBy":"GDEEN","dateModified":"2023-07-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FFD6E96E-1A0C-2F23-E053-731AD00A0C88","beginDate":"2023-07-06","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-06","modifiedBy":"GDEEN","dateModified":"2023-07-06","deletedIndicator":"No"},{"value":"Pregnenolone","valueDescription":null,"ValueMeaning":{"publicId":"3799872","version":"1","preferredName":"Pregnenolone","longName":"3799872","preferredDefinition":"An endogenous steroid hormone synthesized from cholesterol, which can act either as a neuroactive steroid or as a prohormone for progestogens, mineralocorticoids, glucocorticoids, androgens, estrogens, and the neuroactive steroids.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pregnenolone","conceptCode":"C82315","definition":"An endogenous steroid hormone synthesized from cholesterol, which can act either as a neuroactive steroid or as a prohormone for progestogens, mineralocorticoids, glucocorticoids, androgens, estrogens, and the neuroactive steroids.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E0285152-B180-3145-E040-BB89AD436AA6","latestVersionIndicator":"Yes","beginDate":"2013-06-27","endDate":null,"createdBy":"COLBERTM","dateCreated":"2013-06-27","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"003847E2-4B82-7C1F-E063-731AD00A84FB","beginDate":"2023-07-11","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-11","modifiedBy":"GDEEN","dateModified":"2023-07-11","deletedIndicator":"No"},{"value":"ACR 368","valueDescription":null,"ValueMeaning":{"publicId":"6199779","version":"1","preferredName":"Prexasertib","longName":"6199779","preferredDefinition":"An inhibitor of checkpoint kinase 1 (chk1) with potential antineoplastic activity. Upon administration, prexasertib selectively binds to chk1, thereby preventing activity of chk1 and abrogating the repair of damaged DNA. This may lead to an accumulation of damaged DNA and may promote genomic instability and apoptosis. Prexasertib may potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapeutic agents. Chk1, a serine/threonine kinase, mediates cell cycle checkpoint control and is essential for DNA repair and plays a key role in resistance to chemotherapeutic agents.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prexasertib","conceptCode":"C91392","definition":"An inhibitor of checkpoint kinase 1 (chk1) with potential antineoplastic activity. Upon administration, prexasertib selectively binds to chk1, thereby preventing activity of chk1 and abrogating the repair of damaged DNA. This may lead to an accumulation of damaged DNA and may promote genomic instability and apoptosis. Prexasertib may potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapeutic agents. Chk1, a serine/threonine kinase, mediates cell cycle checkpoint control and is essential for DNA repair and plays a key role in resistance to chemotherapeutic agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"69FA0151-F9CE-2B31-E053-F662850A82BD","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-04-16","modifiedBy":"ONEDATA","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0040A160-2D08-6334-E063-731AD00A9977","beginDate":"2023-07-11","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-11","modifiedBy":"GDEEN","dateModified":"2023-07-11","deletedIndicator":"No"},{"value":"Alvimopan","valueDescription":null,"ValueMeaning":{"publicId":"14056144","version":"1","preferredName":"Alvimopan","longName":"14056144v1.00","preferredDefinition":"A synthetic trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine with peripherally selective opioid mu receptor antagonist activity. Alvimopan is a selective and competitive antagonist at mu-opioid receptors, found in myenteric and submucosal neurons and the immune cells of the lamina propria in the human gut. Upon administration, this agent binds to mu-opioid receptors in the gut, thereby reversing opioid-related disturbances in gut motility. Alvimopan is approximately three to nine times more potent than naloxone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alvimopan","conceptCode":"C49096","definition":"A synthetic trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine with peripherally selective opioid mu receptor antagonist activity. Alvimopan is a selective and competitive antagonist at mu-opioid receptors, found in myenteric and submucosal neurons and the immune cells of the lamina propria in the human gut. Upon administration, this agent binds to mu-opioid receptors in the gut, thereby reversing opioid-related disturbances in gut motility. Alvimopan is approximately three to nine times more potent than naloxone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"004092B1-9F08-616F-E063-731AD00A826C","latestVersionIndicator":"Yes","beginDate":"2023-07-11","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-11","modifiedBy":"GDEEN","dateModified":"2023-07-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0040A160-2D09-6334-E063-731AD00A9977","beginDate":"2023-07-11","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-11","modifiedBy":"GDEEN","dateModified":"2023-07-11","deletedIndicator":"No"},{"value":"Bedaquiline fumurate","valueDescription":null,"ValueMeaning":{"publicId":"14056247","version":"1","preferredName":"Bedaquiline Fumarate","longName":"14056247v1.00","preferredDefinition":"The fumarate salt form of bedaquiline, an orally bioavailable diarylquinoline antimycobacterial agent, that can be used in the treatment of pulmonary multi-drug resistant tuberculosis (MDR-TB). Upon oral administration, bedaquiline specifically binds to subunit c of Mycobacterium tuberculosis (M. tuberculosis) adenosine 5'-triphosphate (ATP) synthase, thereby preventing ATP synthase activity. This inhibits ATP synthesis in M. tuberculosis, thereby blocking its energy metabolism and killing M. tuberculosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bedaquiline Fumarate","conceptCode":"C142949","definition":"The fumarate salt form of bedaquiline, an orally bioavailable diarylquinoline antimycobacterial agent, that can be used in the treatment of pulmonary multi-drug resistant tuberculosis (MDR-TB). Upon oral administration, bedaquiline specifically binds to subunit c of Mycobacterium tuberculosis (M. tuberculosis) adenosine 5'-triphosphate (ATP) synthase, thereby preventing ATP synthase activity. This inhibits ATP synthesis in M. tuberculosis, thereby blocking its energy metabolism and killing M. tuberculosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"004BD7C4-7F6D-105A-E063-731AD00AF4DE","latestVersionIndicator":"Yes","beginDate":"2023-07-12","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-12","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"004BE0C2-C1E8-11D4-E063-731AD00AA466","beginDate":"2023-07-12","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-12","modifiedBy":"GDEEN","dateModified":"2023-07-12","deletedIndicator":"No"},{"value":"Lifitegrast","valueDescription":null,"ValueMeaning":{"publicId":"14059580","version":"1","preferredName":"Lifitegrast (Xiidra)","longName":"14059580v1.00","preferredDefinition":"A tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 (LFA-1) antagonist, that can be used as an ophthalmic solution for the treatment of dry eye disease (DED; keratoconjunctivitis sicca; dry eye syndrome). Upon ocular administration and although the exact mechanism of action of lifitegrast in DED is not fully known, lifitegrast targets and binds to the integrin LFA-1, a cell surface protein found on leukocytes. This prevents the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1). As ICAM-1 may be overexpressed in corneal and conjunctival tissues in DED, the blockage of the LFA-1/ICAM-1 interaction by lifitegrast may inhibit T-cell adhesion to ICAM-1 and may abrogate the formation of an immunological synapse. This may prevent T-cell proliferation, activation and migration and the release of pro-inflammatory cytokines in the corneal and conjunctival tissues. This may reduce inflammation, protect the corneal surface from inflammatory-mediated damage and reduce the symptoms of DED.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lifitegrast","conceptCode":"C175726","definition":"A tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 (LFA-1) antagonist, that can be used as an ophthalmic solution for the treatment of dry eye disease (DED; keratoconjunctivitis sicca; dry eye syndrome). Upon ocular administration and although the exact mechanism of action of lifitegrast in DED is not fully known, lifitegrast targets and binds to the integrin LFA-1, a cell surface protein found on leukocytes. This prevents the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1). As ICAM-1 may be overexpressed in corneal and conjunctival tissues in DED, the blockage of the LFA-1/ICAM-1 interaction by lifitegrast may inhibit T-cell adhesion to ICAM-1 and may abrogate the formation of an immunological synapse. This may prevent T-cell proliferation, activation and migration and the release of pro-inflammatory cytokines in the corneal and conjunctival tissues. This may reduce inflammation, protect the corneal surface from inflammatory-mediated damage and reduce the symptoms of DED.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0061E597-02DE-1CCA-E063-731AD00AED08","latestVersionIndicator":"Yes","beginDate":"2023-07-13","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-13","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0061F5E3-1495-1E9C-E063-731AD00A8DB7","beginDate":"2023-07-13","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-13","modifiedBy":"GDEEN","dateModified":"2023-07-13","deletedIndicator":"No"},{"value":"Bortezomib","valueDescription":null,"ValueMeaning":{"publicId":"5127395","version":"1","preferredName":"Bortezomib","longName":"5127395","preferredDefinition":"A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bortezomib","conceptCode":"C1851","definition":"A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FA1B-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"00F0023A-3FFB-1F0C-E063-731AD00A27CB","beginDate":"2023-07-20","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-20","modifiedBy":"GDEEN","dateModified":"2023-07-20","deletedIndicator":"No"},{"value":"Gilteritinib","valueDescription":null,"ValueMeaning":{"publicId":"6429350","version":"1","preferredName":"Gilteritinib","longName":"6429350","preferredDefinition":"An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-related tyrosine kinase 3 (FLT3, STK1, or FLK2), AXL (UFO or JTK11) and anaplastic lymphoma kinase (ALK or CD246), with potential antineoplastic activity. Gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL and ALK. This may result in an inhibition of FLT3, AXL, and ALK-mediated signal transduction pathways and reduces tumor cell proliferation in cancer cell types that overexpress these RTKs. FLT3, AXL and ALK, overexpressed or mutated in a variety of cancer cell types, play a key role in tumor cell growth and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gilteritinib","conceptCode":"C116722","definition":"An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK), with potential antineoplastic activity. Upon administration, gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL, ALK and LTK. This may result in an inhibition of FLT3-, AXL-, ALK-, and LTK-mediated signal transduction pathways and reduced proliferation in cancer cells that overexpress these RTKs. FLT3, AXL, ALK, and LTK, which are overexpressed or mutated in a variety of cancer cell types, play key roles in tumor cell growth and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"759B430D-D70B-045F-E053-F662850AB8F5","latestVersionIndicator":"Yes","beginDate":"2018-09-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-11","modifiedBy":"ONEDATA","dateModified":"2018-09-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"00F0023A-3FFC-1F0C-E063-731AD00A27CB","beginDate":"2023-07-20","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-20","modifiedBy":"GDEEN","dateModified":"2023-07-20","deletedIndicator":"No"},{"value":"Witch Hazel Rectal Pads","valueDescription":null,"ValueMeaning":{"publicId":"14114585","version":"1","preferredName":"Witch Hazel-containing Anti-Hemorroidal Formulation Rectal Pad Dosage Form","longName":"14114585v1.00","preferredDefinition":"A preparation containing witch hazel (Hamamelis virginiana) extract, with anti-pruritic activity. Witch hazel extract has been shown to inhibit alpha-glucosidase as well as human leukocyte elastase, enzymes which contribute to the degradation of connective tissue. Tucks hemorrhoidal wipes are used to relieve and soothe the irritation, burning and pruritis of hemorrhoidal tissue._Of or pertaining to the rectum._A solid composed of a soft, non-adhesive and absorbent piece of fabric or other material.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Witch Hazel-containing Anti-Hemorroidal Formulation","conceptCode":"C29525","definition":"A preparation containing witch hazel (Hamamelis virginiana) extract, with anti-pruritic activity. Witch hazel extract has been shown to inhibit alpha-glucosidase as well as human leukocyte elastase, enzymes which contribute to the degradation of connective tissue. Tucks hemorrhoidal wipes are used to relieve and soothe the irritation, burning and pruritis of hemorrhoidal tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Rectal","conceptCode":"C25224","definition":"Of or pertaining to the rectum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pad Dosage Form","conceptCode":"C69016","definition":"A solid composed of a soft, non-adhesive and absorbent piece of fabric or other material.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"00EFECB8-779E-12C6-E063-731AD00A8A11","latestVersionIndicator":"Yes","beginDate":"2023-07-20","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-20","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"00F0023A-3FFD-1F0C-E063-731AD00A27CB","beginDate":"2023-07-20","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-20","modifiedBy":"GDEEN","dateModified":"2023-07-20","deletedIndicator":"No"},{"value":"Bebtelovimab","valueDescription":null,"ValueMeaning":{"publicId":"14256422","version":"1","preferredName":"Bebtelovimab","longName":"14256422v1.00","preferredDefinition":"A neutralizing human immunoglobulin G1 (IgG1) monoclonal antibody, isolated from a patient who has recovered from the Coronavirus disease 2019 (COVID-19), directed against the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19. Upon administration, bebtelovimab specifically targets and binds to the receptor-binding domain (RBD) of SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bebtelovimab","conceptCode":"C182122","definition":"A neutralizing human immunoglobulin G1 (IgG1) monoclonal antibody, isolated from a patient who has recovered from the Coronavirus disease 2019 (COVID-19), directed against the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19. Upon administration, bebtelovimab specifically targets and binds to the receptor-binding domain (RBD) of SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"01F8D7F5-2EF9-29FD-E063-731AD00A3BDB","latestVersionIndicator":"Yes","beginDate":"2023-08-02","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-02","modifiedBy":"GDEEN","dateModified":"2023-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"01F8D7F5-2EFA-29FD-E063-731AD00A3BDB","beginDate":"2023-08-02","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-02","modifiedBy":"GDEEN","dateModified":"2023-08-02","deletedIndicator":"No"},{"value":"Ciclesonide","valueDescription":null,"ValueMeaning":{"publicId":"14295565","version":"1","preferredName":"Ciclesonide (Omnaris)","longName":"14295565v1.00","preferredDefinition":"A nonhalogenated, synthetic, inhaled corticosteroid (ICS) with anti-inflammatory and potential antiviral activities. Upon administration by oral inhalation into the lungs, ciclesonide (CIC) is converted by local esterases to its active metabolite desisobutyryl-ciclesonide (des-CIC), which binds to intracellular glucocorticoid receptors (GRs). The ligand-bound GRs regulate gene expressions, which lead to inhibitory activities against multiple cell types, such as mast cells, eosinophils, basophils, lymphocytes, macrophages and neutrophils, and various mediators associated with inflammation, such as histamine, eicosanoids, leukotrienes and cytokines. In addition, ciclesonide may suppress the replication of human coronavirus by targeting viral nonstructural protein 15 (NSP15).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ciclesonide","conceptCode":"C65326","definition":"A nonhalogenated, synthetic, inhaled corticosteroid (ICS) with anti-inflammatory and potential antiviral activities. Upon administration by oral inhalation into the lungs, ciclesonide (CIC) is converted by local esterases to its active metabolite desisobutyryl-ciclesonide (des-CIC), which binds to intracellular glucocorticoid receptors (GRs). The ligand-bound GRs regulate gene expressions, which lead to inhibitory activities against multiple cell types, such as mast cells, eosinophils, basophils, lymphocytes, macrophages and neutrophils, and various mediators associated with inflammation, such as histamine, eicosanoids, leukotrienes and cytokines. In addition, ciclesonide may suppress the replication of human coronavirus by targeting viral nonstructural protein 15 (NSP15).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0258701B-CFB9-15EE-E063-731AD00A911E","latestVersionIndicator":"Yes","beginDate":"2023-08-07","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-07","modifiedBy":"GDEEN","dateModified":"2023-08-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0258701B-CFBA-15EE-E063-731AD00A911E","beginDate":"2023-08-07","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-07","modifiedBy":"GDEEN","dateModified":"2023-08-07","deletedIndicator":"No"},{"value":"Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate","valueDescription":null,"ValueMeaning":{"publicId":"13795017","version":"1","preferredName":"Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate","longName":"13795017v1.00","preferredDefinition":"An orally bioavailable fixed combination of bictegravir sodium, the sodium salt form of the human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) bictegravir, emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine, and tenofovir alafenamide fumarate, the fumarate salt form of the lipophilic phosphonamidate prodrug of tenofovir, a NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration of bictegravir/emtricitabine/tenofovir alafenamide, bictegravir inhibits the strand transfer activity of HIV-1 integrase, an HIV-1 coded enzyme that is necessary for viral replication. Inhibition of integrase prevents the integration of linear HIV-1 DNA into host genomic DNA. Emtricitabine and tenofovir inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate","conceptCode":"C199579","definition":"An orally bioavailable fixed combination of bictegravir sodium, the sodium salt form of the human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) bictegravir, emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine, and tenofovir alafenamide fumarate, the fumarate salt form of the lipophilic phosphonamidate prodrug of tenofovir, a NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration of bictegravir/emtricitabine/tenofovir alafenamide, bictegravir inhibits the strand transfer activity of HIV-1 integrase, an HIV-1 coded enzyme that is necessary for viral replication. Inhibition of integrase prevents the integration of linear HIV-1 DNA into host genomic DNA. Emtricitabine and tenofovir inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD2873BC-5D20-6A5C-E053-731AD00A0FF7","latestVersionIndicator":"Yes","beginDate":"2023-06-02","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-06-02","modifiedBy":"GDEEN","dateModified":"2023-06-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FAE1C-DF50-7350-E063-731AD00AEE88","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Emtricitabine/Tenofovir Alafenamide Fumarate","valueDescription":null,"ValueMeaning":{"publicId":"13763498","version":"1","preferredName":"Emtricitabine/Tenofovir Alafenamide Fumarate","longName":"13763498v1.00","preferredDefinition":"A fixed combination of emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine and tenofovir alafenamide fumarate, the fumarate salt form of the lipophilic phosphonamidate prodrug of tenofovir, a NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, emtricitabine and tenofovir inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Emtricitabine/Tenofovir Alafenamide Fumarate","conceptCode":"C157538","definition":"A fixed combination of emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine and tenofovir alafenamide fumarate, the fumarate salt form of the lipophilic phosphonamidate prodrug of tenofovir, a NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, emtricitabine and tenofovir inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD033CFE-0D8D-0308-E053-731AD00A79BE","latestVersionIndicator":"Yes","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FAE1C-DF51-7350-E063-731AD00AEE88","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Melatonin/Magnesium Citrate","valueDescription":null,"ValueMeaning":{"publicId":"14318387","version":"1","preferredName":"Melatonin/Magnesium Citrate","longName":"14318387v1.00","preferredDefinition":"A combination agent containing melatonin, a serotonin-derived neurohormone, and the citrate salt of the element magnesium, that could potentially be used to promote relaxation and sleep. Upon oral administration, melatonin is involved in numerous biological functions including circadian rhythm, sleep, and the stress response. Magnesium may promote relaxation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melatonin/Magnesium Citrate","conceptCode":"C200662","definition":"A combination agent containing melatonin, a serotonin-derived neurohormone, and the citrate salt of the element magnesium, that could potentially be used to promote relaxation and sleep. Upon oral administration, melatonin is involved in numerous biological functions including circadian rhythm, sleep, and the stress response. Magnesium may promote relaxation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"026FAE1C-DF48-7350-E063-731AD00AEE88","latestVersionIndicator":"Yes","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FAE1C-DF52-7350-E063-731AD00AEE88","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Escitalopram","valueDescription":null,"ValueMeaning":{"publicId":"7460883","version":"1","preferredName":"Escitalopram","longName":"7460883","preferredDefinition":"The active S-stereoisomer of the selective serotonin reuptake inhibitor (SSRI) citalopram with antidepressant, anti-obsessive-compulsive and antibulimic properties. Escitalopram inhibits the reuptake of the neurotransmitter serotonin (5-HT) at the serotonin reuptake pump of the neuronal membrane of the presynaptic cell, thereby increasing levels of 5-HT within the synaptic cleft and enhancing the actions of serotonin on 5HT1A autoreceptors. Unlike other SSRIs, escitalopram appears to not only bind to a primary high-affinity site on the serotonin transporter protein but also to a secondary lower-affinity allosteric site that is considered to stabilize and prolong drug binding.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Escitalopram","conceptCode":"C61754","definition":"The active S-stereoisomer of the selective serotonin reuptake inhibitor (SSRI) citalopram with antidepressant, anti-obsessive-compulsive and antibulimic properties. Escitalopram inhibits the reuptake of the neurotransmitter serotonin (5-HT) at the serotonin reuptake pump of the neuronal membrane of the presynaptic cell, thereby increasing levels of 5-HT within the synaptic cleft and enhancing the actions of serotonin on 5HT1A autoreceptors. Unlike other SSRIs, escitalopram appears to not only bind to a primary high-affinity site on the serotonin transporter protein but also to a secondary lower-affinity allosteric site that is considered to stabilize and prolong drug binding.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1047D74-D4A7-632D-E053-4EBD850AB0BF","latestVersionIndicator":"Yes","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FAE1C-DF53-7350-E063-731AD00AEE88","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Witch Hazel-containing Anti-Hemorroidal Formulation","valueDescription":null,"ValueMeaning":{"publicId":"14114585","version":"1","preferredName":"Witch Hazel-containing Anti-Hemorroidal Formulation Rectal Pad Dosage Form","longName":"14114585v1.00","preferredDefinition":"A preparation containing witch hazel (Hamamelis virginiana) extract, with anti-pruritic activity. Witch hazel extract has been shown to inhibit alpha-glucosidase as well as human leukocyte elastase, enzymes which contribute to the degradation of connective tissue. Tucks hemorrhoidal wipes are used to relieve and soothe the irritation, burning and pruritis of hemorrhoidal tissue._Of or pertaining to the rectum._A solid composed of a soft, non-adhesive and absorbent piece of fabric or other material.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Witch Hazel-containing Anti-Hemorroidal Formulation","conceptCode":"C29525","definition":"A preparation containing witch hazel (Hamamelis virginiana) extract, with anti-pruritic activity. Witch hazel extract has been shown to inhibit alpha-glucosidase as well as human leukocyte elastase, enzymes which contribute to the degradation of connective tissue. Tucks hemorrhoidal wipes are used to relieve and soothe the irritation, burning and pruritis of hemorrhoidal tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Rectal","conceptCode":"C25224","definition":"Of or pertaining to the rectum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pad Dosage Form","conceptCode":"C69016","definition":"A solid composed of a soft, non-adhesive and absorbent piece of fabric or other material.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"00EFECB8-779E-12C6-E063-731AD00A8A11","latestVersionIndicator":"Yes","beginDate":"2023-07-20","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-07-20","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FAE1C-DF54-7350-E063-731AD00AEE88","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Beta-Sitosterol/Boron/Silica/Vitamin D3/Calcium/Zinc/Selenium/Copper/Manganese/Chromium/Molybdenum-containing Supplement","valueDescription":null,"ValueMeaning":{"publicId":"14318388","version":"1","preferredName":"Beta-Sitosterol/Boron/Silica/Vitamin D3/Calcium/Zinc/Selenium/Copper/Manganese/Chromium/Molybdenum-containing Supplement","longName":"14318388v1.00","preferredDefinition":"A formulation composed of the phytosterol beta-sitosterol, cholecalciferol, calcium, zinc, selenium, copper, manganese, chromium, molybdenum and boron, that can potentially be used to support a healthy prostate. Upon oral administration, the formulation may help support and maintain prostate function and promote less urges to urinate and improve bladder emptying.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Beta-Sitosterol/Boron/Silica/Vitamin D3/Calcium/Zinc/Selenium/Copper/Manganese/Chromium/Molybdenum-containing Supplement","conceptCode":"C200663","definition":"A formulation composed of the phytosterol beta-sitosterol, cholecalciferol, calcium, zinc, selenium, copper, manganese, chromium, molybdenum and boron, that can potentially be used to support a healthy prostate. Upon oral administration, the formulation may help support and maintain prostate function and promote less urges to urinate and improve bladder emptying.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"026FAE1C-DF49-7350-E063-731AD00AEE88","latestVersionIndicator":"Yes","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FAE1C-DF55-7350-E063-731AD00AEE88","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Omega-3-containing Krill Oil Supplement","valueDescription":null,"ValueMeaning":{"publicId":"14318389","version":"1","preferredName":"Omega-3-containing Krill Oil Supplement","longName":"14318389v1.00","preferredDefinition":"A supplement composed of omega-3 fatty acids derived from krill oil, that can be used for omega-3 fatty acid supplementation. Upon oral administration, omega-3 containing krill oil supplement provides omega-3 fatty acids. Omega-3 fatty acids get incorporated into and are a critical part of cellular membranes where they influence membrane fluidity and deformability. Omega-3 fatty acids play an important role in the proper functioning of heart, brain, blood vessels, lungs, immune system, and endocrine system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Omega-3-containing Krill Oil Supplement","conceptCode":"C200664","definition":"A supplement composed of omega-3 fatty acids derived from krill oil, that can be used for omega-3 fatty acid supplementation. Upon oral administration, omega-3 containing krill oil supplement provides omega-3 fatty acids. Omega-3 fatty acids get incorporated into and are a critical part of cellular membranes where they influence membrane fluidity and deformability. Omega-3 fatty acids play an important role in the proper functioning of heart, brain, blood vessels, lungs, immune system, and endocrine system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"026FAE1C-DF4A-7350-E063-731AD00AEE88","latestVersionIndicator":"Yes","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FAE1C-DF56-7350-E063-731AD00AEE88","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Magnesium Malate","valueDescription":null,"ValueMeaning":{"publicId":"14318390","version":"1","preferredName":"Magnesium Malate","longName":"14318390v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Magnesium Malate","conceptCode":"C87336","definition":"No value exists.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"026FAE1C-DF4B-7350-E063-731AD00AEE88","latestVersionIndicator":"Yes","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FAE1C-DF57-7350-E063-731AD00AEE88","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Zinc Oxide-containing Paste","valueDescription":null,"ValueMeaning":{"publicId":"14318391","version":"1","preferredName":"Zinc Oxide-containing Paste","longName":"14318391v1.00","preferredDefinition":"A topical paste containing zinc oxide, that can be used to protect the skin. Upon application to the affected area(s), zinc oxide forms a thick, protective barrier to help heal and soothe the diaper rash discomfort.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zinc Oxide-containing Paste","conceptCode":"C200665","definition":"A topical paste containing zinc oxide, that can be used to protect the skin. Upon application to the affected area(s), zinc oxide forms a thick, protective barrier to help heal and soothe the diaper rash discomfort.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"026FAE1C-DF4C-7350-E063-731AD00AEE88","latestVersionIndicator":"Yes","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FAE1C-DF58-7350-E063-731AD00AEE88","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Cortisol","valueDescription":null,"ValueMeaning":{"publicId":"3303092","version":"1","preferredName":"Cortisol","longName":"3303092","preferredDefinition":"A hormone made by the adrenal cortex (the outer layer of the adrenal gland). It helps the body use glucose (a sugar), protein, and fats. Cortisol made in the laboratory is called hydrocortisone. It is used to treat many conditions, including inflammation, allergies, and some cancers. Cortisol is a type of glucocorticoid hormone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cortisol","conceptCode":"C2290","definition":"A hormone made by the adrenal cortex (the outer layer of the adrenal gland). It helps the body use glucose (a sugar), protein, and fats. Cortisol made in the laboratory is called hydrocortisone. It is used to treat many conditions, including inflammation, allergies, and some cancers. Cortisol is a type of glucocorticoid hormone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B165DCF6-0287-5175-E040-BB89AD432D3B","latestVersionIndicator":"Yes","beginDate":"2011-11-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-11-10","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FAE1C-DF59-7350-E063-731AD00AEE88","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Amlodipine","valueDescription":null,"ValueMeaning":{"publicId":"7060445","version":"1","preferredName":"Amlodipine","longName":"7060445","preferredDefinition":"A synthetic dihydropyridine and a calcium channel blocker with antihypertensive and antianginal properties. Amlodipine inhibits the influx of extracellular calcium ions into myocardial and peripheral vascular smooth muscle cells, thereby preventing vascular and myocardial contraction. This results in a dilatation of the main coronary and systemic arteries, decreased myocardial contractility, increased blood flow and oxygen delivery to the myocardial tissue, and decreased total peripheral resistance. This agent may also modulate multi-drug response (MDR) activity through inhibition of the p-glycoprotein efflux pump.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amlodipine","conceptCode":"C61635","definition":"A synthetic dihydropyridine and a calcium channel blocker with antihypertensive and antianginal properties. Amlodipine inhibits the influx of extracellular calcium ions into myocardial and peripheral vascular smooth muscle cells, thereby preventing vascular and myocardial contraction. This results in a dilatation of the main coronary and systemic arteries, decreased myocardial contractility, increased blood flow and oxygen delivery to the myocardial tissue, and decreased total peripheral resistance. This agent may also modulate multi-drug resistance (MDR) activity through inhibition of the p-glycoprotein efflux pump.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A00723-66EB-558A-E053-F662850A380C","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FAE1C-DF5A-7350-E063-731AD00AEE88","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Atorvastatin","valueDescription":null,"ValueMeaning":{"publicId":"14318392","version":"1","preferredName":"Atorvastatin","longName":"14318392v1.00","preferredDefinition":"A synthetic lipid-lowering agent. Atorvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. Atorvastatin also increases the number of LDL receptors on hepatic cell surfaces to enhance uptake and catabolism of LDL and reduces LDL production and the number of LDL particles. This agent lowers plasma cholesterol and lipoprotein levels and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atorvastatin","conceptCode":"C61527","definition":"A synthetic lipid-lowering agent. Atorvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. Atorvastatin also increases the number of LDL receptors on hepatic cell surfaces to enhance uptake and catabolism of LDL and reduces LDL production and the number of LDL particles. This agent lowers plasma cholesterol and lipoprotein levels and modulates immune responses by suppressing MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"026FAE1C-DF4D-7350-E063-731AD00AEE88","latestVersionIndicator":"Yes","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FAE1C-DF5B-7350-E063-731AD00AEE88","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate","valueDescription":null,"ValueMeaning":{"publicId":"13763548","version":"1","preferredName":"Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate","longName":"13763548v1.00","preferredDefinition":"A fixed combination of elvitegravir, a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI); cobicistat, a cytochrome P450 3A (CYP3A) inhibitor; emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine; and tenofovir disoproxil fumarate, an NRTI analog of adenosine monophosphate, that is used to treat HIV infection. Upon oral administration, elvitegravir inhibits the activity of integrase, an HIV-1 coded enzyme that is necessary for viral replication. Inhibition of integrase prevents the integration of HIV-1 DNA into host genomic DNA. Cobicistat inhibits CYP3A, thereby limiting the oxidative metabolism of elvitegravir and increases its systemic exposure. Emtricitabine and tenofovir disoproxil fumarate inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate","conceptCode":"C157404","definition":"A fixed combination of elvitegravir, a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI); cobicistat, a cytochrome P450 3A (CYP3A) inhibitor; emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine; and tenofovir disoproxil fumarate, an NRTI analog of adenosine monophosphate, that is used to treat HIV infection. Upon oral administration, elvitegravir inhibits the activity of integrase, an HIV-1 coded enzyme that is necessary for viral replication. Inhibition of integrase prevents the integration of HIV-1 DNA into host genomic DNA. Cobicistat inhibits CYP3A, thereby limiting the oxidative metabolism of elvitegravir and increases its systemic exposure. Emtricitabine and tenofovir disoproxil fumarate inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD0345A9-D5D1-049D-E053-731AD00A7FA4","latestVersionIndicator":"Yes","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FAE1C-DF5C-7350-E063-731AD00AEE88","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Efineptakin alpha","valueDescription":null,"ValueMeaning":{"publicId":"14318393","version":"1","preferredName":"Efineptakin alfa","longName":"14318393v1.00","preferredDefinition":"A long-acting immunoglobulin (Ig) fusion protein composed of a recombinant form of the endogenous human protein interleukin-7 (rhIL-7) and fused to a hybrid Fc (hyFc) region of a human antibody, with hematopoietic and immunopotentiating activities. Upon administration of efineptakin alfa, IL-7 stimulates the proliferation, differentiation, trafficking and survival of a variety of T-cell subsets, including naive, central memory (CM), effector memory (EM), terminally differentiated effector memory (TEMRA) and natural killer (NK) T-cells, and enhances T-cell-mediated anti-tumor immune responses. Compared to rhIL-7 alone, fusion to the hyFc region enhances the half-life of IL-7. The hyFc region is composed of the hinge and N-terminal portion of heavy chain constant (CH) region 2 (hinge-CH2) of human IgD, which is fused to the C-terminal region of CH2 and the entire CH3 region of human IgG4.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Efineptakin alfa","conceptCode":"C151927","definition":"A long-acting immunoglobulin (Ig) fusion protein composed of a recombinant form of the endogenous human protein interleukin-7 (rhIL-7) and fused to a hybrid Fc (hyFc) region of a human antibody, with hematopoietic and immunopotentiating activities. Upon administration of efineptakin alfa, IL-7 stimulates the proliferation, differentiation, trafficking and survival of a variety of T-cell subsets, including naive, central memory (CM), effector memory (EM), terminally differentiated effector memory (TEMRA) and natural killer (NK) T-cells, and enhances T-cell-mediated anti-tumor immune responses. Compared to rhIL-7 alone, fusion to the hyFc region enhances the half-life of IL-7. The hyFc region is composed of the hinge and N-terminal portion of heavy chain constant (CH) region 2 (hinge-CH2) of human IgD, which is fused to the C-terminal region of CH2 and the entire CH3 region of human IgG4.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"026FAE1C-DF4E-7350-E063-731AD00AEE88","latestVersionIndicator":"Yes","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FAE1C-DF5D-7350-E063-731AD00AEE88","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Immunocytokine NHS-IL12","valueDescription":null,"ValueMeaning":{"publicId":"3595594","version":"1","preferredName":"Immunocytokine NHS-IL12","longName":"3595594","preferredDefinition":"A fusion protein consisting of the heavy-chains of the human antibody NHS76, raised against DNA released by necrotic tumor cells, and fused to two molecules of a genetically modified human interleukin-12 (IL-12) with potential immunostimulating and antineoplastic activities. Upon administration, the antibody moiety of immunocytokine NHS-IL12 binds to DNA released from necrotic tumor cells located primarily at the core of necrotic solid tumors, thereby delivering the IL-12 moiety. In turn, the IL-12 moiety of this agent stimulates the host immune system to mount an immune response against tumor cells, thereby inhibiting tumor growth. IL-12 is a proinflammatory cytokine with numerous immunoregulatory functions and may augment host immune responses to tumor cells. By targeting tumor cells, NHS-IL-12 may reduce the toxicity associated with systemic administration of recombinant human IL-12.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunocytokine NHS-IL12","conceptCode":"C97961","definition":"A fusion protein consisting of the heavy-chains of the human antibody NHS76, raised against DNA released by necrotic tumor cells, and fused to two molecules of a genetically modified human interleukin-12 (IL-12) with potential immunostimulating and antineoplastic activities. Upon administration, the antibody moiety of immunocytokine NHS-IL12 binds to DNA released from necrotic tumor cells located primarily at the core of necrotic solid tumors, thereby delivering the IL-12 moiety. In turn, the IL-12 moiety of this agent stimulates the host immune system to mount an immune response against tumor cells, thereby inhibiting tumor growth. IL-12 is a proinflammatory cytokine with numerous immunoregulatory functions and may augment host immune responses to tumor cells. By targeting tumor cells, NHS-IL-12 may reduce the toxicity associated with systemic administration of recombinant human IL-12.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA68E09A-F6F0-E0A9-E040-BB89AD4338DB","latestVersionIndicator":"Yes","beginDate":"2012-09-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-09-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FAE1C-DF5E-7350-E063-731AD00AEE88","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Liposomal Doxorubicin/Pomalidomide Regimen","valueDescription":null,"ValueMeaning":{"publicId":"14318394","version":"1","preferredName":"Liposomal Doxorubicin/Pomalidomide Regimen","longName":"14318394v1.00","preferredDefinition":"A regimen consisting of liposomal doxorubicin and pomalidomide that may be used in the treatment of Kaposi sarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liposomal Doxorubicin/Pomalidomide Regimen","conceptCode":"C200666","definition":"A regimen consisting of liposomal doxorubicin and pomalidomide that may be used in the treatment of Kaposi sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"026FAE1C-DF4F-7350-E063-731AD00AEE88","latestVersionIndicator":"Yes","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FAE1C-DF5F-7350-E063-731AD00AEE88","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Abacavir/Dolutegravir/Lamivudine","valueDescription":null,"ValueMeaning":{"publicId":"13763550","version":"1","preferredName":"Abacavir/Dolutegravir/Lamivudine","longName":"13763550v1.00","preferredDefinition":"A fixed combination of abacavir sulfate, a nucleoside reverse transcriptase inhibitor (NRTI) analog of guanosine; dolutegravir, an integrase strand-transfer inhibitor (INSTI); and lamivudine, an NRTI analog of cytidine, that may be used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, abacavir and lamivudine are phosphorylated into active metabolites that inhibit the HIV reverse transcriptase (RT) enzyme competitively and act as a chain terminator of DNA synthesis. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions. Dolutegravir binds to the active site of integrase, an HIV enzyme that catalyzes the transfer of viral genetic material into human chromosomes. This prevents integrase from binding to retroviral deoxyribonucleic acid (DNA), and blocks the strand transfer step, which is essential for the HIV replication cycle. This further prevents HIV-1 replication.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abacavir/Dolutegravir/Lamivudine","conceptCode":"C157543","definition":"A fixed combination of abacavir sulfate, a nucleoside reverse transcriptase inhibitor (NRTI) analog of guanosine; dolutegravir, an integrase strand-transfer inhibitor (INSTI); and lamivudine, an NRTI analog of cytidine, that may be used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, abacavir and lamivudine are phosphorylated into active metabolites that inhibit the HIV reverse transcriptase (RT) enzyme competitively and act as a chain terminator of DNA synthesis. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions. Dolutegravir binds to the active site of integrase, an HIV enzyme that catalyzes the transfer of viral genetic material into human chromosomes. This prevents integrase from binding to retroviral deoxyribonucleic acid (DNA), and blocks the strand transfer step, which is essential for the HIV replication cycle. This further prevents HIV-1 replication.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD0345A9-D5D3-049D-E053-731AD00A7FA4","latestVersionIndicator":"Yes","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FAE1C-DF60-7350-E063-731AD00AEE88","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Lutetium Lu 177 Dotatate","valueDescription":null,"ValueMeaning":{"publicId":"13689512","version":"1","preferredName":"Lutetium Lu 177 Dotatate","longName":"13689512v1.00","preferredDefinition":"A radioconjugate consisting of the tyrosine-containing somatostatin analog Tyr3-octreotate (TATE) conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope lutetium Lu 177, with potential imaging and antineoplastic activities. Lutetium Lu 177 dotatate binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTR, present on the cell membranes of many types of neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. Tyr3-octreotate (TATE) is an octreotide derivative in which phenylalanine at position 3 is substituted by tyrosine and position 8 threoninol is replaced with threonine. SSTRs have been shown to be present in large numbers on NET and their metastases, while most other normal tissues express low levels of SSTRs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lutetium Lu 177 Dotatate","conceptCode":"C95020","definition":"A radioconjugate consisting of the tyrosine-containing somatostatin analog Tyr3-octreotate (TATE) conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope lutetium Lu 177, with potential imaging and antineoplastic activities. Lutetium Lu 177 dotatate binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTR, present on the cell membranes of many types of neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. Tyr3-octreotate (TATE) is an octreotide derivative in which phenylalanine at position 3 is substituted by tyrosine and position 8 threoninol is replaced with threonine. SSTRs have been shown to be present in large numbers on NET and their metastases, while most other normal tissues express low levels of SSTRs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC8A7A8A-B4B7-7512-E053-731AD00AC851","latestVersionIndicator":"Yes","beginDate":"2023-05-25","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-25","modifiedBy":"GDEEN","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FAE1C-DF61-7350-E063-731AD00AEE88","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Talazoparib","valueDescription":null,"ValueMeaning":{"publicId":"6159964","version":"1","preferredName":"Talazoparib","longName":"6159964","preferredDefinition":"An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. Talazoparib selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Talazoparib","conceptCode":"C95733","definition":"An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. Talazoparib selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68D489E2-0031-7061-E053-F662850A5645","latestVersionIndicator":"Yes","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FAE1C-DF62-7350-E063-731AD00AEE88","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Vepdegestrant","valueDescription":null,"ValueMeaning":{"publicId":"13961725","version":"1","preferredName":"Vepdegestrant","longName":"13961725v1.00","preferredDefinition":"An orally available hetero-bifunctional molecule and selective estrogen receptor (ER) alpha-targeted protein degrader, using the proteolysis targeting chimera (PROTAC) technology, with potential antineoplastic activity. Vepdegestrant is composed of an ER alpha ligand attached to an E3 ligase recognition moiety. Upon oral administration,vepdegestrant targets and binds to the ER ligand binding domain on ER alpha. E3 ligase is recruited to the ER by the E3 ligase recognition moiety and ER alpha is tagged by ubiquitin. This causes ubiquitination and degradation of ER alpha by the proteasome. This decreases ER alpha protein levels, decreases the expression of ER alpha-target genes and halts ER-mediated signaling. This results in an inhibition of proliferation in ER alpha-overexpressing tumor cells. In addition, the degradation of the ER alpha protein releases the ARV-471 and can bind to additional ER alpha target proteins. ER alpha is overexpressed in a variety of cancers and plays a key role in cancer cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vepdegestrant","conceptCode":"C165420","definition":"An orally available hetero-bifunctional molecule and selective estrogen receptor (ER) alpha-targeted protein degrader, using the proteolysis targeting chimera (PROTAC) technology, with potential antineoplastic activity. Vepdegestrant is composed of an ER alpha ligand attached to an E3 ligase recognition moiety. Upon oral administration,vepdegestrant targets and binds to the ER ligand binding domain on ER alpha. E3 ligase is recruited to the ER by the E3 ligase recognition moiety and ER alpha is tagged by ubiquitin. This causes ubiquitination and degradation of ER alpha by the proteasome. This decreases ER alpha protein levels, decreases the expression of ER alpha-target genes and halts ER-mediated signaling. This results in an inhibition of proliferation in ER alpha-overexpressing tumor cells. In addition, the degradation of the ER alpha protein releases the ARV-471 and can bind to additional ER alpha target proteins. ER alpha is overexpressed in a variety of cancers and plays a key role in cancer cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE4692A3-4D05-32AE-E053-731AD00A1782","latestVersionIndicator":"Yes","beginDate":"2023-06-16","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-06-16","modifiedBy":"FINCHAMB","dateModified":"2023-06-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"026FAE1C-DF63-7350-E063-731AD00AEE88","beginDate":"2023-08-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-08","modifiedBy":"GDEEN","dateModified":"2023-08-08","deletedIndicator":"No"},{"value":"Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate","valueDescription":null,"ValueMeaning":{"publicId":"14437347","version":"1","preferredName":"Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate Inhalation Powder","longName":"14437347v1.00","preferredDefinition":"An inhalation powder formulation composed of a fixed combination of the furoate salt form of the glucocorticoid fluticasone, the bromide salt form of the muscarinic receptor antagonist umeclidinium, and the triphenylacetate salt form of the long-acting beta-2 adrenergic agonist vilanterol, with anti-inflammatory and bronchodilator activities. Upon oral inhalation of the fluticasone furoate/umeclidinium bromide/vilanterol trifenatate inhalation powder via an inhaler, fluticasone binds to intracellular glucocorticoid receptors (GRs), exhibiting inhibitory activities against multiple cell types and mediators associated with inflammation. Umeclidinium antagonizes M3 muscarinic receptors located on smooth muscle cells, thereby preventing smooth muscle contraction and resulting in bronchodilation. Vilanterol stimulates beta-2 adrenergic receptors in the lungs, thereby activating the enzyme adenylate cyclase that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increased cAMP concentrations relax bronchial smooth muscle, relieve bronchospasms, and reduce inflammatory cell mediator release, especially from mast cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate Inhalation Powder","conceptCode":"C201084","definition":"An inhalation powder formulation composed of a fixed combination of the furoate salt form of the glucocorticoid fluticasone, the bromide salt form of the muscarinic receptor antagonist umeclidinium, and the triphenylacetate salt form of the long-acting beta-2 adrenergic agonist vilanterol, with anti-inflammatory and bronchodilator activities. Upon oral inhalation of the fluticasone furoate/umeclidinium bromide/vilanterol trifenatate inhalation powder via an inhaler, fluticasone binds to intracellular glucocorticoid receptors (GRs), exhibiting inhibitory activities against multiple cell types and mediators associated with inflammation. Umeclidinium antagonizes M3 muscarinic receptors located on smooth muscle cells, thereby preventing smooth muscle contraction and resulting in bronchodilation. Vilanterol stimulates beta-2 adrenergic receptors in the lungs, thereby activating the enzyme adenylate cyclase that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increased cAMP concentrations relax bronchial smooth muscle, relieve bronchospasms, and reduce inflammatory cell mediator release, especially from mast cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"04175813-40A2-25C7-E063-731AD00A6138","latestVersionIndicator":"Yes","beginDate":"2023-08-29","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-29","modifiedBy":"GDEEN","dateModified":"2023-08-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"04175813-40A3-25C7-E063-731AD00A6138","beginDate":"2023-08-29","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-08-29","modifiedBy":"GDEEN","dateModified":"2023-08-29","deletedIndicator":"No"},{"value":"Active Biologic Anti-AXL Monoclonal Antibody Conjugate","valueDescription":null,"ValueMeaning":{"publicId":"14473415","version":"1","preferredName":"Active Biologic Anti-AXL Monoclonal Antibody Conjugate","longName":"14473415v1.00","preferredDefinition":"Anti-AXL Antibody-drug Conjugate","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-AXL Antibody-drug Conjugate","conceptCode":"C201141","definition":"Any antibody-drug conjugate (ADC) that is directed against AXL receptor tyrosine kinase (AXL; UFO).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"052C1B2E-6B1B-6A45-E063-731AD00A70B0","latestVersionIndicator":"Yes","beginDate":"2023-09-12","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-09-12","modifiedBy":"GDEEN","dateModified":"2023-09-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"052C1B2E-6B1C-6A45-E063-731AD00A70B0","beginDate":"2023-09-12","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-09-12","modifiedBy":"GDEEN","dateModified":"2023-09-12","deletedIndicator":"No"},{"value":"Icosapent Ethyl","valueDescription":null,"ValueMeaning":{"publicId":"14475550","version":"1","preferredName":"Icosapent Ethyl","longName":"14475550v1.00","preferredDefinition":"A highly purified omega-3 fatty acid that can decrease serum triglyceride levels. Icosapent ethyl reduces serum triglycerides without an increase in LDL cholesterol, but increases the cholesterol and triglyceride content in skeletal muscle.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Icosapent Ethyl","conceptCode":"C72986","definition":"A highly purified omega-3 fatty acid that can decrease serum triglyceride levels. Icosapent ethyl reduces serum triglycerides without an increase in LDL cholesterol, but increases the cholesterol and triglyceride content in skeletal muscle.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"053F410D-7212-7421-E063-731AD00AAF9E","latestVersionIndicator":"Yes","beginDate":"2023-09-13","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-09-13","modifiedBy":"GDEEN","dateModified":"2023-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"053F410D-7214-7421-E063-731AD00AAF9E","beginDate":"2023-09-13","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-09-13","modifiedBy":"GDEEN","dateModified":"2023-09-13","deletedIndicator":"No"},{"value":"Ibuprofen and Pseudoephedrine Hydrochloride","valueDescription":null,"ValueMeaning":{"publicId":"14475551","version":"1","preferredName":"Ibuprofen And Pseudoephedrine Hydrochloride","longName":"14475551v1.00","preferredDefinition":"A propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic effects. Ibuprofen inhibits the activity of cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. This leads to decreased prostaglandin synthesis, by prostaglandin synthase, the main physiologic effect of ibuprofen. Ibuprofen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation. (NCI05)_An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._The hydrochloride salt form of pseudoephedrine, a phenethylamine and an diastereomer of ephedrine with sympathomimetic property. Pseudoephedrine hydrochloride displaces norepinephrine from storage vesicles in presynaptic neurones, thereby releasing norepinephrine into the neuronal synapses where it stimulates primarily alpha-adrenergic receptors. It also has weak direct agonist activity at alpha- and beta- adrenergic receptors. Receptor stimulation results in vasoconstriction and decreases nasal and sinus congestion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ibuprofen","conceptCode":"C561","definition":"A propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic effects. Ibuprofen inhibits the activity of cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. This leads to decreased prostaglandin synthesis, by prostaglandin synthase, the main physiologic effect of ibuprofen. Ibuprofen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pseudoephedrine Hydrochloride","conceptCode":"C29390","definition":"The hydrochloride salt form of pseudoephedrine, a phenethylamine and an diastereomer of ephedrine with sympathomimetic property. Pseudoephedrine hydrochloride displaces norepinephrine from storage vesicles in presynaptic neurones, thereby releasing norepinephrine into the neuronal synapses where it stimulates primarily alpha-adrenergic receptors. It also has weak direct agonist activity at alpha- and beta- adrenergic receptors. Receptor stimulation results in vasoconstriction and decreases nasal and sinus congestion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"053F410D-7213-7421-E063-731AD00AAF9E","latestVersionIndicator":"Yes","beginDate":"2023-09-13","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-09-13","modifiedBy":"GDEEN","dateModified":"2023-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"053F410D-7215-7421-E063-731AD00AAF9E","beginDate":"2023-09-13","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-09-13","modifiedBy":"GDEEN","dateModified":"2023-09-13","deletedIndicator":"No"},{"value":"L-Thyroxine","valueDescription":null,"ValueMeaning":{"publicId":"3305288","version":"1","preferredName":"Levothyroxine","longName":"3305288v1.00","preferredDefinition":"A synthetic levoisomer of thyroxine (T4), similar to the endogenous hormone produced by the thyroid gland. Thyroxine is de-iodinated to form triiodothyronine (T3) in the peripheral tissues. T3 enters the cell and binds to nuclear thyroid hormone receptors, and the hormone-receptor complex in turn triggers gene expression and produces proteins required in the regulation of cellular respiration, thermogenesis, cellular growth and differentiation, and metabolism of proteins, carbohydrates and lipids. T4 and T3 also possess cardiac stimulatory effect.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Levothyroxine","conceptCode":"C62080","definition":"A synthetic levoisomer of thyroxine (T4), similar to the endogenous hormone produced by the thyroid gland. Thyroxine is de-iodinated to form triiodothyronine (T3) in the peripheral tissues. T3 enters the cell and binds to nuclear thyroid hormone receptors, and the hormone-receptor complex in turn triggers gene expression and produces proteins required in the regulation of cellular respiration, thermogenesis, cellular growth and differentiation, and metabolism of proteins, carbohydrates and lipids. T4 and T3 also possess cardiac stimulatory effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1F1F71A-70F6-08C4-E040-BB89AD43052C","latestVersionIndicator":"Yes","beginDate":"2011-11-17","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-11-17","modifiedBy":"GDEEN","dateModified":"2023-09-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0555629D-EB02-05B4-E063-731AD00A5ECB","beginDate":"2023-09-14","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-09-14","modifiedBy":"GDEEN","dateModified":"2023-09-14","deletedIndicator":"No"},{"value":"Quizartinib","valueDescription":null,"ValueMeaning":{"publicId":"6429348","version":"1","preferredName":"Quizartinib","longName":"6429348","preferredDefinition":"An orally available small molecule with potential antineoplastic activity. Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Quizartinib","conceptCode":"C68936","definition":"An orally available small molecule with potential antineoplastic activity. Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"759B430D-D6C5-045F-E053-F662850AB8F5","latestVersionIndicator":"Yes","beginDate":"2018-09-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-11","modifiedBy":"ONEDATA","dateModified":"2018-09-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0687EC0F-D689-1BC2-E063-731AD00A3C4A","beginDate":"2023-09-29","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-09-29","modifiedBy":"GDEEN","dateModified":"2023-09-29","deletedIndicator":"No"},{"value":"Sorafenib","valueDescription":null,"ValueMeaning":{"publicId":"3380164","version":"1","preferredName":"Sorafenib","longName":"3380164","preferredDefinition":"A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sorafenib","conceptCode":"C61948","definition":"A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A2A6B-9613-1351-E040-BB89AD432684","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0687EC0F-D68A-1BC2-E063-731AD00A3C4A","beginDate":"2023-09-29","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-09-29","modifiedBy":"GDEEN","dateModified":"2023-09-29","deletedIndicator":"No"},{"value":"Midostaurin","valueDescription":null,"ValueMeaning":{"publicId":"5805895","version":"1","preferredName":"Midostaurin","longName":"5805895","preferredDefinition":"A synthetic indolocarbazole multikinase inhibitor with potential antiangiogenic and antineoplastic activities. Midostaurin inhibits protein kinase C alpha (PKCalpha), vascular endothelial growth factor receptor 2 (VEGFR2), c-kit, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase 3 (FLT3) tyrosine kinases, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Midostaurin","conceptCode":"C1872","definition":"A synthetic indolocarbazole multikinase inhibitor with potential antiangiogenic and antineoplastic activities. Midostaurin inhibits protein kinase C alpha (PKCalpha), vascular endothelial growth factor receptor 2 (VEGFR2), c-kit, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase 3 (FLT3) tyrosine kinases, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4EA05B60-4464-1133-E053-F662850AB1AF","latestVersionIndicator":"Yes","beginDate":"2017-05-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-05-03","modifiedBy":"COOPERM","dateModified":"2020-04-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0687EC0F-D68B-1BC2-E063-731AD00A3C4A","beginDate":"2023-09-29","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-09-29","modifiedBy":"GDEEN","dateModified":"2023-09-29","deletedIndicator":"No"},{"value":"Apoaequorin/Vitamin D Supplement","valueDescription":null,"ValueMeaning":{"publicId":"14540948","version":"1","preferredName":"Apoaequorin/Vitamin D Supplement","longName":"14540948v1.00","preferredDefinition":"A dietary supplement composed of synthetic form of the naturally-occurring protein apoaequorin and vitamin D, that may potentially be used to improve memory. Upon oral administration of apoaequorin/vitamin D supplement, apoaequorin, a calcium binding protein naturally found in luminescent jellyfish (Aequorea victoria), may potentially improve memory through the regulation of intracellular calcium in neuronal cells, though it has not been shown to be able to cross the blood brain barrier (BBB).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Apoaequorin/Vitamin D Supplement","conceptCode":"C201815","definition":"A dietary supplement composed of synthetic form of the naturally-occurring protein apoaequorin and vitamin D, that may potentially be used to improve memory. Upon oral administration of apoaequorin/vitamin D supplement, apoaequorin, a calcium binding protein naturally found in luminescent jellyfish (Aequorea victoria), may potentially improve memory through the regulation of intracellular calcium in neuronal cells, though it has not been shown to be able to cross the blood brain barrier (BBB).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"08012B85-3FF9-6E00-E063-731AD00A17F7","latestVersionIndicator":"Yes","beginDate":"2023-10-18","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-10-18","modifiedBy":"GDEEN","dateModified":"2023-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"08012B85-3FFA-6E00-E063-731AD00A17F7","beginDate":"2023-10-18","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-10-18","modifiedBy":"GDEEN","dateModified":"2023-10-18","deletedIndicator":"No"},{"value":"Liraglutide","valueDescription":null,"ValueMeaning":{"publicId":"14554869","version":"1","preferredName":"Liraglutide","longName":"14554869v1.00","preferredDefinition":"A long-acting, fatty acylated glucagon-like peptide-1 (GLP-1) analog administered subcutaneously, with antihyperglycemic activity. Liraglutide's prolonged action and half-life of 11-15 hours are attributed to the attachment of the fatty acid palmitic acid to GLP-1 that reversibly binds to albumin. Albumin binding protects liraglutide from immediate degradation and elimination and causes GLP-1 to be released from abumin in a slow and consistent manner. This agent may cause thyroid C-cell tumors and increases the risk of acute pancreatitis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liraglutide","conceptCode":"C82239","definition":"A long-acting, fatty acylated glucagon-like peptide-1 (GLP-1) analog administered subcutaneously, with antihyperglycemic activity. Liraglutide's prolonged action and half-life of 11-15 hours are attributed to the attachment of the fatty acid palmitic acid to GLP-1 that reversibly binds to albumin. Albumin binding protects liraglutide from immediate degradation and elimination and causes GLP-1 to be released from abumin in a slow and consistent manner. This agent may cause thyroid C-cell tumors and increases the risk of acute pancreatitis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0830CB5A-345B-0BE7-E063-731AD00A437E","latestVersionIndicator":"Yes","beginDate":"2023-10-20","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-10-20","modifiedBy":"GDEEN","dateModified":"2023-10-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0830CB5A-345D-0BE7-E063-731AD00A437E","beginDate":"2023-10-20","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-10-20","modifiedBy":"GDEEN","dateModified":"2023-10-20","deletedIndicator":"No"},{"value":"Anti-spike Protein SARS-CoV-2 Monoclonal Antibody","valueDescription":null,"ValueMeaning":{"publicId":"14554870","version":"1","preferredName":"Anti-spike Protein SARS-CoV-2 Monoclonal Antibody","longName":"14554870v1.00","preferredDefinition":"Any monoclonal antibody that is directed against the spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-spike Protein SARS-CoV-2 Monoclonal Antibody","conceptCode":"C173741","definition":"Any monoclonal antibody that is directed against the spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0830CB5A-345C-0BE7-E063-731AD00A437E","latestVersionIndicator":"Yes","beginDate":"2023-10-20","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-10-20","modifiedBy":"GDEEN","dateModified":"2023-10-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0830CB5A-345E-0BE7-E063-731AD00A437E","beginDate":"2023-10-20","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-10-20","modifiedBy":"GDEEN","dateModified":"2023-10-20","deletedIndicator":"No"},{"value":"Bio Protect","valueDescription":null,"ValueMeaning":{"publicId":"14598254","version":"1","preferredName":"Vitamin A/Vitamin C/Vitamin E/Zinc Gluconate/Selenium/Coenzyme Q10/L-Glutathione/L-Methionine/Taurine/N-Acetyl-L-Cysteine/Superoxide Dismutase/Catalase-containing Supplement","longName":"14598254v1.00","preferredDefinition":"A dietary supplement containing vitamin A, vitamin C, vitamin E, zinc gluconate, selenium, coenzyme Q10, L-glutathione, L-methionine, taurine, N-acetyl-L-cysteine, superoxide dismutase and catalase, with potential antioxidant activity. Upon administration of vitamin A/vitamin C/vitamin E/zinc gluconate/selenium/coenzyme Q10/L-glutathione/L-methionine/taurine/N-acetyl-L-cysteine/superoxide dismutase/catalase-containing supplement, the vitamins, minerals, phytochemicals and enzymes may exert an antioxidant effect, which may protect against free radical-induced tissue damage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vitamin A/Vitamin C/Vitamin E/Zinc Gluconate/Selenium/Coenzyme Q10/L-Glutathione/L-Methionine/Taurine/N-Acetyl-L-Cysteine/Superoxide Dismutase/Catalase-containing Supplement","conceptCode":"C202043","definition":"A dietary supplement containing vitamin A, vitamin C, vitamin E, zinc gluconate, selenium, coenzyme Q10, L-glutathione, L-methionine, taurine, N-acetyl-L-cysteine, superoxide dismutase and catalase, with potential antioxidant activity. Upon administration of vitamin A/vitamin C/vitamin E/zinc gluconate/selenium/coenzyme Q10/L-glutathione/L-methionine/taurine/N-acetyl-L-cysteine/superoxide dismutase/catalase-containing supplement, the vitamins, minerals, phytochemicals and enzymes may exert an antioxidant effect, which may protect against free radical-induced tissue damage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"09A6B8B0-9B0E-6900-E063-731AD00A8B35","latestVersionIndicator":"Yes","beginDate":"2023-11-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-11-08","modifiedBy":"KUMMEROA","dateModified":"2023-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"09A6B8B0-9B11-6900-E063-731AD00A8B35","beginDate":"2023-11-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-11-08","modifiedBy":"KUMMEROA","dateModified":"2023-11-08","deletedIndicator":"No"},{"value":"Calcium Lactase","valueDescription":null,"ValueMeaning":{"publicId":"14598255","version":"1","preferredName":"Calcium Lactate Supplement","longName":"14598255v1.00","preferredDefinition":"A dietary supplement containing the calcium salt form of lactic acid, that may be used as a calcium supplement and for the prevention and treatment of osteoporosis. Upon administration, calcium lactate supplement helps maintain calcium balance and prevent bone loss. Calcium is a major component of bone and teeth that confers bone strength and structure, and plays an important role in many physiologic functions including nerve, muscle and cardiac functions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Calcium Lactate Supplement","conceptCode":"C202044","definition":"A dietary supplement containing the calcium salt form of lactic acid, that may be used as a calcium supplement and for the prevention and treatment of osteoporosis. Upon administration, calcium lactate supplement helps maintain calcium balance and prevent bone loss. Calcium is a major component of bone and teeth that confers bone strength and structure, and plays an important role in many physiologic functions including nerve, muscle and cardiac functions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"09A6B8B0-9B0F-6900-E063-731AD00A8B35","latestVersionIndicator":"Yes","beginDate":"2023-11-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-11-08","modifiedBy":"KUMMEROA","dateModified":"2023-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"09A6B8B0-9B12-6900-E063-731AD00A8B35","beginDate":"2023-11-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-11-08","modifiedBy":"KUMMEROA","dateModified":"2023-11-08","deletedIndicator":"No"},{"value":"Protease w Calcium (Protease, Amylase, Lipase)","valueDescription":null,"ValueMeaning":{"publicId":"14598256","version":"1","preferredName":"Calcium Lactate/Protease/Amylase/Lipase-containing Supplement","longName":"14598256v1.00","preferredDefinition":"A dietary supplement containing calcium lactate, protease, amylase and lipase, that may be used as a calcium supplement and for the prevention and treatment of osteoporosis, and to decrease inflammation and improve tissue repair. Upon administration of calcium lactate/protease/amylase/lipase-containing supplement, the enzymes catalyze the breakdown of fats, carbohydrates and proteins during the digestion of food. This increases the absorption of amino acids, which may decrease inflammation and improve tissue repair. Calcium lactate helps maintain calcium balance and prevent bone loss. Calcium is a major component of bone and teeth that confers bone strength and structure, and plays an important role in many physiologic functions including nerve, muscle and cardiac functions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Calcium Lactate/Protease/Amylase/Lipase-containing Supplement","conceptCode":"C202045","definition":"A dietary supplement containing calcium lactate, protease, amylase and lipase, that may be used as a calcium supplement and for the prevention and treatment of osteoporosis, and to decrease inflammation and improve tissue repair. Upon administration of calcium lactate/protease/amylase/lipase-containing supplement, the enzymes catalyze the breakdown of fats, carbohydrates and proteins during the digestion of food. This increases the absorption of amino acids, which may decrease inflammation and improve tissue repair. Calcium lactate helps maintain calcium balance and prevent bone loss. Calcium is a major component of bone and teeth that confers bone strength and structure, and plays an important role in many physiologic functions including nerve, muscle and cardiac functions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"09A6B8B0-9B10-6900-E063-731AD00A8B35","latestVersionIndicator":"Yes","beginDate":"2023-11-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-11-08","modifiedBy":"KUMMEROA","dateModified":"2023-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"09A6B8B0-9B13-6900-E063-731AD00A8B35","beginDate":"2023-11-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-11-08","modifiedBy":"KUMMEROA","dateModified":"2023-11-08","deletedIndicator":"No"},{"value":"Bictegravir","valueDescription":null,"ValueMeaning":{"publicId":"14650182","version":"1","preferredName":"Bictegravir","longName":"14650182v1.00","preferredDefinition":"A human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI), that is used to treat HIV infection. Upon oral administration, bictegravir inhibits the strand transfer activity of HIV-1 integrase, an HIV-1 coded enzyme that is necessary for viral replication. Inhibition of integrase prevents the integration of linear HIV-1 DNA into host genomic DNA.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bictegravir","conceptCode":"C171719","definition":"A human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI), that is used to treat HIV infection. Upon oral administration, bictegravir inhibits the strand transfer activity of HIV-1 integrase, an HIV-1 coded enzyme that is necessary for viral replication. Inhibition of integrase prevents the integration of linear HIV-1 DNA into host genomic DNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BEFE112-ED61-0704-E063-731AD00A6637","latestVersionIndicator":"Yes","beginDate":"2023-12-07","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-12-07","modifiedBy":"GDEEN","dateModified":"2023-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BF044FD-74EF-1AEB-E063-731AD00AA4F4","beginDate":"2023-12-07","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-12-07","modifiedBy":"GDEEN","dateModified":"2023-12-07","deletedIndicator":"No"},{"value":"Tetracaine Hydrochloride","valueDescription":null,"ValueMeaning":{"publicId":"14650183","version":"1","preferredName":"Tetracaine Hydrochloride","longName":"14650183v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tetracaine Hydrochloride","conceptCode":"C75104","definition":"The hydrochloride salt form of tetracaine, a benzoate ester, with anesthetic properties. Upon administration, tetracaine reversibly binds voltage-gated sodium ion channels in neuronal cell membranes and inhibits sodium influx. This prevents the initiation and conduction of nerve impulses, and stabilizes neuronal membranes. This results in a loss of sensation, and thereby provides analgesia and anesthesia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BEFE112-ED62-0704-E063-731AD00A6637","latestVersionIndicator":"Yes","beginDate":"2023-12-07","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-12-07","modifiedBy":"GDEEN","dateModified":"2023-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BF044FD-74F0-1AEB-E063-731AD00AA4F4","beginDate":"2023-12-07","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-12-07","modifiedBy":"GDEEN","dateModified":"2023-12-07","deletedIndicator":"No"},{"value":"Potassium Phosphate/Sodium Phosphate","valueDescription":null,"ValueMeaning":{"publicId":"3282731","version":"1","preferredName":"Potassium Phosphate/Sodium Phosphate","longName":"3282731","preferredDefinition":"A combination preparation containing potassium phosphate and sodium phosphate used for electrolyte-replacement purposes, dietary supplementation and to acidify urine. Phosphate, a predominant intracellular anion, plays an important role in energy storage, osteoblastic and osteoclastic activities, regulating serum calcium concentrations and numerous cellular phosphate-transfer reactions. Potassium phosphate and sodium phosphate are used to acidify the urine and lower the urinary calcium concentration. This may reduce rash and odor caused by ammonium in the urine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Potassium Phosphate/Sodium Phosphate","conceptCode":"C29288","definition":"A combination preparation containing potassium phosphate and sodium phosphate used for electrolyte-replacement purposes, dietary supplementation and to acidify urine. Phosphate, a predominant intracellular anion, plays an important role in energy storage, osteoblastic and osteoclastic activities, regulating serum calcium concentrations and numerous cellular phosphate-transfer reactions. Potassium phosphate and sodium phosphate are used to acidify the urine and lower the urinary calcium concentration. This may reduce rash and odor caused by ammonium in the urine.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD7A5918-D768-456E-E040-BB89AD433590","latestVersionIndicator":"Yes","beginDate":"2011-09-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BF044FD-74F1-1AEB-E063-731AD00AA4F4","beginDate":"2023-12-07","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-12-07","modifiedBy":"GDEEN","dateModified":"2023-12-07","deletedIndicator":"No"},{"value":"Dupilumab","valueDescription":null,"ValueMeaning":{"publicId":"13634130","version":"1","preferredName":"Dupilumab","longName":"13634130v1.00","preferredDefinition":"A recombinant human monoclonal immunoglobulin G4 (IgG4) antibody directed against the alpha chain of the interleukin-4 receptor (IL-4R alpha) with potential immunomodulatory activities. Upon injection, dupilumab selectively binds to the IL-4R alpha chain. This disrupts IL-4/IL-13 signaling and prevents the activation of downstream pathways that mediate type 2 inflammation and may potentially inhibit tumor cell proliferation, survival, and metastasis. IL-4 and IL-13 receptors are present on the surface of numerous cells involved in the pathophysiology of type-2 helper T-cell (Th2) allergic responses, including B-lymphocytes, eosinophils, dendritic cells (DCs), monocytes, macrophages, basophils, keratinocytes, bronchial epithelial cells, endothelial cells, fibroblasts, and airway smooth muscle cells. Additionally, both IL-4 and IL-13 receptors are overexpressed in a variety of cancers and IL-4 and IL-13 and may serve as biomarkers for cancer aggressiveness. IL-4 and IL-13 are thought to be key regulatory cytokines in the tumor microenvironment (TME) and may play a role in the activation of tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) that mediate tumor cell survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dupilumab","conceptCode":"C162455","definition":"A recombinant human monoclonal immunoglobulin G4 (IgG4) antibody directed against the alpha chain of the interleukin-4 receptor (IL-4R alpha) with potential immunomodulatory activities. Upon injection, dupilumab selectively binds to the IL-4R alpha chain. This disrupts IL-4/IL-13 signaling and prevents the activation of downstream pathways that mediate type 2 inflammation and may potentially inhibit tumor cell proliferation, survival, and metastasis. IL-4 and IL-13 receptors are present on the surface of numerous cells involved in the pathophysiology of type-2 helper T-cell (Th2) allergic responses, including B-lymphocytes, eosinophils, dendritic cells (DCs), monocytes, macrophages, basophils, keratinocytes, bronchial epithelial cells, endothelial cells, fibroblasts, and airway smooth muscle cells. Additionally, both IL-4 and IL-13 receptors are overexpressed in a variety of cancers and IL-4 and IL-13 and may serve as biomarkers for cancer aggressiveness. IL-4 and IL-13 are thought to be key regulatory cytokines in the tumor microenvironment (TME) and may play a role in the activation of tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) that mediate tumor cell survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC6948FB-949D-4130-E053-731AD00A325E","latestVersionIndicator":"Yes","beginDate":"2023-05-23","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-23","modifiedBy":"GDEEN","dateModified":"2023-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BF044FD-74F2-1AEB-E063-731AD00AA4F4","beginDate":"2023-12-07","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-12-07","modifiedBy":"GDEEN","dateModified":"2023-12-07","deletedIndicator":"No"},{"value":"Tenofovir alafenamide","valueDescription":null,"ValueMeaning":{"publicId":"13763549","version":"1","preferredName":"Tenofovir Alafenamide","longName":"13763549v1.00","preferredDefinition":"A lipophilic phosphonamidate prodrug of tenofovir, a synthetic antiviral acyclic nucleotide analog of adenosine 5-monophosphate and a nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity against hepatitis B virus (HBV) and potentially against human immunodeficiency virus (HIV). Upon oral administration, tenofovir alafenamide is taken up by hepatocytes through passive diffusion and through the hepatic uptake transporters organic anion transporting polypeptides 1B1 (OATP1B1) and 1B3 (OATP1B3). Inside the hepatocytes, tenofovir alafenamide is hydrolyzed and converted to tenofovir by carboxylesterase 1 (CES1). Intracellular tenofovir is phosphorylated by cellular kinases to its pharmacologically active form, tenofovir diphosphate. Tenofovir diphosphate is incorporated into viral DNA instead of the natural substrate deoxyadenosine 5-triphosphate, and inhibits HBV reverse transcriptase, resulting in DNA chain-termination and inhibition of HBV replication. In addition, tenofovir diphosphate is incorporated into HIV DNA instead of the natural substrate deoxyadenosine 5-triphosphate, thereby inhibiting HIV-1 reverse transcriptase (RT) and resulting in DNA chain termination and impairment of HIV replication.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tenofovir Alafenamide","conceptCode":"C148276","definition":"A lipophilic phosphonamidate prodrug of tenofovir, a synthetic antiviral acyclic nucleotide analog of adenosine 5-monophosphate and a nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity against hepatitis B virus (HBV) and potentially against human immunodeficiency virus (HIV). Upon oral administration, tenofovir alafenamide is taken up by hepatocytes through passive diffusion and through the hepatic uptake transporters organic anion transporting polypeptides 1B1 (OATP1B1) and 1B3 (OATP1B3). Inside the hepatocytes, tenofovir alafenamide is hydrolyzed and converted to tenofovir by carboxylesterase 1 (CES1). Intracellular tenofovir is phosphorylated by cellular kinases to its pharmacologically active form, tenofovir diphosphate. Tenofovir diphosphate is incorporated into viral DNA instead of the natural substrate deoxyadenosine 5-triphosphate, and inhibits HBV reverse transcriptase, resulting in DNA chain-termination and inhibition of HBV replication. In addition, tenofovir diphosphate is incorporated into HIV DNA instead of the natural substrate deoxyadenosine 5-triphosphate, thereby inhibiting HIV-1 reverse transcriptase (RT) and resulting in DNA chain termination and impairment of HIV replication.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD0345A9-D5D2-049D-E053-731AD00A7FA4","latestVersionIndicator":"Yes","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BF0C0BE-27D8-3ADA-E063-731AD00A4EBC","beginDate":"2023-12-07","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-12-07","modifiedBy":"GDEEN","dateModified":"2023-12-07","deletedIndicator":"No"},{"value":"Darunavir/Cobicistat","valueDescription":null,"ValueMeaning":{"publicId":"13763546","version":"1","preferredName":"Darunavir/Cobicistat","longName":"13763546v1.00","preferredDefinition":"A fixed combination of darunavir, an inhibitor of the human immunodeficiency virus (HIV) protease; and cobicistat, a cytochrome P450 3A (CYP3A) inhibitor that may be used to treat HIV infection. Upon oral administration, darunavir binds to and inhibits the dimerization and catalytic activity of the HIV aspartyl protease. This inhibits the cleavage of HIV-encoded Gag and Gag-Pol polyproteins in virus-infected cells, which prevents the formation of mature infectious virions. Cobicistat inhibits CYP3A, thereby limiting the metabolism of darunavir and increases its systemic exposure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Darunavir/Cobicistat","conceptCode":"C157536","definition":"A fixed combination of darunavir, an inhibitor of the human immunodeficiency virus (HIV) protease; and cobicistat, a cytochrome P450 3A (CYP3A) inhibitor that may be used to treat HIV infection. Upon oral administration, darunavir binds to and inhibits the dimerization and catalytic activity of the HIV aspartyl protease. This inhibits the cleavage of HIV-encoded Gag and Gag-Pol polyproteins in virus-infected cells, which prevents the formation of mature infectious virions. Cobicistat inhibits CYP3A, thereby limiting the metabolism of darunavir and increases its systemic exposure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD0345A9-D5BF-049D-E053-731AD00A7FA4","latestVersionIndicator":"Yes","beginDate":"2023-05-31","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-31","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BF0C0BE-27D9-3ADA-E063-731AD00A4EBC","beginDate":"2023-12-07","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-12-07","modifiedBy":"GDEEN","dateModified":"2023-12-07","deletedIndicator":"No"},{"value":"Liposomal doxorubicin","valueDescription":null,"ValueMeaning":{"publicId":"3379143","version":"1","preferredName":"Doxorubicin Hydrochloride Liposome","longName":"3379143","preferredDefinition":"A liposome-encapsulated form of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin.  Liposomal delivery of doxorubicin HCL improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects.  Doxorubicin intercalates into DNA and interacts with topoisomerase II, consequently inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pegylated Liposomal Doxorubicin Hydrochloride","conceptCode":"C1555","definition":"A liposome-encapsulated preparation of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin. Doxorubicin intercalates between DNA base pairs, thereby hinders the movement of replication machinery along DNA strands, as well as blocks the activity of topoisomerase II during replication. As a result, this agent causes DNA adducts formation, renders single- and double-stranded DNA breakages that induce DNA repair and or apoptotic processes. Doxorubicin also generates reactive oxygen species that leads to cytotoxicity secondary to lipid peroxidation of cell membrane lipids. Liposomal delivery of doxorubicin HCl improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects. A liposomal formulation of doxorubicin also modulates toxicity, specifically the cardiac effects commonly seen with anthracycline antitumor drugs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B917C4ED-EABF-F265-E040-BB89AD435210","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"GDEEN","dateModified":"2023-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BF0C0BE-27DA-3ADA-E063-731AD00A4EBC","beginDate":"2023-12-07","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-12-07","modifiedBy":"GDEEN","dateModified":"2023-12-07","deletedIndicator":"No"},{"value":"Abatacept","valueDescription":null,"ValueMeaning":{"publicId":"6429536","version":"1","preferredName":"Abatacept","longName":"6429536","preferredDefinition":"A soluble fusion protein consisting of the extracellular domain of human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) linked to a modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1) with immunosuppressive activity. Abatacept binds CD80 and CD86 on antigen presenting cells (APCs), blocking interaction with CD28 on T lymphocytes, which initiates a co-stimulatory signal required for full activation of T lymphocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abatacept","conceptCode":"C28898","definition":"A soluble fusion protein consisting of the extracellular domain of human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) linked to a modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1) with immunosuppressive activity. Abatacept binds CD80 and CD86 on antigen presenting cells (APCs), blocking interaction with CD28 on T lymphocytes, which initiates a co-stimulatory signal required for full activation of T lymphocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"75AF6CD8-495C-4E44-E053-F662850AD113","latestVersionIndicator":"Yes","beginDate":"2018-09-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-12","modifiedBy":"ONEDATA","dateModified":"2018-09-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0BF0C0BE-27DB-3ADA-E063-731AD00A4EBC","beginDate":"2023-12-07","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-12-07","modifiedBy":"GDEEN","dateModified":"2023-12-07","deletedIndicator":"No"},{"value":"Dalbavancin","valueDescription":null,"ValueMeaning":{"publicId":"14652335","version":"1","preferredName":"Dalbavancin","longName":"14652335v1.00","preferredDefinition":"A second-generation, semi-synthetic lipoglycopeptide antibiotic, with bactericidal activity against a variety of gram-positive bacteria. Upon administration, dalbavancin binds, at a site different from that of penicillins and cephalosporins, tightly to the D-alanyl-D-alanine portion of peptidoglycan chains, thereby preventing peptidoglycan elongation and interfering with bacterial cell wall synthesis. This leads to activation of bacterial autolysins and induces cell wall lysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dalbavancin","conceptCode":"C116741","definition":"A second-generation, semi-synthetic lipoglycopeptide antibiotic, with bactericidal activity against a variety of gram-positive bacteria. Upon administration, dalbavancin binds, at a site different from that of penicillins and cephalosporins, tightly to the D-alanyl-D-alanine portion of peptidoglycan chains, thereby preventing peptidoglycan elongation and interfering with bacterial cell wall synthesis. This leads to activation of bacterial autolysins and induces cell wall lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0C06D07D-385D-4B82-E063-731AD00AA616","latestVersionIndicator":"Yes","beginDate":"2023-12-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-12-08","modifiedBy":"GDEEN","dateModified":"2023-12-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0C41F0B9-369F-3E2E-E063-731AD00A23A4","beginDate":"2023-12-11","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-12-11","modifiedBy":"GDEEN","dateModified":"2023-12-11","deletedIndicator":"No"},{"value":"Alpha-1-Proteinase Inhibitor Human","valueDescription":null,"ValueMeaning":{"publicId":"7631837","version":"1","preferredName":"Alpha-1-Proteinase Inhibitor Human","longName":"7631837","preferredDefinition":"Human serum-derived alpha-1 proteinase inhibitor (alpha-1-antitrypsin or AAT) with immunomodulating and anti-inflammatory activity. Upon administration, AAT reduces the production of proinflammatory cytokines, such as tumor necrosis factor-alpha, interleukin (IL)-1 beta, IL-32, IL-6, and proteinase 3, and induces the production of anti-inflammatory cytokines, such as IL-10 and the IL-1 receptor antagonist IL-1RN. This agent also downregulates heparan sulfate and reduces the expansion of cytotoxic effector T cells, interferes with the maturation of dendritic cells and increases T regulatory cells. Altogether, AAT may attenuate acute graft-versus-host disease (GvHD) and may facilitate graft acceptance and survival. In addition, AAT enhances levels of cAMP and activation of cAMP-dependent protein kinase A. AAT, a 52kD protein and serine protease inhibitor, belongs to the serpin superfamily.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alpha-1-Proteinase Inhibitor Human","conceptCode":"C82258","definition":"Human serum-derived alpha-1 proteinase inhibitor (alpha-1-antitrypsin or AAT) with immunomodulating and anti-inflammatory activity. Upon administration, AAT reduces the production of proinflammatory cytokines, such as tumor necrosis factor-alpha, interleukin (IL)-1 beta, IL-32, IL-6, and proteinase 3, and induces the production of anti-inflammatory cytokines, such as IL-10 and the IL-1 receptor antagonist IL-1RN. This agent also downregulates heparan sulfate and reduces the expansion of cytotoxic effector T cells, interferes with the maturation of dendritic cells and increases T regulatory cells. Altogether, AAT may attenuate acute graft-versus-host disease (GvHD) and may facilitate graft acceptance and survival. In addition, AAT enhances levels of cAMP and activation of cAMP-dependent protein kinase A. AAT, a 52kD protein and serine protease inhibitor, belongs to the serpin superfamily.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BFC87F2A-1385-74AF-E053-4EBD850AEF21","latestVersionIndicator":"Yes","beginDate":"2021-04-12","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-04-12","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0DFB079B-107F-7336-E063-731AD00AF853","beginDate":"2024-01-02","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-02","modifiedBy":"GDEEN","dateModified":"2024-01-02","deletedIndicator":"No"},{"value":"Vibegron","valueDescription":null,"ValueMeaning":{"publicId":"14672740","version":"1","preferredName":"Vibegron (Gemtesa)","longName":"14672740v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vibegron","conceptCode":"C152872","definition":"An orally bioavailable agonist of the human beta-3 adrenergic receptor (ADRB3), with muscle relaxing activity. Upon oral administration, vibegron targets, binds to and activates ADRB3, which leads to relaxation of the detrusor smooth muscle during bladder filling. This increases bladder capacity and provides symptomatic relief, including urge urinary incontinence, urgency, and urinary frequency, for overactive bladder.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E216A81-6533-0B42-E063-731AD00A51FA","latestVersionIndicator":"Yes","beginDate":"2024-01-04","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-04","modifiedBy":"GDEEN","dateModified":"2024-01-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E217B9B-88E4-0E46-E063-731AD00A2EF6","beginDate":"2024-01-04","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-04","modifiedBy":"GDEEN","dateModified":"2024-01-04","deletedIndicator":"No"},{"value":"Ponatinib","valueDescription":null,"ValueMeaning":{"publicId":"3776076","version":"1","preferredName":"Ponatinib","longName":"3776076","preferredDefinition":"An orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ponatinib","conceptCode":"C95777","definition":"An orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE84372B-DC57-3F77-E040-BB89AD432E57","latestVersionIndicator":"Yes","beginDate":"2013-06-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E8D64FD-5A9E-0287-E063-731AD00A1D5B","beginDate":"2024-01-09","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-09","modifiedBy":"GDEEN","dateModified":"2024-01-09","deletedIndicator":"No"},{"value":"5-Hydroxytryptophan, DL-","valueDescription":null,"ValueMeaning":{"publicId":"14675155","version":"1","preferredName":"5-Hydroxytryptophan, DL-","longName":"14675155v1.00","preferredDefinition":"A racemic mixture of 5-hydroxytryptophan (5-HTP), a precursor to the neurotransmitter serotonin with anti-depressant, analgesic and appetite-suppressant activities. DL-5-HTP is decarboxylated to serotonin by aromatic-L-amino-acid decarboxylase, and results in increased serotonin levels within the brain. Mediated through serotonin receptors, elevated levels of serotonin causes increased serotonin neurotransmissions, hence leading to release of depression, pain and appetite.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"5-Hydroxytryptophan, DL-","conceptCode":"C61712","definition":"A racemic mixture of 5-hydroxytryptophan (5-HTP), a precursor to the neurotransmitter serotonin with anti-depressant, analgesic and appetite-suppressant activities. DL-5-HTP is decarboxylated to serotonin by aromatic-L-amino-acid decarboxylase, and results in increased serotonin levels within the brain. Mediated through serotonin receptors, elevated levels of serotonin causes increased serotonin neurotransmissions, hence leading to release of depression, pain and appetite.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA05E61-C03C-55F4-E063-731AD00A696E","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA060CC-B7FB-565C-E063-731AD00AC8E6","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Activated Charcoal","valueDescription":null,"ValueMeaning":{"publicId":"5206952","version":"1","preferredName":"Activated Charcoal","longName":"5206952v1.00","preferredDefinition":"Carbon that has been treated to create small, low-volume pores that increase the surface area available for adsorption.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Activated Charcoal","conceptCode":"C77524","definition":"Carbon that has been treated to create small, low-volume pores that increase the surface area available for adsorption.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2F39E58E-6B52-3234-E050-BB89AD43210C","latestVersionIndicator":"Yes","beginDate":"2016-03-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-03-29","modifiedBy":"KUMMEROA","dateModified":"2023-09-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA060CC-B7FC-565C-E063-731AD00AC8E6","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Cultured Lentinula edodes Mycelia Extract","valueDescription":null,"ValueMeaning":{"publicId":"14675156","version":"1","preferredName":"Cultured Lentinula edodes Mycelia Extract","longName":"14675156v1.00","preferredDefinition":"An orally bioavailable capsule-based formulation of a standardized extract of cultured Lentinula edodes (Shiitake mushroom) mycelia (ECLM), which is high in the polysaccharides beta- and alpha-glucans, with potential antioxidant, immunomodulating and antineoplastic activities. Upon oral administration, the cultured Lentinula edodes mycelia extract activates the immune system, by binding to toll-like receptors (TLRs), specifically TLR-4, and induces the activation of dendritic cells (DCs), natural killer (NK) cells, macrophages and T-cells and the release of cytokines. This may clear human papillomavirus (HPV) infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cultured Lentinula edodes Mycelia Extract","conceptCode":"C179283","definition":"An orally bioavailable capsule-based formulation of a standardized extract of cultured Lentinula edodes (Shiitake mushroom) mycelia (ECLM), which is high in the polysaccharides beta- and alpha-glucans, with potential antioxidant, immunomodulating and antineoplastic activities. Upon oral administration, the cultured Lentinula edodes mycelia extract activates the immune system, by binding to toll-like receptors (TLRs), specifically TLR-4, and induces the activation of dendritic cells (DCs), natural killer (NK) cells, macrophages and T-cells and the release of cytokines. This may clear human papillomavirus (HPV) infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA05E61-C03D-55F4-E063-731AD00A696E","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA060CC-B7FD-565C-E063-731AD00AC8E6","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Garlic Extract/Olive Leaf Extract/Elderberry/Oregano Oil/Arabinogalactans/Rosemary Oil-based Supplement","valueDescription":null,"ValueMeaning":{"publicId":"14675157","version":"1","preferredName":"Garlic Extract/Olive Leaf Extract/Elderberry/Oregano Oil/Arabinogalactans/Rosemary Oil-based Supplement","longName":"14675157v1.00","preferredDefinition":"An orally bioavailable herbal combination formulation containing garlic (Allium sativum) bulb extract, olive (Olea europaea) leaf extract, elderberry (Sambucus nigra), oregano (Origanum vulgare) oil, arabinogalactans from the Larch tree (Larix laricina), and rosemary (Rosmarinus officinalis) oil.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Garlic Extract/Olive Leaf Extract/Elderberry/Oregano Oil/Arabinogalactans/Rosemary Oil-based Supplement","conceptCode":"C203501","definition":"An orally bioavailable herbal combination formulation containing garlic (Allium sativum) bulb extract, olive (Olea europaea) leaf extract, elderberry (Sambucus nigra), oregano (Origanum vulgare) oil, arabinogalactans from the Larch tree (Larix laricina), and rosemary (Rosmarinus officinalis) oil.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA05E61-C03E-55F4-E063-731AD00A696E","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA060CC-B7FE-565C-E063-731AD00AC8E6","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Vitamin A/C/E-Zinc/Copper-based Supplement","valueDescription":null,"ValueMeaning":{"publicId":"14675158","version":"1","preferredName":"Vitamin A/C/E-Zinc/Copper-based Supplement","longName":"14675158v1.00","preferredDefinition":"An orally bioavailable combination formulation containing the vitamins A, C and E, as well as the minerals zinc and copper.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vitamin A/C/E-Zinc/Copper-based Supplement","conceptCode":"C203503","definition":"An orally bioavailable combination formulation containing the vitamins A, C and E, as well as the minerals zinc and copper.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA05E61-C03F-55F4-E063-731AD00A696E","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA060CC-B7FF-565C-E063-731AD00AC8E6","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Artemisinin","valueDescription":null,"ValueMeaning":{"publicId":"14675159","version":"1","preferredName":"Artemisinin","longName":"14675159v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Artemisinin","conceptCode":"C78093","definition":"No value exists.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA05E61-C040-55F4-E063-731AD00A696E","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA060CC-B800-565C-E063-731AD00AC8E6","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Berberine","valueDescription":null,"ValueMeaning":{"publicId":"14675160","version":"1","preferredName":"Berberine","longName":"14675160v1.00","preferredDefinition":"A quaternary ammonium salt of an isoquinoline alkaloid and active component of various Chinese herbs, with potential antineoplastic, radiosensitizing, anti-inflammatory, anti-lipidemic and antidiabetic activities. Although the mechanisms of action through which berberine exerts its effects are not yet fully elucidated, upon administration this agent appears to suppress the activation of various proteins and/or modulate the expression of a variety of genes involved in tumorigenesis and inflammation, including, but not limited to transcription factor nuclear factor-kappa B (NF-kB), myeloid cell leukemia 1 (Mcl-1), B-cell lymphoma 2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xl), cyclooxygenase (COX)-2, tumor necrosis factor (TNF), interleukin (IL)-6, IL-12, inducible nitric oxide synthase (iNOS), intercellular adhesion molecule-1 (ICAM-1), E-selectin, monocyte chemoattractant protein-1 (MCP-1), C-X-C motif chemokine 2 (CXCL2), cyclin D1, activator protein (AP-1), hypoxia-inducible factor 1 (HIF-1), signal transducer and activator of transcription 3 (STAT3), peroxisome proliferator-activated receptor (PPAR), arylamine N-acetyltransferase (NAT), and DNA topoisomerase I and II. The modulation of gene expression may induce cell cycle arrest and apoptosis, and inhibit cancer cell proliferation. In addition, berberine modulates lipid and glucose metabolism.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Berberine","conceptCode":"C83551","definition":"A quaternary ammonium salt of an isoquinoline alkaloid and active component of various Chinese herbs, with potential antineoplastic, radiosensitizing, anti-inflammatory, anti-lipidemic and antidiabetic activities. Although the mechanisms of action through which berberine exerts its effects are not yet fully elucidated, upon administration this agent appears to suppress the activation of various proteins and/or modulate the expression of a variety of genes involved in tumorigenesis and inflammation, including, but not limited to transcription factor nuclear factor-kappa B (NF-kB), myeloid cell leukemia 1 (Mcl-1), B-cell lymphoma 2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xl), cyclooxygenase (COX)-2, tumor necrosis factor (TNF), interleukin (IL)-6, IL-12, inducible nitric oxide synthase (iNOS), intercellular adhesion molecule-1 (ICAM-1), E-selectin, monocyte chemoattractant protein-1 (MCP-1), C-X-C motif chemokine 2 (CXCL2), cyclin D1, activator protein (AP-1), hypoxia-inducible factor 1 (HIF-1), signal transducer and activator of transcription 3 (STAT3), peroxisome proliferator-activated receptor (PPAR), arylamine N-acetyltransferase (NAT), and DNA topoisomerase I and II. The modulation of gene expression may induce cell cycle arrest and apoptosis, and inhibit cancer cell proliferation. In addition, berberine modulates lipid and glucose metabolism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA05E61-C041-55F4-E063-731AD00A696E","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA060CC-B801-565C-E063-731AD00AC8E6","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Papaverine Hydrochloride/Phentolamine Mesylate Injectable Formulation","valueDescription":null,"ValueMeaning":{"publicId":"14675161","version":"1","preferredName":"Papaverine Hydrochloride/Phentolamine Mesylate Injectable Formulation","longName":"14675161v1.00","preferredDefinition":"An injectable formulation composed of the hydrochloride (HCl) salt form of papaverine, an opiate alkaloid isolated from the plant Papaver somniferum and produced synthetically, and the mesylate salt form of phentolamine, a synthetic imidazoline and alpha-adrenergic antagonist, that can be used in the treatment of erectile dysfunction (ED). Upon injection of the papaverine HCl/phentolamine mesylate injectable formulation directly into the corpus cavernosum, the two active ingredients work synergistically. Papaverine non-selectively inhibits phosphodiesterases (PDE), increases cyclic adenosine monophosphate (cAMP) production, relaxes penile smooth muscles, causes vasodilation, and increases blood flow to the penis. This causes an erection. Phentolamine binds to and inhibits alpha-1 and alpha-2 adrenergic receptors, resulting in a decrease in peripheral vascular resistance, relaxes penile smooth muscles, causes vasodilatation, and increases blood flow to the penis, thereby simultaneously causing an erection.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Papaverine Hydrochloride/Phentolamine Mesylate Injectable Formulation","conceptCode":"C203505","definition":"An injectable formulation composed of the hydrochloride (HCl) salt form of papaverine, an opiate alkaloid isolated from the plant Papaver somniferum and produced synthetically, and the mesylate salt form of phentolamine, a synthetic imidazoline and alpha-adrenergic antagonist, that can be used in the treatment of erectile dysfunction (ED). Upon injection of the papaverine HCl/phentolamine mesylate injectable formulation directly into the corpus cavernosum, the two active ingredients work synergistically. Papaverine non-selectively inhibits phosphodiesterases (PDE), increases cyclic adenosine monophosphate (cAMP) production, relaxes penile smooth muscles, causes vasodilation, and increases blood flow to the penis. This causes an erection. Phentolamine binds to and inhibits alpha-1 and alpha-2 adrenergic receptors, resulting in a decrease in peripheral vascular resistance, relaxes penile smooth muscles, causes vasodilatation, and increases blood flow to the penis, thereby simultaneously causing an erection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA05E61-C042-55F4-E063-731AD00A696E","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA062EB-F369-56C1-E063-731AD00ADB5E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Mycophenolate Mofetil","valueDescription":null,"ValueMeaning":{"publicId":"5511068","version":"1","preferredName":"Mycophenolate Mofetil (MMF)","longName":"5511068v1.00","preferredDefinition":"The morpholinoethyl ester of mycophenolic acid (MPA) with potent immunosuppressive properties.  Mycophenolate stops T-cell and B-cell proliferation through selective inhibition of the de novo pathway of purine biosynthesis.  In vivo, the active metabolite, MPA, reversibly inhibits inosine 5'-monophosphate dehydrogenase, an enzyme involved in the de novo synthesis of guanine nucleotides.  MPA displays high lymphocyte specificity and cytotoxicity due to the higher dependence of activated lymphocytes on both salvage and de novo synthesis of guanine nucleotides relative to other cell types. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycophenolate Mofetil","conceptCode":"C1468","definition":"The morpholinoethyl ester of mycophenolic acid (MPA) with potent immunosuppressive properties.  Mycophenolate stops T-cell and B-cell proliferation through selective inhibition of the de novo pathway of purine biosynthesis.  In vivo, the active metabolite, MPA, reversibly inhibits inosine 5'-monophosphate dehydrogenase, an enzyme involved in the de novo synthesis of guanine nucleotides.  MPA displays high lymphocyte specificity and cytotoxicity due to the higher dependence of activated lymphocytes on both salvage and de novo synthesis of guanine nucleotides relative to other cell types. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3EB2EF73-1A77-33B0-E053-F662850AB0D7","latestVersionIndicator":"Yes","beginDate":"2016-10-12","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-10-12","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA062EB-F36A-56C1-E063-731AD00ADB5E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Cinacalcet Hydrochloride","valueDescription":null,"ValueMeaning":{"publicId":"13633926","version":"1","preferredName":"Cinacalcet Hydrochloride","longName":"13633926v1.00","preferredDefinition":"The orally bioavailable hydrochloride salt of the calcimimetic cinacalcet. Cinacalcet increases the sensitivity of calcium-sensing receptors on chief cells in the parathyroid gland to extracellular calcium, thereby reducing parathyroid hormone (PTH) secretion. A reduction in PTH levels inhibits osteoclast activity, which may result in a decrease in cortical bone turnover and bone fibrosis, and normalization of serum calcium and phosphorus levels. In addition, by reducing PTH levels, cinacalcet may reduce PSA levels; PTH appears to raise PSA levels and may increase prostate cancer cell growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cinacalcet Hydrochloride","conceptCode":"C47450","definition":"The orally bioavailable hydrochloride salt of the calcimimetic cinacalcet. Cinacalcet increases the sensitivity of calcium-sensing receptors on chief cells in the parathyroid gland to extracellular calcium, thereby reducing parathyroid hormone (PTH) secretion. A reduction in PTH levels inhibits osteoclast activity, which may result in a decrease in cortical bone turnover and bone fibrosis, and normalization of serum calcium and phosphorus levels. In addition, by reducing PTH levels, cinacalcet may reduce PSA levels; PTH appears to raise PSA levels and may increase prostate cancer cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC666493-8747-4554-E053-731AD00A0758","latestVersionIndicator":"Yes","beginDate":"2023-05-23","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-23","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA062EB-F36B-56C1-E063-731AD00ADB5E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Clomipramine Hydrochloride","valueDescription":null,"ValueMeaning":{"publicId":"14675162","version":"1","preferredName":"Clomipramine Hydrochloride","longName":"14675162v1.00","preferredDefinition":"The hydrochloride salt form of clomipramine, a tertiary amine salt derivative of dibenzazepine. Clomipramine hydrochloride is a tricyclic antidepressant that acts by reducing the re-uptake of norepinephrine and serotonin in the central nervous system, thereby enhancing the effects of these neurotransmitters. This drug also binds to alpha-adrenergic, histaminergic, and cholinergic receptors which are responsible for the many side effects seen with this agent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clomipramine Hydrochloride","conceptCode":"C47458","definition":"The hydrochloride salt form of clomipramine, a tertiary amine salt derivative of dibenzazepine. Clomipramine hydrochloride is a tricyclic antidepressant that acts by reducing the re-uptake of norepinephrine and serotonin in the central nervous system, thereby enhancing the effects of these neurotransmitters. This drug also binds to alpha-adrenergic, histaminergic, and cholinergic receptors which are responsible for the many side effects seen with this agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA05E61-C043-55F4-E063-731AD00A696E","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA062EB-F36C-56C1-E063-731AD00ADB5E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Dorzolamide Hydrochloride/Timolol Maleate Ophthalmic Solution","valueDescription":null,"ValueMeaning":{"publicId":"14675163","version":"1","preferredName":"Dorzolamide Hydrochloride/Timolol Maleate Ophthalmic Solution","longName":"14675163v1.00","preferredDefinition":"An ophthalmic combination agent composed of the hydrochloride salt form of dorzolamide, an inhibitor of carbonic anhydrase II, and the maleate salt form of timolol, a propanolamine derivative and a non-selective beta-adrenergic antagonist, with intraocular pressure-reducing activity. Upon topical administration of dorzolamide hydrochloride/timolol maleate ophthalmic solution, dorzolamide targets, binds to and inhibits carbonic anhydrase II, a zinc-containing enzyme that catalyzes the rapid conversion of carbon dioxide and water into carbonic acid, protons and bicarbonate ions, in the eye. This decreases aqueous humor secretion, and reduces sodium and fluid transport. Although the precise mechanism of action of timolol is not clearly established, timolol targets, binds to and inhibits beta adrenoceptors in the ciliary body of the eye which may decrease aqueous humor production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dorzolamide Hydrochloride/Timolol Maleate Ophthalmic Solution","conceptCode":"C203504","definition":"An ophthalmic combination agent composed of the hydrochloride salt form of dorzolamide, an inhibitor of carbonic anhydrase II, and the maleate salt form of timolol, a propanolamine derivative and a non-selective beta-adrenergic antagonist, with intraocular pressure-reducing activity. Upon topical administration of dorzolamide hydrochloride/timolol maleate ophthalmic solution, dorzolamide targets, binds to and inhibits carbonic anhydrase II, a zinc-containing enzyme that catalyzes the rapid conversion of carbon dioxide and water into carbonic acid, protons and bicarbonate ions, in the eye.  This decreases aqueous humor secretion, and reduces sodium and fluid transport. Although the precise mechanism of action of timolol is not clearly established, timolol targets, binds to and inhibits beta adrenoceptors in the ciliary body of the eye which may decrease aqueous humor production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA05E61-C044-55F4-E063-731AD00A696E","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA062EB-F36D-56C1-E063-731AD00ADB5E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Sacubitril/Valsartan","valueDescription":null,"ValueMeaning":{"publicId":"13961838","version":"1","preferredName":"Sacubitril/Valsartan","longName":"13961838v1.00","preferredDefinition":"A combination of sacubitril and valsartan with natriuretic and anti-hypertensive properties. Upon administration, sacubitril is metabolized by esterases to its active metabolite, LBQ657 (sacubitrilat), which inhibits neprilysin, a neutral endopeptidase that cleaves natriuretic peptides such as atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and c-type natriuretic peptide (CNP), as well as certain vasoconstricting peptides including as angiotensin I and II, and endothelin-1. Inhibition of neprilysin leads to increased concentrations of endogenous natriuretic peptides, which function to activate downstream receptors that promote vasodilation, natriuresis and diuresis, while simultaneously increasing the concentration of vasoconstricting peptides such as angiotensin II. Co-administration with valsartan, an angiotensin II receptor blocker, prevents the vasoconstrictive effects of neprilysin inhibition and promotes a decrease in vascular resistance and blood pressure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sacubitril/Valsartan","conceptCode":"C162629","definition":"A combination of sacubitril and valsartan with natriuretic and anti-hypertensive properties. Upon administration, sacubitril is metabolized by esterases to its active metabolite, LBQ657 (sacubitrilat), which inhibits neprilysin, a neutral endopeptidase that cleaves natriuretic peptides such as atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and c-type natriuretic peptide (CNP), as well as certain vasoconstricting peptides including as angiotensin I and II, and endothelin-1. Inhibition of neprilysin leads to increased concentrations of endogenous natriuretic peptides, which function to activate downstream receptors that promote vasodilation, natriuresis and diuresis, while simultaneously increasing the concentration of vasoconstricting peptides such as angiotensin II. Co-administration with valsartan, an angiotensin II receptor blocker, prevents the vasoconstrictive effects of neprilysin inhibition and promotes a decrease in vascular resistance and blood pressure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE474EC3-FB58-54FC-E053-731AD00A91F1","latestVersionIndicator":"Yes","beginDate":"2023-06-16","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-06-16","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA062EB-F36E-56C1-E063-731AD00ADB5E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Azelaic Acid","valueDescription":null,"ValueMeaning":{"publicId":"14675164","version":"1","preferredName":"Azelaic Acid","longName":"14675164v1.00","preferredDefinition":"A naturally occurring dicarboxylic acid produced by Malassezia furfur and found in whole grain cereals, rye, barley and animal products.  Azelaic acid possesses antibacterial, keratolytic, comedolytic, and anti-oxidant activity. Azelaic acid is bactericidal against Proprionibacterium acnes and Staphylococcus epidermidis due to its inhibitory effect on the synthesis of microbial cellular proteins. Azelaic acid exerts its keratolytic and comedolytic effects by reducing the thickness of the stratum corneum and decreasing the number of keratohyalin granules by reducing the amount and distribution of filaggrin in epidermal layers. Azelaic acid also possesses a direct anti-inflammatory effect due to its scavenger activity of free oxygen radical. This drug is used topically to reduce inflammation associated with acne and rosacea.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Azelaic Acid","conceptCode":"C47407","definition":"A naturally occurring dicarboxylic acid produced by Malassezia furfur and found in whole grain cereals, rye, barley and animal products.  Azelaic acid possesses antibacterial, keratolytic, comedolytic, and anti-oxidant activity. Azelaic acid is bactericidal against Proprionibacterium acnes and Staphylococcus epidermidis due to its inhibitory effect on the synthesis of microbial cellular proteins. Azelaic acid exerts its keratolytic and comedolytic effects by reducing the thickness of the stratum corneum and decreasing the number of keratohyalin granules by reducing the amount and distribution of filaggrin in epidermal layers. Azelaic acid also possesses a direct anti-inflammatory effect due to its scavenger activity of free oxygen radical. This drug is used topically to reduce inflammation associated with acne and rosacea.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA05E61-C045-55F4-E063-731AD00A696E","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA062EB-F36F-56C1-E063-731AD00ADB5E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Ginger","valueDescription":null,"ValueMeaning":{"publicId":"14675165","version":"1","preferredName":"Ginger","longName":"14675165v1.00","preferredDefinition":"A fresh, dried or processed form of the rhizome of the Asian perennial plant Zingiber officinale (ginger) with potential anti-emetic activity. Ginger is mainly used in cooking due to its unique fragrance and flavor and has been studied for its use in the treatment of nausea and vomiting. The gingeroles and shoagoles found in ginger may be responsible for ginger's anti-emetic effect.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ginger","conceptCode":"C66725","definition":"A fresh, dried or processed form of the rhizome of the Asian perennial plant Zingiber officinale (ginger) with potential anti-emetic activity. Ginger is mainly used in cooking due to its unique fragrance and flavor and has been studied for its use in the treatment of nausea and vomiting. The gingeroles and shoagoles found in ginger may be responsible for ginger's anti-emetic effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA05E61-C046-55F4-E063-731AD00A696E","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA062EB-F370-56C1-E063-731AD00ADB5E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Levomilnacipran Hydrochloride","valueDescription":null,"ValueMeaning":{"publicId":"14675166","version":"1","preferredName":"Levomilnacipran Hydrochloride","longName":"14675166v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Levomilnacipran Hydrochloride","conceptCode":"C166646","definition":"No value exists.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA05E61-C047-55F4-E063-731AD00A696E","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA062EB-F371-56C1-E063-731AD00ADB5E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Zinc Monomethionine/Copper-based Supplement","valueDescription":null,"ValueMeaning":{"publicId":"14675167","version":"1","preferredName":"Zinc Monomethionine/Copper-based Supplement","longName":"14675167v1.00","preferredDefinition":"An orally bioavailable combination of the minerals zinc, which is complexed with the essential amino acid methionine, and copper.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zinc Monomethionine/Copper-based Supplement","conceptCode":"C203506","definition":"n orally bioavailable combination of the minerals zinc, which is complexed with the essential amino acid methionine, and copper.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA05E61-C048-55F4-E063-731AD00A696E","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA062EB-F372-56C1-E063-731AD00ADB5E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Marigold Extract/Saffron Extract-based Supplement","valueDescription":null,"ValueMeaning":{"publicId":"14675168","version":"1","preferredName":"Marigold Extract/Saffron Extract-based Supplement","longName":"14675168v1.00","preferredDefinition":"An orally bioavailable combination of saffron (Crocus sativus) stigma extract and Marigold (Tagetes erecta) flower extract which provides lutein, (meso-)zeaxanthin, phospholipids, and mixed carotenoids, including alpha-carotene.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Marigold Extract/Saffron Extract-based Supplement","conceptCode":"C203507","definition":"An orally bioavailable combination of saffron (Crocus sativus) stigma extract and Marigold (Tagetes erecta) flower extract which provides lutein, (meso-)zeaxanthin, phospholipids, and mixed carotenoids, including alpha-carotene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA05E61-C049-55F4-E063-731AD00A696E","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA062EB-F373-56C1-E063-731AD00ADB5E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Sodium Borate","valueDescription":null,"ValueMeaning":{"publicId":"14675169","version":"1","preferredName":"Sodium Borate","longName":"14675169v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sodium Borate","conceptCode":"C77496","definition":"No value exists.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA060CC-B7E5-565C-E063-731AD00AC8E6","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA062EB-F374-56C1-E063-731AD00ADB5E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Nattokinase/Serrapeptase-based Supplement","valueDescription":null,"ValueMeaning":{"publicId":"14675170","version":"1","preferredName":"Nattokinase/Serrapeptase-based Supplement","longName":"14675170v1.00","preferredDefinition":"A dietary supplement formulation composed of two proteolytic enzymes nattokinase, a serine protease derived fromBacillus subtilis and produced during nattos fermentation process, and serrapeptase, which is derived from the non-pathogenic enterobacteriaSerratia E15.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nattokinase/Serrapeptase-based Supplement","conceptCode":"C203502","definition":"A dietary supplement formulation composed of two proteolytic enzymes nattokinase, a serine protease derived from Bacillus subtilis and produced during natto's fermentation process, and serrapeptase, which is derived from the non-pathogenic enterobacteria Serratia E15.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA060CC-B7E6-565C-E063-731AD00AC8E6","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA062EB-F375-56C1-E063-731AD00ADB5E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Nicotine Gum","valueDescription":null,"ValueMeaning":{"publicId":"3276683","version":"1","preferredName":"Nicotine Gum","longName":"3276683","preferredDefinition":"A chewing gum containing nicotine used as a substitute for the active ingredient in tobacco. Nicotine chewing gum reduces the withdrawal symptoms associated with smoking cessation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nicotine Gum","conceptCode":"C15663","definition":"A chewing gum containing nicotine used as a substitute for the active ingredient in tobacco. Nicotine chewing gum reduces the withdrawal symptoms associated with smoking cessation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACFBB39A-964C-633A-E040-BB89AD436C25","latestVersionIndicator":"Yes","beginDate":"2011-09-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-09-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA062EB-F376-56C1-E063-731AD00ADB5E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Ocrelizumab","valueDescription":null,"ValueMeaning":{"publicId":"13714642","version":"1","preferredName":"Ocrelizumab","longName":"13714642v1.00","preferredDefinition":"A Fc-modified, humanized monoclonal antibody directed against the B-cell CD20 cell surface antigen, with immunosuppressive activity. Ocrelizumab binds to CD20 on the surfaces of B-cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B-cells overexpressing CD20. The CD20 antigen, a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel, is found on over 90% of B-cells, B-cell lymphomas, and other lymphoid tumor cells of B-cell origin; it plays an important role in B-cell functioning.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ocrelizumab","conceptCode":"C66250","definition":"A Fc-modified, humanized monoclonal antibody directed against the B-cell CD20 cell surface antigen, with immunosuppressive activity. Ocrelizumab binds to CD20 on the surfaces of B-cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B-cells overexpressing CD20. The CD20 antigen, a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel, is found on over 90% of B-cells, B-cell lymphomas, and other lymphoid tumor cells of B-cell origin; it plays an important role in B-cell functioning.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC9B4A16-F173-71DC-E053-731AD00A42F0","latestVersionIndicator":"Yes","beginDate":"2023-05-26","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-26","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA062EB-F377-56C1-E063-731AD00ADB5E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Pomegranate","valueDescription":null,"ValueMeaning":{"publicId":"14675171","version":"1","preferredName":"Pomegranate","longName":"14675171v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pomegranate","conceptCode":"C73929","definition":"No value exists.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA060CC-B7E7-565C-E063-731AD00AC8E6","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA062EB-F378-56C1-E063-731AD00ADB5E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Saw Palmetto Berry Extract/Lycopene/Beta-Sitosterol/Vitamin D3/Zinc/Selenium/Quercetin-based Supplement","valueDescription":null,"ValueMeaning":{"publicId":"14675172","version":"1","preferredName":"Saw Palmetto Berry Extract/Lycopene/Beta-Sitosterol/Vitamin D3/Zinc/Selenium/Quercetin-based Supplement","longName":"14675172v1.00","preferredDefinition":"A dietary supplement formulation composed of saw palmetto berry extract, lycopene, beta-sitosterol, vitamin D3, zinc, selenium, and quercetin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Saw Palmetto Berry Extract/Lycopene/Beta-Sitosterol/Vitamin D3/Zinc/Selenium/Quercetin-based Supplement","conceptCode":"C203500","definition":"A dietary supplement formulation composed of saw palmetto berry extract, lycopene, beta-sitosterol, vitamin D3, zinc, selenium, and quercetin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA060CC-B7E8-565C-E063-731AD00AC8E6","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA062EB-F379-56C1-E063-731AD00ADB5E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Pygeum Extract","valueDescription":null,"ValueMeaning":{"publicId":"14675173","version":"1","preferredName":"Pygeum Extract","longName":"14675173v1.00","preferredDefinition":"An herbal extract derived from the African prune treePygeum africanum.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pygeum Extract","conceptCode":"C203499","definition":"An herbal extract derived from the African prune tree Pygeum africanum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA060CC-B7E9-565C-E063-731AD00AC8E6","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA062EB-F37A-56C1-E063-731AD00ADB5E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Red Yeast Rice Extract","valueDescription":null,"ValueMeaning":{"publicId":"14675174","version":"1","preferredName":"Red Yeast Rice Extract","longName":"14675174v1.00","preferredDefinition":"An extract derived from rice that has been fermented with the yeast Monascus purpureus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Red Yeast Rice Extract","conceptCode":"C203498","definition":"An extract derived from rice that has been fermented with the yeast Monascus purpureus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA060CC-B7EA-565C-E063-731AD00AC8E6","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA062EB-F37B-56C1-E063-731AD00ADB5E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Resveratrol","valueDescription":null,"ValueMeaning":{"publicId":"3630009","version":"1","preferredName":"Resveratrol","longName":"3630009","preferredDefinition":"A phytoalexin derived from grapes and other food products with antioxidant and potential chemopreventive activities. Resveratrol induces phase II drug-metabolizing enzymes (anti-initiation activity); mediates anti-inflammatory effects and inhibits cyclooxygenase and hydroperoxidase functions (anti-promotion activity); and induces promyelocytic leukemia cell differentiation (anti-progression activity), thereby exhibiting activities in three major steps of carcinogenesis. This agent may inhibit TNF-induced activation of NF-kappaB in a dose- and time-dependent manner. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Resveratrol","conceptCode":"C1215","definition":"A phytoalexin derived from grapes and other food products with antioxidant and potential chemopreventive activities. Resveratrol induces phase II drug-metabolizing enzymes (anti-initiation activity); mediates anti-inflammatory effects and inhibits cyclooxygenase and hydroperoxidase functions (anti-promotion activity); and induces promyelocytic leukemia cell differentiation (anti-progression activity), thereby exhibiting activities in three major steps of carcinogenesis. This agent may inhibit TNF-induced activation of NF-kappaB in a dose- and time-dependent manner. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF2CE395-C15E-016C-E040-BB89AD437110","latestVersionIndicator":"Yes","beginDate":"2012-11-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-11-23","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA062EB-F37C-56C1-E063-731AD00ADB5E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Riboflavin","valueDescription":null,"ValueMeaning":{"publicId":"14675175","version":"1","preferredName":"Riboflavin","longName":"14675175v1.00","preferredDefinition":"An essential human nutrient that is a heat-stable and water-soluble flavin belonging to the vitamin B family. Riboflavin is a precursor of the coenzymes flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD). These coenzymes are of vital importance in normal tissue respiration, pyridoxine activation, tryptophan to niacin conversion, fat, carbohydrate, and protein metabolism, and glutathione reductase mediated detoxification. Riboflavin may also be involved in maintaining erythrocyte integrity. This vitamin is essential for healthy skin, nails, and hair.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Riboflavin","conceptCode":"C808","definition":"An essential human nutrient that is a heat-stable and water-soluble flavin belonging to the vitamin B family. Riboflavin is a precursor of the coenzymes flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD). These coenzymes are of vital importance in normal tissue respiration, pyridoxine activation, tryptophan to niacin conversion, fat, carbohydrate, and protein metabolism, and glutathione reductase mediated detoxification. Riboflavin may also be involved in maintaining erythrocyte integrity. This vitamin is essential for healthy skin, nails, and hair.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA060CC-B7EB-565C-E063-731AD00AC8E6","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA062EB-F37D-56C1-E063-731AD00ADB5E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Selenium/Fermented Organic Mushroom Blend/Uncaria tomentosa Bark-based supplement","valueDescription":null,"ValueMeaning":{"publicId":"14675176","version":"1","preferredName":"Selenium/Fermented Organic Mushroom Blend/Uncaria tomentosa Bark-based supplement","longName":"14675176v1.00","preferredDefinition":"A dietary supplement formulation composed of fermented organic mushroom blend, including Maitake (Grifola frondosa) mycelia, Shiitake (Lentinula eddoes) mycelia and Reishi (Ganoderma lucidum) mycelia, selenium, and Uncaria tomentosa (cats claw) bark.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Selenium/Fermented Organic Mushroom Blend/Uncaria tomentosa Bark-based supplement","conceptCode":"C203497","definition":"A dietary supplement formulation composed of fermented organic mushroom blend, including Maitake (Grifola frondosa) mycelia, Shiitake (Lentinula eddoes) mycelia and Reishi (Ganoderma lucidum) mycelia, selenium, and Uncaria tomentosa (cat's claw) bark.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA060CC-B7EC-565C-E063-731AD00AC8E6","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA062EB-F37E-56C1-E063-731AD00ADB5E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Zopiclone","valueDescription":null,"ValueMeaning":{"publicId":"14675177","version":"1","preferredName":"Zopiclone","longName":"14675177v1.00","preferredDefinition":"The racemic form of a nonbenzodiazepine, cyclopyrrolone with hypnotic and sedative activity and without significant anxiolytic activity. Although the exact mechanism of action remains to be fully elucidated, zopiclone is able to bind to and activate the omega-1 subtype of the alpha subunit of the gamma-aminobutyric acid-benzodiazepine GABA receptor complex (GABA-A), a chloride ionophore complex in the central nervous system (CNS). This leads to the opening of chloride channels, causing hyperpolarization, inhibition of neuronal firing, and enhancement of the inhibitory effect of GABA. This eventually leads to a hypnotic effect and allows for an induction of sleep.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zopiclone","conceptCode":"C80279","definition":"The racemic form of a nonbenzodiazepine, cyclopyrrolone with hypnotic and sedative activity and without significant anxiolytic activity. Although the exact mechanism of action remains to be fully elucidated, zopiclone is able to bind to and activate the omega-1 subtype of the alpha subunit of the gamma-aminobutyric acid-benzodiazepine GABA receptor complex (GABA-A), a chloride ionophore complex in the central nervous system (CNS). This leads to the opening of chloride channels, causing hyperpolarization, inhibition of neuronal firing, and enhancement of the inhibitory effect of GABA. This eventually leads to a hypnotic effect and allows for an induction of sleep.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EA060CC-B7ED-565C-E063-731AD00AC8E6","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EA062EB-F37F-56C1-E063-731AD00ADB5E","beginDate":"2024-01-10","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-10","modifiedBy":"GDEEN","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Mushroom Extract","valueDescription":null,"ValueMeaning":{"publicId":"14675364","version":"1","preferredName":"Mushroom Extract","longName":"14675364v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mushroom Extract","conceptCode":"C71949","definition":"An extract of Agaricus bisporus, also known as cultivated mushroom, button mushroom and common mushroom.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EB42A15-FA65-7040-E063-731AD00A8C57","latestVersionIndicator":"Yes","beginDate":"2024-01-11","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-11","modifiedBy":"GDEEN","dateModified":"2024-01-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0EB4370E-F1BF-7284-E063-731AD00AFFCF","beginDate":"2024-01-11","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-11","modifiedBy":"GDEEN","dateModified":"2024-01-11","deletedIndicator":"No"},{"value":"Prebiotic supplements","valueDescription":null,"ValueMeaning":{"publicId":"14688620","version":"1","preferredName":"Synbiotic Supplement","longName":"14688620v1.00","preferredDefinition":"A nutritional supplement comprised of prebiotic and probiotic ingredients, with potential immunomodulating and gastrointestinal (GI) flora restoring activity. Upon ingestion of the synbiotic supplement, the prebiotics and probiotics work synergistically in the GI tract, thereby modulating the GI flora ecosystem and may improve the functions of the intestinal barrier. In addition, synbiotics may have a beneficial effect on the immune system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Synbiotic Supplement","conceptCode":"C99230","definition":"A nutritional supplement comprised of prebiotic and probiotic ingredients, with potential immunomodulating and gastrointestinal (GI) flora restoring activity. Upon ingestion of the synbiotic supplement, the prebiotics and probiotics work synergistically in the GI tract, thereby modulating the GI flora ecosystem and may improve the functions of the intestinal barrier. In addition, synbiotics may have a beneficial effect on the immune system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F3B2DD9-E62A-795A-E063-731AD00A62FC","latestVersionIndicator":"Yes","beginDate":"2024-01-18","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-18","modifiedBy":"GDEEN","dateModified":"2024-01-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F3B2DD9-E62B-795A-E063-731AD00A62FC","beginDate":"2024-01-18","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-18","modifiedBy":"GDEEN","dateModified":"2024-01-18","deletedIndicator":"No"},{"value":"Alrizomadlin","valueDescription":null,"ValueMeaning":{"publicId":"13961798","version":"1","preferredName":"Alrizomadlin","longName":"13961798v1.00","preferredDefinition":"An orally available inhibitor of human homolog of double minute 2 (HDM2; mouse double minute 2 homolog; MDM2), with potential antineoplastic activity. Upon oral administration,alrizomadlin binds to HDM2, preventing the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This may result in the restoration of p53 signaling and lead to the p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger protein and a negative regulator of the p53 pathway, is often overexpressed in cancer cells. It has been implicated in cancer cell proliferation and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alrizomadlin","conceptCode":"C132991","definition":"An orally available inhibitor of human homolog of double minute 2 (HDM2; mouse double minute 2 homolog; MDM2), with potential antineoplastic activity. Upon oral administration,alrizomadlin binds to HDM2, preventing the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This may result in the restoration of p53 signaling and lead to the p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger protein and a negative regulator of the p53 pathway, is often overexpressed in cancer cells. It has been implicated in cancer cell proliferation and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE470C61-592F-4CA4-E053-731AD00ADDA6","latestVersionIndicator":"Yes","beginDate":"2023-06-16","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-06-16","modifiedBy":"GDEEN","dateModified":"2024-01-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F3B2DD9-E62C-795A-E063-731AD00A62FC","beginDate":"2024-01-18","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-18","modifiedBy":"GDEEN","dateModified":"2024-01-18","deletedIndicator":"No"},{"value":"Zotiraciclib Citrate","valueDescription":null,"ValueMeaning":{"publicId":"13746575","version":"1","preferredName":"Zotiraciclib Citrate","longName":"13746575v1.00","preferredDefinition":"An orally bioavailable citrate salt form of zotiraciclib a multi-kinase inhibitor for cyclin dependent kinase (CDK) subtypes 1, 2, 7 and 9, Janus-associated kinase 2 (JAK2), FMS-related tyrosine kinase 3 (FLT3, FLK2, STK1), with potential antineoplastic activity. Upon oral administration, CDK/JAK2/FLT3 Inhibitor TG02 binds to and inhibits the CDK subtypes, JAK2, and FLT3. TG02 also inhibits, to a lesser extent, TYK2, TYRO3, STAT5 and P38delta. This may result in both an induction of apoptosis and an inhibition of tumor cell proliferation in cancer cells that overexpress these kinases. JAK2, often upregulated or mutated in a variety of cancer cells, mediates STAT3 activation and plays a key role in tumor cell proliferation and survival. CDKs are serine/threonine kinases that play key roles in the regulation of the cell cycle and cellular proliferation. FLT3, a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zotiraciclib Citrate","conceptCode":"C105851","definition":"An orally bioavailable citrate salt form of zotiraciclib a multi-kinase inhibitor for cyclin dependent kinase (CDK) subtypes 1, 2, 7 and 9, Janus-associated kinase 2 (JAK2), FMS-related tyrosine kinase 3 (FLT3, FLK2, STK1), with potential antineoplastic activity. Upon oral administration, CDK/JAK2/FLT3 Inhibitor TG02 binds to and inhibits the CDK subtypes, JAK2, and FLT3. TG02 also inhibits, to a lesser extent, TYK2, TYRO3, STAT5 and P38delta. This may result in both an induction of apoptosis and an inhibition of tumor cell proliferation in cancer cells that overexpress these kinases. JAK2, often upregulated or mutated in a variety of cancer cells, mediates STAT3 activation and plays a key role in tumor cell proliferation and survival. CDKs are serine/threonine kinases that play key roles in the regulation of the cell cycle and cellular proliferation. FLT3, a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCA66669-55B6-6FE3-E053-731AD00A12E6","latestVersionIndicator":"Yes","beginDate":"2023-05-27","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-27","modifiedBy":"GDEEN","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102FFBCF-5CF8-046F-E063-731AD00AD14D","beginDate":"2024-01-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-30","modifiedBy":"GDEEN","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"NovoTTF-100A Device","valueDescription":null,"ValueMeaning":{"publicId":"7717906","version":"1","preferredName":"NovoTTF-100A Device","longName":"7717906","preferredDefinition":"A portable, battery-operated device that is used to apply low intensity, alternating electric fields, also called tumor treatment fields (TTFs; TTFields), that can potentially be used to kill cancer cells. Upon placement of the insulated electrodes of the NovoTTF-100A device on the skin's surface encircling the tumor area, electrical charges are delivered, and the resulting electrical fields interfere with cell division. This induces cell death in and inhibits proliferation of tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NovoTTF-100A Device","conceptCode":"C125103","definition":"A portable, battery-operated device that is used to apply low intensity, alternating electric fields, also called tumor treatment fields (TTFs; TTFields), that can potentially be used to kill cancer cells. Upon placement of the insulated electrodes of the NovoTTF-100A device on the skin's surface encircling the tumor area, electrical charges are delivered, and the resulting electrical fields interfere with cell division. This induces cell death in and inhibits proliferation of tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C68E0707-A38D-1753-E053-4EBD850AA75A","latestVersionIndicator":"Yes","beginDate":"2021-07-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-07-07","modifiedBy":"GDEEN","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102FFBCF-5CF9-046F-E063-731AD00AD14D","beginDate":"2024-01-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-30","modifiedBy":"GDEEN","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Valproic Acid","valueDescription":null,"ValueMeaning":{"publicId":"7460887","version":"1","preferredName":"Valproic Acid","longName":"7460887","preferredDefinition":"A synthetic derivative of propylpentanoic acid with antiepileptic properties and potential antineoplastic and antiangiogenesis activities.  In epilepsy, valproic acid appears to act by increasing the concentration of gamma-aminobutyric acid (GABA) in the brain. This agent's antitumor and antiangiogenesis activities may be related to the inhibition of histone deacetylases and nitric oxide synthase, which results in the inhibition of nitric oxide synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Valproic Acid","conceptCode":"C29536","definition":"A synthetic derivative of propylpentanoic acid with antiepileptic properties and potential antineoplastic and antiangiogenesis activities.  In epilepsy, valproic acid appears to act by increasing the concentration of gamma-aminobutyric acid (GABA) in the brain. This agent's antitumor and antiangiogenesis activities may be related to the inhibition of histone deacetylases and nitric oxide synthase, which results in the inhibition of nitric oxide synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1047D74-D54F-632D-E053-4EBD850AB0BF","latestVersionIndicator":"Yes","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102FFBCF-5CFA-046F-E063-731AD00AD14D","beginDate":"2024-01-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-30","modifiedBy":"GDEEN","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Topical Leptospermum Honey","valueDescription":null,"ValueMeaning":{"publicId":"14737557","version":"1","preferredName":"Topical Leptospermum Honey","longName":"14737557v1.00","preferredDefinition":"A topical formulation composed of active Leptospermum honey (ALH), a monofloral honey produced by bees fed on the flowers of the New Zealand Manuka bush (Leptospermum scoparium), with potential wound repair, antibacterial, anti-inflammatory, and protective activities. Upon administration of topical Leptospermum honey, the active ingredients in this honey may promote healing, and prevent inflammation and infection.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Topical Leptospermum Honey","conceptCode":"C203678","definition":"A topical formulation composed of active Leptospermum honey (ALH), a monofloral honey produced by bees fed on the flowers of the New Zealand Manuka bush (Leptospermum scoparium), with potential wound repair, antibacterial, anti-inflammatory, and protective activities. Upon administration of topical Leptospermum honey, the active ingredients in this honey may promote healing, and prevent inflammation and infection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"102FFBCF-5CF7-046F-E063-731AD00AD14D","latestVersionIndicator":"Yes","beginDate":"2024-01-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-30","modifiedBy":"GDEEN","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102FFBCF-5CFB-046F-E063-731AD00AD14D","beginDate":"2024-01-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-30","modifiedBy":"GDEEN","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"DRD2 Antagonist/ClpP Agonist ONC206","valueDescription":null,"ValueMeaning":{"publicId":"14483679","version":"1","preferredName":"DRD2 Antagonist/ClpP Agonist ONC206","longName":"14483679v1.00","preferredDefinition":"An orally bioavailable, selective bitopic dopamine receptor D2 (DRD2) antagonist and mitochondrial caseinolytic protease P (ClpP) agonist, with potential antineoplastic activity. Upon administration, DRD2 antagonist/ClpP agonist ONC206 targets, binds to and inhibits the activity of DRD2. This may inactivate Akt (protein kinase B) and extracellular signal-regulated kinase (ERK), which may result in inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt signal transduction pathway as well as the mitogen-activated protein kinase (MAPK)/ERK-mediated pathway. This may lead to the induction of tumor cell apoptosis mediated by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)/death receptor type 5 (DR5; TRAIL receptor 2) signaling in tumor cells. In addition, ONC206 targets and binds to ClpP and induces proteolysis. This may disrupt mitochondrial structure and function in tumor cells and lead to tumor cell death. DRD2, a G protein-coupled receptor (GPCR), is overexpressed in various malignancies. It is activated by dopamine produced by the tumor cells or present in the tumor microenvironment (TME) and plays an important role in the pro-survival and stress signaling pathways. ONC206 is able to cross the blood-brain barrier (BBB).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"DRD2 Antagonist/ClpP Agonist ONC206","conceptCode":"C176975","definition":"An orally bioavailable, selective bitopic dopamine receptor D2 (DRD2) antagonist and mitochondrial caseinolytic protease P (ClpP) agonist, with potential antineoplastic activity. Upon administration, DRD2 antagonist/ClpP agonist ONC206 targets, binds to and inhibits the activity of DRD2. This may inactivate Akt (protein kinase B) and extracellular signal-regulated kinase (ERK), which may result in inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt signal transduction pathway as well as the mitogen-activated protein kinase (MAPK)/ERK-mediated pathway. This may lead to the induction of tumor cell apoptosis mediated by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)/death receptor type 5 (DR5; TRAIL receptor 2) signaling in tumor cells. In addition, ONC206 targets and binds to ClpP and induces proteolysis. This may disrupt mitochondrial structure and function in tumor cells and lead to tumor cell death. DRD2, a G protein-coupled receptor (GPCR), is overexpressed in various malignancies. It is activated by dopamine produced by the tumor cells or present in the tumor microenvironment (TME) and plays an important role in the pro-survival and stress signaling pathways. ONC206 is able to cross the blood-brain barrier (BBB).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05BC7C2E-28A5-5471-E063-731AD00AEA2B","latestVersionIndicator":"Yes","beginDate":"2023-09-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-09-19","modifiedBy":"GDEEN","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102FFBCF-5CFC-046F-E063-731AD00AD14D","beginDate":"2024-01-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-30","modifiedBy":"GDEEN","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Protein Phosphatase 2A Inhibitor LB-100","valueDescription":null,"ValueMeaning":{"publicId":"13724985","version":"1","preferredName":"Protein Phosphatase 2A Inhibitor LB-100","longName":"13724985v1.00","preferredDefinition":"A water soluble inhibitor of the protein phosphatase 2A (PP2A), with potential chemo- and radiotherapy enhancing activity. Upon injection, PP2A inhibitor LB-100 inhibits the removal of phosphate groups from proteins essential for cell cycle progression. When used with radio- or chemotherapy treatment, this agent prevents the activation of PP2A-mediated repair mechanisms and allows for malignant cells to progress through the cell cycle without having their damaged DNA repaired. This enhances the cytotoxic effect of the chemotherapeutic or radiotherapeutic agent and results in tumor cell apoptosis. PP2A, a serine/threonine phosphatase that plays a key role in the control of cell growth and DNA damage repair.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protein Phosphatase 2A Inhibitor LB-100","conceptCode":"C106430","definition":"A water soluble inhibitor of the protein phosphatase 2A (PP2A), with potential chemo- and radiotherapy enhancing activity. Upon injection, PP2A inhibitor LB-100 inhibits the removal of phosphate groups from proteins essential for cell cycle progression. When used with radio- or chemotherapy treatment, this agent prevents the activation of PP2A-mediated repair mechanisms and allows for malignant cells to progress through the cell cycle without having their damaged DNA repaired. This enhances the cytotoxic effect of the chemotherapeutic or radiotherapeutic agent and results in tumor cell apoptosis. PP2A, a serine/threonine phosphatase that plays a key role in the control of cell growth and DNA damage repair.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC9F3F8C-ECF4-2D42-E053-731AD00AFB41","latestVersionIndicator":"Yes","beginDate":"2023-05-26","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-26","modifiedBy":"DWARZEL","dateModified":"2023-05-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"102FFBCF-5CFD-046F-E063-731AD00AD14D","beginDate":"2024-01-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-01-30","modifiedBy":"GDEEN","dateModified":"2024-01-30","deletedIndicator":"No"},{"value":"Galcanezumab-gnlm","valueDescription":null,"ValueMeaning":{"publicId":"14741291","version":"1","preferredName":"Galcanezumab","longName":"14741291v1.00","preferredDefinition":"No value exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Galcanezumab","conceptCode":"C166816","definition":"A humanized immunoglobulin G4 (IgG4) monoclonal antibody targeting calcitonin-gene related peptide (CGRP) ligand, that can be used in the preventive treatment of migraine. Upon subcutaneous administration, galcanezumab specifically targets and binds to CGRP ligand, and blocks the binding of the CGRP ligand to its receptor. This blocks the CGRP pathway and prevents migraine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"105629E4-1268-7709-E063-731AD00A5990","latestVersionIndicator":"Yes","beginDate":"2024-02-01","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-01","modifiedBy":"GDEEN","dateModified":"2024-02-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"105629E4-1269-7709-E063-731AD00A5990","beginDate":"2024-02-01","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-01","modifiedBy":"GDEEN","dateModified":"2024-02-01","deletedIndicator":"No"},{"value":"Pamiparib","valueDescription":null,"ValueMeaning":{"publicId":"13715000","version":"1","preferredName":"Pamiparib","longName":"13715000v1.00","preferredDefinition":"An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP), with potential antineoplastic activity. Upon administration, pamiparib selectively binds to PARP and prevents PARP-mediated repair of single-strand DNA breaks via the base-excision repair (BER) pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability, and eventually leads to apoptosis. PARP is activated by single-strand DNA breaks and, subsequently, catalyzes post-translational ADP-ribosylation of nuclear proteins which then transduce signals to recruit other proteins to repair damaged DNA. Pamiparib may both potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell chemo- and radioresistance.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pamiparib","conceptCode":"C120553","definition":"An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP), with potential antineoplastic activity. Upon administration, pamiparib selectively binds to PARP and prevents PARP-mediated repair of single-strand DNA breaks via the base-excision repair (BER) pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability, and eventually leads to apoptosis. PARP is activated by single-strand DNA breaks and, subsequently, catalyzes post-translational ADP-ribosylation of nuclear proteins which then transduce signals to recruit other proteins to repair damaged DNA. Pamiparib may both potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell chemo- and radioresistance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC9CCF12-BD7C-3766-E053-731AD00A3FED","latestVersionIndicator":"Yes","beginDate":"2023-05-26","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-26","modifiedBy":"GDEEN","dateModified":"2024-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A63BB8-CC8A-216A-E063-731AD00A9B88","beginDate":"2024-02-05","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-05","modifiedBy":"GDEEN","dateModified":"2024-02-05","deletedIndicator":"No"},{"value":"Cabergoline","valueDescription":null,"ValueMeaning":{"publicId":"3378839","version":"1","preferredName":"Cabergoline","longName":"3378839","preferredDefinition":"A synthetic ergoline derivative and a long-acting dopamine receptor agonist with high affinity for the dopamine D2 receptor. Cabergoline exerts an inhibitory effect on prolactin secretion by acting on dopamine receptors present in pituitary lactotrophs. This drug also binds to dopamine D2 receptors in the corpus striatum, thereby mimicking the actions of dopamine on motor control. Cabergoline also possesses antioxidant and neuroprotective properties due to its free radical scavenging activity. Cabergoline is used in the treatment of Parkinson's disease and in the treatment of hyperprolactinemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cabergoline","conceptCode":"C47428","definition":"A synthetic ergoline derivative and a long-acting dopamine receptor agonist with high affinity for the dopamine D2 receptor. Cabergoline exerts an inhibitory effect on prolactin secretion by acting on dopamine receptors present in pituitary lactotrophs. This drug also binds to dopamine D2 receptors in the corpus striatum, thereby mimicking the actions of dopamine on motor control. Cabergoline also possesses antioxidant and neuroprotective properties due to its free radical scavenging activity. Cabergoline is used in the treatment of Parkinson's disease and in the treatment of hyperprolactinemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-176C-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"11468DE7-C5FA-119B-E063-731AD00ABF5B","beginDate":"2024-02-13","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-13","modifiedBy":"GDEEN","dateModified":"2024-02-13","deletedIndicator":"No"},{"value":"Citrus Pectin","valueDescription":null,"ValueMeaning":{"publicId":"14758300","version":"1","preferredName":"Citrus Pectin","longName":"14758300v1.00","preferredDefinition":"Dietary fiber source, extracted from rind of citrus fruits, and used as a gelling agent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Citrus Pectin","conceptCode":"C82601","definition":"Dietary fiber source, extracted from rind of citrus fruits, and used as a gelling agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"114CB0ED-6772-1551-E063-731AD00A9C96","latestVersionIndicator":"Yes","beginDate":"2024-02-13","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-13","modifiedBy":"GDEEN","dateModified":"2024-02-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"114CB0ED-6775-1551-E063-731AD00A9C96","beginDate":"2024-02-13","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-13","modifiedBy":"GDEEN","dateModified":"2024-02-13","deletedIndicator":"No"},{"value":"Tocotrienol","valueDescription":null,"ValueMeaning":{"publicId":"13744171","version":"1","preferredName":"Tocotrienol","longName":"13744171v1.00","preferredDefinition":"Any of the four forms, alpha, beta, gamma and delta, of a member of the vitamin E family, with potential hypocholesterolemic, antithrombotic, antioxidant, immunomodulating and antineoplastic activities. Tocotrienol inhibits the activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, thereby lowering cholesterol levels. In addition, tocotrienol acts through multiple signal transduction pathways to induce cell cycle arrest and caspase-mediated apoptosis, and to decrease tumor cell proliferation. In addition, this agent may inhibit angiogenesis through the blockage of vascular endothelial growth factor receptor (VEGFR) and the subsequent inhibition of tumor cell-induced vessel formation. Also, this agent prevents free radical formation and inhibits lipid peroxidation, thereby preventing DNA cell damage. Tocotrienol farnesyl isoprenoid side chains contain 3 double bonds, which are absent in tocopherols, likely contribute to its anti-cancer activities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tocotrienol","conceptCode":"C68318","definition":"Any of the four forms, alpha, beta, gamma and delta, of a member of the vitamin E family, with potential hypocholesterolemic, antithrombotic, antioxidant, immunomodulating and antineoplastic activities. Tocotrienol inhibits the activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, thereby lowering cholesterol levels. In addition, tocotrienol acts through multiple signal transduction pathways to induce cell cycle arrest and caspase-mediated apoptosis, and to decrease tumor cell proliferation. In addition, this agent may inhibit angiogenesis through the blockage of vascular endothelial growth factor receptor (VEGFR) and the subsequent inhibition of tumor cell-induced vessel formation. Also, this agent prevents free radical formation and inhibits lipid peroxidation, thereby preventing DNA cell damage. Tocotrienol farnesyl isoprenoid side chains contain 3 double bonds, which are absent in tocopherols, likely contribute to its anti-cancer activities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCA5FCD5-9DFD-630D-E053-731AD00AEE1A","latestVersionIndicator":"Yes","beginDate":"2023-05-27","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-27","modifiedBy":"DWARZEL","dateModified":"2023-05-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"114CB0ED-6776-1551-E063-731AD00A9C96","beginDate":"2024-02-13","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-13","modifiedBy":"GDEEN","dateModified":"2024-02-13","deletedIndicator":"No"},{"value":"Flaxseed","valueDescription":null,"ValueMeaning":{"publicId":"14758301","version":"1","preferredName":"Flaxseed","longName":"14758301v1.00","preferredDefinition":"Seed isolated from one of several species of the plant genus Linum. Flaxseed-derived foods, lignans, and essential fatty acids such as alpha-linolenic acid, possess anti-inflammatory, lipid-lowering, antioxidant, and antineoplastic properties.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Flaxseed","conceptCode":"C26650","definition":"Seed isolated from one of several species of the plant genus Linum. Flaxseed-derived foods, lignans, and essential fatty acids such as alpha-linolenic acid, possess anti-inflammatory, lipid-lowering, antioxidant, and antineoplastic properties.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"114CB0ED-6773-1551-E063-731AD00A9C96","latestVersionIndicator":"Yes","beginDate":"2024-02-13","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-13","modifiedBy":"GDEEN","dateModified":"2024-02-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"114CB0ED-6777-1551-E063-731AD00A9C96","beginDate":"2024-02-13","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-13","modifiedBy":"GDEEN","dateModified":"2024-02-13","deletedIndicator":"No"},{"value":"Abiraterone","valueDescription":null,"ValueMeaning":{"publicId":"3263351","version":"1","preferredName":"Abiraterone (Zytiga)","longName":"3263351","preferredDefinition":"A steroidal compound with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex; CYP17A1), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abiraterone","conceptCode":"C77333","definition":"A steroidal compound with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex; CYP17A1), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AAC9BCD2-6B13-3AEE-E040-BB89AD4375B9","latestVersionIndicator":"Yes","beginDate":"2011-08-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-08-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"114CB0ED-6778-1551-E063-731AD00A9C96","beginDate":"2024-02-13","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-13","modifiedBy":"GDEEN","dateModified":"2024-02-13","deletedIndicator":"No"},{"value":"Vildagliptin","valueDescription":null,"ValueMeaning":{"publicId":"14758302","version":"1","preferredName":"Vildagliptin (Galvus)","longName":"14758302v1.00","preferredDefinition":"A cyanopyrrolidine-based, orally bioavailable inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. Vildagliptin's cyano moiety undergoes hydrolysis and this inactive metabolite is excreted mainly via the urine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vildagliptin","conceptCode":"C66653","definition":"A cyanopyrrolidine-based, orally bioavailable inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. Vildagliptin's cyano moiety undergoes hydrolysis and this inactive metabolite is excreted mainly via the urine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"114CB0ED-6774-1551-E063-731AD00A9C96","latestVersionIndicator":"Yes","beginDate":"2024-02-13","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-13","modifiedBy":"GDEEN","dateModified":"2024-02-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"114CB0ED-6779-1551-E063-731AD00A9C96","beginDate":"2024-02-13","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-13","modifiedBy":"GDEEN","dateModified":"2024-02-13","deletedIndicator":"No"},{"value":"Turkey Tail Mushroom Extract","valueDescription":null,"ValueMeaning":{"publicId":"13633980","version":"1","preferredName":"Coriolus Versicolor Extract","longName":"13633980v1.00","preferredDefinition":"An extract derived from the mushroom Coriolus versicolor, containing polysaccharide K (PSK) and polysaccharide-peptide (PSP), with potential immunomodulating and antineoplastic activities. Coriolus versicolor extract has been shown to stimulate the production of lymphocytes and cytokines, such as interferons and interleukins, and may exhibit antioxidant activities. However, the precise mechanism of action(s) of this agent is unknown.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Coriolus Versicolor Extract","conceptCode":"C78184","definition":"An extract derived from the mushroom Coriolus versicolor, containing polysaccharide K (PSK) and polysaccharide-peptide (PSP), with potential immunomodulating and antineoplastic activities. Coriolus versicolor extract has been shown to stimulate the production of lymphocytes and cytokines, such as interferons and interleukins, and may exhibit antioxidant activities. However, the precise mechanism of action(s) of this agent is unknown.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC6675FF-E022-474A-E053-731AD00A81DA","latestVersionIndicator":"Yes","beginDate":"2023-05-23","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-23","modifiedBy":"GDEEN","dateModified":"2024-02-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"11D7AD44-61FE-26ED-E063-731AD00A929F","beginDate":"2024-02-20","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-20","modifiedBy":"GDEEN","dateModified":"2024-02-20","deletedIndicator":"No"},{"value":"Broccoli/Turmeric/Pomegranate/Green Tea Extract-based Supplement","valueDescription":null,"ValueMeaning":{"publicId":"14765641","version":"1","preferredName":"Broccoli/Turmeric/Pomegranate/Green Tea Extract-based Supplement (Pomi-T)","longName":"14765641v1.00","preferredDefinition":"An orally bioavailable dietary supplement composed of broccoli florets and stalks powder, turmeric root powder, pomegranate powder and green tea leaf extract.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Broccoli/Turmeric/Pomegranate/Green Tea Extract-based Supplement","conceptCode":"C204102","definition":"An orally bioavailable dietary supplement composed of broccoli florets and stalks powder, turmeric root powder, pomegranate powder and green tea leaf extract.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"11D7AD44-61FD-26ED-E063-731AD00A929F","latestVersionIndicator":"Yes","beginDate":"2024-02-20","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-20","modifiedBy":"GDEEN","dateModified":"2024-02-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"11D7AD44-61FF-26ED-E063-731AD00A929F","beginDate":"2024-02-20","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-20","modifiedBy":"GDEEN","dateModified":"2024-02-20","deletedIndicator":"No"},{"value":"Quercetin","valueDescription":null,"ValueMeaning":{"publicId":"3322719","version":"1","preferredName":"Quercetin","longName":"3322719","preferredDefinition":"A polyphenolic flavonoid with potential chemopreventive activity. Quercetin, ubiquitous in plant food sources and a major bioflavonoid in the human diet, may produce antiproliferative effects resulting from the modulation of either EGFR or estrogen-receptor mediated signal transduction pathways. Although the mechanism of action of action is not fully known, the following effects have been described with this agent in vitro: decreased expression of mutant p53 protein and p21-ras oncogene, induction of cell cycle arrest at the G1 phase and inhibition of heat shock protein synthesis. This compound also demonstrates synergy and reversal of the multidrug resistance phenotype, when combined with chemotherapeutic drugs, in vitro. Quercetin also produces anti-inflammatory and anti-allergy effects mediated through the inhibition of the lipoxygenase and cyclooxygenase pathways, thereby preventing the production of pro-inflammatory mediators.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Quercetin","conceptCode":"C792","definition":"A polyphenolic flavonoid with potential chemopreventive activity. Quercetin, ubiquitous in plant food sources and a major bioflavonoid in the human diet, may produce antiproliferative effects resulting from the modulation of either EGFR or estrogen-receptor mediated signal transduction pathways. Although the mechanism of action of action is not fully known, the following effects have been described with this agent in vitro: decreased expression of mutant p53 protein and p21-ras oncogene, induction of cell cycle arrest at the G1 phase and inhibition of heat shock protein synthesis. This compound also demonstrates synergy and reversal of the multidrug resistance phenotype, when combined with chemotherapeutic drugs, in vitro. Quercetin also produces anti-inflammatory and anti-allergy effects mediated through the inhibition of the lipoxygenase and cyclooxygenase pathways, thereby preventing the production of pro-inflammatory mediators.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B37111EB-A198-57A6-E040-BB89AD437D1F","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-12-06","modifiedBy":"COLBERTM","dateModified":"2022-09-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"11D844D9-8C44-4667-E063-731AD00AAB87","beginDate":"2024-02-20","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-20","modifiedBy":"GDEEN","dateModified":"2024-02-20","deletedIndicator":"No"},{"value":"Brinzolamide","valueDescription":null,"ValueMeaning":{"publicId":"14770128","version":"1","preferredName":"Brinzolamide (Azopt)","longName":"14770128v1.00","preferredDefinition":"A sulfonamide and carbonic anhydrase inhibitor with specific affinity for carbonic anhydrase II. Following topical ocular administration, brinzolamide inhibits carbonic anhydrase II, an enzyme that is responsible for the movement of sodium and fluid transport in the eye. This inhibition leads to a decrease in aqueous humor secretion, probably by slowing the formation of bicarbonate ions, and results in a reduction in intraocular pressure. Brinzolamide is used to treat increased pressure in the eye caused by open-angle glaucoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brinzolamide","conceptCode":"C47420","definition":"A sulfonamide and carbonic anhydrase inhibitor with specific affinity for carbonic anhydrase II. Following topical ocular administration, brinzolamide inhibits carbonic anhydrase II, an enzyme that is responsible for the movement of sodium and fluid transport in the eye. This inhibition leads to a decrease in aqueous humor secretion, probably by slowing the formation of bicarbonate ions, and results in a reduction in intraocular pressure. Brinzolamide is used to treat increased pressure in the eye caused by open-angle glaucoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"11EB7D48-1049-3ACB-E063-731AD00AF3DC","latestVersionIndicator":"Yes","beginDate":"2024-02-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-21","modifiedBy":"GDEEN","dateModified":"2024-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"11EB7D48-104A-3ACB-E063-731AD00AF3DC","beginDate":"2024-02-21","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-21","modifiedBy":"GDEEN","dateModified":"2024-02-21","deletedIndicator":"No"},{"value":"Pemigatinib","valueDescription":null,"ValueMeaning":{"publicId":"13722152","version":"1","preferredName":"Pemigatinib","longName":"13722152v1.00","preferredDefinition":"An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), with potential antineoplastic activity. Pemigatinib binds to and inhibits FGFR1/2/3, which may result in the inhibition of FGFR1/2/3-related signal transduction pathways. This inhibits proliferation in FGFR1/2/3-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, plays a key role in cellular proliferation, migration, and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pemigatinib","conceptCode":"C121553","definition":"An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), with potential antineoplastic activity. Pemigatinib binds to and inhibits FGFR1/2/3, which may result in the inhibition of FGFR1/2/3-related signal transduction pathways. This inhibits proliferation in FGFR1/2/3-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, plays a key role in cellular proliferation, migration, and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC9DB049-CBE7-5899-E053-731AD00A2B26","latestVersionIndicator":"Yes","beginDate":"2023-05-26","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-26","modifiedBy":"DWARZEL","dateModified":"2023-05-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"11FC20A1-4FCB-21F8-E063-731AD00A0000","beginDate":"2024-02-22","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-22","modifiedBy":"GDEEN","dateModified":"2024-02-22","deletedIndicator":"No"},{"value":"Futibatinib","valueDescription":null,"ValueMeaning":{"publicId":"13654923","version":"1","preferredName":"Futibatinib","longName":"13654923v1.00","preferredDefinition":"An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. Futibatinib selectively and irreversibly binds to and inhibits FGFR, which may result in the inhibition of both the FGFR-mediated signal transduction pathway and tumor cell proliferation, and increased cell death in FGFR-overexpressing tumor cells. FGFR is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation and survival and its expression is upregulated in many tumor cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Futibatinib","conceptCode":"C114283","definition":"An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. Futibatinib selectively and irreversibly binds to and inhibits FGFR, which may result in the inhibition of both the FGFR-mediated signal transduction pathway and tumor cell proliferation, and increased cell death in FGFR-overexpressing tumor cells. FGFR is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation and survival and its expression is upregulated in many tumor cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC77F54D-2B2D-6942-E053-731AD00A7AC9","latestVersionIndicator":"Yes","beginDate":"2023-05-24","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-24","modifiedBy":"DWARZEL","dateModified":"2023-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"11FC20A1-4FCC-21F8-E063-731AD00A0000","beginDate":"2024-02-22","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-22","modifiedBy":"GDEEN","dateModified":"2024-02-22","deletedIndicator":"No"},{"value":"Cetaphil","valueDescription":null,"ValueMeaning":{"publicId":"14775030","version":"1","preferredName":"Face Wash (Cetaphil)","longName":"14775030v1.00","preferredDefinition":"A topical preparation that is used to cleanse ones face.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Face Wash","conceptCode":"C204117","definition":"A topical preparation that is used to cleanse ones face.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"12030962-7C2A-5E20-E063-731AD00A0867","latestVersionIndicator":"Yes","beginDate":"2024-02-22","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-22","modifiedBy":"GDEEN","dateModified":"2024-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"12030962-7C2B-5E20-E063-731AD00A0867","beginDate":"2024-02-22","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-22","modifiedBy":"GDEEN","dateModified":"2024-02-22","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2632573","version":"1","preferredName":"Concomitant Agent Name","preferredDefinition":"Concomitant; following as a consequence.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI):The words or language units by which a thing is known.","longName":"C25730:C1708:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Concomitant","conceptCode":"C25730","definition":"Accessory, accompanying especially in a subordinate or incidental way, occurring or existing during the same period of time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2EFDCD3E-BF81-477C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2007-04-26","modifiedBy":"ONEDATA","dateModified":"2007-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9768B702-74CF-18F7-E053-F662850A60B1","latestVersionIndicator":"Yes","beginDate":"2019-11-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-15","modifiedBy":"GDEEN","dateModified":"2024-02-22","changeDescription":"Values are included in NCI EVS; do not come from a standard vocabulary or the sponsor. Versioned to add 292 C3D values. mc 11/15/19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"},{"publicId":"2811689","version":"1","longName":"SPOREs","context":"CCR"},{"publicId":"3248617","version":"1","longName":"CCR 2011 Template","context":"CCR"},{"publicId":"3248622","version":"1","longName":"Concomitant Meds/Measures","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812831","version":"1","longName":"Oregon Health & Sciences University","context":"NCIP"},{"publicId":"2812832","version":"1","longName":"OHSU_288","context":"NCIP"},{"publicId":"2811715","version":"1","longName":"Duke University","context":"NCIP"},{"publicId":"2812583","version":"1","longName":"Panvec","context":"NCIP"},{"publicId":"2811716","version":"1","longName":"UC Irvine","context":"NCIP"},{"publicId":"2812578","version":"1","longName":"UCI 0404","context":"NCIP"},{"publicId":"2812571","version":"1","longName":"Lombardi Cancer Center","context":"NCIP"},{"publicId":"2812585","version":"1","longName":"Lombardi 03058","context":"NCIP"},{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"},{"publicId":"2812573","version":"1","longName":"Albert Einstein Medical Center","context":"NCIP"},{"publicId":"2812812","version":"1","longName":"AE_104_085","context":"NCIP"},{"publicId":"2812727","version":"1","longName":"U of Pa Cancer Center","context":"NCIP"},{"publicId":"2812574","version":"1","longName":"UPCC 07403","context":"NCIP"},{"publicId":"2812693","version":"1","longName":"Northwestern University","context":"NCIP"},{"publicId":"2812695","version":"1","longName":"NU 0943_011","context":"NCIP"},{"publicId":"2812582","version":"1","longName":"P1_CPT_BCNU_RD","context":"NCIP"},{"publicId":"2812726","version":"1","longName":"U Nebraska Med Center","context":"NCIP"},{"publicId":"2812981","version":"1","longName":"UNMC 284-04","context":"NCIP"},{"publicId":"2812732","version":"1","longName":"FES Study","context":"NCIP"},{"publicId":"2812733","version":"1","longName":"FMISO Study","context":"NCIP"},{"publicId":"2812731","version":"1","longName":"U Washington","context":"NCIP"}]},{"publicId":"2857175","version":"1","longName":"C3D Adopter CDEs for Reuse","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812490","version":"1","longName":"CTMS 3.12B","context":"CCR"}]},{"publicId":"2976812","version":"1","longName":"GO Trial","context":"SPOREs","ClassificationSchemeItems":[{"publicId":"2976834","version":"1","longName":"GO Trial","context":"SPOREs"}]}],"AlternateNames":[{"name":"CONCT_AGT_NM","type":"C3D Name","context":"CCR"},{"name":"caBIG","type":"USED_BY","context":"NCIP"},{"name":"SPOREs","type":"USED_BY","context":"SPOREs"}],"ReferenceDocuments":[{"name":"Agent Name","type":"Preferred Question Text","description":"Agent Name","url":null,"context":"CCR"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Name of prophylactic agent:","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"0DDF0D1A-269A-6548-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-01","modifiedBy":"KUMMEROA","dateModified":"2023-10-31","changeDescription":"New version uses better DEC. Versioned to add 292 C3D values. mc 11/15/19","administrativeNotes":"2023.10.31 AQT added per ticket request CADSR0003010. ak","unresolvedIssues":null,"deletedIndicator":"No"}}